{"doc_id": "10082597_2", "wnd_id": "10082597_2_1", "text": "Naproxen , the most common offender , has been associated with a dimorphic clinical pattern : a PCT - like presentation and one simulating erythropoietic protoporphyria in the pediatric population .", "tokens": ["Naproxen", ",", "the", "most", "common", "offender", ",", "has", "been", "associated", "with", "a", "dimorphic", "clinical", "pattern", ":", "a", "PCT", "-", "like", "presentation", "and", "one", "simulating", "erythropoietic", "protoporphyria", "in", "the", "pediatric", "population", "."], "event_mentions": [{"id": "10082597_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "10082597_2_Ent3", "role": "Treatment", "text": "Naproxen", "start": 0, "end": 1}, {"entity_id": "10082597_2_Ent4", "role": "Treatment_Drug", "text": "Naproxen", "start": 0, "end": 1}, {"entity_id": "10082597_2_Ent2", "role": "Effect", "text": "erythropoietic protoporphyria", "start": 24, "end": 26}, {"entity_id": "10082597_2_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 28, "end": 29}, {"entity_id": "10082597_2_Ent0", "role": "Subject", "text": "pediatric population", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "10082597_2_Ent3", "text": "Naproxen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10082597_2_Ent4", "text": "Naproxen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10082597_2_Ent2", "text": "erythropoietic protoporphyria", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "10082597_2_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "10082597_2_Ent0", "text": "pediatric population", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "10102531_2", "wnd_id": "10102531_2_1", "text": "We report a case of reversible encephalopathy syndrome in a 16 - year - old girl with acute myelogenous leukemia ( AML ) , who is undergoing during consolidation chemotherapy composed of BH - AC ( N4 - behenoyl - 1 - beta - D - arabinofuranosyl cytosine ) and idarubicin .", "tokens": ["We", "report", "a", "case", "of", "reversible", "encephalopathy", "syndrome", "in", "a", "16", "-", "year", "-", "old", "girl", "with", "acute", "myelogenous", "leukemia", "(", "AML", ")", ",", "who", "is", "undergoing", "during", "consolidation", "chemotherapy", "composed", "of", "BH", "-", "AC", "(", "N4", "-", "behenoyl", "-", "1", "-", "beta", "-", "D", "-", "arabinofuranosyl", "cytosine", ")", "and", "idarubicin", "."], "event_mentions": [{"id": "10102531_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "undergoing", "start": 26, "end": 27}, "arguments": [{"entity_id": "10102531_2_Ent3", "role": "Effect", "text": "reversible encephalopathy syndrome", "start": 5, "end": 8}, {"entity_id": "10102531_2_Ent0", "role": "Subject", "text": "a 16 - year - old girl with acute myelogenous leukemia ( AML )", "start": 9, "end": 23}, {"entity_id": "10102531_2_Ent1", "role": "Subject_Age", "text": "16 - year - old", "start": 10, "end": 15}, {"entity_id": "10102531_2_Ent2", "role": "Subject_Gender", "text": "girl", "start": 15, "end": 16}, {"entity_id": "10102531_2_Ent5", "role": "Treatment_Disorder", "text": "acute myelogenous leukemia", "start": 17, "end": 20}, {"entity_id": "10102531_2_Ent4", "role": "Treatment", "text": "consolidation chemotherapy composed of BH - AC ( N4 - behenoyl - 1 - beta - D - arabinofuranosyl cytosine ) and idarubicin", "start": 28, "end": 51}, {"entity_id": "10102531_2_Ent7", "role": "Treatment_Drug", "text": "BH - AC", "start": 32, "end": 35}, {"entity_id": "10102531_2_Ent9", "role": "Combination_Drug", "text": "BH - AC", "start": 32, "end": 35}, {"entity_id": "10102531_2_Ent6", "role": "Treatment_Drug", "text": "idarubicin", "start": 50, "end": 51}, {"entity_id": "10102531_2_Ent8", "role": "Combination_Drug", "text": "idarubicin", "start": 50, "end": 51}]}], "entity_mentions": [{"id": "10102531_2_Ent3", "text": "reversible encephalopathy syndrome", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "10102531_2_Ent0", "text": "a 16 - year - old girl with acute myelogenous leukemia ( AML )", "entity_type": "Entity", "start": 9, "end": 23}, {"id": "10102531_2_Ent1", "text": "16 - year - old", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "10102531_2_Ent2", "text": "girl", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10102531_2_Ent5", "text": "acute myelogenous leukemia", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "10102531_2_Ent4", "text": "consolidation chemotherapy composed of BH - AC ( N4 - behenoyl - 1 - beta - D - arabinofuranosyl cytosine ) and idarubicin", "entity_type": "Entity", "start": 28, "end": 51}, {"id": "10102531_2_Ent7", "text": "BH - AC", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "10102531_2_Ent9", "text": "BH - AC", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "10102531_2_Ent6", "text": "idarubicin", "entity_type": "Entity", "start": 50, "end": 51}, {"id": "10102531_2_Ent8", "text": "idarubicin", "entity_type": "Entity", "start": 50, "end": 51}], "lang": "en"}
{"doc_id": "10190739_1", "wnd_id": "10190739_1_1", "text": "In one case , the readministration of riluzole was followed by the relapse of hepatitis .", "tokens": ["In", "one", "case", ",", "the", "readministration", "of", "riluzole", "was", "followed", "by", "the", "relapse", "of", "hepatitis", "."], "event_mentions": [{"id": "10190739_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "readministration", "start": 5, "end": 6}, "arguments": [{"entity_id": "10190739_1_Ent1", "role": "Treatment", "text": "riluzole", "start": 7, "end": 8}, {"entity_id": "10190739_1_Ent2", "role": "Treatment_Drug", "text": "riluzole", "start": 7, "end": 8}, {"entity_id": "10190739_1_Ent0", "role": "Effect", "text": "the relapse of hepatitis", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "10190739_1_Ent1", "text": "riluzole", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10190739_1_Ent2", "text": "riluzole", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10190739_1_Ent0", "text": "the relapse of hepatitis", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "10203437_8", "wnd_id": "10203437_8_1", "text": "CONCLUSIONS : Reversible lupus - like syndrome appears to be a rare but significant side effect of 5 - ASA compounds .", "tokens": ["CONCLUSIONS", ":", "Reversible", "lupus", "-", "like", "syndrome", "appears", "to", "be", "a", "rare", "but", "significant", "side", "effect", "of", "5", "-", "ASA", "compounds", "."], "event_mentions": [{"id": "10203437_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effect", "start": 14, "end": 16}, "arguments": [{"entity_id": "10203437_8_Ent0", "role": "Effect", "text": "Reversible lupus - like syndrome", "start": 2, "end": 7}, {"entity_id": "10203437_8_Ent1", "role": "Treatment", "text": "5 - ASA", "start": 17, "end": 20}, {"entity_id": "10203437_8_Ent2", "role": "Treatment_Drug", "text": "5 - ASA", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "10203437_8_Ent0", "text": "Reversible lupus - like syndrome", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "10203437_8_Ent1", "text": "5 - ASA", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "10203437_8_Ent2", "text": "5 - ASA", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "10212021_1", "wnd_id": "10212021_1_1", "text": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine .", "tokens": ["Methadone", "withdrawal", "when", "starting", "an", "antiretroviral", "regimen", "including", "nevirapine", "."], "event_mentions": [{"id": "10212021_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "starting", "start": 3, "end": 4}, "arguments": [{"entity_id": "10212021_1_Ent0", "role": "Effect", "text": "Methadone withdrawal", "start": 0, "end": 2}, {"entity_id": "10212021_1_Ent1", "role": "Treatment", "text": "an antiretroviral regimen including nevirapine", "start": 4, "end": 9}, {"entity_id": "10212021_1_Ent2", "role": "Treatment_Drug", "text": "nevirapine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "10212021_1_Ent0", "text": "Methadone withdrawal", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10212021_1_Ent1", "text": "an antiretroviral regimen including nevirapine", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10212021_1_Ent2", "text": "nevirapine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "10323129_1", "wnd_id": "10323129_1_1", "text": "Possible theophylline toxicity during anesthesia .", "tokens": ["Possible", "theophylline", "toxicity", "during", "anesthesia", "."], "event_mentions": [{"id": "10323129_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "10323129_1_Ent0", "role": "Effect", "text": "theophylline toxicity", "start": 1, "end": 3}, {"entity_id": "10323129_1_Ent1", "role": "Treatment", "text": "anesthesia", "start": 4, "end": 5}, {"entity_id": "10323129_1_Ent2", "role": "Treatment_Drug", "text": "anesthesia", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "10323129_1_Ent0", "text": "theophylline toxicity", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10323129_1_Ent1", "text": "anesthesia", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10323129_1_Ent2", "text": "anesthesia", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "10348150_1", "wnd_id": "10348150_1_1", "text": "Hydroxyurea - induced acute interstitial pneumonitis in a patient with essential thrombocythemia .", "tokens": ["Hydroxyurea", "-", "induced", "acute", "interstitial", "pneumonitis", "in", "a", "patient", "with", "essential", "thrombocythemia", "."], "event_mentions": [{"id": "10348150_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10348150_1_Ent2", "role": "Treatment", "text": "Hydroxyurea", "start": 0, "end": 1}, {"entity_id": "10348150_1_Ent3", "role": "Treatment_Drug", "text": "Hydroxyurea", "start": 0, "end": 1}, {"entity_id": "10348150_1_Ent1", "role": "Effect", "text": "interstitial pneumonitis", "start": 4, "end": 6}, {"entity_id": "10348150_1_Ent0", "role": "Subject", "text": "a patient with essential thrombocythemia", "start": 7, "end": 12}, {"entity_id": "10348150_1_Ent4", "role": "Treatment_Disorder", "text": "essential thrombocythemia", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "10348150_1_Ent2", "text": "Hydroxyurea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10348150_1_Ent3", "text": "Hydroxyurea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10348150_1_Ent1", "text": "interstitial pneumonitis", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10348150_1_Ent0", "text": "a patient with essential thrombocythemia", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "10348150_1_Ent4", "text": "essential thrombocythemia", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "10357715_2", "wnd_id": "10357715_2_1", "text": "Calcipotriol ( Daivonex R ; Leo Pharmaceuticals , Zurich , Switzerland ) may cause irritation of the skin , whereas allergic reactions are less common .", "tokens": ["Calcipotriol", "(", "Daivonex", "R", ";", "Leo", "Pharmaceuticals", ",", "Zurich", ",", "Switzerland", ")", "may", "cause", "irritation", "of", "the", "skin", ",", "whereas", "allergic", "reactions", "are", "less", "common", "."], "event_mentions": [{"id": "10357715_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 13, "end": 14}, "arguments": [{"entity_id": "10357715_2_Ent1", "role": "Treatment", "text": "Calcipotriol", "start": 0, "end": 1}, {"entity_id": "10357715_2_Ent2", "role": "Treatment_Drug", "text": "Calcipotriol", "start": 0, "end": 1}, {"entity_id": "10357715_2_Ent0", "role": "Effect", "text": "irritation of the skin", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "10357715_2_Ent1", "text": "Calcipotriol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10357715_2_Ent2", "text": "Calcipotriol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10357715_2_Ent0", "text": "irritation of the skin", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "10367184_1", "wnd_id": "10367184_1_1", "text": "Myotonia associated with sarcoidosis : marked exacerbation with pravastatin .", "tokens": ["Myotonia", "associated", "with", "sarcoidosis", ":", "marked", "exacerbation", "with", "pravastatin", "."], "event_mentions": [{"id": "10367184_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "10367184_1_Ent3", "role": "Effect", "text": "Myotonia", "start": 0, "end": 1}, {"entity_id": "10367184_1_Ent0", "role": "Subject", "text": "sarcoidosis", "start": 3, "end": 4}, {"entity_id": "10367184_1_Ent1", "role": "Subject_Disorder", "text": "sarcoidosis", "start": 3, "end": 4}, {"entity_id": "10367184_1_Ent2", "role": "Effect", "text": "exacerbation", "start": 6, "end": 7}, {"entity_id": "10367184_1_Ent4", "role": "Treatment", "text": "pravastatin", "start": 8, "end": 9}, {"entity_id": "10367184_1_Ent5", "role": "Treatment_Drug", "text": "pravastatin", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "10367184_1_Ent3", "text": "Myotonia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10367184_1_Ent0", "text": "sarcoidosis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10367184_1_Ent1", "text": "sarcoidosis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10367184_1_Ent2", "text": "exacerbation", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10367184_1_Ent4", "text": "pravastatin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10367184_1_Ent5", "text": "pravastatin", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "10393393_1", "wnd_id": "10393393_1_1", "text": "Hypersensitivity to aspirin can be manifested as acute asthma , urticaria and/or angioedema , or a systemic anaphylactoid reaction .", "tokens": ["Hypersensitivity", "to", "aspirin", "can", "be", "manifested", "as", "acute", "asthma", ",", "urticaria", "and/or", "angioedema", ",", "or", "a", "systemic", "anaphylactoid", "reaction", "."], "event_mentions": [{"id": "10393393_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifested", "start": 5, "end": 6}, "arguments": [{"entity_id": "10393393_1_Ent4", "role": "Effect", "text": "Hypersensitivity", "start": 0, "end": 1}, {"entity_id": "10393393_1_Ent5", "role": "Treatment", "text": "aspirin", "start": 2, "end": 3}, {"entity_id": "10393393_1_Ent6", "role": "Treatment_Drug", "text": "aspirin", "start": 2, "end": 3}, {"entity_id": "10393393_1_Ent0", "role": "Effect", "text": "acute asthma", "start": 7, "end": 9}, {"entity_id": "10393393_1_Ent1", "role": "Effect", "text": "urticaria", "start": 10, "end": 11}, {"entity_id": "10393393_1_Ent2", "role": "Effect", "text": "angioedema", "start": 12, "end": 13}, {"entity_id": "10393393_1_Ent3", "role": "Effect", "text": "systemic anaphylactoid reaction", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "10393393_1_Ent4", "text": "Hypersensitivity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10393393_1_Ent5", "text": "aspirin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10393393_1_Ent6", "text": "aspirin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10393393_1_Ent0", "text": "acute asthma", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "10393393_1_Ent1", "text": "urticaria", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10393393_1_Ent2", "text": "angioedema", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10393393_1_Ent3", "text": "systemic anaphylactoid reaction", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "10405480_1", "wnd_id": "10405480_1_1", "text": "A 26 - year - old Japanese man , who had been receiving medical attention for ulcerative colitis for one year , presented with diffuse erythema and pustules on his face and trunk , malaise , and fever up to 39 degrees C one day after the administration of salazosulfapyridine .", "tokens": ["A", "26", "-", "year", "-", "old", "Japanese", "man", ",", "who", "had", "been", "receiving", "medical", "attention", "for", "ulcerative", "colitis", "for", "one", "year", ",", "presented", "with", "diffuse", "erythema", "and", "pustules", "on", "his", "face", "and", "trunk", ",", "malaise", ",", "and", "fever", "up", "to", "39", "degrees", "C", "one", "day", "after", "the", "administration", "of", "salazosulfapyridine", "."], "event_mentions": [{"id": "10405480_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 45, "end": 46}, "arguments": [{"entity_id": "10405480_1_Ent0", "role": "Subject", "text": "A 26 - year - old Japanese man , who had been receiving medical attention for ulcerative colitis for one year", "start": 0, "end": 21}, {"entity_id": "10405480_1_Ent1", "role": "Subject_Age", "text": "26 - year - old", "start": 1, "end": 6}, {"entity_id": "10405480_1_Ent3", "role": "Subject_Race", "text": "Japanese", "start": 6, "end": 7}, {"entity_id": "10405480_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "10405480_1_Ent6", "role": "Treatment_Disorder", "text": "ulcerative colitis", "start": 16, "end": 18}, {"entity_id": "10405480_1_Ent4", "role": "Effect", "text": "diffuse erythema and pustules on his face and trunk , malaise , and fever up to 39 degrees C", "start": 24, "end": 43}, {"entity_id": "10405480_1_Ent7", "role": "Treatment_Time_elapsed", "text": "one day", "start": 43, "end": 45}, {"entity_id": "10405480_1_Ent5", "role": "Treatment", "text": "salazosulfapyridine", "start": 49, "end": 50}, {"entity_id": "10405480_1_Ent8", "role": "Treatment_Drug", "text": "salazosulfapyridine", "start": 49, "end": 50}]}], "entity_mentions": [{"id": "10405480_1_Ent0", "text": "A 26 - year - old Japanese man , who had been receiving medical attention for ulcerative colitis for one year", "entity_type": "Entity", "start": 0, "end": 21}, {"id": "10405480_1_Ent1", "text": "26 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10405480_1_Ent3", "text": "Japanese", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10405480_1_Ent2", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10405480_1_Ent6", "text": "ulcerative colitis", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "10405480_1_Ent4", "text": "diffuse erythema and pustules on his face and trunk , malaise , and fever up to 39 degrees C", "entity_type": "Entity", "start": 24, "end": 43}, {"id": "10405480_1_Ent7", "text": "one day", "entity_type": "Entity", "start": 43, "end": 45}, {"id": "10405480_1_Ent5", "text": "salazosulfapyridine", "entity_type": "Entity", "start": 49, "end": 50}, {"id": "10405480_1_Ent8", "text": "salazosulfapyridine", "entity_type": "Entity", "start": 49, "end": 50}], "lang": "en"}
{"doc_id": "10410183_6", "wnd_id": "10410183_6_1", "text": "DISCUSSION : Olanzapine , like other atypical antipsychotic drugs , may cause muscle injury with concomitant elevations of serum CK of muscle origin .", "tokens": ["DISCUSSION", ":", "Olanzapine", ",", "like", "other", "atypical", "antipsychotic", "drugs", ",", "may", "cause", "muscle", "injury", "with", "concomitant", "elevations", "of", "serum", "CK", "of", "muscle", "origin", "."], "event_mentions": [{"id": "10410183_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "10410183_6_Ent1", "role": "Treatment", "text": "Olanzapine", "start": 2, "end": 3}, {"entity_id": "10410183_6_Ent3", "role": "Treatment_Drug", "text": "Olanzapine", "start": 2, "end": 3}, {"entity_id": "10410183_6_Ent2", "role": "Treatment", "text": "atypical antipsychotic drugs", "start": 6, "end": 9}, {"entity_id": "10410183_6_Ent0", "role": "Effect", "text": "muscle injury with concomitant elevations of serum CK of muscle origin", "start": 12, "end": 23}]}], "entity_mentions": [{"id": "10410183_6_Ent1", "text": "Olanzapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10410183_6_Ent3", "text": "Olanzapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10410183_6_Ent2", "text": "atypical antipsychotic drugs", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "10410183_6_Ent0", "text": "muscle injury with concomitant elevations of serum CK of muscle origin", "entity_type": "Entity", "start": 12, "end": 23}], "lang": "en"}
{"doc_id": "10439378_1", "wnd_id": "10439378_1_1", "text": "Acute neutrophilic dermatosis induced by all - trans - retinoic acid treatment for acute promyelocytic leukemia .", "tokens": ["Acute", "neutrophilic", "dermatosis", "induced", "by", "all", "-", "trans", "-", "retinoic", "acid", "treatment", "for", "acute", "promyelocytic", "leukemia", "."], "event_mentions": [{"id": "10439378_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced by", "start": 3, "end": 5}, "arguments": [{"entity_id": "10439378_1_Ent0", "role": "Effect", "text": "Acute neutrophilic dermatosis", "start": 0, "end": 3}, {"entity_id": "10439378_1_Ent1", "role": "Treatment", "text": "all - trans - retinoic acid", "start": 5, "end": 11}, {"entity_id": "10439378_1_Ent3", "role": "Treatment_Drug", "text": "all - trans - retinoic acid", "start": 5, "end": 11}, {"entity_id": "10439378_1_Ent2", "role": "Treatment_Disorder", "text": "acute promyelocytic leukemia", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "10439378_1_Ent0", "text": "Acute neutrophilic dermatosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10439378_1_Ent1", "text": "all - trans - retinoic acid", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "10439378_1_Ent3", "text": "all - trans - retinoic acid", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "10439378_1_Ent2", "text": "acute promyelocytic leukemia", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "10442258_2", "wnd_id": "10442258_2_1", "text": "Alopecia and hair loss are rare side effects of psychotropic drugs .", "tokens": ["Alopecia", "and", "hair", "loss", "are", "rare", "side", "effects", "of", "psychotropic", "drugs", "."], "event_mentions": [{"id": "10442258_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 6, "end": 8}, "arguments": [{"entity_id": "10442258_2_Ent0", "role": "Effect", "text": "Alopecia and hair loss", "start": 0, "end": 4}, {"entity_id": "10442258_2_Ent2", "role": "Treatment_Drug", "text": "psychotropic", "start": 9, "end": 10}, {"entity_id": "10442258_2_Ent1", "role": "Treatment", "text": "psychotropic drugs", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "10442258_2_Ent0", "text": "Alopecia and hair loss", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10442258_2_Ent2", "text": "psychotropic", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10442258_2_Ent1", "text": "psychotropic drugs", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "10473079_1", "wnd_id": "10473079_1_1", "text": "We conclude that the presence of this metabolic defect combined with topical 5 - FU ( a drug demonstrating a narrow therapeutic index ) results in the unusual presentation of life - threatening toxicity after treatment with a topical drug .", "tokens": ["We", "conclude", "that", "the", "presence", "of", "this", "metabolic", "defect", "combined", "with", "topical", "5", "-", "FU", "(", "a", "drug", "demonstrating", "a", "narrow", "therapeutic", "index", ")", "results", "in", "the", "unusual", "presentation", "of", "life", "-", "threatening", "toxicity", "after", "treatment", "with", "a", "topical", "drug", "."], "event_mentions": [{"id": "10473079_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "results in", "start": 24, "end": 26}, "arguments": [{"entity_id": "10473079_1_Ent0", "role": "Subject", "text": "this metabolic defect", "start": 6, "end": 9}, {"entity_id": "10473079_1_Ent1", "role": "Subject_Disorder", "text": "metabolic defect", "start": 7, "end": 9}, {"entity_id": "10473079_1_Ent5", "role": "Treatment_Route", "text": "topical", "start": 11, "end": 12}, {"entity_id": "10473079_1_Ent3", "role": "Treatment", "text": "topical 5 - FU ( a drug demonstrating a narrow therapeutic index )", "start": 11, "end": 24}, {"entity_id": "10473079_1_Ent4", "role": "Treatment_Drug", "text": "5 - FU", "start": 12, "end": 15}, {"entity_id": "10473079_1_Ent2", "role": "Effect", "text": "unusual presentation of life - threatening toxicity", "start": 27, "end": 34}]}], "entity_mentions": [{"id": "10473079_1_Ent0", "text": "this metabolic defect", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "10473079_1_Ent1", "text": "metabolic defect", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "10473079_1_Ent5", "text": "topical", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10473079_1_Ent3", "text": "topical 5 - FU ( a drug demonstrating a narrow therapeutic index )", "entity_type": "Entity", "start": 11, "end": 24}, {"id": "10473079_1_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10473079_1_Ent2", "text": "unusual presentation of life - threatening toxicity", "entity_type": "Entity", "start": 27, "end": 34}], "lang": "en"}
{"doc_id": "10475726_2", "wnd_id": "10475726_2_1", "text": "The association of venlafaxine treatment with ischaemic events could be explained by its unique pharmacological and haemodynamic properties .", "tokens": ["The", "association", "of", "venlafaxine", "treatment", "with", "ischaemic", "events", "could", "be", "explained", "by", "its", "unique", "pharmacological", "and", "haemodynamic", "properties", "."], "event_mentions": [{"id": "10475726_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 1, "end": 2}, "arguments": [{"entity_id": "10475726_2_Ent2", "role": "Treatment_Drug", "text": "venlafaxine", "start": 3, "end": 4}, {"entity_id": "10475726_2_Ent1", "role": "Treatment", "text": "venlafaxine treatment", "start": 3, "end": 5}, {"entity_id": "10475726_2_Ent0", "role": "Effect", "text": "ischaemic events", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "10475726_2_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10475726_2_Ent1", "text": "venlafaxine treatment", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10475726_2_Ent0", "text": "ischaemic events", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "10510017_3", "wnd_id": "10510017_3_1", "text": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin - induced thrombocytopenia , especially in children .", "tokens": ["There", "remains", "a", "paucity", "of", "information", "pertaining", "to", "alternative", "anticoagulation", "strategies", "for", "use", "during", "cardiopulmonary", "bypass", "concomitant", "with", "heparin", "-", "induced", "thrombocytopenia", ",", "especially", "in", "children", "."], "event_mentions": [{"id": "10510017_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 20, "end": 21}, "arguments": [{"entity_id": "10510017_3_Ent3", "role": "Treatment", "text": "heparin", "start": 18, "end": 19}, {"entity_id": "10510017_3_Ent4", "role": "Treatment_Drug", "text": "heparin", "start": 18, "end": 19}, {"entity_id": "10510017_3_Ent2", "role": "Effect", "text": "thrombocytopenia", "start": 21, "end": 22}, {"entity_id": "10510017_3_Ent0", "role": "Subject", "text": "children", "start": 25, "end": 26}, {"entity_id": "10510017_3_Ent1", "role": "Subject_Age", "text": "children", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "10510017_3_Ent3", "text": "heparin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10510017_3_Ent4", "text": "heparin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10510017_3_Ent2", "text": "thrombocytopenia", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10510017_3_Ent0", "text": "children", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "10510017_3_Ent1", "text": "children", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "10516999_2", "wnd_id": "10516999_2_1", "text": "We report a case of acute hyperphosphatemia secondary to rectal administration of sodium phosphate and sodium biphosphate ( Fleet enema ) .", "tokens": ["We", "report", "a", "case", "of", "acute", "hyperphosphatemia", "secondary", "to", "rectal", "administration", "of", "sodium", "phosphate", "and", "sodium", "biphosphate", "(", "Fleet", "enema", ")", "."], "event_mentions": [{"id": "10516999_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 7, "end": 8}, "arguments": [{"entity_id": "10516999_2_Ent0", "role": "Effect", "text": "acute hyperphosphatemia", "start": 5, "end": 7}, {"entity_id": "10516999_2_Ent2", "role": "Treatment_Route", "text": "rectal", "start": 9, "end": 10}, {"entity_id": "10516999_2_Ent1", "role": "Treatment", "text": "rectal administration of sodium phosphate and sodium biphosphate ( Fleet enema )", "start": 9, "end": 21}, {"entity_id": "10516999_2_Ent3", "role": "Treatment_Drug", "text": "sodium phosphate", "start": 12, "end": 14}, {"entity_id": "10516999_2_Ent5", "role": "Combination_Drug", "text": "sodium phosphate", "start": 12, "end": 14}, {"entity_id": "10516999_2_Ent4", "role": "Treatment_Drug", "text": "sodium biphosphate", "start": 15, "end": 17}, {"entity_id": "10516999_2_Ent6", "role": "Combination_Drug", "text": "sodium biphosphate", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "10516999_2_Ent0", "text": "acute hyperphosphatemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10516999_2_Ent2", "text": "rectal", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10516999_2_Ent1", "text": "rectal administration of sodium phosphate and sodium biphosphate ( Fleet enema )", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "10516999_2_Ent3", "text": "sodium phosphate", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "10516999_2_Ent5", "text": "sodium phosphate", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "10516999_2_Ent4", "text": "sodium biphosphate", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "10516999_2_Ent6", "text": "sodium biphosphate", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "10546851_1", "wnd_id": "10546851_1_1", "text": "Interaction of sildenafil and indinavir when co - administered to HIV - positive patients .", "tokens": ["Interaction", "of", "sildenafil", "and", "indinavir", "when", "co", "-", "administered", "to", "HIV", "-", "positive", "patients", "."], "event_mentions": [{"id": "10546851_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "co - administered", "start": 6, "end": 9}, "arguments": [{"entity_id": "10546851_1_Ent1", "role": "Treatment", "text": "Interaction of sildenafil and indinavir", "start": 0, "end": 5}, {"entity_id": "10546851_1_Ent3", "role": "Treatment_Drug", "text": "sildenafil", "start": 2, "end": 3}, {"entity_id": "10546851_1_Ent5", "role": "Combination_Drug", "text": "sildenafil", "start": 2, "end": 3}, {"entity_id": "10546851_1_Ent4", "role": "Treatment_Drug", "text": "indinavir", "start": 4, "end": 5}, {"entity_id": "10546851_1_Ent6", "role": "Combination_Drug", "text": "indinavir", "start": 4, "end": 5}, {"entity_id": "10546851_1_Ent2", "role": "Treatment_Disorder", "text": "HIV - positive", "start": 10, "end": 13}, {"entity_id": "10546851_1_Ent0", "role": "Subject", "text": "HIV - positive patients", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "10546851_1_Ent1", "text": "Interaction of sildenafil and indinavir", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "10546851_1_Ent3", "text": "sildenafil", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10546851_1_Ent5", "text": "sildenafil", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10546851_1_Ent4", "text": "indinavir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10546851_1_Ent6", "text": "indinavir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10546851_1_Ent2", "text": "HIV - positive", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "10546851_1_Ent0", "text": "HIV - positive patients", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "10555917_3", "wnd_id": "10555917_3_1", "text": "In vitro inhibition of hematopoiesis in a patient with systemic sclerosis treated with D - penicillamine .", "tokens": ["In", "vitro", "inhibition", "of", "hematopoiesis", "in", "a", "patient", "with", "systemic", "sclerosis", "treated", "with", "D", "-", "penicillamine", "."], "event_mentions": [{"id": "10555917_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inhibition", "start": 2, "end": 3}, "arguments": [{"entity_id": "10555917_3_Ent1", "role": "Effect", "text": "vitro inhibition of hematopoiesis", "start": 1, "end": 5}, {"entity_id": "10555917_3_Ent0", "role": "Subject", "text": "a patient with systemic sclerosis", "start": 6, "end": 11}, {"entity_id": "10555917_3_Ent3", "role": "Treatment_Disorder", "text": "systemic sclerosis", "start": 9, "end": 11}, {"entity_id": "10555917_3_Ent2", "role": "Treatment", "text": "D - penicillamine", "start": 13, "end": 16}, {"entity_id": "10555917_3_Ent4", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "10555917_3_Ent1", "text": "vitro inhibition of hematopoiesis", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "10555917_3_Ent0", "text": "a patient with systemic sclerosis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "10555917_3_Ent3", "text": "systemic sclerosis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10555917_3_Ent2", "text": "D - penicillamine", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "10555917_3_Ent4", "text": "D - penicillamine", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "10566542_2", "wnd_id": "10566542_2_1", "text": "This case report describes a patient who was previously prescribed alendronate ( Fosamax ) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho - Soda .", "tokens": ["This", "case", "report", "describes", "a", "patient", "who", "was", "previously", "prescribed", "alendronate", "(", "Fosamax", ")", "and", "presented", "with", "postoperative", "hypophosphatemia", "and", "hypocalcemic", "tetany", "after", "bowel", "preparation", "with", "Fleet", "Phospho", "-", "Soda", "."], "event_mentions": [{"id": "10566542_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 15, "end": 16}, "arguments": [{"entity_id": "10566542_2_Ent0", "role": "Subject", "text": "patient", "start": 5, "end": 6}, {"entity_id": "10566542_2_Ent4", "role": "Treatment_Drug", "text": "alendronate", "start": 10, "end": 11}, {"entity_id": "10566542_2_Ent6", "role": "Combination_Drug", "text": "alendronate", "start": 10, "end": 11}, {"entity_id": "10566542_2_Ent2", "role": "Treatment", "text": "alendronate ( Fosamax )", "start": 10, "end": 14}, {"entity_id": "10566542_2_Ent1", "role": "Effect", "text": "postoperative hypophosphatemia and hypocalcemic tetany", "start": 17, "end": 22}, {"entity_id": "10566542_2_Ent3", "role": "Treatment", "text": "after bowel preparation with Fleet Phospho - Soda", "start": 22, "end": 30}, {"entity_id": "10566542_2_Ent5", "role": "Treatment_Drug", "text": "Fleet Phospho - Soda", "start": 26, "end": 30}, {"entity_id": "10566542_2_Ent7", "role": "Combination_Drug", "text": "Fleet Phospho - Soda", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "10566542_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10566542_2_Ent4", "text": "alendronate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10566542_2_Ent6", "text": "alendronate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10566542_2_Ent2", "text": "alendronate ( Fosamax )", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "10566542_2_Ent1", "text": "postoperative hypophosphatemia and hypocalcemic tetany", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "10566542_2_Ent3", "text": "after bowel preparation with Fleet Phospho - Soda", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "10566542_2_Ent5", "text": "Fleet Phospho - Soda", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "10566542_2_Ent7", "text": "Fleet Phospho - Soda", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "10573314_12", "wnd_id": "10573314_12_1", "text": "The temporal association of the course of tolterodine with an elevated INR , the return to the previous warfarin dose - INR response relationship after tolterodine discontinuation , and the absence of other causes for the elevated INR were factors found in both patients .", "tokens": ["The", "temporal", "association", "of", "the", "course", "of", "tolterodine", "with", "an", "elevated", "INR", ",", "the", "return", "to", "the", "previous", "warfarin", "dose", "-", "INR", "response", "relationship", "after", "tolterodine", "discontinuation", ",", "and", "the", "absence", "of", "other", "causes", "for", "the", "elevated", "INR", "were", "factors", "found", "in", "both", "patients", "."], "event_mentions": [{"id": "10573314_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "course", "start": 5, "end": 6}, "arguments": [{"entity_id": "10573314_12_Ent3", "role": "Treatment", "text": "tolterodine", "start": 7, "end": 8}, {"entity_id": "10573314_12_Ent4", "role": "Treatment_Drug", "text": "tolterodine", "start": 7, "end": 8}, {"entity_id": "10573314_12_Ent2", "role": "Effect", "text": "elevated INR", "start": 10, "end": 12}, {"entity_id": "10573314_12_Ent1", "role": "Subject_Population", "text": "both", "start": 42, "end": 43}, {"entity_id": "10573314_12_Ent0", "role": "Subject", "text": "both patients", "start": 42, "end": 44}]}, {"id": "10573314_12_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "return", "start": 14, "end": 15}, "arguments": [{"entity_id": "10573314_12_Ent9", "role": "Treatment_Disorder", "text": "elevated INR", "start": 10, "end": 12}, {"entity_id": "10573314_12_Ent7", "role": "Effect", "text": "return to the previous warfarin dose - INR response relationship", "start": 14, "end": 24}, {"entity_id": "10573314_12_Ent10", "role": "Treatment_Drug", "text": "tolterodine", "start": 25, "end": 26}, {"entity_id": "10573314_12_Ent8", "role": "Treatment", "text": "tolterodine discontinuation", "start": 25, "end": 27}, {"entity_id": "10573314_12_Ent6", "role": "Subject_Population", "text": "both", "start": 42, "end": 43}, {"entity_id": "10573314_12_Ent5", "role": "Subject", "text": "both patients", "start": 42, "end": 44}]}], "entity_mentions": [{"id": "10573314_12_Ent3", "text": "tolterodine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10573314_12_Ent4", "text": "tolterodine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10573314_12_Ent2", "text": "elevated INR", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "10573314_12_Ent9", "text": "elevated INR", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "10573314_12_Ent7", "text": "return to the previous warfarin dose - INR response relationship", "entity_type": "Entity", "start": 14, "end": 24}, {"id": "10573314_12_Ent10", "text": "tolterodine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "10573314_12_Ent8", "text": "tolterodine discontinuation", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "10573314_12_Ent1", "text": "both", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "10573314_12_Ent6", "text": "both", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "10573314_12_Ent0", "text": "both patients", "entity_type": "Entity", "start": 42, "end": 44}, {"id": "10573314_12_Ent5", "text": "both patients", "entity_type": "Entity", "start": 42, "end": 44}], "lang": "en"}
{"doc_id": "10573314_7", "wnd_id": "10573314_7_1", "text": "In each patient , the initiation of tolterodine was associated with a significant increase in the patient 's INR measured 10 - 14 days later .", "tokens": ["In", "each", "patient", ",", "the", "initiation", "of", "tolterodine", "was", "associated", "with", "a", "significant", "increase", "in", "the", "patient", "'s", "INR", "measured", "10", "-", "14", "days", "later", "."], "event_mentions": [{"id": "10573314_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 9, "end": 11}, "arguments": [{"entity_id": "10573314_7_Ent0", "role": "Subject", "text": "each patient", "start": 1, "end": 3}, {"entity_id": "10573314_7_Ent2", "role": "Treatment", "text": "the initiation of tolterodine", "start": 4, "end": 8}, {"entity_id": "10573314_7_Ent3", "role": "Treatment_Drug", "text": "tolterodine", "start": 7, "end": 8}, {"entity_id": "10573314_7_Ent1", "role": "Effect", "text": "significant increase in the patient 's INR", "start": 12, "end": 19}, {"entity_id": "10573314_7_Ent4", "role": "Treatment_Time_elapsed", "text": "10 - 14 days later .", "start": 20, "end": 26}]}], "entity_mentions": [{"id": "10573314_7_Ent0", "text": "each patient", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10573314_7_Ent2", "text": "the initiation of tolterodine", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "10573314_7_Ent3", "text": "tolterodine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10573314_7_Ent1", "text": "significant increase in the patient 's INR", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "10573314_7_Ent4", "text": "10 - 14 days later .", "entity_type": "Entity", "start": 20, "end": 26}], "lang": "en"}
{"doc_id": "10589077_6", "wnd_id": "10589077_6_1", "text": "We describe the clinical response , as determined by increases in total Hb and decreased transfusion needs , in five patients with thalassemia intermedia treated with HU alone or in combination with SPB .", "tokens": ["We", "describe", "the", "clinical", "response", ",", "as", "determined", "by", "increases", "in", "total", "Hb", "and", "decreased", "transfusion", "needs", ",", "in", "five", "patients", "with", "thalassemia", "intermedia", "treated", "with", "HU", "alone", "or", "in", "combination", "with", "SPB", "."], "event_mentions": [{"id": "10589077_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 24, "end": 25}, "arguments": [{"entity_id": "10589077_6_Ent2", "role": "Effect", "text": "increases in total Hb and decreased transfusion needs", "start": 9, "end": 17}, {"entity_id": "10589077_6_Ent0", "role": "Subject", "text": "in five patients with thalassemia intermedia", "start": 18, "end": 24}, {"entity_id": "10589077_6_Ent1", "role": "Subject_Population", "text": "five", "start": 19, "end": 20}, {"entity_id": "10589077_6_Ent6", "role": "Treatment_Disorder", "text": "thalassemia intermedia", "start": 22, "end": 24}, {"entity_id": "10589077_6_Ent4", "role": "Treatment_Drug", "text": "HU", "start": 26, "end": 27}, {"entity_id": "10589077_6_Ent7", "role": "Combination_Drug", "text": "HU", "start": 26, "end": 27}, {"entity_id": "10589077_6_Ent3", "role": "Treatment", "text": "HU alone or in combination with SPB", "start": 26, "end": 33}, {"entity_id": "10589077_6_Ent5", "role": "Treatment_Drug", "text": "SPB", "start": 32, "end": 33}, {"entity_id": "10589077_6_Ent8", "role": "Combination_Drug", "text": "SPB", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "10589077_6_Ent2", "text": "increases in total Hb and decreased transfusion needs", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "10589077_6_Ent0", "text": "in five patients with thalassemia intermedia", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "10589077_6_Ent1", "text": "five", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "10589077_6_Ent6", "text": "thalassemia intermedia", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "10589077_6_Ent4", "text": "HU", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "10589077_6_Ent7", "text": "HU", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "10589077_6_Ent3", "text": "HU alone or in combination with SPB", "entity_type": "Entity", "start": 26, "end": 33}, {"id": "10589077_6_Ent5", "text": "SPB", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "10589077_6_Ent8", "text": "SPB", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "10592946_2", "wnd_id": "10592946_2_1", "text": "After abstinence from oolong tea his delirium resolved .", "tokens": ["After", "abstinence", "from", "oolong", "tea", "his", "delirium", "resolved", "."], "event_mentions": [{"id": "10592946_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "10592946_2_Ent0", "role": "Treatment", "text": "oolong tea", "start": 3, "end": 5}, {"entity_id": "10592946_2_Ent1", "role": "Treatment_Disorder", "text": "delirium", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "10592946_2_Ent0", "text": "oolong tea", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10592946_2_Ent1", "text": "delirium", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "10592946_5", "wnd_id": "10592946_5_1", "text": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine - containing beverages .", "tokens": ["The", "possibility", "of", "severe", "rhabdomyolysis", "should", "be", "considered", "in", "a", "patient", "with", "water", "intoxication", "due", "to", "massive", "ingestion", "of", "caffeine", "-", "containing", "beverages", "."], "event_mentions": [{"id": "10592946_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 14, "end": 16}, "arguments": [{"entity_id": "10592946_5_Ent1", "role": "Effect", "text": "severe rhabdomyolysis", "start": 3, "end": 5}, {"entity_id": "10592946_5_Ent0", "role": "Subject", "text": "a patient", "start": 9, "end": 11}, {"entity_id": "10592946_5_Ent2", "role": "Effect", "text": "water intoxication", "start": 12, "end": 14}, {"entity_id": "10592946_5_Ent6", "role": "Treatment_Dosage", "text": "massive", "start": 16, "end": 17}, {"entity_id": "10592946_5_Ent3", "role": "Treatment", "text": "massive ingestion of caffeine - containing beverages", "start": 16, "end": 23}, {"entity_id": "10592946_5_Ent5", "role": "Treatment_Route", "text": "ingestion", "start": 17, "end": 18}, {"entity_id": "10592946_5_Ent4", "role": "Treatment_Drug", "text": "caffeine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "10592946_5_Ent1", "text": "severe rhabdomyolysis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10592946_5_Ent0", "text": "a patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10592946_5_Ent2", "text": "water intoxication", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "10592946_5_Ent6", "text": "massive", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10592946_5_Ent3", "text": "massive ingestion of caffeine - containing beverages", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "10592946_5_Ent5", "text": "ingestion", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10592946_5_Ent4", "text": "caffeine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "10599932_2", "wnd_id": "10599932_2_1", "text": "A pharmacokinetic interaction between the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant , clomipramine , was noted in a patient treated for major depression and obsessive - compulsive disorder .", "tokens": ["A", "pharmacokinetic", "interaction", "between", "the", "selective", "serotonin", "reuptake", "inhibitor", "citalopram", "and", "a", "tricyclic", "antidepressant", ",", "clomipramine", ",", "was", "noted", "in", "a", "patient", "treated", "for", "major", "depression", "and", "obsessive", "-", "compulsive", "disorder", "."], "event_mentions": [{"id": "10599932_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interaction", "start": 2, "end": 3}, "arguments": [{"entity_id": "10599932_2_Ent1", "role": "Effect", "text": "A pharmacokinetic interaction", "start": 0, "end": 3}, {"entity_id": "10599932_2_Ent2", "role": "Treatment", "text": "the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant , clomipramine", "start": 4, "end": 16}, {"entity_id": "10599932_2_Ent3", "role": "Treatment_Drug", "text": "citalopram", "start": 9, "end": 10}, {"entity_id": "10599932_2_Ent7", "role": "Combination_Drug", "text": "citalopram", "start": 9, "end": 10}, {"entity_id": "10599932_2_Ent4", "role": "Treatment_Drug", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "10599932_2_Ent8", "role": "Combination_Drug", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "10599932_2_Ent0", "role": "Subject", "text": "a patient treated for major depression and obsessive - compulsive disorder", "start": 20, "end": 31}, {"entity_id": "10599932_2_Ent5", "role": "Treatment_Disorder", "text": "depression", "start": 25, "end": 26}, {"entity_id": "10599932_2_Ent6", "role": "Treatment_Disorder", "text": "obsessive - compulsive disorder", "start": 27, "end": 31}]}], "entity_mentions": [{"id": "10599932_2_Ent1", "text": "A pharmacokinetic interaction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10599932_2_Ent2", "text": "the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant , clomipramine", "entity_type": "Entity", "start": 4, "end": 16}, {"id": "10599932_2_Ent3", "text": "citalopram", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10599932_2_Ent7", "text": "citalopram", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10599932_2_Ent4", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10599932_2_Ent8", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10599932_2_Ent0", "text": "a patient treated for major depression and obsessive - compulsive disorder", "entity_type": "Entity", "start": 20, "end": 31}, {"id": "10599932_2_Ent5", "text": "depression", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "10599932_2_Ent6", "text": "obsessive - compulsive disorder", "entity_type": "Entity", "start": 27, "end": 31}], "lang": "en"}
{"doc_id": "10646879_1", "wnd_id": "10646879_1_1", "text": "Methylene blue in the treatment and prevention of ifosfamide - induced encephalopathy : report of 12 cases and a review of the literature .", "tokens": ["Methylene", "blue", "in", "the", "treatment", "and", "prevention", "of", "ifosfamide", "-", "induced", "encephalopathy", ":", "report", "of", "12", "cases", "and", "a", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "10646879_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "10646879_1_Ent1", "role": "Treatment", "text": "ifosfamide", "start": 8, "end": 9}, {"entity_id": "10646879_1_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 8, "end": 9}, {"entity_id": "10646879_1_Ent0", "role": "Effect", "text": "encephalopathy", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "10646879_1_Ent1", "text": "ifosfamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10646879_1_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10646879_1_Ent0", "text": "encephalopathy", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "10646879_2", "wnd_id": "10646879_2_1", "text": "Ten to 15 % of patients treated with ifosfamide develop an encephalopathy .", "tokens": ["Ten", "to", "15", "%", "of", "patients", "treated", "with", "ifosfamide", "develop", "an", "encephalopathy", "."], "event_mentions": [{"id": "10646879_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 9, "end": 10}, "arguments": [{"entity_id": "10646879_2_Ent1", "role": "Subject_Population", "text": "Ten to 15 %", "start": 0, "end": 4}, {"entity_id": "10646879_2_Ent0", "role": "Subject", "text": "Ten to 15 % of patients", "start": 0, "end": 6}, {"entity_id": "10646879_2_Ent3", "role": "Treatment", "text": "ifosfamide", "start": 8, "end": 9}, {"entity_id": "10646879_2_Ent4", "role": "Treatment_Drug", "text": "ifosfamide", "start": 8, "end": 9}, {"entity_id": "10646879_2_Ent2", "role": "Effect", "text": "encephalopathy .", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "10646879_2_Ent1", "text": "Ten to 15 %", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10646879_2_Ent0", "text": "Ten to 15 % of patients", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "10646879_2_Ent3", "text": "ifosfamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10646879_2_Ent4", "text": "ifosfamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10646879_2_Ent2", "text": "encephalopathy .", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "10679548_2", "wnd_id": "10679548_2_1", "text": "Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin .", "tokens": ["Bronchiolitis", "obliterans", "organising", "pneumonia", "associated", "with", "the", "use", "of", "nitrofurantoin", "."], "event_mentions": [{"id": "10679548_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 4, "end": 6}, "arguments": [{"entity_id": "10679548_2_Ent0", "role": "Effect", "text": "Bronchiolitis obliterans organising pneumonia", "start": 0, "end": 4}, {"entity_id": "10679548_2_Ent1", "role": "Treatment", "text": "use of nitrofurantoin", "start": 7, "end": 10}, {"entity_id": "10679548_2_Ent2", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "10679548_2_Ent0", "text": "Bronchiolitis obliterans organising pneumonia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10679548_2_Ent1", "text": "use of nitrofurantoin", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "10679548_2_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "10679548_6", "wnd_id": "10679548_6_1", "text": "The two middle aged women presented with respiratory symptoms after prolonged treatment with nitrofurantoin .", "tokens": ["The", "two", "middle", "aged", "women", "presented", "with", "respiratory", "symptoms", "after", "prolonged", "treatment", "with", "nitrofurantoin", "."], "event_mentions": [{"id": "10679548_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 5, "end": 6}, "arguments": [{"entity_id": "10679548_6_Ent0", "role": "Subject", "text": "The two middle aged women", "start": 0, "end": 5}, {"entity_id": "10679548_6_Ent1", "role": "Subject_Population", "text": "two", "start": 1, "end": 2}, {"entity_id": "10679548_6_Ent2", "role": "Subject_Age", "text": "middle aged", "start": 2, "end": 4}, {"entity_id": "10679548_6_Ent3", "role": "Subject_Gender", "text": "women", "start": 4, "end": 5}, {"entity_id": "10679548_6_Ent4", "role": "Effect", "text": "respiratory symptoms", "start": 7, "end": 9}, {"entity_id": "10679548_6_Ent6", "role": "Treatment_Freq", "text": "prolonged treatment", "start": 10, "end": 12}, {"entity_id": "10679548_6_Ent5", "role": "Treatment", "text": "prolonged treatment with nitrofurantoin", "start": 10, "end": 14}, {"entity_id": "10679548_6_Ent7", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "10679548_6_Ent0", "text": "The two middle aged women", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "10679548_6_Ent1", "text": "two", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10679548_6_Ent2", "text": "middle aged", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10679548_6_Ent3", "text": "women", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10679548_6_Ent4", "text": "respiratory symptoms", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "10679548_6_Ent6", "text": "prolonged treatment", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "10679548_6_Ent5", "text": "prolonged treatment with nitrofurantoin", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "10679548_6_Ent7", "text": "nitrofurantoin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "10682234_2", "wnd_id": "10682234_2_1", "text": "A 28 year - old man with chronic hepatitis B was administered interferon - alpha ( 5 x 10(6 ) IU ) intramuscularly once a day for 28 days .", "tokens": ["A", "28", "year", "-", "old", "man", "with", "chronic", "hepatitis", "B", "was", "administered", "interferon", "-", "alpha", "(", "5", "x", "10(6", ")", "IU", ")", "intramuscularly", "once", "a", "day", "for", "28", "days", "."], "event_mentions": [{"id": "10682234_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "administered", "start": 11, "end": 12}, "arguments": [{"entity_id": "10682234_2_Ent0", "role": "Subject", "text": "A 28 year - old man with chronic hepatitis B", "start": 0, "end": 10}, {"entity_id": "10682234_2_Ent1", "role": "Subject_Age", "text": "28 year - old", "start": 1, "end": 5}, {"entity_id": "10682234_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 5, "end": 6}, {"entity_id": "10682234_2_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis B", "start": 7, "end": 10}, {"entity_id": "10682234_2_Ent5", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 12, "end": 15}, {"entity_id": "10682234_2_Ent3", "role": "Treatment", "text": "interferon - alpha ( 5 x 10(6 ) IU ) intramuscularly once a day for 28 days", "start": 12, "end": 29}, {"entity_id": "10682234_2_Ent6", "role": "Treatment_Route", "text": "intramuscularly", "start": 22, "end": 23}, {"entity_id": "10682234_2_Ent7", "role": "Treatment_Freq", "text": "once a day", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "10682234_2_Ent0", "text": "A 28 year - old man with chronic hepatitis B", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "10682234_2_Ent1", "text": "28 year - old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "10682234_2_Ent2", "text": "man", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10682234_2_Ent4", "text": "chronic hepatitis B", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "10682234_2_Ent5", "text": "interferon - alpha", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10682234_2_Ent3", "text": "interferon - alpha ( 5 x 10(6 ) IU ) intramuscularly once a day for 28 days", "entity_type": "Entity", "start": 12, "end": 29}, {"id": "10682234_2_Ent6", "text": "intramuscularly", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10682234_2_Ent7", "text": "once a day", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "10682234_9", "wnd_id": "10682234_9_1", "text": "The present report illustrates a rare case of refractory akathisia after interferon - alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon - alpha .", "tokens": ["The", "present", "report", "illustrates", "a", "rare", "case", "of", "refractory", "akathisia", "after", "interferon", "-", "alpha", "treatment", "and", "also", "that", "levodopa", "treatment", "would", "be", "theoretically", "and", "practically", "useful", "in", "reducing", "the", "neurotoxicity", "associated", "with", "interferon", "-", "alpha", "."], "event_mentions": [{"id": "10682234_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "10682234_9_Ent0", "role": "Effect", "text": "refractory akathisia", "start": 8, "end": 10}, {"entity_id": "10682234_9_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 11, "end": 14}, {"entity_id": "10682234_9_Ent1", "role": "Treatment", "text": "interferon - alpha treatment", "start": 11, "end": 15}]}, {"id": "10682234_9_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "useful", "start": 25, "end": 26}, "arguments": [{"entity_id": "10682234_9_Ent4", "role": "Treatment_Drug", "text": "levodopa", "start": 18, "end": 19}, {"entity_id": "10682234_9_Ent3", "role": "Treatment", "text": "levodopa treatment", "start": 18, "end": 20}, {"entity_id": "10682234_9_Ent5", "role": "Treatment_Disorder", "text": "neurotoxicity associated with interferon - alpha", "start": 29, "end": 35}]}, {"id": "10682234_9_Evt2", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 30, "end": 31}, "arguments": [{"entity_id": "10682234_9_Ent6", "role": "Effect", "text": "neurotoxicity", "start": 29, "end": 30}, {"entity_id": "10682234_9_Ent7", "role": "Treatment", "text": "interferon - alpha", "start": 32, "end": 35}, {"entity_id": "10682234_9_Ent8", "role": "Treatment_Drug", "text": "interferon - alpha .", "start": 32, "end": 36}]}], "entity_mentions": [{"id": "10682234_9_Ent0", "text": "refractory akathisia", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "10682234_9_Ent2", "text": "interferon - alpha", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10682234_9_Ent1", "text": "interferon - alpha treatment", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "10682234_9_Ent4", "text": "levodopa", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10682234_9_Ent3", "text": "levodopa treatment", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "10682234_9_Ent6", "text": "neurotoxicity", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "10682234_9_Ent5", "text": "neurotoxicity associated with interferon - alpha", "entity_type": "Entity", "start": 29, "end": 35}, {"id": "10682234_9_Ent7", "text": "interferon - alpha", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "10682234_9_Ent8", "text": "interferon - alpha .", "entity_type": "Entity", "start": 32, "end": 36}], "lang": "en"}
{"doc_id": "10698143_1", "wnd_id": "10698143_1_1", "text": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone .", "tokens": ["Central", "nervous", "system", "manifestations", "of", "an", "ibuprofen", "overdose", "reversed", "by", "naloxone", "."], "event_mentions": [{"id": "10698143_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "by", "start": 9, "end": 10}, "arguments": [{"entity_id": "10698143_1_Ent1", "role": "Treatment_Disorder", "text": "Central nervous system manifestations", "start": 0, "end": 4}, {"entity_id": "10698143_1_Ent2", "role": "Treatment_Drug", "text": "ibuprofen", "start": 6, "end": 7}, {"entity_id": "10698143_1_Ent0", "role": "Treatment", "text": "naloxone", "start": 10, "end": 11}, {"entity_id": "10698143_1_Ent3", "role": "Treatment_Drug", "text": "naloxone", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10698143_1_Ent1", "text": "Central nervous system manifestations", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10698143_1_Ent2", "text": "ibuprofen", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10698143_1_Ent0", "text": "naloxone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10698143_1_Ent3", "text": "naloxone", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10698143_2", "wnd_id": "10698143_2_1", "text": "Ibuprofen overdose is usually characterized by GI upset , dizziness , and mild sedation .", "tokens": ["Ibuprofen", "overdose", "is", "usually", "characterized", "by", "GI", "upset", ",", "dizziness", ",", "and", "mild", "sedation", "."], "event_mentions": [{"id": "10698143_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "characterized", "start": 4, "end": 5}, "arguments": [{"entity_id": "10698143_2_Ent2", "role": "Treatment_Drug", "text": "Ibuprofen", "start": 0, "end": 1}, {"entity_id": "10698143_2_Ent1", "role": "Treatment", "text": "Ibuprofen overdose", "start": 0, "end": 2}, {"entity_id": "10698143_2_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 1, "end": 2}, {"entity_id": "10698143_2_Ent0", "role": "Effect", "text": "GI upset , dizziness , and mild sedation", "start": 6, "end": 14}]}], "entity_mentions": [{"id": "10698143_2_Ent2", "text": "Ibuprofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10698143_2_Ent1", "text": "Ibuprofen overdose", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10698143_2_Ent3", "text": "overdose", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10698143_2_Ent0", "text": "GI upset , dizziness , and mild sedation", "entity_type": "Entity", "start": 6, "end": 14}], "lang": "en"}
{"doc_id": "10707759_1", "wnd_id": "10707759_1_1", "text": "Flecainide - associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome .", "tokens": ["Flecainide", "-", "associated", "pneumonitis", "with", "acute", "respiratory", "failure", "in", "a", "patient", "with", "the", "LEOPARD", "syndrome", "."], "event_mentions": [{"id": "10707759_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "10707759_1_Ent2", "role": "Treatment", "text": "Flecainide", "start": 0, "end": 1}, {"entity_id": "10707759_1_Ent3", "role": "Treatment_Drug", "text": "Flecainide", "start": 0, "end": 1}, {"entity_id": "10707759_1_Ent1", "role": "Effect", "text": "pneumonitis with acute respiratory failure", "start": 3, "end": 8}, {"entity_id": "10707759_1_Ent0", "role": "Subject", "text": "a patient with the LEOPARD syndrome", "start": 9, "end": 15}, {"entity_id": "10707759_1_Ent4", "role": "Treatment_Disorder", "text": "LEOPARD syndrome .", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "10707759_1_Ent2", "text": "Flecainide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10707759_1_Ent3", "text": "Flecainide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10707759_1_Ent1", "text": "pneumonitis with acute respiratory failure", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "10707759_1_Ent0", "text": "a patient with the LEOPARD syndrome", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "10707759_1_Ent4", "text": "LEOPARD syndrome .", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "10707759_3", "wnd_id": "10707759_3_1", "text": "We describe a case of interstitial hypoxaemiant pneumonitis probably related to flecainide in a patient with the LEOPARD syndrome , a rare congenital disorder .", "tokens": ["We", "describe", "a", "case", "of", "interstitial", "hypoxaemiant", "pneumonitis", "probably", "related", "to", "flecainide", "in", "a", "patient", "with", "the", "LEOPARD", "syndrome", ",", "a", "rare", "congenital", "disorder", "."], "event_mentions": [{"id": "10707759_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 9, "end": 10}, "arguments": [{"entity_id": "10707759_3_Ent1", "role": "Effect", "text": "interstitial hypoxaemiant pneumonitis", "start": 5, "end": 8}, {"entity_id": "10707759_3_Ent2", "role": "Treatment", "text": "flecainide", "start": 11, "end": 12}, {"entity_id": "10707759_3_Ent3", "role": "Treatment_Drug", "text": "flecainide", "start": 11, "end": 12}, {"entity_id": "10707759_3_Ent0", "role": "Subject", "text": "a patient with the LEOPARD syndrome", "start": 13, "end": 19}, {"entity_id": "10707759_3_Ent4", "role": "Treatment_Disorder", "text": "LEOPARD syndrome", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "10707759_3_Ent1", "text": "interstitial hypoxaemiant pneumonitis", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "10707759_3_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10707759_3_Ent3", "text": "flecainide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10707759_3_Ent0", "text": "a patient with the LEOPARD syndrome", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "10707759_3_Ent4", "text": "LEOPARD syndrome", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "10745478_1", "wnd_id": "10745478_1_1", "text": "This case report illustrates the use of continuous high - dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with cocaine - induced refractory coronary vasospasm .", "tokens": ["This", "case", "report", "illustrates", "the", "use", "of", "continuous", "high", "-", "dose", "intracoronary", "nitroglycerin", "infusion", "through", "a", "6", "French", "coronary", "guiding", "catheter", "in", "the", "treatment", "of", "a", "patient", "with", "cocaine", "-", "induced", "refractory", "coronary", "vasospasm", "."], "event_mentions": [{"id": "10745478_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 23, "end": 24}, "arguments": [{"entity_id": "10745478_1_Ent3", "role": "Treatment", "text": "use of continuous high - dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter", "start": 5, "end": 21}, {"entity_id": "10745478_1_Ent7", "role": "Treatment_Dosage", "text": "high - dose", "start": 8, "end": 11}, {"entity_id": "10745478_1_Ent5", "role": "Treatment_Drug", "text": "intracoronary nitroglycerin", "start": 11, "end": 13}, {"entity_id": "10745478_1_Ent6", "role": "Treatment_Route", "text": "infusion through a 6 French coronary guiding catheter", "start": 13, "end": 21}, {"entity_id": "10745478_1_Ent4", "role": "Treatment_Disorder", "text": "cocaine - induced refractory coronary vasospasm", "start": 28, "end": 34}]}, {"id": "10745478_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 30, "end": 31}, "arguments": [{"entity_id": "10745478_1_Ent1", "role": "Treatment", "text": "cocaine", "start": 28, "end": 29}, {"entity_id": "10745478_1_Ent2", "role": "Treatment_Drug", "text": "cocaine", "start": 28, "end": 29}, {"entity_id": "10745478_1_Ent0", "role": "Effect", "text": "refractory coronary vasospasm", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "10745478_1_Ent3", "text": "use of continuous high - dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter", "entity_type": "Entity", "start": 5, "end": 21}, {"id": "10745478_1_Ent7", "text": "high - dose", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "10745478_1_Ent5", "text": "intracoronary nitroglycerin", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10745478_1_Ent6", "text": "infusion through a 6 French coronary guiding catheter", "entity_type": "Entity", "start": 13, "end": 21}, {"id": "10745478_1_Ent1", "text": "cocaine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "10745478_1_Ent2", "text": "cocaine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "10745478_1_Ent4", "text": "cocaine - induced refractory coronary vasospasm", "entity_type": "Entity", "start": 28, "end": 34}, {"id": "10745478_1_Ent0", "text": "refractory coronary vasospasm", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "10755579_2", "wnd_id": "10755579_2_1", "text": "The medical examiner 's report indicated death caused by fluoxetine toxicity .", "tokens": ["The", "medical", "examiner", "'s", "report", "indicated", "death", "caused", "by", "fluoxetine", "toxicity", "."], "event_mentions": [{"id": "10755579_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 7, "end": 8}, "arguments": [{"entity_id": "10755579_2_Ent0", "role": "Effect", "text": "death", "start": 6, "end": 7}, {"entity_id": "10755579_2_Ent2", "role": "Treatment_Drug", "text": "fluoxetine", "start": 9, "end": 10}, {"entity_id": "10755579_2_Ent1", "role": "Treatment", "text": "fluoxetine toxicity", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "10755579_2_Ent0", "text": "death", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10755579_2_Ent2", "text": "fluoxetine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10755579_2_Ent1", "text": "fluoxetine toxicity", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "10774758_1", "wnd_id": "10774758_1_1", "text": "Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use .", "tokens": ["Perinatal", "vasoconstrictive", "renal", "insufficiency", "associated", "with", "maternal", "nimesulide", "use", "."], "event_mentions": [{"id": "10774758_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "10774758_1_Ent0", "role": "Effect", "text": "Perinatal vasoconstrictive renal insufficiency", "start": 0, "end": 4}, {"entity_id": "10774758_1_Ent1", "role": "Treatment", "text": "maternal nimesulide use", "start": 6, "end": 9}, {"entity_id": "10774758_1_Ent2", "role": "Treatment_Drug", "text": "nimesulide", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "10774758_1_Ent0", "text": "Perinatal vasoconstrictive renal insufficiency", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10774758_1_Ent1", "text": "maternal nimesulide use", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "10774758_1_Ent2", "text": "nimesulide", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "10779995_1", "wnd_id": "10779995_1_1", "text": "Although the t - AML developed following oral etoposide therapy , the child had previously received high - dose , multiagent chemotherapy , and rearrangement of the MLL gene was not demonstrated .", "tokens": ["Although", "the", "t", "-", "AML", "developed", "following", "oral", "etoposide", "therapy", ",", "the", "child", "had", "previously", "received", "high", "-", "dose", ",", "multiagent", "chemotherapy", ",", "and", "rearrangement", "of", "the", "MLL", "gene", "was", "not", "demonstrated", "."], "event_mentions": [{"id": "10779995_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "10779995_1_Ent2", "role": "Effect", "text": "the t - AML", "start": 1, "end": 5}, {"entity_id": "10779995_1_Ent7", "role": "Treatment_Route", "text": "oral", "start": 7, "end": 8}, {"entity_id": "10779995_1_Ent3", "role": "Treatment", "text": "oral etoposide therapy", "start": 7, "end": 10}, {"entity_id": "10779995_1_Ent5", "role": "Treatment_Drug", "text": "etoposide", "start": 8, "end": 9}, {"entity_id": "10779995_1_Ent10", "role": "Combination_Drug", "text": "etoposide", "start": 8, "end": 9}, {"entity_id": "10779995_1_Ent0", "role": "Subject", "text": "the child", "start": 11, "end": 13}, {"entity_id": "10779995_1_Ent1", "role": "Subject_Age", "text": "child", "start": 12, "end": 13}, {"entity_id": "10779995_1_Ent8", "role": "Treatment_Dosage", "text": "high - dose", "start": 16, "end": 19}, {"entity_id": "10779995_1_Ent4", "role": "Treatment", "text": "high - dose , multiagent chemotherapy", "start": 16, "end": 22}, {"entity_id": "10779995_1_Ent6", "role": "Treatment_Drug", "text": "chemotherapy", "start": 21, "end": 22}, {"entity_id": "10779995_1_Ent9", "role": "Combination_Drug", "text": "chemotherapy", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "10779995_1_Ent2", "text": "the t - AML", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "10779995_1_Ent7", "text": "oral", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10779995_1_Ent3", "text": "oral etoposide therapy", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "10779995_1_Ent5", "text": "etoposide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10779995_1_Ent10", "text": "etoposide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10779995_1_Ent0", "text": "the child", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10779995_1_Ent1", "text": "child", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10779995_1_Ent8", "text": "high - dose", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "10779995_1_Ent4", "text": "high - dose , multiagent chemotherapy", "entity_type": "Entity", "start": 16, "end": 22}, {"id": "10779995_1_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10779995_1_Ent9", "text": "chemotherapy", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "10803790_4", "wnd_id": "10803790_4_1", "text": "Case 4 : A 61 - year - old male alcoholic who remained completely abstinent while taking cyanamide for 3 years showed slight elevation of serum transaminases .", "tokens": ["Case", "4", ":", "A", "61", "-", "year", "-", "old", "male", "alcoholic", "who", "remained", "completely", "abstinent", "while", "taking", "cyanamide", "for", "3", "years", "showed", "slight", "elevation", "of", "serum", "transaminases", "."], "event_mentions": [{"id": "10803790_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 16, "end": 17}, "arguments": [{"entity_id": "10803790_4_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 4, "end": 9}, {"entity_id": "10803790_4_Ent0", "role": "Subject", "text": "61 - year - old male alcoholic who remained completely abstinent", "start": 4, "end": 15}, {"entity_id": "10803790_4_Ent2", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "10803790_4_Ent7", "role": "Treatment_Disorder", "text": "alcoholic", "start": 10, "end": 11}, {"entity_id": "10803790_4_Ent5", "role": "Treatment_Drug", "text": "cyanamide", "start": 17, "end": 18}, {"entity_id": "10803790_4_Ent4", "role": "Treatment", "text": "cyanamide for 3 years", "start": 17, "end": 21}, {"entity_id": "10803790_4_Ent6", "role": "Treatment_Duration", "text": "3 years", "start": 19, "end": 21}, {"entity_id": "10803790_4_Ent3", "role": "Effect", "text": "elevation of serum transaminases", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "10803790_4_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10803790_4_Ent0", "text": "61 - year - old male alcoholic who remained completely abstinent", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "10803790_4_Ent2", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10803790_4_Ent7", "text": "alcoholic", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10803790_4_Ent5", "text": "cyanamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10803790_4_Ent4", "text": "cyanamide for 3 years", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "10803790_4_Ent6", "text": "3 years", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "10803790_4_Ent3", "text": "elevation of serum transaminases", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "1082426_1", "wnd_id": "1082426_1_1", "text": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy .", "tokens": ["Spontaneous", "bacterial", "peritonitis", "induced", "by", "intraarterial", "vasopressin", "therapy", "."], "event_mentions": [{"id": "1082426_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "1082426_1_Ent0", "role": "Effect", "text": "Spontaneous bacterial peritonitis", "start": 0, "end": 3}, {"entity_id": "1082426_1_Ent3", "role": "Treatment_Route", "text": "intraarterial", "start": 5, "end": 6}, {"entity_id": "1082426_1_Ent1", "role": "Treatment", "text": "intraarterial vasopressin therapy", "start": 5, "end": 8}, {"entity_id": "1082426_1_Ent2", "role": "Treatment_Drug", "text": "vasopressin", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "1082426_1_Ent0", "text": "Spontaneous bacterial peritonitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1082426_1_Ent3", "text": "intraarterial", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1082426_1_Ent1", "text": "intraarterial vasopressin therapy", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1082426_1_Ent2", "text": "vasopressin", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "10891991_6", "wnd_id": "10891991_6_1", "text": "RESULTS : Replacing valproate with lamotrigine resulted in a decrease in serum testosterone concentrations in all 3 women .", "tokens": ["RESULTS", ":", "Replacing", "valproate", "with", "lamotrigine", "resulted", "in", "a", "decrease", "in", "serum", "testosterone", "concentrations", "in", "all", "3", "women", "."], "event_mentions": [{"id": "10891991_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 6, "end": 7}, "arguments": [{"entity_id": "10891991_6_Ent4", "role": "Treatment", "text": "Replacing valproate with lamotrigine", "start": 2, "end": 6}, {"entity_id": "10891991_6_Ent5", "role": "Treatment_Drug", "text": "lamotrigine", "start": 5, "end": 6}, {"entity_id": "10891991_6_Ent3", "role": "Effect", "text": "a decrease in serum testosterone concentrations", "start": 8, "end": 14}, {"entity_id": "10891991_6_Ent0", "role": "Subject", "text": "all 3 women", "start": 15, "end": 18}, {"entity_id": "10891991_6_Ent1", "role": "Subject_Population", "text": "3", "start": 16, "end": 17}, {"entity_id": "10891991_6_Ent2", "role": "Subject_Gender", "text": "women", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "10891991_6_Ent4", "text": "Replacing valproate with lamotrigine", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "10891991_6_Ent5", "text": "lamotrigine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10891991_6_Ent3", "text": "a decrease in serum testosterone concentrations", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "10891991_6_Ent0", "text": "all 3 women", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "10891991_6_Ent1", "text": "3", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10891991_6_Ent2", "text": "women", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "10904571_1", "wnd_id": "10904571_1_1", "text": "A 60 year - old woman with chronic renal failure developed acute proximal muscle weakness after receiving a regular dosage of colchicine .", "tokens": ["A", "60", "year", "-", "old", "woman", "with", "chronic", "renal", "failure", "developed", "acute", "proximal", "muscle", "weakness", "after", "receiving", "a", "regular", "dosage", "of", "colchicine", "."], "event_mentions": [{"id": "10904571_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "10904571_1_Ent0", "role": "Subject", "text": "A 60 year - old woman with chronic renal failure", "start": 0, "end": 10}, {"entity_id": "10904571_1_Ent1", "role": "Subject_Age", "text": "60 year - old", "start": 1, "end": 5}, {"entity_id": "10904571_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 5, "end": 6}, {"entity_id": "10904571_1_Ent5", "role": "Treatment_Disorder", "text": "chronic renal failure", "start": 7, "end": 10}, {"entity_id": "10904571_1_Ent3", "role": "Effect", "text": "acute proximal muscle weakness", "start": 11, "end": 15}, {"entity_id": "10904571_1_Ent7", "role": "Treatment_Dosage", "text": "regular dosage", "start": 18, "end": 20}, {"entity_id": "10904571_1_Ent4", "role": "Treatment", "text": "regular dosage of colchicine", "start": 18, "end": 22}, {"entity_id": "10904571_1_Ent6", "role": "Treatment_Drug", "text": "colchicine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "10904571_1_Ent0", "text": "A 60 year - old woman with chronic renal failure", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "10904571_1_Ent1", "text": "60 year - old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "10904571_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10904571_1_Ent5", "text": "chronic renal failure", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "10904571_1_Ent3", "text": "acute proximal muscle weakness", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "10904571_1_Ent7", "text": "regular dosage", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "10904571_1_Ent4", "text": "regular dosage of colchicine", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "10904571_1_Ent6", "text": "colchicine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "10904571_2", "wnd_id": "10904571_2_1", "text": "Colchicine - induced myopathy in renal failure .", "tokens": ["Colchicine", "-", "induced", "myopathy", "in", "renal", "failure", "."], "event_mentions": [{"id": "10904571_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10904571_2_Ent1", "role": "Treatment", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "10904571_2_Ent2", "role": "Treatment_Drug", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "10904571_2_Ent0", "role": "Effect", "text": "myopathy", "start": 3, "end": 4}, {"entity_id": "10904571_2_Ent3", "role": "Treatment_Disorder", "text": "renal failure", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "10904571_2_Ent1", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10904571_2_Ent2", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10904571_2_Ent0", "text": "myopathy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10904571_2_Ent3", "text": "renal failure", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "10907391_2", "wnd_id": "10907391_2_1", "text": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity .", "tokens": ["Phantom", "limb", "pain", "as", "a", "manifestation", "of", "paclitaxel", "neurotoxicity", "."], "event_mentions": [{"id": "10907391_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifestation", "start": 5, "end": 6}, "arguments": [{"entity_id": "10907391_2_Ent0", "role": "Effect", "text": "Phantom limb pain", "start": 0, "end": 3}, {"entity_id": "10907391_2_Ent1", "role": "Treatment", "text": "paclitaxel", "start": 7, "end": 8}, {"entity_id": "10907391_2_Ent2", "role": "Treatment_Drug", "text": "paclitaxel", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "10907391_2_Ent0", "text": "Phantom limb pain", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10907391_2_Ent1", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10907391_2_Ent2", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "10923593_1", "wnd_id": "10923593_1_1", "text": "Skin manifestations of a case of phenylbutazone - induced serum sickness - like reactions .", "tokens": ["Skin", "manifestations", "of", "a", "case", "of", "phenylbutazone", "-", "induced", "serum", "sickness", "-", "like", "reactions", "."], "event_mentions": [{"id": "10923593_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "10923593_1_Ent1", "role": "Treatment", "text": "phenylbutazone", "start": 6, "end": 7}, {"entity_id": "10923593_1_Ent2", "role": "Treatment_Drug", "text": "phenylbutazone", "start": 6, "end": 7}, {"entity_id": "10923593_1_Ent0", "role": "Effect", "text": "serum sickness - like reactions", "start": 9, "end": 14}]}], "entity_mentions": [{"id": "10923593_1_Ent1", "text": "phenylbutazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10923593_1_Ent2", "text": "phenylbutazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10923593_1_Ent0", "text": "serum sickness - like reactions", "entity_type": "Entity", "start": 9, "end": 14}], "lang": "en"}
{"doc_id": "10970989_1", "wnd_id": "10970989_1_1", "text": "This is the second report of lactic acidosis in a patient on stavudine and lamivudine .", "tokens": ["This", "is", "the", "second", "report", "of", "lactic", "acidosis", "in", "a", "patient", "on", "stavudine", "and", "lamivudine", "."], "event_mentions": [{"id": "10970989_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 11, "end": 12}, "arguments": [{"entity_id": "10970989_1_Ent1", "role": "Effect", "text": "lactic acidosis", "start": 6, "end": 8}, {"entity_id": "10970989_1_Ent0", "role": "Subject", "text": "a patient", "start": 9, "end": 11}, {"entity_id": "10970989_1_Ent3", "role": "Treatment_Drug", "text": "stavudine", "start": 12, "end": 13}, {"entity_id": "10970989_1_Ent6", "role": "Combination_Drug", "text": "stavudine", "start": 12, "end": 13}, {"entity_id": "10970989_1_Ent2", "role": "Treatment", "text": "stavudine and lamivudine", "start": 12, "end": 15}, {"entity_id": "10970989_1_Ent4", "role": "Treatment_Drug", "text": "lamivudine", "start": 14, "end": 15}, {"entity_id": "10970989_1_Ent5", "role": "Combination_Drug", "text": "lamivudine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "10970989_1_Ent1", "text": "lactic acidosis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10970989_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10970989_1_Ent3", "text": "stavudine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10970989_1_Ent6", "text": "stavudine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10970989_1_Ent2", "text": "stavudine and lamivudine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10970989_1_Ent4", "text": "lamivudine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "10970989_1_Ent5", "text": "lamivudine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "10970989_2", "wnd_id": "10970989_2_1", "text": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine .", "tokens": ["We", "present", "an", "AIDS", "patient", "with", "severe", "and", "prolonged", "lactic", "acidosis", "on", "stavudine", "and", "lamivudine", "."], "event_mentions": [{"id": "10970989_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "present", "start": 1, "end": 2}, "arguments": [{"entity_id": "10970989_2_Ent0", "role": "Subject", "text": "an AIDS patient", "start": 2, "end": 5}, {"entity_id": "10970989_2_Ent3", "role": "Treatment_Disorder", "text": "AIDS", "start": 3, "end": 4}, {"entity_id": "10970989_2_Ent1", "role": "Effect", "text": "severe and prolonged lactic acidosis", "start": 6, "end": 11}, {"entity_id": "10970989_2_Ent4", "role": "Treatment_Drug", "text": "stavudine", "start": 12, "end": 13}, {"entity_id": "10970989_2_Ent6", "role": "Combination_Drug", "text": "stavudine", "start": 12, "end": 13}, {"entity_id": "10970989_2_Ent2", "role": "Treatment", "text": "stavudine and lamivudine", "start": 12, "end": 15}, {"entity_id": "10970989_2_Ent5", "role": "Treatment_Drug", "text": "lamivudine", "start": 14, "end": 15}, {"entity_id": "10970989_2_Ent7", "role": "Combination_Drug", "text": "lamivudine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "10970989_2_Ent0", "text": "an AIDS patient", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "10970989_2_Ent3", "text": "AIDS", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10970989_2_Ent1", "text": "severe and prolonged lactic acidosis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "10970989_2_Ent4", "text": "stavudine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10970989_2_Ent6", "text": "stavudine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10970989_2_Ent2", "text": "stavudine and lamivudine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10970989_2_Ent5", "text": "lamivudine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "10970989_2_Ent7", "text": "lamivudine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "10987357_7", "wnd_id": "10987357_7_1", "text": "When pilsicainide is prescribed in patients with coronary artery disease or renal dysfunction , close attention must be paid to avoid life - threatening arrhythmias due to high plasma concentrations of the drug .", "tokens": ["When", "pilsicainide", "is", "prescribed", "in", "patients", "with", "coronary", "artery", "disease", "or", "renal", "dysfunction", ",", "close", "attention", "must", "be", "paid", "to", "avoid", "life", "-", "threatening", "arrhythmias", "due", "to", "high", "plasma", "concentrations", "of", "the", "drug", "."], "event_mentions": [{"id": "10987357_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 25, "end": 26}, "arguments": [{"entity_id": "10987357_7_Ent4", "role": "Treatment", "text": "pilsicainide", "start": 1, "end": 2}, {"entity_id": "10987357_7_Ent5", "role": "Treatment_Drug", "text": "pilsicainide", "start": 1, "end": 2}, {"entity_id": "10987357_7_Ent0", "role": "Subject", "text": "patients with coronary artery disease or renal dysfunction ,", "start": 5, "end": 14}, {"entity_id": "10987357_7_Ent1", "role": "Subject_Disorder", "text": "coronary artery disease", "start": 7, "end": 10}, {"entity_id": "10987357_7_Ent2", "role": "Subject_Disorder", "text": "renal dysfunction", "start": 11, "end": 13}, {"entity_id": "10987357_7_Ent3", "role": "Effect", "text": "life - threatening arrhythmias", "start": 21, "end": 25}]}], "entity_mentions": [{"id": "10987357_7_Ent4", "text": "pilsicainide", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10987357_7_Ent5", "text": "pilsicainide", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10987357_7_Ent0", "text": "patients with coronary artery disease or renal dysfunction ,", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "10987357_7_Ent1", "text": "coronary artery disease", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "10987357_7_Ent2", "text": "renal dysfunction", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10987357_7_Ent3", "text": "life - threatening arrhythmias", "entity_type": "Entity", "start": 21, "end": 25}], "lang": "en"}
{"doc_id": "11008259_2", "wnd_id": "11008259_2_1", "text": "The events of non - convulsive status epilepticus subsided following reduction in tiagabine dosages .", "tokens": ["The", "events", "of", "non", "-", "convulsive", "status", "epilepticus", "subsided", "following", "reduction", "in", "tiagabine", "dosages", "."], "event_mentions": [{"id": "11008259_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "11008259_2_Ent0", "role": "Effect", "text": "non - convulsive status epilepticus subsided", "start": 3, "end": 9}, {"entity_id": "11008259_2_Ent1", "role": "Treatment", "text": "reduction in tiagabine dosages", "start": 10, "end": 14}, {"entity_id": "11008259_2_Ent2", "role": "Treatment_Drug", "text": "tiagabine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11008259_2_Ent0", "text": "non - convulsive status epilepticus subsided", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "11008259_2_Ent1", "text": "reduction in tiagabine dosages", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "11008259_2_Ent2", "text": "tiagabine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "110153_1", "wnd_id": "110153_1_1", "text": "There have been many reports of probable lithium - induced organic brain syndromes occurring when serum lithium levels are within or close to the therapeutic range .", "tokens": ["There", "have", "been", "many", "reports", "of", "probable", "lithium", "-", "induced", "organic", "brain", "syndromes", "occurring", "when", "serum", "lithium", "levels", "are", "within", "or", "close", "to", "the", "therapeutic", "range", "."], "event_mentions": [{"id": "110153_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "110153_1_Ent1", "role": "Treatment", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "110153_1_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "110153_1_Ent0", "role": "Effect", "text": "organic brain syndromes", "start": 10, "end": 13}, {"entity_id": "110153_1_Ent2", "role": "Treatment", "text": "when serum lithium levels are within or close to the therapeutic range", "start": 14, "end": 26}]}], "entity_mentions": [{"id": "110153_1_Ent1", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "110153_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "110153_1_Ent0", "text": "organic brain syndromes", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "110153_1_Ent2", "text": "when serum lithium levels are within or close to the therapeutic range", "entity_type": "Entity", "start": 14, "end": 26}], "lang": "en"}
{"doc_id": "11020127_1", "wnd_id": "11020127_1_1", "text": "Protease inhibitor - induced carbamazepine toxicity .", "tokens": ["Protease", "inhibitor", "-", "induced", "carbamazepine", "toxicity", "."], "event_mentions": [{"id": "11020127_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "11020127_1_Ent1", "role": "Treatment", "text": "Protease inhibitor", "start": 0, "end": 2}, {"entity_id": "11020127_1_Ent2", "role": "Treatment_Drug", "text": "Protease inhibitor", "start": 0, "end": 2}, {"entity_id": "11020127_1_Ent0", "role": "Effect", "text": "carbamazepine toxicity", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "11020127_1_Ent1", "text": "Protease inhibitor", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11020127_1_Ent2", "text": "Protease inhibitor", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11020127_1_Ent0", "text": "carbamazepine toxicity", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "11026106_1", "wnd_id": "11026106_1_1", "text": "Minocycline as a cause of drug - induced autoimmune hepatitis .", "tokens": ["Minocycline", "as", "a", "cause", "of", "drug", "-", "induced", "autoimmune", "hepatitis", "."], "event_mentions": [{"id": "11026106_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "11026106_1_Ent1", "role": "Treatment", "text": "Minocycline", "start": 0, "end": 1}, {"entity_id": "11026106_1_Ent2", "role": "Treatment_Drug", "text": "Minocycline", "start": 0, "end": 1}, {"entity_id": "11026106_1_Ent0", "role": "Effect", "text": "autoimmune hepatitis", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "11026106_1_Ent1", "text": "Minocycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11026106_1_Ent2", "text": "Minocycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11026106_1_Ent0", "text": "autoimmune hepatitis", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "11030530_3", "wnd_id": "11030530_3_1", "text": "We report a case of seizure associated with L - asparaginase therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events .", "tokens": ["We", "report", "a", "case", "of", "seizure", "associated", "with", "L", "-", "asparaginase", "therapy", "but", "no", "evidence", "of", "hemorrhagic", "or", "thrombotic", "cerebrovascular", "events", "."], "event_mentions": [{"id": "11030530_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "11030530_3_Ent0", "role": "Effect", "text": "seizure", "start": 5, "end": 6}, {"entity_id": "11030530_3_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 8, "end": 11}, {"entity_id": "11030530_3_Ent1", "role": "Treatment", "text": "L - asparaginase therapy", "start": 8, "end": 12}]}], "entity_mentions": [{"id": "11030530_3_Ent0", "text": "seizure", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11030530_3_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "11030530_3_Ent1", "text": "L - asparaginase therapy", "entity_type": "Entity", "start": 8, "end": 12}], "lang": "en"}
{"doc_id": "11033734_2", "wnd_id": "11033734_2_1", "text": "Incidence of seizures in pediatric cancer patients treated with imipenem / cilastatin .", "tokens": ["Incidence", "of", "seizures", "in", "pediatric", "cancer", "patients", "treated", "with", "imipenem", "/", "cilastatin", "."], "event_mentions": [{"id": "11033734_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "11033734_2_Ent3", "role": "Effect", "text": "seizures", "start": 2, "end": 3}, {"entity_id": "11033734_2_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 4, "end": 5}, {"entity_id": "11033734_2_Ent0", "role": "Subject", "text": "pediatric cancer patients", "start": 4, "end": 7}, {"entity_id": "11033734_2_Ent2", "role": "Subject_Disorder", "text": "cancer", "start": 5, "end": 6}, {"entity_id": "11033734_2_Ent5", "role": "Treatment_Drug", "text": "imipenem", "start": 9, "end": 10}, {"entity_id": "11033734_2_Ent7", "role": "Combination_Drug", "text": "imipenem", "start": 9, "end": 10}, {"entity_id": "11033734_2_Ent4", "role": "Treatment", "text": "imipenem / cilastatin", "start": 9, "end": 12}, {"entity_id": "11033734_2_Ent6", "role": "Treatment_Drug", "text": "cilastatin", "start": 11, "end": 12}, {"entity_id": "11033734_2_Ent8", "role": "Combination_Drug", "text": "cilastatin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11033734_2_Ent3", "text": "seizures", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11033734_2_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11033734_2_Ent0", "text": "pediatric cancer patients", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11033734_2_Ent2", "text": "cancer", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11033734_2_Ent5", "text": "imipenem", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11033734_2_Ent7", "text": "imipenem", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11033734_2_Ent4", "text": "imipenem / cilastatin", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11033734_2_Ent6", "text": "cilastatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11033734_2_Ent8", "text": "cilastatin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11049910_11", "wnd_id": "11049910_11_1", "text": "Implications : Clinicians should be aware of the possibility of increased toxicity of ropivacaine when used together with inhibitors of CYP1A2 .", "tokens": ["Implications", ":", "Clinicians", "should", "be", "aware", "of", "the", "possibility", "of", "increased", "toxicity", "of", "ropivacaine", "when", "used", "together", "with", "inhibitors", "of", "CYP1A2", "."], "event_mentions": [{"id": "11049910_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 10, "end": 11}, "arguments": [{"entity_id": "11049910_11_Ent0", "role": "Effect", "text": "toxicity", "start": 11, "end": 12}, {"entity_id": "11049910_11_Ent1", "role": "Treatment", "text": "ropivacaine", "start": 13, "end": 14}, {"entity_id": "11049910_11_Ent3", "role": "Treatment_Drug", "text": "ropivacaine", "start": 13, "end": 14}, {"entity_id": "11049910_11_Ent6", "role": "Combination_Drug", "text": "ropivacaine", "start": 13, "end": 14}, {"entity_id": "11049910_11_Ent2", "role": "Treatment", "text": "inhibitors of CYP1A2", "start": 18, "end": 21}, {"entity_id": "11049910_11_Ent4", "role": "Treatment_Drug", "text": "inhibitors of CYP1A2", "start": 18, "end": 21}, {"entity_id": "11049910_11_Ent5", "role": "Combination_Drug", "text": "inhibitors of CYP1A2", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "11049910_11_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11049910_11_Ent1", "text": "ropivacaine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11049910_11_Ent3", "text": "ropivacaine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11049910_11_Ent6", "text": "ropivacaine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11049910_11_Ent2", "text": "inhibitors of CYP1A2", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "11049910_11_Ent4", "text": "inhibitors of CYP1A2", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "11049910_11_Ent5", "text": "inhibitors of CYP1A2", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "11077455_2", "wnd_id": "11077455_2_1", "text": "Electro - oculography , electroretinography , visual evoked potentials , and multifocal electroretinography in patients with vigabatrin - attributed visual field constriction .", "tokens": ["Electro", "-", "oculography", ",", "electroretinography", ",", "visual", "evoked", "potentials", ",", "and", "multifocal", "electroretinography", "in", "patients", "with", "vigabatrin", "-", "attributed", "visual", "field", "constriction", "."], "event_mentions": [{"id": "11077455_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attributed", "start": 18, "end": 19}, "arguments": [{"entity_id": "11077455_2_Ent0", "role": "Subject", "text": "patients", "start": 14, "end": 15}, {"entity_id": "11077455_2_Ent2", "role": "Treatment", "text": "vigabatrin", "start": 16, "end": 17}, {"entity_id": "11077455_2_Ent3", "role": "Treatment_Drug", "text": "vigabatrin", "start": 16, "end": 17}, {"entity_id": "11077455_2_Ent1", "role": "Effect", "text": "visual field constriction", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "11077455_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11077455_2_Ent2", "text": "vigabatrin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11077455_2_Ent3", "text": "vigabatrin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11077455_2_Ent1", "text": "visual field constriction", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "1109248_9", "wnd_id": "1109248_9_1", "text": "It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy .", "tokens": ["It", "is", "concluded", "that", "chloral", "hydrate", "and", "methaqualone", "may", "be", "administered", "safely", "without", "additional", "caution", "in", "prothrombin", "test", "monitoring", "during", "oral", "anticoagulant", "therapy", "."], "event_mentions": [{"id": "1109248_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caution", "start": 14, "end": 15}, "arguments": [{"entity_id": "1109248_9_Ent2", "role": "Treatment_Drug", "text": "chloral hydrate", "start": 4, "end": 6}, {"entity_id": "1109248_9_Ent6", "role": "Combination_Drug", "text": "chloral hydrate", "start": 4, "end": 6}, {"entity_id": "1109248_9_Ent0", "role": "Treatment", "text": "chloral hydrate and methaqualone", "start": 4, "end": 8}, {"entity_id": "1109248_9_Ent3", "role": "Treatment_Drug", "text": "methaqualone", "start": 7, "end": 8}, {"entity_id": "1109248_9_Ent7", "role": "Combination_Drug", "text": "methaqualone", "start": 7, "end": 8}, {"entity_id": "1109248_9_Ent1", "role": "Treatment", "text": "during oral anticoagulant therapy", "start": 19, "end": 23}, {"entity_id": "1109248_9_Ent5", "role": "Treatment_Route", "text": "oral", "start": 20, "end": 21}, {"entity_id": "1109248_9_Ent4", "role": "Treatment_Drug", "text": "anticoagulant", "start": 21, "end": 22}, {"entity_id": "1109248_9_Ent8", "role": "Combination_Drug", "text": "anticoagulant", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "1109248_9_Ent2", "text": "chloral hydrate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1109248_9_Ent6", "text": "chloral hydrate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1109248_9_Ent0", "text": "chloral hydrate and methaqualone", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "1109248_9_Ent3", "text": "methaqualone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1109248_9_Ent7", "text": "methaqualone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1109248_9_Ent1", "text": "during oral anticoagulant therapy", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "1109248_9_Ent5", "text": "oral", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "1109248_9_Ent4", "text": "anticoagulant", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "1109248_9_Ent8", "text": "anticoagulant", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11126885_1", "wnd_id": "11126885_1_1", "text": "Occult quinine - induced thrombocytopenia .", "tokens": ["Occult", "quinine", "-", "induced", "thrombocytopenia", "."], "event_mentions": [{"id": "11126885_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "11126885_1_Ent1", "role": "Treatment", "text": "quinine", "start": 1, "end": 2}, {"entity_id": "11126885_1_Ent2", "role": "Treatment_Drug", "text": "quinine", "start": 1, "end": 2}, {"entity_id": "11126885_1_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "11126885_1_Ent1", "text": "quinine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11126885_1_Ent2", "text": "quinine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11126885_1_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "11144696_10", "wnd_id": "11144696_10_1", "text": "Venlafaxine - associated seizures at therapeutic doses have not been reported in the literature .", "tokens": ["Venlafaxine", "-", "associated", "seizures", "at", "therapeutic", "doses", "have", "not", "been", "reported", "in", "the", "literature", "."], "event_mentions": [{"id": "11144696_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11144696_10_Ent1", "role": "Treatment", "text": "Venlafaxine", "start": 0, "end": 1}, {"entity_id": "11144696_10_Ent2", "role": "Treatment_Drug", "text": "Venlafaxine", "start": 0, "end": 1}, {"entity_id": "11144696_10_Ent0", "role": "Effect", "text": "seizures", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "11144696_10_Ent1", "text": "Venlafaxine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11144696_10_Ent2", "text": "Venlafaxine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11144696_10_Ent0", "text": "seizures", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "11144696_2", "wnd_id": "11144696_2_1", "text": "To report a patient having a first - time seizure after receiving venlafaxine and trimipramine for depression .", "tokens": ["To", "report", "a", "patient", "having", "a", "first", "-", "time", "seizure", "after", "receiving", "venlafaxine", "and", "trimipramine", "for", "depression", "."], "event_mentions": [{"id": "11144696_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 11, "end": 12}, "arguments": [{"entity_id": "11144696_2_Ent0", "role": "Subject", "text": "patient", "start": 3, "end": 4}, {"entity_id": "11144696_2_Ent1", "role": "Effect", "text": "seizure", "start": 9, "end": 10}, {"entity_id": "11144696_2_Ent3", "role": "Treatment_Drug", "text": "venlafaxine", "start": 12, "end": 13}, {"entity_id": "11144696_2_Ent6", "role": "Combination_Drug", "text": "venlafaxine", "start": 12, "end": 13}, {"entity_id": "11144696_2_Ent2", "role": "Treatment", "text": "venlafaxine and trimipramine", "start": 12, "end": 15}, {"entity_id": "11144696_2_Ent4", "role": "Treatment_Drug", "text": "trimipramine", "start": 14, "end": 15}, {"entity_id": "11144696_2_Ent7", "role": "Combination_Drug", "text": "trimipramine", "start": 14, "end": 15}, {"entity_id": "11144696_2_Ent5", "role": "Treatment_Disorder", "text": "depression", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "11144696_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11144696_2_Ent1", "text": "seizure", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11144696_2_Ent3", "text": "venlafaxine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11144696_2_Ent6", "text": "venlafaxine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11144696_2_Ent2", "text": "venlafaxine and trimipramine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "11144696_2_Ent4", "text": "trimipramine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11144696_2_Ent7", "text": "trimipramine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11144696_2_Ent5", "text": "depression", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11160777_1", "wnd_id": "11160777_1_1", "text": "New oral therapies for type 2 diabetes mellitus :", "tokens": ["New", "oral", "therapies", "for", "type", "2", "diabetes", "mellitus", ":"], "event_mentions": [{"id": "11160777_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 3, "end": 4}, "arguments": [{"entity_id": "11160777_1_Ent2", "role": "Treatment_Route", "text": "oral", "start": 1, "end": 2}, {"entity_id": "11160777_1_Ent0", "role": "Treatment", "text": "oral therapies", "start": 1, "end": 3}, {"entity_id": "11160777_1_Ent1", "role": "Treatment_Disorder", "text": "type 2 diabetes mellitus", "start": 4, "end": 8}]}], "entity_mentions": [{"id": "11160777_1_Ent2", "text": "oral", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11160777_1_Ent0", "text": "oral therapies", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "11160777_1_Ent1", "text": "type 2 diabetes mellitus", "entity_type": "Entity", "start": 4, "end": 8}], "lang": "en"}
{"doc_id": "11174414_4", "wnd_id": "11174414_4_1", "text": "Though physicians treating large populations of patients with HIV are well aware of this complication , only one other report of nevirapine - associated SJS has been documented in the dermatology literature .", "tokens": ["Though", "physicians", "treating", "large", "populations", "of", "patients", "with", "HIV", "are", "well", "aware", "of", "this", "complication", ",", "only", "one", "other", "report", "of", "nevirapine", "-", "associated", "SJS", "has", "been", "documented", "in", "the", "dermatology", "literature", "."], "event_mentions": [{"id": "11174414_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 23, "end": 24}, "arguments": [{"entity_id": "11174414_4_Ent0", "role": "Subject", "text": "patients with HIV", "start": 6, "end": 9}, {"entity_id": "11174414_4_Ent4", "role": "Treatment_Disorder", "text": "HIV", "start": 8, "end": 9}, {"entity_id": "11174414_4_Ent2", "role": "Treatment", "text": "nevirapine", "start": 21, "end": 22}, {"entity_id": "11174414_4_Ent3", "role": "Treatment_Drug", "text": "nevirapine", "start": 21, "end": 22}, {"entity_id": "11174414_4_Ent1", "role": "Effect", "text": "SJS", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "11174414_4_Ent0", "text": "patients with HIV", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "11174414_4_Ent4", "text": "HIV", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11174414_4_Ent2", "text": "nevirapine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11174414_4_Ent3", "text": "nevirapine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11174414_4_Ent1", "text": "SJS", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "11180704_1", "wnd_id": "11180704_1_1", "text": "Oral intake and acarbose were withheld and the ileus spontaneously resolved after 2 days .", "tokens": ["Oral", "intake", "and", "acarbose", "were", "withheld", "and", "the", "ileus", "spontaneously", "resolved", "after", "2", "days", "."], "event_mentions": [{"id": "11180704_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "11180704_1_Ent3", "role": "Treatment_Route", "text": "Oral intake", "start": 0, "end": 2}, {"entity_id": "11180704_1_Ent1", "role": "Treatment", "text": "Oral intake and acarbose", "start": 0, "end": 4}, {"entity_id": "11180704_1_Ent2", "role": "Treatment_Drug", "text": "acarbose", "start": 3, "end": 4}, {"entity_id": "11180704_1_Ent0", "role": "Effect", "text": "the ileus spontaneously resolved", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "11180704_1_Ent3", "text": "Oral intake", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11180704_1_Ent1", "text": "Oral intake and acarbose", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11180704_1_Ent2", "text": "acarbose", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11180704_1_Ent0", "text": "the ileus spontaneously resolved", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "11197767_3", "wnd_id": "11197767_3_1", "text": "Cercarial encystment at concentrations of 25000 microg / l or higher was significantly impaired by all test metals ; however , at lower concentrations only zinc demonstrated toxicity .", "tokens": ["Cercarial", "encystment", "at", "concentrations", "of", "25000", "microg", "/", "l", "or", "higher", "was", "significantly", "impaired", "by", "all", "test", "metals", ";", "however", ",", "at", "lower", "concentrations", "only", "zinc", "demonstrated", "toxicity", "."], "event_mentions": [{"id": "11197767_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "demonstrated", "start": 26, "end": 27}, "arguments": [{"entity_id": "11197767_3_Ent1", "role": "Treatment", "text": "lower concentrations", "start": 22, "end": 24}, {"entity_id": "11197767_3_Ent3", "role": "Treatment_Dosage", "text": "lower concentrations", "start": 22, "end": 24}, {"entity_id": "11197767_3_Ent2", "role": "Treatment", "text": "zinc", "start": 25, "end": 26}, {"entity_id": "11197767_3_Ent4", "role": "Treatment_Drug", "text": "zinc", "start": 25, "end": 26}, {"entity_id": "11197767_3_Ent0", "role": "Effect", "text": "toxicity", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "11197767_3_Ent1", "text": "lower concentrations", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "11197767_3_Ent3", "text": "lower concentrations", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "11197767_3_Ent2", "text": "zinc", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11197767_3_Ent4", "text": "zinc", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11197767_3_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "11206417_1", "wnd_id": "11206417_1_1", "text": "Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans .", "tokens": ["Glucose", "and", "insulin", "exert", "additive", "ocular", "and", "renal", "vasodilator", "effects", "on", "healthy", "humans", "."], "event_mentions": [{"id": "11206417_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exert", "start": 3, "end": 4}, "arguments": [{"entity_id": "11206417_1_Ent3", "role": "Treatment_Drug", "text": "Glucose", "start": 0, "end": 1}, {"entity_id": "11206417_1_Ent5", "role": "Combination_Drug", "text": "Glucose", "start": 0, "end": 1}, {"entity_id": "11206417_1_Ent2", "role": "Treatment", "text": "Glucose and insulin", "start": 0, "end": 3}, {"entity_id": "11206417_1_Ent4", "role": "Treatment_Drug", "text": "insulin", "start": 2, "end": 3}, {"entity_id": "11206417_1_Ent6", "role": "Combination_Drug", "text": "insulin", "start": 2, "end": 3}, {"entity_id": "11206417_1_Ent1", "role": "Effect", "text": "additive ocular and renal vasodilator effects", "start": 4, "end": 10}, {"entity_id": "11206417_1_Ent0", "role": "Subject", "text": "healthy humans", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "11206417_1_Ent3", "text": "Glucose", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11206417_1_Ent5", "text": "Glucose", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11206417_1_Ent2", "text": "Glucose and insulin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11206417_1_Ent4", "text": "insulin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11206417_1_Ent6", "text": "insulin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11206417_1_Ent1", "text": "additive ocular and renal vasodilator effects", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "11206417_1_Ent0", "text": "healthy humans", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "11215836_1", "wnd_id": "11215836_1_1", "text": "He was diagnosed with possible serotonin syndrome ; his symptoms resolved after clomipramine was stopped but before clozapine was restarted eight days later .", "tokens": ["He", "was", "diagnosed", "with", "possible", "serotonin", "syndrome", ";", "his", "symptoms", "resolved", "after", "clomipramine", "was", "stopped", "but", "before", "clozapine", "was", "restarted", "eight", "days", "later", "."], "event_mentions": [{"id": "11215836_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resolved", "start": 10, "end": 11}, "arguments": [{"entity_id": "11215836_1_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "11215836_1_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "11215836_1_Ent2", "role": "Effect", "text": "possible serotonin syndrome", "start": 4, "end": 7}, {"entity_id": "11215836_1_Ent3", "role": "Treatment", "text": "clozapine", "start": 17, "end": 18}, {"entity_id": "11215836_1_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "11215836_1_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11215836_1_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11215836_1_Ent2", "text": "possible serotonin syndrome", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11215836_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11215836_1_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "11215836_2", "wnd_id": "11215836_2_1", "text": "OBJECTIVE : To report on the possible development of serotonin syndrome in a patient receiving clomipramine after clozapine was withdrawn from the treatment regimen .", "tokens": ["OBJECTIVE", ":", "To", "report", "on", "the", "possible", "development", "of", "serotonin", "syndrome", "in", "a", "patient", "receiving", "clomipramine", "after", "clozapine", "was", "withdrawn", "from", "the", "treatment", "regimen", "."], "event_mentions": [{"id": "11215836_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 14, "end": 15}, "arguments": [{"entity_id": "11215836_2_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 9, "end": 11}, {"entity_id": "11215836_2_Ent0", "role": "Subject", "text": "patient", "start": 13, "end": 14}, {"entity_id": "11215836_2_Ent2", "role": "Treatment", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "11215836_2_Ent3", "role": "Treatment_Drug", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "11215836_2_Ent5", "role": "Combination_Drug", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "11215836_2_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 17, "end": 18}, {"entity_id": "11215836_2_Ent6", "role": "Combination_Drug", "text": "clozapine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "11215836_2_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11215836_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11215836_2_Ent2", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11215836_2_Ent3", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11215836_2_Ent5", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11215836_2_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11215836_2_Ent6", "text": "clozapine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "11225532_1", "wnd_id": "11225532_1_1", "text": "Quinine induced coagulopathy -- a near fatal experience .", "tokens": ["Quinine", "induced", "coagulopathy", "--", "a", "near", "fatal", "experience", "."], "event_mentions": [{"id": "11225532_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "11225532_1_Ent1", "role": "Treatment", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "11225532_1_Ent2", "role": "Treatment_Drug", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "11225532_1_Ent0", "role": "Effect", "text": "coagulopathy -- a near fatal experience", "start": 2, "end": 8}]}], "entity_mentions": [{"id": "11225532_1_Ent1", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11225532_1_Ent2", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11225532_1_Ent0", "text": "coagulopathy -- a near fatal experience", "entity_type": "Entity", "start": 2, "end": 8}], "lang": "en"}
{"doc_id": "11243427_3", "wnd_id": "11243427_3_1", "text": "DISCUSSION : Patients with 5 - FU - induced ectropion experience tender , red , scaled lids , making contact lens wear difficult .", "tokens": ["DISCUSSION", ":", "Patients", "with", "5", "-", "FU", "-", "induced", "ectropion", "experience", "tender", ",", "red", ",", "scaled", "lids", ",", "making", "contact", "lens", "wear", "difficult", "."], "event_mentions": [{"id": "11243427_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "11243427_3_Ent0", "role": "Subject", "text": "Patients with 5 - FU - induced ectropion", "start": 2, "end": 10}, {"entity_id": "11243427_3_Ent3", "role": "Treatment", "text": "5 - FU", "start": 4, "end": 7}, {"entity_id": "11243427_3_Ent4", "role": "Treatment_Drug", "text": "5 - FU", "start": 4, "end": 7}, {"entity_id": "11243427_3_Ent1", "role": "Effect", "text": "ectropion", "start": 9, "end": 10}, {"entity_id": "11243427_3_Ent2", "role": "Effect", "text": "tender , red , scaled lids", "start": 11, "end": 17}]}], "entity_mentions": [{"id": "11243427_3_Ent0", "text": "Patients with 5 - FU - induced ectropion", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "11243427_3_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11243427_3_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11243427_3_Ent1", "text": "ectropion", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11243427_3_Ent2", "text": "tender , red , scaled lids", "entity_type": "Entity", "start": 11, "end": 17}], "lang": "en"}
{"doc_id": "11243427_5", "wnd_id": "11243427_5_1", "text": "Exacerbation of 5 - FU dermatologic toxicities in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis , using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre - existing dermatologic conditions .", "tokens": ["Exacerbation", "of", "5", "-", "FU", "dermatologic", "toxicities", "in", "patients", "with", "preexisting", "conditions", "suggests", "the", "importance", "of", "aggressive", "ocular", "prophylaxis", ",", "using", "frequent", "ocular", "lubrication", "and", "topical", "steroid", "preparations", "with", "concurrent", "medical", "management", "of", "pre", "-", "existing", "dermatologic", "conditions", "."], "event_mentions": [{"id": "11243427_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicities", "start": 6, "end": 7}, "arguments": [{"entity_id": "11243427_5_Ent1", "role": "Treatment", "text": "5 - FU", "start": 2, "end": 5}, {"entity_id": "11243427_5_Ent2", "role": "Treatment_Drug", "text": "5 - FU", "start": 2, "end": 5}, {"entity_id": "11243427_5_Ent0", "role": "Effect", "text": "dermatologic toxicities", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "11243427_5_Ent1", "text": "5 - FU", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "11243427_5_Ent2", "text": "5 - FU", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "11243427_5_Ent0", "text": "dermatologic toxicities", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "11247558_1", "wnd_id": "11247558_1_1", "text": "Ischaemic colitis in a patient taking meloxicam .", "tokens": ["Ischaemic", "colitis", "in", "a", "patient", "taking", "meloxicam", "."], "event_mentions": [{"id": "11247558_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 5, "end": 6}, "arguments": [{"entity_id": "11247558_1_Ent1", "role": "Effect", "text": "Ischaemic colitis", "start": 0, "end": 2}, {"entity_id": "11247558_1_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "11247558_1_Ent2", "role": "Treatment", "text": "meloxicam", "start": 6, "end": 7}, {"entity_id": "11247558_1_Ent3", "role": "Treatment_Drug", "text": "meloxicam", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "11247558_1_Ent1", "text": "Ischaemic colitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11247558_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11247558_1_Ent2", "text": "meloxicam", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11247558_1_Ent3", "text": "meloxicam", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "11247558_4", "wnd_id": "11247558_4_1", "text": "We suggest that meloxicam might have intestinal toxic effects when taken in high doses , because of reduced COX - 2 selectivity .", "tokens": ["We", "suggest", "that", "meloxicam", "might", "have", "intestinal", "toxic", "effects", "when", "taken", "in", "high", "doses", ",", "because", "of", "reduced", "COX", "-", "2", "selectivity", "."], "event_mentions": [{"id": "11247558_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 5, "end": 6}, "arguments": [{"entity_id": "11247558_4_Ent1", "role": "Treatment", "text": "meloxicam", "start": 3, "end": 4}, {"entity_id": "11247558_4_Ent2", "role": "Treatment_Drug", "text": "meloxicam", "start": 3, "end": 4}, {"entity_id": "11247558_4_Ent0", "role": "Effect", "text": "intestinal toxic effects", "start": 6, "end": 9}, {"entity_id": "11247558_4_Ent3", "role": "Treatment_Dosage", "text": "high doses", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "11247558_4_Ent1", "text": "meloxicam", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11247558_4_Ent2", "text": "meloxicam", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11247558_4_Ent0", "text": "intestinal toxic effects", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "11247558_4_Ent3", "text": "high doses", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "11250985_4", "wnd_id": "11250985_4_1", "text": "Serious adverse events experienced by patients with chronic heart failure taking spironolactone .", "tokens": ["Serious", "adverse", "events", "experienced", "by", "patients", "with", "chronic", "heart", "failure", "taking", "spironolactone", "."], "event_mentions": [{"id": "11250985_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 3, "end": 4}, "arguments": [{"entity_id": "11250985_4_Ent2", "role": "Effect", "text": "Serious adverse events", "start": 0, "end": 3}, {"entity_id": "11250985_4_Ent0", "role": "Subject", "text": "patients with chronic heart failure", "start": 5, "end": 10}, {"entity_id": "11250985_4_Ent1", "role": "Subject_Disorder", "text": "chronic heart failure", "start": 7, "end": 10}, {"entity_id": "11250985_4_Ent3", "role": "Treatment", "text": "spironolactone", "start": 11, "end": 12}, {"entity_id": "11250985_4_Ent4", "role": "Treatment_Drug", "text": "spironolactone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11250985_4_Ent2", "text": "Serious adverse events", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11250985_4_Ent0", "text": "patients with chronic heart failure", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "11250985_4_Ent1", "text": "chronic heart failure", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11250985_4_Ent3", "text": "spironolactone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11250985_4_Ent4", "text": "spironolactone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11283125_9", "wnd_id": "11283125_9_1", "text": "Disappointingly , with the dose schedule used in this protocol , HD Ara - C added to HD MTX , although well tolerated , failed to further decrease the incidence of CNS relapse or to improve the overall DFS .", "tokens": ["Disappointingly", ",", "with", "the", "dose", "schedule", "used", "in", "this", "protocol", ",", "HD", "Ara", "-", "C", "added", "to", "HD", "MTX", ",", "although", "well", "tolerated", ",", "failed", "to", "further", "decrease", "the", "incidence", "of", "CNS", "relapse", "or", "to", "improve", "the", "overall", "DFS", "."], "event_mentions": [{"id": "11283125_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "failed", "start": 24, "end": 25}, "arguments": [{"entity_id": "11283125_9_Ent1", "role": "Treatment", "text": "HD Ara - C", "start": 11, "end": 15}, {"entity_id": "11283125_9_Ent3", "role": "Treatment_Drug", "text": "HD Ara - C", "start": 11, "end": 15}, {"entity_id": "11283125_9_Ent5", "role": "Combination_Drug", "text": "HD Ara - C", "start": 11, "end": 15}, {"entity_id": "11283125_9_Ent2", "role": "Treatment", "text": "HD MTX", "start": 17, "end": 19}, {"entity_id": "11283125_9_Ent4", "role": "Treatment_Drug", "text": "HD MTX", "start": 17, "end": 19}, {"entity_id": "11283125_9_Ent6", "role": "Combination_Drug", "text": "HD MTX", "start": 17, "end": 19}, {"entity_id": "11283125_9_Ent0", "role": "Effect", "text": "further decrease the incidence of CNS relapse or to improve the overall DFS", "start": 26, "end": 39}]}], "entity_mentions": [{"id": "11283125_9_Ent1", "text": "HD Ara - C", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "11283125_9_Ent3", "text": "HD Ara - C", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "11283125_9_Ent5", "text": "HD Ara - C", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "11283125_9_Ent2", "text": "HD MTX", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11283125_9_Ent4", "text": "HD MTX", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11283125_9_Ent6", "text": "HD MTX", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11283125_9_Ent0", "text": "further decrease the incidence of CNS relapse or to improve the overall DFS", "entity_type": "Entity", "start": 26, "end": 39}], "lang": "en"}
{"doc_id": "11315123_1", "wnd_id": "11315123_1_1", "text": "We cared for a patient with progressive renal impairment who presented with blurred vision , QRS broadening and cardiac failure due to chronic cibenzoline intoxication .", "tokens": ["We", "cared", "for", "a", "patient", "with", "progressive", "renal", "impairment", "who", "presented", "with", "blurred", "vision", ",", "QRS", "broadening", "and", "cardiac", "failure", "due", "to", "chronic", "cibenzoline", "intoxication", "."], "event_mentions": [{"id": "11315123_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 20, "end": 21}, "arguments": [{"entity_id": "11315123_1_Ent0", "role": "Subject", "text": "a patient with progressive renal impairment", "start": 3, "end": 9}, {"entity_id": "11315123_1_Ent1", "role": "Subject_Disorder", "text": "progressive renal impairment", "start": 6, "end": 9}, {"entity_id": "11315123_1_Ent2", "role": "Effect", "text": "blurred vision , QRS broadening and cardiac failure", "start": 12, "end": 20}, {"entity_id": "11315123_1_Ent6", "role": "Treatment_Duration", "text": "chronic", "start": 22, "end": 23}, {"entity_id": "11315123_1_Ent3", "role": "Treatment", "text": "chronic cibenzoline intoxication", "start": 22, "end": 25}, {"entity_id": "11315123_1_Ent4", "role": "Treatment_Drug", "text": "cibenzoline", "start": 23, "end": 24}, {"entity_id": "11315123_1_Ent5", "role": "Treatment_Dosage", "text": "intoxication", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "11315123_1_Ent0", "text": "a patient with progressive renal impairment", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "11315123_1_Ent1", "text": "progressive renal impairment", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "11315123_1_Ent2", "text": "blurred vision , QRS broadening and cardiac failure", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "11315123_1_Ent6", "text": "chronic", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "11315123_1_Ent3", "text": "chronic cibenzoline intoxication", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "11315123_1_Ent4", "text": "cibenzoline", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11315123_1_Ent5", "text": "intoxication", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "11328247_1", "wnd_id": "11328247_1_1", "text": "CONCLUSION : The present findings suggest that fluvoxamine can cause increased libido in some patients .", "tokens": ["CONCLUSION", ":", "The", "present", "findings", "suggest", "that", "fluvoxamine", "can", "cause", "increased", "libido", "in", "some", "patients", "."], "event_mentions": [{"id": "11328247_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 9, "end": 10}, "arguments": [{"entity_id": "11328247_1_Ent2", "role": "Treatment", "text": "fluvoxamine", "start": 7, "end": 8}, {"entity_id": "11328247_1_Ent3", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 7, "end": 8}, {"entity_id": "11328247_1_Ent1", "role": "Effect", "text": "increased libido", "start": 10, "end": 12}, {"entity_id": "11328247_1_Ent0", "role": "Subject", "text": "some patients", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "11328247_1_Ent2", "text": "fluvoxamine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11328247_1_Ent3", "text": "fluvoxamine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11328247_1_Ent1", "text": "increased libido", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11328247_1_Ent0", "text": "some patients", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "11328247_3", "wnd_id": "11328247_3_1", "text": "OBJECTIVE : The aim of this paper is to describe a case of increased libido during fluvoxamine therapy .", "tokens": ["OBJECTIVE", ":", "The", "aim", "of", "this", "paper", "is", "to", "describe", "a", "case", "of", "increased", "libido", "during", "fluvoxamine", "therapy", "."], "event_mentions": [{"id": "11328247_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 15, "end": 16}, "arguments": [{"entity_id": "11328247_3_Ent0", "role": "Subject", "text": "a case", "start": 10, "end": 12}, {"entity_id": "11328247_3_Ent1", "role": "Effect", "text": "increased libido", "start": 13, "end": 15}, {"entity_id": "11328247_3_Ent3", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 16, "end": 17}, {"entity_id": "11328247_3_Ent2", "role": "Treatment", "text": "fluvoxamine therapy .", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "11328247_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11328247_3_Ent1", "text": "increased libido", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "11328247_3_Ent3", "text": "fluvoxamine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11328247_3_Ent2", "text": "fluvoxamine therapy .", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "11328247_5", "wnd_id": "11328247_5_1", "text": "The increased libido disappeared after fluvoxamine was discontinued .", "tokens": ["The", "increased", "libido", "disappeared", "after", "fluvoxamine", "was", "discontinued", "."], "event_mentions": [{"id": "11328247_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "11328247_5_Ent0", "role": "Effect", "text": "increased libido", "start": 1, "end": 3}, {"entity_id": "11328247_5_Ent1", "role": "Treatment", "text": "fluvoxamine", "start": 5, "end": 6}, {"entity_id": "11328247_5_Ent2", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "11328247_5_Ent0", "text": "increased libido", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "11328247_5_Ent1", "text": "fluvoxamine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11328247_5_Ent2", "text": "fluvoxamine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "11332679_2", "wnd_id": "11332679_2_1", "text": "Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate .", "tokens": ["Successful", "treatment", "of", "visceral", "leishmaniasis", "with", "allopurinol", "plus", "ketoconazole", "in", "an", "infant", "who", "developed", "pancreatitis", "caused", "by", "meglumine", "antimoniate", "."], "event_mentions": [{"id": "11332679_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 1, "end": 2}, "arguments": [{"entity_id": "11332679_2_Ent4", "role": "Treatment_Disorder", "text": "visceral leishmaniasis", "start": 3, "end": 5}, {"entity_id": "11332679_2_Ent3", "role": "Treatment", "text": "visceral leishmaniasis with allopurinol plus ketoconazole", "start": 3, "end": 9}, {"entity_id": "11332679_2_Ent5", "role": "Treatment_Drug", "text": "allopurinol", "start": 6, "end": 7}, {"entity_id": "11332679_2_Ent8", "role": "Combination_Drug", "text": "allopurinol", "start": 6, "end": 7}, {"entity_id": "11332679_2_Ent6", "role": "Treatment_Drug", "text": "ketoconazole", "start": 8, "end": 9}, {"entity_id": "11332679_2_Ent7", "role": "Combination_Drug", "text": "ketoconazole", "start": 8, "end": 9}, {"entity_id": "11332679_2_Ent0", "role": "Subject", "text": "an infant who developed pancreatitis caused by meglumine antimoniate", "start": 10, "end": 19}, {"entity_id": "11332679_2_Ent2", "role": "Subject_Age", "text": "infant", "start": 11, "end": 12}, {"entity_id": "11332679_2_Ent1", "role": "Subject_Disorder", "text": "pancreatitis caused by meglumine antimoniate", "start": 14, "end": 19}]}, {"id": "11332679_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 15, "end": 16}, "arguments": [{"entity_id": "11332679_2_Ent9", "role": "Effect", "text": "pancreatitis", "start": 14, "end": 15}, {"entity_id": "11332679_2_Ent10", "role": "Treatment", "text": "meglumine antimoniate", "start": 17, "end": 19}, {"entity_id": "11332679_2_Ent11", "role": "Treatment_Drug", "text": "meglumine antimoniate", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "11332679_2_Ent4", "text": "visceral leishmaniasis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11332679_2_Ent3", "text": "visceral leishmaniasis with allopurinol plus ketoconazole", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "11332679_2_Ent5", "text": "allopurinol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11332679_2_Ent8", "text": "allopurinol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11332679_2_Ent6", "text": "ketoconazole", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11332679_2_Ent7", "text": "ketoconazole", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11332679_2_Ent0", "text": "an infant who developed pancreatitis caused by meglumine antimoniate", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "11332679_2_Ent2", "text": "infant", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11332679_2_Ent9", "text": "pancreatitis", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11332679_2_Ent1", "text": "pancreatitis caused by meglumine antimoniate", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "11332679_2_Ent10", "text": "meglumine antimoniate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11332679_2_Ent11", "text": "meglumine antimoniate", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "11373877_2", "wnd_id": "11373877_2_1", "text": "We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate , both of whom had been treated with steroidal anti - androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation , and who subsequently developed femoral head avascular necrosis .", "tokens": ["We", "report", "the", "case", "histories", "of", "two", "patients", "with", "histologically", "confirmed", "adenocarcinoma", "of", "the", "prostate", ",", "both", "of", "whom", "had", "been", "treated", "with", "steroidal", "anti", "-", "androgen", "therapy", "in", "the", "form", "of", "cyproterone", "acetate", "prior", "to", "radical", "or", "palliative", "pelvic", "irradiation", ",", "and", "who", "subsequently", "developed", "femoral", "head", "avascular", "necrosis", "."], "event_mentions": [{"id": "11373877_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "11373877_2_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "11373877_2_Ent0", "role": "Subject", "text": "two patients with histologically confirmed adenocarcinoma of the prostate", "start": 6, "end": 15}, {"entity_id": "11373877_2_Ent4", "role": "Treatment_Disorder", "text": "adenocarcinoma of the prostate", "start": 11, "end": 15}, {"entity_id": "11373877_2_Ent3", "role": "Treatment", "text": "steroidal anti - androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation", "start": 23, "end": 41}, {"entity_id": "11373877_2_Ent5", "role": "Treatment_Drug", "text": "cyproterone acetate", "start": 32, "end": 34}, {"entity_id": "11373877_2_Ent2", "role": "Effect", "text": "femoral head avascular necrosis .", "start": 46, "end": 51}]}], "entity_mentions": [{"id": "11373877_2_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11373877_2_Ent0", "text": "two patients with histologically confirmed adenocarcinoma of the prostate", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "11373877_2_Ent4", "text": "adenocarcinoma of the prostate", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "11373877_2_Ent3", "text": "steroidal anti - androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation", "entity_type": "Entity", "start": 23, "end": 41}, {"id": "11373877_2_Ent5", "text": "cyproterone acetate", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "11373877_2_Ent2", "text": "femoral head avascular necrosis .", "entity_type": "Entity", "start": 46, "end": 51}], "lang": "en"}
{"doc_id": "11399735_4", "wnd_id": "11399735_4_1", "text": "We report a case of interstitial pulmonary disease that occurred together with lymphocytic colitis during treatment with ticlopidine .", "tokens": ["We", "report", "a", "case", "of", "interstitial", "pulmonary", "disease", "that", "occurred", "together", "with", "lymphocytic", "colitis", "during", "treatment", "with", "ticlopidine", "."], "event_mentions": [{"id": "11399735_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 14, "end": 15}, "arguments": [{"entity_id": "11399735_4_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "11399735_4_Ent1", "role": "Effect", "text": "interstitial pulmonary disease", "start": 5, "end": 8}, {"entity_id": "11399735_4_Ent2", "role": "Effect", "text": "lymphocytic colitis", "start": 12, "end": 14}, {"entity_id": "11399735_4_Ent3", "role": "Treatment", "text": "ticlopidine", "start": 17, "end": 18}, {"entity_id": "11399735_4_Ent4", "role": "Treatment_Drug", "text": "ticlopidine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "11399735_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11399735_4_Ent1", "text": "interstitial pulmonary disease", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11399735_4_Ent2", "text": "lymphocytic colitis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "11399735_4_Ent3", "text": "ticlopidine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11399735_4_Ent4", "text": "ticlopidine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "11406880_1", "wnd_id": "11406880_1_1", "text": "Methadone - induced myoclonus in advanced cancer .", "tokens": ["Methadone", "-", "induced", "myoclonus", "in", "advanced", "cancer", "."], "event_mentions": [{"id": "11406880_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11406880_1_Ent1", "role": "Treatment", "text": "Methadone", "start": 0, "end": 1}, {"entity_id": "11406880_1_Ent3", "role": "Treatment_Drug", "text": "Methadone", "start": 0, "end": 1}, {"entity_id": "11406880_1_Ent0", "role": "Effect", "text": "myoclonus", "start": 3, "end": 4}, {"entity_id": "11406880_1_Ent2", "role": "Treatment_Disorder", "text": "advanced cancer", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "11406880_1_Ent1", "text": "Methadone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11406880_1_Ent3", "text": "Methadone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11406880_1_Ent0", "text": "myoclonus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11406880_1_Ent2", "text": "advanced cancer", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "11406880_3", "wnd_id": "11406880_3_1", "text": "A patient that received methadone for cancer - associated pain developed myoclonus as a side effect .", "tokens": ["A", "patient", "that", "received", "methadone", "for", "cancer", "-", "associated", "pain", "developed", "myoclonus", "as", "a", "side", "effect", "."], "event_mentions": [{"id": "11406880_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "11406880_3_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "11406880_3_Ent2", "role": "Treatment", "text": "methadone", "start": 4, "end": 5}, {"entity_id": "11406880_3_Ent4", "role": "Treatment_Drug", "text": "methadone", "start": 4, "end": 5}, {"entity_id": "11406880_3_Ent3", "role": "Treatment_Disorder", "text": "cancer - associated pain", "start": 6, "end": 10}, {"entity_id": "11406880_3_Ent1", "role": "Effect", "text": "myoclonus", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11406880_3_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11406880_3_Ent2", "text": "methadone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11406880_3_Ent4", "text": "methadone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11406880_3_Ent3", "text": "cancer - associated pain", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "11406880_3_Ent1", "text": "myoclonus", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11424102_3", "wnd_id": "11424102_3_1", "text": "We describe a case of needle - track cutaneous seeding of hepatocellular carcinoma ( HCC ) after sonographically guided percutaneous ethanol injection ( PEI ) .", "tokens": ["We", "describe", "a", "case", "of", "needle", "-", "track", "cutaneous", "seeding", "of", "hepatocellular", "carcinoma", "(", "HCC", ")", "after", "sonographically", "guided", "percutaneous", "ethanol", "injection", "(", "PEI", ")", "."], "event_mentions": [{"id": "11424102_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "11424102_3_Ent0", "role": "Effect", "text": "needle - track cutaneous seeding of hepatocellular carcinoma", "start": 5, "end": 13}, {"entity_id": "11424102_3_Ent1", "role": "Treatment", "text": "sonographically guided percutaneous ethanol injection", "start": 17, "end": 22}, {"entity_id": "11424102_3_Ent3", "role": "Treatment_Drug", "text": "ethanol", "start": 20, "end": 21}, {"entity_id": "11424102_3_Ent2", "role": "Treatment_Route", "text": "injection", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "11424102_3_Ent0", "text": "needle - track cutaneous seeding of hepatocellular carcinoma", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "11424102_3_Ent1", "text": "sonographically guided percutaneous ethanol injection", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "11424102_3_Ent3", "text": "ethanol", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11424102_3_Ent2", "text": "injection", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11424102_5", "wnd_id": "11424102_5_1", "text": "Despite the risk of needle - track seeding , PEI remains useful in the treatment of HCC .", "tokens": ["Despite", "the", "risk", "of", "needle", "-", "track", "seeding", ",", "PEI", "remains", "useful", "in", "the", "treatment", "of", "HCC", "."], "event_mentions": [{"id": "11424102_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "remains", "start": 10, "end": 11}, "arguments": [{"entity_id": "11424102_5_Ent0", "role": "Treatment", "text": "PEI", "start": 9, "end": 10}, {"entity_id": "11424102_5_Ent1", "role": "Treatment_Drug", "text": "PEI", "start": 9, "end": 10}, {"entity_id": "11424102_5_Ent2", "role": "Treatment_Disorder", "text": "HCC", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "11424102_5_Ent0", "text": "PEI", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11424102_5_Ent1", "text": "PEI", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11424102_5_Ent2", "text": "HCC", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11468878_1", "wnd_id": "11468878_1_1", "text": "Although no coagulation study was done and the Meckel 's diverticulum is normally associated with bleeding , the particular intensity of the following hemorrhage may have been favored by metformin .", "tokens": ["Although", "no", "coagulation", "study", "was", "done", "and", "the", "Meckel", "'s", "diverticulum", "is", "normally", "associated", "with", "bleeding", ",", "the", "particular", "intensity", "of", "the", "following", "hemorrhage", "may", "have", "been", "favored", "by", "metformin", "."], "event_mentions": [{"id": "11468878_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "favored", "start": 27, "end": 28}, "arguments": [{"entity_id": "11468878_1_Ent0", "role": "Effect", "text": "hemorrhage", "start": 23, "end": 24}, {"entity_id": "11468878_1_Ent1", "role": "Treatment", "text": "metformin", "start": 29, "end": 30}, {"entity_id": "11468878_1_Ent2", "role": "Treatment_Drug", "text": "metformin", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "11468878_1_Ent0", "text": "hemorrhage", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11468878_1_Ent1", "text": "metformin", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "11468878_1_Ent2", "text": "metformin", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "11476690_1", "wnd_id": "11476690_1_1", "text": "Ulcer became worse after tobramycin and gentamycin treatment for 2 days .", "tokens": ["Ulcer", "became", "worse", "after", "tobramycin", "and", "gentamycin", "treatment", "for", "2", "days", "."], "event_mentions": [{"id": "11476690_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "11476690_1_Ent2", "role": "Treatment_Disorder", "text": "Ulcer", "start": 0, "end": 1}, {"entity_id": "11476690_1_Ent0", "role": "Effect", "text": "Ulcer became worse", "start": 0, "end": 3}, {"entity_id": "11476690_1_Ent3", "role": "Treatment_Drug", "text": "tobramycin", "start": 4, "end": 5}, {"entity_id": "11476690_1_Ent6", "role": "Combination_Drug", "text": "tobramycin", "start": 4, "end": 5}, {"entity_id": "11476690_1_Ent1", "role": "Treatment", "text": "tobramycin and gentamycin", "start": 4, "end": 7}, {"entity_id": "11476690_1_Ent4", "role": "Treatment_Drug", "text": "gentamycin", "start": 6, "end": 7}, {"entity_id": "11476690_1_Ent5", "role": "Combination_Drug", "text": "gentamycin", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "11476690_1_Ent2", "text": "Ulcer", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11476690_1_Ent0", "text": "Ulcer became worse", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11476690_1_Ent3", "text": "tobramycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11476690_1_Ent6", "text": "tobramycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11476690_1_Ent1", "text": "tobramycin and gentamycin", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11476690_1_Ent4", "text": "gentamycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11476690_1_Ent5", "text": "gentamycin", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "11483161_2", "wnd_id": "11483161_2_1", "text": "The bleeding resolved on discontinuation of APV .", "tokens": ["The", "bleeding", "resolved", "on", "discontinuation", "of", "APV", "."], "event_mentions": [{"id": "11483161_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 2, "end": 3}, "arguments": [{"entity_id": "11483161_2_Ent1", "role": "Treatment_Disorder", "text": "The bleeding", "start": 0, "end": 2}, {"entity_id": "11483161_2_Ent0", "role": "Treatment", "text": "discontinuation of APV", "start": 4, "end": 7}, {"entity_id": "11483161_2_Ent2", "role": "Treatment_Drug", "text": "APV", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "11483161_2_Ent1", "text": "The bleeding", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11483161_2_Ent0", "text": "discontinuation of APV", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11483161_2_Ent2", "text": "APV", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "11510798_5", "wnd_id": "11510798_5_1", "text": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction , a feature never previously associated with oxaliplatinum and 5 - fluorouracil regimens .", "tokens": ["It", "is", "concluded", "that", "the", "aforementioned", "pathological", "manifestations", "were", "due", "to", "chemotherapy", "and", "included", "a", "pulmonary", "adverse", "reaction", ",", "a", "feature", "never", "previously", "associated", "with", "oxaliplatinum", "and", "5", "-", "fluorouracil", "regimens", "."], "event_mentions": [{"id": "11510798_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 23, "end": 24}, "arguments": [{"entity_id": "11510798_5_Ent0", "role": "Effect", "text": "a pulmonary adverse reaction", "start": 14, "end": 18}, {"entity_id": "11510798_5_Ent2", "role": "Treatment_Drug", "text": "oxaliplatinum", "start": 25, "end": 26}, {"entity_id": "11510798_5_Ent4", "role": "Combination_Drug", "text": "oxaliplatinum", "start": 25, "end": 26}, {"entity_id": "11510798_5_Ent1", "role": "Treatment", "text": "oxaliplatinum and 5 - fluorouracil regimens", "start": 25, "end": 31}, {"entity_id": "11510798_5_Ent3", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 27, "end": 30}, {"entity_id": "11510798_5_Ent5", "role": "Combination_Drug", "text": "5 - fluorouracil", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "11510798_5_Ent0", "text": "a pulmonary adverse reaction", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "11510798_5_Ent2", "text": "oxaliplatinum", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11510798_5_Ent4", "text": "oxaliplatinum", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11510798_5_Ent1", "text": "oxaliplatinum and 5 - fluorouracil regimens", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "11510798_5_Ent3", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "11510798_5_Ent5", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "11518127_1", "wnd_id": "11518127_1_1", "text": "A 62 - year - old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever .", "tokens": ["A", "62", "-", "year", "-", "old", "woman", "treated", "with", "pranlukast", "for", "2", "months", "developed", "interstitial", "pneumonitis", "with", "a", "high", "fever", "."], "event_mentions": [{"id": "11518127_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "11518127_1_Ent0", "role": "Subject", "text": "A 62 - year - old woman", "start": 0, "end": 7}, {"entity_id": "11518127_1_Ent1", "role": "Subject_Age", "text": "62 - year - old", "start": 1, "end": 6}, {"entity_id": "11518127_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "11518127_1_Ent4", "role": "Treatment", "text": "treated with pranlukast for 2 months", "start": 7, "end": 13}, {"entity_id": "11518127_1_Ent5", "role": "Treatment_Drug", "text": "pranlukast", "start": 9, "end": 10}, {"entity_id": "11518127_1_Ent6", "role": "Treatment_Duration", "text": "2 months", "start": 11, "end": 13}, {"entity_id": "11518127_1_Ent3", "role": "Effect", "text": "interstitial pneumonitis with a high fever", "start": 14, "end": 20}]}], "entity_mentions": [{"id": "11518127_1_Ent0", "text": "A 62 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11518127_1_Ent1", "text": "62 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11518127_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11518127_1_Ent4", "text": "treated with pranlukast for 2 months", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "11518127_1_Ent5", "text": "pranlukast", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11518127_1_Ent6", "text": "2 months", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "11518127_1_Ent3", "text": "interstitial pneumonitis with a high fever", "entity_type": "Entity", "start": 14, "end": 20}], "lang": "en"}
{"doc_id": "11518127_2", "wnd_id": "11518127_2_1", "text": "Acute interstitial pneumonia induced by ONO - 1078 ( pranlukast ) , a leukotriene receptor antagonist .", "tokens": ["Acute", "interstitial", "pneumonia", "induced", "by", "ONO", "-", "1078", "(", "pranlukast", ")", ",", "a", "leukotriene", "receptor", "antagonist", "."], "event_mentions": [{"id": "11518127_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "11518127_2_Ent0", "role": "Effect", "text": "Acute interstitial pneumonia", "start": 0, "end": 3}, {"entity_id": "11518127_2_Ent2", "role": "Treatment_Drug", "text": "ONO - 1078", "start": 5, "end": 8}, {"entity_id": "11518127_2_Ent1", "role": "Treatment", "text": "ONO - 1078 ( pranlukast )", "start": 5, "end": 11}]}], "entity_mentions": [{"id": "11518127_2_Ent0", "text": "Acute interstitial pneumonia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11518127_2_Ent2", "text": "ONO - 1078", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11518127_2_Ent1", "text": "ONO - 1078 ( pranlukast )", "entity_type": "Entity", "start": 5, "end": 11}], "lang": "en"}
{"doc_id": "11545487_4", "wnd_id": "11545487_4_1", "text": "Physicians should be aware that indinavir nephrolithiasis may cause papillary necrosis .", "tokens": ["Physicians", "should", "be", "aware", "that", "indinavir", "nephrolithiasis", "may", "cause", "papillary", "necrosis", "."], "event_mentions": [{"id": "11545487_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 8, "end": 9}, "arguments": [{"entity_id": "11545487_4_Ent2", "role": "Treatment_Drug", "text": "indinavir", "start": 5, "end": 6}, {"entity_id": "11545487_4_Ent1", "role": "Treatment", "text": "indinavir nephrolithiasis", "start": 5, "end": 7}, {"entity_id": "11545487_4_Ent0", "role": "Effect", "text": "papillary necrosis", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "11545487_4_Ent2", "text": "indinavir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11545487_4_Ent1", "text": "indinavir nephrolithiasis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11545487_4_Ent0", "text": "papillary necrosis", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "11545487_6", "wnd_id": "11545487_6_1", "text": "The renal consequences of indinavir - associated nephrotoxicity are uncertain .", "tokens": ["The", "renal", "consequences", "of", "indinavir", "-", "associated", "nephrotoxicity", "are", "uncertain", "."], "event_mentions": [{"id": "11545487_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "11545487_6_Ent1", "role": "Treatment", "text": "indinavir", "start": 4, "end": 5}, {"entity_id": "11545487_6_Ent2", "role": "Treatment_Drug", "text": "indinavir", "start": 4, "end": 5}, {"entity_id": "11545487_6_Ent0", "role": "Effect", "text": "nephrotoxicity", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "11545487_6_Ent1", "text": "indinavir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11545487_6_Ent2", "text": "indinavir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11545487_6_Ent0", "text": "nephrotoxicity", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "11554897_1", "wnd_id": "11554897_1_1", "text": "CONCLUSIONS : LTG overdose may result in a severe but reversible encephalopathy , a previously undescribed phenomenon .", "tokens": ["CONCLUSIONS", ":", "LTG", "overdose", "may", "result", "in", "a", "severe", "but", "reversible", "encephalopathy", ",", "a", "previously", "undescribed", "phenomenon", "."], "event_mentions": [{"id": "11554897_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 5, "end": 6}, "arguments": [{"entity_id": "11554897_1_Ent2", "role": "Treatment_Drug", "text": "LTG", "start": 2, "end": 3}, {"entity_id": "11554897_1_Ent1", "role": "Treatment", "text": "LTG overdose", "start": 2, "end": 4}, {"entity_id": "11554897_1_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 3, "end": 4}, {"entity_id": "11554897_1_Ent0", "role": "Effect", "text": "reversible encephalopathy", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "11554897_1_Ent2", "text": "LTG", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11554897_1_Ent1", "text": "LTG overdose", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11554897_1_Ent3", "text": "overdose", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11554897_1_Ent0", "text": "reversible encephalopathy", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "11568758_3", "wnd_id": "11568758_3_1", "text": "We describe a patient who experienced a lichenoid eruption after the initiation of salsalate for relief of arthritic pain .", "tokens": ["We", "describe", "a", "patient", "who", "experienced", "a", "lichenoid", "eruption", "after", "the", "initiation", "of", "salsalate", "for", "relief", "of", "arthritic", "pain", "."], "event_mentions": [{"id": "11568758_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "11568758_3_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "11568758_3_Ent1", "role": "Effect", "text": "lichenoid eruption", "start": 7, "end": 9}, {"entity_id": "11568758_3_Ent2", "role": "Treatment", "text": "the initiation of salsalate", "start": 10, "end": 14}, {"entity_id": "11568758_3_Ent3", "role": "Treatment_Duration", "text": "initiation", "start": 11, "end": 12}, {"entity_id": "11568758_3_Ent4", "role": "Treatment_Drug", "text": "salsalate", "start": 13, "end": 14}, {"entity_id": "11568758_3_Ent5", "role": "Treatment_Disorder", "text": "arthritic pain", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "11568758_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11568758_3_Ent1", "text": "lichenoid eruption", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11568758_3_Ent2", "text": "the initiation of salsalate", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "11568758_3_Ent3", "text": "initiation", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11568758_3_Ent4", "text": "salsalate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11568758_3_Ent5", "text": "arthritic pain", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "11573852_2", "wnd_id": "11573852_2_1", "text": "CASE SUMMARY : A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time .", "tokens": ["CASE", "SUMMARY", ":", "A", "46", "-", "year", "-", "old", "African", "-", "American", "man", "experienced", "recurrent", "grand", "mal", "seizures", "during", "intravenous", "infusion", "of", "amphotericin", "B", ",", "then", "petit", "mal", "seizures", "as", "the", "infusion", "was", "stopped", "and", "the", "drug", "concentrations", "decreased", "with", "time", "."], "event_mentions": [{"id": "11573852_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 13, "end": 14}, "arguments": [{"entity_id": "11573852_2_Ent0", "role": "Subject", "text": "A 46 - year - old African - American man", "start": 3, "end": 13}, {"entity_id": "11573852_2_Ent1", "role": "Subject_Age", "text": "46 - year - old", "start": 4, "end": 9}, {"entity_id": "11573852_2_Ent2", "role": "Subject_Race", "text": "African - American", "start": 9, "end": 12}, {"entity_id": "11573852_2_Ent3", "role": "Subject_Gender", "text": "man", "start": 12, "end": 13}, {"entity_id": "11573852_2_Ent4", "role": "Effect", "text": "recurrent grand mal seizures", "start": 14, "end": 18}, {"entity_id": "11573852_2_Ent6", "role": "Treatment_Route", "text": "intravenous infusion", "start": 19, "end": 21}, {"entity_id": "11573852_2_Ent5", "role": "Treatment", "text": "intravenous infusion of amphotericin B", "start": 19, "end": 24}, {"entity_id": "11573852_2_Ent7", "role": "Treatment_Drug", "text": "amphotericin B", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "11573852_2_Ent0", "text": "A 46 - year - old African - American man", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "11573852_2_Ent1", "text": "46 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "11573852_2_Ent2", "text": "African - American", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11573852_2_Ent3", "text": "man", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11573852_2_Ent4", "text": "recurrent grand mal seizures", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "11573852_2_Ent6", "text": "intravenous infusion", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "11573852_2_Ent5", "text": "intravenous infusion of amphotericin B", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "11573852_2_Ent7", "text": "amphotericin B", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "11573852_6", "wnd_id": "11573852_6_1", "text": "OBJECTIVE : To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "multiple", "episodes", "of", "seizure", "activity", "in", "an", "AIDS", "patent", "following", "amphotericin", "B", "infusion", "."], "event_mentions": [{"id": "11573852_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 16, "end": 17}, "arguments": [{"entity_id": "11573852_6_Ent1", "role": "Effect", "text": "multiple episodes of seizure activity", "start": 7, "end": 12}, {"entity_id": "11573852_6_Ent0", "role": "Subject", "text": "an AIDS patent", "start": 13, "end": 16}, {"entity_id": "11573852_6_Ent3", "role": "Treatment_Disorder", "text": "AIDS", "start": 14, "end": 15}, {"entity_id": "11573852_6_Ent4", "role": "Treatment_Drug", "text": "amphotericin B", "start": 17, "end": 19}, {"entity_id": "11573852_6_Ent2", "role": "Treatment", "text": "amphotericin B infusion", "start": 17, "end": 20}, {"entity_id": "11573852_6_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "11573852_6_Ent1", "text": "multiple episodes of seizure activity", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "11573852_6_Ent0", "text": "an AIDS patent", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "11573852_6_Ent3", "text": "AIDS", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11573852_6_Ent4", "text": "amphotericin B", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11573852_6_Ent2", "text": "amphotericin B infusion", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "11573852_6_Ent5", "text": "infusion", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "11576059_2", "wnd_id": "11576059_2_1", "text": "We present the case of a 5 - year - old girl who developed bilateral vocal cord paralysis following preoperative peritonsillar bupivacaine infiltration .", "tokens": ["We", "present", "the", "case", "of", "a", "5", "-", "year", "-", "old", "girl", "who", "developed", "bilateral", "vocal", "cord", "paralysis", "following", "preoperative", "peritonsillar", "bupivacaine", "infiltration", "."], "event_mentions": [{"id": "11576059_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 18, "end": 19}, "arguments": [{"entity_id": "11576059_2_Ent0", "role": "Subject", "text": "a 5 - year - old girl", "start": 5, "end": 12}, {"entity_id": "11576059_2_Ent1", "role": "Subject_Age", "text": "5 - year - old", "start": 6, "end": 11}, {"entity_id": "11576059_2_Ent2", "role": "Subject_Gender", "text": "girl", "start": 11, "end": 12}, {"entity_id": "11576059_2_Ent3", "role": "Effect", "text": "bilateral vocal cord paralysis", "start": 14, "end": 18}, {"entity_id": "11576059_2_Ent4", "role": "Treatment", "text": "preoperative peritonsillar bupivacaine infiltration", "start": 19, "end": 23}, {"entity_id": "11576059_2_Ent6", "role": "Treatment_Route", "text": "peritonsillar", "start": 20, "end": 21}, {"entity_id": "11576059_2_Ent5", "role": "Treatment_Drug", "text": "bupivacaine", "start": 21, "end": 22}, {"entity_id": "11576059_2_Ent7", "role": "Treatment_Route", "text": "infiltration", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "11576059_2_Ent0", "text": "a 5 - year - old girl", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "11576059_2_Ent1", "text": "5 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "11576059_2_Ent2", "text": "girl", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11576059_2_Ent3", "text": "bilateral vocal cord paralysis", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "11576059_2_Ent4", "text": "preoperative peritonsillar bupivacaine infiltration", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "11576059_2_Ent6", "text": "peritonsillar", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11576059_2_Ent5", "text": "bupivacaine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11576059_2_Ent7", "text": "infiltration", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "11597289_14", "wnd_id": "11597289_14_1", "text": "In patients receiving antithrombin III and concomitant heparin , a significantly increased bleeding incidence was observed ( 23.8 % for antithrombin III group vs 13.5 % for placebo group ; P<.001 ) .", "tokens": ["In", "patients", "receiving", "antithrombin", "III", "and", "concomitant", "heparin", ",", "a", "significantly", "increased", "bleeding", "incidence", "was", "observed", "(", "23.8", "%", "for", "antithrombin", "III", "group", "vs", "13.5", "%", "for", "placebo", "group", ";", "P<.001", ")", "."], "event_mentions": [{"id": "11597289_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 11, "end": 12}, "arguments": [{"entity_id": "11597289_14_Ent0", "role": "Subject", "text": "patients", "start": 1, "end": 2}, {"entity_id": "11597289_14_Ent4", "role": "Treatment_Drug", "text": "antithrombin III", "start": 3, "end": 5}, {"entity_id": "11597289_14_Ent5", "role": "Combination_Drug", "text": "antithrombin III", "start": 3, "end": 5}, {"entity_id": "11597289_14_Ent2", "role": "Treatment", "text": "antithrombin III and concomitant heparin", "start": 3, "end": 8}, {"entity_id": "11597289_14_Ent3", "role": "Treatment_Drug", "text": "concomitant heparin", "start": 6, "end": 8}, {"entity_id": "11597289_14_Ent6", "role": "Combination_Drug", "text": "concomitant heparin", "start": 6, "end": 8}, {"entity_id": "11597289_14_Ent1", "role": "Effect", "text": "bleeding incidence", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "11597289_14_Ent0", "text": "patients", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11597289_14_Ent4", "text": "antithrombin III", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11597289_14_Ent5", "text": "antithrombin III", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11597289_14_Ent2", "text": "antithrombin III and concomitant heparin", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11597289_14_Ent3", "text": "concomitant heparin", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11597289_14_Ent6", "text": "concomitant heparin", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11597289_14_Ent1", "text": "bleeding incidence", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "11597289_16", "wnd_id": "11597289_16_1", "text": "High - dose antithrombin III was associated with an increased risk of hemorrhage when administered with heparin .", "tokens": ["High", "-", "dose", "antithrombin", "III", "was", "associated", "with", "an", "increased", "risk", "of", "hemorrhage", "when", "administered", "with", "heparin", "."], "event_mentions": [{"id": "11597289_16_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 9, "end": 10}, "arguments": [{"entity_id": "11597289_16_Ent3", "role": "Treatment_Dosage", "text": "High - dose", "start": 0, "end": 3}, {"entity_id": "11597289_16_Ent1", "role": "Treatment", "text": "High - dose antithrombin III", "start": 0, "end": 5}, {"entity_id": "11597289_16_Ent4", "role": "Treatment_Drug", "text": "antithrombin III", "start": 3, "end": 5}, {"entity_id": "11597289_16_Ent6", "role": "Combination_Drug", "text": "antithrombin III", "start": 3, "end": 5}, {"entity_id": "11597289_16_Ent0", "role": "Effect", "text": "hemorrhage", "start": 12, "end": 13}, {"entity_id": "11597289_16_Ent2", "role": "Treatment", "text": "heparin", "start": 16, "end": 17}, {"entity_id": "11597289_16_Ent5", "role": "Treatment_Drug", "text": "heparin", "start": 16, "end": 17}, {"entity_id": "11597289_16_Ent7", "role": "Combination_Drug", "text": "heparin", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "11597289_16_Ent3", "text": "High - dose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11597289_16_Ent1", "text": "High - dose antithrombin III", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "11597289_16_Ent4", "text": "antithrombin III", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11597289_16_Ent6", "text": "antithrombin III", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11597289_16_Ent0", "text": "hemorrhage", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11597289_16_Ent2", "text": "heparin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11597289_16_Ent5", "text": "heparin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11597289_16_Ent7", "text": "heparin", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11642488_1", "wnd_id": "11642488_1_1", "text": "Cicatricial entropion associated with chronic dipivefrin application .", "tokens": ["Cicatricial", "entropion", "associated", "with", "chronic", "dipivefrin", "application", "."], "event_mentions": [{"id": "11642488_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11642488_1_Ent0", "role": "Effect", "text": "Cicatricial entropion", "start": 0, "end": 2}, {"entity_id": "11642488_1_Ent1", "role": "Treatment", "text": "chronic dipivefrin application", "start": 4, "end": 7}, {"entity_id": "11642488_1_Ent2", "role": "Treatment_Drug", "text": "dipivefrin", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "11642488_1_Ent0", "text": "Cicatricial entropion", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11642488_1_Ent1", "text": "chronic dipivefrin application", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11642488_1_Ent2", "text": "dipivefrin", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "11642488_2", "wnd_id": "11642488_2_1", "text": "CONCLUSIONS : Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion .", "tokens": ["CONCLUSIONS", ":", "Cicatrization", "in", "the", "substantia", "propria", "of", "the", "conjunctiva", "by", "excessive", "lymphocytic", "infiltration", "after", "topically", "administered", "antiglaucoma", "drugs", "including", "dipivefrin", "is", "a", "possible", "mechanism", "of", "action", "for", "entropion", "."], "event_mentions": [{"id": "11642488_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "mechanism of action", "start": 24, "end": 27}, "arguments": [{"entity_id": "11642488_2_Ent3", "role": "Treatment_Drug", "text": "antiglaucoma drugs", "start": 17, "end": 19}, {"entity_id": "11642488_2_Ent1", "role": "Treatment", "text": "antiglaucoma drugs including dipivefrin", "start": 17, "end": 21}, {"entity_id": "11642488_2_Ent2", "role": "Treatment_Drug", "text": "dipivefrin", "start": 20, "end": 21}, {"entity_id": "11642488_2_Ent0", "role": "Effect", "text": "entropion", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "11642488_2_Ent3", "text": "antiglaucoma drugs", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11642488_2_Ent1", "text": "antiglaucoma drugs including dipivefrin", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "11642488_2_Ent2", "text": "dipivefrin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11642488_2_Ent0", "text": "entropion", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "11675845_9", "wnd_id": "11675845_9_1", "text": "Furthermore , the warfarin dose was again increased after discontinuation of ropinirole due to common gastrointestinal adverse effects .", "tokens": ["Furthermore", ",", "the", "warfarin", "dose", "was", "again", "increased", "after", "discontinuation", "of", "ropinirole", "due", "to", "common", "gastrointestinal", "adverse", "effects", "."], "event_mentions": [{"id": "11675845_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "due to", "start": 12, "end": 14}, "arguments": [{"entity_id": "11675845_9_Ent0", "role": "Treatment", "text": "the warfarin dose was again increased after discontinuation of ropinirole", "start": 2, "end": 12}, {"entity_id": "11675845_9_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "11675845_9_Ent1", "role": "Treatment_Disorder", "text": "gastrointestinal adverse effects", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "11675845_9_Ent0", "text": "the warfarin dose was again increased after discontinuation of ropinirole", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "11675845_9_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11675845_9_Ent1", "text": "gastrointestinal adverse effects", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "11688826_2", "wnd_id": "11688826_2_1", "text": "Syndrome of inappropriate secretion of ADH ( SIADH ) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion .", "tokens": ["Syndrome", "of", "inappropriate", "secretion", "of", "ADH", "(", "SIADH", ")", "following", "cisplatin", "administration", "in", "a", "pulmonary", "adenocarcinoma", "patient", "with", "a", "malignant", "pleural", "effusion", "."], "event_mentions": [{"id": "11688826_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "11688826_2_Ent2", "role": "Effect", "text": "Syndrome of inappropriate secretion of ADH ( SIADH )", "start": 0, "end": 9}, {"entity_id": "11688826_2_Ent3", "role": "Treatment", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "11688826_2_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "11688826_2_Ent0", "role": "Subject", "text": "a pulmonary adenocarcinoma patient with a malignant pleural effusion", "start": 13, "end": 22}, {"entity_id": "11688826_2_Ent4", "role": "Treatment_Disorder", "text": "pulmonary adenocarcinoma", "start": 14, "end": 16}, {"entity_id": "11688826_2_Ent1", "role": "Subject_Disorder", "text": "malignant pleural effusion", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "11688826_2_Ent2", "text": "Syndrome of inappropriate secretion of ADH ( SIADH )", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "11688826_2_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11688826_2_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11688826_2_Ent0", "text": "a pulmonary adenocarcinoma patient with a malignant pleural effusion", "entity_type": "Entity", "start": 13, "end": 22}, {"id": "11688826_2_Ent4", "text": "pulmonary adenocarcinoma", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11688826_2_Ent1", "text": "malignant pleural effusion", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "11703329_1", "wnd_id": "11703329_1_1", "text": "Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life - threatening vincristine neurotoxicity .", "tokens": ["Early", "recognition", "of", "hereditary", "motor", "and", "sensory", "neuropathy", "type", "1", "can", "avoid", "life", "-", "threatening", "vincristine", "neurotoxicity", "."], "event_mentions": [{"id": "11703329_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "can", "start": 10, "end": 11}, "arguments": [{"entity_id": "11703329_1_Ent0", "role": "Treatment", "text": "Early recognition of hereditary motor and sensory neuropathy type 1", "start": 0, "end": 10}]}], "entity_mentions": [{"id": "11703329_1_Ent0", "text": "Early recognition of hereditary motor and sensory neuropathy type 1", "entity_type": "Entity", "start": 0, "end": 10}], "lang": "en"}
{"doc_id": "11712064_1", "wnd_id": "11712064_1_1", "text": "Systemic allergic contact dermatitis to 8 - methoxypsoralen ( 8 - MOP ) .", "tokens": ["Systemic", "allergic", "contact", "dermatitis", "to", "8", "-", "methoxypsoralen", "(", "8", "-", "MOP", ")", "."], "event_mentions": [{"id": "11712064_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 4, "end": 5}, "arguments": [{"entity_id": "11712064_1_Ent0", "role": "Effect", "text": "Systemic allergic contact dermatitis", "start": 0, "end": 4}, {"entity_id": "11712064_1_Ent2", "role": "Treatment_Drug", "text": "8 - methoxypsoralen", "start": 5, "end": 8}, {"entity_id": "11712064_1_Ent1", "role": "Treatment", "text": "8 - methoxypsoralen ( 8 - MOP )", "start": 5, "end": 13}]}], "entity_mentions": [{"id": "11712064_1_Ent0", "text": "Systemic allergic contact dermatitis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11712064_1_Ent2", "text": "8 - methoxypsoralen", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11712064_1_Ent1", "text": "8 - methoxypsoralen ( 8 - MOP )", "entity_type": "Entity", "start": 5, "end": 13}], "lang": "en"}
{"doc_id": "11722307_1", "wnd_id": "11722307_1_1", "text": "Agranulocytosis and granulocytopenia associated with quetiapine .", "tokens": ["Agranulocytosis", "and", "granulocytopenia", "associated", "with", "quetiapine", "."], "event_mentions": [{"id": "11722307_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "11722307_1_Ent0", "role": "Effect", "text": "Agranulocytosis and granulocytopenia", "start": 0, "end": 3}, {"entity_id": "11722307_1_Ent1", "role": "Treatment", "text": "quetiapine", "start": 5, "end": 6}, {"entity_id": "11722307_1_Ent2", "role": "Treatment_Drug", "text": "quetiapine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "11722307_1_Ent0", "text": "Agranulocytosis and granulocytopenia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11722307_1_Ent1", "text": "quetiapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11722307_1_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "11737689_1", "wnd_id": "11737689_1_1", "text": "A boy with chronic neutropenia and recurrent inflammatory skin lesions developed multiple erythematous nodules following administration of G - CSF .", "tokens": ["A", "boy", "with", "chronic", "neutropenia", "and", "recurrent", "inflammatory", "skin", "lesions", "developed", "multiple", "erythematous", "nodules", "following", "administration", "of", "G", "-", "CSF", "."], "event_mentions": [{"id": "11737689_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "11737689_1_Ent0", "role": "Subject", "text": "A boy with chronic neutropenia and recurrent inflammatory skin lesions", "start": 0, "end": 10}, {"entity_id": "11737689_1_Ent1", "role": "Subject_Gender", "text": "boy", "start": 1, "end": 2}, {"entity_id": "11737689_1_Ent4", "role": "Treatment_Disorder", "text": "chronic neutropenia and recurrent inflammatory skin lesions", "start": 3, "end": 10}, {"entity_id": "11737689_1_Ent2", "role": "Effect", "text": "multiple erythematous nodules", "start": 11, "end": 14}, {"entity_id": "11737689_1_Ent3", "role": "Treatment", "text": "G - CSF", "start": 17, "end": 20}, {"entity_id": "11737689_1_Ent5", "role": "Treatment_Drug", "text": "G - CSF", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "11737689_1_Ent0", "text": "A boy with chronic neutropenia and recurrent inflammatory skin lesions", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "11737689_1_Ent1", "text": "boy", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11737689_1_Ent4", "text": "chronic neutropenia and recurrent inflammatory skin lesions", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "11737689_1_Ent2", "text": "multiple erythematous nodules", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "11737689_1_Ent3", "text": "G - CSF", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "11737689_1_Ent5", "text": "G - CSF", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "11737689_4", "wnd_id": "11737689_4_1", "text": "Painful neutrophilic skin lesions were observed in two children receiving granulocyte colony - stimulating factor ( G - CSF ) for treatment of idiopathic neutropenia .", "tokens": ["Painful", "neutrophilic", "skin", "lesions", "were", "observed", "in", "two", "children", "receiving", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "for", "treatment", "of", "idiopathic", "neutropenia", "."], "event_mentions": [{"id": "11737689_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 5, "end": 6}, "arguments": [{"entity_id": "11737689_4_Ent3", "role": "Effect", "text": "Painful neutrophilic skin lesions", "start": 0, "end": 4}, {"entity_id": "11737689_4_Ent1", "role": "Subject_Population", "text": "two", "start": 7, "end": 8}, {"entity_id": "11737689_4_Ent0", "role": "Subject", "text": "two children", "start": 7, "end": 9}, {"entity_id": "11737689_4_Ent2", "role": "Subject_Age", "text": "children", "start": 8, "end": 9}, {"entity_id": "11737689_4_Ent5", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 10, "end": 15}, {"entity_id": "11737689_4_Ent4", "role": "Treatment", "text": "granulocyte colony - stimulating factor ( G - CSF )", "start": 10, "end": 20}, {"entity_id": "11737689_4_Ent6", "role": "Treatment_Disorder", "text": "idiopathic neutropenia", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "11737689_4_Ent3", "text": "Painful neutrophilic skin lesions", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11737689_4_Ent1", "text": "two", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11737689_4_Ent0", "text": "two children", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11737689_4_Ent2", "text": "children", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11737689_4_Ent5", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "11737689_4_Ent4", "text": "granulocyte colony - stimulating factor ( G - CSF )", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "11737689_4_Ent6", "text": "idiopathic neutropenia", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "11807466_1", "wnd_id": "11807466_1_1", "text": "Linear IgA bullous dermatosis occurring after carbamazepine .", "tokens": ["Linear", "IgA", "bullous", "dermatosis", "occurring", "after", "carbamazepine", "."], "event_mentions": [{"id": "11807466_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 4, "end": 5}, "arguments": [{"entity_id": "11807466_1_Ent0", "role": "Effect", "text": "Linear IgA bullous dermatosis", "start": 0, "end": 4}, {"entity_id": "11807466_1_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 6, "end": 7}, {"entity_id": "11807466_1_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "11807466_1_Ent0", "text": "Linear IgA bullous dermatosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11807466_1_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11807466_1_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "11807466_2", "wnd_id": "11807466_2_1", "text": "We report a patient who experienced LABD shortly after starting carbamazepine therapy .", "tokens": ["We", "report", "a", "patient", "who", "experienced", "LABD", "shortly", "after", "starting", "carbamazepine", "therapy", "."], "event_mentions": [{"id": "11807466_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "11807466_2_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "11807466_2_Ent1", "role": "Effect", "text": "experienced LABD shortly", "start": 5, "end": 8}, {"entity_id": "11807466_2_Ent4", "role": "Treatment_Route", "text": "starting", "start": 9, "end": 10}, {"entity_id": "11807466_2_Ent2", "role": "Treatment", "text": "starting carbamazepine therapy", "start": 9, "end": 12}, {"entity_id": "11807466_2_Ent3", "role": "Treatment_Drug", "text": "carbamazepine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11807466_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11807466_2_Ent1", "text": "experienced LABD shortly", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11807466_2_Ent4", "text": "starting", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11807466_2_Ent2", "text": "starting carbamazepine therapy", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11807466_2_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11834188_3", "wnd_id": "11834188_3_1", "text": "Dermatitis to captopril .", "tokens": ["Dermatitis", "to", "captopril", "."], "event_mentions": [{"id": "11834188_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "11834188_3_Ent2", "role": "Treatment_Disorder", "text": "Dermatitis", "start": 0, "end": 1}, {"entity_id": "11834188_3_Ent0", "role": "Treatment", "text": "captopril", "start": 2, "end": 3}, {"entity_id": "11834188_3_Ent1", "role": "Treatment_Drug", "text": "captopril", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "11834188_3_Ent2", "text": "Dermatitis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11834188_3_Ent0", "text": "captopril", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11834188_3_Ent1", "text": "captopril", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "11850606_4", "wnd_id": "11850606_4_1", "text": "To treat hepatitis B , interferon alpha was administered until the proximal muscle weakness developed .", "tokens": ["To", "treat", "hepatitis", "B", ",", "interferon", "alpha", "was", "administered", "until", "the", "proximal", "muscle", "weakness", "developed", "."], "event_mentions": [{"id": "11850606_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "11850606_4_Ent2", "role": "Treatment_Disorder", "text": "hepatitis B", "start": 2, "end": 4}, {"entity_id": "11850606_4_Ent1", "role": "Treatment", "text": "interferon alpha", "start": 5, "end": 7}, {"entity_id": "11850606_4_Ent3", "role": "Treatment_Drug", "text": "interferon alpha", "start": 5, "end": 7}, {"entity_id": "11850606_4_Ent0", "role": "Effect", "text": "proximal muscle weakness", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "11850606_4_Ent2", "text": "hepatitis B", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11850606_4_Ent1", "text": "interferon alpha", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11850606_4_Ent3", "text": "interferon alpha", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11850606_4_Ent0", "text": "proximal muscle weakness", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "11881322_2", "wnd_id": "11881322_2_1", "text": "CONCLUSIONS : Itraconazole - induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts , possibly leading to ductopenia .", "tokens": ["CONCLUSIONS", ":", "Itraconazole", "-", "induced", "liver", "injury", "presents", "with", "a", "cholestatic", "pattern", "of", "injury", "with", "damage", "to", "the", "interlobular", "bile", "ducts", ",", "possibly", "leading", "to", "ductopenia", "."], "event_mentions": [{"id": "11881322_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "11881322_2_Ent1", "role": "Treatment", "text": "Itraconazole", "start": 2, "end": 3}, {"entity_id": "11881322_2_Ent2", "role": "Treatment_Drug", "text": "Itraconazole", "start": 2, "end": 3}, {"entity_id": "11881322_2_Ent0", "role": "Effect", "text": "liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts , possibly leading to ductopenia", "start": 5, "end": 26}]}], "entity_mentions": [{"id": "11881322_2_Ent1", "text": "Itraconazole", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11881322_2_Ent2", "text": "Itraconazole", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11881322_2_Ent0", "text": "liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts , possibly leading to ductopenia", "entity_type": "Entity", "start": 5, "end": 26}], "lang": "en"}
{"doc_id": "11886466_2", "wnd_id": "11886466_2_1", "text": "Porcine factor VIII ( pFVIII ) , which is used to control bleeding in patients with congenital or acquired haemophilia who have high - titre neutralizing antibodies to human FVIII , is not known to increase the risk of arterial or venous thrombosis .", "tokens": ["Porcine", "factor", "VIII", "(", "pFVIII", ")", ",", "which", "is", "used", "to", "control", "bleeding", "in", "patients", "with", "congenital", "or", "acquired", "haemophilia", "who", "have", "high", "-", "titre", "neutralizing", "antibodies", "to", "human", "FVIII", ",", "is", "not", "known", "to", "increase", "the", "risk", "of", "arterial", "or", "venous", "thrombosis", "."], "event_mentions": [{"id": "11886466_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 35, "end": 36}, "arguments": [{"entity_id": "11886466_2_Ent6", "role": "Treatment_Drug", "text": "Porcine factor VIII", "start": 0, "end": 3}, {"entity_id": "11886466_2_Ent2", "role": "Treatment", "text": "Porcine factor VIII ( pFVIII )", "start": 0, "end": 6}, {"entity_id": "11886466_2_Ent4", "role": "Treatment_Disorder", "text": "bleeding", "start": 12, "end": 13}, {"entity_id": "11886466_2_Ent0", "role": "Subject", "text": "patients with congenital or acquired haemophilia who have high - titre neutralizing antibodies to human FVIII", "start": 14, "end": 30}, {"entity_id": "11886466_2_Ent5", "role": "Treatment_Disorder", "text": "congenital or acquired haemophilia", "start": 16, "end": 20}, {"entity_id": "11886466_2_Ent3", "role": "Treatment_Disorder", "text": "high - titre neutralizing antibodies to human FVIII", "start": 22, "end": 30}, {"entity_id": "11886466_2_Ent1", "role": "Effect", "text": "risk of arterial or venous thrombosis .", "start": 37, "end": 44}]}], "entity_mentions": [{"id": "11886466_2_Ent6", "text": "Porcine factor VIII", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11886466_2_Ent2", "text": "Porcine factor VIII ( pFVIII )", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "11886466_2_Ent4", "text": "bleeding", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11886466_2_Ent0", "text": "patients with congenital or acquired haemophilia who have high - titre neutralizing antibodies to human FVIII", "entity_type": "Entity", "start": 14, "end": 30}, {"id": "11886466_2_Ent5", "text": "congenital or acquired haemophilia", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "11886466_2_Ent3", "text": "high - titre neutralizing antibodies to human FVIII", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "11886466_2_Ent1", "text": "risk of arterial or venous thrombosis .", "entity_type": "Entity", "start": 37, "end": 44}], "lang": "en"}
{"doc_id": "11886466_3", "wnd_id": "11886466_3_1", "text": "We have recently encountered a patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke while being treated with pFVIII .", "tokens": ["We", "have", "recently", "encountered", "a", "patient", "with", "acquired", "haemophilia", "who", "developed", "a", "thrombotic", "left", "middle", "cerebral", "artery", "distribution", "stroke", "while", "being", "treated", "with", "pFVIII", "."], "event_mentions": [{"id": "11886466_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "11886466_3_Ent0", "role": "Subject", "text": "patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke", "start": 5, "end": 19}, {"entity_id": "11886466_3_Ent3", "role": "Treatment_Disorder", "text": "acquired haemophilia", "start": 7, "end": 9}, {"entity_id": "11886466_3_Ent1", "role": "Effect", "text": "thrombotic left middle cerebral artery distribution stroke", "start": 12, "end": 19}, {"entity_id": "11886466_3_Ent2", "role": "Treatment", "text": "pFVIII", "start": 23, "end": 24}, {"entity_id": "11886466_3_Ent4", "role": "Treatment_Drug", "text": "pFVIII", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "11886466_3_Ent0", "text": "patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "11886466_3_Ent3", "text": "acquired haemophilia", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11886466_3_Ent1", "text": "thrombotic left middle cerebral artery distribution stroke", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "11886466_3_Ent2", "text": "pFVIII", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11886466_3_Ent4", "text": "pFVIII", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "11889149_4", "wnd_id": "11889149_4_1", "text": "Women ( aged < or = 75 yr ; > or = 2 yr since their last menstrual period ) received placebo , RLX 60 mg / d , ALN 10 mg / d , or RLX 60 mg / d and ALN 10 mg / d combined .", "tokens": ["Women", "(", "aged", "<", "or", "=", "75", "yr", ";", ">", "or", "=", "2", "yr", "since", "their", "last", "menstrual", "period", ")", "received", "placebo", ",", "RLX", "60", "mg", "/", "d", ",", "ALN", "10", "mg", "/", "d", ",", "or", "RLX", "60", "mg", "/", "d", "and", "ALN", "10", "mg", "/", "d", "combined", "."], "event_mentions": [{"id": "11889149_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 20, "end": 21}, "arguments": [{"entity_id": "11889149_4_Ent1", "role": "Subject_Gender", "text": "Women", "start": 0, "end": 1}, {"entity_id": "11889149_4_Ent0", "role": "Subject", "text": "Women ( aged < or = 75 yr ; > or = 2 yr since their last menstrual period )", "start": 0, "end": 20}, {"entity_id": "11889149_4_Ent2", "role": "Subject_Age", "text": "aged < or = 75 yr ; > or = 2 yr", "start": 2, "end": 14}, {"entity_id": "11889149_4_Ent8", "role": "Treatment_Drug", "text": "RLX", "start": 23, "end": 24}, {"entity_id": "11889149_4_Ent3", "role": "Treatment", "text": "RLX 60 mg / d , ALN 10 mg / d , or RLX 60 mg / d and ALN 10 mg / d combined", "start": 23, "end": 48}, {"entity_id": "11889149_4_Ent4", "role": "Treatment_Dosage", "text": "60 mg / d", "start": 24, "end": 28}, {"entity_id": "11889149_4_Ent9", "role": "Treatment_Drug", "text": "ALN", "start": 29, "end": 30}, {"entity_id": "11889149_4_Ent5", "role": "Treatment_Dosage", "text": "10 mg / d", "start": 30, "end": 34}, {"entity_id": "11889149_4_Ent10", "role": "Treatment_Drug", "text": "RLX", "start": 36, "end": 37}, {"entity_id": "11889149_4_Ent13", "role": "Combination_Drug", "text": "RLX", "start": 36, "end": 37}, {"entity_id": "11889149_4_Ent6", "role": "Treatment_Dosage", "text": "60 mg / d", "start": 37, "end": 41}, {"entity_id": "11889149_4_Ent11", "role": "Treatment_Drug", "text": "ALN", "start": 42, "end": 43}, {"entity_id": "11889149_4_Ent12", "role": "Combination_Drug", "text": "ALN", "start": 42, "end": 43}, {"entity_id": "11889149_4_Ent7", "role": "Treatment_Dosage", "text": "10 mg / d", "start": 43, "end": 47}]}], "entity_mentions": [{"id": "11889149_4_Ent1", "text": "Women", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_4_Ent0", "text": "Women ( aged < or = 75 yr ; > or = 2 yr since their last menstrual period )", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "11889149_4_Ent2", "text": "aged < or = 75 yr ; > or = 2 yr", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "11889149_4_Ent8", "text": "RLX", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11889149_4_Ent3", "text": "RLX 60 mg / d , ALN 10 mg / d , or RLX 60 mg / d and ALN 10 mg / d combined", "entity_type": "Entity", "start": 23, "end": 48}, {"id": "11889149_4_Ent4", "text": "60 mg / d", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "11889149_4_Ent9", "text": "ALN", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "11889149_4_Ent5", "text": "10 mg / d", "entity_type": "Entity", "start": 30, "end": 34}, {"id": "11889149_4_Ent10", "text": "RLX", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "11889149_4_Ent13", "text": "RLX", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "11889149_4_Ent6", "text": "60 mg / d", "entity_type": "Entity", "start": 37, "end": 41}, {"id": "11889149_4_Ent11", "text": "ALN", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "11889149_4_Ent12", "text": "ALN", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "11889149_4_Ent7", "text": "10 mg / d", "entity_type": "Entity", "start": 43, "end": 47}], "lang": "en"}
{"doc_id": "11978156_3", "wnd_id": "11978156_3_1", "text": "He was started on oral lansoprazole 60 mg twice daily and , on hospital day 2 , his platelet count decreased to 102 x 10(3)/mm(3 ) ; on hospital day 3 , the platelet count was 36 x 10(3)/mm(3 ) .", "tokens": ["He", "was", "started", "on", "oral", "lansoprazole", "60", "mg", "twice", "daily", "and", ",", "on", "hospital", "day", "2", ",", "his", "platelet", "count", "decreased", "to", "102", "x", "10(3)/mm(3", ")", ";", "on", "hospital", "day", "3", ",", "the", "platelet", "count", "was", "36", "x", "10(3)/mm(3", ")", "."], "event_mentions": [{"id": "11978156_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 12, "end": 13}, "arguments": [{"entity_id": "11978156_3_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "11978156_3_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "11978156_3_Ent4", "role": "Treatment_Route", "text": "oral", "start": 4, "end": 5}, {"entity_id": "11978156_3_Ent3", "role": "Treatment", "text": "oral lansoprazole 60 mg twice daily", "start": 4, "end": 10}, {"entity_id": "11978156_3_Ent5", "role": "Treatment_Drug", "text": "lansoprazole", "start": 5, "end": 6}, {"entity_id": "11978156_3_Ent6", "role": "Treatment_Dosage", "text": "60 mg", "start": 6, "end": 8}, {"entity_id": "11978156_3_Ent7", "role": "Treatment_Freq", "text": "twice daily", "start": 8, "end": 10}, {"entity_id": "11978156_3_Ent8", "role": "Treatment_Duration", "text": "day 2", "start": 14, "end": 16}, {"entity_id": "11978156_3_Ent2", "role": "Effect", "text": "platelet count decreased", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "11978156_3_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11978156_3_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11978156_3_Ent4", "text": "oral", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11978156_3_Ent3", "text": "oral lansoprazole 60 mg twice daily", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "11978156_3_Ent5", "text": "lansoprazole", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11978156_3_Ent6", "text": "60 mg", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11978156_3_Ent7", "text": "twice daily", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "11978156_3_Ent8", "text": "day 2", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11978156_3_Ent2", "text": "platelet count decreased", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "11978156_4", "wnd_id": "11978156_4_1", "text": "Lansoprazole - induced thrombocytopenia .", "tokens": ["Lansoprazole", "-", "induced", "thrombocytopenia", "."], "event_mentions": [{"id": "11978156_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11978156_4_Ent1", "role": "Treatment", "text": "Lansoprazole", "start": 0, "end": 1}, {"entity_id": "11978156_4_Ent2", "role": "Treatment_Drug", "text": "Lansoprazole", "start": 0, "end": 1}, {"entity_id": "11978156_4_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "11978156_4_Ent1", "text": "Lansoprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11978156_4_Ent2", "text": "Lansoprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11978156_4_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "11978156_5", "wnd_id": "11978156_5_1", "text": "OBJECTIVE : To describe a case of thrombocytopenia associated with the administration of lansoprazole .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "case", "of", "thrombocytopenia", "associated", "with", "the", "administration", "of", "lansoprazole", "."], "event_mentions": [{"id": "11978156_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "11978156_5_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "11978156_5_Ent1", "role": "Effect", "text": "thrombocytopenia", "start": 7, "end": 8}, {"entity_id": "11978156_5_Ent2", "role": "Treatment", "text": "lansoprazole", "start": 13, "end": 14}, {"entity_id": "11978156_5_Ent3", "role": "Treatment_Drug", "text": "lansoprazole", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "11978156_5_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11978156_5_Ent1", "text": "thrombocytopenia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11978156_5_Ent2", "text": "lansoprazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11978156_5_Ent3", "text": "lansoprazole", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "11984077_2", "wnd_id": "11984077_2_1", "text": "The most common side effects associated with amifostine are nausea , vomiting , hypotension , hypocalcemia and allergic reactions .", "tokens": ["The", "most", "common", "side", "effects", "associated", "with", "amifostine", "are", "nausea", ",", "vomiting", ",", "hypotension", ",", "hypocalcemia", "and", "allergic", "reactions", "."], "event_mentions": [{"id": "11984077_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "11984077_2_Ent2", "role": "Treatment", "text": "amifostine", "start": 7, "end": 8}, {"entity_id": "11984077_2_Ent3", "role": "Treatment_Drug", "text": "amifostine", "start": 7, "end": 8}, {"entity_id": "11984077_2_Ent0", "role": "Effect", "text": "nausea , vomiting , hypotension , hypocalcemia", "start": 9, "end": 16}, {"entity_id": "11984077_2_Ent1", "role": "Effect", "text": "allergic reactions .", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "11984077_2_Ent2", "text": "amifostine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11984077_2_Ent3", "text": "amifostine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11984077_2_Ent0", "text": "nausea , vomiting , hypotension , hypocalcemia", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "11984077_2_Ent1", "text": "allergic reactions .", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "11999915_2", "wnd_id": "11999915_2_1", "text": "Granulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of clozapine .", "tokens": ["Granulocytopenia", "and", "agranulocytosis", "are", "considered", "among", "the", "most", "dangerous", "adverse", "effects", "of", "clozapine", "."], "event_mentions": [{"id": "11999915_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "among", "start": 5, "end": 6}, "arguments": [{"entity_id": "11999915_2_Ent0", "role": "Effect", "text": "Granulocytopenia and agranulocytosis", "start": 0, "end": 3}, {"entity_id": "11999915_2_Ent1", "role": "Treatment", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "11999915_2_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11999915_2_Ent0", "text": "Granulocytopenia and agranulocytosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11999915_2_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11999915_2_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12042592_1", "wnd_id": "12042592_1_1", "text": "After identification of the index patient , additional inquiry revealed that the patient 's mother was hospitalized previously for overwhelming sepsis associated with metamizole use .", "tokens": ["After", "identification", "of", "the", "index", "patient", ",", "additional", "inquiry", "revealed", "that", "the", "patient", "'s", "mother", "was", "hospitalized", "previously", "for", "overwhelming", "sepsis", "associated", "with", "metamizole", "use", "."], "event_mentions": [{"id": "12042592_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 21, "end": 22}, "arguments": [{"entity_id": "12042592_1_Ent0", "role": "Subject", "text": "the patient 's mother", "start": 11, "end": 15}, {"entity_id": "12042592_1_Ent1", "role": "Effect", "text": "overwhelming sepsis", "start": 19, "end": 21}, {"entity_id": "12042592_1_Ent2", "role": "Treatment", "text": "metamizole", "start": 23, "end": 24}, {"entity_id": "12042592_1_Ent3", "role": "Treatment_Drug", "text": "metamizole", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "12042592_1_Ent0", "text": "the patient 's mother", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "12042592_1_Ent1", "text": "overwhelming sepsis", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "12042592_1_Ent2", "text": "metamizole", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "12042592_1_Ent3", "text": "metamizole", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "12095907_1", "wnd_id": "12095907_1_1", "text": "The authors describe valproate - induced hyperammonemia and mental status changes in an 88 - year - old man , the first known reported case in an elderly patient .", "tokens": ["The", "authors", "describe", "valproate", "-", "induced", "hyperammonemia", "and", "mental", "status", "changes", "in", "an", "88", "-", "year", "-", "old", "man", ",", "the", "first", "known", "reported", "case", "in", "an", "elderly", "patient", "."], "event_mentions": [{"id": "12095907_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "12095907_1_Ent4", "role": "Treatment", "text": "valproate", "start": 3, "end": 4}, {"entity_id": "12095907_1_Ent5", "role": "Treatment_Drug", "text": "valproate", "start": 3, "end": 4}, {"entity_id": "12095907_1_Ent3", "role": "Effect", "text": "hyperammonemia and mental status changes", "start": 6, "end": 11}, {"entity_id": "12095907_1_Ent0", "role": "Subject", "text": "an 88 - year - old man", "start": 12, "end": 19}, {"entity_id": "12095907_1_Ent1", "role": "Subject_Age", "text": "88 - year - old", "start": 13, "end": 18}, {"entity_id": "12095907_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12095907_1_Ent4", "text": "valproate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12095907_1_Ent5", "text": "valproate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12095907_1_Ent3", "text": "hyperammonemia and mental status changes", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "12095907_1_Ent0", "text": "an 88 - year - old man", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "12095907_1_Ent1", "text": "88 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "12095907_1_Ent2", "text": "man", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12095907_2", "wnd_id": "12095907_2_1", "text": "Valproate - induced hyperammonemia as a cause of altered mental status .", "tokens": ["Valproate", "-", "induced", "hyperammonemia", "as", "a", "cause", "of", "altered", "mental", "status", "."], "event_mentions": [{"id": "12095907_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12095907_2_Ent2", "role": "Treatment", "text": "Valproate", "start": 0, "end": 1}, {"entity_id": "12095907_2_Ent3", "role": "Treatment_Drug", "text": "Valproate", "start": 0, "end": 1}, {"entity_id": "12095907_2_Ent1", "role": "Effect", "text": "hyperammonemia", "start": 3, "end": 4}, {"entity_id": "12095907_2_Ent0", "role": "Effect", "text": "altered mental status", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "12095907_2_Ent2", "text": "Valproate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12095907_2_Ent3", "text": "Valproate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12095907_2_Ent1", "text": "hyperammonemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12095907_2_Ent0", "text": "altered mental status", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "12111771_1", "wnd_id": "12111771_1_1", "text": "A 73 - year - old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia ( CLL ) .", "tokens": ["A", "73", "-", "year", "-", "old", "woman", "presented", "with", "fever", "and", "cough", "2", "weeks", "after", "completing", "the", "third", "cycle", "of", "fludarabine", "for", "chronic", "lymphocytic", "leukemia", "(", "CLL", ")", "."], "event_mentions": [{"id": "12111771_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 7, "end": 8}, "arguments": [{"entity_id": "12111771_1_Ent0", "role": "Subject", "text": "A 73 - year - old woman", "start": 0, "end": 7}, {"entity_id": "12111771_1_Ent1", "role": "Subject_Age", "text": "73 - year - old", "start": 1, "end": 6}, {"entity_id": "12111771_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "12111771_1_Ent3", "role": "Effect", "text": "fever and cough", "start": 9, "end": 12}, {"entity_id": "12111771_1_Ent6", "role": "Treatment_Time_elapsed", "text": "2 weeks", "start": 12, "end": 14}, {"entity_id": "12111771_1_Ent4", "role": "Treatment", "text": "2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia ( CLL )", "start": 12, "end": 28}, {"entity_id": "12111771_1_Ent7", "role": "Treatment_Drug", "text": "fludarabine", "start": 20, "end": 21}, {"entity_id": "12111771_1_Ent5", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia ( CLL )", "start": 22, "end": 28}]}], "entity_mentions": [{"id": "12111771_1_Ent0", "text": "A 73 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12111771_1_Ent1", "text": "73 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12111771_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12111771_1_Ent3", "text": "fever and cough", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12111771_1_Ent6", "text": "2 weeks", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "12111771_1_Ent4", "text": "2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia ( CLL )", "entity_type": "Entity", "start": 12, "end": 28}, {"id": "12111771_1_Ent7", "text": "fludarabine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "12111771_1_Ent5", "text": "chronic lymphocytic leukemia ( CLL )", "entity_type": "Entity", "start": 22, "end": 28}], "lang": "en"}
{"doc_id": "12111771_3", "wnd_id": "12111771_3_1", "text": "Multiple pulmonary nodules : an unusual presentation of fludarabine pulmonary toxicity : case report and review of literature .", "tokens": ["Multiple", "pulmonary", "nodules", ":", "an", "unusual", "presentation", "of", "fludarabine", "pulmonary", "toxicity", ":", "case", "report", "and", "review", "of", "literature", "."], "event_mentions": [{"id": "12111771_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presentation", "start": 6, "end": 7}, "arguments": [{"entity_id": "12111771_3_Ent0", "role": "Effect", "text": "Multiple pulmonary nodules", "start": 0, "end": 3}, {"entity_id": "12111771_3_Ent1", "role": "Treatment", "text": "fludarabine", "start": 8, "end": 9}, {"entity_id": "12111771_3_Ent2", "role": "Treatment_Drug", "text": "fludarabine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "12111771_3_Ent0", "text": "Multiple pulmonary nodules", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12111771_3_Ent1", "text": "fludarabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12111771_3_Ent2", "text": "fludarabine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "12114387_1", "wnd_id": "12114387_1_1", "text": "Epoprostenol may be associated rarely with severe erythroderma .", "tokens": ["Epoprostenol", "may", "be", "associated", "rarely", "with", "severe", "erythroderma", "."], "event_mentions": [{"id": "12114387_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "12114387_1_Ent1", "role": "Treatment", "text": "Epoprostenol", "start": 0, "end": 1}, {"entity_id": "12114387_1_Ent2", "role": "Treatment_Drug", "text": "Epoprostenol", "start": 0, "end": 1}, {"entity_id": "12114387_1_Ent0", "role": "Effect", "text": "severe erythroderma .", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "12114387_1_Ent1", "text": "Epoprostenol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12114387_1_Ent2", "text": "Epoprostenol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12114387_1_Ent0", "text": "severe erythroderma .", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "12149193_7", "wnd_id": "12149193_7_1", "text": "Only patients on DT - PACE but not DCEP - T experienced an increased incidence of DVT .", "tokens": ["Only", "patients", "on", "DT", "-", "PACE", "but", "not", "DCEP", "-", "T", "experienced", "an", "increased", "incidence", "of", "DVT", "."], "event_mentions": [{"id": "12149193_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 11, "end": 12}, "arguments": [{"entity_id": "12149193_7_Ent0", "role": "Subject", "text": "patients", "start": 1, "end": 2}, {"entity_id": "12149193_7_Ent3", "role": "Treatment_Drug", "text": "DT - PACE", "start": 3, "end": 6}, {"entity_id": "12149193_7_Ent2", "role": "Treatment", "text": "DT - PACE but not DCEP - T", "start": 3, "end": 11}, {"entity_id": "12149193_7_Ent4", "role": "Treatment_Drug", "text": "DCEP - T", "start": 8, "end": 11}, {"entity_id": "12149193_7_Ent1", "role": "Effect", "text": "an increased incidence of DVT", "start": 12, "end": 17}]}], "entity_mentions": [{"id": "12149193_7_Ent0", "text": "patients", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12149193_7_Ent3", "text": "DT - PACE", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "12149193_7_Ent2", "text": "DT - PACE but not DCEP - T", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "12149193_7_Ent4", "text": "DCEP - T", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "12149193_7_Ent1", "text": "an increased incidence of DVT", "entity_type": "Entity", "start": 12, "end": 17}], "lang": "en"}
{"doc_id": "12149193_8", "wnd_id": "12149193_8_1", "text": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin ( P = .02 ) was observed ; this association was confirmed on multivariate analysis .", "tokens": ["A", "statistical", "association", "between", "the", "incidence", "of", "DVT", "and", "combination", "chemotherapy", "including", "doxorubicin", "(", "P", "=", ".02", ")", "was", "observed", ";", "this", "association", "was", "confirmed", "on", "multivariate", "analysis", "."], "event_mentions": [{"id": "12149193_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 2, "end": 3}, "arguments": [{"entity_id": "12149193_8_Ent0", "role": "Effect", "text": "DVT", "start": 7, "end": 8}, {"entity_id": "12149193_8_Ent1", "role": "Treatment", "text": "combination chemotherapy including doxorubicin ( P = .02 )", "start": 9, "end": 18}, {"entity_id": "12149193_8_Ent2", "role": "Treatment_Drug", "text": "chemotherapy", "start": 10, "end": 11}, {"entity_id": "12149193_8_Ent4", "role": "Combination_Drug", "text": "chemotherapy", "start": 10, "end": 11}, {"entity_id": "12149193_8_Ent3", "role": "Treatment_Drug", "text": "doxorubicin", "start": 12, "end": 13}, {"entity_id": "12149193_8_Ent5", "role": "Combination_Drug", "text": "doxorubicin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12149193_8_Ent0", "text": "DVT", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12149193_8_Ent1", "text": "combination chemotherapy including doxorubicin ( P = .02 )", "entity_type": "Entity", "start": 9, "end": 18}, {"id": "12149193_8_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12149193_8_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12149193_8_Ent3", "text": "doxorubicin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12149193_8_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12181031_2", "wnd_id": "12181031_2_1", "text": "Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine .", "tokens": ["Systemic", "vasculitis", "complicating", "hairy", "cell", "leukaemia", "treatment", "with", "cladribine", "."], "event_mentions": [{"id": "12181031_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 6, "end": 7}, "arguments": [{"entity_id": "12181031_2_Ent0", "role": "Effect", "text": "Systemic vasculitis", "start": 0, "end": 2}, {"entity_id": "12181031_2_Ent2", "role": "Treatment_Disorder", "text": "hairy cell leukaemia", "start": 3, "end": 6}, {"entity_id": "12181031_2_Ent1", "role": "Treatment", "text": "cladribine", "start": 8, "end": 9}, {"entity_id": "12181031_2_Ent3", "role": "Treatment_Drug", "text": "cladribine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "12181031_2_Ent0", "text": "Systemic vasculitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12181031_2_Ent2", "text": "hairy cell leukaemia", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "12181031_2_Ent1", "text": "cladribine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12181031_2_Ent3", "text": "cladribine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "12187348_3", "wnd_id": "12187348_3_1", "text": "The authors report the first case of bucillamine - induced giant mammary hyperplasia .", "tokens": ["The", "authors", "report", "the", "first", "case", "of", "bucillamine", "-", "induced", "giant", "mammary", "hyperplasia", "."], "event_mentions": [{"id": "12187348_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "12187348_3_Ent1", "role": "Treatment", "text": "bucillamine", "start": 7, "end": 8}, {"entity_id": "12187348_3_Ent2", "role": "Treatment_Drug", "text": "bucillamine", "start": 7, "end": 8}, {"entity_id": "12187348_3_Ent0", "role": "Effect", "text": "giant mammary hyperplasia", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "12187348_3_Ent1", "text": "bucillamine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12187348_3_Ent2", "text": "bucillamine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12187348_3_Ent0", "text": "giant mammary hyperplasia", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "12187348_6", "wnd_id": "12187348_6_1", "text": "She had been on a combined treatment of steroid and lobenzarit disodium for the first 3 years , and then continued with a combined treatment of steroid and bucillamine for the following years until she was found to have pulmonary tuberculosis , at which time the steroid was suspended 10 months before she visited the authors ' clinic .", "tokens": ["She", "had", "been", "on", "a", "combined", "treatment", "of", "steroid", "and", "lobenzarit", "disodium", "for", "the", "first", "3", "years", ",", "and", "then", "continued", "with", "a", "combined", "treatment", "of", "steroid", "and", "bucillamine", "for", "the", "following", "years", "until", "she", "was", "found", "to", "have", "pulmonary", "tuberculosis", ",", "at", "which", "time", "the", "steroid", "was", "suspended", "10", "months", "before", "she", "visited", "the", "authors", "'", "clinic", "."], "event_mentions": [{"id": "12187348_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 6, "end": 7}, "arguments": [{"entity_id": "12187348_6_Ent5", "role": "Treatment_Drug", "text": "steroid", "start": 8, "end": 9}, {"entity_id": "12187348_6_Ent11", "role": "Combination_Drug", "text": "steroid", "start": 8, "end": 9}, {"entity_id": "12187348_6_Ent1", "role": "Treatment", "text": "steroid and lobenzarit disodium for the first 3 years , and then continued with a combined treatment of steroid and bucillamine for the following years", "start": 8, "end": 33}, {"entity_id": "12187348_6_Ent4", "role": "Treatment_Drug", "text": "lobenzarit disodium", "start": 10, "end": 12}, {"entity_id": "12187348_6_Ent10", "role": "Combination_Drug", "text": "lobenzarit disodium", "start": 10, "end": 12}, {"entity_id": "12187348_6_Ent6", "role": "Treatment_Time_elapsed", "text": "3 years", "start": 15, "end": 17}, {"entity_id": "12187348_6_Ent2", "role": "Treatment_Drug", "text": "steroid", "start": 26, "end": 27}, {"entity_id": "12187348_6_Ent8", "role": "Combination_Drug", "text": "steroid", "start": 26, "end": 27}, {"entity_id": "12187348_6_Ent3", "role": "Treatment_Drug", "text": "bucillamine", "start": 28, "end": 29}, {"entity_id": "12187348_6_Ent9", "role": "Combination_Drug", "text": "bucillamine", "start": 28, "end": 29}, {"entity_id": "12187348_6_Ent7", "role": "Treatment_Duration", "text": "for the following years", "start": 29, "end": 33}, {"entity_id": "12187348_6_Ent0", "role": "Effect", "text": "pulmonary tuberculosis", "start": 39, "end": 41}]}], "entity_mentions": [{"id": "12187348_6_Ent5", "text": "steroid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12187348_6_Ent11", "text": "steroid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12187348_6_Ent1", "text": "steroid and lobenzarit disodium for the first 3 years , and then continued with a combined treatment of steroid and bucillamine for the following years", "entity_type": "Entity", "start": 8, "end": 33}, {"id": "12187348_6_Ent4", "text": "lobenzarit disodium", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12187348_6_Ent10", "text": "lobenzarit disodium", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12187348_6_Ent6", "text": "3 years", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "12187348_6_Ent2", "text": "steroid", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12187348_6_Ent8", "text": "steroid", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12187348_6_Ent3", "text": "bucillamine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "12187348_6_Ent9", "text": "bucillamine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "12187348_6_Ent7", "text": "for the following years", "entity_type": "Entity", "start": 29, "end": 33}, {"id": "12187348_6_Ent0", "text": "pulmonary tuberculosis", "entity_type": "Entity", "start": 39, "end": 41}], "lang": "en"}
{"doc_id": "12187348_8", "wnd_id": "12187348_8_1", "text": "Retrospectively , bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D - penicillamine , which was the subject of an abundance of reports of mammary hyperplasia .", "tokens": ["Retrospectively", ",", "bucillamine", "was", "believed", "to", "be", "the", "cause", "of", "the", "giant", "hypertrophy", "because", "of", "its", "structural", "similarity", "to", "D", "-", "penicillamine", ",", "which", "was", "the", "subject", "of", "an", "abundance", "of", "reports", "of", "mammary", "hyperplasia", "."], "event_mentions": [{"id": "12187348_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause of", "start": 8, "end": 10}, "arguments": [{"entity_id": "12187348_8_Ent1", "role": "Treatment", "text": "bucillamine", "start": 2, "end": 3}, {"entity_id": "12187348_8_Ent2", "role": "Treatment_Drug", "text": "bucillamine", "start": 2, "end": 3}, {"entity_id": "12187348_8_Ent0", "role": "Effect", "text": "giant hypertrophy", "start": 11, "end": 13}, {"entity_id": "12187348_8_Ent3", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "12187348_8_Ent1", "text": "bucillamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12187348_8_Ent2", "text": "bucillamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12187348_8_Ent0", "text": "giant hypertrophy", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "12187348_8_Ent3", "text": "D - penicillamine", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "12221670_4", "wnd_id": "12221670_4_1", "text": "Ticlopidine - induced aplastic anemia : two new case reports , review , and meta - analysis of 55 additional cases .", "tokens": ["Ticlopidine", "-", "induced", "aplastic", "anemia", ":", "two", "new", "case", "reports", ",", "review", ",", "and", "meta", "-", "analysis", "of", "55", "additional", "cases", "."], "event_mentions": [{"id": "12221670_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12221670_4_Ent1", "role": "Treatment", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "12221670_4_Ent2", "role": "Treatment_Drug", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "12221670_4_Ent0", "role": "Effect", "text": "aplastic anemia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "12221670_4_Ent1", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12221670_4_Ent2", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12221670_4_Ent0", "text": "aplastic anemia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "12234159_1", "wnd_id": "12234159_1_1", "text": "Fixed drug eruption to rofecoxib .", "tokens": ["Fixed", "drug", "eruption", "to", "rofecoxib", "."], "event_mentions": [{"id": "12234159_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 3, "end": 4}, "arguments": [{"entity_id": "12234159_1_Ent0", "role": "Effect", "text": "Fixed drug eruption", "start": 0, "end": 3}, {"entity_id": "12234159_1_Ent1", "role": "Treatment", "text": "rofecoxib", "start": 4, "end": 5}, {"entity_id": "12234159_1_Ent2", "role": "Treatment_Drug", "text": "rofecoxib", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "12234159_1_Ent0", "text": "Fixed drug eruption", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12234159_1_Ent1", "text": "rofecoxib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12234159_1_Ent2", "text": "rofecoxib", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "12243603_10", "wnd_id": "12243603_10_1", "text": "We describe a patient with a complex medication regimen who was admitted for rhabdomyolysis and accompanying acute renal failure , along with acute hepatitis , thought to be secondary to a drug interaction between atorvastatin and diltiazem .", "tokens": ["We", "describe", "a", "patient", "with", "a", "complex", "medication", "regimen", "who", "was", "admitted", "for", "rhabdomyolysis", "and", "accompanying", "acute", "renal", "failure", ",", "along", "with", "acute", "hepatitis", ",", "thought", "to", "be", "secondary", "to", "a", "drug", "interaction", "between", "atorvastatin", "and", "diltiazem", "."], "event_mentions": [{"id": "12243603_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 28, "end": 29}, "arguments": [{"entity_id": "12243603_10_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "12243603_10_Ent1", "role": "Effect", "text": "rhabdomyolysis and accompanying acute renal failure , along with acute hepatitis", "start": 13, "end": 24}, {"entity_id": "12243603_10_Ent2", "role": "Treatment", "text": "atorvastatin", "start": 34, "end": 35}, {"entity_id": "12243603_10_Ent4", "role": "Treatment_Drug", "text": "atorvastatin", "start": 34, "end": 35}, {"entity_id": "12243603_10_Ent6", "role": "Combination_Drug", "text": "atorvastatin", "start": 34, "end": 35}, {"entity_id": "12243603_10_Ent3", "role": "Treatment", "text": "diltiazem", "start": 36, "end": 37}, {"entity_id": "12243603_10_Ent5", "role": "Treatment_Drug", "text": "diltiazem", "start": 36, "end": 37}, {"entity_id": "12243603_10_Ent7", "role": "Combination_Drug", "text": "diltiazem", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "12243603_10_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12243603_10_Ent1", "text": "rhabdomyolysis and accompanying acute renal failure , along with acute hepatitis", "entity_type": "Entity", "start": 13, "end": 24}, {"id": "12243603_10_Ent2", "text": "atorvastatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "12243603_10_Ent4", "text": "atorvastatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "12243603_10_Ent6", "text": "atorvastatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "12243603_10_Ent3", "text": "diltiazem", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "12243603_10_Ent5", "text": "diltiazem", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "12243603_10_Ent7", "text": "diltiazem", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "12243603_2", "wnd_id": "12243603_2_1", "text": "To report a case of rhabdomyolysis and acute hepatitis associated with the coadministration of atorvastatin and diltiazem .", "tokens": ["To", "report", "a", "case", "of", "rhabdomyolysis", "and", "acute", "hepatitis", "associated", "with", "the", "coadministration", "of", "atorvastatin", "and", "diltiazem", "."], "event_mentions": [{"id": "12243603_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "12243603_2_Ent0", "role": "Effect", "text": "rhabdomyolysis and acute hepatitis", "start": 5, "end": 9}, {"entity_id": "12243603_2_Ent1", "role": "Treatment", "text": "coadministration of atorvastatin and diltiazem", "start": 12, "end": 17}, {"entity_id": "12243603_2_Ent2", "role": "Treatment_Drug", "text": "atorvastatin", "start": 14, "end": 15}, {"entity_id": "12243603_2_Ent4", "role": "Combination_Drug", "text": "atorvastatin", "start": 14, "end": 15}, {"entity_id": "12243603_2_Ent3", "role": "Treatment_Drug", "text": "diltiazem", "start": 16, "end": 17}, {"entity_id": "12243603_2_Ent5", "role": "Combination_Drug", "text": "diltiazem", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12243603_2_Ent0", "text": "rhabdomyolysis and acute hepatitis", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "12243603_2_Ent1", "text": "coadministration of atorvastatin and diltiazem", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "12243603_2_Ent2", "text": "atorvastatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12243603_2_Ent4", "text": "atorvastatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12243603_2_Ent3", "text": "diltiazem", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12243603_2_Ent5", "text": "diltiazem", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12365708_4", "wnd_id": "12365708_4_1", "text": "Visual changes secondary to initiation of amiodarone : a case report and review involving ocular management in cardiac polypharmacy .", "tokens": ["Visual", "changes", "secondary", "to", "initiation", "of", "amiodarone", ":", "a", "case", "report", "and", "review", "involving", "ocular", "management", "in", "cardiac", "polypharmacy", "."], "event_mentions": [{"id": "12365708_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 2, "end": 3}, "arguments": [{"entity_id": "12365708_4_Ent1", "role": "Effect", "text": "Visual changes", "start": 0, "end": 2}, {"entity_id": "12365708_4_Ent2", "role": "Treatment", "text": "amiodarone", "start": 6, "end": 7}, {"entity_id": "12365708_4_Ent3", "role": "Treatment_Drug", "text": "amiodarone", "start": 6, "end": 7}, {"entity_id": "12365708_4_Ent0", "role": "Subject", "text": "a case", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "12365708_4_Ent1", "text": "Visual changes", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12365708_4_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12365708_4_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12365708_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "12390172_3", "wnd_id": "12390172_3_1", "text": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin .", "tokens": ["Retinal", "dysfunction", "and", "anterior", "segment", "deposits", "in", "a", "patient", "treated", "with", "rifabutin", "."], "event_mentions": [{"id": "12390172_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 9, "end": 10}, "arguments": [{"entity_id": "12390172_3_Ent1", "role": "Effect", "text": "Retinal dysfunction and anterior segment deposits", "start": 0, "end": 6}, {"entity_id": "12390172_3_Ent0", "role": "Subject", "text": "patient", "start": 8, "end": 9}, {"entity_id": "12390172_3_Ent2", "role": "Treatment", "text": "rifabutin", "start": 11, "end": 12}, {"entity_id": "12390172_3_Ent3", "role": "Treatment_Drug", "text": "rifabutin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "12390172_3_Ent1", "text": "Retinal dysfunction and anterior segment deposits", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "12390172_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12390172_3_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12390172_3_Ent3", "text": "rifabutin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "12410494_1", "wnd_id": "12410494_1_1", "text": "Simvastatin - nelfinavir interaction implicated in rhabdomyolysis and death .", "tokens": ["Simvastatin", "-", "nelfinavir", "interaction", "implicated", "in", "rhabdomyolysis", "and", "death", "."], "event_mentions": [{"id": "12410494_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "implicated", "start": 4, "end": 5}, "arguments": [{"entity_id": "12410494_1_Ent3", "role": "Treatment_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "12410494_1_Ent5", "role": "Combination_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "12410494_1_Ent1", "role": "Treatment", "text": "Simvastatin - nelfinavir interaction", "start": 0, "end": 4}, {"entity_id": "12410494_1_Ent2", "role": "Treatment_Drug", "text": "nelfinavir", "start": 2, "end": 3}, {"entity_id": "12410494_1_Ent4", "role": "Combination_Drug", "text": "nelfinavir", "start": 2, "end": 3}, {"entity_id": "12410494_1_Ent0", "role": "Effect", "text": "rhabdomyolysis and death", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "12410494_1_Ent3", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12410494_1_Ent5", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12410494_1_Ent1", "text": "Simvastatin - nelfinavir interaction", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12410494_1_Ent2", "text": "nelfinavir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12410494_1_Ent4", "text": "nelfinavir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12410494_1_Ent0", "text": "rhabdomyolysis and death", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "12452753_2", "wnd_id": "12452753_2_1", "text": "CONCLUSIONS : The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine .", "tokens": ["CONCLUSIONS", ":", "The", "use", "of", "fluorouracil", "treatment", "with", "careful", "monitoring", "can", "be", "considered", "in", "a", "patient", "with", "mild", "allergic", "reactions", "to", "capecitabine", "."], "event_mentions": [{"id": "12452753_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "can be considered", "start": 10, "end": 13}, "arguments": [{"entity_id": "12452753_2_Ent3", "role": "Treatment_Drug", "text": "fluorouracil", "start": 5, "end": 6}, {"entity_id": "12452753_2_Ent2", "role": "Treatment", "text": "fluorouracil treatment with careful monitoring", "start": 5, "end": 10}, {"entity_id": "12452753_2_Ent0", "role": "Subject", "text": "a patient with mild allergic reactions to capecitabine", "start": 14, "end": 22}, {"entity_id": "12452753_2_Ent1", "role": "Subject_Disorder", "text": "allergic reactions to capecitabine", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "12452753_2_Ent3", "text": "fluorouracil", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12452753_2_Ent2", "text": "fluorouracil treatment with careful monitoring", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12452753_2_Ent0", "text": "a patient with mild allergic reactions to capecitabine", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "12452753_2_Ent1", "text": "allergic reactions to capecitabine", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "12460237_4", "wnd_id": "12460237_4_1", "text": "We report a patient with recurrent , increasingly severe episodes of PPE , ultimately complicated by a severe bullous eruption , following successive cycles of high - dose cytarabine for the treatment of acute lymphoblastic leukaemia .", "tokens": ["We", "report", "a", "patient", "with", "recurrent", ",", "increasingly", "severe", "episodes", "of", "PPE", ",", "ultimately", "complicated", "by", "a", "severe", "bullous", "eruption", ",", "following", "successive", "cycles", "of", "high", "-", "dose", "cytarabine", "for", "the", "treatment", "of", "acute", "lymphoblastic", "leukaemia", "."], "event_mentions": [{"id": "12460237_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 21, "end": 22}, "arguments": [{"entity_id": "12460237_4_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "12460237_4_Ent1", "role": "Effect", "text": "recurrent , increasingly severe episodes of PPE , ultimately complicated by a severe bullous eruption", "start": 5, "end": 20}, {"entity_id": "12460237_4_Ent2", "role": "Treatment", "text": "cycles of high - dose cytarabine for the treatment of acute lymphoblastic leukaemia", "start": 23, "end": 36}, {"entity_id": "12460237_4_Ent4", "role": "Treatment_Dosage", "text": "high - dose", "start": 25, "end": 28}, {"entity_id": "12460237_4_Ent5", "role": "Treatment_Drug", "text": "cytarabine", "start": 28, "end": 29}, {"entity_id": "12460237_4_Ent3", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukaemia", "start": 33, "end": 36}]}], "entity_mentions": [{"id": "12460237_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12460237_4_Ent1", "text": "recurrent , increasingly severe episodes of PPE , ultimately complicated by a severe bullous eruption", "entity_type": "Entity", "start": 5, "end": 20}, {"id": "12460237_4_Ent2", "text": "cycles of high - dose cytarabine for the treatment of acute lymphoblastic leukaemia", "entity_type": "Entity", "start": 23, "end": 36}, {"id": "12460237_4_Ent4", "text": "high - dose", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "12460237_4_Ent5", "text": "cytarabine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "12460237_4_Ent3", "text": "acute lymphoblastic leukaemia", "entity_type": "Entity", "start": 33, "end": 36}], "lang": "en"}
{"doc_id": "12477460_4", "wnd_id": "12477460_4_1", "text": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer : a case report .", "tokens": ["Ovarian", "endometrioid", "adenocarcinoma", "arising", "from", "an", "endometriotic", "cyst", "in", "a", "postmenopausal", "woman", "under", "tamoxifen", "therapy", "for", "breast", "cancer", ":", "a", "case", "report", "."], "event_mentions": [{"id": "12477460_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "under", "start": 12, "end": 13}, "arguments": [{"entity_id": "12477460_4_Ent3", "role": "Effect", "text": "Ovarian endometrioid adenocarcinoma", "start": 0, "end": 3}, {"entity_id": "12477460_4_Ent0", "role": "Subject", "text": "a postmenopausal woman", "start": 9, "end": 12}, {"entity_id": "12477460_4_Ent1", "role": "Subject_Age", "text": "postmenopausal", "start": 10, "end": 11}, {"entity_id": "12477460_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "12477460_4_Ent5", "role": "Treatment_Drug", "text": "tamoxifen", "start": 13, "end": 14}, {"entity_id": "12477460_4_Ent4", "role": "Treatment", "text": "tamoxifen therapy", "start": 13, "end": 15}, {"entity_id": "12477460_4_Ent6", "role": "Treatment_Disorder", "text": "breast cancer", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "12477460_4_Ent3", "text": "Ovarian endometrioid adenocarcinoma", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12477460_4_Ent0", "text": "a postmenopausal woman", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12477460_4_Ent1", "text": "postmenopausal", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12477460_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12477460_4_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12477460_4_Ent4", "text": "tamoxifen therapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12477460_4_Ent6", "text": "breast cancer", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "12488741_1", "wnd_id": "12488741_1_1", "text": "Clinical , spectroscopic , and imaging abnormalities resolved with discontinuation of metronidazole .", "tokens": ["Clinical", ",", "spectroscopic", ",", "and", "imaging", "abnormalities", "resolved", "with", "discontinuation", "of", "metronidazole", "."], "event_mentions": [{"id": "12488741_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 7, "end": 8}, "arguments": [{"entity_id": "12488741_1_Ent0", "role": "Effect", "text": "Clinical , spectroscopic , and imaging abnormalities", "start": 0, "end": 7}, {"entity_id": "12488741_1_Ent1", "role": "Treatment", "text": "metronidazole", "start": 11, "end": 12}, {"entity_id": "12488741_1_Ent2", "role": "Treatment_Drug", "text": "metronidazole", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "12488741_1_Ent0", "text": "Clinical , spectroscopic , and imaging abnormalities", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12488741_1_Ent1", "text": "metronidazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12488741_1_Ent2", "text": "metronidazole", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "12503933_6", "wnd_id": "12503933_6_1", "text": "OBJECTIVE : To report a patient developing fulminant liver failure while being treated with clarithromycin for pneumonia .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "patient", "developing", "fulminant", "liver", "failure", "while", "being", "treated", "with", "clarithromycin", "for", "pneumonia", "."], "event_mentions": [{"id": "12503933_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 12, "end": 13}, "arguments": [{"entity_id": "12503933_6_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "12503933_6_Ent1", "role": "Effect", "text": "fulminant liver failure", "start": 7, "end": 10}, {"entity_id": "12503933_6_Ent2", "role": "Treatment", "text": "clarithromycin", "start": 14, "end": 15}, {"entity_id": "12503933_6_Ent3", "role": "Treatment_Drug", "text": "clarithromycin", "start": 14, "end": 15}, {"entity_id": "12503933_6_Ent4", "role": "Treatment_Disorder", "text": "pneumonia", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12503933_6_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "12503933_6_Ent1", "text": "fulminant liver failure", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12503933_6_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12503933_6_Ent3", "text": "clarithromycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12503933_6_Ent4", "text": "pneumonia", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12561997_1", "wnd_id": "12561997_1_1", "text": "Gelatinous transformation of bone marrow following chemotherapy for myeloma .", "tokens": ["Gelatinous", "transformation", "of", "bone", "marrow", "following", "chemotherapy", "for", "myeloma", "."], "event_mentions": [{"id": "12561997_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "12561997_1_Ent0", "role": "Effect", "text": "Gelatinous transformation of bone marrow", "start": 0, "end": 5}, {"entity_id": "12561997_1_Ent1", "role": "Treatment", "text": "chemotherapy", "start": 6, "end": 7}, {"entity_id": "12561997_1_Ent2", "role": "Treatment_Route", "text": "chemotherapy", "start": 6, "end": 7}, {"entity_id": "12561997_1_Ent3", "role": "Treatment_Disorder", "text": "myeloma", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "12561997_1_Ent0", "text": "Gelatinous transformation of bone marrow", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "12561997_1_Ent1", "text": "chemotherapy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12561997_1_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12561997_1_Ent3", "text": "myeloma", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "12587815_1", "wnd_id": "12587815_1_1", "text": "A 16 - year - old boy developed fever , generalized rigidity , leukocytosis , and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium .", "tokens": ["A", "16", "-", "year", "-", "old", "boy", "developed", "fever", ",", "generalized", "rigidity", ",", "leukocytosis", ",", "and", "increased", "serum", "transaminase", "and", "creatine", "kinase", "levels", "while", "receiving", "treatment", "with", "olanzapine", "and", "lithium", "."], "event_mentions": [{"id": "12587815_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "while", "start": 23, "end": 24}, "arguments": [{"entity_id": "12587815_1_Ent0", "role": "Subject", "text": "A 16 - year - old boy", "start": 0, "end": 7}, {"entity_id": "12587815_1_Ent1", "role": "Subject_Age", "text": "16 - year - old", "start": 1, "end": 6}, {"entity_id": "12587815_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "12587815_1_Ent3", "role": "Effect", "text": "fever , generalized rigidity , leukocytosis , and increased serum transaminase and creatine kinase levels", "start": 8, "end": 23}, {"entity_id": "12587815_1_Ent5", "role": "Treatment_Drug", "text": "olanzapine", "start": 27, "end": 28}, {"entity_id": "12587815_1_Ent7", "role": "Combination_Drug", "text": "olanzapine", "start": 27, "end": 28}, {"entity_id": "12587815_1_Ent4", "role": "Treatment", "text": "olanzapine and lithium", "start": 27, "end": 30}, {"entity_id": "12587815_1_Ent6", "role": "Treatment_Drug", "text": "lithium", "start": 29, "end": 30}, {"entity_id": "12587815_1_Ent8", "role": "Combination_Drug", "text": "lithium", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "12587815_1_Ent0", "text": "A 16 - year - old boy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12587815_1_Ent1", "text": "16 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12587815_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12587815_1_Ent3", "text": "fever , generalized rigidity , leukocytosis , and increased serum transaminase and creatine kinase levels", "entity_type": "Entity", "start": 8, "end": 23}, {"id": "12587815_1_Ent5", "text": "olanzapine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "12587815_1_Ent7", "text": "olanzapine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "12587815_1_Ent4", "text": "olanzapine and lithium", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "12587815_1_Ent6", "text": "lithium", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "12587815_1_Ent8", "text": "lithium", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "12587815_2", "wnd_id": "12587815_2_1", "text": "Concomitant administration of lithium with olanzapine may place patients at risk for NMS .", "tokens": ["Concomitant", "administration", "of", "lithium", "with", "olanzapine", "may", "place", "patients", "at", "risk", "for", "NMS", "."], "event_mentions": [{"id": "12587815_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 1, "end": 2}, "arguments": [{"entity_id": "12587815_2_Ent2", "role": "Treatment", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "12587815_2_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "12587815_2_Ent6", "role": "Combination_Drug", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "12587815_2_Ent3", "role": "Treatment", "text": "olanzapine", "start": 5, "end": 6}, {"entity_id": "12587815_2_Ent5", "role": "Treatment_Drug", "text": "olanzapine", "start": 5, "end": 6}, {"entity_id": "12587815_2_Ent7", "role": "Combination_Drug", "text": "olanzapine", "start": 5, "end": 6}, {"entity_id": "12587815_2_Ent0", "role": "Subject", "text": "patients", "start": 8, "end": 9}, {"entity_id": "12587815_2_Ent1", "role": "Effect", "text": "NMS", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12587815_2_Ent2", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12587815_2_Ent4", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12587815_2_Ent6", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12587815_2_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12587815_2_Ent5", "text": "olanzapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12587815_2_Ent7", "text": "olanzapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12587815_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12587815_2_Ent1", "text": "NMS", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12590235_5", "wnd_id": "12590235_5_1", "text": "We describe a case of significant elevation of serum transaminases in a patient treated with 6 - TG for a flare of Crohn 's disease .", "tokens": ["We", "describe", "a", "case", "of", "significant", "elevation", "of", "serum", "transaminases", "in", "a", "patient", "treated", "with", "6", "-", "TG", "for", "a", "flare", "of", "Crohn", "'s", "disease", "."], "event_mentions": [{"id": "12590235_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "elevation", "start": 6, "end": 7}, "arguments": [{"entity_id": "12590235_5_Ent1", "role": "Effect", "text": "significant elevation of serum transaminases", "start": 5, "end": 10}, {"entity_id": "12590235_5_Ent0", "role": "Subject", "text": "a patient", "start": 11, "end": 13}, {"entity_id": "12590235_5_Ent2", "role": "Treatment", "text": "6 - TG", "start": 15, "end": 18}, {"entity_id": "12590235_5_Ent4", "role": "Treatment_Drug", "text": "6 - TG", "start": 15, "end": 18}, {"entity_id": "12590235_5_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "12590235_5_Ent1", "text": "significant elevation of serum transaminases", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12590235_5_Ent0", "text": "a patient", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "12590235_5_Ent2", "text": "6 - TG", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "12590235_5_Ent4", "text": "6 - TG", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "12590235_5_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "1261772_1", "wnd_id": "1261772_1_1", "text": "Fulminant hepatic failure developed in a 24 - year - old black woman who had been treated with propylthiouracil and propranolol for hyperthyroidism .", "tokens": ["Fulminant", "hepatic", "failure", "developed", "in", "a", "24", "-", "year", "-", "old", "black", "woman", "who", "had", "been", "treated", "with", "propylthiouracil", "and", "propranolol", "for", "hyperthyroidism", "."], "event_mentions": [{"id": "1261772_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "1261772_1_Ent4", "role": "Effect", "text": "Fulminant hepatic failure", "start": 0, "end": 3}, {"entity_id": "1261772_1_Ent0", "role": "Subject", "text": "a 24 - year - old black woman", "start": 5, "end": 13}, {"entity_id": "1261772_1_Ent1", "role": "Subject_Age", "text": "24 - year - old", "start": 6, "end": 11}, {"entity_id": "1261772_1_Ent2", "role": "Subject_Race", "text": "black", "start": 11, "end": 12}, {"entity_id": "1261772_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 12, "end": 13}, {"entity_id": "1261772_1_Ent6", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 18, "end": 19}, {"entity_id": "1261772_1_Ent10", "role": "Combination_Drug", "text": "propylthiouracil", "start": 18, "end": 19}, {"entity_id": "1261772_1_Ent5", "role": "Treatment", "text": "propylthiouracil and propranolol", "start": 18, "end": 21}, {"entity_id": "1261772_1_Ent7", "role": "Treatment_Drug", "text": "propranolol", "start": 20, "end": 21}, {"entity_id": "1261772_1_Ent9", "role": "Combination_Drug", "text": "propranolol", "start": 20, "end": 21}, {"entity_id": "1261772_1_Ent8", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "1261772_1_Ent4", "text": "Fulminant hepatic failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1261772_1_Ent0", "text": "a 24 - year - old black woman", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "1261772_1_Ent1", "text": "24 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "1261772_1_Ent2", "text": "black", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1261772_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1261772_1_Ent6", "text": "propylthiouracil", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1261772_1_Ent10", "text": "propylthiouracil", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1261772_1_Ent5", "text": "propylthiouracil and propranolol", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "1261772_1_Ent7", "text": "propranolol", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "1261772_1_Ent9", "text": "propranolol", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "1261772_1_Ent8", "text": "hyperthyroidism", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "12621956_2", "wnd_id": "12621956_2_1", "text": "This is a case report of subtle , mild hypothermia in a 54 - year old female patient receiving risperidone for schizophrenia .", "tokens": ["This", "is", "a", "case", "report", "of", "subtle", ",", "mild", "hypothermia", "in", "a", "54", "-", "year", "old", "female", "patient", "receiving", "risperidone", "for", "schizophrenia", "."], "event_mentions": [{"id": "12621956_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 18, "end": 19}, "arguments": [{"entity_id": "12621956_2_Ent3", "role": "Effect", "text": "mild hypothermia", "start": 8, "end": 10}, {"entity_id": "12621956_2_Ent0", "role": "Subject", "text": "a 54 - year old female patient", "start": 11, "end": 18}, {"entity_id": "12621956_2_Ent1", "role": "Subject_Age", "text": "54 - year old", "start": 12, "end": 16}, {"entity_id": "12621956_2_Ent2", "role": "Subject_Gender", "text": "female", "start": 16, "end": 17}, {"entity_id": "12621956_2_Ent4", "role": "Treatment", "text": "risperidone", "start": 19, "end": 20}, {"entity_id": "12621956_2_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 19, "end": 20}, {"entity_id": "12621956_2_Ent6", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "12621956_2_Ent3", "text": "mild hypothermia", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12621956_2_Ent0", "text": "a 54 - year old female patient", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "12621956_2_Ent1", "text": "54 - year old", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "12621956_2_Ent2", "text": "female", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12621956_2_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "12621956_2_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "12621956_2_Ent6", "text": "schizophrenia", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "12625995_3", "wnd_id": "12625995_3_1", "text": "Two cases of childhood - onset schizophrenia associated with clozapine - induced akathisia responsive to beta - blocker treatment are described .", "tokens": ["Two", "cases", "of", "childhood", "-", "onset", "schizophrenia", "associated", "with", "clozapine", "-", "induced", "akathisia", "responsive", "to", "beta", "-", "blocker", "treatment", "are", "described", "."], "event_mentions": [{"id": "12625995_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "12625995_3_Ent8", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "12625995_3_Ent7", "role": "Subject", "text": "Two cases of childhood - onset schizophrenia", "start": 0, "end": 7}, {"entity_id": "12625995_3_Ent9", "role": "Subject_Age", "text": "childhood", "start": 3, "end": 4}, {"entity_id": "12625995_3_Ent12", "role": "Treatment_Disorder", "text": "clozapine - induced akathisia responsive", "start": 9, "end": 14}, {"entity_id": "12625995_3_Ent11", "role": "Treatment_Drug", "text": "beta - blocker", "start": 15, "end": 18}, {"entity_id": "12625995_3_Ent10", "role": "Treatment", "text": "beta - blocker treatment", "start": 15, "end": 19}]}, {"id": "12625995_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "12625995_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "12625995_3_Ent0", "role": "Subject", "text": "Two cases of childhood - onset schizophrenia", "start": 0, "end": 7}, {"entity_id": "12625995_3_Ent2", "role": "Subject_Age", "text": "childhood", "start": 3, "end": 4}, {"entity_id": "12625995_3_Ent6", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 6, "end": 7}, {"entity_id": "12625995_3_Ent4", "role": "Treatment", "text": "clozapine", "start": 9, "end": 10}, {"entity_id": "12625995_3_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 9, "end": 10}, {"entity_id": "12625995_3_Ent3", "role": "Effect", "text": "akathisia responsive", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "12625995_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12625995_3_Ent8", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12625995_3_Ent0", "text": "Two cases of childhood - onset schizophrenia", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12625995_3_Ent7", "text": "Two cases of childhood - onset schizophrenia", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12625995_3_Ent2", "text": "childhood", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12625995_3_Ent9", "text": "childhood", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12625995_3_Ent6", "text": "schizophrenia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12625995_3_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12625995_3_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12625995_3_Ent12", "text": "clozapine - induced akathisia responsive", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "12625995_3_Ent3", "text": "akathisia responsive", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "12625995_3_Ent11", "text": "beta - blocker", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "12625995_3_Ent10", "text": "beta - blocker treatment", "entity_type": "Entity", "start": 15, "end": 19}], "lang": "en"}
{"doc_id": "12656748_3", "wnd_id": "12656748_3_1", "text": "There are no previous reports in the literature about the emergence of CML during treatment with hydroxyurea .", "tokens": ["There", "are", "no", "previous", "reports", "in", "the", "literature", "about", "the", "emergence", "of", "CML", "during", "treatment", "with", "hydroxyurea", "."], "event_mentions": [{"id": "12656748_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 13, "end": 14}, "arguments": [{"entity_id": "12656748_3_Ent0", "role": "Effect", "text": "CML", "start": 12, "end": 13}, {"entity_id": "12656748_3_Ent1", "role": "Treatment", "text": "treatment with hydroxyurea", "start": 14, "end": 17}, {"entity_id": "12656748_3_Ent2", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12656748_3_Ent0", "text": "CML", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12656748_3_Ent1", "text": "treatment with hydroxyurea", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "12656748_3_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12659609_3", "wnd_id": "12659609_3_1", "text": "CASE SUMMARY : A febrile 36 - year - old seaman from Mumbai ( Bombay ) was prescribed > 5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship .", "tokens": ["CASE", "SUMMARY", ":", "A", "febrile", "36", "-", "year", "-", "old", "seaman", "from", "Mumbai", "(", "Bombay", ")", "was", "prescribed", ">", "5", "times", "the", "usual", "dose", "of", "chloroquine", "for", "malaria", "diagnosed", "empirically", "onboard", "ship", "."], "event_mentions": [{"id": "12659609_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 17, "end": 18}, "arguments": [{"entity_id": "12659609_3_Ent0", "role": "Subject", "text": "A febrile 36 - year - old seaman from Mumbai ( Bombay )", "start": 3, "end": 16}, {"entity_id": "12659609_3_Ent1", "role": "Subject_Disorder", "text": "febrile", "start": 4, "end": 5}, {"entity_id": "12659609_3_Ent2", "role": "Subject_Age", "text": "36 - year - old", "start": 5, "end": 10}, {"entity_id": "12659609_3_Ent3", "role": "Subject_Race", "text": "Mumbai ( Bombay )", "start": 12, "end": 16}, {"entity_id": "12659609_3_Ent7", "role": "Treatment_Dosage", "text": "> 5 times the usual dose", "start": 18, "end": 24}, {"entity_id": "12659609_3_Ent4", "role": "Treatment", "text": "> 5 times the usual dose of chloroquine", "start": 18, "end": 26}, {"entity_id": "12659609_3_Ent6", "role": "Treatment_Drug", "text": "chloroquine", "start": 25, "end": 26}, {"entity_id": "12659609_3_Ent5", "role": "Treatment_Disorder", "text": "malaria", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "12659609_3_Ent0", "text": "A febrile 36 - year - old seaman from Mumbai ( Bombay )", "entity_type": "Entity", "start": 3, "end": 16}, {"id": "12659609_3_Ent1", "text": "febrile", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12659609_3_Ent2", "text": "36 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12659609_3_Ent3", "text": "Mumbai ( Bombay )", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "12659609_3_Ent7", "text": "> 5 times the usual dose", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "12659609_3_Ent4", "text": "> 5 times the usual dose of chloroquine", "entity_type": "Entity", "start": 18, "end": 26}, {"id": "12659609_3_Ent6", "text": "chloroquine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "12659609_3_Ent5", "text": "malaria", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "12659609_4", "wnd_id": "12659609_4_1", "text": "His fever resolved , but he developed symptoms consistent with those of chloroquine toxicity .", "tokens": ["His", "fever", "resolved", ",", "but", "he", "developed", "symptoms", "consistent", "with", "those", "of", "chloroquine", "toxicity", "."], "event_mentions": [{"id": "12659609_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "12659609_4_Ent0", "role": "Subject", "text": "he", "start": 5, "end": 6}, {"entity_id": "12659609_4_Ent1", "role": "Subject_Gender", "text": "he", "start": 5, "end": 6}, {"entity_id": "12659609_4_Ent2", "role": "Effect", "text": "symptoms consistent with those of chloroquine toxicity", "start": 7, "end": 14}, {"entity_id": "12659609_4_Ent3", "role": "Treatment", "text": "chloroquine", "start": 12, "end": 13}, {"entity_id": "12659609_4_Ent4", "role": "Treatment_Drug", "text": "chloroquine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12659609_4_Ent0", "text": "he", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12659609_4_Ent1", "text": "he", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12659609_4_Ent2", "text": "symptoms consistent with those of chloroquine toxicity", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "12659609_4_Ent3", "text": "chloroquine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12659609_4_Ent4", "text": "chloroquine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12661801_3", "wnd_id": "12661801_3_1", "text": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor ( G - CSF ) .", "tokens": ["We", "present", "the", "management", "of", "agranulocytosis", "and", "neutropenic", "sepsis", "secondary", "to", "carbimazole", "with", "recombinant", "human", "granulocyte", "colony", "stimulating", "factor", "(", "G", "-", "CSF", ")", "."], "event_mentions": [{"id": "12661801_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 9, "end": 10}, "arguments": [{"entity_id": "12661801_3_Ent0", "role": "Effect", "text": "agranulocytosis and neutropenic sepsis", "start": 5, "end": 9}, {"entity_id": "12661801_3_Ent2", "role": "Treatment_Drug", "text": "carbimazole", "start": 11, "end": 12}, {"entity_id": "12661801_3_Ent5", "role": "Combination_Drug", "text": "carbimazole", "start": 11, "end": 12}, {"entity_id": "12661801_3_Ent1", "role": "Treatment", "text": "carbimazole with recombinant human granulocyte colony stimulating factor ( G - CSF )", "start": 11, "end": 24}, {"entity_id": "12661801_3_Ent3", "role": "Treatment_Drug", "text": "recombinant human granulocyte colony stimulating factor", "start": 13, "end": 19}, {"entity_id": "12661801_3_Ent4", "role": "Combination_Drug", "text": "recombinant human granulocyte colony stimulating factor", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "12661801_3_Ent0", "text": "agranulocytosis and neutropenic sepsis", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "12661801_3_Ent2", "text": "carbimazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12661801_3_Ent5", "text": "carbimazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12661801_3_Ent1", "text": "carbimazole with recombinant human granulocyte colony stimulating factor ( G - CSF )", "entity_type": "Entity", "start": 11, "end": 24}, {"id": "12661801_3_Ent3", "text": "recombinant human granulocyte colony stimulating factor", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "12661801_3_Ent4", "text": "recombinant human granulocyte colony stimulating factor", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "1267457_2", "wnd_id": "1267457_2_1", "text": "The patient received only the ophthalmic sulfonamide , and it was used for one day , but he developed Stevens - Johnson syndrome .", "tokens": ["The", "patient", "received", "only", "the", "ophthalmic", "sulfonamide", ",", "and", "it", "was", "used", "for", "one", "day", ",", "but", "he", "developed", "Stevens", "-", "Johnson", "syndrome", "."], "event_mentions": [{"id": "1267457_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "1267457_2_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "1267457_2_Ent5", "role": "Treatment_Route", "text": "ophthalmic", "start": 5, "end": 6}, {"entity_id": "1267457_2_Ent4", "role": "Treatment", "text": "ophthalmic sulfonamide , and it was used for one day", "start": 5, "end": 15}, {"entity_id": "1267457_2_Ent6", "role": "Treatment_Drug", "text": "sulfonamide", "start": 6, "end": 7}, {"entity_id": "1267457_2_Ent7", "role": "Treatment_Duration", "text": "one day", "start": 13, "end": 15}, {"entity_id": "1267457_2_Ent1", "role": "Subject", "text": "he", "start": 17, "end": 18}, {"entity_id": "1267457_2_Ent2", "role": "Subject_Gender", "text": "he", "start": 17, "end": 18}, {"entity_id": "1267457_2_Ent3", "role": "Effect", "text": "Stevens - Johnson syndrome", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "1267457_2_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1267457_2_Ent5", "text": "ophthalmic", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1267457_2_Ent4", "text": "ophthalmic sulfonamide , and it was used for one day", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "1267457_2_Ent6", "text": "sulfonamide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1267457_2_Ent7", "text": "one day", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "1267457_2_Ent1", "text": "he", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1267457_2_Ent2", "text": "he", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1267457_2_Ent3", "text": "Stevens - Johnson syndrome", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "12692521_2", "wnd_id": "12692521_2_1", "text": "We present two cases in which both patients suffered with CLS , which we believe was caused following administration of granulocyte colony - stimulating factor , to our knowledge not described in the intensive care patient previously .", "tokens": ["We", "present", "two", "cases", "in", "which", "both", "patients", "suffered", "with", "CLS", ",", "which", "we", "believe", "was", "caused", "following", "administration", "of", "granulocyte", "colony", "-", "stimulating", "factor", ",", "to", "our", "knowledge", "not", "described", "in", "the", "intensive", "care", "patient", "previously", "."], "event_mentions": [{"id": "12692521_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 18, "end": 19}, "arguments": [{"entity_id": "12692521_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "12692521_2_Ent0", "role": "Subject", "text": "two cases in which both patients suffered with CLS", "start": 2, "end": 11}, {"entity_id": "12692521_2_Ent2", "role": "Effect", "text": "CLS", "start": 10, "end": 11}, {"entity_id": "12692521_2_Ent3", "role": "Treatment", "text": "granulocyte colony - stimulating factor", "start": 20, "end": 25}, {"entity_id": "12692521_2_Ent4", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "12692521_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12692521_2_Ent0", "text": "two cases in which both patients suffered with CLS", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "12692521_2_Ent2", "text": "CLS", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12692521_2_Ent3", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "12692521_2_Ent4", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "12699871_1", "wnd_id": "12699871_1_1", "text": "FK506 , which began to be administered 12 days earlier , rose to a level of 44 ng / mL ( normal range , 10 - 20 ng / mL ) 1 day before neurologic abnormalities began .", "tokens": ["FK506", ",", "which", "began", "to", "be", "administered", "12", "days", "earlier", ",", "rose", "to", "a", "level", "of", "44", "ng", "/", "mL", "(", "normal", "range", ",", "10", "-", "20", "ng", "/", "mL", ")", "1", "day", "before", "neurologic", "abnormalities", "began", "."], "event_mentions": [{"id": "12699871_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "before", "start": 33, "end": 34}, "arguments": [{"entity_id": "12699871_1_Ent2", "role": "Treatment_Drug", "text": "FK506", "start": 0, "end": 1}, {"entity_id": "12699871_1_Ent1", "role": "Treatment", "text": "FK506 , which began to be administered 12 days earlier , rose to a level of 44 ng / mL ( normal range , 10 - 20 ng / mL )", "start": 0, "end": 31}, {"entity_id": "12699871_1_Ent3", "role": "Treatment_Time_elapsed", "text": "12 days earlier", "start": 7, "end": 10}, {"entity_id": "12699871_1_Ent0", "role": "Effect", "text": "neurologic abnormalities began", "start": 34, "end": 37}]}], "entity_mentions": [{"id": "12699871_1_Ent2", "text": "FK506", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12699871_1_Ent1", "text": "FK506 , which began to be administered 12 days earlier , rose to a level of 44 ng / mL ( normal range , 10 - 20 ng / mL )", "entity_type": "Entity", "start": 0, "end": 31}, {"id": "12699871_1_Ent3", "text": "12 days earlier", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12699871_1_Ent0", "text": "neurologic abnormalities began", "entity_type": "Entity", "start": 34, "end": 37}], "lang": "en"}
{"doc_id": "12729371_2", "wnd_id": "12729371_2_1", "text": "We report a case of AILD in an 80 - year - old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration .", "tokens": ["We", "report", "a", "case", "of", "AILD", "in", "an", "80", "-", "year", "-", "old", "male", "who", "presented", "with", "a", "generalized", "pruritic", "maculopapular", "eruption", "and", "fever", "following", "doxycycline", "administration", "."], "event_mentions": [{"id": "12729371_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 15, "end": 16}, "arguments": [{"entity_id": "12729371_2_Ent0", "role": "Subject", "text": "a case of AILD in an 80 - year - old male", "start": 2, "end": 14}, {"entity_id": "12729371_2_Ent1", "role": "Subject_Disorder", "text": "AILD", "start": 5, "end": 6}, {"entity_id": "12729371_2_Ent2", "role": "Subject_Age", "text": "80 - year - old", "start": 8, "end": 13}, {"entity_id": "12729371_2_Ent3", "role": "Subject_Gender", "text": "male", "start": 13, "end": 14}, {"entity_id": "12729371_2_Ent4", "role": "Effect", "text": "generalized pruritic maculopapular eruption and fever", "start": 18, "end": 24}, {"entity_id": "12729371_2_Ent6", "role": "Treatment_Drug", "text": "doxycycline", "start": 25, "end": 26}, {"entity_id": "12729371_2_Ent5", "role": "Treatment", "text": "doxycycline administration", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "12729371_2_Ent0", "text": "a case of AILD in an 80 - year - old male", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "12729371_2_Ent1", "text": "AILD", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12729371_2_Ent2", "text": "80 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "12729371_2_Ent3", "text": "male", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12729371_2_Ent4", "text": "generalized pruritic maculopapular eruption and fever", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "12729371_2_Ent6", "text": "doxycycline", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "12729371_2_Ent5", "text": "doxycycline administration", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "1275625_4", "wnd_id": "1275625_4_1", "text": "A case is reported in which severe hypocalcemia , with a low plasma parathyroid hormone ( PTH ) concentration , resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy .", "tokens": ["A", "case", "is", "reported", "in", "which", "severe", "hypocalcemia", ",", "with", "a", "low", "plasma", "parathyroid", "hormone", "(", "PTH", ")", "concentration", ",", "resulted", "from", "the", "therapeutic", "use", "of", "magnesium", "sulfate", "for", "toxemia", "of", "pregnancy", "."], "event_mentions": [{"id": "1275625_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 20, "end": 21}, "arguments": [{"entity_id": "1275625_4_Ent0", "role": "Effect", "text": "severe hypocalcemia , with a low plasma parathyroid hormone ( PTH ) concentration", "start": 6, "end": 19}, {"entity_id": "1275625_4_Ent1", "role": "Treatment", "text": "magnesium sulfate", "start": 26, "end": 28}, {"entity_id": "1275625_4_Ent3", "role": "Treatment_Drug", "text": "magnesium sulfate", "start": 26, "end": 28}, {"entity_id": "1275625_4_Ent2", "role": "Treatment_Disorder", "text": "toxemia of pregnancy", "start": 29, "end": 32}]}], "entity_mentions": [{"id": "1275625_4_Ent0", "text": "severe hypocalcemia , with a low plasma parathyroid hormone ( PTH ) concentration", "entity_type": "Entity", "start": 6, "end": 19}, {"id": "1275625_4_Ent1", "text": "magnesium sulfate", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "1275625_4_Ent3", "text": "magnesium sulfate", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "1275625_4_Ent2", "text": "toxemia of pregnancy", "entity_type": "Entity", "start": 29, "end": 32}], "lang": "en"}
{"doc_id": "12776809_2", "wnd_id": "12776809_2_1", "text": "Coumarin is reported to elevate liver function tests ( LFT ) values .", "tokens": ["Coumarin", "is", "reported", "to", "elevate", "liver", "function", "tests", "(", "LFT", ")", "values", "."], "event_mentions": [{"id": "12776809_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 2, "end": 3}, "arguments": [{"entity_id": "12776809_2_Ent1", "role": "Treatment", "text": "Coumarin", "start": 0, "end": 1}, {"entity_id": "12776809_2_Ent2", "role": "Treatment_Drug", "text": "Coumarin", "start": 0, "end": 1}, {"entity_id": "12776809_2_Ent0", "role": "Effect", "text": "elevate liver function tests ( LFT ) values", "start": 4, "end": 12}]}], "entity_mentions": [{"id": "12776809_2_Ent1", "text": "Coumarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12776809_2_Ent2", "text": "Coumarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12776809_2_Ent0", "text": "elevate liver function tests ( LFT ) values", "entity_type": "Entity", "start": 4, "end": 12}], "lang": "en"}
{"doc_id": "12786839_1", "wnd_id": "12786839_1_1", "text": "In both cases , high fever , skin rash , liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP .", "tokens": ["In", "both", "cases", ",", "high", "fever", ",", "skin", "rash", ",", "liver", "dysfunction", "and", "atypical", "lymphocytosis", "developed", "3", "weeks", "after", "initiating", "treatment", "with", "SASP", "."], "event_mentions": [{"id": "12786839_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "12786839_1_Ent0", "role": "Subject", "text": "In both cases", "start": 0, "end": 3}, {"entity_id": "12786839_1_Ent1", "role": "Subject_Population", "text": "both", "start": 1, "end": 2}, {"entity_id": "12786839_1_Ent2", "role": "Effect", "text": "high fever , skin rash , liver dysfunction and atypical lymphocytosis", "start": 4, "end": 15}, {"entity_id": "12786839_1_Ent3", "role": "Treatment", "text": "SASP", "start": 22, "end": 23}, {"entity_id": "12786839_1_Ent4", "role": "Treatment_Drug", "text": "SASP", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "12786839_1_Ent0", "text": "In both cases", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12786839_1_Ent1", "text": "both", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12786839_1_Ent2", "text": "high fever , skin rash , liver dysfunction and atypical lymphocytosis", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "12786839_1_Ent3", "text": "SASP", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12786839_1_Ent4", "text": "SASP", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "12792223_3", "wnd_id": "12792223_3_1", "text": "Infliximab therapy may cause a lupus - like syndrome that is reversible upon discontinuing this agent .", "tokens": ["Infliximab", "therapy", "may", "cause", "a", "lupus", "-", "like", "syndrome", "that", "is", "reversible", "upon", "discontinuing", "this", "agent", "."], "event_mentions": [{"id": "12792223_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "12792223_3_Ent2", "role": "Treatment_Drug", "text": "Infliximab", "start": 0, "end": 1}, {"entity_id": "12792223_3_Ent1", "role": "Treatment", "text": "Infliximab therapy", "start": 0, "end": 2}, {"entity_id": "12792223_3_Ent0", "role": "Effect", "text": "lupus - like syndrome", "start": 5, "end": 9}]}], "entity_mentions": [{"id": "12792223_3_Ent2", "text": "Infliximab", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12792223_3_Ent1", "text": "Infliximab therapy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12792223_3_Ent0", "text": "lupus - like syndrome", "entity_type": "Entity", "start": 5, "end": 9}], "lang": "en"}
{"doc_id": "12802933_2", "wnd_id": "12802933_2_1", "text": "The pathophysiological mechanisms remain unknown , although the drug could act through massive cytokines liberation after destruction of CD20 positive cells by rituximab .", "tokens": ["The", "pathophysiological", "mechanisms", "remain", "unknown", ",", "although", "the", "drug", "could", "act", "through", "massive", "cytokines", "liberation", "after", "destruction", "of", "CD20", "positive", "cells", "by", "rituximab", "."], "event_mentions": [{"id": "12802933_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "act", "start": 10, "end": 11}, "arguments": [{"entity_id": "12802933_2_Ent0", "role": "Effect", "text": "massive cytokines liberation", "start": 12, "end": 15}, {"entity_id": "12802933_2_Ent1", "role": "Effect", "text": "destruction of CD20 positive cells", "start": 16, "end": 21}, {"entity_id": "12802933_2_Ent2", "role": "Treatment", "text": "rituximab", "start": 22, "end": 23}, {"entity_id": "12802933_2_Ent3", "role": "Treatment_Drug", "text": "rituximab", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "12802933_2_Ent0", "text": "massive cytokines liberation", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "12802933_2_Ent1", "text": "destruction of CD20 positive cells", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "12802933_2_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12802933_2_Ent3", "text": "rituximab", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "12811715_3", "wnd_id": "12811715_3_1", "text": "However , because diphenhydramine also exhibits type IA sodium channel blockade , cardiac toxicity is also possible .", "tokens": ["However", ",", "because", "diphenhydramine", "also", "exhibits", "type", "IA", "sodium", "channel", "blockade", ",", "cardiac", "toxicity", "is", "also", "possible", "."], "event_mentions": [{"id": "12811715_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "because", "start": 2, "end": 3}, "arguments": [{"entity_id": "12811715_3_Ent1", "role": "Treatment", "text": "diphenhydramine", "start": 3, "end": 4}, {"entity_id": "12811715_3_Ent2", "role": "Treatment_Drug", "text": "diphenhydramine", "start": 3, "end": 4}, {"entity_id": "12811715_3_Ent0", "role": "Effect", "text": "also exhibits type IA sodium channel blockade , cardiac toxicity", "start": 4, "end": 14}]}], "entity_mentions": [{"id": "12811715_3_Ent1", "text": "diphenhydramine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12811715_3_Ent2", "text": "diphenhydramine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12811715_3_Ent0", "text": "also exhibits type IA sodium channel blockade , cardiac toxicity", "entity_type": "Entity", "start": 4, "end": 14}], "lang": "en"}
{"doc_id": "12823045_1", "wnd_id": "12823045_1_1", "text": "We describe a patient with extranodal non - Hodgkin lymphoma who developed systemic candidiasis after treatment with a cyclophosphamide - based chemotherapy regimen .", "tokens": ["We", "describe", "a", "patient", "with", "extranodal", "non", "-", "Hodgkin", "lymphoma", "who", "developed", "systemic", "candidiasis", "after", "treatment", "with", "a", "cyclophosphamide", "-", "based", "chemotherapy", "regimen", "."], "event_mentions": [{"id": "12823045_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 15, "end": 16}, "arguments": [{"entity_id": "12823045_1_Ent0", "role": "Subject", "text": "a patient with extranodal non - Hodgkin lymphoma", "start": 2, "end": 10}, {"entity_id": "12823045_1_Ent3", "role": "Treatment_Disorder", "text": "extranodal non - Hodgkin lymphoma", "start": 5, "end": 10}, {"entity_id": "12823045_1_Ent1", "role": "Effect", "text": "systemic candidiasis", "start": 12, "end": 14}, {"entity_id": "12823045_1_Ent2", "role": "Treatment", "text": "a cyclophosphamide - based chemotherapy regimen .", "start": 17, "end": 24}, {"entity_id": "12823045_1_Ent4", "role": "Treatment_Drug", "text": "cyclophosphamide - based chemotherapy", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "12823045_1_Ent0", "text": "a patient with extranodal non - Hodgkin lymphoma", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "12823045_1_Ent3", "text": "extranodal non - Hodgkin lymphoma", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12823045_1_Ent1", "text": "systemic candidiasis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "12823045_1_Ent2", "text": "a cyclophosphamide - based chemotherapy regimen .", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "12823045_1_Ent4", "text": "cyclophosphamide - based chemotherapy", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "12836099_1", "wnd_id": "12836099_1_1", "text": "Stevens - Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy .", "tokens": ["Stevens", "-", "Johnson", "syndrome", "in", "a", "boy", "with", "nephrotic", "syndrome", "during", "prednisolone", "therapy", "."], "event_mentions": [{"id": "12836099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "12836099_1_Ent2", "role": "Effect", "text": "Stevens - Johnson syndrome", "start": 0, "end": 4}, {"entity_id": "12836099_1_Ent0", "role": "Subject", "text": "a boy with nephrotic syndrome", "start": 5, "end": 10}, {"entity_id": "12836099_1_Ent1", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "12836099_1_Ent5", "role": "Treatment_Disorder", "text": "nephrotic syndrome", "start": 8, "end": 10}, {"entity_id": "12836099_1_Ent3", "role": "Treatment", "text": "prednisolone", "start": 11, "end": 12}, {"entity_id": "12836099_1_Ent4", "role": "Treatment_Drug", "text": "prednisolone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "12836099_1_Ent2", "text": "Stevens - Johnson syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12836099_1_Ent0", "text": "a boy with nephrotic syndrome", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12836099_1_Ent1", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12836099_1_Ent5", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12836099_1_Ent3", "text": "prednisolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12836099_1_Ent4", "text": "prednisolone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "12851279_1", "wnd_id": "12851279_1_1", "text": "Efficacy and safety of tifacogin ( recombinant tissue factor pathway inhibitor ) in severe sepsis : a randomized controlled trial .", "tokens": ["Efficacy", "and", "safety", "of", "tifacogin", "(", "recombinant", "tissue", "factor", "pathway", "inhibitor", ")", "in", "severe", "sepsis", ":", "a", "randomized", "controlled", "trial", "."], "event_mentions": [{"id": "12851279_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 12, "end": 13}, "arguments": [{"entity_id": "12851279_1_Ent0", "role": "Treatment", "text": "tifacogin ( recombinant tissue factor pathway inhibitor )", "start": 4, "end": 12}, {"entity_id": "12851279_1_Ent2", "role": "Treatment_Drug", "text": "tifacogin ( recombinant tissue factor pathway inhibitor )", "start": 4, "end": 12}, {"entity_id": "12851279_1_Ent1", "role": "Treatment_Disorder", "text": "severe sepsis", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "12851279_1_Ent0", "text": "tifacogin ( recombinant tissue factor pathway inhibitor )", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "12851279_1_Ent2", "text": "tifacogin ( recombinant tissue factor pathway inhibitor )", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "12851279_1_Ent1", "text": "severe sepsis", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "12854039_5", "wnd_id": "12854039_5_1", "text": "Multiple sclerosis - like disease secondary to alpha interferon .", "tokens": ["Multiple", "sclerosis", "-", "like", "disease", "secondary", "to", "alpha", "interferon", "."], "event_mentions": [{"id": "12854039_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 5, "end": 6}, "arguments": [{"entity_id": "12854039_5_Ent0", "role": "Effect", "text": "Multiple sclerosis - like disease", "start": 0, "end": 5}, {"entity_id": "12854039_5_Ent1", "role": "Treatment", "text": "alpha interferon", "start": 7, "end": 9}, {"entity_id": "12854039_5_Ent2", "role": "Treatment_Drug", "text": "alpha interferon", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "12854039_5_Ent0", "text": "Multiple sclerosis - like disease", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "12854039_5_Ent1", "text": "alpha interferon", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12854039_5_Ent2", "text": "alpha interferon", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "12875956_3", "wnd_id": "12875956_3_1", "text": "The psychotic behavior resolved completely soon after the discontinuation of levetiracetam .", "tokens": ["The", "psychotic", "behavior", "resolved", "completely", "soon", "after", "the", "discontinuation", "of", "levetiracetam", "."], "event_mentions": [{"id": "12875956_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 3, "end": 4}, "arguments": [{"entity_id": "12875956_3_Ent1", "role": "Treatment_Disorder", "text": "psychotic behavior", "start": 1, "end": 3}, {"entity_id": "12875956_3_Ent2", "role": "Treatment_Time_elapsed", "text": "soon after", "start": 5, "end": 7}, {"entity_id": "12875956_3_Ent0", "role": "Treatment", "text": "discontinuation of levetiracetam", "start": 8, "end": 11}, {"entity_id": "12875956_3_Ent3", "role": "Treatment_Drug", "text": "levetiracetam", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "12875956_3_Ent1", "text": "psychotic behavior", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "12875956_3_Ent2", "text": "soon after", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12875956_3_Ent0", "text": "discontinuation of levetiracetam", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "12875956_3_Ent3", "text": "levetiracetam", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "12880504_2", "wnd_id": "12880504_2_1", "text": "Obsessive - compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation .", "tokens": ["Obsessive", "-", "compulsive", "symptoms", "suddenly", "emerged", "10", "days", "after", "starting", "risperidone", "and", "resolved", "within", "3", "days", "of", "discontinuation", "."], "event_mentions": [{"id": "12880504_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "emerged", "start": 5, "end": 6}, "arguments": [{"entity_id": "12880504_2_Ent0", "role": "Effect", "text": "Obsessive - compulsive symptoms", "start": 0, "end": 4}, {"entity_id": "12880504_2_Ent1", "role": "Treatment", "text": "risperidone", "start": 10, "end": 11}, {"entity_id": "12880504_2_Ent2", "role": "Treatment_Drug", "text": "risperidone", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "12880504_2_Ent0", "text": "Obsessive - compulsive symptoms", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12880504_2_Ent1", "text": "risperidone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12880504_2_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "12880504_3", "wnd_id": "12880504_3_1", "text": "Risperidone - induced obsessive - compulsive symptoms in two children .", "tokens": ["Risperidone", "-", "induced", "obsessive", "-", "compulsive", "symptoms", "in", "two", "children", "."], "event_mentions": [{"id": "12880504_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12880504_3_Ent4", "role": "Treatment", "text": "Risperidone", "start": 0, "end": 1}, {"entity_id": "12880504_3_Ent5", "role": "Treatment_Drug", "text": "Risperidone", "start": 0, "end": 1}, {"entity_id": "12880504_3_Ent3", "role": "Effect", "text": "obsessive - compulsive symptoms", "start": 3, "end": 7}, {"entity_id": "12880504_3_Ent1", "role": "Subject_Population", "text": "two", "start": 8, "end": 9}, {"entity_id": "12880504_3_Ent0", "role": "Subject", "text": "two children", "start": 8, "end": 10}, {"entity_id": "12880504_3_Ent2", "role": "Subject_Age", "text": "children", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "12880504_3_Ent4", "text": "Risperidone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12880504_3_Ent5", "text": "Risperidone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12880504_3_Ent3", "text": "obsessive - compulsive symptoms", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "12880504_3_Ent1", "text": "two", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12880504_3_Ent0", "text": "two children", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12880504_3_Ent2", "text": "children", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "12885108_1", "wnd_id": "12885108_1_1", "text": "Possible heart failure exacerbation associated with rosiglitazone : case report and literature review .", "tokens": ["Possible", "heart", "failure", "exacerbation", "associated", "with", "rosiglitazone", ":", "case", "report", "and", "literature", "review", "."], "event_mentions": [{"id": "12885108_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "12885108_1_Ent0", "role": "Effect", "text": "heart failure exacerbation", "start": 1, "end": 4}, {"entity_id": "12885108_1_Ent1", "role": "Treatment", "text": "rosiglitazone", "start": 6, "end": 7}, {"entity_id": "12885108_1_Ent2", "role": "Treatment_Drug", "text": "rosiglitazone", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "12885108_1_Ent0", "text": "heart failure exacerbation", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "12885108_1_Ent1", "text": "rosiglitazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12885108_1_Ent2", "text": "rosiglitazone", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "12891225_2", "wnd_id": "12891225_2_1", "text": "Aprepitant is a neurokinin(1 ) receptor antagonist that enhances prevention of chemotherapy - induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist .", "tokens": ["Aprepitant", "is", "a", "neurokinin(1", ")", "receptor", "antagonist", "that", "enhances", "prevention", "of", "chemotherapy", "-", "induced", "nausea", "and", "vomiting", "when", "added", "to", "conventional", "therapy", "with", "a", "corticosteroid", "and", "a", "5", "-", "hydroxytryptamine(3", ")", "(", "5", "-", "HT(3", ")", ")", "antagonist", "."], "event_mentions": [{"id": "12891225_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "enhances", "start": 8, "end": 9}, "arguments": [{"entity_id": "12891225_2_Ent1", "role": "Treatment", "text": "Aprepitant", "start": 0, "end": 1}, {"entity_id": "12891225_2_Ent3", "role": "Treatment_Drug", "text": "Aprepitant", "start": 0, "end": 1}, {"entity_id": "12891225_2_Ent6", "role": "Combination_Drug", "text": "Aprepitant", "start": 0, "end": 1}, {"entity_id": "12891225_2_Ent0", "role": "Effect", "text": "prevention of chemotherapy - induced nausea and vomiting", "start": 9, "end": 17}, {"entity_id": "12891225_2_Ent2", "role": "Treatment", "text": "added to conventional therapy with a corticosteroid and a 5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist", "start": 18, "end": 38}, {"entity_id": "12891225_2_Ent4", "role": "Treatment_Drug", "text": "corticosteroid", "start": 24, "end": 25}, {"entity_id": "12891225_2_Ent7", "role": "Combination_Drug", "text": "corticosteroid", "start": 24, "end": 25}, {"entity_id": "12891225_2_Ent5", "role": "Treatment_Drug", "text": "5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist", "start": 27, "end": 38}, {"entity_id": "12891225_2_Ent8", "role": "Combination_Drug", "text": "5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist", "start": 27, "end": 38}]}], "entity_mentions": [{"id": "12891225_2_Ent1", "text": "Aprepitant", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12891225_2_Ent3", "text": "Aprepitant", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12891225_2_Ent6", "text": "Aprepitant", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12891225_2_Ent0", "text": "prevention of chemotherapy - induced nausea and vomiting", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "12891225_2_Ent2", "text": "added to conventional therapy with a corticosteroid and a 5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist", "entity_type": "Entity", "start": 18, "end": 38}, {"id": "12891225_2_Ent4", "text": "corticosteroid", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "12891225_2_Ent7", "text": "corticosteroid", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "12891225_2_Ent5", "text": "5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist", "entity_type": "Entity", "start": 27, "end": 38}, {"id": "12891225_2_Ent8", "text": "5 - hydroxytryptamine(3 ) ( 5 - HT(3 ) ) antagonist", "entity_type": "Entity", "start": 27, "end": 38}], "lang": "en"}
{"doc_id": "12908837_1", "wnd_id": "12908837_1_1", "text": "Behavioral side effects associated with clonazepam may include agitation , aggression , hyperactivity , irritability , property destruction , and temper tantrums .", "tokens": ["Behavioral", "side", "effects", "associated", "with", "clonazepam", "may", "include", "agitation", ",", "aggression", ",", "hyperactivity", ",", "irritability", ",", "property", "destruction", ",", "and", "temper", "tantrums", "."], "event_mentions": [{"id": "12908837_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "12908837_1_Ent1", "role": "Treatment", "text": "clonazepam", "start": 5, "end": 6}, {"entity_id": "12908837_1_Ent2", "role": "Treatment_Drug", "text": "clonazepam", "start": 5, "end": 6}, {"entity_id": "12908837_1_Ent0", "role": "Effect", "text": "agitation , aggression , hyperactivity , irritability , property destruction , and temper tantrums", "start": 8, "end": 22}]}], "entity_mentions": [{"id": "12908837_1_Ent1", "text": "clonazepam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12908837_1_Ent2", "text": "clonazepam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12908837_1_Ent0", "text": "agitation , aggression , hyperactivity , irritability , property destruction , and temper tantrums", "entity_type": "Entity", "start": 8, "end": 22}], "lang": "en"}
{"doc_id": "12923827_3", "wnd_id": "12923827_3_1", "text": "This communication describes a patient who developed Schneiderian first - rank symptoms in the course of treatment with fluvoxamine .", "tokens": ["This", "communication", "describes", "a", "patient", "who", "developed", "Schneiderian", "first", "-", "rank", "symptoms", "in", "the", "course", "of", "treatment", "with", "fluvoxamine", "."], "event_mentions": [{"id": "12923827_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "12923827_3_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "12923827_3_Ent1", "role": "Effect", "text": "Schneiderian first - rank symptoms", "start": 7, "end": 12}, {"entity_id": "12923827_3_Ent2", "role": "Treatment", "text": "fluvoxamine", "start": 18, "end": 19}, {"entity_id": "12923827_3_Ent3", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12923827_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "12923827_3_Ent1", "text": "Schneiderian first - rank symptoms", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12923827_3_Ent2", "text": "fluvoxamine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12923827_3_Ent3", "text": "fluvoxamine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12923827_4", "wnd_id": "12923827_4_1", "text": "This finding suggests that fluvoxamine can precipitate Schneiderian first - rank symptoms in some susceptible patients .", "tokens": ["This", "finding", "suggests", "that", "fluvoxamine", "can", "precipitate", "Schneiderian", "first", "-", "rank", "symptoms", "in", "some", "susceptible", "patients", "."], "event_mentions": [{"id": "12923827_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitate", "start": 6, "end": 7}, "arguments": [{"entity_id": "12923827_4_Ent2", "role": "Treatment", "text": "fluvoxamine", "start": 4, "end": 5}, {"entity_id": "12923827_4_Ent3", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 4, "end": 5}, {"entity_id": "12923827_4_Ent1", "role": "Effect", "text": "Schneiderian first - rank symptoms", "start": 7, "end": 12}, {"entity_id": "12923827_4_Ent0", "role": "Subject", "text": "some susceptible patients", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "12923827_4_Ent2", "text": "fluvoxamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12923827_4_Ent3", "text": "fluvoxamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12923827_4_Ent1", "text": "Schneiderian first - rank symptoms", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12923827_4_Ent0", "text": "some susceptible patients", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "12932249_3", "wnd_id": "12932249_3_1", "text": "We describe two dark - skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with IFN and ribavirin .", "tokens": ["We", "describe", "two", "dark", "-", "skinned", "patients", "who", "developed", "hyperpigmented", "skin", "and", "tongue", "lesions", "during", "combination", "therapy", "with", "IFN", "and", "ribavirin", "."], "event_mentions": [{"id": "12932249_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 14, "end": 15}, "arguments": [{"entity_id": "12932249_3_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "12932249_3_Ent0", "role": "Subject", "text": "two dark - skinned patients", "start": 2, "end": 7}, {"entity_id": "12932249_3_Ent2", "role": "Subject_Race", "text": "dark - skinned", "start": 3, "end": 6}, {"entity_id": "12932249_3_Ent3", "role": "Effect", "text": "hyperpigmented skin and tongue lesions", "start": 9, "end": 14}, {"entity_id": "12932249_3_Ent4", "role": "Treatment", "text": "combination therapy with IFN and ribavirin .", "start": 15, "end": 22}, {"entity_id": "12932249_3_Ent5", "role": "Treatment_Drug", "text": "IFN", "start": 18, "end": 19}, {"entity_id": "12932249_3_Ent7", "role": "Combination_Drug", "text": "IFN", "start": 18, "end": 19}, {"entity_id": "12932249_3_Ent6", "role": "Treatment_Drug", "text": "ribavirin", "start": 20, "end": 21}, {"entity_id": "12932249_3_Ent8", "role": "Combination_Drug", "text": "ribavirin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "12932249_3_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12932249_3_Ent0", "text": "two dark - skinned patients", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "12932249_3_Ent2", "text": "dark - skinned", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "12932249_3_Ent3", "text": "hyperpigmented skin and tongue lesions", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "12932249_3_Ent4", "text": "combination therapy with IFN and ribavirin .", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "12932249_3_Ent5", "text": "IFN", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12932249_3_Ent7", "text": "IFN", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12932249_3_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "12932249_3_Ent8", "text": "ribavirin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "12944250_3", "wnd_id": "12944250_3_1", "text": "Thrombocytosis under ciprofloxacin and tazobactam / piperacillin .", "tokens": ["Thrombocytosis", "under", "ciprofloxacin", "and", "tazobactam", "/", "piperacillin", "."], "event_mentions": [{"id": "12944250_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "under", "start": 1, "end": 2}, "arguments": [{"entity_id": "12944250_3_Ent0", "role": "Effect", "text": "Thrombocytosis", "start": 0, "end": 1}, {"entity_id": "12944250_3_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 2, "end": 3}, {"entity_id": "12944250_3_Ent5", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 2, "end": 3}, {"entity_id": "12944250_3_Ent1", "role": "Treatment", "text": "ciprofloxacin and tazobactam / piperacillin", "start": 2, "end": 7}, {"entity_id": "12944250_3_Ent3", "role": "Treatment_Drug", "text": "tazobactam", "start": 4, "end": 5}, {"entity_id": "12944250_3_Ent6", "role": "Combination_Drug", "text": "tazobactam", "start": 4, "end": 5}, {"entity_id": "12944250_3_Ent4", "role": "Treatment_Drug", "text": "piperacillin", "start": 6, "end": 7}, {"entity_id": "12944250_3_Ent7", "role": "Combination_Drug", "text": "piperacillin", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "12944250_3_Ent0", "text": "Thrombocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12944250_3_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12944250_3_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12944250_3_Ent1", "text": "ciprofloxacin and tazobactam / piperacillin", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "12944250_3_Ent3", "text": "tazobactam", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12944250_3_Ent6", "text": "tazobactam", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12944250_3_Ent4", "text": "piperacillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12944250_3_Ent7", "text": "piperacillin", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "129501_1", "wnd_id": "129501_1_1", "text": "Anaphylaxis after the injection of chymopapain occurs in about 1 % of such cases .", "tokens": ["Anaphylaxis", "after", "the", "injection", "of", "chymopapain", "occurs", "in", "about", "1", "%", "of", "such", "cases", "."], "event_mentions": [{"id": "129501_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurs", "start": 6, "end": 7}, "arguments": [{"entity_id": "129501_1_Ent1", "role": "Effect", "text": "Anaphylaxis", "start": 0, "end": 1}, {"entity_id": "129501_1_Ent2", "role": "Treatment", "text": "the injection of chymopapain", "start": 2, "end": 6}, {"entity_id": "129501_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 3, "end": 4}, {"entity_id": "129501_1_Ent4", "role": "Treatment_Drug", "text": "chymopapain", "start": 5, "end": 6}, {"entity_id": "129501_1_Ent0", "role": "Subject", "text": "cases", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "129501_1_Ent1", "text": "Anaphylaxis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "129501_1_Ent2", "text": "the injection of chymopapain", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "129501_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "129501_1_Ent4", "text": "chymopapain", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "129501_1_Ent0", "text": "cases", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "1295628_2", "wnd_id": "1295628_2_1", "text": "A 14 - year - old female developed systemic lupus erythematosus ( SLE) - like symptoms , rash , fever , leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy .", "tokens": ["A", "14", "-", "year", "-", "old", "female", "developed", "systemic", "lupus", "erythematosus", "(", "SLE)", "-", "like", "symptoms", ",", "rash", ",", "fever", ",", "leukopenia", "and", "positive", "anti", "-", "nuclear", "antibody", "(", "ANA", ")", "two", "weeks", "after", "administration", "of", "carbamazepine", "(", "CBZ", ";", "Tegretol", ")", "used", "against", "benign", "Rolandic", "epilepsy", "."], "event_mentions": [{"id": "1295628_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "1295628_2_Ent0", "role": "Subject", "text": "A 14 - year - old female", "start": 0, "end": 7}, {"entity_id": "1295628_2_Ent1", "role": "Subject_Age", "text": "14 - year - old", "start": 1, "end": 6}, {"entity_id": "1295628_2_Ent2", "role": "Subject_Gender", "text": "female", "start": 6, "end": 7}, {"entity_id": "1295628_2_Ent3", "role": "Effect", "text": "systemic lupus erythematosus ( SLE) - like symptoms , rash , fever , leukopenia and positive anti - nuclear antibody ( ANA )", "start": 8, "end": 31}, {"entity_id": "1295628_2_Ent4", "role": "Treatment", "text": "administration of carbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy", "start": 34, "end": 47}, {"entity_id": "1295628_2_Ent5", "role": "Treatment_Drug", "text": "carbamazepine", "start": 36, "end": 37}, {"entity_id": "1295628_2_Ent6", "role": "Treatment_Disorder", "text": "benign Rolandic epilepsy", "start": 44, "end": 47}]}], "entity_mentions": [{"id": "1295628_2_Ent0", "text": "A 14 - year - old female", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "1295628_2_Ent1", "text": "14 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1295628_2_Ent2", "text": "female", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1295628_2_Ent3", "text": "systemic lupus erythematosus ( SLE) - like symptoms , rash , fever , leukopenia and positive anti - nuclear antibody ( ANA )", "entity_type": "Entity", "start": 8, "end": 31}, {"id": "1295628_2_Ent4", "text": "administration of carbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy", "entity_type": "Entity", "start": 34, "end": 47}, {"id": "1295628_2_Ent5", "text": "carbamazepine", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "1295628_2_Ent6", "text": "benign Rolandic epilepsy", "entity_type": "Entity", "start": 44, "end": 47}], "lang": "en"}
{"doc_id": "1310879_3", "wnd_id": "1310879_3_1", "text": "Heparin - associated thrombocytopenia : successful therapy with the heparinoid Org 10172 in a patient showing cross - reaction to LMW heparins .", "tokens": ["Heparin", "-", "associated", "thrombocytopenia", ":", "successful", "therapy", "with", "the", "heparinoid", "Org", "10172", "in", "a", "patient", "showing", "cross", "-", "reaction", "to", "LMW", "heparins", "."], "event_mentions": [{"id": "1310879_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1310879_3_Ent2", "role": "Treatment", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "1310879_3_Ent3", "role": "Treatment_Drug", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "1310879_3_Ent1", "role": "Effect", "text": "thrombocytopenia", "start": 3, "end": 4}, {"entity_id": "1310879_3_Ent0", "role": "Subject", "text": "a patient", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "1310879_3_Ent2", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1310879_3_Ent3", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1310879_3_Ent1", "text": "thrombocytopenia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1310879_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "1316047_1", "wnd_id": "1316047_1_1", "text": "Hemodynamic collapse following labetalol administration in preeclampsia .", "tokens": ["Hemodynamic", "collapse", "following", "labetalol", "administration", "in", "preeclampsia", "."], "event_mentions": [{"id": "1316047_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "1316047_1_Ent0", "role": "Effect", "text": "Hemodynamic collapse", "start": 0, "end": 2}, {"entity_id": "1316047_1_Ent1", "role": "Treatment", "text": "labetalol", "start": 3, "end": 4}, {"entity_id": "1316047_1_Ent2", "role": "Treatment_Drug", "text": "labetalol", "start": 3, "end": 4}, {"entity_id": "1316047_1_Ent3", "role": "Treatment_Disorder", "text": "preeclampsia", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "1316047_1_Ent0", "text": "Hemodynamic collapse", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1316047_1_Ent1", "text": "labetalol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1316047_1_Ent2", "text": "labetalol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1316047_1_Ent3", "text": "preeclampsia", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "1359782_2", "wnd_id": "1359782_2_1", "text": "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine .", "tokens": ["Pulmonary", "infiltrates", "and", "skin", "pigmentation", "associated", "with", "sulfasalazine", "."], "event_mentions": [{"id": "1359782_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "1359782_2_Ent0", "role": "Effect", "text": "Pulmonary infiltrates and skin pigmentation", "start": 0, "end": 5}, {"entity_id": "1359782_2_Ent1", "role": "Treatment", "text": "sulfasalazine", "start": 7, "end": 8}, {"entity_id": "1359782_2_Ent2", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1359782_2_Ent0", "text": "Pulmonary infiltrates and skin pigmentation", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "1359782_2_Ent1", "text": "sulfasalazine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1359782_2_Ent2", "text": "sulfasalazine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "1393348_2", "wnd_id": "1393348_2_1", "text": "Although both the spontaneous occurrence of SLE and the psychosis as a sign of CNS involvement of SLE can not be excluded , SLE could be considered as an adverse effect of carbamazepine .", "tokens": ["Although", "both", "the", "spontaneous", "occurrence", "of", "SLE", "and", "the", "psychosis", "as", "a", "sign", "of", "CNS", "involvement", "of", "SLE", "can", "not", "be", "excluded", ",", "SLE", "could", "be", "considered", "as", "an", "adverse", "effect", "of", "carbamazepine", "."], "event_mentions": [{"id": "1393348_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "considered", "start": 26, "end": 27}, "arguments": [{"entity_id": "1393348_2_Ent0", "role": "Effect", "text": "SLE", "start": 23, "end": 24}, {"entity_id": "1393348_2_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 32, "end": 33}, {"entity_id": "1393348_2_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "1393348_2_Ent0", "text": "SLE", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "1393348_2_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "1393348_2_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "1422497_4", "wnd_id": "1422497_4_1", "text": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum .", "tokens": ["We", "report", "four", "cases", "of", "encephalopathy", "coincident", "with", "elevated", "aluminum", "levels", "as", "well", "as", "one", "patient", "who", "developed", "seizures", "while", "receiving", "continuous", "bladder", "irrigations", "with", "alum", "."], "event_mentions": [{"id": "1422497_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "1422497_4_Ent1", "role": "Subject_Population", "text": "one", "start": 14, "end": 15}, {"entity_id": "1422497_4_Ent0", "role": "Subject", "text": "one patient", "start": 14, "end": 16}, {"entity_id": "1422497_4_Ent2", "role": "Effect", "text": "seizures", "start": 18, "end": 19}, {"entity_id": "1422497_4_Ent3", "role": "Treatment", "text": "receiving continuous bladder irrigations with alum", "start": 20, "end": 26}, {"entity_id": "1422497_4_Ent4", "role": "Treatment_Drug", "text": "alum", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "1422497_4_Ent1", "text": "one", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1422497_4_Ent0", "text": "one patient", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "1422497_4_Ent2", "text": "seizures", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1422497_4_Ent3", "text": "receiving continuous bladder irrigations with alum", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "1422497_4_Ent4", "text": "alum", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "1433432_2", "wnd_id": "1433432_2_1", "text": "We report a case of hyponatremia associated with a grand mal seizure in a 28 month - old child after intra - nasal desmopressin administration for high fluid intake with nocturnal enuresis .", "tokens": ["We", "report", "a", "case", "of", "hyponatremia", "associated", "with", "a", "grand", "mal", "seizure", "in", "a", "28", "month", "-", "old", "child", "after", "intra", "-", "nasal", "desmopressin", "administration", "for", "high", "fluid", "intake", "with", "nocturnal", "enuresis", "."], "event_mentions": [{"id": "1433432_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 19, "end": 20}, "arguments": [{"entity_id": "1433432_2_Ent2", "role": "Effect", "text": "hyponatremia associated with a grand mal seizure", "start": 5, "end": 12}, {"entity_id": "1433432_2_Ent0", "role": "Subject", "text": "a 28 month - old child", "start": 13, "end": 19}, {"entity_id": "1433432_2_Ent1", "role": "Subject_Age", "text": "28 month - old child", "start": 14, "end": 19}, {"entity_id": "1433432_2_Ent6", "role": "Treatment_Route", "text": "intra - nasal", "start": 20, "end": 23}, {"entity_id": "1433432_2_Ent3", "role": "Treatment", "text": "intra - nasal desmopressin administration", "start": 20, "end": 25}, {"entity_id": "1433432_2_Ent5", "role": "Treatment_Drug", "text": "desmopressin", "start": 23, "end": 24}, {"entity_id": "1433432_2_Ent4", "role": "Treatment_Disorder", "text": "high fluid intake with nocturnal enuresis", "start": 26, "end": 32}]}], "entity_mentions": [{"id": "1433432_2_Ent2", "text": "hyponatremia associated with a grand mal seizure", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "1433432_2_Ent0", "text": "a 28 month - old child", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "1433432_2_Ent1", "text": "28 month - old child", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "1433432_2_Ent6", "text": "intra - nasal", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "1433432_2_Ent3", "text": "intra - nasal desmopressin administration", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "1433432_2_Ent5", "text": "desmopressin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "1433432_2_Ent4", "text": "high fluid intake with nocturnal enuresis", "entity_type": "Entity", "start": 26, "end": 32}], "lang": "en"}
{"doc_id": "1445134_2", "wnd_id": "1445134_2_1", "text": "However , follow - up revealed that gestational diabetes when associated with norethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance .", "tokens": ["However", ",", "follow", "-", "up", "revealed", "that", "gestational", "diabetes", "when", "associated", "with", "norethisterone", "had", "a", "lesser", "risk", "of", "emerging", "diabetes", "mellitus", "and", "impaired", "glucose", "tolerance", "."], "event_mentions": [{"id": "1445134_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "emerging", "start": 18, "end": 19}, "arguments": [{"entity_id": "1445134_2_Ent1", "role": "Treatment", "text": "norethisterone", "start": 12, "end": 13}, {"entity_id": "1445134_2_Ent2", "role": "Treatment_Drug", "text": "norethisterone", "start": 12, "end": 13}, {"entity_id": "1445134_2_Ent0", "role": "Effect", "text": "diabetes mellitus and impaired glucose tolerance", "start": 19, "end": 25}]}], "entity_mentions": [{"id": "1445134_2_Ent1", "text": "norethisterone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1445134_2_Ent2", "text": "norethisterone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1445134_2_Ent0", "text": "diabetes mellitus and impaired glucose tolerance", "entity_type": "Entity", "start": 19, "end": 25}], "lang": "en"}
{"doc_id": "1450506_1", "wnd_id": "1450506_1_1", "text": "An adverse reaction to IFN was strongly suspected as the cause of CHF .", "tokens": ["An", "adverse", "reaction", "to", "IFN", "was", "strongly", "suspected", "as", "the", "cause", "of", "CHF", "."], "event_mentions": [{"id": "1450506_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 10, "end": 11}, "arguments": [{"entity_id": "1450506_1_Ent1", "role": "Treatment", "text": "IFN", "start": 4, "end": 5}, {"entity_id": "1450506_1_Ent2", "role": "Treatment_Drug", "text": "IFN", "start": 4, "end": 5}, {"entity_id": "1450506_1_Ent0", "role": "Effect", "text": "CHF", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "1450506_1_Ent1", "text": "IFN", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1450506_1_Ent2", "text": "IFN", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1450506_1_Ent0", "text": "CHF", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "1450506_3", "wnd_id": "1450506_3_1", "text": "Sixteen hours after the first administration of IFN , IFN was suspended by the symptoms of congestive heart failure ( CHF ) .", "tokens": ["Sixteen", "hours", "after", "the", "first", "administration", "of", "IFN", ",", "IFN", "was", "suspended", "by", "the", "symptoms", "of", "congestive", "heart", "failure", "(", "CHF", ")", "."], "event_mentions": [{"id": "1450506_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspended", "start": 11, "end": 12}, "arguments": [{"entity_id": "1450506_3_Ent1", "role": "Treatment", "text": "IFN", "start": 9, "end": 10}, {"entity_id": "1450506_3_Ent2", "role": "Treatment_Drug", "text": "IFN", "start": 9, "end": 10}, {"entity_id": "1450506_3_Ent0", "role": "Effect", "text": "congestive heart failure ( CHF )", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "1450506_3_Ent1", "text": "IFN", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1450506_3_Ent2", "text": "IFN", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1450506_3_Ent0", "text": "congestive heart failure ( CHF )", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "14530108_1", "wnd_id": "14530108_1_1", "text": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation : a case report .", "tokens": ["Renal", "tubular", "acidosis", "secondary", "to", "FK506", "in", "living", "donor", "liver", "transplantation", ":", "a", "case", "report", "."], "event_mentions": [{"id": "14530108_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 3, "end": 4}, "arguments": [{"entity_id": "14530108_1_Ent1", "role": "Effect", "text": "Renal tubular acidosis", "start": 0, "end": 3}, {"entity_id": "14530108_1_Ent2", "role": "Treatment", "text": "FK506", "start": 5, "end": 6}, {"entity_id": "14530108_1_Ent3", "role": "Treatment_Drug", "text": "FK506", "start": 5, "end": 6}, {"entity_id": "14530108_1_Ent0", "role": "Subject", "text": "a case", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "14530108_1_Ent1", "text": "Renal tubular acidosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14530108_1_Ent2", "text": "FK506", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14530108_1_Ent3", "text": "FK506", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14530108_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "14530108_3", "wnd_id": "14530108_3_1", "text": "Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation .", "tokens": ["Surgeons", "and", "physicians", "should", "therefore", "be", "aware", "of", "the", "potential", "for", "RTA", "to", "occur", "with", "FK506", "after", "any", "organ", "transplantation", "."], "event_mentions": [{"id": "14530108_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 13, "end": 14}, "arguments": [{"entity_id": "14530108_3_Ent0", "role": "Effect", "text": "RTA", "start": 11, "end": 12}, {"entity_id": "14530108_3_Ent2", "role": "Treatment_Drug", "text": "FK506", "start": 15, "end": 16}, {"entity_id": "14530108_3_Ent1", "role": "Treatment", "text": "FK506 after any organ transplantation", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "14530108_3_Ent0", "text": "RTA", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14530108_3_Ent2", "text": "FK506", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "14530108_3_Ent1", "text": "FK506 after any organ transplantation", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "14530108_6", "wnd_id": "14530108_6_1", "text": "We report a case of RTA secondary to FK506 administration in liver transplantation .", "tokens": ["We", "report", "a", "case", "of", "RTA", "secondary", "to", "FK506", "administration", "in", "liver", "transplantation", "."], "event_mentions": [{"id": "14530108_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 6, "end": 7}, "arguments": [{"entity_id": "14530108_6_Ent0", "role": "Subject", "text": "a case of RTA", "start": 2, "end": 6}, {"entity_id": "14530108_6_Ent1", "role": "Effect", "text": "RTA", "start": 5, "end": 6}, {"entity_id": "14530108_6_Ent3", "role": "Treatment_Drug", "text": "FK506", "start": 8, "end": 9}, {"entity_id": "14530108_6_Ent2", "role": "Treatment", "text": "FK506 administration in liver transplantation", "start": 8, "end": 13}]}], "entity_mentions": [{"id": "14530108_6_Ent0", "text": "a case of RTA", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "14530108_6_Ent1", "text": "RTA", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14530108_6_Ent3", "text": "FK506", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14530108_6_Ent2", "text": "FK506 administration in liver transplantation", "entity_type": "Entity", "start": 8, "end": 13}], "lang": "en"}
{"doc_id": "14607011_2", "wnd_id": "14607011_2_1", "text": "The case history and toxicological findings of an infant fatality involving pseudoephedrine , brompheniramine , and dextromethorphan are presented .", "tokens": ["The", "case", "history", "and", "toxicological", "findings", "of", "an", "infant", "fatality", "involving", "pseudoephedrine", ",", "brompheniramine", ",", "and", "dextromethorphan", "are", "presented", "."], "event_mentions": [{"id": "14607011_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "involving", "start": 10, "end": 11}, "arguments": [{"entity_id": "14607011_2_Ent0", "role": "Subject", "text": "an infant", "start": 7, "end": 9}, {"entity_id": "14607011_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 8, "end": 9}, {"entity_id": "14607011_2_Ent2", "role": "Effect", "text": "infant fatality", "start": 8, "end": 10}, {"entity_id": "14607011_2_Ent4", "role": "Treatment_Drug", "text": "pseudoephedrine", "start": 11, "end": 12}, {"entity_id": "14607011_2_Ent3", "role": "Treatment", "text": "pseudoephedrine , brompheniramine , and dextromethorphan", "start": 11, "end": 17}, {"entity_id": "14607011_2_Ent5", "role": "Treatment_Drug", "text": "brompheniramine", "start": 13, "end": 14}, {"entity_id": "14607011_2_Ent6", "role": "Treatment_Drug", "text": "dextromethorphan", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "14607011_2_Ent0", "text": "an infant", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "14607011_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14607011_2_Ent2", "text": "infant fatality", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "14607011_2_Ent4", "text": "pseudoephedrine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14607011_2_Ent3", "text": "pseudoephedrine , brompheniramine , and dextromethorphan", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "14607011_2_Ent5", "text": "brompheniramine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14607011_2_Ent6", "text": "dextromethorphan", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "14632592_1", "wnd_id": "14632592_1_1", "text": "Colchicine - induced myopathy in a teenager with familial Mediterranean fever .", "tokens": ["Colchicine", "-", "induced", "myopathy", "in", "a", "teenager", "with", "familial", "Mediterranean", "fever", "."], "event_mentions": [{"id": "14632592_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "14632592_1_Ent3", "role": "Treatment", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "14632592_1_Ent5", "role": "Treatment_Drug", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "14632592_1_Ent2", "role": "Effect", "text": "myopathy", "start": 3, "end": 4}, {"entity_id": "14632592_1_Ent0", "role": "Subject", "text": "a teenager with familial Mediterranean fever", "start": 5, "end": 11}, {"entity_id": "14632592_1_Ent1", "role": "Subject_Age", "text": "teenager", "start": 6, "end": 7}, {"entity_id": "14632592_1_Ent4", "role": "Treatment_Disorder", "text": "Mediterranean fever", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "14632592_1_Ent3", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14632592_1_Ent5", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14632592_1_Ent2", "text": "myopathy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14632592_1_Ent0", "text": "a teenager with familial Mediterranean fever", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "14632592_1_Ent1", "text": "teenager", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14632592_1_Ent4", "text": "Mediterranean fever", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "14632592_4", "wnd_id": "14632592_4_1", "text": "In our patient , an objective causality scale showed that therapeutic doses of colchicine for FMF were the definite cause of myopathy , even though his renal and hepatic function were normal .", "tokens": ["In", "our", "patient", ",", "an", "objective", "causality", "scale", "showed", "that", "therapeutic", "doses", "of", "colchicine", "for", "FMF", "were", "the", "definite", "cause", "of", "myopathy", ",", "even", "though", "his", "renal", "and", "hepatic", "function", "were", "normal", "."], "event_mentions": [{"id": "14632592_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 19, "end": 20}, "arguments": [{"entity_id": "14632592_4_Ent0", "role": "Subject", "text": "our patient", "start": 1, "end": 3}, {"entity_id": "14632592_4_Ent7", "role": "Treatment_Dosage", "text": "therapeutic doses", "start": 10, "end": 12}, {"entity_id": "14632592_4_Ent4", "role": "Treatment", "text": "therapeutic doses of colchicine for FMF", "start": 10, "end": 16}, {"entity_id": "14632592_4_Ent5", "role": "Treatment_Drug", "text": "colchicine", "start": 13, "end": 14}, {"entity_id": "14632592_4_Ent6", "role": "Treatment_Disorder", "text": "FMF", "start": 15, "end": 16}, {"entity_id": "14632592_4_Ent3", "role": "Effect", "text": "myopathy", "start": 21, "end": 22}, {"entity_id": "14632592_4_Ent2", "role": "Subject_Gender", "text": "his", "start": 25, "end": 26}, {"entity_id": "14632592_4_Ent1", "role": "Subject", "text": "his renal and hepatic function were normal", "start": 25, "end": 32}]}], "entity_mentions": [{"id": "14632592_4_Ent0", "text": "our patient", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14632592_4_Ent7", "text": "therapeutic doses", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "14632592_4_Ent4", "text": "therapeutic doses of colchicine for FMF", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "14632592_4_Ent5", "text": "colchicine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14632592_4_Ent6", "text": "FMF", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "14632592_4_Ent3", "text": "myopathy", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14632592_4_Ent2", "text": "his", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "14632592_4_Ent1", "text": "his renal and hepatic function were normal", "entity_type": "Entity", "start": 25, "end": 32}], "lang": "en"}
{"doc_id": "14641354_2", "wnd_id": "14641354_2_1", "text": "We report a 43 - year - old woman who developed sore throat , swelling of the lips and oral cavity and dysphagia , 2 weeks after the use of budesonide spray ( Budefat ) for treatment of bronchial asthma .", "tokens": ["We", "report", "a", "43", "-", "year", "-", "old", "woman", "who", "developed", "sore", "throat", ",", "swelling", "of", "the", "lips", "and", "oral", "cavity", "and", "dysphagia", ",", "2", "weeks", "after", "the", "use", "of", "budesonide", "spray", "(", "Budefat", ")", "for", "treatment", "of", "bronchial", "asthma", "."], "event_mentions": [{"id": "14641354_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "14641354_2_Ent0", "role": "Subject", "text": "a 43 - year - old woman", "start": 2, "end": 9}, {"entity_id": "14641354_2_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 3, "end": 8}, {"entity_id": "14641354_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "14641354_2_Ent3", "role": "Effect", "text": "sore throat , swelling of the lips and oral cavity and dysphagia", "start": 11, "end": 23}, {"entity_id": "14641354_2_Ent5", "role": "Treatment_Time_elapsed", "text": "2 weeks after", "start": 24, "end": 27}, {"entity_id": "14641354_2_Ent4", "role": "Treatment", "text": "2 weeks after the use of budesonide spray ( Budefat )", "start": 24, "end": 35}, {"entity_id": "14641354_2_Ent6", "role": "Treatment_Drug", "text": "budesonide", "start": 30, "end": 31}, {"entity_id": "14641354_2_Ent9", "role": "Treatment_Route", "text": "spray", "start": 31, "end": 32}, {"entity_id": "14641354_2_Ent7", "role": "Treatment_Drug", "text": "Budefat", "start": 33, "end": 34}, {"entity_id": "14641354_2_Ent8", "role": "Treatment_Disorder", "text": "bronchial asthma .", "start": 38, "end": 41}]}], "entity_mentions": [{"id": "14641354_2_Ent0", "text": "a 43 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "14641354_2_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "14641354_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14641354_2_Ent3", "text": "sore throat , swelling of the lips and oral cavity and dysphagia", "entity_type": "Entity", "start": 11, "end": 23}, {"id": "14641354_2_Ent5", "text": "2 weeks after", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "14641354_2_Ent4", "text": "2 weeks after the use of budesonide spray ( Budefat )", "entity_type": "Entity", "start": 24, "end": 35}, {"id": "14641354_2_Ent6", "text": "budesonide", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "14641354_2_Ent9", "text": "spray", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "14641354_2_Ent7", "text": "Budefat", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "14641354_2_Ent8", "text": "bronchial asthma .", "entity_type": "Entity", "start": 38, "end": 41}], "lang": "en"}
{"doc_id": "14660304_4", "wnd_id": "14660304_4_1", "text": "We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone ( 10 mg / m(2)/day for 4 weeks with gradual tapering ) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone .", "tokens": ["We", "describe", "the", "infectious", "toxicities", "experienced", "by", "the", "first", "two", "patients", "in", "our", "institution", "treated", "with", "dexamethasone", "(", "10", "mg", "/", "m(2)/day", "for", "4", "weeks", "with", "gradual", "tapering", ")", "during", "induction", "according", "to", "the", "dexamethasone", "arm", "of", "BFM", "2000", "and", "review", "the", "relevant", "literature", "that", "suggests", "an", "increased", "risk", "of", "infectious", "complications", "with", "dexamethasone", "."], "event_mentions": [{"id": "14660304_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced by", "start": 5, "end": 7}, "arguments": [{"entity_id": "14660304_4_Ent2", "role": "Effect", "text": "infectious toxicities", "start": 3, "end": 5}, {"entity_id": "14660304_4_Ent0", "role": "Subject", "text": "first two patients in our institution", "start": 8, "end": 14}, {"entity_id": "14660304_4_Ent1", "role": "Subject_Age", "text": "two", "start": 9, "end": 10}, {"entity_id": "14660304_4_Ent3", "role": "Treatment", "text": "treated with dexamethasone ( 10 mg / m(2)/day for 4 weeks with gradual tapering ) during induction according to the dexamethasone arm of BFM 2000", "start": 14, "end": 39}, {"entity_id": "14660304_4_Ent4", "role": "Treatment_Drug", "text": "dexamethasone", "start": 16, "end": 17}, {"entity_id": "14660304_4_Ent6", "role": "Treatment_Dosage", "text": "10 mg / m(2)/day", "start": 18, "end": 22}, {"entity_id": "14660304_4_Ent7", "role": "Treatment_Freq", "text": "m(2)/day", "start": 21, "end": 22}, {"entity_id": "14660304_4_Ent8", "role": "Treatment_Time_elapsed", "text": "4 weeks", "start": 23, "end": 25}, {"entity_id": "14660304_4_Ent5", "role": "Treatment_Drug", "text": "dexamethasone", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "14660304_4_Ent2", "text": "infectious toxicities", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "14660304_4_Ent0", "text": "first two patients in our institution", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "14660304_4_Ent1", "text": "two", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "14660304_4_Ent3", "text": "treated with dexamethasone ( 10 mg / m(2)/day for 4 weeks with gradual tapering ) during induction according to the dexamethasone arm of BFM 2000", "entity_type": "Entity", "start": 14, "end": 39}, {"id": "14660304_4_Ent4", "text": "dexamethasone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "14660304_4_Ent6", "text": "10 mg / m(2)/day", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "14660304_4_Ent7", "text": "m(2)/day", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14660304_4_Ent8", "text": "4 weeks", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "14660304_4_Ent5", "text": "dexamethasone", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "14674674_1", "wnd_id": "14674674_1_1", "text": "A diagnosis of infliximab - induced lupus was made and the drug treatment was withdrawn .", "tokens": ["A", "diagnosis", "of", "infliximab", "-", "induced", "lupus", "was", "made", "and", "the", "drug", "treatment", "was", "withdrawn", "."], "event_mentions": [{"id": "14674674_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "14674674_1_Ent1", "role": "Treatment", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "14674674_1_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "14674674_1_Ent0", "role": "Effect", "text": "lupus", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "14674674_1_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14674674_1_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14674674_1_Ent0", "text": "lupus", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "14677199_1", "wnd_id": "14677199_1_1", "text": "Severe Raynaud 's phenomenon with yohimbine therapy for erectile dysfunction .", "tokens": ["Severe", "Raynaud", "'s", "phenomenon", "with", "yohimbine", "therapy", "for", "erectile", "dysfunction", "."], "event_mentions": [{"id": "14677199_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 4, "end": 5}, "arguments": [{"entity_id": "14677199_1_Ent0", "role": "Effect", "text": "Raynaud 's phenomenon", "start": 1, "end": 4}, {"entity_id": "14677199_1_Ent1", "role": "Treatment", "text": "yohimbine", "start": 5, "end": 6}, {"entity_id": "14677199_1_Ent2", "role": "Treatment_Drug", "text": "yohimbine", "start": 5, "end": 6}, {"entity_id": "14677199_1_Ent3", "role": "Treatment_Disorder", "text": "erectile dysfunction", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "14677199_1_Ent0", "text": "Raynaud 's phenomenon", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "14677199_1_Ent1", "text": "yohimbine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14677199_1_Ent2", "text": "yohimbine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14677199_1_Ent3", "text": "erectile dysfunction", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "1469187_3", "wnd_id": "1469187_3_1", "text": "Since this amount of FAB was insufficient to bind all DGTX present in the serum , cardiac DGTX toxicity ( total AV - block ) persisted .", "tokens": ["Since", "this", "amount", "of", "FAB", "was", "insufficient", "to", "bind", "all", "DGTX", "present", "in", "the", "serum", ",", "cardiac", "DGTX", "toxicity", "(", "total", "AV", "-", "block", ")", "persisted", "."], "event_mentions": [{"id": "1469187_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "persisted", "start": 25, "end": 26}, "arguments": [{"entity_id": "1469187_3_Ent3", "role": "Treatment_Drug", "text": "FAB", "start": 4, "end": 5}, {"entity_id": "1469187_3_Ent1", "role": "Treatment", "text": "DGTX", "start": 10, "end": 11}, {"entity_id": "1469187_3_Ent2", "role": "Treatment_Drug", "text": "DGTX", "start": 10, "end": 11}, {"entity_id": "1469187_3_Ent0", "role": "Effect", "text": "cardiac DGTX toxicity ( total AV - block )", "start": 16, "end": 25}]}], "entity_mentions": [{"id": "1469187_3_Ent3", "text": "FAB", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1469187_3_Ent1", "text": "DGTX", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1469187_3_Ent2", "text": "DGTX", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1469187_3_Ent0", "text": "cardiac DGTX toxicity ( total AV - block )", "entity_type": "Entity", "start": 16, "end": 25}], "lang": "en"}
{"doc_id": "14700673_2", "wnd_id": "14700673_2_1", "text": "Mechanism of topiramate - induced acute - onset myopia and angle closure glaucoma .", "tokens": ["Mechanism", "of", "topiramate", "-", "induced", "acute", "-", "onset", "myopia", "and", "angle", "closure", "glaucoma", "."], "event_mentions": [{"id": "14700673_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "14700673_2_Ent1", "role": "Treatment", "text": "topiramate", "start": 2, "end": 3}, {"entity_id": "14700673_2_Ent2", "role": "Treatment_Drug", "text": "topiramate", "start": 2, "end": 3}, {"entity_id": "14700673_2_Ent0", "role": "Effect", "text": "acute - onset myopia and angle closure glaucoma", "start": 5, "end": 13}]}], "entity_mentions": [{"id": "14700673_2_Ent1", "text": "topiramate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14700673_2_Ent2", "text": "topiramate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14700673_2_Ent0", "text": "acute - onset myopia and angle closure glaucoma", "entity_type": "Entity", "start": 5, "end": 13}], "lang": "en"}
{"doc_id": "14711147_1", "wnd_id": "14711147_1_1", "text": "Doxycycline - induced photo - onycholysis .", "tokens": ["Doxycycline", "-", "induced", "photo", "-", "onycholysis", "."], "event_mentions": [{"id": "14711147_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "14711147_1_Ent1", "role": "Treatment", "text": "Doxycycline", "start": 0, "end": 1}, {"entity_id": "14711147_1_Ent2", "role": "Treatment_Drug", "text": "Doxycycline", "start": 0, "end": 1}, {"entity_id": "14711147_1_Ent0", "role": "Effect", "text": "photo - onycholysis", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "14711147_1_Ent1", "text": "Doxycycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14711147_1_Ent2", "text": "Doxycycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14711147_1_Ent0", "text": "photo - onycholysis", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "14712320_5", "wnd_id": "14712320_5_1", "text": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin .", "tokens": ["Rhabdomyolysis", "can", "occur", "with", "all", "statins", "when", "used", "alone", "and", "particularly", "when", "combined", "with", "other", "drugs", "that", "are", "themselves", "myotoxic", "or", "that", "elevate", "the", "concentration", "of", "the", "statin", "."], "event_mentions": [{"id": "14712320_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 2, "end": 3}, "arguments": [{"entity_id": "14712320_5_Ent0", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "14712320_5_Ent1", "role": "Treatment", "text": "statins", "start": 5, "end": 6}, {"entity_id": "14712320_5_Ent3", "role": "Treatment_Drug", "text": "statins", "start": 5, "end": 6}, {"entity_id": "14712320_5_Ent2", "role": "Treatment", "text": "other drugs that are themselves myotoxic or that elevate the concentration of the statin", "start": 14, "end": 28}]}], "entity_mentions": [{"id": "14712320_5_Ent0", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14712320_5_Ent1", "text": "statins", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14712320_5_Ent3", "text": "statins", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14712320_5_Ent2", "text": "other drugs that are themselves myotoxic or that elevate the concentration of the statin", "entity_type": "Entity", "start": 14, "end": 28}], "lang": "en"}
{"doc_id": "14712320_7", "wnd_id": "14712320_7_1", "text": "In this report , we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin .", "tokens": ["In", "this", "report", ",", "we", "describe", "a", "case", "of", "rhabdomyolysis", "and", "acute", "renal", "failure", "secondary", "to", "the", "interaction", "between", "danazol", "and", "simvastatin", "."], "event_mentions": [{"id": "14712320_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 14, "end": 15}, "arguments": [{"entity_id": "14712320_7_Ent0", "role": "Effect", "text": "rhabdomyolysis and acute renal failure", "start": 9, "end": 14}, {"entity_id": "14712320_7_Ent1", "role": "Treatment", "text": "interaction between danazol and simvastatin", "start": 17, "end": 22}, {"entity_id": "14712320_7_Ent2", "role": "Treatment_Drug", "text": "danazol", "start": 19, "end": 20}, {"entity_id": "14712320_7_Ent4", "role": "Combination_Drug", "text": "danazol", "start": 19, "end": 20}, {"entity_id": "14712320_7_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 21, "end": 22}, {"entity_id": "14712320_7_Ent5", "role": "Combination_Drug", "text": "simvastatin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "14712320_7_Ent0", "text": "rhabdomyolysis and acute renal failure", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "14712320_7_Ent1", "text": "interaction between danazol and simvastatin", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "14712320_7_Ent2", "text": "danazol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "14712320_7_Ent4", "text": "danazol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "14712320_7_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14712320_7_Ent5", "text": "simvastatin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "14964753_7", "wnd_id": "14964753_7_1", "text": "Ramipril - induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before .", "tokens": ["Ramipril", "-", "induced", "cutaneous", "vasculitis", "is", "particularly", "rare", "and", "our", "case", "was", "atypical", "because", "the", "patient", "had", "tolerated", "lisinopril", "before", "."], "event_mentions": [{"id": "14964753_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "14964753_7_Ent3", "role": "Treatment", "text": "Ramipril", "start": 0, "end": 1}, {"entity_id": "14964753_7_Ent4", "role": "Treatment_Drug", "text": "Ramipril", "start": 0, "end": 1}, {"entity_id": "14964753_7_Ent2", "role": "Effect", "text": "cutaneous vasculitis", "start": 3, "end": 5}, {"entity_id": "14964753_7_Ent0", "role": "Subject", "text": "the patient had tolerated lisinopril before", "start": 14, "end": 20}, {"entity_id": "14964753_7_Ent1", "role": "Subject_Disorder", "text": "tolerated lisinopril", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "14964753_7_Ent3", "text": "Ramipril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14964753_7_Ent4", "text": "Ramipril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14964753_7_Ent2", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "14964753_7_Ent0", "text": "the patient had tolerated lisinopril before", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "14964753_7_Ent1", "text": "tolerated lisinopril", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "14964753_9", "wnd_id": "14964753_9_1", "text": "Here we report ramipril - induced cutaneous vasculitis in a patient who required steroid therapy to control it .", "tokens": ["Here", "we", "report", "ramipril", "-", "induced", "cutaneous", "vasculitis", "in", "a", "patient", "who", "required", "steroid", "therapy", "to", "control", "it", "."], "event_mentions": [{"id": "14964753_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "14964753_9_Ent2", "role": "Treatment", "text": "ramipril", "start": 3, "end": 4}, {"entity_id": "14964753_9_Ent3", "role": "Treatment_Drug", "text": "ramipril", "start": 3, "end": 4}, {"entity_id": "14964753_9_Ent1", "role": "Effect", "text": "cutaneous vasculitis", "start": 6, "end": 8}, {"entity_id": "14964753_9_Ent0", "role": "Subject", "text": "a patient", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "14964753_9_Ent2", "text": "ramipril", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14964753_9_Ent3", "text": "ramipril", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14964753_9_Ent1", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "14964753_9_Ent0", "text": "a patient", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "14996269_1", "wnd_id": "14996269_1_1", "text": "Hypernatraemia induced by sodium polystyrene sulphonate ( Kayexalate ) in two extremely low birth weight newborns .", "tokens": ["Hypernatraemia", "induced", "by", "sodium", "polystyrene", "sulphonate", "(", "Kayexalate", ")", "in", "two", "extremely", "low", "birth", "weight", "newborns", "."], "event_mentions": [{"id": "14996269_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced by", "start": 1, "end": 3}, "arguments": [{"entity_id": "14996269_1_Ent3", "role": "Effect", "text": "Hypernatraemia", "start": 0, "end": 1}, {"entity_id": "14996269_1_Ent5", "role": "Treatment_Drug", "text": "sodium polystyrene sulphonate ( Kayexalate", "start": 3, "end": 8}, {"entity_id": "14996269_1_Ent4", "role": "Treatment", "text": "sodium polystyrene sulphonate ( Kayexalate )", "start": 3, "end": 9}, {"entity_id": "14996269_1_Ent1", "role": "Subject_Population", "text": "two", "start": 10, "end": 11}, {"entity_id": "14996269_1_Ent0", "role": "Subject", "text": "two extremely low birth weight newborns", "start": 10, "end": 16}, {"entity_id": "14996269_1_Ent2", "role": "Subject_Age", "text": "newborns", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "14996269_1_Ent3", "text": "Hypernatraemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14996269_1_Ent5", "text": "sodium polystyrene sulphonate ( Kayexalate", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "14996269_1_Ent4", "text": "sodium polystyrene sulphonate ( Kayexalate )", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "14996269_1_Ent1", "text": "two", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "14996269_1_Ent0", "text": "two extremely low birth weight newborns", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "14996269_1_Ent2", "text": "newborns", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "14998226_2", "wnd_id": "14998226_2_1", "text": "A 67 - year - old man receiving a stable maintenance dosage of warfarin experienced an increased international normalized ratio ( INR ) without bleeding when his atorvastatin therapy was switched to fluvastatin .", "tokens": ["A", "67", "-", "year", "-", "old", "man", "receiving", "a", "stable", "maintenance", "dosage", "of", "warfarin", "experienced", "an", "increased", "international", "normalized", "ratio", "(", "INR", ")", "without", "bleeding", "when", "his", "atorvastatin", "therapy", "was", "switched", "to", "fluvastatin", "."], "event_mentions": [{"id": "14998226_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 14, "end": 15}, "arguments": [{"entity_id": "14998226_2_Ent0", "role": "Subject", "text": "A 67 - year - old man", "start": 0, "end": 7}, {"entity_id": "14998226_2_Ent1", "role": "Subject_Age", "text": "67 - year - old", "start": 1, "end": 6}, {"entity_id": "14998226_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "14998226_2_Ent4", "role": "Treatment", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "14998226_2_Ent5", "role": "Treatment_Drug", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "14998226_2_Ent3", "role": "Effect", "text": "increased international normalized ratio ( INR )", "start": 16, "end": 23}]}, {"id": "14998226_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "switched", "start": 30, "end": 31}, "arguments": [{"entity_id": "14998226_2_Ent9", "role": "Treatment_Disorder", "text": "bleeding", "start": 24, "end": 25}, {"entity_id": "14998226_2_Ent8", "role": "Treatment_Drug", "text": "atorvastatin", "start": 27, "end": 28}, {"entity_id": "14998226_2_Ent6", "role": "Treatment", "text": "atorvastatin therapy was switched to fluvastatin", "start": 27, "end": 33}, {"entity_id": "14998226_2_Ent7", "role": "Treatment_Drug", "text": "fluvastatin", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "14998226_2_Ent0", "text": "A 67 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "14998226_2_Ent1", "text": "67 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "14998226_2_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14998226_2_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14998226_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14998226_2_Ent3", "text": "increased international normalized ratio ( INR )", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "14998226_2_Ent9", "text": "bleeding", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "14998226_2_Ent8", "text": "atorvastatin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "14998226_2_Ent6", "text": "atorvastatin therapy was switched to fluvastatin", "entity_type": "Entity", "start": 27, "end": 33}, {"id": "14998226_2_Ent7", "text": "fluvastatin", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "14998226_9", "wnd_id": "14998226_9_1", "text": "One case report describes an interaction between simvastatin and the anticoagulant acenocoumarol , which resulted in an elevated INR .", "tokens": ["One", "case", "report", "describes", "an", "interaction", "between", "simvastatin", "and", "the", "anticoagulant", "acenocoumarol", ",", "which", "resulted", "in", "an", "elevated", "INR", "."], "event_mentions": [{"id": "14998226_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 14, "end": 15}, "arguments": [{"entity_id": "14998226_9_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "14998226_9_Ent0", "role": "Subject", "text": "One case", "start": 0, "end": 2}, {"entity_id": "14998226_9_Ent4", "role": "Treatment_Drug", "text": "simvastatin", "start": 7, "end": 8}, {"entity_id": "14998226_9_Ent6", "role": "Combination_Drug", "text": "simvastatin", "start": 7, "end": 8}, {"entity_id": "14998226_9_Ent3", "role": "Treatment", "text": "simvastatin and the anticoagulant acenocoumarol", "start": 7, "end": 12}, {"entity_id": "14998226_9_Ent5", "role": "Treatment_Drug", "text": "anticoagulant acenocoumarol", "start": 10, "end": 12}, {"entity_id": "14998226_9_Ent7", "role": "Combination_Drug", "text": "anticoagulant acenocoumarol", "start": 10, "end": 12}, {"entity_id": "14998226_9_Ent2", "role": "Effect", "text": "elevated INR", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "14998226_9_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_9_Ent0", "text": "One case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14998226_9_Ent4", "text": "simvastatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14998226_9_Ent6", "text": "simvastatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14998226_9_Ent3", "text": "simvastatin and the anticoagulant acenocoumarol", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "14998226_9_Ent5", "text": "anticoagulant acenocoumarol", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "14998226_9_Ent7", "text": "anticoagulant acenocoumarol", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "14998226_9_Ent2", "text": "elevated INR", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "15013892_3", "wnd_id": "15013892_3_1", "text": "RESULTS : A patient developed a bilaterally symmetric bull's - eye maculopathy 45 years after taking quinacrine for 18 months as prophylaxis against malaria .", "tokens": ["RESULTS", ":", "A", "patient", "developed", "a", "bilaterally", "symmetric", "bull's", "-", "eye", "maculopathy", "45", "years", "after", "taking", "quinacrine", "for", "18", "months", "as", "prophylaxis", "against", "malaria", "."], "event_mentions": [{"id": "15013892_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "15013892_3_Ent0", "role": "Effect", "text": "A patient", "start": 2, "end": 4}, {"entity_id": "15013892_3_Ent1", "role": "Effect", "text": "bilaterally symmetric bull's - eye maculopathy", "start": 6, "end": 12}, {"entity_id": "15013892_3_Ent3", "role": "Treatment_Time_elapsed", "text": "45 years after", "start": 12, "end": 15}, {"entity_id": "15013892_3_Ent2", "role": "Treatment", "text": "45 years after taking quinacrine for 18 months", "start": 12, "end": 20}, {"entity_id": "15013892_3_Ent5", "role": "Treatment_Drug", "text": "quinacrine", "start": 16, "end": 17}, {"entity_id": "15013892_3_Ent4", "role": "Treatment_Time_elapsed", "text": "18 months", "start": 18, "end": 20}, {"entity_id": "15013892_3_Ent6", "role": "Treatment_Disorder", "text": "malaria", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15013892_3_Ent0", "text": "A patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15013892_3_Ent1", "text": "bilaterally symmetric bull's - eye maculopathy", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "15013892_3_Ent3", "text": "45 years after", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15013892_3_Ent2", "text": "45 years after taking quinacrine for 18 months", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "15013892_3_Ent5", "text": "quinacrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15013892_3_Ent4", "text": "18 months", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "15013892_3_Ent6", "text": "malaria", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15028328_1", "wnd_id": "15028328_1_1", "text": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine , a recalled medication .", "tokens": ["Cerebral", "infarcts", "in", "a", "pediatric", "patient", "secondary", "to", "phenylpropanolamine", ",", "a", "recalled", "medication", "."], "event_mentions": [{"id": "15028328_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 6, "end": 7}, "arguments": [{"entity_id": "15028328_1_Ent2", "role": "Effect", "text": "Cerebral infarcts", "start": 0, "end": 2}, {"entity_id": "15028328_1_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 4, "end": 5}, {"entity_id": "15028328_1_Ent0", "role": "Subject", "text": "pediatric patient", "start": 4, "end": 6}, {"entity_id": "15028328_1_Ent3", "role": "Treatment", "text": "phenylpropanolamine", "start": 8, "end": 9}, {"entity_id": "15028328_1_Ent4", "role": "Treatment_Drug", "text": "phenylpropanolamine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "15028328_1_Ent2", "text": "Cerebral infarcts", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15028328_1_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15028328_1_Ent0", "text": "pediatric patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15028328_1_Ent3", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15028328_1_Ent4", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "15028328_2", "wnd_id": "15028328_2_1", "text": "Phenylpropanolamine ( PPA ) recently has been publicly implicated as a cause of stroke and other neurologic events .", "tokens": ["Phenylpropanolamine", "(", "PPA", ")", "recently", "has", "been", "publicly", "implicated", "as", "a", "cause", "of", "stroke", "and", "other", "neurologic", "events", "."], "event_mentions": [{"id": "15028328_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "15028328_2_Ent2", "role": "Treatment_Drug", "text": "Phenylpropanolamine", "start": 0, "end": 1}, {"entity_id": "15028328_2_Ent1", "role": "Treatment", "text": "Phenylpropanolamine ( PPA )", "start": 0, "end": 4}, {"entity_id": "15028328_2_Ent0", "role": "Effect", "text": "stroke and other neurologic events", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "15028328_2_Ent2", "text": "Phenylpropanolamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15028328_2_Ent1", "text": "Phenylpropanolamine ( PPA )", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15028328_2_Ent0", "text": "stroke and other neurologic events", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "15028964_2", "wnd_id": "15028964_2_1", "text": "Many patients with cardiac arrhythmias require concomitant therapy with warfarin and amiodarone .", "tokens": ["Many", "patients", "with", "cardiac", "arrhythmias", "require", "concomitant", "therapy", "with", "warfarin", "and", "amiodarone", "."], "event_mentions": [{"id": "15028964_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "require", "start": 5, "end": 6}, "arguments": [{"entity_id": "15028964_2_Ent0", "role": "Subject", "text": "Many patients with cardiac arrhythmias", "start": 0, "end": 5}, {"entity_id": "15028964_2_Ent4", "role": "Treatment_Disorder", "text": "cardiac arrhythmias", "start": 3, "end": 5}, {"entity_id": "15028964_2_Ent1", "role": "Treatment", "text": "concomitant therapy with warfarin and amiodarone", "start": 6, "end": 12}, {"entity_id": "15028964_2_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 9, "end": 10}, {"entity_id": "15028964_2_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 9, "end": 10}, {"entity_id": "15028964_2_Ent3", "role": "Treatment_Drug", "text": "amiodarone", "start": 11, "end": 12}, {"entity_id": "15028964_2_Ent6", "role": "Combination_Drug", "text": "amiodarone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15028964_2_Ent0", "text": "Many patients with cardiac arrhythmias", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "15028964_2_Ent4", "text": "cardiac arrhythmias", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15028964_2_Ent1", "text": "concomitant therapy with warfarin and amiodarone", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "15028964_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15028964_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15028964_2_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15028964_2_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "1504404_2", "wnd_id": "1504404_2_1", "text": "Ciprofloxacin - induced psychosis .", "tokens": ["Ciprofloxacin", "-", "induced", "psychosis", "."], "event_mentions": [{"id": "1504404_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1504404_2_Ent1", "role": "Treatment", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "1504404_2_Ent2", "role": "Treatment_Drug", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "1504404_2_Ent0", "role": "Effect", "text": "psychosis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "1504404_2_Ent1", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1504404_2_Ent2", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1504404_2_Ent0", "text": "psychosis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "15053046_4", "wnd_id": "15053046_4_1", "text": "The agranulocytosis was rapidly resolved by granulocyte colony - stimulating factor ( G - CSF ) therapy and by the discontinuation of vancomycin .", "tokens": ["The", "agranulocytosis", "was", "rapidly", "resolved", "by", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "therapy", "and", "by", "the", "discontinuation", "of", "vancomycin", "."], "event_mentions": [{"id": "15053046_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 4, "end": 5}, "arguments": [{"entity_id": "15053046_4_Ent0", "role": "Effect", "text": "agranulocytosis", "start": 1, "end": 2}, {"entity_id": "15053046_4_Ent2", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 6, "end": 11}, {"entity_id": "15053046_4_Ent1", "role": "Treatment", "text": "granulocyte colony - stimulating factor ( G - CSF ) therapy and by the discontinuation of vancomycin", "start": 6, "end": 23}, {"entity_id": "15053046_4_Ent3", "role": "Treatment_Drug", "text": "vancomycin", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "15053046_4_Ent0", "text": "agranulocytosis", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15053046_4_Ent2", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "15053046_4_Ent1", "text": "granulocyte colony - stimulating factor ( G - CSF ) therapy and by the discontinuation of vancomycin", "entity_type": "Entity", "start": 6, "end": 23}, {"id": "15053046_4_Ent3", "text": "vancomycin", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "15097937_3", "wnd_id": "15097937_3_1", "text": "We report a case of a previously healthy , postmenopausal woman who developed anticonvulsant hypersensitivity syndrome while taking Bellamine S ( belladonna alkaloids ; ergotamine ; phenobarbital ) for hot flashes .", "tokens": ["We", "report", "a", "case", "of", "a", "previously", "healthy", ",", "postmenopausal", "woman", "who", "developed", "anticonvulsant", "hypersensitivity", "syndrome", "while", "taking", "Bellamine", "S", "(", "belladonna", "alkaloids", ";", "ergotamine", ";", "phenobarbital", ")", "for", "hot", "flashes", "."], "event_mentions": [{"id": "15097937_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "15097937_3_Ent0", "role": "Subject", "text": "a previously healthy , postmenopausal woman", "start": 5, "end": 11}, {"entity_id": "15097937_3_Ent1", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "15097937_3_Ent2", "role": "Effect", "text": "anticonvulsant hypersensitivity syndrome", "start": 13, "end": 16}, {"entity_id": "15097937_3_Ent5", "role": "Treatment_Drug", "text": "Bellamine S", "start": 18, "end": 20}, {"entity_id": "15097937_3_Ent3", "role": "Treatment", "text": "Bellamine S ( belladonna alkaloids ; ergotamine ; phenobarbital )", "start": 18, "end": 28}, {"entity_id": "15097937_3_Ent6", "role": "Treatment_Drug", "text": "belladonna alkaloids", "start": 21, "end": 23}, {"entity_id": "15097937_3_Ent7", "role": "Treatment_Drug", "text": "ergotamine", "start": 24, "end": 25}, {"entity_id": "15097937_3_Ent8", "role": "Treatment_Drug", "text": "phenobarbital", "start": 26, "end": 27}, {"entity_id": "15097937_3_Ent4", "role": "Treatment_Disorder", "text": "hot flashes", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "15097937_3_Ent0", "text": "a previously healthy , postmenopausal woman", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "15097937_3_Ent1", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15097937_3_Ent2", "text": "anticonvulsant hypersensitivity syndrome", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "15097937_3_Ent5", "text": "Bellamine S", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "15097937_3_Ent3", "text": "Bellamine S ( belladonna alkaloids ; ergotamine ; phenobarbital )", "entity_type": "Entity", "start": 18, "end": 28}, {"id": "15097937_3_Ent6", "text": "belladonna alkaloids", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "15097937_3_Ent7", "text": "ergotamine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "15097937_3_Ent8", "text": "phenobarbital", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "15097937_3_Ent4", "text": "hot flashes", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "15107195_1", "wnd_id": "15107195_1_1", "text": "A case of heatstroke is reported in a 32 - year - old man diagnosed with schizophrenia and on clozapine monotherapy .", "tokens": ["A", "case", "of", "heatstroke", "is", "reported", "in", "a", "32", "-", "year", "-", "old", "man", "diagnosed", "with", "schizophrenia", "and", "on", "clozapine", "monotherapy", "."], "event_mentions": [{"id": "15107195_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 5, "end": 6}, "arguments": [{"entity_id": "15107195_1_Ent3", "role": "Effect", "text": "heatstroke", "start": 3, "end": 4}, {"entity_id": "15107195_1_Ent0", "role": "Subject", "text": "a 32 - year - old man diagnosed with schizophrenia", "start": 7, "end": 17}, {"entity_id": "15107195_1_Ent1", "role": "Subject_Age", "text": "32 - year - old", "start": 8, "end": 13}, {"entity_id": "15107195_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 13, "end": 14}, {"entity_id": "15107195_1_Ent6", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 16, "end": 17}, {"entity_id": "15107195_1_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 19, "end": 20}, {"entity_id": "15107195_1_Ent4", "role": "Treatment", "text": "clozapine monotherapy", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "15107195_1_Ent3", "text": "heatstroke", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15107195_1_Ent0", "text": "a 32 - year - old man diagnosed with schizophrenia", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "15107195_1_Ent1", "text": "32 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "15107195_1_Ent2", "text": "man", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15107195_1_Ent6", "text": "schizophrenia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15107195_1_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15107195_1_Ent4", "text": "clozapine monotherapy", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "15112258_14", "wnd_id": "15112258_14_1", "text": "In contrast , other common agents for the most part trigger cutaneous inflammation .", "tokens": ["In", "contrast", ",", "other", "common", "agents", "for", "the", "most", "part", "trigger", "cutaneous", "inflammation", "."], "event_mentions": [{"id": "15112258_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "trigger", "start": 10, "end": 11}, "arguments": [{"entity_id": "15112258_14_Ent2", "role": "Treatment_Drug", "text": "other common agents", "start": 3, "end": 6}, {"entity_id": "15112258_14_Ent1", "role": "Treatment", "text": "other common agents for the most part", "start": 3, "end": 10}, {"entity_id": "15112258_14_Ent0", "role": "Effect", "text": "cutaneous inflammation", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "15112258_14_Ent2", "text": "other common agents", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15112258_14_Ent1", "text": "other common agents for the most part", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "15112258_14_Ent0", "text": "cutaneous inflammation", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "15112258_9", "wnd_id": "15112258_9_1", "text": "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall , thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13 .", "tokens": ["The", "authors", "also", "determined", "that", "their", "case", "of", "myositis", "developing", "in", "the", "rectus", "abdominus", "muscle", "of", "a", "patient", "with", "pancreatic", "adenocarcinoma", "was", "the", "manifestation", "of", "radiation", "recall", ",", "thereby", "bringing", "the", "number", "of", "patients", "who", "developed", "radiation", "recall", "to", "gemcitabine", "and", "were", "discussed", "in", "the", "current", "study", "to", "13", "."], "event_mentions": [{"id": "15112258_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 35, "end": 36}, "arguments": [{"entity_id": "15112258_9_Ent1", "role": "Effect", "text": "myositis developing in the rectus abdominus muscle", "start": 8, "end": 15}, {"entity_id": "15112258_9_Ent0", "role": "Subject", "text": "a patient with pancreatic adenocarcinoma", "start": 16, "end": 21}, {"entity_id": "15112258_9_Ent4", "role": "Treatment_Disorder", "text": "pancreatic adenocarcinoma", "start": 19, "end": 21}, {"entity_id": "15112258_9_Ent2", "role": "Effect", "text": "radiation recall", "start": 36, "end": 38}, {"entity_id": "15112258_9_Ent3", "role": "Treatment", "text": "gemcitabine", "start": 39, "end": 40}, {"entity_id": "15112258_9_Ent5", "role": "Treatment_Drug", "text": "gemcitabine", "start": 39, "end": 40}]}], "entity_mentions": [{"id": "15112258_9_Ent1", "text": "myositis developing in the rectus abdominus muscle", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "15112258_9_Ent0", "text": "a patient with pancreatic adenocarcinoma", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "15112258_9_Ent4", "text": "pancreatic adenocarcinoma", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "15112258_9_Ent2", "text": "radiation recall", "entity_type": "Entity", "start": 36, "end": 38}, {"id": "15112258_9_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "15112258_9_Ent5", "text": "gemcitabine", "entity_type": "Entity", "start": 39, "end": 40}], "lang": "en"}
{"doc_id": "15133245_2", "wnd_id": "15133245_2_1", "text": "Oxatomide is an antiallergic drug used for the treatment of diseases mediated by type I allergy .", "tokens": ["Oxatomide", "is", "an", "antiallergic", "drug", "used", "for", "the", "treatment", "of", "diseases", "mediated", "by", "type", "I", "allergy", "."], "event_mentions": [{"id": "15133245_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 5, "end": 6}, "arguments": [{"entity_id": "15133245_2_Ent0", "role": "Treatment", "text": "Oxatomide", "start": 0, "end": 1}, {"entity_id": "15133245_2_Ent2", "role": "Treatment_Drug", "text": "Oxatomide", "start": 0, "end": 1}, {"entity_id": "15133245_2_Ent1", "role": "Treatment_Disorder", "text": "diseases mediated by type I allergy", "start": 10, "end": 16}]}], "entity_mentions": [{"id": "15133245_2_Ent0", "text": "Oxatomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15133245_2_Ent2", "text": "Oxatomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15133245_2_Ent1", "text": "diseases mediated by type I allergy", "entity_type": "Entity", "start": 10, "end": 16}], "lang": "en"}
{"doc_id": "15176542_1", "wnd_id": "15176542_1_1", "text": "One patient developed large intramural esophageal hematoma as a complication of heparin therapy .", "tokens": ["One", "patient", "developed", "large", "intramural", "esophageal", "hematoma", "as", "a", "complication", "of", "heparin", "therapy", "."], "event_mentions": [{"id": "15176542_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "15176542_1_Ent0", "role": "Subject", "text": "One patient", "start": 0, "end": 2}, {"entity_id": "15176542_1_Ent1", "role": "Effect", "text": "large intramural esophageal hematoma", "start": 3, "end": 7}, {"entity_id": "15176542_1_Ent2", "role": "Treatment", "text": "a complication of heparin therapy", "start": 8, "end": 13}, {"entity_id": "15176542_1_Ent3", "role": "Treatment_Drug", "text": "heparin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15176542_1_Ent0", "text": "One patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15176542_1_Ent1", "text": "large intramural esophageal hematoma", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "15176542_1_Ent2", "text": "a complication of heparin therapy", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "15176542_1_Ent3", "text": "heparin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15183980_1", "wnd_id": "15183980_1_1", "text": "Eosinophilic cystitis after bladder instillation with dimethyl sulfoxide .", "tokens": ["Eosinophilic", "cystitis", "after", "bladder", "instillation", "with", "dimethyl", "sulfoxide", "."], "event_mentions": [{"id": "15183980_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "15183980_1_Ent0", "role": "Effect", "text": "Eosinophilic cystitis", "start": 0, "end": 2}, {"entity_id": "15183980_1_Ent3", "role": "Treatment_Route", "text": "bladder instillation", "start": 3, "end": 5}, {"entity_id": "15183980_1_Ent1", "role": "Treatment", "text": "bladder instillation with dimethyl sulfoxide", "start": 3, "end": 8}, {"entity_id": "15183980_1_Ent2", "role": "Treatment_Drug", "text": "dimethyl sulfoxide", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "15183980_1_Ent0", "text": "Eosinophilic cystitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15183980_1_Ent3", "text": "bladder instillation", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15183980_1_Ent1", "text": "bladder instillation with dimethyl sulfoxide", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15183980_1_Ent2", "text": "dimethyl sulfoxide", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "15190230_1", "wnd_id": "15190230_1_1", "text": "Acute dystonia during pegylated interferon alpha therapy in a case with chronic hepatitis B infection .", "tokens": ["Acute", "dystonia", "during", "pegylated", "interferon", "alpha", "therapy", "in", "a", "case", "with", "chronic", "hepatitis", "B", "infection", "."], "event_mentions": [{"id": "15190230_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "therapy", "start": 6, "end": 7}, "arguments": [{"entity_id": "15190230_1_Ent0", "role": "Effect", "text": "Acute dystonia", "start": 0, "end": 2}, {"entity_id": "15190230_1_Ent1", "role": "Treatment", "text": "pegylated interferon alpha", "start": 3, "end": 6}, {"entity_id": "15190230_1_Ent3", "role": "Treatment_Drug", "text": "pegylated interferon alpha", "start": 3, "end": 6}, {"entity_id": "15190230_1_Ent2", "role": "Treatment_Disorder", "text": "chronic hepatitis B infection", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "15190230_1_Ent0", "text": "Acute dystonia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15190230_1_Ent1", "text": "pegylated interferon alpha", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15190230_1_Ent3", "text": "pegylated interferon alpha", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15190230_1_Ent2", "text": "chronic hepatitis B infection", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "15190230_3", "wnd_id": "15190230_3_1", "text": "Therapy with IFN - alpha may be associated with a number of neuropsychiatric symptoms , such as Parkinsonism , akathisia , seizure , and depressive disorders .", "tokens": ["Therapy", "with", "IFN", "-", "alpha", "may", "be", "associated", "with", "a", "number", "of", "neuropsychiatric", "symptoms", ",", "such", "as", "Parkinsonism", ",", "akathisia", ",", "seizure", ",", "and", "depressive", "disorders", "."], "event_mentions": [{"id": "15190230_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 7, "end": 9}, "arguments": [{"entity_id": "15190230_3_Ent1", "role": "Treatment", "text": "Therapy with IFN - alpha", "start": 0, "end": 5}, {"entity_id": "15190230_3_Ent2", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 2, "end": 5}, {"entity_id": "15190230_3_Ent0", "role": "Effect", "text": "neuropsychiatric symptoms , such as Parkinsonism , akathisia , seizure , and depressive disorders", "start": 12, "end": 26}]}], "entity_mentions": [{"id": "15190230_3_Ent1", "text": "Therapy with IFN - alpha", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "15190230_3_Ent2", "text": "IFN - alpha", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "15190230_3_Ent0", "text": "neuropsychiatric symptoms , such as Parkinsonism , akathisia , seizure , and depressive disorders", "entity_type": "Entity", "start": 12, "end": 26}], "lang": "en"}
{"doc_id": "15197722_1", "wnd_id": "15197722_1_1", "text": "A patient developed restless legs symptoms paralleling the course of interferon - alpha ( IFN alpha ) therapy for chronic hepatitis C.", "tokens": ["A", "patient", "developed", "restless", "legs", "symptoms", "paralleling", "the", "course", "of", "interferon", "-", "alpha", "(", "IFN", "alpha", ")", "therapy", "for", "chronic", "hepatitis", "C."], "event_mentions": [{"id": "15197722_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "15197722_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "15197722_1_Ent1", "role": "Effect", "text": "restless legs symptoms", "start": 3, "end": 6}, {"entity_id": "15197722_1_Ent3", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 10, "end": 13}, {"entity_id": "15197722_1_Ent2", "role": "Treatment", "text": "interferon - alpha ( IFN alpha ) therapy", "start": 10, "end": 18}, {"entity_id": "15197722_1_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis C.", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "15197722_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15197722_1_Ent1", "text": "restless legs symptoms", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15197722_1_Ent3", "text": "interferon - alpha", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "15197722_1_Ent2", "text": "interferon - alpha ( IFN alpha ) therapy", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "15197722_1_Ent4", "text": "chronic hepatitis C.", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "15224368_2", "wnd_id": "15224368_2_1", "text": "Sweet 's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of filgrastim , a drug that causes increased neutrophil proliferation and differentiation .", "tokens": ["Sweet", "'s", "syndrome", "is", "an", "acute", "febrile", "neutrophilic", "dermatosis", "that", "is", "a", "known", "complication", "of", "the", "administration", "of", "filgrastim", ",", "a", "drug", "that", "causes", "increased", "neutrophil", "proliferation", "and", "differentiation", "."], "event_mentions": [{"id": "15224368_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 23, "end": 24}, "arguments": [{"entity_id": "15224368_2_Ent0", "role": "Effect", "text": "Sweet 's syndrome is an acute febrile neutrophilic dermatosis", "start": 0, "end": 9}, {"entity_id": "15224368_2_Ent2", "role": "Treatment", "text": "filgrastim", "start": 18, "end": 19}, {"entity_id": "15224368_2_Ent3", "role": "Treatment_Drug", "text": "filgrastim", "start": 18, "end": 19}, {"entity_id": "15224368_2_Ent1", "role": "Effect", "text": "increased neutrophil proliferation and differentiation", "start": 24, "end": 29}]}], "entity_mentions": [{"id": "15224368_2_Ent0", "text": "Sweet 's syndrome is an acute febrile neutrophilic dermatosis", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "15224368_2_Ent2", "text": "filgrastim", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15224368_2_Ent3", "text": "filgrastim", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15224368_2_Ent1", "text": "increased neutrophil proliferation and differentiation", "entity_type": "Entity", "start": 24, "end": 29}], "lang": "en"}
{"doc_id": "15239684_1", "wnd_id": "15239684_1_1", "text": "Purple glove syndrome , named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove , is an uncommon complication of intravenous phenytoin administration through small dorsal veins of the hands .", "tokens": ["Purple", "glove", "syndrome", ",", "named", "for", "its", "distinctive", "purple", "discoloration", "and", "swelling", "of", "the", "hands", "in", "the", "distribution", "of", "a", "glove", ",", "is", "an", "uncommon", "complication", "of", "intravenous", "phenytoin", "administration", "through", "small", "dorsal", "veins", "of", "the", "hands", "."], "event_mentions": [{"id": "15239684_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 25, "end": 26}, "arguments": [{"entity_id": "15239684_1_Ent0", "role": "Effect", "text": "Purple glove syndrome", "start": 0, "end": 3}, {"entity_id": "15239684_1_Ent1", "role": "Effect", "text": "purple discoloration and swelling of the hands in the distribution of a glove", "start": 8, "end": 21}, {"entity_id": "15239684_1_Ent3", "role": "Treatment_Route", "text": "intravenous", "start": 27, "end": 28}, {"entity_id": "15239684_1_Ent2", "role": "Treatment", "text": "intravenous phenytoin administration through small dorsal veins of the hands", "start": 27, "end": 37}, {"entity_id": "15239684_1_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "15239684_1_Ent0", "text": "Purple glove syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15239684_1_Ent1", "text": "purple discoloration and swelling of the hands in the distribution of a glove", "entity_type": "Entity", "start": 8, "end": 21}, {"id": "15239684_1_Ent3", "text": "intravenous", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "15239684_1_Ent2", "text": "intravenous phenytoin administration through small dorsal veins of the hands", "entity_type": "Entity", "start": 27, "end": 37}, {"id": "15239684_1_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "15266150_1", "wnd_id": "15266150_1_1", "text": "A patient with monocular open - angle glaucoma had trichiasis , a condition associated with the use of a prostaglandin analog .", "tokens": ["A", "patient", "with", "monocular", "open", "-", "angle", "glaucoma", "had", "trichiasis", ",", "a", "condition", "associated", "with", "the", "use", "of", "a", "prostaglandin", "analog", "."], "event_mentions": [{"id": "15266150_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 8, "end": 9}, "arguments": [{"entity_id": "15266150_1_Ent0", "role": "Subject", "text": "A patient with monocular open - angle glaucoma", "start": 0, "end": 8}, {"entity_id": "15266150_1_Ent3", "role": "Treatment_Disorder", "text": "monocular open - angle glaucoma", "start": 3, "end": 8}, {"entity_id": "15266150_1_Ent1", "role": "Effect", "text": "trichiasis", "start": 9, "end": 10}, {"entity_id": "15266150_1_Ent2", "role": "Treatment", "text": "a prostaglandin analog", "start": 18, "end": 21}, {"entity_id": "15266150_1_Ent4", "role": "Treatment_Drug", "text": "prostaglandin analog", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "15266150_1_Ent0", "text": "A patient with monocular open - angle glaucoma", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15266150_1_Ent3", "text": "monocular open - angle glaucoma", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15266150_1_Ent1", "text": "trichiasis", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15266150_1_Ent2", "text": "a prostaglandin analog", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "15266150_1_Ent4", "text": "prostaglandin analog", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "15266150_2", "wnd_id": "15266150_2_1", "text": "Increased lash length , thickness , and pigmentation are well - documented side effects of prostaglandin analog glaucoma drops .", "tokens": ["Increased", "lash", "length", ",", "thickness", ",", "and", "pigmentation", "are", "well", "-", "documented", "side", "effects", "of", "prostaglandin", "analog", "glaucoma", "drops", "."], "event_mentions": [{"id": "15266150_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "are", "start": 8, "end": 9}, "arguments": [{"entity_id": "15266150_2_Ent0", "role": "Effect", "text": "Increased lash length , thickness , and pigmentation", "start": 0, "end": 8}, {"entity_id": "15266150_2_Ent3", "role": "Treatment_Drug", "text": "prostaglandin analog", "start": 15, "end": 17}, {"entity_id": "15266150_2_Ent1", "role": "Treatment", "text": "prostaglandin analog glaucoma drops", "start": 15, "end": 19}, {"entity_id": "15266150_2_Ent4", "role": "Treatment_Disorder", "text": "glaucoma", "start": 17, "end": 18}, {"entity_id": "15266150_2_Ent2", "role": "Treatment_Route", "text": "drops", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "15266150_2_Ent0", "text": "Increased lash length , thickness , and pigmentation", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15266150_2_Ent3", "text": "prostaglandin analog", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "15266150_2_Ent1", "text": "prostaglandin analog glaucoma drops", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "15266150_2_Ent4", "text": "glaucoma", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15266150_2_Ent2", "text": "drops", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "15286697_1", "wnd_id": "15286697_1_1", "text": "Fatal pulmonary fibrosis associated with BCNU : the relative role of platelet - derived growth factor - B , insulin - like growth factor I , transforming growth factor - beta1 and cyclooxygenase - 2 .", "tokens": ["Fatal", "pulmonary", "fibrosis", "associated", "with", "BCNU", ":", "the", "relative", "role", "of", "platelet", "-", "derived", "growth", "factor", "-", "B", ",", "insulin", "-", "like", "growth", "factor", "I", ",", "transforming", "growth", "factor", "-", "beta1", "and", "cyclooxygenase", "-", "2", "."], "event_mentions": [{"id": "15286697_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "15286697_1_Ent0", "role": "Effect", "text": "pulmonary fibrosis", "start": 1, "end": 3}, {"entity_id": "15286697_1_Ent1", "role": "Treatment", "text": "BCNU", "start": 5, "end": 6}, {"entity_id": "15286697_1_Ent2", "role": "Treatment_Drug", "text": "BCNU", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "15286697_1_Ent0", "text": "pulmonary fibrosis", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "15286697_1_Ent1", "text": "BCNU", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15286697_1_Ent2", "text": "BCNU", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "15286697_5", "wnd_id": "15286697_5_1", "text": "We report here a 26 - year - old female with diffuse large B - cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high - dose BCNU ( 600 mg / m2 ) .", "tokens": ["We", "report", "here", "a", "26", "-", "year", "-", "old", "female", "with", "diffuse", "large", "B", "-", "cell", "lymphoma", "who", "died", "of", "severe", "pulmonary", "fibrosis", "81", "days", "after", "the", "administration", "of", "high", "-", "dose", "BCNU", "(", "600", "mg", "/", "m2", ")", "."], "event_mentions": [{"id": "15286697_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 27, "end": 28}, "arguments": [{"entity_id": "15286697_5_Ent1", "role": "Subject_Age", "text": "26 - year - old", "start": 4, "end": 9}, {"entity_id": "15286697_5_Ent0", "role": "Subject", "text": "26 - year - old female with diffuse large B - cell lymphoma", "start": 4, "end": 17}, {"entity_id": "15286697_5_Ent2", "role": "Subject_Gender", "text": "female", "start": 9, "end": 10}, {"entity_id": "15286697_5_Ent8", "role": "Treatment_Disorder", "text": "diffuse large B - cell lymphoma", "start": 11, "end": 17}, {"entity_id": "15286697_5_Ent3", "role": "Effect", "text": "died of severe pulmonary fibrosis", "start": 18, "end": 23}, {"entity_id": "15286697_5_Ent7", "role": "Treatment_Time_elapsed", "text": "81 days after", "start": 23, "end": 26}, {"entity_id": "15286697_5_Ent4", "role": "Treatment", "text": "high - dose BCNU ( 600 mg / m2 )", "start": 29, "end": 39}, {"entity_id": "15286697_5_Ent5", "role": "Treatment_Drug", "text": "BCNU", "start": 32, "end": 33}, {"entity_id": "15286697_5_Ent6", "role": "Treatment_Dosage", "text": "600 mg / m2", "start": 34, "end": 38}]}], "entity_mentions": [{"id": "15286697_5_Ent1", "text": "26 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "15286697_5_Ent0", "text": "26 - year - old female with diffuse large B - cell lymphoma", "entity_type": "Entity", "start": 4, "end": 17}, {"id": "15286697_5_Ent2", "text": "female", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15286697_5_Ent8", "text": "diffuse large B - cell lymphoma", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "15286697_5_Ent3", "text": "died of severe pulmonary fibrosis", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "15286697_5_Ent7", "text": "81 days after", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "15286697_5_Ent4", "text": "high - dose BCNU ( 600 mg / m2 )", "entity_type": "Entity", "start": 29, "end": 39}, {"id": "15286697_5_Ent5", "text": "BCNU", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "15286697_5_Ent6", "text": "600 mg / m2", "entity_type": "Entity", "start": 34, "end": 38}], "lang": "en"}
{"doc_id": "15289139_1", "wnd_id": "15289139_1_1", "text": "Dorzolamide - induced choroidal detachment in a surgically untreated eye .", "tokens": ["Dorzolamide", "-", "induced", "choroidal", "detachment", "in", "a", "surgically", "untreated", "eye", "."], "event_mentions": [{"id": "15289139_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15289139_1_Ent2", "role": "Treatment", "text": "Dorzolamide", "start": 0, "end": 1}, {"entity_id": "15289139_1_Ent3", "role": "Treatment_Drug", "text": "Dorzolamide", "start": 0, "end": 1}, {"entity_id": "15289139_1_Ent1", "role": "Effect", "text": "choroidal detachment", "start": 3, "end": 5}, {"entity_id": "15289139_1_Ent0", "role": "Subject", "text": "a surgically untreated eye", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "15289139_1_Ent2", "text": "Dorzolamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15289139_1_Ent3", "text": "Dorzolamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15289139_1_Ent1", "text": "choroidal detachment", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15289139_1_Ent0", "text": "a surgically untreated eye", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "15289139_2", "wnd_id": "15289139_2_1", "text": "METHODS : A 76 - year - old woman with primary open - angle glaucoma and no history of ocular surgery developed a choroidal detachment 12 hours after initiation of therapy with dorzolamide eye drops .", "tokens": ["METHODS", ":", "A", "76", "-", "year", "-", "old", "woman", "with", "primary", "open", "-", "angle", "glaucoma", "and", "no", "history", "of", "ocular", "surgery", "developed", "a", "choroidal", "detachment", "12", "hours", "after", "initiation", "of", "therapy", "with", "dorzolamide", "eye", "drops", "."], "event_mentions": [{"id": "15289139_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 21, "end": 22}, "arguments": [{"entity_id": "15289139_2_Ent0", "role": "Subject", "text": "A 76 - year - old woman with primary open - angle glaucoma and no history of ocular surgery", "start": 2, "end": 21}, {"entity_id": "15289139_2_Ent1", "role": "Subject_Age", "text": "76 - year - old", "start": 3, "end": 8}, {"entity_id": "15289139_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "15289139_2_Ent7", "role": "Treatment_Disorder", "text": "open - angle glaucoma", "start": 11, "end": 15}, {"entity_id": "15289139_2_Ent3", "role": "Effect", "text": "choroidal detachment", "start": 23, "end": 25}, {"entity_id": "15289139_2_Ent5", "role": "Treatment_Time_elapsed", "text": "12 hours", "start": 25, "end": 27}, {"entity_id": "15289139_2_Ent4", "role": "Treatment", "text": "12 hours after initiation of therapy with dorzolamide eye drops", "start": 25, "end": 35}, {"entity_id": "15289139_2_Ent6", "role": "Treatment_Drug", "text": "dorzolamide", "start": 32, "end": 33}, {"entity_id": "15289139_2_Ent8", "role": "Treatment_Route", "text": "eye drops", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "15289139_2_Ent0", "text": "A 76 - year - old woman with primary open - angle glaucoma and no history of ocular surgery", "entity_type": "Entity", "start": 2, "end": 21}, {"id": "15289139_2_Ent1", "text": "76 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15289139_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15289139_2_Ent7", "text": "open - angle glaucoma", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "15289139_2_Ent3", "text": "choroidal detachment", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "15289139_2_Ent5", "text": "12 hours", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "15289139_2_Ent4", "text": "12 hours after initiation of therapy with dorzolamide eye drops", "entity_type": "Entity", "start": 25, "end": 35}, {"id": "15289139_2_Ent6", "text": "dorzolamide", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "15289139_2_Ent8", "text": "eye drops", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "15316423_2", "wnd_id": "15316423_2_1", "text": "Here we describe a patient with Crohn 's disease who developed a severe infliximab infusion reaction ( IIR ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion .", "tokens": ["Here", "we", "describe", "a", "patient", "with", "Crohn", "'s", "disease", "who", "developed", "a", "severe", "infliximab", "infusion", "reaction", "(", "IIR", ")", ",", "complicated", "1", "day", "later", "by", "severe", "swelling", "of", "the", "forearm", "and", "hand", "ipsilateral", "to", "the", "site", "of", "infliximab", "infusion", "."], "event_mentions": [{"id": "15316423_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "15316423_2_Ent0", "role": "Subject", "text": "a patient with Crohn 's disease", "start": 3, "end": 9}, {"entity_id": "15316423_2_Ent5", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 6, "end": 9}, {"entity_id": "15316423_2_Ent1", "role": "Effect", "text": "severe infliximab infusion reaction ( IIR ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral", "start": 12, "end": 33}, {"entity_id": "15316423_2_Ent3", "role": "Treatment_Drug", "text": "infliximab", "start": 37, "end": 38}, {"entity_id": "15316423_2_Ent2", "role": "Treatment", "text": "infliximab infusion", "start": 37, "end": 39}, {"entity_id": "15316423_2_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "15316423_2_Ent0", "text": "a patient with Crohn 's disease", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "15316423_2_Ent5", "text": "Crohn 's disease", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15316423_2_Ent1", "text": "severe infliximab infusion reaction ( IIR ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral", "entity_type": "Entity", "start": 12, "end": 33}, {"id": "15316423_2_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "15316423_2_Ent2", "text": "infliximab infusion", "entity_type": "Entity", "start": 37, "end": 39}, {"id": "15316423_2_Ent4", "text": "infusion", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "15331204_1", "wnd_id": "15331204_1_1", "text": "Possible induction of diabetes by treatment of hypertension with indapamide ( with four case reports ) .", "tokens": ["Possible", "induction", "of", "diabetes", "by", "treatment", "of", "hypertension", "with", "indapamide", "(", "with", "four", "case", "reports", ")", "."], "event_mentions": [{"id": "15331204_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induction", "start": 1, "end": 2}, "arguments": [{"entity_id": "15331204_1_Ent0", "role": "Effect", "text": "diabetes", "start": 3, "end": 4}, {"entity_id": "15331204_1_Ent2", "role": "Treatment_Disorder", "text": "hypertension", "start": 7, "end": 8}, {"entity_id": "15331204_1_Ent1", "role": "Treatment", "text": "indapamide", "start": 9, "end": 10}, {"entity_id": "15331204_1_Ent3", "role": "Treatment_Drug", "text": "indapamide", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15331204_1_Ent0", "text": "diabetes", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15331204_1_Ent2", "text": "hypertension", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15331204_1_Ent1", "text": "indapamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15331204_1_Ent3", "text": "indapamide", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15331204_2", "wnd_id": "15331204_2_1", "text": "OBJECTIVE : To study therapy with indapamide impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention , diagnoses and treatment of diabetes induced by indapamide .", "tokens": ["OBJECTIVE", ":", "To", "study", "therapy", "with", "indapamide", "impairing", "carbohydrate", "metabolism", "in", "essential", "hypertension", "patients", "and", "achieve", "earlier", "prevention", ",", "diagnoses", "and", "treatment", "of", "diabetes", "induced", "by", "indapamide", "."], "event_mentions": [{"id": "15331204_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 4, "end": 5}, "arguments": [{"entity_id": "15331204_2_Ent1", "role": "Treatment", "text": "indapamide", "start": 6, "end": 7}, {"entity_id": "15331204_2_Ent4", "role": "Treatment_Drug", "text": "indapamide", "start": 6, "end": 7}, {"entity_id": "15331204_2_Ent2", "role": "Treatment_Disorder", "text": "carbohydrate metabolism", "start": 8, "end": 10}, {"entity_id": "15331204_2_Ent0", "role": "Subject", "text": "essential hypertension patients", "start": 11, "end": 14}, {"entity_id": "15331204_2_Ent3", "role": "Treatment_Disorder", "text": "hypertension", "start": 12, "end": 13}]}, {"id": "15331204_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 24, "end": 25}, "arguments": [{"entity_id": "15331204_2_Ent5", "role": "Effect", "text": "diabetes", "start": 23, "end": 24}, {"entity_id": "15331204_2_Ent6", "role": "Treatment", "text": "indapamide", "start": 26, "end": 27}, {"entity_id": "15331204_2_Ent7", "role": "Treatment_Drug", "text": "indapamide", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "15331204_2_Ent1", "text": "indapamide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15331204_2_Ent4", "text": "indapamide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15331204_2_Ent2", "text": "carbohydrate metabolism", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15331204_2_Ent0", "text": "essential hypertension patients", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "15331204_2_Ent3", "text": "hypertension", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15331204_2_Ent5", "text": "diabetes", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15331204_2_Ent6", "text": "indapamide", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "15331204_2_Ent7", "text": "indapamide", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "15331204_6", "wnd_id": "15331204_6_1", "text": "CONCLUSION : Therapy with indapamide may induce diabetes in essential hypertension patients .", "tokens": ["CONCLUSION", ":", "Therapy", "with", "indapamide", "may", "induce", "diabetes", "in", "essential", "hypertension", "patients", "."], "event_mentions": [{"id": "15331204_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 6, "end": 7}, "arguments": [{"entity_id": "15331204_6_Ent2", "role": "Treatment", "text": "indapamide", "start": 4, "end": 5}, {"entity_id": "15331204_6_Ent3", "role": "Treatment_Drug", "text": "indapamide", "start": 4, "end": 5}, {"entity_id": "15331204_6_Ent1", "role": "Effect", "text": "diabetes", "start": 7, "end": 8}, {"entity_id": "15331204_6_Ent4", "role": "Treatment_Disorder", "text": "essential hypertension", "start": 9, "end": 11}, {"entity_id": "15331204_6_Ent0", "role": "Subject", "text": "essential hypertension patients", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "15331204_6_Ent2", "text": "indapamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15331204_6_Ent3", "text": "indapamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15331204_6_Ent1", "text": "diabetes", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15331204_6_Ent4", "text": "essential hypertension", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15331204_6_Ent0", "text": "essential hypertension patients", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "15338554_6", "wnd_id": "15338554_6_1", "text": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate .", "tokens": ["Progression", "of", "chronic", "myeloid", "leukemia", "to", "blast", "crisis", "during", "treatment", "with", "imatinib", "mesylate", "."], "event_mentions": [{"id": "15338554_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "15338554_6_Ent0", "role": "Effect", "text": "Progression of chronic myeloid leukemia to blast crisis", "start": 0, "end": 8}, {"entity_id": "15338554_6_Ent1", "role": "Treatment", "text": "imatinib mesylate", "start": 11, "end": 13}, {"entity_id": "15338554_6_Ent2", "role": "Treatment_Drug", "text": "imatinib mesylate", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "15338554_6_Ent0", "text": "Progression of chronic myeloid leukemia to blast crisis", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15338554_6_Ent1", "text": "imatinib mesylate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "15338554_6_Ent2", "text": "imatinib mesylate", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "15359206_2", "wnd_id": "15359206_2_1", "text": "In this paper we report a case of nimodipine overdosage resulting in prolonged hypotension and hypoxemia , which was successfully treated with calcium gluconate .", "tokens": ["In", "this", "paper", "we", "report", "a", "case", "of", "nimodipine", "overdosage", "resulting", "in", "prolonged", "hypotension", "and", "hypoxemia", ",", "which", "was", "successfully", "treated", "with", "calcium", "gluconate", "."], "event_mentions": [{"id": "15359206_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 10, "end": 11}, "arguments": [{"entity_id": "15359206_2_Ent3", "role": "Treatment_Drug", "text": "nimodipine", "start": 8, "end": 9}, {"entity_id": "15359206_2_Ent1", "role": "Treatment", "text": "nimodipine overdosage", "start": 8, "end": 10}, {"entity_id": "15359206_2_Ent2", "role": "Treatment_Dosage", "text": "overdosage", "start": 9, "end": 10}, {"entity_id": "15359206_2_Ent0", "role": "Effect", "text": "prolonged hypotension and hypoxemia", "start": 12, "end": 16}]}, {"id": "15359206_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 20, "end": 21}, "arguments": [{"entity_id": "15359206_2_Ent5", "role": "Treatment_Disorder", "text": "prolonged hypotension and hypoxemia", "start": 12, "end": 16}, {"entity_id": "15359206_2_Ent4", "role": "Treatment", "text": "calcium gluconate", "start": 22, "end": 24}, {"entity_id": "15359206_2_Ent6", "role": "Treatment_Drug", "text": "calcium gluconate", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "15359206_2_Ent3", "text": "nimodipine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15359206_2_Ent1", "text": "nimodipine overdosage", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15359206_2_Ent2", "text": "overdosage", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15359206_2_Ent0", "text": "prolonged hypotension and hypoxemia", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "15359206_2_Ent5", "text": "prolonged hypotension and hypoxemia", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "15359206_2_Ent4", "text": "calcium gluconate", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "15359206_2_Ent6", "text": "calcium gluconate", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "15362597_1", "wnd_id": "15362597_1_1", "text": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction .", "tokens": ["Refractory", "hypoglycemia", "from", "ciprofloxacin", "and", "glyburide", "interaction", "."], "event_mentions": [{"id": "15362597_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "15362597_1_Ent0", "role": "Effect", "text": "Refractory hypoglycemia", "start": 0, "end": 2}, {"entity_id": "15362597_1_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "15362597_1_Ent5", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "15362597_1_Ent1", "role": "Treatment", "text": "ciprofloxacin and glyburide interaction", "start": 3, "end": 7}, {"entity_id": "15362597_1_Ent3", "role": "Treatment_Drug", "text": "glyburide", "start": 5, "end": 6}, {"entity_id": "15362597_1_Ent4", "role": "Combination_Drug", "text": "glyburide", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "15362597_1_Ent0", "text": "Refractory hypoglycemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15362597_1_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15362597_1_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15362597_1_Ent1", "text": "ciprofloxacin and glyburide interaction", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "15362597_1_Ent3", "text": "glyburide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15362597_1_Ent4", "text": "glyburide", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "15373932_2", "wnd_id": "15373932_2_1", "text": "Fungal infection is a significant comorbidity in patients with diabetes mellitus , and ketoconazole , an antifungal agent , causes a number of drug interactions with coadministered drugs .", "tokens": ["Fungal", "infection", "is", "a", "significant", "comorbidity", "in", "patients", "with", "diabetes", "mellitus", ",", "and", "ketoconazole", ",", "an", "antifungal", "agent", ",", "causes", "a", "number", "of", "drug", "interactions", "with", "coadministered", "drugs", "."], "event_mentions": [{"id": "15373932_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 19, "end": 20}, "arguments": [{"entity_id": "15373932_2_Ent5", "role": "Treatment_Disorder", "text": "Fungal infection", "start": 0, "end": 2}, {"entity_id": "15373932_2_Ent0", "role": "Subject", "text": "patients with diabetes mellitus", "start": 7, "end": 11}, {"entity_id": "15373932_2_Ent1", "role": "Subject_Disorder", "text": "diabetes mellitus", "start": 9, "end": 11}, {"entity_id": "15373932_2_Ent3", "role": "Treatment", "text": "ketoconazole", "start": 13, "end": 14}, {"entity_id": "15373932_2_Ent4", "role": "Treatment_Drug", "text": "ketoconazole", "start": 13, "end": 14}, {"entity_id": "15373932_2_Ent2", "role": "Effect", "text": "a number of drug interactions with coadministered drugs", "start": 20, "end": 28}]}], "entity_mentions": [{"id": "15373932_2_Ent5", "text": "Fungal infection", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15373932_2_Ent0", "text": "patients with diabetes mellitus", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "15373932_2_Ent1", "text": "diabetes mellitus", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15373932_2_Ent3", "text": "ketoconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15373932_2_Ent4", "text": "ketoconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15373932_2_Ent2", "text": "a number of drug interactions with coadministered drugs", "entity_type": "Entity", "start": 20, "end": 28}], "lang": "en"}
{"doc_id": "15379082_2", "wnd_id": "15379082_2_1", "text": "Fulminant hepatic failure is a rare complication of disulfiram treatment for alcoholism .", "tokens": ["Fulminant", "hepatic", "failure", "is", "a", "rare", "complication", "of", "disulfiram", "treatment", "for", "alcoholism", "."], "event_mentions": [{"id": "15379082_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 6, "end": 7}, "arguments": [{"entity_id": "15379082_2_Ent0", "role": "Effect", "text": "Fulminant hepatic failure", "start": 0, "end": 3}, {"entity_id": "15379082_2_Ent1", "role": "Treatment", "text": "disulfiram", "start": 8, "end": 9}, {"entity_id": "15379082_2_Ent3", "role": "Treatment_Drug", "text": "disulfiram", "start": 8, "end": 9}, {"entity_id": "15379082_2_Ent2", "role": "Treatment_Disorder", "text": "alcoholism", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15379082_2_Ent0", "text": "Fulminant hepatic failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15379082_2_Ent1", "text": "disulfiram", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15379082_2_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15379082_2_Ent2", "text": "alcoholism", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15468380_2", "wnd_id": "15468380_2_1", "text": "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis , respectively , in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other .", "tokens": ["We", "describe", "2", "patients", "with", "severe", "erosive", "rheumatoid", "arthritis", "and", "rheumatoid", "vasculitis", ",", "respectively", ",", "in", "whom", "infliximab", "therapy", "was", "associated", "with", "peripheral", "neuropathy", "due", "to", "necrotizing", "vasculitis", "in", "one", "patient", "and", "to", "progression", "of", "preexisting", "mononeuritis", "multiplex", "in", "the", "other", "."], "event_mentions": [{"id": "15468380_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 20, "end": 21}, "arguments": [{"entity_id": "15468380_2_Ent4", "role": "Treatment_Drug", "text": "infliximab", "start": 17, "end": 18}, {"entity_id": "15468380_2_Ent2", "role": "Treatment", "text": "infliximab therapy", "start": 17, "end": 19}, {"entity_id": "15468380_2_Ent1", "role": "Effect", "text": "peripheral neuropathy", "start": 22, "end": 24}, {"entity_id": "15468380_2_Ent3", "role": "Treatment_Disorder", "text": "necrotizing vasculitis", "start": 26, "end": 28}, {"entity_id": "15468380_2_Ent0", "role": "Subject", "text": "one patient", "start": 29, "end": 31}]}, {"id": "15468380_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 20, "end": 21}, "arguments": [{"entity_id": "15468380_2_Ent10", "role": "Treatment_Drug", "text": "infliximab", "start": 17, "end": 18}, {"entity_id": "15468380_2_Ent8", "role": "Treatment", "text": "infliximab therapy", "start": 17, "end": 19}, {"entity_id": "15468380_2_Ent7", "role": "Effect", "text": "peripheral neuropathy", "start": 22, "end": 24}, {"entity_id": "15468380_2_Ent9", "role": "Treatment_Disorder", "text": "necrotizing vasculitis", "start": 26, "end": 28}, {"entity_id": "15468380_2_Ent6", "role": "Subject_Disorder", "text": "preexisting mononeuritis multiplex", "start": 35, "end": 38}, {"entity_id": "15468380_2_Ent5", "role": "Subject", "text": "preexisting mononeuritis multiplex in the other", "start": 35, "end": 41}]}], "entity_mentions": [{"id": "15468380_2_Ent4", "text": "infliximab", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15468380_2_Ent10", "text": "infliximab", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15468380_2_Ent2", "text": "infliximab therapy", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "15468380_2_Ent8", "text": "infliximab therapy", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "15468380_2_Ent1", "text": "peripheral neuropathy", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "15468380_2_Ent7", "text": "peripheral neuropathy", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "15468380_2_Ent3", "text": "necrotizing vasculitis", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "15468380_2_Ent9", "text": "necrotizing vasculitis", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "15468380_2_Ent0", "text": "one patient", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "15468380_2_Ent6", "text": "preexisting mononeuritis multiplex", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "15468380_2_Ent5", "text": "preexisting mononeuritis multiplex in the other", "entity_type": "Entity", "start": 35, "end": 41}], "lang": "en"}
{"doc_id": "15494638_18", "wnd_id": "15494638_18_1", "text": "The etiology of neurotoxicity in our two patients remains unclear ; however , as CAP is rapidly metabolized to 5 - FU in patients with normal liver function , it is likely that 5 - FU or its active metabolites ( fluoro - beta - alanine ) were contributing factors .", "tokens": ["The", "etiology", "of", "neurotoxicity", "in", "our", "two", "patients", "remains", "unclear", ";", "however", ",", "as", "CAP", "is", "rapidly", "metabolized", "to", "5", "-", "FU", "in", "patients", "with", "normal", "liver", "function", ",", "it", "is", "likely", "that", "5", "-", "FU", "or", "its", "active", "metabolites", "(", "fluoro", "-", "beta", "-", "alanine", ")", "were", "contributing", "factors", "."], "event_mentions": [{"id": "15494638_18_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributing", "start": 48, "end": 49}, "arguments": [{"entity_id": "15494638_18_Ent2", "role": "Effect", "text": "neurotoxicity", "start": 3, "end": 4}, {"entity_id": "15494638_18_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "15494638_18_Ent0", "role": "Subject", "text": "two patients", "start": 6, "end": 8}, {"entity_id": "15494638_18_Ent4", "role": "Treatment_Drug", "text": "5 - FU", "start": 33, "end": 36}, {"entity_id": "15494638_18_Ent3", "role": "Treatment", "text": "5 - FU or its active metabolites ( fluoro - beta - alanine )", "start": 33, "end": 47}, {"entity_id": "15494638_18_Ent5", "role": "Treatment_Drug", "text": "fluoro - beta - alanine", "start": 41, "end": 46}]}], "entity_mentions": [{"id": "15494638_18_Ent2", "text": "neurotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15494638_18_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15494638_18_Ent0", "text": "two patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15494638_18_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 33, "end": 36}, {"id": "15494638_18_Ent3", "text": "5 - FU or its active metabolites ( fluoro - beta - alanine )", "entity_type": "Entity", "start": 33, "end": 47}, {"id": "15494638_18_Ent5", "text": "fluoro - beta - alanine", "entity_type": "Entity", "start": 41, "end": 46}], "lang": "en"}
{"doc_id": "15494638_4", "wnd_id": "15494638_4_1", "text": "During analysis of 28 patients receiving CAP with concomitant radiation ( XRT ) for pancreatic cancer ( resected or locally advanced ) , two patients developed signs and symptoms consistent with peripheral neuropathy .", "tokens": ["During", "analysis", "of", "28", "patients", "receiving", "CAP", "with", "concomitant", "radiation", "(", "XRT", ")", "for", "pancreatic", "cancer", "(", "resected", "or", "locally", "advanced", ")", ",", "two", "patients", "developed", "signs", "and", "symptoms", "consistent", "with", "peripheral", "neuropathy", "."], "event_mentions": [{"id": "15494638_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "15494638_4_Ent5", "role": "Treatment_Drug", "text": "CAP", "start": 6, "end": 7}, {"entity_id": "15494638_4_Ent3", "role": "Treatment", "text": "CAP with concomitant radiation ( XRT )", "start": 6, "end": 13}, {"entity_id": "15494638_4_Ent6", "role": "Treatment_Route", "text": "concomitant radiation", "start": 8, "end": 10}, {"entity_id": "15494638_4_Ent4", "role": "Treatment_Disorder", "text": "pancreatic cancer", "start": 14, "end": 16}, {"entity_id": "15494638_4_Ent1", "role": "Subject_Population", "text": "two", "start": 23, "end": 24}, {"entity_id": "15494638_4_Ent0", "role": "Subject", "text": "two patients", "start": 23, "end": 25}, {"entity_id": "15494638_4_Ent2", "role": "Effect", "text": "peripheral neuropathy", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "15494638_4_Ent5", "text": "CAP", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15494638_4_Ent3", "text": "CAP with concomitant radiation ( XRT )", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "15494638_4_Ent6", "text": "concomitant radiation", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15494638_4_Ent4", "text": "pancreatic cancer", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "15494638_4_Ent1", "text": "two", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15494638_4_Ent0", "text": "two patients", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "15494638_4_Ent2", "text": "peripheral neuropathy", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "15507779_1", "wnd_id": "15507779_1_1", "text": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine .", "tokens": ["Severe", "leukopenia", "associated", "with", "mild", "hepatotoxicity", "in", "an", "HIV", "carrier", "treated", "with", "nevirapine", "."], "event_mentions": [{"id": "15507779_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 11, "end": 12}, "arguments": [{"entity_id": "15507779_1_Ent1", "role": "Effect", "text": "leukopenia", "start": 1, "end": 2}, {"entity_id": "15507779_1_Ent0", "role": "Subject", "text": "an HIV carrier", "start": 7, "end": 10}, {"entity_id": "15507779_1_Ent4", "role": "Treatment_Disorder", "text": "HIV carrier", "start": 8, "end": 10}, {"entity_id": "15507779_1_Ent2", "role": "Treatment", "text": "nevirapine", "start": 12, "end": 13}, {"entity_id": "15507779_1_Ent3", "role": "Treatment_Drug", "text": "nevirapine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15507779_1_Ent1", "text": "leukopenia", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15507779_1_Ent0", "text": "an HIV carrier", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15507779_1_Ent4", "text": "HIV carrier", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15507779_1_Ent2", "text": "nevirapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15507779_1_Ent3", "text": "nevirapine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "15516308_10", "wnd_id": "15516308_10_1", "text": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor .", "tokens": ["These", "cases", "were", "chosen", "for", "study", "because", "they", "were", "all", "deaths", "as", "a", "result", "of", "suicidal", "ingestion", "of", "drugs", "in", "which", "quetiapine", "was", "considered", "a", "significant", "factor", "."], "event_mentions": [{"id": "15516308_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "considered", "start": 23, "end": 24}, "arguments": [{"entity_id": "15516308_10_Ent0", "role": "Effect", "text": "they were all deaths", "start": 7, "end": 11}, {"entity_id": "15516308_10_Ent1", "role": "Treatment", "text": "quetiapine", "start": 21, "end": 22}, {"entity_id": "15516308_10_Ent2", "role": "Treatment_Drug", "text": "quetiapine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "15516308_10_Ent0", "text": "they were all deaths", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "15516308_10_Ent1", "text": "quetiapine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15516308_10_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "15522120_10", "wnd_id": "15522120_10_1", "text": "The symptoms disappeared with clemastine and betametasone treatment .", "tokens": ["The", "symptoms", "disappeared", "with", "clemastine", "and", "betametasone", "treatment", "."], "event_mentions": [{"id": "15522120_10_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "disappeared", "start": 2, "end": 3}, "arguments": [{"entity_id": "15522120_10_Ent0", "role": "Effect", "text": "The symptoms disappeared", "start": 0, "end": 3}, {"entity_id": "15522120_10_Ent2", "role": "Treatment_Drug", "text": "clemastine", "start": 4, "end": 5}, {"entity_id": "15522120_10_Ent5", "role": "Combination_Drug", "text": "clemastine", "start": 4, "end": 5}, {"entity_id": "15522120_10_Ent1", "role": "Treatment", "text": "clemastine and betametasone", "start": 4, "end": 7}, {"entity_id": "15522120_10_Ent3", "role": "Treatment_Drug", "text": "betametasone", "start": 6, "end": 7}, {"entity_id": "15522120_10_Ent4", "role": "Combination_Drug", "text": "betametasone", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "15522120_10_Ent0", "text": "The symptoms disappeared", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15522120_10_Ent2", "text": "clemastine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15522120_10_Ent5", "text": "clemastine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15522120_10_Ent1", "text": "clemastine and betametasone", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "15522120_10_Ent3", "text": "betametasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15522120_10_Ent4", "text": "betametasone", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "15522120_11", "wnd_id": "15522120_11_1", "text": "Since the depressive symptoms returned sertraline medication was initiated .", "tokens": ["Since", "the", "depressive", "symptoms", "returned", "sertraline", "medication", "was", "initiated", "."], "event_mentions": [{"id": "15522120_11_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "initiated", "start": 8, "end": 9}, "arguments": [{"entity_id": "15522120_11_Ent1", "role": "Treatment_Disorder", "text": "depressive symptoms", "start": 2, "end": 4}, {"entity_id": "15522120_11_Ent0", "role": "Treatment", "text": "sertraline", "start": 5, "end": 6}, {"entity_id": "15522120_11_Ent2", "role": "Treatment_Drug", "text": "sertraline", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "15522120_11_Ent1", "text": "depressive symptoms", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15522120_11_Ent0", "text": "sertraline", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15522120_11_Ent2", "text": "sertraline", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "15522120_13", "wnd_id": "15522120_13_1", "text": "The itch spread to the arms , abdomen and legs and the patient treated himself with clemastine and the itch disappeared .", "tokens": ["The", "itch", "spread", "to", "the", "arms", ",", "abdomen", "and", "legs", "and", "the", "patient", "treated", "himself", "with", "clemastine", "and", "the", "itch", "disappeared", "."], "event_mentions": [{"id": "15522120_13_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "disappeared", "start": 20, "end": 21}, "arguments": [{"entity_id": "15522120_13_Ent0", "role": "Subject", "text": "The itch spread to the arms , abdomen and legs and the patient", "start": 0, "end": 13}, {"entity_id": "15522120_13_Ent6", "role": "Treatment_Disorder", "text": "itch", "start": 1, "end": 2}, {"entity_id": "15522120_13_Ent1", "role": "Subject", "text": "himself", "start": 14, "end": 15}, {"entity_id": "15522120_13_Ent2", "role": "Subject_Gender", "text": "himself", "start": 14, "end": 15}, {"entity_id": "15522120_13_Ent4", "role": "Treatment", "text": "clemastine", "start": 16, "end": 17}, {"entity_id": "15522120_13_Ent5", "role": "Treatment_Drug", "text": "clemastine", "start": 16, "end": 17}, {"entity_id": "15522120_13_Ent3", "role": "Effect", "text": "itch disappeared", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "15522120_13_Ent0", "text": "The itch spread to the arms , abdomen and legs and the patient", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "15522120_13_Ent6", "text": "itch", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15522120_13_Ent1", "text": "himself", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15522120_13_Ent2", "text": "himself", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15522120_13_Ent4", "text": "clemastine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15522120_13_Ent5", "text": "clemastine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15522120_13_Ent3", "text": "itch disappeared", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "1557089_1", "wnd_id": "1557089_1_1", "text": "In a postoperative patient with pre - existent myasthenia gravis , oral verapamil caused a marked exacerbation in myasthenic weakness .", "tokens": ["In", "a", "postoperative", "patient", "with", "pre", "-", "existent", "myasthenia", "gravis", ",", "oral", "verapamil", "caused", "a", "marked", "exacerbation", "in", "myasthenic", "weakness", "."], "event_mentions": [{"id": "1557089_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 13, "end": 14}, "arguments": [{"entity_id": "1557089_1_Ent0", "role": "Subject", "text": "a postoperative patient with pre - existent myasthenia gravis", "start": 1, "end": 10}, {"entity_id": "1557089_1_Ent1", "role": "Subject_Disorder", "text": "pre - existent myasthenia gravis", "start": 5, "end": 10}, {"entity_id": "1557089_1_Ent4", "role": "Treatment_Route", "text": "oral", "start": 11, "end": 12}, {"entity_id": "1557089_1_Ent3", "role": "Treatment", "text": "oral verapamil", "start": 11, "end": 13}, {"entity_id": "1557089_1_Ent5", "role": "Treatment_Drug", "text": "verapamil", "start": 12, "end": 13}, {"entity_id": "1557089_1_Ent2", "role": "Effect", "text": "marked exacerbation in myasthenic weakness", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "1557089_1_Ent0", "text": "a postoperative patient with pre - existent myasthenia gravis", "entity_type": "Entity", "start": 1, "end": 10}, {"id": "1557089_1_Ent1", "text": "pre - existent myasthenia gravis", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "1557089_1_Ent4", "text": "oral", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1557089_1_Ent3", "text": "oral verapamil", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "1557089_1_Ent5", "text": "verapamil", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1557089_1_Ent2", "text": "marked exacerbation in myasthenic weakness", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "15588385_1", "wnd_id": "15588385_1_1", "text": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil ( PTU ) use for hyperthyroidism .", "tokens": ["Acute", "hepatic", "failure", "is", "a", "rare", "and", "potentially", "lethal", "complication", "of", "propylthiouracil", "(", "PTU", ")", "use", "for", "hyperthyroidism", "."], "event_mentions": [{"id": "15588385_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 9, "end": 10}, "arguments": [{"entity_id": "15588385_1_Ent0", "role": "Effect", "text": "Acute hepatic failure", "start": 0, "end": 3}, {"entity_id": "15588385_1_Ent3", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 11, "end": 12}, {"entity_id": "15588385_1_Ent1", "role": "Treatment", "text": "propylthiouracil ( PTU )", "start": 11, "end": 15}, {"entity_id": "15588385_1_Ent2", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "15588385_1_Ent0", "text": "Acute hepatic failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15588385_1_Ent3", "text": "propylthiouracil", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15588385_1_Ent1", "text": "propylthiouracil ( PTU )", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "15588385_1_Ent2", "text": "hyperthyroidism", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15611427_3", "wnd_id": "15611427_3_1", "text": "Since imiquimod induces large amounts of type I interferon production from TLR7 - expressing plasmacytoid dendritic cell precursors ( PDCs ) , the natural interferon - producing cells of the peripheral blood , we asked whether PDCs are present in psoriatic skin .", "tokens": ["Since", "imiquimod", "induces", "large", "amounts", "of", "type", "I", "interferon", "production", "from", "TLR7", "-", "expressing", "plasmacytoid", "dendritic", "cell", "precursors", "(", "PDCs", ")", ",", "the", "natural", "interferon", "-", "producing", "cells", "of", "the", "peripheral", "blood", ",", "we", "asked", "whether", "PDCs", "are", "present", "in", "psoriatic", "skin", "."], "event_mentions": [{"id": "15611427_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induces", "start": 2, "end": 3}, "arguments": [{"entity_id": "15611427_3_Ent1", "role": "Treatment", "text": "imiquimod", "start": 1, "end": 2}, {"entity_id": "15611427_3_Ent2", "role": "Treatment_Drug", "text": "imiquimod", "start": 1, "end": 2}, {"entity_id": "15611427_3_Ent0", "role": "Effect", "text": "large amounts of type I interferon production", "start": 3, "end": 10}]}], "entity_mentions": [{"id": "15611427_3_Ent1", "text": "imiquimod", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15611427_3_Ent2", "text": "imiquimod", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15611427_3_Ent0", "text": "large amounts of type I interferon production", "entity_type": "Entity", "start": 3, "end": 10}], "lang": "en"}
{"doc_id": "15611427_4", "wnd_id": "15611427_4_1", "text": "The exacerbation of psoriasis was accompanied by a massive induction of lesional type I interferon activity , detected by MxA expression after imiquimod therapy .", "tokens": ["The", "exacerbation", "of", "psoriasis", "was", "accompanied", "by", "a", "massive", "induction", "of", "lesional", "type", "I", "interferon", "activity", ",", "detected", "by", "MxA", "expression", "after", "imiquimod", "therapy", "."], "event_mentions": [{"id": "15611427_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "detected", "start": 17, "end": 18}, "arguments": [{"entity_id": "15611427_4_Ent0", "role": "Effect", "text": "exacerbation of psoriasis", "start": 1, "end": 4}, {"entity_id": "15611427_4_Ent1", "role": "Effect", "text": "a massive induction of lesional type I interferon activity", "start": 7, "end": 16}, {"entity_id": "15611427_4_Ent2", "role": "Treatment", "text": "imiquimod", "start": 22, "end": 23}, {"entity_id": "15611427_4_Ent3", "role": "Treatment_Drug", "text": "imiquimod", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "15611427_4_Ent0", "text": "exacerbation of psoriasis", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "15611427_4_Ent1", "text": "a massive induction of lesional type I interferon activity", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "15611427_4_Ent2", "text": "imiquimod", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15611427_4_Ent3", "text": "imiquimod", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "15644988_1", "wnd_id": "15644988_1_1", "text": "Tardive dyskinesia in 2 patients treated with ziprasidone .", "tokens": ["Tardive", "dyskinesia", "in", "2", "patients", "treated", "with", "ziprasidone", "."], "event_mentions": [{"id": "15644988_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "15644988_1_Ent2", "role": "Effect", "text": "Tardive dyskinesia", "start": 0, "end": 2}, {"entity_id": "15644988_1_Ent1", "role": "Subject_Population", "text": "2", "start": 3, "end": 4}, {"entity_id": "15644988_1_Ent0", "role": "Subject", "text": "2 patients", "start": 3, "end": 5}, {"entity_id": "15644988_1_Ent3", "role": "Treatment", "text": "ziprasidone", "start": 7, "end": 8}, {"entity_id": "15644988_1_Ent4", "role": "Treatment_Drug", "text": "ziprasidone", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "15644988_1_Ent2", "text": "Tardive dyskinesia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15644988_1_Ent1", "text": "2", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15644988_1_Ent0", "text": "2 patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15644988_1_Ent3", "text": "ziprasidone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15644988_1_Ent4", "text": "ziprasidone", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "15681911_1", "wnd_id": "15681911_1_1", "text": "CONCLUSIONS : Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib .", "tokens": ["CONCLUSIONS", ":", "Symptoms", "and", "pathologic", "changes", "of", "colitis", "are", "associated", "with", "exposure", "to", "rofecoxib", "."], "event_mentions": [{"id": "15681911_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 9, "end": 11}, "arguments": [{"entity_id": "15681911_1_Ent0", "role": "Effect", "text": "Symptoms and pathologic changes of colitis", "start": 2, "end": 8}, {"entity_id": "15681911_1_Ent3", "role": "Treatment_Route", "text": "exposure", "start": 11, "end": 12}, {"entity_id": "15681911_1_Ent1", "role": "Treatment", "text": "rofecoxib", "start": 13, "end": 14}, {"entity_id": "15681911_1_Ent2", "role": "Treatment_Drug", "text": "rofecoxib", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "15681911_1_Ent0", "text": "Symptoms and pathologic changes of colitis", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "15681911_1_Ent3", "text": "exposure", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15681911_1_Ent1", "text": "rofecoxib", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15681911_1_Ent2", "text": "rofecoxib", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "1569260_1", "wnd_id": "1569260_1_1", "text": "To the best of our knowledge , this is the first reported patient with captopril - induced pemphigus in whom no new lesions developed after subsequent treatment with enalapril .", "tokens": ["To", "the", "best", "of", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "patient", "with", "captopril", "-", "induced", "pemphigus", "in", "whom", "no", "new", "lesions", "developed", "after", "subsequent", "treatment", "with", "enalapril", "."], "event_mentions": [{"id": "1569260_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 16, "end": 17}, "arguments": [{"entity_id": "1569260_1_Ent0", "role": "Subject", "text": "patient", "start": 12, "end": 13}, {"entity_id": "1569260_1_Ent2", "role": "Treatment", "text": "captopril", "start": 14, "end": 15}, {"entity_id": "1569260_1_Ent3", "role": "Treatment_Drug", "text": "captopril", "start": 14, "end": 15}, {"entity_id": "1569260_1_Ent1", "role": "Effect", "text": "pemphigus", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "1569260_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1569260_1_Ent2", "text": "captopril", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1569260_1_Ent3", "text": "captopril", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1569260_1_Ent1", "text": "pemphigus", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "1569260_2", "wnd_id": "1569260_2_1", "text": "We report a case of drug - induced pemphigus caused by an angiotensin - converting enzyme inhibitor , captopril .", "tokens": ["We", "report", "a", "case", "of", "drug", "-", "induced", "pemphigus", "caused", "by", "an", "angiotensin", "-", "converting", "enzyme", "inhibitor", ",", "captopril", "."], "event_mentions": [{"id": "1569260_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "1569260_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "1569260_2_Ent1", "role": "Effect", "text": "pemphigus", "start": 8, "end": 9}, {"entity_id": "1569260_2_Ent2", "role": "Treatment", "text": "captopril", "start": 18, "end": 19}, {"entity_id": "1569260_2_Ent3", "role": "Treatment_Drug", "text": "captopril", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "1569260_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1569260_2_Ent1", "text": "pemphigus", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1569260_2_Ent2", "text": "captopril", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1569260_2_Ent3", "text": "captopril", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "15694139_4", "wnd_id": "15694139_4_1", "text": "Neuropathy is a significant side effect of thalidomide therapy , which may limit its clinical use .", "tokens": ["Neuropathy", "is", "a", "significant", "side", "effect", "of", "thalidomide", "therapy", ",", "which", "may", "limit", "its", "clinical", "use", "."], "event_mentions": [{"id": "15694139_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effect", "start": 4, "end": 6}, "arguments": [{"entity_id": "15694139_4_Ent0", "role": "Effect", "text": "Neuropathy", "start": 0, "end": 1}, {"entity_id": "15694139_4_Ent1", "role": "Treatment", "text": "thalidomide", "start": 7, "end": 8}, {"entity_id": "15694139_4_Ent2", "role": "Treatment_Drug", "text": "thalidomide", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "15694139_4_Ent0", "text": "Neuropathy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_4_Ent1", "text": "thalidomide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15694139_4_Ent2", "text": "thalidomide", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "15701285_3", "wnd_id": "15701285_3_1", "text": "While the introduction of carmustine wafers ( Gliadel wafers ) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma , it is recognized that clinically significant cerebral edema is a potential adverse effect .", "tokens": ["While", "the", "introduction", "of", "carmustine", "wafers", "(", "Gliadel", "wafers", ")", "into", "the", "tumor", "resection", "cavity", "has", "been", "shown", "to", "be", "a", "beneficial", "therapy", "for", "malignant", "glioma", ",", "it", "is", "recognized", "that", "clinically", "significant", "cerebral", "edema", "is", "a", "potential", "adverse", "effect", "."], "event_mentions": [{"id": "15701285_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse", "start": 38, "end": 39}, "arguments": [{"entity_id": "15701285_3_Ent1", "role": "Treatment", "text": "the introduction of carmustine wafers ( Gliadel wafers ) into the tumor resection cavity", "start": 1, "end": 15}, {"entity_id": "15701285_3_Ent3", "role": "Treatment_Drug", "text": "carmustine wafers", "start": 4, "end": 6}, {"entity_id": "15701285_3_Ent2", "role": "Treatment_Disorder", "text": "malignant glioma", "start": 24, "end": 26}, {"entity_id": "15701285_3_Ent0", "role": "Effect", "text": "significant cerebral edema", "start": 32, "end": 35}]}], "entity_mentions": [{"id": "15701285_3_Ent1", "text": "the introduction of carmustine wafers ( Gliadel wafers ) into the tumor resection cavity", "entity_type": "Entity", "start": 1, "end": 15}, {"id": "15701285_3_Ent3", "text": "carmustine wafers", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15701285_3_Ent2", "text": "malignant glioma", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "15701285_3_Ent0", "text": "significant cerebral edema", "entity_type": "Entity", "start": 32, "end": 35}], "lang": "en"}
{"doc_id": "15719254_3", "wnd_id": "15719254_3_1", "text": "Retinoic acid may increase the risk of bone marrow transplant nephropathy .", "tokens": ["Retinoic", "acid", "may", "increase", "the", "risk", "of", "bone", "marrow", "transplant", "nephropathy", "."], "event_mentions": [{"id": "15719254_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 3, "end": 4}, "arguments": [{"entity_id": "15719254_3_Ent1", "role": "Treatment", "text": "Retinoic acid", "start": 0, "end": 2}, {"entity_id": "15719254_3_Ent2", "role": "Treatment_Drug", "text": "Retinoic acid", "start": 0, "end": 2}, {"entity_id": "15719254_3_Ent0", "role": "Effect", "text": "bone marrow transplant nephropathy", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "15719254_3_Ent1", "text": "Retinoic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15719254_3_Ent2", "text": "Retinoic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15719254_3_Ent0", "text": "bone marrow transplant nephropathy", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "1575118_1", "wnd_id": "1575118_1_1", "text": "Typically , drug - induced neutropenia occurs in a patient receiving a semisynthetic penicillin for two weeks or more .", "tokens": ["Typically", ",", "drug", "-", "induced", "neutropenia", "occurs", "in", "a", "patient", "receiving", "a", "semisynthetic", "penicillin", "for", "two", "weeks", "or", "more", "."], "event_mentions": [{"id": "1575118_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurs", "start": 6, "end": 7}, "arguments": [{"entity_id": "1575118_1_Ent1", "role": "Effect", "text": "drug - induced neutropenia", "start": 2, "end": 6}, {"entity_id": "1575118_1_Ent0", "role": "Subject", "text": "a patient", "start": 8, "end": 10}, {"entity_id": "1575118_1_Ent2", "role": "Treatment", "text": "a semisynthetic penicillin for two weeks or more", "start": 11, "end": 19}, {"entity_id": "1575118_1_Ent3", "role": "Treatment_Drug", "text": "semisynthetic penicillin", "start": 12, "end": 14}, {"entity_id": "1575118_1_Ent4", "role": "Treatment_Duration", "text": "two weeks", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "1575118_1_Ent1", "text": "drug - induced neutropenia", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "1575118_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "1575118_1_Ent2", "text": "a semisynthetic penicillin for two weeks or more", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "1575118_1_Ent3", "text": "semisynthetic penicillin", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "1575118_1_Ent4", "text": "two weeks", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "15752306_1", "wnd_id": "15752306_1_1", "text": "Livedo reticularis associated with interferon alpha therapy in two melanoma patients .", "tokens": ["Livedo", "reticularis", "associated", "with", "interferon", "alpha", "therapy", "in", "two", "melanoma", "patients", "."], "event_mentions": [{"id": "15752306_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "15752306_1_Ent2", "role": "Effect", "text": "Livedo reticularis", "start": 0, "end": 2}, {"entity_id": "15752306_1_Ent5", "role": "Treatment_Drug", "text": "interferon alpha", "start": 4, "end": 6}, {"entity_id": "15752306_1_Ent3", "role": "Treatment", "text": "interferon alpha therapy", "start": 4, "end": 7}, {"entity_id": "15752306_1_Ent1", "role": "Subject_Population", "text": "two", "start": 8, "end": 9}, {"entity_id": "15752306_1_Ent0", "role": "Subject", "text": "two melanoma patients", "start": 8, "end": 11}, {"entity_id": "15752306_1_Ent4", "role": "Treatment_Disorder", "text": "melanoma", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15752306_1_Ent2", "text": "Livedo reticularis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15752306_1_Ent5", "text": "interferon alpha", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15752306_1_Ent3", "text": "interferon alpha therapy", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "15752306_1_Ent1", "text": "two", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15752306_1_Ent0", "text": "two melanoma patients", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15752306_1_Ent4", "text": "melanoma", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15760792_3", "wnd_id": "15760792_3_1", "text": "Propylthiouracil - induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies .", "tokens": ["Propylthiouracil", "-", "induced", "sensorineural", "hearing", "loss", "associated", "with", "antineutrophil", "cytoplasmic", "antibodies", "."], "event_mentions": [{"id": "15760792_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15760792_3_Ent1", "role": "Treatment", "text": "Propylthiouracil", "start": 0, "end": 1}, {"entity_id": "15760792_3_Ent2", "role": "Treatment_Drug", "text": "Propylthiouracil", "start": 0, "end": 1}, {"entity_id": "15760792_3_Ent0", "role": "Effect", "text": "sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies", "start": 3, "end": 11}]}], "entity_mentions": [{"id": "15760792_3_Ent1", "text": "Propylthiouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15760792_3_Ent2", "text": "Propylthiouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15760792_3_Ent0", "text": "sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies", "entity_type": "Entity", "start": 3, "end": 11}], "lang": "en"}
{"doc_id": "15770343_1", "wnd_id": "15770343_1_1", "text": "Anti - tuberculous drugs had been stopped on the 2nd day of therapy due to development of optic neuritis secondary to ethambutol administration at another hospital .", "tokens": ["Anti", "-", "tuberculous", "drugs", "had", "been", "stopped", "on", "the", "2nd", "day", "of", "therapy", "due", "to", "development", "of", "optic", "neuritis", "secondary", "to", "ethambutol", "administration", "at", "another", "hospital", "."], "event_mentions": [{"id": "15770343_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 20, "end": 21}, "arguments": [{"entity_id": "15770343_1_Ent0", "role": "Effect", "text": "optic neuritis secondary", "start": 17, "end": 20}, {"entity_id": "15770343_1_Ent1", "role": "Treatment", "text": "ethambutol", "start": 21, "end": 22}, {"entity_id": "15770343_1_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "15770343_1_Ent0", "text": "optic neuritis secondary", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "15770343_1_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15770343_1_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "15785053_1", "wnd_id": "15785053_1_1", "text": "Mucosal pigmentation after oral lichen planus treatment with topical tacrolimus .", "tokens": ["Mucosal", "pigmentation", "after", "oral", "lichen", "planus", "treatment", "with", "topical", "tacrolimus", "."], "event_mentions": [{"id": "15785053_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 6, "end": 7}, "arguments": [{"entity_id": "15785053_1_Ent0", "role": "Effect", "text": "Mucosal pigmentation", "start": 0, "end": 2}, {"entity_id": "15785053_1_Ent2", "role": "Treatment_Disorder", "text": "oral lichen planus", "start": 3, "end": 6}, {"entity_id": "15785053_1_Ent4", "role": "Treatment_Route", "text": "topical", "start": 8, "end": 9}, {"entity_id": "15785053_1_Ent1", "role": "Treatment", "text": "topical tacrolimus", "start": 8, "end": 10}, {"entity_id": "15785053_1_Ent3", "role": "Treatment_Drug", "text": "tacrolimus", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15785053_1_Ent0", "text": "Mucosal pigmentation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15785053_1_Ent2", "text": "oral lichen planus", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15785053_1_Ent4", "text": "topical", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15785053_1_Ent1", "text": "topical tacrolimus", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15785053_1_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15785053_3", "wnd_id": "15785053_3_1", "text": "We report the first histopathologically documented case of oral mucosa pigmentation after OLP treatment with topical tacrolimus .", "tokens": ["We", "report", "the", "first", "histopathologically", "documented", "case", "of", "oral", "mucosa", "pigmentation", "after", "OLP", "treatment", "with", "topical", "tacrolimus", "."], "event_mentions": [{"id": "15785053_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 13, "end": 14}, "arguments": [{"entity_id": "15785053_3_Ent0", "role": "Effect", "text": "oral mucosa pigmentation", "start": 8, "end": 11}, {"entity_id": "15785053_3_Ent3", "role": "Treatment_Disorder", "text": "OLP", "start": 12, "end": 13}, {"entity_id": "15785053_3_Ent4", "role": "Treatment_Route", "text": "topical", "start": 15, "end": 16}, {"entity_id": "15785053_3_Ent1", "role": "Treatment", "text": "topical tacrolimus", "start": 15, "end": 17}, {"entity_id": "15785053_3_Ent2", "role": "Treatment_Drug", "text": "tacrolimus", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "15785053_3_Ent0", "text": "oral mucosa pigmentation", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15785053_3_Ent3", "text": "OLP", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15785053_3_Ent4", "text": "topical", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15785053_3_Ent1", "text": "topical tacrolimus", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "15785053_3_Ent2", "text": "tacrolimus", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "15790469_4", "wnd_id": "15790469_4_1", "text": "Recently , some studies have also reported association between patients with juvenile rheumatoid arthritis ( JRA ) treated with Methotrexate ( MTX ) and malignant lymphoma developing .", "tokens": ["Recently", ",", "some", "studies", "have", "also", "reported", "association", "between", "patients", "with", "juvenile", "rheumatoid", "arthritis", "(", "JRA", ")", "treated", "with", "Methotrexate", "(", "MTX", ")", "and", "malignant", "lymphoma", "developing", "."], "event_mentions": [{"id": "15790469_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 7, "end": 8}, "arguments": [{"entity_id": "15790469_4_Ent0", "role": "Subject", "text": "patients with juvenile rheumatoid arthritis ( JRA", "start": 9, "end": 16}, {"entity_id": "15790469_4_Ent4", "role": "Treatment_Disorder", "text": "juvenile rheumatoid arthritis", "start": 11, "end": 14}, {"entity_id": "15790469_4_Ent3", "role": "Treatment_Drug", "text": "Methotrexate", "start": 19, "end": 20}, {"entity_id": "15790469_4_Ent2", "role": "Treatment", "text": "Methotrexate ( MTX )", "start": 19, "end": 23}, {"entity_id": "15790469_4_Ent1", "role": "Effect", "text": "malignant lymphoma", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "15790469_4_Ent0", "text": "patients with juvenile rheumatoid arthritis ( JRA", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "15790469_4_Ent4", "text": "juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "15790469_4_Ent3", "text": "Methotrexate", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15790469_4_Ent2", "text": "Methotrexate ( MTX )", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "15790469_4_Ent1", "text": "malignant lymphoma", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "15795553_1", "wnd_id": "15795553_1_1", "text": "Risperidone is a frequently used member of a new class of atypical antipsychotics - the serotonin - dopamine antagonists ( SDAs) - due to its comparatively high efficacy and low D2/5HT2 binding ratio , which results in a low incidence of extrapyramidal side effects including tardive dyskinesia ( TD ) .", "tokens": ["Risperidone", "is", "a", "frequently", "used", "member", "of", "a", "new", "class", "of", "atypical", "antipsychotics", "-", "the", "serotonin", "-", "dopamine", "antagonists", "(", "SDAs)", "-", "due", "to", "its", "comparatively", "high", "efficacy", "and", "low", "D2/5HT2", "binding", "ratio", ",", "which", "results", "in", "a", "low", "incidence", "of", "extrapyramidal", "side", "effects", "including", "tardive", "dyskinesia", "(", "TD", ")", "."], "event_mentions": [{"id": "15795553_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "results", "start": 35, "end": 36}, "arguments": [{"entity_id": "15795553_1_Ent1", "role": "Treatment", "text": "Risperidone", "start": 0, "end": 1}, {"entity_id": "15795553_1_Ent2", "role": "Treatment_Drug", "text": "Risperidone", "start": 0, "end": 1}, {"entity_id": "15795553_1_Ent0", "role": "Effect", "text": "tardive dyskinesia", "start": 45, "end": 47}]}], "entity_mentions": [{"id": "15795553_1_Ent1", "text": "Risperidone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15795553_1_Ent2", "text": "Risperidone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15795553_1_Ent0", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 45, "end": 47}], "lang": "en"}
{"doc_id": "15840734_8", "wnd_id": "15840734_8_1", "text": "DISCUSSION : NMS is a rare but potentially fatal reaction associated with neuroleptic drugs .", "tokens": ["DISCUSSION", ":", "NMS", "is", "a", "rare", "but", "potentially", "fatal", "reaction", "associated", "with", "neuroleptic", "drugs", "."], "event_mentions": [{"id": "15840734_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "15840734_8_Ent0", "role": "Effect", "text": "NMS", "start": 2, "end": 3}, {"entity_id": "15840734_8_Ent2", "role": "Treatment_Drug", "text": "neuroleptic", "start": 12, "end": 13}, {"entity_id": "15840734_8_Ent1", "role": "Treatment", "text": "neuroleptic drugs", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "15840734_8_Ent0", "text": "NMS", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15840734_8_Ent2", "text": "neuroleptic", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15840734_8_Ent1", "text": "neuroleptic drugs", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "15857283_3", "wnd_id": "15857283_3_1", "text": "PURPOSE : The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin .", "tokens": ["PURPOSE", ":", "The", "aim", "of", "this", "study", "was", "to", "report", "on", "the", "possible", "development", "of", "corneal", "endothelial", "deposits", "resulting", "from", "the", "use", "of", "rifabutin", "."], "event_mentions": [{"id": "15857283_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 18, "end": 19}, "arguments": [{"entity_id": "15857283_3_Ent0", "role": "Effect", "text": "corneal endothelial deposits", "start": 15, "end": 18}, {"entity_id": "15857283_3_Ent1", "role": "Treatment", "text": "rifabutin", "start": 23, "end": 24}, {"entity_id": "15857283_3_Ent2", "role": "Treatment_Drug", "text": "rifabutin", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15857283_3_Ent0", "text": "corneal endothelial deposits", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "15857283_3_Ent1", "text": "rifabutin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15857283_3_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15857283_4", "wnd_id": "15857283_4_1", "text": "RESULTS : All cases developed corneal endothelial deposits after previous use of rifabutin .", "tokens": ["RESULTS", ":", "All", "cases", "developed", "corneal", "endothelial", "deposits", "after", "previous", "use", "of", "rifabutin", "."], "event_mentions": [{"id": "15857283_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "15857283_4_Ent0", "role": "Subject", "text": "All cases", "start": 2, "end": 4}, {"entity_id": "15857283_4_Ent1", "role": "Effect", "text": "corneal endothelial deposits", "start": 5, "end": 8}, {"entity_id": "15857283_4_Ent2", "role": "Treatment", "text": "rifabutin", "start": 12, "end": 13}, {"entity_id": "15857283_4_Ent3", "role": "Treatment_Drug", "text": "rifabutin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15857283_4_Ent0", "text": "All cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15857283_4_Ent1", "text": "corneal endothelial deposits", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "15857283_4_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15857283_4_Ent3", "text": "rifabutin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "15863610_7", "wnd_id": "15863610_7_1", "text": "CONCLUSION : There may be an association between raloxifene and the development of malignant mixed mesodermal tumor .", "tokens": ["CONCLUSION", ":", "There", "may", "be", "an", "association", "between", "raloxifene", "and", "the", "development", "of", "malignant", "mixed", "mesodermal", "tumor", "."], "event_mentions": [{"id": "15863610_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 6, "end": 7}, "arguments": [{"entity_id": "15863610_7_Ent1", "role": "Treatment", "text": "raloxifene", "start": 8, "end": 9}, {"entity_id": "15863610_7_Ent2", "role": "Treatment_Drug", "text": "raloxifene", "start": 8, "end": 9}, {"entity_id": "15863610_7_Ent0", "role": "Effect", "text": "malignant mixed mesodermal tumor", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "15863610_7_Ent1", "text": "raloxifene", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15863610_7_Ent2", "text": "raloxifene", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15863610_7_Ent0", "text": "malignant mixed mesodermal tumor", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "15866658_2", "wnd_id": "15866658_2_1", "text": "Mycophenolate mofetil - induced neutropenia in liver transplantation .", "tokens": ["Mycophenolate", "mofetil", "-", "induced", "neutropenia", "in", "liver", "transplantation", "."], "event_mentions": [{"id": "15866658_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "15866658_2_Ent1", "role": "Treatment", "text": "Mycophenolate mofetil", "start": 0, "end": 2}, {"entity_id": "15866658_2_Ent2", "role": "Treatment_Drug", "text": "Mycophenolate mofetil", "start": 0, "end": 2}, {"entity_id": "15866658_2_Ent0", "role": "Effect", "text": "neutropenia in liver transplantation", "start": 4, "end": 8}]}], "entity_mentions": [{"id": "15866658_2_Ent1", "text": "Mycophenolate mofetil", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15866658_2_Ent2", "text": "Mycophenolate mofetil", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15866658_2_Ent0", "text": "neutropenia in liver transplantation", "entity_type": "Entity", "start": 4, "end": 8}], "lang": "en"}
{"doc_id": "15895899_3", "wnd_id": "15895899_3_1", "text": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis .", "tokens": ["These", "data", "indicated", "that", "infliximab", "possibly", "triggered", "production", "of", "granulocyte", "and", "neutrophil", "autoantibodies", "with", "resultant", "autoimmune", "agranulocytosis", "."], "event_mentions": [{"id": "15895899_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "triggered", "start": 6, "end": 7}, "arguments": [{"entity_id": "15895899_3_Ent1", "role": "Treatment", "text": "infliximab", "start": 4, "end": 5}, {"entity_id": "15895899_3_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 4, "end": 5}, {"entity_id": "15895899_3_Ent0", "role": "Effect", "text": "production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis", "start": 7, "end": 17}]}], "entity_mentions": [{"id": "15895899_3_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15895899_3_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15895899_3_Ent0", "text": "production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis", "entity_type": "Entity", "start": 7, "end": 17}], "lang": "en"}
{"doc_id": "15920338_3", "wnd_id": "15920338_3_1", "text": "In deciding if tamoxifen therapy is warranted , all potentially life - threatening adverse events associated with tamoxifen should be considered , including endometrial adenocarcinoma or uterine sarcoma .", "tokens": ["In", "deciding", "if", "tamoxifen", "therapy", "is", "warranted", ",", "all", "potentially", "life", "-", "threatening", "adverse", "events", "associated", "with", "tamoxifen", "should", "be", "considered", ",", "including", "endometrial", "adenocarcinoma", "or", "uterine", "sarcoma", "."], "event_mentions": [{"id": "15920338_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 15, "end": 17}, "arguments": [{"entity_id": "15920338_3_Ent3", "role": "Treatment_Drug", "text": "tamoxifen", "start": 3, "end": 4}, {"entity_id": "15920338_3_Ent5", "role": "Treatment_Drug", "text": "tamoxifen", "start": 3, "end": 4}, {"entity_id": "15920338_3_Ent0", "role": "Effect", "text": "potentially life - threatening adverse events", "start": 9, "end": 15}, {"entity_id": "15920338_3_Ent2", "role": "Treatment", "text": "tamoxifen", "start": 17, "end": 18}, {"entity_id": "15920338_3_Ent4", "role": "Treatment_Drug", "text": "tamoxifen", "start": 17, "end": 18}, {"entity_id": "15920338_3_Ent1", "role": "Effect", "text": "including endometrial adenocarcinoma or uterine sarcoma", "start": 22, "end": 28}]}], "entity_mentions": [{"id": "15920338_3_Ent3", "text": "tamoxifen", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15920338_3_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15920338_3_Ent0", "text": "potentially life - threatening adverse events", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "15920338_3_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15920338_3_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15920338_3_Ent1", "text": "including endometrial adenocarcinoma or uterine sarcoma", "entity_type": "Entity", "start": 22, "end": 28}], "lang": "en"}
{"doc_id": "15927910_1", "wnd_id": "15927910_1_1", "text": "After only the third dose of pentamidine , it was noted that the patient 's heart rate had decreased to 48 beats / minute .", "tokens": ["After", "only", "the", "third", "dose", "of", "pentamidine", ",", "it", "was", "noted", "that", "the", "patient", "'s", "heart", "rate", "had", "decreased", "to", "48", "beats", "/", "minute", "."], "event_mentions": [{"id": "15927910_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "15927910_1_Ent3", "role": "Treatment_Dosage", "text": "third dose", "start": 3, "end": 5}, {"entity_id": "15927910_1_Ent2", "role": "Treatment", "text": "third dose of pentamidine", "start": 3, "end": 7}, {"entity_id": "15927910_1_Ent4", "role": "Treatment_Drug", "text": "pentamidine", "start": 6, "end": 7}, {"entity_id": "15927910_1_Ent0", "role": "Subject", "text": "patient 's", "start": 13, "end": 15}, {"entity_id": "15927910_1_Ent1", "role": "Effect", "text": "heart rate had decreased to 48 beats / minute", "start": 15, "end": 24}]}], "entity_mentions": [{"id": "15927910_1_Ent3", "text": "third dose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15927910_1_Ent2", "text": "third dose of pentamidine", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "15927910_1_Ent4", "text": "pentamidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15927910_1_Ent0", "text": "patient 's", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "15927910_1_Ent1", "text": "heart rate had decreased to 48 beats / minute", "entity_type": "Entity", "start": 15, "end": 24}], "lang": "en"}
{"doc_id": "15941649_3", "wnd_id": "15941649_3_1", "text": "Vigabatrin - induced visual field defects are at present the most important safety issue in the use of the drug .", "tokens": ["Vigabatrin", "-", "induced", "visual", "field", "defects", "are", "at", "present", "the", "most", "important", "safety", "issue", "in", "the", "use", "of", "the", "drug", "."], "event_mentions": [{"id": "15941649_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15941649_3_Ent1", "role": "Treatment", "text": "Vigabatrin", "start": 0, "end": 1}, {"entity_id": "15941649_3_Ent2", "role": "Treatment_Drug", "text": "Vigabatrin", "start": 0, "end": 1}, {"entity_id": "15941649_3_Ent0", "role": "Effect", "text": "visual field defects", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "15941649_3_Ent1", "text": "Vigabatrin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15941649_3_Ent2", "text": "Vigabatrin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15941649_3_Ent0", "text": "visual field defects", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "15944830_2", "wnd_id": "15944830_2_1", "text": "Clinical course of macular edema in two cases of interferon - associated retinopathy observed by optical coherence tomography .", "tokens": ["Clinical", "course", "of", "macular", "edema", "in", "two", "cases", "of", "interferon", "-", "associated", "retinopathy", "observed", "by", "optical", "coherence", "tomography", "."], "event_mentions": [{"id": "15944830_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "15944830_2_Ent2", "role": "Effect", "text": "macular edema", "start": 3, "end": 5}, {"entity_id": "15944830_2_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "15944830_2_Ent0", "role": "Subject", "text": "two cases", "start": 6, "end": 8}, {"entity_id": "15944830_2_Ent4", "role": "Treatment", "text": "interferon", "start": 9, "end": 10}, {"entity_id": "15944830_2_Ent5", "role": "Treatment_Drug", "text": "interferon", "start": 9, "end": 10}, {"entity_id": "15944830_2_Ent3", "role": "Effect", "text": "retinopathy", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15944830_2_Ent2", "text": "macular edema", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15944830_2_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15944830_2_Ent0", "text": "two cases", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15944830_2_Ent4", "text": "interferon", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15944830_2_Ent5", "text": "interferon", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15944830_2_Ent3", "text": "retinopathy", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "15944830_4", "wnd_id": "15944830_4_1", "text": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia .", "tokens": ["Ophthalmologists", "should", "be", "aware", "of", "the", "ocular", "side", "effects", "of", "IFN", "therapy", "and", "carefully", "monitor", "patients", "for", "the", "possible", "occurrence", "of", "hypoalbuminemia", "and", "thrombocytopenia", "."], "event_mentions": [{"id": "15944830_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "aware", "start": 3, "end": 4}, "arguments": [{"entity_id": "15944830_4_Ent1", "role": "Effect", "text": "ocular side effects", "start": 6, "end": 9}, {"entity_id": "15944830_4_Ent3", "role": "Treatment", "text": "IFN", "start": 10, "end": 11}, {"entity_id": "15944830_4_Ent4", "role": "Treatment_Drug", "text": "IFN", "start": 10, "end": 11}, {"entity_id": "15944830_4_Ent0", "role": "Subject", "text": "patients", "start": 15, "end": 16}, {"entity_id": "15944830_4_Ent2", "role": "Effect", "text": "hypoalbuminemia and thrombocytopenia", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "15944830_4_Ent1", "text": "ocular side effects", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15944830_4_Ent3", "text": "IFN", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15944830_4_Ent4", "text": "IFN", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15944830_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15944830_4_Ent2", "text": "hypoalbuminemia and thrombocytopenia", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "15961942_1", "wnd_id": "15961942_1_1", "text": "Late development of diabetes mellitus after interferon - alfa and ribavirin therapy for chronic hepatitis C : a case report .", "tokens": ["Late", "development", "of", "diabetes", "mellitus", "after", "interferon", "-", "alfa", "and", "ribavirin", "therapy", "for", "chronic", "hepatitis", "C", ":", "a", "case", "report", "."], "event_mentions": [{"id": "15961942_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "15961942_1_Ent0", "role": "Effect", "text": "diabetes mellitus", "start": 3, "end": 5}, {"entity_id": "15961942_1_Ent1", "role": "Treatment", "text": "interferon - alfa", "start": 6, "end": 9}, {"entity_id": "15961942_1_Ent5", "role": "Treatment_Drug", "text": "interferon - alfa", "start": 6, "end": 9}, {"entity_id": "15961942_1_Ent7", "role": "Combination_Drug", "text": "interferon - alfa", "start": 6, "end": 9}, {"entity_id": "15961942_1_Ent2", "role": "Treatment", "text": "ribavirin", "start": 10, "end": 11}, {"entity_id": "15961942_1_Ent4", "role": "Treatment_Drug", "text": "ribavirin", "start": 10, "end": 11}, {"entity_id": "15961942_1_Ent6", "role": "Combination_Drug", "text": "ribavirin", "start": 10, "end": 11}, {"entity_id": "15961942_1_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis C", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "15961942_1_Ent0", "text": "diabetes mellitus", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15961942_1_Ent1", "text": "interferon - alfa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15961942_1_Ent5", "text": "interferon - alfa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15961942_1_Ent7", "text": "interferon - alfa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15961942_1_Ent2", "text": "ribavirin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15961942_1_Ent4", "text": "ribavirin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15961942_1_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15961942_1_Ent3", "text": "chronic hepatitis C", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "15977922_1", "wnd_id": "15977922_1_1", "text": "Potential mechanisms involved in the occurrence of ischemic colitis in patients receiving tegaserod are also discussed .", "tokens": ["Potential", "mechanisms", "involved", "in", "the", "occurrence", "of", "ischemic", "colitis", "in", "patients", "receiving", "tegaserod", "are", "also", "discussed", "."], "event_mentions": [{"id": "15977922_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 5, "end": 6}, "arguments": [{"entity_id": "15977922_1_Ent1", "role": "Effect", "text": "ischemic colitis", "start": 7, "end": 9}, {"entity_id": "15977922_1_Ent0", "role": "Subject", "text": "patients", "start": 10, "end": 11}, {"entity_id": "15977922_1_Ent2", "role": "Treatment", "text": "tegaserod", "start": 12, "end": 13}, {"entity_id": "15977922_1_Ent3", "role": "Treatment_Drug", "text": "tegaserod", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15977922_1_Ent1", "text": "ischemic colitis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15977922_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15977922_1_Ent2", "text": "tegaserod", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15977922_1_Ent3", "text": "tegaserod", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16001348_1", "wnd_id": "16001348_1_1", "text": "Lansoprazole - associated collagenous colitis : a case report .", "tokens": ["Lansoprazole", "-", "associated", "collagenous", "colitis", ":", "a", "case", "report", "."], "event_mentions": [{"id": "16001348_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "16001348_1_Ent1", "role": "Treatment", "text": "Lansoprazole", "start": 0, "end": 1}, {"entity_id": "16001348_1_Ent2", "role": "Treatment_Drug", "text": "Lansoprazole", "start": 0, "end": 1}, {"entity_id": "16001348_1_Ent0", "role": "Effect", "text": "collagenous colitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "16001348_1_Ent1", "text": "Lansoprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16001348_1_Ent2", "text": "Lansoprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16001348_1_Ent0", "text": "collagenous colitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "16012330_1", "wnd_id": "16012330_1_1", "text": "Itraconazole - related increased vincristine neurotoxicity : case report and review of literature .", "tokens": ["Itraconazole", "-", "related", "increased", "vincristine", "neurotoxicity", ":", "case", "report", "and", "review", "of", "literature", "."], "event_mentions": [{"id": "16012330_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "16012330_1_Ent1", "role": "Treatment", "text": "Itraconazole", "start": 0, "end": 1}, {"entity_id": "16012330_1_Ent2", "role": "Treatment_Drug", "text": "Itraconazole", "start": 0, "end": 1}, {"entity_id": "16012330_1_Ent4", "role": "Combination_Drug", "text": "Itraconazole", "start": 0, "end": 1}, {"entity_id": "16012330_1_Ent0", "role": "Effect", "text": "increased vincristine neurotoxicity", "start": 3, "end": 6}, {"entity_id": "16012330_1_Ent3", "role": "Treatment_Drug", "text": "vincristine", "start": 4, "end": 5}, {"entity_id": "16012330_1_Ent5", "role": "Combination_Drug", "text": "vincristine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "16012330_1_Ent1", "text": "Itraconazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16012330_1_Ent2", "text": "Itraconazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16012330_1_Ent4", "text": "Itraconazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16012330_1_Ent0", "text": "increased vincristine neurotoxicity", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "16012330_1_Ent3", "text": "vincristine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16012330_1_Ent5", "text": "vincristine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "16012330_11", "wnd_id": "16012330_11_1", "text": "The authors suggest that in the absence of any proven benefit of itraconazole prophylaxis , and given the interaction of this drug with vincristine leading to severe and even potentially fatal toxicities , the combination use of these drugs should be avoided .", "tokens": ["The", "authors", "suggest", "that", "in", "the", "absence", "of", "any", "proven", "benefit", "of", "itraconazole", "prophylaxis", ",", "and", "given", "the", "interaction", "of", "this", "drug", "with", "vincristine", "leading", "to", "severe", "and", "even", "potentially", "fatal", "toxicities", ",", "the", "combination", "use", "of", "these", "drugs", "should", "be", "avoided", "."], "event_mentions": [{"id": "16012330_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leading", "start": 24, "end": 25}, "arguments": [{"entity_id": "16012330_11_Ent1", "role": "Treatment", "text": "itraconazole", "start": 12, "end": 13}, {"entity_id": "16012330_11_Ent3", "role": "Treatment_Drug", "text": "itraconazole", "start": 12, "end": 13}, {"entity_id": "16012330_11_Ent5", "role": "Combination_Drug", "text": "itraconazole", "start": 12, "end": 13}, {"entity_id": "16012330_11_Ent2", "role": "Treatment", "text": "vincristine", "start": 23, "end": 24}, {"entity_id": "16012330_11_Ent4", "role": "Treatment_Drug", "text": "vincristine", "start": 23, "end": 24}, {"entity_id": "16012330_11_Ent6", "role": "Combination_Drug", "text": "vincristine", "start": 23, "end": 24}, {"entity_id": "16012330_11_Ent0", "role": "Effect", "text": "severe and even potentially fatal toxicities", "start": 26, "end": 32}]}], "entity_mentions": [{"id": "16012330_11_Ent1", "text": "itraconazole", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16012330_11_Ent3", "text": "itraconazole", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16012330_11_Ent5", "text": "itraconazole", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16012330_11_Ent2", "text": "vincristine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16012330_11_Ent4", "text": "vincristine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16012330_11_Ent6", "text": "vincristine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16012330_11_Ent0", "text": "severe and even potentially fatal toxicities", "entity_type": "Entity", "start": 26, "end": 32}], "lang": "en"}
{"doc_id": "16012330_2", "wnd_id": "16012330_2_1", "text": "Itraconazole is particularly attractive in fungal prophylaxis for cancer patients due to its broad spectrum , including Candida and Aspergillus .", "tokens": ["Itraconazole", "is", "particularly", "attractive", "in", "fungal", "prophylaxis", "for", "cancer", "patients", "due", "to", "its", "broad", "spectrum", ",", "including", "Candida", "and", "Aspergillus", "."], "event_mentions": [{"id": "16012330_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prophylaxis", "start": 6, "end": 7}, "arguments": [{"entity_id": "16012330_2_Ent2", "role": "Treatment", "text": "Itraconazole", "start": 0, "end": 1}, {"entity_id": "16012330_2_Ent4", "role": "Treatment_Drug", "text": "Itraconazole", "start": 0, "end": 1}, {"entity_id": "16012330_2_Ent3", "role": "Treatment_Disorder", "text": "fungal", "start": 5, "end": 6}, {"entity_id": "16012330_2_Ent1", "role": "Subject_Disorder", "text": "cancer", "start": 8, "end": 9}, {"entity_id": "16012330_2_Ent0", "role": "Subject", "text": "cancer patients", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "16012330_2_Ent2", "text": "Itraconazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16012330_2_Ent4", "text": "Itraconazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16012330_2_Ent3", "text": "fungal", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16012330_2_Ent1", "text": "cancer", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16012330_2_Ent0", "text": "cancer patients", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "16012330_7", "wnd_id": "16012330_7_1", "text": "Ten days after itraconazole was started , he developed paralytic ileus , neurogenic bladder , mild left ptosis , and absence of deep reflexes , with severe paralysis of the lower extremities and mild weakness of the upper extremities .", "tokens": ["Ten", "days", "after", "itraconazole", "was", "started", ",", "he", "developed", "paralytic", "ileus", ",", "neurogenic", "bladder", ",", "mild", "left", "ptosis", ",", "and", "absence", "of", "deep", "reflexes", ",", "with", "severe", "paralysis", "of", "the", "lower", "extremities", "and", "mild", "weakness", "of", "the", "upper", "extremities", "."], "event_mentions": [{"id": "16012330_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "16012330_7_Ent1", "role": "Treatment", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "16012330_7_Ent2", "role": "Treatment_Drug", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "16012330_7_Ent0", "role": "Effect", "text": "paralytic ileus , neurogenic bladder , mild left ptosis , and absence of deep reflexes , with severe paralysis of the lower extremities and mild weakness of the upper extremities", "start": 9, "end": 39}]}], "entity_mentions": [{"id": "16012330_7_Ent1", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16012330_7_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16012330_7_Ent0", "text": "paralytic ileus , neurogenic bladder , mild left ptosis , and absence of deep reflexes , with severe paralysis of the lower extremities and mild weakness of the upper extremities", "entity_type": "Entity", "start": 9, "end": 39}], "lang": "en"}
{"doc_id": "16025424_1", "wnd_id": "16025424_1_1", "text": "Rapid onset of quetiapine - induced diabetic ketoacidosis in an elderly patient : a case report .", "tokens": ["Rapid", "onset", "of", "quetiapine", "-", "induced", "diabetic", "ketoacidosis", "in", "an", "elderly", "patient", ":", "a", "case", "report", "."], "event_mentions": [{"id": "16025424_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "16025424_1_Ent3", "role": "Treatment", "text": "quetiapine", "start": 3, "end": 4}, {"entity_id": "16025424_1_Ent4", "role": "Treatment_Drug", "text": "quetiapine", "start": 3, "end": 4}, {"entity_id": "16025424_1_Ent2", "role": "Effect", "text": "diabetic ketoacidosis", "start": 6, "end": 8}, {"entity_id": "16025424_1_Ent0", "role": "Subject", "text": "an elderly patient", "start": 9, "end": 12}, {"entity_id": "16025424_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "16025424_1_Ent3", "text": "quetiapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16025424_1_Ent4", "text": "quetiapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16025424_1_Ent2", "text": "diabetic ketoacidosis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16025424_1_Ent0", "text": "an elderly patient", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16025424_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "16046172_1", "wnd_id": "16046172_1_1", "text": "In the other patient , a 78 - year - old woman , Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection .", "tokens": ["In", "the", "other", "patient", ",", "a", "78", "-", "year", "-", "old", "woman", ",", "Neisseria", "mucosa", "knee", "arthritis", "occurred", "after", "a", "single", "sodium", "hyaluronate", "injection", "."], "event_mentions": [{"id": "16046172_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 17, "end": 18}, "arguments": [{"entity_id": "16046172_1_Ent0", "role": "Subject", "text": "a 78 - year - old woman", "start": 5, "end": 12}, {"entity_id": "16046172_1_Ent1", "role": "Subject_Age", "text": "78 - year - old", "start": 6, "end": 11}, {"entity_id": "16046172_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "16046172_1_Ent3", "role": "Effect", "text": "Neisseria mucosa knee arthritis", "start": 13, "end": 17}, {"entity_id": "16046172_1_Ent4", "role": "Treatment", "text": "a single sodium hyaluronate injection", "start": 19, "end": 24}, {"entity_id": "16046172_1_Ent7", "role": "Treatment_Dosage", "text": "single", "start": 20, "end": 21}, {"entity_id": "16046172_1_Ent6", "role": "Treatment_Drug", "text": "sodium hyaluronate", "start": 21, "end": 23}, {"entity_id": "16046172_1_Ent5", "role": "Treatment_Route", "text": "injection", "start": 23, "end": 24}, {"entity_id": "16046172_1_Ent8", "role": "Treatment_Dosage", "text": "injection", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "16046172_1_Ent0", "text": "a 78 - year - old woman", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "16046172_1_Ent1", "text": "78 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16046172_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16046172_1_Ent3", "text": "Neisseria mucosa knee arthritis", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "16046172_1_Ent4", "text": "a single sodium hyaluronate injection", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "16046172_1_Ent7", "text": "single", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16046172_1_Ent6", "text": "sodium hyaluronate", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "16046172_1_Ent5", "text": "injection", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16046172_1_Ent8", "text": "injection", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "16062101_3", "wnd_id": "16062101_3_1", "text": "The authors report two cases of acute dystonic reactions ( ADRs ) as a side effect of lamivudine .", "tokens": ["The", "authors", "report", "two", "cases", "of", "acute", "dystonic", "reactions", "(", "ADRs", ")", "as", "a", "side", "effect", "of", "lamivudine", "."], "event_mentions": [{"id": "16062101_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "effect", "start": 15, "end": 16}, "arguments": [{"entity_id": "16062101_3_Ent1", "role": "Subject_Population", "text": "two", "start": 3, "end": 4}, {"entity_id": "16062101_3_Ent0", "role": "Subject", "text": "two cases", "start": 3, "end": 5}, {"entity_id": "16062101_3_Ent2", "role": "Effect", "text": "acute dystonic reactions ( ADRs )", "start": 6, "end": 12}, {"entity_id": "16062101_3_Ent3", "role": "Treatment", "text": "lamivudine", "start": 17, "end": 18}, {"entity_id": "16062101_3_Ent4", "role": "Treatment_Drug", "text": "lamivudine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "16062101_3_Ent1", "text": "two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16062101_3_Ent0", "text": "two cases", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16062101_3_Ent2", "text": "acute dystonic reactions ( ADRs )", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "16062101_3_Ent3", "text": "lamivudine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16062101_3_Ent4", "text": "lamivudine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "16092915_1", "wnd_id": "16092915_1_1", "text": "CONCLUSIONS : This observation of \" on - off \" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent .", "tokens": ["CONCLUSIONS", ":", "This", "observation", "of", "\"", "on", "-", "off", "\"", "risperidone", "treatment", "suggests", "that", "risperidone", "may", "have", "worsened", "both", "psychiatric", "and", "physical", "manifestations", "of", "the", "mitochondrial", "disorder", "in", "this", "adolescent", "."], "event_mentions": [{"id": "16092915_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have worsened", "start": 16, "end": 18}, "arguments": [{"entity_id": "16092915_1_Ent4", "role": "Treatment", "text": "risperidone", "start": 14, "end": 15}, {"entity_id": "16092915_1_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 14, "end": 15}, {"entity_id": "16092915_1_Ent3", "role": "Effect", "text": "psychiatric and physical manifestations", "start": 19, "end": 23}, {"entity_id": "16092915_1_Ent2", "role": "Subject_Disorder", "text": "mitochondrial disorder", "start": 25, "end": 27}, {"entity_id": "16092915_1_Ent0", "role": "Subject", "text": "mitochondrial disorder in this adolescent", "start": 25, "end": 30}, {"entity_id": "16092915_1_Ent1", "role": "Subject_Age", "text": "adolescent", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "16092915_1_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16092915_1_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16092915_1_Ent3", "text": "psychiatric and physical manifestations", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "16092915_1_Ent2", "text": "mitochondrial disorder", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "16092915_1_Ent0", "text": "mitochondrial disorder in this adolescent", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "16092915_1_Ent1", "text": "adolescent", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "16099004_3", "wnd_id": "16099004_3_1", "text": "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use .", "tokens": ["We", "report", "recrudescence", "of", "imported", "Plasmodium", "falciparum", "malaria", "following", "quinine", "treatment", "in", "the", "context", "of", "concurrent", "phenytoin", "use", "."], "event_mentions": [{"id": "16099004_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "16099004_3_Ent0", "role": "Effect", "text": "Plasmodium falciparum malaria", "start": 5, "end": 8}, {"entity_id": "16099004_3_Ent2", "role": "Treatment_Drug", "text": "quinine", "start": 9, "end": 10}, {"entity_id": "16099004_3_Ent5", "role": "Combination_Drug", "text": "quinine", "start": 9, "end": 10}, {"entity_id": "16099004_3_Ent1", "role": "Treatment", "text": "quinine treatment in the context of concurrent phenytoin use", "start": 9, "end": 18}, {"entity_id": "16099004_3_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 16, "end": 17}, {"entity_id": "16099004_3_Ent4", "role": "Combination_Drug", "text": "phenytoin", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "16099004_3_Ent0", "text": "Plasmodium falciparum malaria", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16099004_3_Ent2", "text": "quinine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16099004_3_Ent5", "text": "quinine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16099004_3_Ent1", "text": "quinine treatment in the context of concurrent phenytoin use", "entity_type": "Entity", "start": 9, "end": 18}, {"id": "16099004_3_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16099004_3_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "16109609_4", "wnd_id": "16109609_4_1", "text": "We report four cases of hemodynamically significant pericardial effusion in patients with refractory lymphoma who were receiving gemcitabine , all of whom had a history of mediastinal radiation without subcarinal blocking .", "tokens": ["We", "report", "four", "cases", "of", "hemodynamically", "significant", "pericardial", "effusion", "in", "patients", "with", "refractory", "lymphoma", "who", "were", "receiving", "gemcitabine", ",", "all", "of", "whom", "had", "a", "history", "of", "mediastinal", "radiation", "without", "subcarinal", "blocking", "."], "event_mentions": [{"id": "16109609_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 9, "end": 10}, "arguments": [{"entity_id": "16109609_4_Ent2", "role": "Subject_Population", "text": "four", "start": 2, "end": 3}, {"entity_id": "16109609_4_Ent3", "role": "Effect", "text": "hemodynamically significant pericardial effusion", "start": 5, "end": 9}, {"entity_id": "16109609_4_Ent5", "role": "Treatment_Disorder", "text": "refractory lymphoma", "start": 12, "end": 14}, {"entity_id": "16109609_4_Ent4", "role": "Treatment", "text": "gemcitabine", "start": 17, "end": 18}, {"entity_id": "16109609_4_Ent6", "role": "Treatment_Drug", "text": "gemcitabine", "start": 17, "end": 18}, {"entity_id": "16109609_4_Ent0", "role": "Subject", "text": "had a history of mediastinal radiation without subcarinal blocking", "start": 22, "end": 31}, {"entity_id": "16109609_4_Ent1", "role": "Subject_Disorder", "text": "mediastinal radiation without subcarinal blocking", "start": 26, "end": 31}]}], "entity_mentions": [{"id": "16109609_4_Ent2", "text": "four", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16109609_4_Ent3", "text": "hemodynamically significant pericardial effusion", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "16109609_4_Ent5", "text": "refractory lymphoma", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16109609_4_Ent4", "text": "gemcitabine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16109609_4_Ent6", "text": "gemcitabine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16109609_4_Ent0", "text": "had a history of mediastinal radiation without subcarinal blocking", "entity_type": "Entity", "start": 22, "end": 31}, {"id": "16109609_4_Ent1", "text": "mediastinal radiation without subcarinal blocking", "entity_type": "Entity", "start": 26, "end": 31}], "lang": "en"}
{"doc_id": "16116136_1", "wnd_id": "16116136_1_1", "text": "A patient with generalized MG was effectively managed with MM but developed CNS lymphoma after 3 years of treatment .", "tokens": ["A", "patient", "with", "generalized", "MG", "was", "effectively", "managed", "with", "MM", "but", "developed", "CNS", "lymphoma", "after", "3", "years", "of", "treatment", "."], "event_mentions": [{"id": "16116136_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "managed", "start": 7, "end": 8}, "arguments": [{"entity_id": "16116136_1_Ent1", "role": "Treatment_Disorder", "text": "generalized MG", "start": 3, "end": 5}, {"entity_id": "16116136_1_Ent0", "role": "Treatment", "text": "MM", "start": 9, "end": 10}, {"entity_id": "16116136_1_Ent2", "role": "Treatment_Drug", "text": "MM", "start": 9, "end": 10}]}, {"id": "16116136_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "16116136_1_Ent3", "role": "Subject", "text": "A patient with generalized MG", "start": 0, "end": 5}, {"entity_id": "16116136_1_Ent5", "role": "Treatment", "text": "MM", "start": 9, "end": 10}, {"entity_id": "16116136_1_Ent4", "role": "Effect", "text": "CNS lymphoma", "start": 12, "end": 14}, {"entity_id": "16116136_1_Ent6", "role": "Treatment_Duration", "text": "3 years", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "16116136_1_Ent3", "text": "A patient with generalized MG", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16116136_1_Ent1", "text": "generalized MG", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16116136_1_Ent0", "text": "MM", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16116136_1_Ent2", "text": "MM", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16116136_1_Ent5", "text": "MM", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16116136_1_Ent4", "text": "CNS lymphoma", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16116136_1_Ent6", "text": "3 years", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "16116136_2", "wnd_id": "16116136_2_1", "text": "Despite minimal short - term side effects and apparent efficacy , chronic treatment of MG with MM may be associated with increased risk of lymphoproliferative disorders .", "tokens": ["Despite", "minimal", "short", "-", "term", "side", "effects", "and", "apparent", "efficacy", ",", "chronic", "treatment", "of", "MG", "with", "MM", "may", "be", "associated", "with", "increased", "risk", "of", "lymphoproliferative", "disorders", "."], "event_mentions": [{"id": "16116136_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 19, "end": 20}, "arguments": [{"entity_id": "16116136_2_Ent2", "role": "Treatment_Disorder", "text": "MG", "start": 14, "end": 15}, {"entity_id": "16116136_2_Ent1", "role": "Treatment", "text": "MG with MM", "start": 14, "end": 17}, {"entity_id": "16116136_2_Ent3", "role": "Treatment_Drug", "text": "MM", "start": 16, "end": 17}, {"entity_id": "16116136_2_Ent0", "role": "Effect", "text": "increased risk of lymphoproliferative", "start": 21, "end": 25}]}], "entity_mentions": [{"id": "16116136_2_Ent2", "text": "MG", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16116136_2_Ent1", "text": "MG with MM", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "16116136_2_Ent3", "text": "MM", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16116136_2_Ent0", "text": "increased risk of lymphoproliferative", "entity_type": "Entity", "start": 21, "end": 25}], "lang": "en"}
{"doc_id": "16119501_3", "wnd_id": "16119501_3_1", "text": "The patient continued to have fever and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral baclofen .", "tokens": ["The", "patient", "continued", "to", "have", "fever", "and", "autonomic", "instability", "without", "evidence", "of", "infection", "which", "entirely", "resolved", "within", "24", "hours", "of", "reinstitution", "of", "full", "preadmission", "dosing", "of", "oral", "baclofen", "."], "event_mentions": [{"id": "16119501_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 4, "end": 5}, "arguments": [{"entity_id": "16119501_3_Ent0", "role": "Effect", "text": "fever and autonomic instability without evidence of infection which entirely resolved", "start": 5, "end": 16}, {"entity_id": "16119501_3_Ent4", "role": "Treatment_Time_elapsed", "text": "24 hours", "start": 17, "end": 19}, {"entity_id": "16119501_3_Ent1", "role": "Treatment", "text": "24 hours of reinstitution of full preadmission dosing of oral baclofen", "start": 17, "end": 28}, {"entity_id": "16119501_3_Ent2", "role": "Treatment_Route", "text": "oral", "start": 26, "end": 27}, {"entity_id": "16119501_3_Ent3", "role": "Treatment_Drug", "text": "baclofen", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "16119501_3_Ent0", "text": "fever and autonomic instability without evidence of infection which entirely resolved", "entity_type": "Entity", "start": 5, "end": 16}, {"id": "16119501_3_Ent4", "text": "24 hours", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "16119501_3_Ent1", "text": "24 hours of reinstitution of full preadmission dosing of oral baclofen", "entity_type": "Entity", "start": 17, "end": 28}, {"id": "16119501_3_Ent2", "text": "oral", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16119501_3_Ent3", "text": "baclofen", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "16119501_4", "wnd_id": "16119501_4_1", "text": "We report a case of baclofen withdrawal syndrome resulting from oral baclofen underdosing .", "tokens": ["We", "report", "a", "case", "of", "baclofen", "withdrawal", "syndrome", "resulting", "from", "oral", "baclofen", "underdosing", "."], "event_mentions": [{"id": "16119501_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 8, "end": 9}, "arguments": [{"entity_id": "16119501_4_Ent0", "role": "Effect", "text": "baclofen withdrawal syndrome", "start": 5, "end": 8}, {"entity_id": "16119501_4_Ent2", "role": "Treatment_Route", "text": "oral", "start": 10, "end": 11}, {"entity_id": "16119501_4_Ent1", "role": "Treatment", "text": "oral baclofen underdosing", "start": 10, "end": 13}, {"entity_id": "16119501_4_Ent3", "role": "Treatment_Drug", "text": "baclofen", "start": 11, "end": 12}, {"entity_id": "16119501_4_Ent4", "role": "Treatment_Dosage", "text": "underdosing", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16119501_4_Ent0", "text": "baclofen withdrawal syndrome", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16119501_4_Ent2", "text": "oral", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16119501_4_Ent1", "text": "oral baclofen underdosing", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16119501_4_Ent3", "text": "baclofen", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16119501_4_Ent4", "text": "underdosing", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16122280_3", "wnd_id": "16122280_3_1", "text": "Clinical experience in infectious patients has shown that oral telithromycin 800 mg once daily for 5 - 10 days is effective for the treatment of community - acquired upper and lower respiratory tract infections .", "tokens": ["Clinical", "experience", "in", "infectious", "patients", "has", "shown", "that", "oral", "telithromycin", "800", "mg", "once", "daily", "for", "5", "-", "10", "days", "is", "effective", "for", "the", "treatment", "of", "community", "-", "acquired", "upper", "and", "lower", "respiratory", "tract", "infections", "."], "event_mentions": [{"id": "16122280_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 23, "end": 24}, "arguments": [{"entity_id": "16122280_3_Ent1", "role": "Subject_Disorder", "text": "infectious", "start": 3, "end": 4}, {"entity_id": "16122280_3_Ent0", "role": "Subject", "text": "infectious patients", "start": 3, "end": 5}, {"entity_id": "16122280_3_Ent8", "role": "Treatment_Route", "text": "oral", "start": 8, "end": 9}, {"entity_id": "16122280_3_Ent2", "role": "Treatment", "text": "oral telithromycin 800 mg once daily for 5 - 10 days", "start": 8, "end": 19}, {"entity_id": "16122280_3_Ent3", "role": "Treatment_Drug", "text": "telithromycin", "start": 9, "end": 10}, {"entity_id": "16122280_3_Ent4", "role": "Treatment_Dosage", "text": "800 mg", "start": 10, "end": 12}, {"entity_id": "16122280_3_Ent5", "role": "Treatment_Freq", "text": "once daily", "start": 12, "end": 14}, {"entity_id": "16122280_3_Ent6", "role": "Treatment_Duration", "text": "5 - 10 days", "start": 15, "end": 19}, {"entity_id": "16122280_3_Ent7", "role": "Treatment_Disorder", "text": "community - acquired upper and lower respiratory tract infections", "start": 25, "end": 34}]}], "entity_mentions": [{"id": "16122280_3_Ent1", "text": "infectious", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16122280_3_Ent0", "text": "infectious patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16122280_3_Ent8", "text": "oral", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16122280_3_Ent2", "text": "oral telithromycin 800 mg once daily for 5 - 10 days", "entity_type": "Entity", "start": 8, "end": 19}, {"id": "16122280_3_Ent3", "text": "telithromycin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16122280_3_Ent4", "text": "800 mg", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16122280_3_Ent5", "text": "once daily", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16122280_3_Ent6", "text": "5 - 10 days", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "16122280_3_Ent7", "text": "community - acquired upper and lower respiratory tract infections", "entity_type": "Entity", "start": 25, "end": 34}], "lang": "en"}
{"doc_id": "16200540_3", "wnd_id": "16200540_3_1", "text": "Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation , with anarchic discharges of motor unit potentials , tonic grouped discharges and flexor spasms , associated with painful dysesthesia .", "tokens": ["Videopolysomnographic", "and", "pharmacokinetic", "studies", "with", "monitoring", "of", "plasma", "levodopa", "levels", "demonstrated", "marked", "motor", "hyperactivity", "during", "augmentation", ",", "with", "anarchic", "discharges", "of", "motor", "unit", "potentials", ",", "tonic", "grouped", "discharges", "and", "flexor", "spasms", ",", "associated", "with", "painful", "dysesthesia", "."], "event_mentions": [{"id": "16200540_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "demonstrated", "start": 10, "end": 11}, "arguments": [{"entity_id": "16200540_3_Ent1", "role": "Treatment", "text": "levodopa", "start": 8, "end": 9}, {"entity_id": "16200540_3_Ent2", "role": "Treatment_Drug", "text": "levodopa", "start": 8, "end": 9}, {"entity_id": "16200540_3_Ent0", "role": "Effect", "text": "marked motor hyperactivity during augmentation , with anarchic discharges of motor unit potentials , tonic grouped discharges and flexor spasms , associated with painful dysesthesia", "start": 11, "end": 36}]}], "entity_mentions": [{"id": "16200540_3_Ent1", "text": "levodopa", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16200540_3_Ent2", "text": "levodopa", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16200540_3_Ent0", "text": "marked motor hyperactivity during augmentation , with anarchic discharges of motor unit potentials , tonic grouped discharges and flexor spasms , associated with painful dysesthesia", "entity_type": "Entity", "start": 11, "end": 36}], "lang": "en"}
{"doc_id": "16207263_1", "wnd_id": "16207263_1_1", "text": "Linezolid - induced dyserythropoiesis : chloramphenicol toxicity revisited .", "tokens": ["Linezolid", "-", "induced", "dyserythropoiesis", ":", "chloramphenicol", "toxicity", "revisited", "."], "event_mentions": [{"id": "16207263_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16207263_1_Ent1", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "16207263_1_Ent2", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "16207263_1_Ent0", "role": "Effect", "text": "dyserythropoiesis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "16207263_1_Ent1", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16207263_1_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16207263_1_Ent0", "text": "dyserythropoiesis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "16207263_2", "wnd_id": "16207263_2_1", "text": "We report here two cases of dyserythropoietic anaemia associated with long - term linezolid use that share striking similarities to chloramphenicol - associated myelotoxicity .", "tokens": ["We", "report", "here", "two", "cases", "of", "dyserythropoietic", "anaemia", "associated", "with", "long", "-", "term", "linezolid", "use", "that", "share", "striking", "similarities", "to", "chloramphenicol", "-", "associated", "myelotoxicity", "."], "event_mentions": [{"id": "16207263_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "16207263_2_Ent0", "role": "Effect", "text": "dyserythropoietic anaemia", "start": 6, "end": 8}, {"entity_id": "16207263_2_Ent3", "role": "Treatment_Duration", "text": "long - term", "start": 10, "end": 13}, {"entity_id": "16207263_2_Ent1", "role": "Treatment", "text": "long - term linezolid", "start": 10, "end": 14}, {"entity_id": "16207263_2_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "16207263_2_Ent0", "text": "dyserythropoietic anaemia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16207263_2_Ent3", "text": "long - term", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16207263_2_Ent1", "text": "long - term linezolid", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "16207263_2_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "16211208_1", "wnd_id": "16211208_1_1", "text": "Because of serious side effects of an increase in the QT interval causing torsades de pointes , dofetilide must be initiated with close monitoring of the QT interval in an inpatient setting .", "tokens": ["Because", "of", "serious", "side", "effects", "of", "an", "increase", "in", "the", "QT", "interval", "causing", "torsades", "de", "pointes", ",", "dofetilide", "must", "be", "initiated", "with", "close", "monitoring", "of", "the", "QT", "interval", "in", "an", "inpatient", "setting", "."], "event_mentions": [{"id": "16211208_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 7, "end": 8}, "arguments": [{"entity_id": "16211208_1_Ent0", "role": "Effect", "text": "QT interval causing torsades de pointes", "start": 10, "end": 16}, {"entity_id": "16211208_1_Ent1", "role": "Treatment", "text": "dofetilide", "start": 17, "end": 18}, {"entity_id": "16211208_1_Ent2", "role": "Treatment_Drug", "text": "dofetilide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "16211208_1_Ent0", "text": "QT interval causing torsades de pointes", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "16211208_1_Ent1", "text": "dofetilide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16211208_1_Ent2", "text": "dofetilide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "16239768_1", "wnd_id": "16239768_1_1", "text": "A 56 - year - old white woman with a diagnosis of reactive depression developed severe UI after a 30 days ' treatment with venlafaxine 75 mg / day .", "tokens": ["A", "56", "-", "year", "-", "old", "white", "woman", "with", "a", "diagnosis", "of", "reactive", "depression", "developed", "severe", "UI", "after", "a", "30", "days", "'", "treatment", "with", "venlafaxine", "75", "mg", "/", "day", "."], "event_mentions": [{"id": "16239768_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 17, "end": 18}, "arguments": [{"entity_id": "16239768_1_Ent0", "role": "Subject", "text": "A 56 - year - old white woman with a diagnosis of reactive depression", "start": 0, "end": 14}, {"entity_id": "16239768_1_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 1, "end": 6}, {"entity_id": "16239768_1_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "16239768_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "16239768_1_Ent6", "role": "Treatment_Disorder", "text": "reactive depression", "start": 12, "end": 14}, {"entity_id": "16239768_1_Ent4", "role": "Effect", "text": "severe UI", "start": 15, "end": 17}, {"entity_id": "16239768_1_Ent7", "role": "Treatment_Time_elapsed", "text": "30 days", "start": 19, "end": 21}, {"entity_id": "16239768_1_Ent5", "role": "Treatment", "text": "30 days ' treatment with venlafaxine 75 mg / day .", "start": 19, "end": 30}, {"entity_id": "16239768_1_Ent8", "role": "Treatment_Drug", "text": "venlafaxine", "start": 24, "end": 25}, {"entity_id": "16239768_1_Ent9", "role": "Treatment_Dosage", "text": "75 mg / day", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "16239768_1_Ent0", "text": "A 56 - year - old white woman with a diagnosis of reactive depression", "entity_type": "Entity", "start": 0, "end": 14}, {"id": "16239768_1_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16239768_1_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16239768_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16239768_1_Ent6", "text": "reactive depression", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16239768_1_Ent4", "text": "severe UI", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "16239768_1_Ent7", "text": "30 days", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16239768_1_Ent5", "text": "30 days ' treatment with venlafaxine 75 mg / day .", "entity_type": "Entity", "start": 19, "end": 30}, {"id": "16239768_1_Ent8", "text": "venlafaxine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16239768_1_Ent9", "text": "75 mg / day", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "16244351_1", "wnd_id": "16244351_1_1", "text": "Atrial fibrillation after vardenafil therapy .", "tokens": ["Atrial", "fibrillation", "after", "vardenafil", "therapy", "."], "event_mentions": [{"id": "16244351_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "16244351_1_Ent0", "role": "Effect", "text": "Atrial fibrillation", "start": 0, "end": 2}, {"entity_id": "16244351_1_Ent2", "role": "Treatment_Drug", "text": "vardenafil", "start": 3, "end": 4}, {"entity_id": "16244351_1_Ent1", "role": "Treatment", "text": "vardenafil therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "16244351_1_Ent0", "text": "Atrial fibrillation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16244351_1_Ent2", "text": "vardenafil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16244351_1_Ent1", "text": "vardenafil therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "16265343_1", "wnd_id": "16265343_1_1", "text": "DIAGNOSIS : Interferon alpha - 2b - induced cardiomyopathy .", "tokens": ["DIAGNOSIS", ":", "Interferon", "alpha", "-", "2b", "-", "induced", "cardiomyopathy", "."], "event_mentions": [{"id": "16265343_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "16265343_1_Ent1", "role": "Treatment", "text": "Interferon alpha - 2b", "start": 2, "end": 6}, {"entity_id": "16265343_1_Ent2", "role": "Treatment_Drug", "text": "Interferon alpha - 2b", "start": 2, "end": 6}, {"entity_id": "16265343_1_Ent0", "role": "Effect", "text": "cardiomyopathy", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "16265343_1_Ent1", "text": "Interferon alpha - 2b", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "16265343_1_Ent2", "text": "Interferon alpha - 2b", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "16265343_1_Ent0", "text": "cardiomyopathy", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "16284443_1", "wnd_id": "16284443_1_1", "text": "Based on the history and clinical features , a diagnosis of insulin - induced lipohypertrophy was made .", "tokens": ["Based", "on", "the", "history", "and", "clinical", "features", ",", "a", "diagnosis", "of", "insulin", "-", "induced", "lipohypertrophy", "was", "made", "."], "event_mentions": [{"id": "16284443_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "16284443_1_Ent1", "role": "Treatment", "text": "insulin", "start": 11, "end": 12}, {"entity_id": "16284443_1_Ent2", "role": "Treatment_Drug", "text": "insulin", "start": 11, "end": 12}, {"entity_id": "16284443_1_Ent0", "role": "Effect", "text": "lipohypertrophy", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "16284443_1_Ent1", "text": "insulin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16284443_1_Ent2", "text": "insulin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16284443_1_Ent0", "text": "lipohypertrophy", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16298824_1", "wnd_id": "16298824_1_1", "text": "Acute respiratory distress syndrome after rituximab infusion .", "tokens": ["Acute", "respiratory", "distress", "syndrome", "after", "rituximab", "infusion", "."], "event_mentions": [{"id": "16298824_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "16298824_1_Ent0", "role": "Effect", "text": "Acute respiratory distress syndrome", "start": 0, "end": 4}, {"entity_id": "16298824_1_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 5, "end": 6}, {"entity_id": "16298824_1_Ent1", "role": "Treatment", "text": "rituximab infusion", "start": 5, "end": 7}, {"entity_id": "16298824_1_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "16298824_1_Ent0", "text": "Acute respiratory distress syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16298824_1_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16298824_1_Ent1", "text": "rituximab infusion", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16298824_1_Ent3", "text": "infusion", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "16298824_4", "wnd_id": "16298824_4_1", "text": "Dyspnea , hypoxemia , and pleuritic chest pain occurred within 24 hours of rituximab administration , and there was no other apparent explanation .", "tokens": ["Dyspnea", ",", "hypoxemia", ",", "and", "pleuritic", "chest", "pain", "occurred", "within", "24", "hours", "of", "rituximab", "administration", ",", "and", "there", "was", "no", "other", "apparent", "explanation", "."], "event_mentions": [{"id": "16298824_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 8, "end": 9}, "arguments": [{"entity_id": "16298824_4_Ent0", "role": "Effect", "text": "Dyspnea , hypoxemia , and pleuritic chest pain", "start": 0, "end": 8}, {"entity_id": "16298824_4_Ent2", "role": "Treatment_Time_elapsed", "text": "24 hours", "start": 10, "end": 12}, {"entity_id": "16298824_4_Ent3", "role": "Treatment_Drug", "text": "rituximab", "start": 13, "end": 14}, {"entity_id": "16298824_4_Ent1", "role": "Treatment", "text": "rituximab administration", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "16298824_4_Ent0", "text": "Dyspnea , hypoxemia , and pleuritic chest pain", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "16298824_4_Ent2", "text": "24 hours", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16298824_4_Ent3", "text": "rituximab", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16298824_4_Ent1", "text": "rituximab administration", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "16298824_5", "wnd_id": "16298824_5_1", "text": "Progressive hypoxemia mandated endotracheal intubation 1 week after rituximab administration and led to death 4 weeks after admission .", "tokens": ["Progressive", "hypoxemia", "mandated", "endotracheal", "intubation", "1", "week", "after", "rituximab", "administration", "and", "led", "to", "death", "4", "weeks", "after", "admission", "."], "event_mentions": [{"id": "16298824_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "16298824_5_Ent0", "role": "Effect", "text": "Progressive hypoxemia", "start": 0, "end": 2}, {"entity_id": "16298824_5_Ent4", "role": "Treatment_Time_elapsed", "text": "1 week", "start": 5, "end": 7}, {"entity_id": "16298824_5_Ent3", "role": "Treatment_Drug", "text": "rituximab", "start": 8, "end": 9}, {"entity_id": "16298824_5_Ent2", "role": "Treatment", "text": "rituximab administration", "start": 8, "end": 10}, {"entity_id": "16298824_5_Ent1", "role": "Effect", "text": "led to death", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "16298824_5_Ent0", "text": "Progressive hypoxemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16298824_5_Ent4", "text": "1 week", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16298824_5_Ent3", "text": "rituximab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16298824_5_Ent2", "text": "rituximab administration", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16298824_5_Ent1", "text": "led to death", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "16326413_2", "wnd_id": "16326413_2_1", "text": "High - dose methotrexate - associated acute renal failure may be an avoidable complication .", "tokens": ["High", "-", "dose", "methotrexate", "-", "associated", "acute", "renal", "failure", "may", "be", "an", "avoidable", "complication", "."], "event_mentions": [{"id": "16326413_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "16326413_2_Ent2", "role": "Treatment_Dosage", "text": "High - dose", "start": 0, "end": 3}, {"entity_id": "16326413_2_Ent1", "role": "Treatment", "text": "High - dose methotrexate", "start": 0, "end": 4}, {"entity_id": "16326413_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "16326413_2_Ent0", "role": "Effect", "text": "acute renal failure", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "16326413_2_Ent2", "text": "High - dose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16326413_2_Ent1", "text": "High - dose methotrexate", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16326413_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16326413_2_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "16352777_3", "wnd_id": "16352777_3_1", "text": "Torsemide appears to also be a part of a long list of agents that can cause pancreatitis .", "tokens": ["Torsemide", "appears", "to", "also", "be", "a", "part", "of", "a", "long", "list", "of", "agents", "that", "can", "cause", "pancreatitis", "."], "event_mentions": [{"id": "16352777_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 15, "end": 16}, "arguments": [{"entity_id": "16352777_3_Ent1", "role": "Treatment", "text": "Torsemide", "start": 0, "end": 1}, {"entity_id": "16352777_3_Ent2", "role": "Treatment_Drug", "text": "Torsemide", "start": 0, "end": 1}, {"entity_id": "16352777_3_Ent0", "role": "Effect", "text": "pancreatitis", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "16352777_3_Ent1", "text": "Torsemide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16352777_3_Ent2", "text": "Torsemide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16352777_3_Ent0", "text": "pancreatitis", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "16357738_1", "wnd_id": "16357738_1_1", "text": "Moreover , treatment with immunosuppressive drugs such as cyclosporine , cisplatin , tacrolimus , and interferon - alpha can induce a condition resembling RPLS .", "tokens": ["Moreover", ",", "treatment", "with", "immunosuppressive", "drugs", "such", "as", "cyclosporine", ",", "cisplatin", ",", "tacrolimus", ",", "and", "interferon", "-", "alpha", "can", "induce", "a", "condition", "resembling", "RPLS", "."], "event_mentions": [{"id": "16357738_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 19, "end": 20}, "arguments": [{"entity_id": "16357738_1_Ent1", "role": "Treatment", "text": "immunosuppressive drugs such as cyclosporine , cisplatin , tacrolimus , and interferon - alpha", "start": 4, "end": 18}, {"entity_id": "16357738_1_Ent2", "role": "Treatment_Drug", "text": "cyclosporine", "start": 8, "end": 9}, {"entity_id": "16357738_1_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "16357738_1_Ent4", "role": "Treatment_Drug", "text": "tacrolimus", "start": 12, "end": 13}, {"entity_id": "16357738_1_Ent5", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 15, "end": 18}, {"entity_id": "16357738_1_Ent0", "role": "Effect", "text": "RPLS", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "16357738_1_Ent1", "text": "immunosuppressive drugs such as cyclosporine , cisplatin , tacrolimus , and interferon - alpha", "entity_type": "Entity", "start": 4, "end": 18}, {"id": "16357738_1_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16357738_1_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16357738_1_Ent4", "text": "tacrolimus", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16357738_1_Ent5", "text": "interferon - alpha", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "16357738_1_Ent0", "text": "RPLS", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "16371793_1", "wnd_id": "16371793_1_1", "text": "Intravitreal triamcinolone acetonide for persisting cystoid macular edema after penetrating keratoplasty .", "tokens": ["Intravitreal", "triamcinolone", "acetonide", "for", "persisting", "cystoid", "macular", "edema", "after", "penetrating", "keratoplasty", "."], "event_mentions": [{"id": "16371793_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 3, "end": 4}, "arguments": [{"entity_id": "16371793_1_Ent3", "role": "Treatment_Route", "text": "Intravitreal", "start": 0, "end": 1}, {"entity_id": "16371793_1_Ent0", "role": "Treatment", "text": "Intravitreal triamcinolone acetonide", "start": 0, "end": 3}, {"entity_id": "16371793_1_Ent2", "role": "Treatment_Drug", "text": "triamcinolone acetonide", "start": 1, "end": 3}, {"entity_id": "16371793_1_Ent1", "role": "Treatment_Disorder", "text": "persisting cystoid macular edema", "start": 4, "end": 8}]}, {"id": "16371793_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "16371793_1_Ent4", "role": "Effect", "text": "persisting cystoid macular edema", "start": 4, "end": 8}, {"entity_id": "16371793_1_Ent5", "role": "Treatment", "text": "penetrating keratoplasty", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "16371793_1_Ent3", "text": "Intravitreal", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16371793_1_Ent0", "text": "Intravitreal triamcinolone acetonide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16371793_1_Ent2", "text": "triamcinolone acetonide", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "16371793_1_Ent1", "text": "persisting cystoid macular edema", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "16371793_1_Ent4", "text": "persisting cystoid macular edema", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "16371793_1_Ent5", "text": "penetrating keratoplasty", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "16371793_11", "wnd_id": "16371793_11_1", "text": "CONCLUSIONS : Intravitreal injection of triamcinolone acetonide may be an additional tool in the treatment of therapy - resistant cystoid macular edema after penetrating keratoplasty .", "tokens": ["CONCLUSIONS", ":", "Intravitreal", "injection", "of", "triamcinolone", "acetonide", "may", "be", "an", "additional", "tool", "in", "the", "treatment", "of", "therapy", "-", "resistant", "cystoid", "macular", "edema", "after", "penetrating", "keratoplasty", "."], "event_mentions": [{"id": "16371793_11_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 14, "end": 15}, "arguments": [{"entity_id": "16371793_11_Ent1", "role": "Treatment_Route", "text": "Intravitreal injection", "start": 2, "end": 4}, {"entity_id": "16371793_11_Ent0", "role": "Treatment", "text": "Intravitreal injection of triamcinolone acetonide", "start": 2, "end": 7}, {"entity_id": "16371793_11_Ent2", "role": "Treatment_Drug", "text": "triamcinolone acetonide", "start": 5, "end": 7}, {"entity_id": "16371793_11_Ent3", "role": "Treatment_Disorder", "text": "therapy - resistant cystoid macular edema", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "16371793_11_Ent1", "text": "Intravitreal injection", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16371793_11_Ent0", "text": "Intravitreal injection of triamcinolone acetonide", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "16371793_11_Ent2", "text": "triamcinolone acetonide", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16371793_11_Ent3", "text": "therapy - resistant cystoid macular edema", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "16404563_4", "wnd_id": "16404563_4_1", "text": "Nocardia is an important opportunistic infectious agent in immunocompromised hosts , i.e. in patients taking corticosteroids .", "tokens": ["Nocardia", "is", "an", "important", "opportunistic", "infectious", "agent", "in", "immunocompromised", "hosts", ",", "i.e.", "in", "patients", "taking", "corticosteroids", "."], "event_mentions": [{"id": "16404563_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "infectious agent", "start": 5, "end": 7}, "arguments": [{"entity_id": "16404563_4_Ent2", "role": "Effect", "text": "Nocardia", "start": 0, "end": 1}, {"entity_id": "16404563_4_Ent1", "role": "Subject_Disorder", "text": "immunocompromised", "start": 8, "end": 9}, {"entity_id": "16404563_4_Ent0", "role": "Subject", "text": "immunocompromised hosts", "start": 8, "end": 10}, {"entity_id": "16404563_4_Ent3", "role": "Treatment", "text": "corticosteroids", "start": 15, "end": 16}, {"entity_id": "16404563_4_Ent4", "role": "Treatment_Drug", "text": "corticosteroids", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16404563_4_Ent2", "text": "Nocardia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16404563_4_Ent1", "text": "immunocompromised", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16404563_4_Ent0", "text": "immunocompromised hosts", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16404563_4_Ent3", "text": "corticosteroids", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16404563_4_Ent4", "text": "corticosteroids", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "16405935_3", "wnd_id": "16405935_3_1", "text": "This report describes a case of bilateral ptosis induced by chloroquine .", "tokens": ["This", "report", "describes", "a", "case", "of", "bilateral", "ptosis", "induced", "by", "chloroquine", "."], "event_mentions": [{"id": "16405935_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "16405935_3_Ent0", "role": "Subject", "text": "a case", "start": 3, "end": 5}, {"entity_id": "16405935_3_Ent1", "role": "Effect", "text": "bilateral ptosis", "start": 6, "end": 8}, {"entity_id": "16405935_3_Ent2", "role": "Treatment", "text": "chloroquine", "start": 10, "end": 11}, {"entity_id": "16405935_3_Ent3", "role": "Treatment_Drug", "text": "chloroquine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "16405935_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16405935_3_Ent1", "text": "bilateral ptosis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16405935_3_Ent2", "text": "chloroquine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16405935_3_Ent3", "text": "chloroquine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "16432996_5", "wnd_id": "16432996_5_1", "text": "The combination therapy of interferon alpha and ribavirin was given to a 50 - year - old female with CHC who had not responded to a previous treatment by interferon alpha .", "tokens": ["The", "combination", "therapy", "of", "interferon", "alpha", "and", "ribavirin", "was", "given", "to", "a", "50", "-", "year", "-", "old", "female", "with", "CHC", "who", "had", "not", "responded", "to", "a", "previous", "treatment", "by", "interferon", "alpha", "."], "event_mentions": [{"id": "16432996_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "given", "start": 9, "end": 10}, "arguments": [{"entity_id": "16432996_5_Ent3", "role": "Treatment", "text": "combination therapy of interferon alpha and ribavirin", "start": 1, "end": 8}, {"entity_id": "16432996_5_Ent5", "role": "Treatment_Drug", "text": "interferon alpha", "start": 4, "end": 6}, {"entity_id": "16432996_5_Ent7", "role": "Combination_Drug", "text": "interferon alpha", "start": 4, "end": 6}, {"entity_id": "16432996_5_Ent6", "role": "Treatment_Drug", "text": "ribavirin", "start": 7, "end": 8}, {"entity_id": "16432996_5_Ent8", "role": "Combination_Drug", "text": "ribavirin", "start": 7, "end": 8}, {"entity_id": "16432996_5_Ent0", "role": "Subject", "text": "a 50 - year - old female with CHC who had not responded to a previous treatment by interferon alpha", "start": 11, "end": 31}, {"entity_id": "16432996_5_Ent1", "role": "Subject_Age", "text": "50 - year - old", "start": 12, "end": 17}, {"entity_id": "16432996_5_Ent2", "role": "Subject_Gender", "text": "female", "start": 17, "end": 18}, {"entity_id": "16432996_5_Ent4", "role": "Treatment_Disorder", "text": "CHC", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "16432996_5_Ent3", "text": "combination therapy of interferon alpha and ribavirin", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "16432996_5_Ent5", "text": "interferon alpha", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16432996_5_Ent7", "text": "interferon alpha", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16432996_5_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16432996_5_Ent8", "text": "ribavirin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16432996_5_Ent0", "text": "a 50 - year - old female with CHC who had not responded to a previous treatment by interferon alpha", "entity_type": "Entity", "start": 11, "end": 31}, {"id": "16432996_5_Ent1", "text": "50 - year - old", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "16432996_5_Ent2", "text": "female", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16432996_5_Ent4", "text": "CHC", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "16446228_1", "wnd_id": "16446228_1_1", "text": "Here , we present a case of sirolimus - associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids .", "tokens": ["Here", ",", "we", "present", "a", "case", "of", "sirolimus", "-", "associated", "interstitial", "pneumonitis", "in", "a", "cardiac", "transplant", "recipient", "that", "resolved", "completely", "with", "withdrawal", "of", "the", "drug", "and", "treatment", "with", "corticosteroids", "."], "event_mentions": [{"id": "16446228_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "16446228_1_Ent4", "role": "Treatment", "text": "sirolimus", "start": 7, "end": 8}, {"entity_id": "16446228_1_Ent5", "role": "Treatment_Drug", "text": "sirolimus", "start": 7, "end": 8}, {"entity_id": "16446228_1_Ent6", "role": "Treatment_Disorder", "text": "sirolimus - associated interstitial pneumonitis", "start": 7, "end": 12}, {"entity_id": "16446228_1_Ent3", "role": "Effect", "text": "interstitial pneumonitis", "start": 10, "end": 12}]}, {"id": "16446228_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 18, "end": 19}, "arguments": [{"entity_id": "16446228_1_Ent0", "role": "Subject", "text": "a case of sirolimus - associated interstitial pneumonitis in a cardiac transplant recipient", "start": 4, "end": 17}, {"entity_id": "16446228_1_Ent1", "role": "Treatment", "text": "withdrawal of the drug and treatment with corticosteroids", "start": 21, "end": 29}, {"entity_id": "16446228_1_Ent2", "role": "Treatment_Drug", "text": "corticosteroids", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "16446228_1_Ent0", "text": "a case of sirolimus - associated interstitial pneumonitis in a cardiac transplant recipient", "entity_type": "Entity", "start": 4, "end": 17}, {"id": "16446228_1_Ent4", "text": "sirolimus", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16446228_1_Ent5", "text": "sirolimus", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16446228_1_Ent6", "text": "sirolimus - associated interstitial pneumonitis", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "16446228_1_Ent3", "text": "interstitial pneumonitis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16446228_1_Ent1", "text": "withdrawal of the drug and treatment with corticosteroids", "entity_type": "Entity", "start": 21, "end": 29}, {"id": "16446228_1_Ent2", "text": "corticosteroids", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "16459502_1", "wnd_id": "16459502_1_1", "text": "Cutaneous mycobacterial infection post intravesical BCG installation .", "tokens": ["Cutaneous", "mycobacterial", "infection", "post", "intravesical", "BCG", "installation", "."], "event_mentions": [{"id": "16459502_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "post", "start": 3, "end": 4}, "arguments": [{"entity_id": "16459502_1_Ent0", "role": "Effect", "text": "Cutaneous mycobacterial infection", "start": 0, "end": 3}, {"entity_id": "16459502_1_Ent2", "role": "Treatment_Route", "text": "intravesical", "start": 4, "end": 5}, {"entity_id": "16459502_1_Ent1", "role": "Treatment", "text": "intravesical BCG installation", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "16459502_1_Ent0", "text": "Cutaneous mycobacterial infection", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16459502_1_Ent2", "text": "intravesical", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16459502_1_Ent1", "text": "intravesical BCG installation", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "16498048_4", "wnd_id": "16498048_4_1", "text": "Interferon - alpha - induced hyperthyroidism : a three - stage evolution from silent thyroiditis towards Graves ' disease .", "tokens": ["Interferon", "-", "alpha", "-", "induced", "hyperthyroidism", ":", "a", "three", "-", "stage", "evolution", "from", "silent", "thyroiditis", "towards", "Graves", "'", "disease", "."], "event_mentions": [{"id": "16498048_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "16498048_4_Ent2", "role": "Treatment", "text": "Interferon - alpha", "start": 0, "end": 3}, {"entity_id": "16498048_4_Ent3", "role": "Treatment_Drug", "text": "Interferon - alpha", "start": 0, "end": 3}, {"entity_id": "16498048_4_Ent0", "role": "Effect", "text": "hyperthyroidism", "start": 5, "end": 6}, {"entity_id": "16498048_4_Ent1", "role": "Effect", "text": "Graves ' disease", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "16498048_4_Ent2", "text": "Interferon - alpha", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16498048_4_Ent3", "text": "Interferon - alpha", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16498048_4_Ent0", "text": "hyperthyroidism", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16498048_4_Ent1", "text": "Graves ' disease", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "16507211_1", "wnd_id": "16507211_1_1", "text": "Herein , we describe 2 patients who developed unusual CD8 + cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab .", "tokens": ["Herein", ",", "we", "describe", "2", "patients", "who", "developed", "unusual", "CD8", "+", "cutaneous", "lymphoproliferative", "disorders", "after", "treatment", "with", "efalizumab", "and", "infliximab", "."], "event_mentions": [{"id": "16507211_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "16507211_1_Ent1", "role": "Subject_Population", "text": "2", "start": 4, "end": 5}, {"entity_id": "16507211_1_Ent0", "role": "Subject", "text": "2 patients", "start": 4, "end": 6}, {"entity_id": "16507211_1_Ent2", "role": "Effect", "text": "CD8 + cutaneous lymphoproliferative", "start": 9, "end": 13}, {"entity_id": "16507211_1_Ent4", "role": "Treatment_Drug", "text": "efalizumab", "start": 17, "end": 18}, {"entity_id": "16507211_1_Ent6", "role": "Combination_Drug", "text": "efalizumab", "start": 17, "end": 18}, {"entity_id": "16507211_1_Ent3", "role": "Treatment", "text": "efalizumab and infliximab", "start": 17, "end": 20}, {"entity_id": "16507211_1_Ent5", "role": "Treatment_Drug", "text": "infliximab", "start": 19, "end": 20}, {"entity_id": "16507211_1_Ent7", "role": "Combination_Drug", "text": "infliximab", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "16507211_1_Ent1", "text": "2", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16507211_1_Ent0", "text": "2 patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16507211_1_Ent2", "text": "CD8 + cutaneous lymphoproliferative", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "16507211_1_Ent4", "text": "efalizumab", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16507211_1_Ent6", "text": "efalizumab", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16507211_1_Ent3", "text": "efalizumab and infliximab", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "16507211_1_Ent5", "text": "infliximab", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16507211_1_Ent7", "text": "infliximab", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "16521231_3", "wnd_id": "16521231_3_1", "text": "Subfulminant hepatitis B after infliximab in Crohn 's disease : need for HBV - screening ?", "tokens": ["Subfulminant", "hepatitis", "B", "after", "infliximab", "in", "Crohn", "'s", "disease", ":", "need", "for", "HBV", "-", "screening", "?"], "event_mentions": [{"id": "16521231_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "16521231_3_Ent0", "role": "Effect", "text": "Subfulminant hepatitis B", "start": 0, "end": 3}, {"entity_id": "16521231_3_Ent1", "role": "Treatment", "text": "infliximab", "start": 4, "end": 5}, {"entity_id": "16521231_3_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 4, "end": 5}, {"entity_id": "16521231_3_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "16521231_3_Ent0", "text": "Subfulminant hepatitis B", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16521231_3_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16521231_3_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16521231_3_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "16540070_1", "wnd_id": "16540070_1_1", "text": "A 55 - year - old woman presented an episode of acute urticaria and labial angioedema 60 minutes after ingesting 500 mg of cloxacillin for a skin abscess .", "tokens": ["A", "55", "-", "year", "-", "old", "woman", "presented", "an", "episode", "of", "acute", "urticaria", "and", "labial", "angioedema", "60", "minutes", "after", "ingesting", "500", "mg", "of", "cloxacillin", "for", "a", "skin", "abscess", "."], "event_mentions": [{"id": "16540070_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 7, "end": 8}, "arguments": [{"entity_id": "16540070_1_Ent0", "role": "Subject", "text": "A 55 - year - old woman", "start": 0, "end": 7}, {"entity_id": "16540070_1_Ent2", "role": "Subject_Age", "text": "55 - year - old", "start": 1, "end": 6}, {"entity_id": "16540070_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "16540070_1_Ent4", "role": "Effect", "text": "acute urticaria and labial angioedema", "start": 11, "end": 16}, {"entity_id": "16540070_1_Ent6", "role": "Treatment_Time_elapsed", "text": "60 minutes", "start": 16, "end": 18}, {"entity_id": "16540070_1_Ent7", "role": "Treatment_Route", "text": "ingesting", "start": 19, "end": 20}, {"entity_id": "16540070_1_Ent5", "role": "Treatment", "text": "ingesting 500 mg of cloxacillin", "start": 19, "end": 24}, {"entity_id": "16540070_1_Ent8", "role": "Treatment_Dosage", "text": "500 mg", "start": 20, "end": 22}, {"entity_id": "16540070_1_Ent9", "role": "Treatment_Drug", "text": "cloxacillin", "start": 23, "end": 24}, {"entity_id": "16540070_1_Ent1", "role": "Subject", "text": "a skin abscess", "start": 25, "end": 28}, {"entity_id": "16540070_1_Ent10", "role": "Treatment_Disorder", "text": "skin abscess", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "16540070_1_Ent0", "text": "A 55 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "16540070_1_Ent2", "text": "55 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16540070_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16540070_1_Ent4", "text": "acute urticaria and labial angioedema", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "16540070_1_Ent6", "text": "60 minutes", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "16540070_1_Ent7", "text": "ingesting", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16540070_1_Ent5", "text": "ingesting 500 mg of cloxacillin", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "16540070_1_Ent8", "text": "500 mg", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "16540070_1_Ent9", "text": "cloxacillin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16540070_1_Ent1", "text": "a skin abscess", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "16540070_1_Ent10", "text": "skin abscess", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "16540070_3", "wnd_id": "16540070_3_1", "text": "Several hypersensitivity reactions to cloxacillin have been reported , although IgE - mediated allergic reactions to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with cloxacillin allergy .", "tokens": ["Several", "hypersensitivity", "reactions", "to", "cloxacillin", "have", "been", "reported", ",", "although", "IgE", "-", "mediated", "allergic", "reactions", "to", "the", "drug", "are", "rare", "and", "there", "is", "little", "information", "about", "possible", "tolerance", "to", "other", "semisynthetic", "penicillins", "or", "cephalosporins", "in", "patients", "with", "cloxacillin", "allergy", "."], "event_mentions": [{"id": "16540070_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reactions to", "start": 2, "end": 4}, "arguments": [{"entity_id": "16540070_3_Ent0", "role": "Effect", "text": "hypersensitivity", "start": 1, "end": 2}, {"entity_id": "16540070_3_Ent1", "role": "Treatment", "text": "cloxacillin", "start": 4, "end": 5}, {"entity_id": "16540070_3_Ent2", "role": "Treatment_Drug", "text": "cloxacillin", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "16540070_3_Ent0", "text": "hypersensitivity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16540070_3_Ent1", "text": "cloxacillin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16540070_3_Ent2", "text": "cloxacillin", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "1655228_3", "wnd_id": "1655228_3_1", "text": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion .", "tokens": ["Three", "patients", "are", "reported", "without", "a", "history", "of", "angina", "pectoris", "who", "had", "clinical", "and", "electrocardiographic", "evidence", "of", "myocardial", "ischemia", "during", "and", "immediately", "after", "BCNU", "infusion", "."], "event_mentions": [{"id": "1655228_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 11, "end": 12}, "arguments": [{"entity_id": "1655228_3_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "1655228_3_Ent0", "role": "Subject", "text": "Three patients are reported without a history of angina pectoris", "start": 0, "end": 10}, {"entity_id": "1655228_3_Ent2", "role": "Effect", "text": "myocardial ischemia", "start": 17, "end": 19}, {"entity_id": "1655228_3_Ent3", "role": "Treatment", "text": "during and immediately after BCNU infusion", "start": 19, "end": 25}, {"entity_id": "1655228_3_Ent5", "role": "Treatment_Time_elapsed", "text": "immediately after", "start": 21, "end": 23}, {"entity_id": "1655228_3_Ent4", "role": "Treatment_Drug", "text": "BCNU", "start": 23, "end": 24}, {"entity_id": "1655228_3_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "1655228_3_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1655228_3_Ent0", "text": "Three patients are reported without a history of angina pectoris", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "1655228_3_Ent2", "text": "myocardial ischemia", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "1655228_3_Ent3", "text": "during and immediately after BCNU infusion", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "1655228_3_Ent5", "text": "immediately after", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "1655228_3_Ent4", "text": "BCNU", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "1655228_3_Ent6", "text": "infusion", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "16580907_5", "wnd_id": "16580907_5_1", "text": "The plasma concentrations of both drugs were significantly increased during the coadministration , and the cetirizine concentration decreased on cessation of pilsicainide despite the fact that treatment with cetirizine was continued , which suggested that the fainting was induced by the pharmacokinetic drug interaction .", "tokens": ["The", "plasma", "concentrations", "of", "both", "drugs", "were", "significantly", "increased", "during", "the", "coadministration", ",", "and", "the", "cetirizine", "concentration", "decreased", "on", "cessation", "of", "pilsicainide", "despite", "the", "fact", "that", "treatment", "with", "cetirizine", "was", "continued", ",", "which", "suggested", "that", "the", "fainting", "was", "induced", "by", "the", "pharmacokinetic", "drug", "interaction", "."], "event_mentions": [{"id": "16580907_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 38, "end": 39}, "arguments": [{"entity_id": "16580907_5_Ent1", "role": "Treatment", "text": "pilsicainide", "start": 21, "end": 22}, {"entity_id": "16580907_5_Ent3", "role": "Treatment_Drug", "text": "pilsicainide", "start": 21, "end": 22}, {"entity_id": "16580907_5_Ent5", "role": "Combination_Drug", "text": "pilsicainide", "start": 21, "end": 22}, {"entity_id": "16580907_5_Ent2", "role": "Treatment", "text": "cetirizine", "start": 28, "end": 29}, {"entity_id": "16580907_5_Ent4", "role": "Treatment_Drug", "text": "cetirizine", "start": 28, "end": 29}, {"entity_id": "16580907_5_Ent6", "role": "Combination_Drug", "text": "cetirizine", "start": 28, "end": 29}, {"entity_id": "16580907_5_Ent0", "role": "Effect", "text": "fainting", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "16580907_5_Ent1", "text": "pilsicainide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16580907_5_Ent3", "text": "pilsicainide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16580907_5_Ent5", "text": "pilsicainide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16580907_5_Ent2", "text": "cetirizine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "16580907_5_Ent4", "text": "cetirizine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "16580907_5_Ent6", "text": "cetirizine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "16580907_5_Ent0", "text": "fainting", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "16609346_2", "wnd_id": "16609346_2_1", "text": "Statin - associated myasthenia gravis : report of 4 cases and review of the literature .", "tokens": ["Statin", "-", "associated", "myasthenia", "gravis", ":", "report", "of", "4", "cases", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "16609346_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "16609346_2_Ent3", "role": "Treatment", "text": "Statin", "start": 0, "end": 1}, {"entity_id": "16609346_2_Ent4", "role": "Treatment_Drug", "text": "Statin", "start": 0, "end": 1}, {"entity_id": "16609346_2_Ent2", "role": "Effect", "text": "myasthenia gravis", "start": 3, "end": 5}, {"entity_id": "16609346_2_Ent1", "role": "Subject_Population", "text": "4", "start": 8, "end": 9}, {"entity_id": "16609346_2_Ent0", "role": "Subject", "text": "4 cases", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "16609346_2_Ent3", "text": "Statin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16609346_2_Ent4", "text": "Statin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16609346_2_Ent2", "text": "myasthenia gravis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16609346_2_Ent1", "text": "4", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16609346_2_Ent0", "text": "4 cases", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "16609346_3", "wnd_id": "16609346_3_1", "text": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug .", "tokens": ["We", "report", "4", "patients", "who", "developed", "symptoms", "of", "myasthenia", "gravis", "within", "2", "weeks", "of", "starting", "treatment", "with", "a", "statin", "drug", "."], "event_mentions": [{"id": "16609346_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "16609346_3_Ent1", "role": "Subject_Population", "text": "4", "start": 2, "end": 3}, {"entity_id": "16609346_3_Ent0", "role": "Subject", "text": "4 patients", "start": 2, "end": 4}, {"entity_id": "16609346_3_Ent2", "role": "Effect", "text": "symptoms of myasthenia gravis", "start": 6, "end": 10}, {"entity_id": "16609346_3_Ent3", "role": "Treatment", "text": "within 2 weeks of starting treatment with a statin", "start": 10, "end": 19}, {"entity_id": "16609346_3_Ent5", "role": "Treatment_Time_elapsed", "text": "2 weeks", "start": 11, "end": 13}, {"entity_id": "16609346_3_Ent4", "role": "Treatment_Drug", "text": "statin", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "16609346_3_Ent1", "text": "4", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16609346_3_Ent0", "text": "4 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16609346_3_Ent2", "text": "symptoms of myasthenia gravis", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "16609346_3_Ent3", "text": "within 2 weeks of starting treatment with a statin", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "16609346_3_Ent5", "text": "2 weeks", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "16609346_3_Ent4", "text": "statin", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "16620273_1", "wnd_id": "16620273_1_1", "text": "CONCLUSIONS : The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis .", "tokens": ["CONCLUSIONS", ":", "The", "increasing", "prevalence", "of", "Type", "2", "diabetes", "and", "its", "treatment", "with", "metformin", "might", "result", "in", "more", "cases", "of", "lactic", "acidosis", "."], "event_mentions": [{"id": "16620273_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 15, "end": 16}, "arguments": [{"entity_id": "16620273_1_Ent3", "role": "Treatment_Disorder", "text": "Type 2 diabetes", "start": 6, "end": 9}, {"entity_id": "16620273_1_Ent1", "role": "Treatment", "text": "metformin", "start": 13, "end": 14}, {"entity_id": "16620273_1_Ent2", "role": "Treatment_Drug", "text": "metformin", "start": 13, "end": 14}, {"entity_id": "16620273_1_Ent0", "role": "Effect", "text": "lactic acidosis", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "16620273_1_Ent3", "text": "Type 2 diabetes", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "16620273_1_Ent1", "text": "metformin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16620273_1_Ent2", "text": "metformin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16620273_1_Ent0", "text": "lactic acidosis", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "16620273_2", "wnd_id": "16620273_2_1", "text": "Severe acidosis in patients taking metformin -- rapid reversal and survival despite high APACHE score .", "tokens": ["Severe", "acidosis", "in", "patients", "taking", "metformin", "--", "rapid", "reversal", "and", "survival", "despite", "high", "APACHE", "score", "."], "event_mentions": [{"id": "16620273_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 4, "end": 5}, "arguments": [{"entity_id": "16620273_2_Ent1", "role": "Effect", "text": "Severe acidosis", "start": 0, "end": 2}, {"entity_id": "16620273_2_Ent0", "role": "Subject", "text": "patients", "start": 3, "end": 4}, {"entity_id": "16620273_2_Ent2", "role": "Treatment", "text": "metformin", "start": 5, "end": 6}, {"entity_id": "16620273_2_Ent3", "role": "Treatment_Drug", "text": "metformin", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "16620273_2_Ent1", "text": "Severe acidosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16620273_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16620273_2_Ent2", "text": "metformin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16620273_2_Ent3", "text": "metformin", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "16623611_3", "wnd_id": "16623611_3_1", "text": "The patient was enrolled in a weight - loss clinic , and his diabetes medications were adjusted . Subsequently , olanzapine was discontinued because of weight gain and uncontrolled diabetes .", "tokens": ["The", "patient", "was", "enrolled", "in", "a", "weight", "-", "loss", "clinic", ",", "and", "his", "diabetes", "medications", "were", "adjusted", ".", "Subsequently", ",", "olanzapine", "was", "discontinued", "because", "of", "weight", "gain", "and", "uncontrolled", "diabetes", "."], "event_mentions": [{"id": "16623611_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "because", "start": 23, "end": 24}, "arguments": [{"entity_id": "16623611_3_Ent0", "role": "Subject", "text": "patient", "start": 1, "end": 2}, {"entity_id": "16623611_3_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 20, "end": 21}, {"entity_id": "16623611_3_Ent2", "role": "Treatment", "text": "olanzapine was discontinued", "start": 20, "end": 23}, {"entity_id": "16623611_3_Ent1", "role": "Effect", "text": "weight gain and uncontrolled diabetes", "start": 25, "end": 30}]}], "entity_mentions": [{"id": "16623611_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16623611_3_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16623611_3_Ent2", "text": "olanzapine was discontinued", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "16623611_3_Ent1", "text": "weight gain and uncontrolled diabetes", "entity_type": "Entity", "start": 25, "end": 30}], "lang": "en"}
{"doc_id": "16632429_1", "wnd_id": "16632429_1_1", "text": "We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency , and simulating a progression of the tumor .", "tokens": ["We", "report", "the", "case", "of", "a", "lung", "cancer", "patient", "with", "bronquiloalveolar", "carcinoma", "(", "BAC", ")", "presenting", "with", "BOOP", "after", "chemotherapy", "with", "docetaxel", "and", "gemcitabine", "producing", "severe", "respiratory", "insufficiency", ",", "and", "simulating", "a", "progression", "of", "the", "tumor", "."], "event_mentions": [{"id": "16632429_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 18, "end": 19}, "arguments": [{"entity_id": "16632429_1_Ent4", "role": "Treatment_Disorder", "text": "lung cancer", "start": 6, "end": 8}, {"entity_id": "16632429_1_Ent0", "role": "Subject", "text": "lung cancer patient with bronquiloalveolar carcinoma ( BAC )", "start": 6, "end": 15}, {"entity_id": "16632429_1_Ent5", "role": "Treatment_Disorder", "text": "bronquiloalveolar carcinoma ( BAC )", "start": 10, "end": 15}, {"entity_id": "16632429_1_Ent2", "role": "Effect", "text": "BOOP", "start": 17, "end": 18}, {"entity_id": "16632429_1_Ent8", "role": "Treatment_Route", "text": "chemotherapy", "start": 19, "end": 20}, {"entity_id": "16632429_1_Ent3", "role": "Treatment", "text": "chemotherapy with docetaxel and gemcitabine", "start": 19, "end": 24}, {"entity_id": "16632429_1_Ent6", "role": "Treatment_Drug", "text": "docetaxel", "start": 21, "end": 22}, {"entity_id": "16632429_1_Ent9", "role": "Combination_Drug", "text": "docetaxel", "start": 21, "end": 22}, {"entity_id": "16632429_1_Ent7", "role": "Treatment_Drug", "text": "gemcitabine", "start": 23, "end": 24}, {"entity_id": "16632429_1_Ent10", "role": "Combination_Drug", "text": "gemcitabine", "start": 23, "end": 24}, {"entity_id": "16632429_1_Ent1", "role": "Effect", "text": "producing severe respiratory insufficiency , and simulating a progression of the tumor", "start": 24, "end": 36}]}], "entity_mentions": [{"id": "16632429_1_Ent4", "text": "lung cancer", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16632429_1_Ent0", "text": "lung cancer patient with bronquiloalveolar carcinoma ( BAC )", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "16632429_1_Ent5", "text": "bronquiloalveolar carcinoma ( BAC )", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "16632429_1_Ent2", "text": "BOOP", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16632429_1_Ent8", "text": "chemotherapy", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16632429_1_Ent3", "text": "chemotherapy with docetaxel and gemcitabine", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "16632429_1_Ent6", "text": "docetaxel", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16632429_1_Ent9", "text": "docetaxel", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16632429_1_Ent7", "text": "gemcitabine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16632429_1_Ent10", "text": "gemcitabine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16632429_1_Ent1", "text": "producing severe respiratory insufficiency , and simulating a progression of the tumor", "entity_type": "Entity", "start": 24, "end": 36}], "lang": "en"}
{"doc_id": "16637972_1", "wnd_id": "16637972_1_1", "text": "A 65 - year - old man on warfarin therapy with a sudden spontaneous onset of sub - conjunctival haematoma associated with bloody tears was assessed in the clinic following a referral from an optometrist .", "tokens": ["A", "65", "-", "year", "-", "old", "man", "on", "warfarin", "therapy", "with", "a", "sudden", "spontaneous", "onset", "of", "sub", "-", "conjunctival", "haematoma", "associated", "with", "bloody", "tears", "was", "assessed", "in", "the", "clinic", "following", "a", "referral", "from", "an", "optometrist", "."], "event_mentions": [{"id": "16637972_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "16637972_1_Ent0", "role": "Subject", "text": "A 65 - year - old man", "start": 0, "end": 7}, {"entity_id": "16637972_1_Ent1", "role": "Subject_Age", "text": "65 - year - old", "start": 1, "end": 6}, {"entity_id": "16637972_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "16637972_1_Ent5", "role": "Treatment_Drug", "text": "warfarin", "start": 8, "end": 9}, {"entity_id": "16637972_1_Ent4", "role": "Treatment", "text": "warfarin therapy", "start": 8, "end": 10}, {"entity_id": "16637972_1_Ent3", "role": "Effect", "text": "a sudden spontaneous onset of sub - conjunctival haematoma associated with bloody tears", "start": 11, "end": 24}]}], "entity_mentions": [{"id": "16637972_1_Ent0", "text": "A 65 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "16637972_1_Ent1", "text": "65 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16637972_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16637972_1_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16637972_1_Ent4", "text": "warfarin therapy", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16637972_1_Ent3", "text": "a sudden spontaneous onset of sub - conjunctival haematoma associated with bloody tears", "entity_type": "Entity", "start": 11, "end": 24}], "lang": "en"}
{"doc_id": "16641839_1", "wnd_id": "16641839_1_1", "text": "Angioedema and maculopapular eruptions associated with carbamazepine administration .", "tokens": ["Angioedema", "and", "maculopapular", "eruptions", "associated", "with", "carbamazepine", "administration", "."], "event_mentions": [{"id": "16641839_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "16641839_1_Ent0", "role": "Effect", "text": "Angioedema and maculopapular eruptions", "start": 0, "end": 4}, {"entity_id": "16641839_1_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 6, "end": 7}, {"entity_id": "16641839_1_Ent1", "role": "Treatment", "text": "carbamazepine administration .", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "16641839_1_Ent0", "text": "Angioedema and maculopapular eruptions", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16641839_1_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16641839_1_Ent1", "text": "carbamazepine administration .", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "16641839_3", "wnd_id": "16641839_3_1", "text": "Cutaneous eruptions occur in 3 % of individuals administered carbamazepine .", "tokens": ["Cutaneous", "eruptions", "occur", "in", "3", "%", "of", "individuals", "administered", "carbamazepine", "."], "event_mentions": [{"id": "16641839_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 2, "end": 3}, "arguments": [{"entity_id": "16641839_3_Ent0", "role": "Effect", "text": "Cutaneous eruptions", "start": 0, "end": 2}, {"entity_id": "16641839_3_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 9, "end": 10}, {"entity_id": "16641839_3_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16641839_3_Ent0", "text": "Cutaneous eruptions", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16641839_3_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16641839_3_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "16641839_5", "wnd_id": "16641839_5_1", "text": "We report the case of a 27 - year - old Indian woman who developed maculopapular rash and angioedema secondary to carbamazepine administration .", "tokens": ["We", "report", "the", "case", "of", "a", "27", "-", "year", "-", "old", "Indian", "woman", "who", "developed", "maculopapular", "rash", "and", "angioedema", "secondary", "to", "carbamazepine", "administration", "."], "event_mentions": [{"id": "16641839_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "16641839_5_Ent0", "role": "Subject", "text": "a 27 - year - old Indian woman", "start": 5, "end": 13}, {"entity_id": "16641839_5_Ent1", "role": "Subject_Age", "text": "27 - year - old", "start": 6, "end": 11}, {"entity_id": "16641839_5_Ent2", "role": "Subject_Race", "text": "Indian", "start": 11, "end": 12}, {"entity_id": "16641839_5_Ent3", "role": "Subject_Gender", "text": "woman", "start": 12, "end": 13}, {"entity_id": "16641839_5_Ent4", "role": "Effect", "text": "maculopapular rash and angioedema", "start": 15, "end": 19}, {"entity_id": "16641839_5_Ent6", "role": "Treatment_Drug", "text": "carbamazepine", "start": 21, "end": 22}, {"entity_id": "16641839_5_Ent5", "role": "Treatment", "text": "carbamazepine administration", "start": 21, "end": 23}, {"entity_id": "16641839_5_Ent7", "role": "Treatment_Route", "text": "administration", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "16641839_5_Ent0", "text": "a 27 - year - old Indian woman", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "16641839_5_Ent1", "text": "27 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16641839_5_Ent2", "text": "Indian", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16641839_5_Ent3", "text": "woman", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16641839_5_Ent4", "text": "maculopapular rash and angioedema", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "16641839_5_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16641839_5_Ent5", "text": "carbamazepine administration", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "16641839_5_Ent7", "text": "administration", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "16678268_1", "wnd_id": "16678268_1_1", "text": "Severe adenovirus pneumonia ( AVP ) following infliximab infusion for the treatment of Crohn 's disease .", "tokens": ["Severe", "adenovirus", "pneumonia", "(", "AVP", ")", "following", "infliximab", "infusion", "for", "the", "treatment", "of", "Crohn", "'s", "disease", "."], "event_mentions": [{"id": "16678268_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "16678268_1_Ent0", "role": "Effect", "text": "adenovirus pneumonia", "start": 1, "end": 3}, {"entity_id": "16678268_1_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "16678268_1_Ent1", "role": "Treatment", "text": "infliximab infusion", "start": 7, "end": 9}, {"entity_id": "16678268_1_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 8, "end": 9}, {"entity_id": "16678268_1_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "16678268_1_Ent0", "text": "adenovirus pneumonia", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "16678268_1_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16678268_1_Ent1", "text": "infliximab infusion", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16678268_1_Ent3", "text": "infusion", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16678268_1_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "16697705_1", "wnd_id": "16697705_1_1", "text": "Acute coronary syndrome induced by capecitabine therapy .", "tokens": ["Acute", "coronary", "syndrome", "induced", "by", "capecitabine", "therapy", "."], "event_mentions": [{"id": "16697705_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "16697705_1_Ent0", "role": "Effect", "text": "Acute coronary syndrome", "start": 0, "end": 3}, {"entity_id": "16697705_1_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 5, "end": 6}, {"entity_id": "16697705_1_Ent1", "role": "Treatment", "text": "capecitabine therapy", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "16697705_1_Ent0", "text": "Acute coronary syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16697705_1_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16697705_1_Ent1", "text": "capecitabine therapy", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "16728538_2", "wnd_id": "16728538_2_1", "text": "Drug - induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long - acting repeatable attributed to the use of pegvisomant .", "tokens": ["Drug", "-", "induced", "hepatitis", "in", "an", "acromegalic", "patient", "during", "combined", "treatment", "with", "pegvisomant", "and", "octreotide", "long", "-", "acting", "repeatable", "attributed", "to", "the", "use", "of", "pegvisomant", "."], "event_mentions": [{"id": "16728538_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16728538_2_Ent1", "role": "Effect", "text": "hepatitis", "start": 3, "end": 4}, {"entity_id": "16728538_2_Ent0", "role": "Subject", "text": "an acromegalic patient", "start": 5, "end": 8}, {"entity_id": "16728538_2_Ent3", "role": "Treatment_Disorder", "text": "acromegalic", "start": 6, "end": 7}, {"entity_id": "16728538_2_Ent2", "role": "Treatment", "text": "combined treatment with pegvisomant and octreotide long - acting repeatable", "start": 9, "end": 19}, {"entity_id": "16728538_2_Ent4", "role": "Treatment_Drug", "text": "pegvisomant", "start": 12, "end": 13}, {"entity_id": "16728538_2_Ent6", "role": "Combination_Drug", "text": "pegvisomant", "start": 12, "end": 13}, {"entity_id": "16728538_2_Ent5", "role": "Treatment_Drug", "text": "octreotide", "start": 14, "end": 15}, {"entity_id": "16728538_2_Ent7", "role": "Combination_Drug", "text": "octreotide", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "16728538_2_Ent1", "text": "hepatitis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16728538_2_Ent0", "text": "an acromegalic patient", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16728538_2_Ent3", "text": "acromegalic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16728538_2_Ent2", "text": "combined treatment with pegvisomant and octreotide long - acting repeatable", "entity_type": "Entity", "start": 9, "end": 19}, {"id": "16728538_2_Ent4", "text": "pegvisomant", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16728538_2_Ent6", "text": "pegvisomant", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16728538_2_Ent5", "text": "octreotide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16728538_2_Ent7", "text": "octreotide", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16843118_1", "wnd_id": "16843118_1_1", "text": "Acute generalized exanthematous pustulosis caused by morphine , confirmed by positive patch test and lymphocyte transformation test .", "tokens": ["Acute", "generalized", "exanthematous", "pustulosis", "caused", "by", "morphine", ",", "confirmed", "by", "positive", "patch", "test", "and", "lymphocyte", "transformation", "test", "."], "event_mentions": [{"id": "16843118_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 4, "end": 5}, "arguments": [{"entity_id": "16843118_1_Ent0", "role": "Effect", "text": "Acute generalized exanthematous pustulosis", "start": 0, "end": 4}, {"entity_id": "16843118_1_Ent1", "role": "Treatment", "text": "morphine", "start": 6, "end": 7}, {"entity_id": "16843118_1_Ent2", "role": "Treatment_Drug", "text": "morphine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "16843118_1_Ent0", "text": "Acute generalized exanthematous pustulosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16843118_1_Ent1", "text": "morphine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16843118_1_Ent2", "text": "morphine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "16882112_1", "wnd_id": "16882112_1_1", "text": "Lithium and venlafaxine interaction : a case of serotonin syndrome .", "tokens": ["Lithium", "and", "venlafaxine", "interaction", ":", "a", "case", "of", "serotonin", "syndrome", "."], "event_mentions": [{"id": "16882112_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "case", "start": 6, "end": 7}, "arguments": [{"entity_id": "16882112_1_Ent2", "role": "Treatment_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "16882112_1_Ent4", "role": "Combination_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "16882112_1_Ent1", "role": "Treatment", "text": "Lithium and venlafaxine interaction", "start": 0, "end": 4}, {"entity_id": "16882112_1_Ent3", "role": "Treatment_Drug", "text": "venlafaxine", "start": 2, "end": 3}, {"entity_id": "16882112_1_Ent5", "role": "Combination_Drug", "text": "venlafaxine", "start": 2, "end": 3}, {"entity_id": "16882112_1_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "16882112_1_Ent2", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16882112_1_Ent4", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16882112_1_Ent1", "text": "Lithium and venlafaxine interaction", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16882112_1_Ent3", "text": "venlafaxine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16882112_1_Ent5", "text": "venlafaxine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16882112_1_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "16923659_2", "wnd_id": "16923659_2_1", "text": "Serotonin syndrome ( SS ) and neuroleptic malignant syndrome ( NMS ) are medical emergencies associated with psychotropic administration .", "tokens": ["Serotonin", "syndrome", "(", "SS", ")", "and", "neuroleptic", "malignant", "syndrome", "(", "NMS", ")", "are", "medical", "emergencies", "associated", "with", "psychotropic", "administration", "."], "event_mentions": [{"id": "16923659_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "16923659_2_Ent0", "role": "Effect", "text": "Serotonin syndrome ( SS ) and neuroleptic malignant syndrome ( NMS )", "start": 0, "end": 12}, {"entity_id": "16923659_2_Ent2", "role": "Treatment_Drug", "text": "psychotropic", "start": 17, "end": 18}, {"entity_id": "16923659_2_Ent1", "role": "Treatment", "text": "psychotropic administration", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "16923659_2_Ent0", "text": "Serotonin syndrome ( SS ) and neuroleptic malignant syndrome ( NMS )", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "16923659_2_Ent2", "text": "psychotropic", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16923659_2_Ent1", "text": "psychotropic administration", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "16935446_1", "wnd_id": "16935446_1_1", "text": "Fever and maculopapular rashes appeared at 10 days after phenytoin initiation , and then the drug was discontinued .", "tokens": ["Fever", "and", "maculopapular", "rashes", "appeared", "at", "10", "days", "after", "phenytoin", "initiation", ",", "and", "then", "the", "drug", "was", "discontinued", "."], "event_mentions": [{"id": "16935446_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared", "start": 4, "end": 5}, "arguments": [{"entity_id": "16935446_1_Ent0", "role": "Effect", "text": "Fever and maculopapular rashes", "start": 0, "end": 4}, {"entity_id": "16935446_1_Ent2", "role": "Treatment_Time_elapsed", "text": "10 days", "start": 6, "end": 8}, {"entity_id": "16935446_1_Ent1", "role": "Treatment", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "16935446_1_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16935446_1_Ent0", "text": "Fever and maculopapular rashes", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16935446_1_Ent2", "text": "10 days", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16935446_1_Ent1", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16935446_1_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "16939867_1", "wnd_id": "16939867_1_1", "text": "Localized purpura associated with lamotrigine .", "tokens": ["Localized", "purpura", "associated", "with", "lamotrigine", "."], "event_mentions": [{"id": "16939867_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "16939867_1_Ent0", "role": "Effect", "text": "Localized purpura", "start": 0, "end": 2}, {"entity_id": "16939867_1_Ent1", "role": "Treatment", "text": "lamotrigine", "start": 4, "end": 5}, {"entity_id": "16939867_1_Ent2", "role": "Treatment_Drug", "text": "lamotrigine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "16939867_1_Ent0", "text": "Localized purpura", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16939867_1_Ent1", "text": "lamotrigine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16939867_1_Ent2", "text": "lamotrigine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "16948177_1", "wnd_id": "16948177_1_1", "text": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non - Hodgkin 's lymphoma .", "tokens": ["Bronchiolitis", "obliterans", "with", "organizing", "pneumonia", "after", "rituximab", "therapy", "for", "non", "-", "Hodgkin", "'s", "lymphoma", "."], "event_mentions": [{"id": "16948177_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "16948177_1_Ent0", "role": "Effect", "text": "Bronchiolitis obliterans with organizing pneumonia", "start": 0, "end": 5}, {"entity_id": "16948177_1_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 6, "end": 7}, {"entity_id": "16948177_1_Ent1", "role": "Treatment", "text": "rituximab therapy", "start": 6, "end": 8}, {"entity_id": "16948177_1_Ent3", "role": "Treatment_Disorder", "text": "non - Hodgkin 's lymphoma", "start": 9, "end": 14}]}], "entity_mentions": [{"id": "16948177_1_Ent0", "text": "Bronchiolitis obliterans with organizing pneumonia", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16948177_1_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16948177_1_Ent1", "text": "rituximab therapy", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16948177_1_Ent3", "text": "non - Hodgkin 's lymphoma", "entity_type": "Entity", "start": 9, "end": 14}], "lang": "en"}
{"doc_id": "16948177_2", "wnd_id": "16948177_2_1", "text": "Moreover , these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated .", "tokens": ["Moreover", ",", "these", "findings", "suggest", "that", "the", "incidence", "of", "BOOP", "following", "rituximab", "therapy", "may", "be", "higher", "than", "has", "been", "previously", "appreciated", "."], "event_mentions": [{"id": "16948177_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 10, "end": 11}, "arguments": [{"entity_id": "16948177_2_Ent0", "role": "Effect", "text": "BOOP", "start": 9, "end": 10}, {"entity_id": "16948177_2_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 11, "end": 12}, {"entity_id": "16948177_2_Ent1", "role": "Treatment", "text": "rituximab therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "16948177_2_Ent0", "text": "BOOP", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16948177_2_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16948177_2_Ent1", "text": "rituximab therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "16948177_3", "wnd_id": "16948177_3_1", "text": "This is the first reported case of BOOP associated with single - agent rituximab , and along with two other patients we describe , as well as two prior reports of BOOP in NHL patients receiving rituximab - based combinations , strengthens the possibility of a causal relationship .", "tokens": ["This", "is", "the", "first", "reported", "case", "of", "BOOP", "associated", "with", "single", "-", "agent", "rituximab", ",", "and", "along", "with", "two", "other", "patients", "we", "describe", ",", "as", "well", "as", "two", "prior", "reports", "of", "BOOP", "in", "NHL", "patients", "receiving", "rituximab", "-", "based", "combinations", ",", "strengthens", "the", "possibility", "of", "a", "causal", "relationship", "."], "event_mentions": [{"id": "16948177_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "16948177_3_Ent0", "role": "Effect", "text": "BOOP", "start": 7, "end": 8}, {"entity_id": "16948177_3_Ent1", "role": "Treatment", "text": "single - agent rituximab", "start": 10, "end": 14}, {"entity_id": "16948177_3_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "16948177_3_Ent0", "text": "BOOP", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16948177_3_Ent1", "text": "single - agent rituximab", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "16948177_3_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "16960880_3", "wnd_id": "16960880_3_1", "text": "Native arterial thrombosis , though recognized as a severe complication of thrombin injection , has not been well described in the literature .", "tokens": ["Native", "arterial", "thrombosis", ",", "though", "recognized", "as", "a", "severe", "complication", "of", "thrombin", "injection", ",", "has", "not", "been", "well", "described", "in", "the", "literature", "."], "event_mentions": [{"id": "16960880_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 9, "end": 10}, "arguments": [{"entity_id": "16960880_3_Ent0", "role": "Effect", "text": "Native arterial thrombosis", "start": 0, "end": 3}, {"entity_id": "16960880_3_Ent2", "role": "Treatment_Drug", "text": "thrombin", "start": 11, "end": 12}, {"entity_id": "16960880_3_Ent1", "role": "Treatment", "text": "thrombin injection", "start": 11, "end": 13}, {"entity_id": "16960880_3_Ent3", "role": "Treatment_Route", "text": "injection", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16960880_3_Ent0", "text": "Native arterial thrombosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16960880_3_Ent2", "text": "thrombin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16960880_3_Ent1", "text": "thrombin injection", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "16960880_3_Ent3", "text": "injection", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16968538_2", "wnd_id": "16968538_2_1", "text": "BACKGROUND : Oxaliplatin is a platinum derivative , which is used in the treatment of colorectal cancer .", "tokens": ["BACKGROUND", ":", "Oxaliplatin", "is", "a", "platinum", "derivative", ",", "which", "is", "used", "in", "the", "treatment", "of", "colorectal", "cancer", "."], "event_mentions": [{"id": "16968538_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 13, "end": 14}, "arguments": [{"entity_id": "16968538_2_Ent1", "role": "Treatment_Drug", "text": "Oxaliplatin", "start": 2, "end": 3}, {"entity_id": "16968538_2_Ent0", "role": "Treatment", "text": "Oxaliplatin is a platinum derivative", "start": 2, "end": 7}, {"entity_id": "16968538_2_Ent2", "role": "Treatment_Drug", "text": "platinum derivative", "start": 5, "end": 7}, {"entity_id": "16968538_2_Ent3", "role": "Treatment_Disorder", "text": "colorectal cancer", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "16968538_2_Ent1", "text": "Oxaliplatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16968538_2_Ent0", "text": "Oxaliplatin is a platinum derivative", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "16968538_2_Ent2", "text": "platinum derivative", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16968538_2_Ent3", "text": "colorectal cancer", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "16978752_3", "wnd_id": "16978752_3_1", "text": "Second , we report a case of neutropenia , which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide .", "tokens": ["Second", ",", "we", "report", "a", "case", "of", "neutropenia", ",", "which", "proved", "to", "be", "fatal", "in", "a", "schizophrenia", "patient", "receiving", "olanzapine", "and", "thiazide", "."], "event_mentions": [{"id": "16978752_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 18, "end": 19}, "arguments": [{"entity_id": "16978752_3_Ent1", "role": "Effect", "text": "neutropenia", "start": 7, "end": 8}, {"entity_id": "16978752_3_Ent0", "role": "Subject", "text": "a schizophrenia patient", "start": 15, "end": 18}, {"entity_id": "16978752_3_Ent3", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 16, "end": 17}, {"entity_id": "16978752_3_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 19, "end": 20}, {"entity_id": "16978752_3_Ent6", "role": "Combination_Drug", "text": "olanzapine", "start": 19, "end": 20}, {"entity_id": "16978752_3_Ent2", "role": "Treatment", "text": "olanzapine and thiazide", "start": 19, "end": 22}, {"entity_id": "16978752_3_Ent5", "role": "Treatment_Drug", "text": "thiazide", "start": 21, "end": 22}, {"entity_id": "16978752_3_Ent7", "role": "Combination_Drug", "text": "thiazide", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16978752_3_Ent1", "text": "neutropenia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16978752_3_Ent0", "text": "a schizophrenia patient", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "16978752_3_Ent3", "text": "schizophrenia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16978752_3_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16978752_3_Ent6", "text": "olanzapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16978752_3_Ent2", "text": "olanzapine and thiazide", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "16978752_3_Ent5", "text": "thiazide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16978752_3_Ent7", "text": "thiazide", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "16997047_2", "wnd_id": "16997047_2_1", "text": "In this case , unlike those previously reported , hyponatremia recurred 5 months after switching from citalopram to mirtazapine , which is believed to be a safe antidepressant .", "tokens": ["In", "this", "case", ",", "unlike", "those", "previously", "reported", ",", "hyponatremia", "recurred", "5", "months", "after", "switching", "from", "citalopram", "to", "mirtazapine", ",", "which", "is", "believed", "to", "be", "a", "safe", "antidepressant", "."], "event_mentions": [{"id": "16997047_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "16997047_2_Ent0", "role": "Effect", "text": "hyponatremia", "start": 9, "end": 10}, {"entity_id": "16997047_2_Ent4", "role": "Treatment_Time_elapsed", "text": "5 months", "start": 11, "end": 13}, {"entity_id": "16997047_2_Ent1", "role": "Treatment", "text": "switching from citalopram to mirtazapine", "start": 14, "end": 19}, {"entity_id": "16997047_2_Ent2", "role": "Treatment_Drug", "text": "citalopram", "start": 16, "end": 17}, {"entity_id": "16997047_2_Ent3", "role": "Treatment_Drug", "text": "mirtazapine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "16997047_2_Ent0", "text": "hyponatremia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16997047_2_Ent4", "text": "5 months", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "16997047_2_Ent1", "text": "switching from citalopram to mirtazapine", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "16997047_2_Ent2", "text": "citalopram", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16997047_2_Ent3", "text": "mirtazapine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "16997047_3", "wnd_id": "16997047_3_1", "text": "Recurrent hyponatremia associated with citalopram and mirtazapine .", "tokens": ["Recurrent", "hyponatremia", "associated", "with", "citalopram", "and", "mirtazapine", "."], "event_mentions": [{"id": "16997047_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "16997047_3_Ent0", "role": "Effect", "text": "Recurrent hyponatremia", "start": 0, "end": 2}, {"entity_id": "16997047_3_Ent2", "role": "Treatment_Drug", "text": "citalopram", "start": 4, "end": 5}, {"entity_id": "16997047_3_Ent1", "role": "Treatment", "text": "citalopram and mirtazapine", "start": 4, "end": 7}, {"entity_id": "16997047_3_Ent3", "role": "Treatment_Drug", "text": "mirtazapine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "16997047_3_Ent0", "text": "Recurrent hyponatremia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16997047_3_Ent2", "text": "citalopram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16997047_3_Ent1", "text": "citalopram and mirtazapine", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "16997047_3_Ent3", "text": "mirtazapine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "17016002_1", "wnd_id": "17016002_1_1", "text": "A 70 - year - old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent ( homochlorcyclizine hydrochloride ) for itching .", "tokens": ["A", "70", "-", "year", "-", "old", "man", "was", "admitted", "to", "our", "hospital", "because", "of", "dyspnea", "after", "taking", "an", "antihistaminic", "agent", "(", "homochlorcyclizine", "hydrochloride", ")", "for", "itching", "."], "event_mentions": [{"id": "17016002_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 16, "end": 17}, "arguments": [{"entity_id": "17016002_1_Ent0", "role": "Subject", "text": "A 70 - year - old man", "start": 0, "end": 7}, {"entity_id": "17016002_1_Ent1", "role": "Subject_Age", "text": "70 - year - old", "start": 1, "end": 6}, {"entity_id": "17016002_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "17016002_1_Ent3", "role": "Effect", "text": "dyspnea", "start": 14, "end": 15}, {"entity_id": "17016002_1_Ent4", "role": "Treatment", "text": "an antihistaminic agent ( homochlorcyclizine hydrochloride )", "start": 17, "end": 24}, {"entity_id": "17016002_1_Ent6", "role": "Treatment_Drug", "text": "homochlorcyclizine hydrochloride", "start": 21, "end": 23}, {"entity_id": "17016002_1_Ent5", "role": "Treatment_Disorder", "text": "itching", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "17016002_1_Ent0", "text": "A 70 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "17016002_1_Ent1", "text": "70 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17016002_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17016002_1_Ent3", "text": "dyspnea", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17016002_1_Ent4", "text": "an antihistaminic agent ( homochlorcyclizine hydrochloride )", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "17016002_1_Ent6", "text": "homochlorcyclizine hydrochloride", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "17016002_1_Ent5", "text": "itching", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "1703754_1", "wnd_id": "1703754_1_1", "text": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine .", "tokens": ["This", "is", "a", "case", "report", "of", "fatal", "cryptococcal", "meningitis", "in", "a", "child", "with", "systemic", "lupus", "erythematosus", "being", "treated", "with", "prednisolone", "and", "azathioprine", "."], "event_mentions": [{"id": "1703754_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 9, "end": 10}, "arguments": [{"entity_id": "1703754_1_Ent2", "role": "Effect", "text": "fatal cryptococcal meningitis", "start": 6, "end": 9}, {"entity_id": "1703754_1_Ent0", "role": "Subject", "text": "a child with systemic lupus erythematosus", "start": 10, "end": 16}, {"entity_id": "1703754_1_Ent1", "role": "Subject_Age", "text": "child", "start": 11, "end": 12}, {"entity_id": "1703754_1_Ent4", "role": "Treatment_Disorder", "text": "systemic lupus erythematosus", "start": 13, "end": 16}, {"entity_id": "1703754_1_Ent5", "role": "Treatment_Drug", "text": "prednisolone", "start": 19, "end": 20}, {"entity_id": "1703754_1_Ent7", "role": "Combination_Drug", "text": "prednisolone", "start": 19, "end": 20}, {"entity_id": "1703754_1_Ent3", "role": "Treatment", "text": "prednisolone and azathioprine", "start": 19, "end": 22}, {"entity_id": "1703754_1_Ent6", "role": "Treatment_Drug", "text": "azathioprine", "start": 21, "end": 22}, {"entity_id": "1703754_1_Ent8", "role": "Combination_Drug", "text": "azathioprine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "1703754_1_Ent2", "text": "fatal cryptococcal meningitis", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1703754_1_Ent0", "text": "a child with systemic lupus erythematosus", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "1703754_1_Ent1", "text": "child", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1703754_1_Ent4", "text": "systemic lupus erythematosus", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "1703754_1_Ent5", "text": "prednisolone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1703754_1_Ent7", "text": "prednisolone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1703754_1_Ent3", "text": "prednisolone and azathioprine", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "1703754_1_Ent6", "text": "azathioprine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "1703754_1_Ent8", "text": "azathioprine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "17044380_2", "wnd_id": "17044380_2_1", "text": "Warfarin - induced skin necrosis and heparin - induced thrombocytopenia following mitral valve replacement for marantic endocarditis .", "tokens": ["Warfarin", "-", "induced", "skin", "necrosis", "and", "heparin", "-", "induced", "thrombocytopenia", "following", "mitral", "valve", "replacement", "for", "marantic", "endocarditis", "."], "event_mentions": [{"id": "17044380_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17044380_2_Ent1", "role": "Treatment", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "17044380_2_Ent2", "role": "Treatment_Drug", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "17044380_2_Ent0", "role": "Effect", "text": "skin necrosis", "start": 3, "end": 5}]}, {"id": "17044380_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "17044380_2_Ent4", "role": "Treatment", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "17044380_2_Ent6", "role": "Treatment_Drug", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "17044380_2_Ent3", "role": "Effect", "text": "thrombocytopenia", "start": 9, "end": 10}, {"entity_id": "17044380_2_Ent5", "role": "Treatment_Disorder", "text": "marantic endocarditis", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "17044380_2_Ent1", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17044380_2_Ent2", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17044380_2_Ent0", "text": "skin necrosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "17044380_2_Ent4", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17044380_2_Ent6", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17044380_2_Ent3", "text": "thrombocytopenia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17044380_2_Ent5", "text": "marantic endocarditis", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "17060191_2", "wnd_id": "17060191_2_1", "text": "Exposure of the fetus to indomethacin by administration of the drug to the mother may cause many side effects , including premature closure of the ductus arteriosus .", "tokens": ["Exposure", "of", "the", "fetus", "to", "indomethacin", "by", "administration", "of", "the", "drug", "to", "the", "mother", "may", "cause", "many", "side", "effects", ",", "including", "premature", "closure", "of", "the", "ductus", "arteriosus", "."], "event_mentions": [{"id": "17060191_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 17, "end": 19}, "arguments": [{"entity_id": "17060191_2_Ent0", "role": "Subject", "text": "fetus", "start": 3, "end": 4}, {"entity_id": "17060191_2_Ent1", "role": "Subject_Age", "text": "fetus", "start": 3, "end": 4}, {"entity_id": "17060191_2_Ent3", "role": "Treatment", "text": "indomethacin", "start": 5, "end": 6}, {"entity_id": "17060191_2_Ent4", "role": "Treatment_Drug", "text": "indomethacin", "start": 5, "end": 6}, {"entity_id": "17060191_2_Ent2", "role": "Effect", "text": "premature closure of the ductus arteriosus", "start": 21, "end": 27}]}], "entity_mentions": [{"id": "17060191_2_Ent0", "text": "fetus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17060191_2_Ent1", "text": "fetus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17060191_2_Ent3", "text": "indomethacin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17060191_2_Ent4", "text": "indomethacin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17060191_2_Ent2", "text": "premature closure of the ductus arteriosus", "entity_type": "Entity", "start": 21, "end": 27}], "lang": "en"}
{"doc_id": "17060191_5", "wnd_id": "17060191_5_1", "text": "This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to ductal closure in response to indomethacin exposure .", "tokens": ["This", "selective", "closure", "of", "the", "ductus", "arteriosus", "suggests", "that", "the", "affected", "twin", "was", "predisposed", "to", "hypoxia", "and", "thus", "was", "more", "susceptible", "to", "ductal", "closure", "in", "response", "to", "indomethacin", "exposure", "."], "event_mentions": [{"id": "17060191_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "response", "start": 25, "end": 26}, "arguments": [{"entity_id": "17060191_5_Ent0", "role": "Effect", "text": "ductal closure", "start": 22, "end": 24}, {"entity_id": "17060191_5_Ent2", "role": "Treatment_Drug", "text": "indomethacin", "start": 27, "end": 28}, {"entity_id": "17060191_5_Ent1", "role": "Treatment", "text": "indomethacin exposure", "start": 27, "end": 29}, {"entity_id": "17060191_5_Ent3", "role": "Treatment_Route", "text": "exposure", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "17060191_5_Ent0", "text": "ductal closure", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "17060191_5_Ent2", "text": "indomethacin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17060191_5_Ent1", "text": "indomethacin exposure", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "17060191_5_Ent3", "text": "exposure", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "17068466_1", "wnd_id": "17068466_1_1", "text": "CONCLUSION : These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers .", "tokens": ["CONCLUSION", ":", "These", "cases", "suggest", "that", "moxifloxacin", "may", "interfere", "with", "the", "healing", "of", "corneal", "ulcers", "."], "event_mentions": [{"id": "17068466_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interfere", "start": 8, "end": 9}, "arguments": [{"entity_id": "17068466_1_Ent0", "role": "Subject", "text": "These cases", "start": 2, "end": 4}, {"entity_id": "17068466_1_Ent2", "role": "Treatment", "text": "moxifloxacin", "start": 6, "end": 7}, {"entity_id": "17068466_1_Ent3", "role": "Treatment_Drug", "text": "moxifloxacin", "start": 6, "end": 7}, {"entity_id": "17068466_1_Ent1", "role": "Effect", "text": "interfere with the healing of corneal ulcers", "start": 8, "end": 15}]}], "entity_mentions": [{"id": "17068466_1_Ent0", "text": "These cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17068466_1_Ent2", "text": "moxifloxacin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17068466_1_Ent3", "text": "moxifloxacin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17068466_1_Ent1", "text": "interfere with the healing of corneal ulcers", "entity_type": "Entity", "start": 8, "end": 15}], "lang": "en"}
{"doc_id": "17123120_2", "wnd_id": "17123120_2_1", "text": "Thus , tacrolimus - induced HUS is a rare cause of ARF in nephrotic syndrome .", "tokens": ["Thus", ",", "tacrolimus", "-", "induced", "HUS", "is", "a", "rare", "cause", "of", "ARF", "in", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "17123120_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "17123120_2_Ent1", "role": "Treatment", "text": "tacrolimus", "start": 2, "end": 3}, {"entity_id": "17123120_2_Ent2", "role": "Treatment_Drug", "text": "tacrolimus", "start": 2, "end": 3}, {"entity_id": "17123120_2_Ent0", "role": "Effect", "text": "HUS", "start": 5, "end": 6}, {"entity_id": "17123120_2_Ent3", "role": "Treatment_Disorder", "text": "nephrotic syndrome", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17123120_2_Ent1", "text": "tacrolimus", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17123120_2_Ent2", "text": "tacrolimus", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17123120_2_Ent0", "text": "HUS", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17123120_2_Ent3", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17182354_2", "wnd_id": "17182354_2_1", "text": "Large dose of methylphenidate may cause cataract and glaucoma .", "tokens": ["Large", "dose", "of", "methylphenidate", "may", "cause", "cataract", "and", "glaucoma", "."], "event_mentions": [{"id": "17182354_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 5, "end": 6}, "arguments": [{"entity_id": "17182354_2_Ent1", "role": "Treatment", "text": "methylphenidate", "start": 3, "end": 4}, {"entity_id": "17182354_2_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 3, "end": 4}, {"entity_id": "17182354_2_Ent0", "role": "Effect", "text": "cataract and glaucoma", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "17182354_2_Ent1", "text": "methylphenidate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17182354_2_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17182354_2_Ent0", "text": "cataract and glaucoma", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "17188061_1", "wnd_id": "17188061_1_1", "text": "CONCLUSIONS : We report a typical symptoms of Charles - Bonnet syndrome ( CBS ) in patients with severe AMD after intravitreal Avastin - injections .", "tokens": ["CONCLUSIONS", ":", "We", "report", "a", "typical", "symptoms", "of", "Charles", "-", "Bonnet", "syndrome", "(", "CBS", ")", "in", "patients", "with", "severe", "AMD", "after", "intravitreal", "Avastin", "-", "injections", "."], "event_mentions": [{"id": "17188061_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "17188061_1_Ent1", "role": "Effect", "text": "typical symptoms of Charles - Bonnet syndrome ( CBS )", "start": 5, "end": 15}, {"entity_id": "17188061_1_Ent0", "role": "Subject", "text": "patients with severe AMD", "start": 16, "end": 20}, {"entity_id": "17188061_1_Ent6", "role": "Treatment_Disorder", "text": "AMD", "start": 19, "end": 20}, {"entity_id": "17188061_1_Ent4", "role": "Treatment_Route", "text": "intravitreal", "start": 21, "end": 22}, {"entity_id": "17188061_1_Ent2", "role": "Treatment", "text": "intravitreal Avastin - injections", "start": 21, "end": 25}, {"entity_id": "17188061_1_Ent3", "role": "Treatment_Drug", "text": "Avastin", "start": 22, "end": 23}, {"entity_id": "17188061_1_Ent5", "role": "Treatment_Route", "text": "injections", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "17188061_1_Ent1", "text": "typical symptoms of Charles - Bonnet syndrome ( CBS )", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "17188061_1_Ent0", "text": "patients with severe AMD", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "17188061_1_Ent6", "text": "AMD", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17188061_1_Ent4", "text": "intravitreal", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17188061_1_Ent2", "text": "intravitreal Avastin - injections", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "17188061_1_Ent3", "text": "Avastin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17188061_1_Ent5", "text": "injections", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "17189581_11", "wnd_id": "17189581_11_1", "text": "After a total of four doses of linezolid , the patient reported further discomfort .", "tokens": ["After", "a", "total", "of", "four", "doses", "of", "linezolid", ",", "the", "patient", "reported", "further", "discomfort", "."], "event_mentions": [{"id": "17189581_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 11, "end": 12}, "arguments": [{"entity_id": "17189581_11_Ent2", "role": "Treatment", "text": "a total of four doses of linezolid", "start": 1, "end": 8}, {"entity_id": "17189581_11_Ent4", "role": "Treatment_Dosage", "text": "four doses", "start": 4, "end": 6}, {"entity_id": "17189581_11_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 7, "end": 8}, {"entity_id": "17189581_11_Ent0", "role": "Subject", "text": "the patient", "start": 9, "end": 11}, {"entity_id": "17189581_11_Ent1", "role": "Effect", "text": "further discomfort", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "17189581_11_Ent2", "text": "a total of four doses of linezolid", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "17189581_11_Ent4", "text": "four doses", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17189581_11_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17189581_11_Ent0", "text": "the patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17189581_11_Ent1", "text": "further discomfort", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "17189581_2", "wnd_id": "17189581_2_1", "text": "A case of serotonin syndrome that developed during concurrent linezolid and fluoxetine is presented .", "tokens": ["A", "case", "of", "serotonin", "syndrome", "that", "developed", "during", "concurrent", "linezolid", "and", "fluoxetine", "is", "presented", "."], "event_mentions": [{"id": "17189581_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "17189581_2_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 3, "end": 5}, {"entity_id": "17189581_2_Ent1", "role": "Treatment", "text": "concurrent linezolid and fluoxetine", "start": 8, "end": 12}, {"entity_id": "17189581_2_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 9, "end": 10}, {"entity_id": "17189581_2_Ent4", "role": "Combination_Drug", "text": "linezolid", "start": 9, "end": 10}, {"entity_id": "17189581_2_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 11, "end": 12}, {"entity_id": "17189581_2_Ent5", "role": "Combination_Drug", "text": "fluoxetine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "17189581_2_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "17189581_2_Ent1", "text": "concurrent linezolid and fluoxetine", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "17189581_2_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17189581_2_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17189581_2_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17189581_2_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "17195428_2", "wnd_id": "17195428_2_1", "text": "A case of oculogyric crisis induced by metoclopramide is described in this paper .", "tokens": ["A", "case", "of", "oculogyric", "crisis", "induced", "by", "metoclopramide", "is", "described", "in", "this", "paper", "."], "event_mentions": [{"id": "17195428_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17195428_2_Ent0", "role": "Effect", "text": "oculogyric crisis", "start": 3, "end": 5}, {"entity_id": "17195428_2_Ent1", "role": "Treatment", "text": "metoclopramide", "start": 7, "end": 8}, {"entity_id": "17195428_2_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "17195428_2_Ent0", "text": "oculogyric crisis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "17195428_2_Ent1", "text": "metoclopramide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17195428_2_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "1722991_1", "wnd_id": "1722991_1_1", "text": "Usefulness of antiplatelet drugs in the management of heparin - associated thrombocytopenia and thrombosis .", "tokens": ["Usefulness", "of", "antiplatelet", "drugs", "in", "the", "management", "of", "heparin", "-", "associated", "thrombocytopenia", "and", "thrombosis", "."], "event_mentions": [{"id": "1722991_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Usefulness", "start": 0, "end": 1}, "arguments": [{"entity_id": "1722991_1_Ent3", "role": "Treatment", "text": "antiplatelet drugs", "start": 2, "end": 4}, {"entity_id": "1722991_1_Ent5", "role": "Treatment_Drug", "text": "antiplatelet drugs", "start": 2, "end": 4}, {"entity_id": "1722991_1_Ent4", "role": "Treatment_Disorder", "text": "heparin - associated thrombocytopenia and thrombosis", "start": 8, "end": 14}]}, {"id": "1722991_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "1722991_1_Ent1", "role": "Treatment", "text": "heparin", "start": 8, "end": 9}, {"entity_id": "1722991_1_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 8, "end": 9}, {"entity_id": "1722991_1_Ent0", "role": "Effect", "text": "thrombocytopenia and thrombosis", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "1722991_1_Ent3", "text": "antiplatelet drugs", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1722991_1_Ent5", "text": "antiplatelet drugs", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1722991_1_Ent1", "text": "heparin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1722991_1_Ent2", "text": "heparin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1722991_1_Ent4", "text": "heparin - associated thrombocytopenia and thrombosis", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "1722991_1_Ent0", "text": "thrombocytopenia and thrombosis", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "1722991_9", "wnd_id": "1722991_9_1", "text": "This experience supports the hypothesis that heparin can be readministered early to patients with heparin - associated thrombocytopenia and thrombosis , provided antiplatelet therapy is given .", "tokens": ["This", "experience", "supports", "the", "hypothesis", "that", "heparin", "can", "be", "readministered", "early", "to", "patients", "with", "heparin", "-", "associated", "thrombocytopenia", "and", "thrombosis", ",", "provided", "antiplatelet", "therapy", "is", "given", "."], "event_mentions": [{"id": "1722991_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "readministered", "start": 9, "end": 10}, "arguments": [{"entity_id": "1722991_9_Ent0", "role": "Treatment", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "1722991_9_Ent3", "role": "Treatment_Drug", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "1722991_9_Ent6", "role": "Combination_Drug", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "1722991_9_Ent2", "role": "Treatment_Disorder", "text": "heparin - associated thrombocytopenia", "start": 14, "end": 18}, {"entity_id": "1722991_9_Ent4", "role": "Treatment_Drug", "text": "antiplatelet", "start": 22, "end": 23}, {"entity_id": "1722991_9_Ent5", "role": "Combination_Drug", "text": "antiplatelet", "start": 22, "end": 23}, {"entity_id": "1722991_9_Ent1", "role": "Treatment", "text": "antiplatelet therapy is given", "start": 22, "end": 26}]}, {"id": "1722991_9_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 16, "end": 17}, "arguments": [{"entity_id": "1722991_9_Ent8", "role": "Treatment", "text": "heparin", "start": 14, "end": 15}, {"entity_id": "1722991_9_Ent9", "role": "Treatment_Drug", "text": "heparin", "start": 14, "end": 15}, {"entity_id": "1722991_9_Ent7", "role": "Effect", "text": "thrombocytopenia and thrombosis", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "1722991_9_Ent0", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1722991_9_Ent3", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1722991_9_Ent6", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1722991_9_Ent8", "text": "heparin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1722991_9_Ent9", "text": "heparin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1722991_9_Ent2", "text": "heparin - associated thrombocytopenia", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "1722991_9_Ent7", "text": "thrombocytopenia and thrombosis", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "1722991_9_Ent4", "text": "antiplatelet", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1722991_9_Ent5", "text": "antiplatelet", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1722991_9_Ent1", "text": "antiplatelet therapy is given", "entity_type": "Entity", "start": 22, "end": 26}], "lang": "en"}
{"doc_id": "17260498_1", "wnd_id": "17260498_1_1", "text": "Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone - refractory prostate cancer .", "tokens": ["Fatal", "interstitial", "pneumonitis", "associated", "with", "docetaxel", "administration", "in", "a", "patient", "with", "hormone", "-", "refractory", "prostate", "cancer", "."], "event_mentions": [{"id": "17260498_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "17260498_1_Ent1", "role": "Effect", "text": "Fatal interstitial pneumonitis", "start": 0, "end": 3}, {"entity_id": "17260498_1_Ent2", "role": "Treatment", "text": "docetaxel", "start": 5, "end": 6}, {"entity_id": "17260498_1_Ent3", "role": "Treatment_Drug", "text": "docetaxel", "start": 5, "end": 6}, {"entity_id": "17260498_1_Ent0", "role": "Subject", "text": "a patient with hormone - refractory prostate cancer", "start": 8, "end": 16}, {"entity_id": "17260498_1_Ent4", "role": "Treatment_Disorder", "text": "hormone - refractory prostate cancer", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "17260498_1_Ent1", "text": "Fatal interstitial pneumonitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17260498_1_Ent2", "text": "docetaxel", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17260498_1_Ent3", "text": "docetaxel", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17260498_1_Ent0", "text": "a patient with hormone - refractory prostate cancer", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "17260498_1_Ent4", "text": "hormone - refractory prostate cancer", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "17260498_2", "wnd_id": "17260498_2_1", "text": "Taxanes are widely used chemotherapeutic agents with the potential to induce pulmonary injury through a variety of mechanisms .", "tokens": ["Taxanes", "are", "widely", "used", "chemotherapeutic", "agents", "with", "the", "potential", "to", "induce", "pulmonary", "injury", "through", "a", "variety", "of", "mechanisms", "."], "event_mentions": [{"id": "17260498_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 10, "end": 11}, "arguments": [{"entity_id": "17260498_2_Ent1", "role": "Treatment", "text": "Taxanes", "start": 0, "end": 1}, {"entity_id": "17260498_2_Ent2", "role": "Treatment_Drug", "text": "Taxanes", "start": 0, "end": 1}, {"entity_id": "17260498_2_Ent0", "role": "Effect", "text": "pulmonary injury", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "17260498_2_Ent1", "text": "Taxanes", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17260498_2_Ent2", "text": "Taxanes", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17260498_2_Ent0", "text": "pulmonary injury", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "17260498_5", "wnd_id": "17260498_5_1", "text": "Even though only a few cases of this adverse event have been reported in the literature , severe docetaxel - induced pulmonary toxicity needs to be considered in the differential diagnosis when such patients present with respiratory symptoms .", "tokens": ["Even", "though", "only", "a", "few", "cases", "of", "this", "adverse", "event", "have", "been", "reported", "in", "the", "literature", ",", "severe", "docetaxel", "-", "induced", "pulmonary", "toxicity", "needs", "to", "be", "considered", "in", "the", "differential", "diagnosis", "when", "such", "patients", "present", "with", "respiratory", "symptoms", "."], "event_mentions": [{"id": "17260498_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 20, "end": 21}, "arguments": [{"entity_id": "17260498_5_Ent2", "role": "Treatment", "text": "docetaxel", "start": 18, "end": 19}, {"entity_id": "17260498_5_Ent3", "role": "Treatment_Drug", "text": "docetaxel", "start": 18, "end": 19}, {"entity_id": "17260498_5_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 21, "end": 23}, {"entity_id": "17260498_5_Ent1", "role": "Effect", "text": "respiratory symptoms", "start": 36, "end": 38}]}], "entity_mentions": [{"id": "17260498_5_Ent2", "text": "docetaxel", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17260498_5_Ent3", "text": "docetaxel", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17260498_5_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "17260498_5_Ent1", "text": "respiratory symptoms", "entity_type": "Entity", "start": 36, "end": 38}], "lang": "en"}
{"doc_id": "17275666_4", "wnd_id": "17275666_4_1", "text": "Similar to antiarrhythmic drugs aggravating particular arrhythmias , antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones .", "tokens": ["Similar", "to", "antiarrhythmic", "drugs", "aggravating", "particular", "arrhythmias", ",", "antiepileptic", "drugs", "can", "paradoxically", "induce", "new", "seizure", "types", "or", "exacerbate", "existing", "ones", "."], "event_mentions": [{"id": "17275666_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 12, "end": 13}, "arguments": [{"entity_id": "17275666_4_Ent2", "role": "Treatment_Drug", "text": "antiarrhythmic drugs", "start": 2, "end": 4}, {"entity_id": "17275666_4_Ent1", "role": "Treatment", "text": "antiepileptic drugs", "start": 8, "end": 10}, {"entity_id": "17275666_4_Ent3", "role": "Treatment_Drug", "text": "antiepileptic drugs", "start": 8, "end": 10}, {"entity_id": "17275666_4_Ent0", "role": "Effect", "text": "new seizure types or exacerbate existing ones", "start": 13, "end": 20}]}], "entity_mentions": [{"id": "17275666_4_Ent2", "text": "antiarrhythmic drugs", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17275666_4_Ent1", "text": "antiepileptic drugs", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17275666_4_Ent3", "text": "antiepileptic drugs", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17275666_4_Ent0", "text": "new seizure types or exacerbate existing ones", "entity_type": "Entity", "start": 13, "end": 20}], "lang": "en"}
{"doc_id": "17275666_6", "wnd_id": "17275666_6_1", "text": "This report describes a case of paradoxical , intravenous valproic acid - induced seizure exacerbation in a child with juvenile absence epilepsy , documented by video - electroencephalography .", "tokens": ["This", "report", "describes", "a", "case", "of", "paradoxical", ",", "intravenous", "valproic", "acid", "-", "induced", "seizure", "exacerbation", "in", "a", "child", "with", "juvenile", "absence", "epilepsy", ",", "documented", "by", "video", "-", "electroencephalography", "."], "event_mentions": [{"id": "17275666_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "17275666_6_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 8, "end": 9}, {"entity_id": "17275666_6_Ent3", "role": "Treatment", "text": "intravenous valproic acid", "start": 8, "end": 11}, {"entity_id": "17275666_6_Ent4", "role": "Treatment_Drug", "text": "valproic acid", "start": 9, "end": 11}, {"entity_id": "17275666_6_Ent2", "role": "Effect", "text": "seizure exacerbation", "start": 13, "end": 15}, {"entity_id": "17275666_6_Ent0", "role": "Subject", "text": "a child with juvenile absence epilepsy", "start": 16, "end": 22}, {"entity_id": "17275666_6_Ent1", "role": "Subject_Age", "text": "child", "start": 17, "end": 18}, {"entity_id": "17275666_6_Ent6", "role": "Treatment_Disorder", "text": "juvenile absence epilepsy", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "17275666_6_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17275666_6_Ent3", "text": "intravenous valproic acid", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "17275666_6_Ent4", "text": "valproic acid", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17275666_6_Ent2", "text": "seizure exacerbation", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17275666_6_Ent0", "text": "a child with juvenile absence epilepsy", "entity_type": "Entity", "start": 16, "end": 22}, {"id": "17275666_6_Ent1", "text": "child", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17275666_6_Ent6", "text": "juvenile absence epilepsy", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "17285101_1", "wnd_id": "17285101_1_1", "text": "Pulmonary hypertension during lithium therapy : clinical case study .", "tokens": ["Pulmonary", "hypertension", "during", "lithium", "therapy", ":", "clinical", "case", "study", "."], "event_mentions": [{"id": "17285101_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "17285101_1_Ent0", "role": "Effect", "text": "Pulmonary hypertension", "start": 0, "end": 2}, {"entity_id": "17285101_1_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "17285101_1_Ent1", "role": "Treatment", "text": "lithium therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "17285101_1_Ent0", "text": "Pulmonary hypertension", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17285101_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17285101_1_Ent1", "text": "lithium therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "17301517_2", "wnd_id": "17301517_2_1", "text": "The risk of new - onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind .", "tokens": ["The", "risk", "of", "new", "-", "onset", "diabetic", "ketoacidosis", "in", "patients", "with", "diabetic", "risk", "factors", "who", "are", "taking", "perospirone", "hydrochloride", "or", "other", "atypical", "antipsychotics", "should", "be", "kept", "in", "mind", "."], "event_mentions": [{"id": "17301517_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 1, "end": 2}, "arguments": [{"entity_id": "17301517_2_Ent2", "role": "Effect", "text": "new - onset diabetic ketoacidosis", "start": 3, "end": 8}, {"entity_id": "17301517_2_Ent0", "role": "Subject", "text": "patients with diabetic risk factors", "start": 9, "end": 14}, {"entity_id": "17301517_2_Ent1", "role": "Subject_Disorder", "text": "diabetic risk factors", "start": 11, "end": 14}, {"entity_id": "17301517_2_Ent4", "role": "Treatment_Drug", "text": "perospirone hydrochloride", "start": 17, "end": 19}, {"entity_id": "17301517_2_Ent3", "role": "Treatment", "text": "perospirone hydrochloride or other atypical antipsychotics", "start": 17, "end": 23}]}], "entity_mentions": [{"id": "17301517_2_Ent2", "text": "new - onset diabetic ketoacidosis", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "17301517_2_Ent0", "text": "patients with diabetic risk factors", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "17301517_2_Ent1", "text": "diabetic risk factors", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17301517_2_Ent4", "text": "perospirone hydrochloride", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "17301517_2_Ent3", "text": "perospirone hydrochloride or other atypical antipsychotics", "entity_type": "Entity", "start": 17, "end": 23}], "lang": "en"}
{"doc_id": "17310853_1", "wnd_id": "17310853_1_1", "text": "Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor .", "tokens": ["Fatal", "venous", "thrombembolism", "complicating", "imatinib", "therapy", "in", "a", "patient", "with", "metastatic", "gastrointestinal", "stromal", "tumor", "."], "event_mentions": [{"id": "17310853_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicating", "start": 3, "end": 4}, "arguments": [{"entity_id": "17310853_1_Ent1", "role": "Effect", "text": "Fatal venous thrombembolism", "start": 0, "end": 3}, {"entity_id": "17310853_1_Ent2", "role": "Treatment", "text": "imatinib", "start": 4, "end": 5}, {"entity_id": "17310853_1_Ent3", "role": "Treatment_Drug", "text": "imatinib", "start": 4, "end": 5}, {"entity_id": "17310853_1_Ent0", "role": "Subject", "text": "a patient with metastatic gastrointestinal stromal tumor", "start": 7, "end": 14}, {"entity_id": "17310853_1_Ent4", "role": "Treatment_Disorder", "text": "metastatic gastrointestinal stromal tumor", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "17310853_1_Ent1", "text": "Fatal venous thrombembolism", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17310853_1_Ent2", "text": "imatinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17310853_1_Ent3", "text": "imatinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17310853_1_Ent0", "text": "a patient with metastatic gastrointestinal stromal tumor", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "17310853_1_Ent4", "text": "metastatic gastrointestinal stromal tumor", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "17316160_1", "wnd_id": "17316160_1_1", "text": "Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin .", "tokens": ["Decreased", "serum", "linezolid", "levels", "in", "a", "critically", "ill", "patient", "receiving", "concomitant", "linezolid", "and", "rifampin", "."], "event_mentions": [{"id": "17316160_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 9, "end": 10}, "arguments": [{"entity_id": "17316160_1_Ent2", "role": "Effect", "text": "Decreased serum linezolid levels", "start": 0, "end": 4}, {"entity_id": "17316160_1_Ent0", "role": "Subject", "text": "a critically ill patient", "start": 5, "end": 9}, {"entity_id": "17316160_1_Ent1", "role": "Subject_Disorder", "text": "critically ill", "start": 6, "end": 8}, {"entity_id": "17316160_1_Ent3", "role": "Treatment", "text": "concomitant linezolid and rifampin", "start": 10, "end": 14}, {"entity_id": "17316160_1_Ent4", "role": "Treatment_Drug", "text": "linezolid", "start": 11, "end": 12}, {"entity_id": "17316160_1_Ent6", "role": "Combination_Drug", "text": "linezolid", "start": 11, "end": 12}, {"entity_id": "17316160_1_Ent5", "role": "Treatment_Drug", "text": "rifampin", "start": 13, "end": 14}, {"entity_id": "17316160_1_Ent7", "role": "Combination_Drug", "text": "rifampin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17316160_1_Ent2", "text": "Decreased serum linezolid levels", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17316160_1_Ent0", "text": "a critically ill patient", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "17316160_1_Ent1", "text": "critically ill", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17316160_1_Ent3", "text": "concomitant linezolid and rifampin", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "17316160_1_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17316160_1_Ent6", "text": "linezolid", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17316160_1_Ent5", "text": "rifampin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17316160_1_Ent7", "text": "rifampin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17316160_5", "wnd_id": "17316160_5_1", "text": "To our knowledge , this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "published", "report", "of", "a", "possible", "drug", "interaction", "in", "a", "critically", "ill", "patient", "receiving", "concomitant", "linezolid", "and", "rifampin", "."], "event_mentions": [{"id": "17316160_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 20, "end": 21}, "arguments": [{"entity_id": "17316160_5_Ent2", "role": "Effect", "text": "drug interaction", "start": 13, "end": 15}, {"entity_id": "17316160_5_Ent0", "role": "Subject", "text": "a critically ill patient", "start": 16, "end": 20}, {"entity_id": "17316160_5_Ent1", "role": "Subject_Disorder", "text": "critically ill", "start": 17, "end": 19}, {"entity_id": "17316160_5_Ent3", "role": "Treatment", "text": "concomitant linezolid and rifampin", "start": 21, "end": 25}, {"entity_id": "17316160_5_Ent4", "role": "Treatment_Drug", "text": "linezolid", "start": 22, "end": 23}, {"entity_id": "17316160_5_Ent6", "role": "Combination_Drug", "text": "linezolid", "start": 22, "end": 23}, {"entity_id": "17316160_5_Ent5", "role": "Treatment_Drug", "text": "rifampin", "start": 24, "end": 25}, {"entity_id": "17316160_5_Ent7", "role": "Combination_Drug", "text": "rifampin", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "17316160_5_Ent2", "text": "drug interaction", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17316160_5_Ent0", "text": "a critically ill patient", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "17316160_5_Ent1", "text": "critically ill", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "17316160_5_Ent3", "text": "concomitant linezolid and rifampin", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "17316160_5_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17316160_5_Ent6", "text": "linezolid", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17316160_5_Ent5", "text": "rifampin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17316160_5_Ent7", "text": "rifampin", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "17316891_1", "wnd_id": "17316891_1_1", "text": "We describe the case of a 50 - year - old woman with advanced non - small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy .", "tokens": ["We", "describe", "the", "case", "of", "a", "50", "-", "year", "-", "old", "woman", "with", "advanced", "non", "-", "small", "cell", "lung", "cancer", "who", "developed", "status", "epilepticus", "shortly", "after", "receiving", "cisplatin", "and", "gemcitabine", "chemotherapy", "."], "event_mentions": [{"id": "17316891_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 21, "end": 22}, "arguments": [{"entity_id": "17316891_1_Ent0", "role": "Subject", "text": "a 50 - year - old woman with advanced non - small cell lung cancer", "start": 5, "end": 20}, {"entity_id": "17316891_1_Ent1", "role": "Subject_Age", "text": "50 - year - old", "start": 6, "end": 11}, {"entity_id": "17316891_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "17316891_1_Ent7", "role": "Treatment_Disorder", "text": "lung cancer", "start": 18, "end": 20}, {"entity_id": "17316891_1_Ent3", "role": "Effect", "text": "status epilepticus", "start": 22, "end": 24}, {"entity_id": "17316891_1_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 27, "end": 28}, {"entity_id": "17316891_1_Ent9", "role": "Combination_Drug", "text": "cisplatin", "start": 27, "end": 28}, {"entity_id": "17316891_1_Ent4", "role": "Treatment", "text": "cisplatin and gemcitabine chemotherapy", "start": 27, "end": 31}, {"entity_id": "17316891_1_Ent6", "role": "Treatment_Drug", "text": "gemcitabine", "start": 29, "end": 30}, {"entity_id": "17316891_1_Ent10", "role": "Combination_Drug", "text": "gemcitabine", "start": 29, "end": 30}, {"entity_id": "17316891_1_Ent8", "role": "Treatment_Route", "text": "chemotherapy", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "17316891_1_Ent0", "text": "a 50 - year - old woman with advanced non - small cell lung cancer", "entity_type": "Entity", "start": 5, "end": 20}, {"id": "17316891_1_Ent1", "text": "50 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "17316891_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17316891_1_Ent7", "text": "lung cancer", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "17316891_1_Ent3", "text": "status epilepticus", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "17316891_1_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17316891_1_Ent9", "text": "cisplatin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17316891_1_Ent4", "text": "cisplatin and gemcitabine chemotherapy", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "17316891_1_Ent6", "text": "gemcitabine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "17316891_1_Ent10", "text": "gemcitabine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "17316891_1_Ent8", "text": "chemotherapy", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "17329303_2", "wnd_id": "17329303_2_1", "text": "As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications , there is a need to know more about their safety , in particular during switching to and from methylphenidate treatment , as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission .", "tokens": ["As", "atypical", "antipsychotics", "are", "increasingly", "used", "in", "the", "treatment", "of", "childhood", "behavioural", "disorders", "either", "as", "monotherapy", "or", "in", "combination", "with", "other", "medications", ",", "there", "is", "a", "need", "to", "know", "more", "about", "their", "safety", ",", "in", "particular", "during", "switching", "to", "and", "from", "methylphenidate", "treatment", ",", "as", "antipsychotics", "and", "methylphenidate", "have", "opposing", "effects", "on", "dopaminergic", "neurotransmission", "."], "event_mentions": [{"id": "17329303_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 8, "end": 9}, "arguments": [{"entity_id": "17329303_2_Ent0", "role": "Treatment", "text": "atypical antipsychotics", "start": 1, "end": 3}, {"entity_id": "17329303_2_Ent3", "role": "Treatment_Drug", "text": "atypical antipsychotics", "start": 1, "end": 3}, {"entity_id": "17329303_2_Ent2", "role": "Treatment_Disorder", "text": "childhood behavioural disorders", "start": 10, "end": 13}, {"entity_id": "17329303_2_Ent1", "role": "Treatment", "text": "as monotherapy or in combination with other medications", "start": 14, "end": 22}]}], "entity_mentions": [{"id": "17329303_2_Ent0", "text": "atypical antipsychotics", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "17329303_2_Ent3", "text": "atypical antipsychotics", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "17329303_2_Ent2", "text": "childhood behavioural disorders", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "17329303_2_Ent1", "text": "as monotherapy or in combination with other medications", "entity_type": "Entity", "start": 14, "end": 22}], "lang": "en"}
{"doc_id": "17331261_1", "wnd_id": "17331261_1_1", "text": "CASE PRESENTATION : We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative - free tobramycin by inhalation , beginning at 16 months of age .", "tokens": ["CASE", "PRESENTATION", ":", "We", "report", "a", "patient", "with", "CF", "who", "developed", "recurrent", "eosinophilia", "and", "severe", "persistent", "bronchospasm", "following", "repeated", "administration", "of", "preservative", "-", "free", "tobramycin", "by", "inhalation", ",", "beginning", "at", "16", "months", "of", "age", "."], "event_mentions": [{"id": "17331261_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "17331261_1_Ent0", "role": "Subject", "text": "a patient with CF", "start": 5, "end": 9}, {"entity_id": "17331261_1_Ent5", "role": "Treatment_Disorder", "text": "CF", "start": 8, "end": 9}, {"entity_id": "17331261_1_Ent3", "role": "Effect", "text": "recurrent eosinophilia and severe persistent bronchospasm", "start": 11, "end": 17}, {"entity_id": "17331261_1_Ent4", "role": "Treatment", "text": "repeated administration of preservative - free tobramycin by inhalation", "start": 18, "end": 27}, {"entity_id": "17331261_1_Ent6", "role": "Treatment_Drug", "text": "tobramycin", "start": 24, "end": 25}, {"entity_id": "17331261_1_Ent7", "role": "Treatment_Route", "text": "inhalation", "start": 26, "end": 27}, {"entity_id": "17331261_1_Ent1", "role": "Subject", "text": "beginning at 16 months of age", "start": 28, "end": 34}, {"entity_id": "17331261_1_Ent2", "role": "Subject_Age", "text": "16 months", "start": 30, "end": 32}]}], "entity_mentions": [{"id": "17331261_1_Ent0", "text": "a patient with CF", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "17331261_1_Ent5", "text": "CF", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17331261_1_Ent3", "text": "recurrent eosinophilia and severe persistent bronchospasm", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "17331261_1_Ent4", "text": "repeated administration of preservative - free tobramycin by inhalation", "entity_type": "Entity", "start": 18, "end": 27}, {"id": "17331261_1_Ent6", "text": "tobramycin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17331261_1_Ent7", "text": "inhalation", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "17331261_1_Ent1", "text": "beginning at 16 months of age", "entity_type": "Entity", "start": 28, "end": 34}, {"id": "17331261_1_Ent2", "text": "16 months", "entity_type": "Entity", "start": 30, "end": 32}], "lang": "en"}
{"doc_id": "17352036_2", "wnd_id": "17352036_2_1", "text": "Pancreatitis is a very rare adverse effect associated with the use of amiodarone , and only four cases of amiodarone - induced pancreatitis have been reported in literature .", "tokens": ["Pancreatitis", "is", "a", "very", "rare", "adverse", "effect", "associated", "with", "the", "use", "of", "amiodarone", ",", "and", "only", "four", "cases", "of", "amiodarone", "-", "induced", "pancreatitis", "have", "been", "reported", "in", "literature", "."], "event_mentions": [{"id": "17352036_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 21, "end": 22}, "arguments": [{"entity_id": "17352036_2_Ent1", "role": "Subject_Population", "text": "four", "start": 16, "end": 17}, {"entity_id": "17352036_2_Ent0", "role": "Subject", "text": "four cases", "start": 16, "end": 18}, {"entity_id": "17352036_2_Ent3", "role": "Treatment", "text": "amiodarone", "start": 19, "end": 20}, {"entity_id": "17352036_2_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 19, "end": 20}, {"entity_id": "17352036_2_Ent2", "role": "Effect", "text": "pancreatitis", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "17352036_2_Ent1", "text": "four", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17352036_2_Ent0", "text": "four cases", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "17352036_2_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17352036_2_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17352036_2_Ent2", "text": "pancreatitis", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "17352036_3", "wnd_id": "17352036_3_1", "text": "Under the suspicion of amiodarone - induced acute pancreatitis , amiodarone was substituted by propafenone .", "tokens": ["Under", "the", "suspicion", "of", "amiodarone", "-", "induced", "acute", "pancreatitis", ",", "amiodarone", "was", "substituted", "by", "propafenone", "."], "event_mentions": [{"id": "17352036_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "17352036_3_Ent1", "role": "Treatment", "text": "amiodarone", "start": 4, "end": 5}, {"entity_id": "17352036_3_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 4, "end": 5}, {"entity_id": "17352036_3_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "17352036_3_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17352036_3_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17352036_3_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "17364199_14", "wnd_id": "17364199_14_1", "text": "DISCUSSION : To our knowledge this is the first reported case of tuberculous uveitis following treatment with etanercept .", "tokens": ["DISCUSSION", ":", "To", "our", "knowledge", "this", "is", "the", "first", "reported", "case", "of", "tuberculous", "uveitis", "following", "treatment", "with", "etanercept", "."], "event_mentions": [{"id": "17364199_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 16, "end": 17}, "arguments": [{"entity_id": "17364199_14_Ent0", "role": "Effect", "text": "tuberculous uveitis", "start": 12, "end": 14}, {"entity_id": "17364199_14_Ent1", "role": "Treatment", "text": "etanercept", "start": 17, "end": 18}, {"entity_id": "17364199_14_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17364199_14_Ent0", "text": "tuberculous uveitis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "17364199_14_Ent1", "text": "etanercept", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17364199_14_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17364199_7", "wnd_id": "17364199_7_1", "text": "She was on etanercept and methotrexate for rheumatoid arthritis .", "tokens": ["She", "was", "on", "etanercept", "and", "methotrexate", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "17364199_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 6, "end": 7}, "arguments": [{"entity_id": "17364199_7_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "17364199_7_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "17364199_7_Ent4", "role": "Treatment_Drug", "text": "etanercept", "start": 3, "end": 4}, {"entity_id": "17364199_7_Ent6", "role": "Combination_Drug", "text": "etanercept", "start": 3, "end": 4}, {"entity_id": "17364199_7_Ent2", "role": "Treatment", "text": "etanercept and methotrexate", "start": 3, "end": 6}, {"entity_id": "17364199_7_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "17364199_7_Ent7", "role": "Combination_Drug", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "17364199_7_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "17364199_7_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17364199_7_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17364199_7_Ent4", "text": "etanercept", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17364199_7_Ent6", "text": "etanercept", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17364199_7_Ent2", "text": "etanercept and methotrexate", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "17364199_7_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17364199_7_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17364199_7_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "17381671_1", "wnd_id": "17381671_1_1", "text": "Serotonin syndrome caused by interaction between citalopram and fentanyl .", "tokens": ["Serotonin", "syndrome", "caused", "by", "interaction", "between", "citalopram", "and", "fentanyl", "."], "event_mentions": [{"id": "17381671_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 2, "end": 3}, "arguments": [{"entity_id": "17381671_1_Ent0", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "17381671_1_Ent2", "role": "Treatment_Drug", "text": "citalopram", "start": 6, "end": 7}, {"entity_id": "17381671_1_Ent4", "role": "Combination_Drug", "text": "citalopram", "start": 6, "end": 7}, {"entity_id": "17381671_1_Ent1", "role": "Treatment", "text": "citalopram and fentanyl", "start": 6, "end": 9}, {"entity_id": "17381671_1_Ent3", "role": "Treatment_Drug", "text": "fentanyl", "start": 8, "end": 9}, {"entity_id": "17381671_1_Ent5", "role": "Combination_Drug", "text": "fentanyl", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "17381671_1_Ent0", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17381671_1_Ent2", "text": "citalopram", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17381671_1_Ent4", "text": "citalopram", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17381671_1_Ent1", "text": "citalopram and fentanyl", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "17381671_1_Ent3", "text": "fentanyl", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17381671_1_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "17420198_19", "wnd_id": "17420198_19_1", "text": "A patient with developmental disabilities who had no history of movement disorders developed EPS following initiation of aripiprazole .", "tokens": ["A", "patient", "with", "developmental", "disabilities", "who", "had", "no", "history", "of", "movement", "disorders", "developed", "EPS", "following", "initiation", "of", "aripiprazole", "."], "event_mentions": [{"id": "17420198_19_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 14, "end": 15}, "arguments": [{"entity_id": "17420198_19_Ent0", "role": "Subject", "text": "A patient with developmental disabilities who had no history of movement disorders", "start": 0, "end": 12}, {"entity_id": "17420198_19_Ent1", "role": "Subject_Disorder", "text": "developmental disabilities", "start": 3, "end": 5}, {"entity_id": "17420198_19_Ent2", "role": "Effect", "text": "EPS", "start": 13, "end": 14}, {"entity_id": "17420198_19_Ent3", "role": "Treatment", "text": "initiation of aripiprazole", "start": 15, "end": 18}, {"entity_id": "17420198_19_Ent4", "role": "Treatment_Drug", "text": "aripiprazole", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17420198_19_Ent0", "text": "A patient with developmental disabilities who had no history of movement disorders", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "17420198_19_Ent1", "text": "developmental disabilities", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "17420198_19_Ent2", "text": "EPS", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17420198_19_Ent3", "text": "initiation of aripiprazole", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "17420198_19_Ent4", "text": "aripiprazole", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17438184_3", "wnd_id": "17438184_3_1", "text": "OBSERVATIONS : A 48 - year - old woman presented with disfiguring facial edema 10 weeks after she began antiviral therapy with peginterferon alfa - 2a and ribavirin for chronic hepatitis C infection .", "tokens": ["OBSERVATIONS", ":", "A", "48", "-", "year", "-", "old", "woman", "presented", "with", "disfiguring", "facial", "edema", "10", "weeks", "after", "she", "began", "antiviral", "therapy", "with", "peginterferon", "alfa", "-", "2a", "and", "ribavirin", "for", "chronic", "hepatitis", "C", "infection", "."], "event_mentions": [{"id": "17438184_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "17438184_3_Ent0", "role": "Subject", "text": "A 48 - year - old woman", "start": 2, "end": 9}, {"entity_id": "17438184_3_Ent1", "role": "Subject_Age", "text": "48 - year - old", "start": 3, "end": 8}, {"entity_id": "17438184_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "17438184_3_Ent3", "role": "Effect", "text": "disfiguring facial edema", "start": 11, "end": 14}, {"entity_id": "17438184_3_Ent4", "role": "Treatment", "text": "10 weeks", "start": 14, "end": 16}, {"entity_id": "17438184_3_Ent7", "role": "Treatment_Time_elapsed", "text": "10 weeks", "start": 14, "end": 16}, {"entity_id": "17438184_3_Ent5", "role": "Treatment", "text": "antiviral therapy with peginterferon alfa - 2a and ribavirin", "start": 19, "end": 28}, {"entity_id": "17438184_3_Ent8", "role": "Treatment_Drug", "text": "peginterferon alfa - 2a", "start": 22, "end": 26}, {"entity_id": "17438184_3_Ent10", "role": "Combination_Drug", "text": "peginterferon alfa - 2a", "start": 22, "end": 26}, {"entity_id": "17438184_3_Ent9", "role": "Treatment_Drug", "text": "ribavirin", "start": 27, "end": 28}, {"entity_id": "17438184_3_Ent11", "role": "Combination_Drug", "text": "ribavirin", "start": 27, "end": 28}, {"entity_id": "17438184_3_Ent6", "role": "Treatment_Disorder", "text": "chronic hepatitis C infection", "start": 29, "end": 33}]}], "entity_mentions": [{"id": "17438184_3_Ent0", "text": "A 48 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "17438184_3_Ent1", "text": "48 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "17438184_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17438184_3_Ent3", "text": "disfiguring facial edema", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17438184_3_Ent4", "text": "10 weeks", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17438184_3_Ent7", "text": "10 weeks", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17438184_3_Ent5", "text": "antiviral therapy with peginterferon alfa - 2a and ribavirin", "entity_type": "Entity", "start": 19, "end": 28}, {"id": "17438184_3_Ent8", "text": "peginterferon alfa - 2a", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "17438184_3_Ent10", "text": "peginterferon alfa - 2a", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "17438184_3_Ent9", "text": "ribavirin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17438184_3_Ent11", "text": "ribavirin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17438184_3_Ent6", "text": "chronic hepatitis C infection", "entity_type": "Entity", "start": 29, "end": 33}], "lang": "en"}
{"doc_id": "17444802_14", "wnd_id": "17444802_14_1", "text": "CONCLUSIONS : Topical INF alpha 2 - beta is a valid choice for the treatment of CIN in patients for whom surgery is not possible .", "tokens": ["CONCLUSIONS", ":", "Topical", "INF", "alpha", "2", "-", "beta", "is", "a", "valid", "choice", "for", "the", "treatment", "of", "CIN", "in", "patients", "for", "whom", "surgery", "is", "not", "possible", "."], "event_mentions": [{"id": "17444802_14_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "a valid choice", "start": 9, "end": 12}, "arguments": [{"entity_id": "17444802_14_Ent3", "role": "Treatment_Route", "text": "Topical", "start": 2, "end": 3}, {"entity_id": "17444802_14_Ent1", "role": "Treatment", "text": "Topical INF alpha 2 - beta", "start": 2, "end": 8}, {"entity_id": "17444802_14_Ent4", "role": "Treatment_Drug", "text": "INF alpha 2 - beta", "start": 3, "end": 8}, {"entity_id": "17444802_14_Ent2", "role": "Treatment_Disorder", "text": "CIN", "start": 16, "end": 17}, {"entity_id": "17444802_14_Ent0", "role": "Subject", "text": "patients for whom surgery is not possible", "start": 18, "end": 25}]}], "entity_mentions": [{"id": "17444802_14_Ent3", "text": "Topical", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17444802_14_Ent1", "text": "Topical INF alpha 2 - beta", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "17444802_14_Ent4", "text": "INF alpha 2 - beta", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "17444802_14_Ent2", "text": "CIN", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17444802_14_Ent0", "text": "patients for whom surgery is not possible", "entity_type": "Entity", "start": 18, "end": 25}], "lang": "en"}
{"doc_id": "17448102_1", "wnd_id": "17448102_1_1", "text": "Managing cardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy .", "tokens": ["Managing", "cardiovascular", "collapse", "in", "severe", "flecainide", "overdose", "without", "recourse", "to", "extracorporeal", "therapy", "."], "event_mentions": [{"id": "17448102_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "17448102_1_Ent0", "role": "Effect", "text": "cardiovascular collapse", "start": 1, "end": 3}, {"entity_id": "17448102_1_Ent1", "role": "Treatment", "text": "severe flecainide overdose", "start": 4, "end": 7}, {"entity_id": "17448102_1_Ent2", "role": "Treatment_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "17448102_1_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "17448102_1_Ent0", "text": "cardiovascular collapse", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "17448102_1_Ent1", "text": "severe flecainide overdose", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "17448102_1_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17448102_1_Ent3", "text": "overdose", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "1747495_2", "wnd_id": "1747495_2_1", "text": "A case of liver damage following treatment with Danazol for fibrocystic breast disease is reported .", "tokens": ["A", "case", "of", "liver", "damage", "following", "treatment", "with", "Danazol", "for", "fibrocystic", "breast", "disease", "is", "reported", "."], "event_mentions": [{"id": "1747495_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "1747495_2_Ent0", "role": "Effect", "text": "liver damage", "start": 3, "end": 5}, {"entity_id": "1747495_2_Ent1", "role": "Treatment", "text": "Danazol", "start": 8, "end": 9}, {"entity_id": "1747495_2_Ent2", "role": "Treatment_Drug", "text": "Danazol", "start": 8, "end": 9}, {"entity_id": "1747495_2_Ent3", "role": "Treatment_Disorder", "text": "fibrocystic breast disease", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "1747495_2_Ent0", "text": "liver damage", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "1747495_2_Ent1", "text": "Danazol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1747495_2_Ent2", "text": "Danazol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1747495_2_Ent3", "text": "fibrocystic breast disease", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "17519584_1", "wnd_id": "17519584_1_1", "text": "A 61 - year - old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed generalized erythema with high fever 3 weeks after taking sulfamethoxazole / trimethoprim .", "tokens": ["A", "61", "-", "year", "-", "old", "man", "with", "early", "diffuse", "cutaneous", "scleroderma", "with", "myositis", "and", "progressive", "interstitial", "pneumonia", "developed", "generalized", "erythema", "with", "high", "fever", "3", "weeks", "after", "taking", "sulfamethoxazole", "/", "trimethoprim", "."], "event_mentions": [{"id": "17519584_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 27, "end": 28}, "arguments": [{"entity_id": "17519584_1_Ent0", "role": "Subject", "text": "A 61 - year - old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia", "start": 0, "end": 18}, {"entity_id": "17519584_1_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 1, "end": 6}, {"entity_id": "17519584_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "17519584_1_Ent3", "role": "Subject_Disorder", "text": "early diffuse cutaneous scleroderma with myositis", "start": 8, "end": 14}, {"entity_id": "17519584_1_Ent4", "role": "Subject_Disorder", "text": "progressive interstitial pneumonia", "start": 15, "end": 18}, {"entity_id": "17519584_1_Ent5", "role": "Effect", "text": "generalized erythema with high fever", "start": 19, "end": 24}, {"entity_id": "17519584_1_Ent9", "role": "Treatment_Time_elapsed", "text": "3 weeks after", "start": 24, "end": 27}, {"entity_id": "17519584_1_Ent7", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 28, "end": 29}, {"entity_id": "17519584_1_Ent11", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 28, "end": 29}, {"entity_id": "17519584_1_Ent6", "role": "Treatment", "text": "sulfamethoxazole / trimethoprim", "start": 28, "end": 31}, {"entity_id": "17519584_1_Ent8", "role": "Treatment_Drug", "text": "trimethoprim", "start": 30, "end": 31}, {"entity_id": "17519584_1_Ent10", "role": "Combination_Drug", "text": "trimethoprim", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "17519584_1_Ent0", "text": "A 61 - year - old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "17519584_1_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17519584_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17519584_1_Ent3", "text": "early diffuse cutaneous scleroderma with myositis", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "17519584_1_Ent4", "text": "progressive interstitial pneumonia", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "17519584_1_Ent5", "text": "generalized erythema with high fever", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "17519584_1_Ent9", "text": "3 weeks after", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "17519584_1_Ent7", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "17519584_1_Ent11", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "17519584_1_Ent6", "text": "sulfamethoxazole / trimethoprim", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "17519584_1_Ent8", "text": "trimethoprim", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "17519584_1_Ent10", "text": "trimethoprim", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "17526968_1", "wnd_id": "17526968_1_1", "text": "Bleomycin induced hyperpigmentation with yolk sac tumor .", "tokens": ["Bleomycin", "induced", "hyperpigmentation", "with", "yolk", "sac", "tumor", "."], "event_mentions": [{"id": "17526968_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "17526968_1_Ent1", "role": "Treatment", "text": "Bleomycin", "start": 0, "end": 1}, {"entity_id": "17526968_1_Ent2", "role": "Treatment_Drug", "text": "Bleomycin", "start": 0, "end": 1}, {"entity_id": "17526968_1_Ent0", "role": "Effect", "text": "hyperpigmentation with yolk sac tumor", "start": 2, "end": 7}]}], "entity_mentions": [{"id": "17526968_1_Ent1", "text": "Bleomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17526968_1_Ent2", "text": "Bleomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17526968_1_Ent0", "text": "hyperpigmentation with yolk sac tumor", "entity_type": "Entity", "start": 2, "end": 7}], "lang": "en"}
{"doc_id": "17536204_4", "wnd_id": "17536204_4_1", "text": "CCBs should be considered in the treatment of 5 - FU or capecitabine - induced headaches .", "tokens": ["CCBs", "should", "be", "considered", "in", "the", "treatment", "of", "5", "-", "FU", "or", "capecitabine", "-", "induced", "headaches", "."], "event_mentions": [{"id": "17536204_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 6, "end": 7}, "arguments": [{"entity_id": "17536204_4_Ent0", "role": "Treatment", "text": "CCBs", "start": 0, "end": 1}, {"entity_id": "17536204_4_Ent1", "role": "Treatment_Drug", "text": "CCBs", "start": 0, "end": 1}, {"entity_id": "17536204_4_Ent2", "role": "Treatment_Disorder", "text": "headaches", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "17536204_4_Ent0", "text": "CCBs", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17536204_4_Ent1", "text": "CCBs", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17536204_4_Ent2", "text": "headaches", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "1756352_2", "wnd_id": "1756352_2_1", "text": "Delusional parasitosis associated with phenelzine .", "tokens": ["Delusional", "parasitosis", "associated", "with", "phenelzine", "."], "event_mentions": [{"id": "1756352_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1756352_2_Ent0", "role": "Effect", "text": "Delusional parasitosis", "start": 0, "end": 2}, {"entity_id": "1756352_2_Ent1", "role": "Treatment", "text": "phenelzine", "start": 4, "end": 5}, {"entity_id": "1756352_2_Ent2", "role": "Treatment_Drug", "text": "phenelzine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "1756352_2_Ent0", "text": "Delusional parasitosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1756352_2_Ent1", "text": "phenelzine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1756352_2_Ent2", "text": "phenelzine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "17596682_2", "wnd_id": "17596682_2_1", "text": "The use of rituximab has been uncommonly associated with delayed pulmonary toxicity .", "tokens": ["The", "use", "of", "rituximab", "has", "been", "uncommonly", "associated", "with", "delayed", "pulmonary", "toxicity", "."], "event_mentions": [{"id": "17596682_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "17596682_2_Ent1", "role": "Treatment", "text": "rituximab", "start": 3, "end": 4}, {"entity_id": "17596682_2_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 3, "end": 4}, {"entity_id": "17596682_2_Ent0", "role": "Effect", "text": "delayed pulmonary toxicity", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "17596682_2_Ent1", "text": "rituximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17596682_2_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17596682_2_Ent0", "text": "delayed pulmonary toxicity", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "17619811_2", "wnd_id": "17619811_2_1", "text": "A case of colchicine - induced rhabdomyolysis is reported .", "tokens": ["A", "case", "of", "colchicine", "-", "induced", "rhabdomyolysis", "is", "reported", "."], "event_mentions": [{"id": "17619811_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17619811_2_Ent1", "role": "Treatment", "text": "colchicine", "start": 3, "end": 4}, {"entity_id": "17619811_2_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 3, "end": 4}, {"entity_id": "17619811_2_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "17619811_2_Ent1", "text": "colchicine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17619811_2_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17619811_2_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "17619811_3", "wnd_id": "17619811_3_1", "text": "Colchicine - induced rhabdomyolysis is a rare complication , and the postulated mechanisms and risk factors for this severe complication are discussed .", "tokens": ["Colchicine", "-", "induced", "rhabdomyolysis", "is", "a", "rare", "complication", ",", "and", "the", "postulated", "mechanisms", "and", "risk", "factors", "for", "this", "severe", "complication", "are", "discussed", "."], "event_mentions": [{"id": "17619811_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17619811_3_Ent1", "role": "Treatment", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "17619811_3_Ent2", "role": "Treatment_Drug", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "17619811_3_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "17619811_3_Ent1", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17619811_3_Ent2", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17619811_3_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "17619811_4", "wnd_id": "17619811_4_1", "text": "Colchicine - induced rhabdomyolysis .", "tokens": ["Colchicine", "-", "induced", "rhabdomyolysis", "."], "event_mentions": [{"id": "17619811_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17619811_4_Ent1", "role": "Treatment", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "17619811_4_Ent2", "role": "Treatment_Drug", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "17619811_4_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "17619811_4_Ent1", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17619811_4_Ent2", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17619811_4_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "17619811_5", "wnd_id": "17619811_5_1", "text": "Investigation confirmed the diagnosis of rhabdomyolysis , and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis .", "tokens": ["Investigation", "confirmed", "the", "diagnosis", "of", "rhabdomyolysis", ",", "and", "discontinuation", "of", "colchicine", "resulted", "in", "resolution", "of", "clinical", "and", "biochemical", "features", "of", "rhabdomylysis", "."], "event_mentions": [{"id": "17619811_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 11, "end": 12}, "arguments": [{"entity_id": "17619811_5_Ent1", "role": "Treatment", "text": "colchicine", "start": 10, "end": 11}, {"entity_id": "17619811_5_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 10, "end": 11}, {"entity_id": "17619811_5_Ent0", "role": "Effect", "text": "rhabdomylysis", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "17619811_5_Ent1", "text": "colchicine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17619811_5_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17619811_5_Ent0", "text": "rhabdomylysis", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "17624096_1", "wnd_id": "17624096_1_1", "text": "5 - Fluorouracil cardiotoxicity complicating treatment of stage IIB cervical cancer -- case report .", "tokens": ["5", "-", "Fluorouracil", "cardiotoxicity", "complicating", "treatment", "of", "stage", "IIB", "cervical", "cancer", "--", "case", "report", "."], "event_mentions": [{"id": "17624096_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicating", "start": 4, "end": 5}, "arguments": [{"entity_id": "17624096_1_Ent1", "role": "Treatment", "text": "5 - Fluorouracil", "start": 0, "end": 3}, {"entity_id": "17624096_1_Ent2", "role": "Treatment_Drug", "text": "5 - Fluorouracil", "start": 0, "end": 3}, {"entity_id": "17624096_1_Ent0", "role": "Effect", "text": "cardiotoxicity", "start": 3, "end": 4}, {"entity_id": "17624096_1_Ent3", "role": "Treatment_Disorder", "text": "cervical cancer", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "17624096_1_Ent1", "text": "5 - Fluorouracil", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17624096_1_Ent2", "text": "5 - Fluorouracil", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17624096_1_Ent0", "text": "cardiotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17624096_1_Ent3", "text": "cervical cancer", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "17667887_3", "wnd_id": "17667887_3_1", "text": "The first case is a 69 - year - old man who was admitted for depression with psychosis and treated with trazodone , risperidone , and sertraline .", "tokens": ["The", "first", "case", "is", "a", "69", "-", "year", "-", "old", "man", "who", "was", "admitted", "for", "depression", "with", "psychosis", "and", "treated", "with", "trazodone", ",", "risperidone", ",", "and", "sertraline", "."], "event_mentions": [{"id": "17667887_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 19, "end": 20}, "arguments": [{"entity_id": "17667887_3_Ent0", "role": "Subject", "text": "a 69 - year - old man who was admitted for depression with psychosis", "start": 4, "end": 18}, {"entity_id": "17667887_3_Ent1", "role": "Subject_Age", "text": "69 - year - old", "start": 5, "end": 10}, {"entity_id": "17667887_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 10, "end": 11}, {"entity_id": "17667887_3_Ent7", "role": "Treatment_Disorder", "text": "depression with psychosis", "start": 15, "end": 18}, {"entity_id": "17667887_3_Ent4", "role": "Treatment_Drug", "text": "trazodone", "start": 21, "end": 22}, {"entity_id": "17667887_3_Ent10", "role": "Combination_Drug", "text": "trazodone", "start": 21, "end": 22}, {"entity_id": "17667887_3_Ent3", "role": "Treatment", "text": "trazodone , risperidone , and sertraline", "start": 21, "end": 27}, {"entity_id": "17667887_3_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 23, "end": 24}, {"entity_id": "17667887_3_Ent8", "role": "Combination_Drug", "text": "risperidone", "start": 23, "end": 24}, {"entity_id": "17667887_3_Ent6", "role": "Treatment_Drug", "text": "sertraline", "start": 26, "end": 27}, {"entity_id": "17667887_3_Ent9", "role": "Combination_Drug", "text": "sertraline", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "17667887_3_Ent0", "text": "a 69 - year - old man who was admitted for depression with psychosis", "entity_type": "Entity", "start": 4, "end": 18}, {"id": "17667887_3_Ent1", "text": "69 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "17667887_3_Ent2", "text": "man", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17667887_3_Ent7", "text": "depression with psychosis", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "17667887_3_Ent4", "text": "trazodone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17667887_3_Ent10", "text": "trazodone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17667887_3_Ent3", "text": "trazodone , risperidone , and sertraline", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "17667887_3_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17667887_3_Ent8", "text": "risperidone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17667887_3_Ent6", "text": "sertraline", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "17667887_3_Ent9", "text": "sertraline", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "17667887_8", "wnd_id": "17667887_8_1", "text": "In both cases , we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic .", "tokens": ["In", "both", "cases", ",", "we", "believe", "that", "serotonin", "syndrome", "was", "produced", "by", "a", "combination", "of", "an", "antidepressant", "and", "an", "atypical", "antipsychotic", "."], "event_mentions": [{"id": "17667887_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produced", "start": 10, "end": 11}, "arguments": [{"entity_id": "17667887_8_Ent0", "role": "Subject", "text": "In both cases", "start": 0, "end": 3}, {"entity_id": "17667887_8_Ent1", "role": "Subject_Population", "text": "both", "start": 1, "end": 2}, {"entity_id": "17667887_8_Ent2", "role": "Effect", "text": "serotonin syndrome", "start": 7, "end": 9}, {"entity_id": "17667887_8_Ent3", "role": "Treatment", "text": "a combination of an antidepressant and an atypical antipsychotic", "start": 12, "end": 21}, {"entity_id": "17667887_8_Ent4", "role": "Treatment_Drug", "text": "antidepressant", "start": 16, "end": 17}, {"entity_id": "17667887_8_Ent6", "role": "Combination_Drug", "text": "antidepressant", "start": 16, "end": 17}, {"entity_id": "17667887_8_Ent5", "role": "Treatment_Drug", "text": "atypical antipsychotic", "start": 19, "end": 21}, {"entity_id": "17667887_8_Ent7", "role": "Combination_Drug", "text": "atypical antipsychotic", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "17667887_8_Ent0", "text": "In both cases", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17667887_8_Ent1", "text": "both", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17667887_8_Ent2", "text": "serotonin syndrome", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "17667887_8_Ent3", "text": "a combination of an antidepressant and an atypical antipsychotic", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "17667887_8_Ent4", "text": "antidepressant", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17667887_8_Ent6", "text": "antidepressant", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17667887_8_Ent5", "text": "atypical antipsychotic", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "17667887_8_Ent7", "text": "atypical antipsychotic", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "17671884_3", "wnd_id": "17671884_3_1", "text": "An apparent link is described between the use of MMF with prednisone to treat pemphigus vulgaris and the development of red blood cell anemia .", "tokens": ["An", "apparent", "link", "is", "described", "between", "the", "use", "of", "MMF", "with", "prednisone", "to", "treat", "pemphigus", "vulgaris", "and", "the", "development", "of", "red", "blood", "cell", "anemia", "."], "event_mentions": [{"id": "17671884_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 18, "end": 19}, "arguments": [{"entity_id": "17671884_3_Ent3", "role": "Treatment_Drug", "text": "MMF", "start": 9, "end": 10}, {"entity_id": "17671884_3_Ent5", "role": "Combination_Drug", "text": "MMF", "start": 9, "end": 10}, {"entity_id": "17671884_3_Ent1", "role": "Treatment", "text": "MMF with prednisone to treat pemphigus vulgaris", "start": 9, "end": 16}, {"entity_id": "17671884_3_Ent4", "role": "Treatment_Drug", "text": "prednisone", "start": 11, "end": 12}, {"entity_id": "17671884_3_Ent6", "role": "Combination_Drug", "text": "prednisone", "start": 11, "end": 12}, {"entity_id": "17671884_3_Ent2", "role": "Treatment_Disorder", "text": "pemphigus vulgaris", "start": 14, "end": 16}, {"entity_id": "17671884_3_Ent0", "role": "Effect", "text": "red blood cell anemia", "start": 20, "end": 24}]}], "entity_mentions": [{"id": "17671884_3_Ent3", "text": "MMF", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17671884_3_Ent5", "text": "MMF", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17671884_3_Ent1", "text": "MMF with prednisone to treat pemphigus vulgaris", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "17671884_3_Ent4", "text": "prednisone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17671884_3_Ent6", "text": "prednisone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17671884_3_Ent2", "text": "pemphigus vulgaris", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17671884_3_Ent0", "text": "red blood cell anemia", "entity_type": "Entity", "start": 20, "end": 24}], "lang": "en"}
{"doc_id": "17671884_7", "wnd_id": "17671884_7_1", "text": "One previous study of four transplant patients whose immediate post - transplantation immunosuppression utilized corticosteroids , cyclosporine , MMF , and anti - T - lymphocyte globulin noted anemia in 13 % of them .", "tokens": ["One", "previous", "study", "of", "four", "transplant", "patients", "whose", "immediate", "post", "-", "transplantation", "immunosuppression", "utilized", "corticosteroids", ",", "cyclosporine", ",", "MMF", ",", "and", "anti", "-", "T", "-", "lymphocyte", "globulin", "noted", "anemia", "in", "13", "%", "of", "them", "."], "event_mentions": [{"id": "17671884_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "noted", "start": 27, "end": 28}, "arguments": [{"entity_id": "17671884_7_Ent1", "role": "Subject_Population", "text": "four", "start": 4, "end": 5}, {"entity_id": "17671884_7_Ent0", "role": "Subject", "text": "four transplant patients", "start": 4, "end": 7}, {"entity_id": "17671884_7_Ent2", "role": "Subject_Disorder", "text": "transplant", "start": 5, "end": 6}, {"entity_id": "17671884_7_Ent4", "role": "Treatment", "text": "immediate post - transplantation immunosuppression utilized corticosteroids , cyclosporine , MMF , and anti - T - lymphocyte globulin", "start": 8, "end": 27}, {"entity_id": "17671884_7_Ent9", "role": "Treatment_Disorder", "text": "post - transplantation immunosuppression", "start": 9, "end": 13}, {"entity_id": "17671884_7_Ent5", "role": "Treatment_Drug", "text": "corticosteroids", "start": 14, "end": 15}, {"entity_id": "17671884_7_Ent10", "role": "Combination_Drug", "text": "corticosteroids", "start": 14, "end": 15}, {"entity_id": "17671884_7_Ent6", "role": "Treatment_Drug", "text": "cyclosporine", "start": 16, "end": 17}, {"entity_id": "17671884_7_Ent11", "role": "Combination_Drug", "text": "cyclosporine", "start": 16, "end": 17}, {"entity_id": "17671884_7_Ent7", "role": "Treatment_Drug", "text": "MMF", "start": 18, "end": 19}, {"entity_id": "17671884_7_Ent12", "role": "Combination_Drug", "text": "MMF", "start": 18, "end": 19}, {"entity_id": "17671884_7_Ent8", "role": "Treatment_Drug", "text": "anti - T - lymphocyte globulin", "start": 21, "end": 27}, {"entity_id": "17671884_7_Ent13", "role": "Combination_Drug", "text": "anti - T - lymphocyte globulin", "start": 21, "end": 27}, {"entity_id": "17671884_7_Ent3", "role": "Effect", "text": "anemia", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "17671884_7_Ent1", "text": "four", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17671884_7_Ent0", "text": "four transplant patients", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "17671884_7_Ent2", "text": "transplant", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17671884_7_Ent4", "text": "immediate post - transplantation immunosuppression utilized corticosteroids , cyclosporine , MMF , and anti - T - lymphocyte globulin", "entity_type": "Entity", "start": 8, "end": 27}, {"id": "17671884_7_Ent9", "text": "post - transplantation immunosuppression", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "17671884_7_Ent5", "text": "corticosteroids", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17671884_7_Ent10", "text": "corticosteroids", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17671884_7_Ent6", "text": "cyclosporine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17671884_7_Ent11", "text": "cyclosporine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17671884_7_Ent7", "text": "MMF", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17671884_7_Ent12", "text": "MMF", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17671884_7_Ent8", "text": "anti - T - lymphocyte globulin", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "17671884_7_Ent13", "text": "anti - T - lymphocyte globulin", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "17671884_7_Ent3", "text": "anemia", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "17671884_8", "wnd_id": "17671884_8_1", "text": "The dermatology literature heretofore has not noted that anemia is a side effect of patients taking MMF to treat pemphigus .", "tokens": ["The", "dermatology", "literature", "heretofore", "has", "not", "noted", "that", "anemia", "is", "a", "side", "effect", "of", "patients", "taking", "MMF", "to", "treat", "pemphigus", "."], "event_mentions": [{"id": "17671884_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "is", "start": 9, "end": 10}, "arguments": [{"entity_id": "17671884_8_Ent1", "role": "Effect", "text": "anemia", "start": 8, "end": 9}, {"entity_id": "17671884_8_Ent0", "role": "Subject", "text": "patients", "start": 14, "end": 15}, {"entity_id": "17671884_8_Ent2", "role": "Treatment", "text": "MMF", "start": 16, "end": 17}, {"entity_id": "17671884_8_Ent3", "role": "Treatment_Disorder", "text": "pemphigus", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "17671884_8_Ent1", "text": "anemia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17671884_8_Ent0", "text": "patients", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17671884_8_Ent2", "text": "MMF", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17671884_8_Ent3", "text": "pemphigus", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "17675030_2", "wnd_id": "17675030_2_1", "text": "Clinical profile of oxcarbazepine - related angioneurotic edema : case report and review .", "tokens": ["Clinical", "profile", "of", "oxcarbazepine", "-", "related", "angioneurotic", "edema", ":", "case", "report", "and", "review", "."], "event_mentions": [{"id": "17675030_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 5, "end": 6}, "arguments": [{"entity_id": "17675030_2_Ent2", "role": "Treatment", "text": "oxcarbazepine", "start": 3, "end": 4}, {"entity_id": "17675030_2_Ent3", "role": "Treatment_Drug", "text": "oxcarbazepine", "start": 3, "end": 4}, {"entity_id": "17675030_2_Ent1", "role": "Effect", "text": "angioneurotic edema", "start": 6, "end": 8}, {"entity_id": "17675030_2_Ent0", "role": "Subject", "text": "case", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "17675030_2_Ent2", "text": "oxcarbazepine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17675030_2_Ent3", "text": "oxcarbazepine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17675030_2_Ent1", "text": "angioneurotic edema", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17675030_2_Ent0", "text": "case", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "17697264_2", "wnd_id": "17697264_2_1", "text": "One case of tacrolimus - induced hepatic VOD developing after lung transplantation ( LT ) has been recently reported .", "tokens": ["One", "case", "of", "tacrolimus", "-", "induced", "hepatic", "VOD", "developing", "after", "lung", "transplantation", "(", "LT", ")", "has", "been", "recently", "reported", "."], "event_mentions": [{"id": "17697264_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17697264_2_Ent1", "role": "Treatment", "text": "tacrolimus", "start": 3, "end": 4}, {"entity_id": "17697264_2_Ent3", "role": "Treatment_Drug", "text": "tacrolimus", "start": 3, "end": 4}, {"entity_id": "17697264_2_Ent0", "role": "Effect", "text": "hepatic VOD", "start": 6, "end": 8}, {"entity_id": "17697264_2_Ent2", "role": "Treatment", "text": "after lung transplantation ( LT )", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "17697264_2_Ent1", "text": "tacrolimus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17697264_2_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17697264_2_Ent0", "text": "hepatic VOD", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17697264_2_Ent2", "text": "after lung transplantation ( LT )", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "17873198_4", "wnd_id": "17873198_4_1", "text": "This case and other published evidence should alert physicians to the possibility of fatal erlotinib - induced ILD .", "tokens": ["This", "case", "and", "other", "published", "evidence", "should", "alert", "physicians", "to", "the", "possibility", "of", "fatal", "erlotinib", "-", "induced", "ILD", "."], "event_mentions": [{"id": "17873198_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 16, "end": 17}, "arguments": [{"entity_id": "17873198_4_Ent0", "role": "Subject", "text": "This case", "start": 0, "end": 2}, {"entity_id": "17873198_4_Ent2", "role": "Treatment", "text": "erlotinib", "start": 14, "end": 15}, {"entity_id": "17873198_4_Ent3", "role": "Treatment_Drug", "text": "erlotinib", "start": 14, "end": 15}, {"entity_id": "17873198_4_Ent1", "role": "Effect", "text": "ILD", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17873198_4_Ent0", "text": "This case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17873198_4_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17873198_4_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17873198_4_Ent1", "text": "ILD", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17873198_5", "wnd_id": "17873198_5_1", "text": "We report a case of fatal pulmonary toxicity in a patient with advanced non - small cell lung cancer who received erlotinib .", "tokens": ["We", "report", "a", "case", "of", "fatal", "pulmonary", "toxicity", "in", "a", "patient", "with", "advanced", "non", "-", "small", "cell", "lung", "cancer", "who", "received", "erlotinib", "."], "event_mentions": [{"id": "17873198_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "received", "start": 20, "end": 21}, "arguments": [{"entity_id": "17873198_5_Ent1", "role": "Effect", "text": "pulmonary toxicity", "start": 6, "end": 8}, {"entity_id": "17873198_5_Ent0", "role": "Subject", "text": "a patient with advanced non - small cell lung cancer", "start": 9, "end": 19}, {"entity_id": "17873198_5_Ent3", "role": "Treatment_Disorder", "text": "advanced non - small cell lung cancer", "start": 12, "end": 19}, {"entity_id": "17873198_5_Ent2", "role": "Treatment", "text": "erlotinib", "start": 21, "end": 22}, {"entity_id": "17873198_5_Ent4", "role": "Treatment_Drug", "text": "erlotinib", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "17873198_5_Ent1", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17873198_5_Ent0", "text": "a patient with advanced non - small cell lung cancer", "entity_type": "Entity", "start": 9, "end": 19}, {"id": "17873198_5_Ent3", "text": "advanced non - small cell lung cancer", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "17873198_5_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17873198_5_Ent4", "text": "erlotinib", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "17921794_2", "wnd_id": "17921794_2_1", "text": "Rapid onset of muscle weakness ( rhabdomyolysis ) associated with the combined use of simvastatin and colchicine .", "tokens": ["Rapid", "onset", "of", "muscle", "weakness", "(", "rhabdomyolysis", ")", "associated", "with", "the", "combined", "use", "of", "simvastatin", "and", "colchicine", "."], "event_mentions": [{"id": "17921794_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 8, "end": 10}, "arguments": [{"entity_id": "17921794_2_Ent0", "role": "Effect", "text": "Rapid onset of muscle weakness ( rhabdomyolysis )", "start": 0, "end": 8}, {"entity_id": "17921794_2_Ent1", "role": "Treatment", "text": "the combined use of simvastatin and colchicine", "start": 10, "end": 17}, {"entity_id": "17921794_2_Ent2", "role": "Treatment_Drug", "text": "simvastatin", "start": 14, "end": 15}, {"entity_id": "17921794_2_Ent4", "role": "Combination_Drug", "text": "simvastatin", "start": 14, "end": 15}, {"entity_id": "17921794_2_Ent3", "role": "Treatment_Drug", "text": "colchicine", "start": 16, "end": 17}, {"entity_id": "17921794_2_Ent5", "role": "Combination_Drug", "text": "colchicine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "17921794_2_Ent0", "text": "Rapid onset of muscle weakness ( rhabdomyolysis )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "17921794_2_Ent1", "text": "the combined use of simvastatin and colchicine", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "17921794_2_Ent2", "text": "simvastatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17921794_2_Ent4", "text": "simvastatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17921794_2_Ent3", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17921794_2_Ent5", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "1792646_1", "wnd_id": "1792646_1_1", "text": "Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma .", "tokens": ["Pneumocystis", "carinii", "pneumonia", "as", "a", "complication", "of", "methotrexate", "treatment", "of", "asthma", "."], "event_mentions": [{"id": "1792646_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 5, "end": 6}, "arguments": [{"entity_id": "1792646_1_Ent0", "role": "Effect", "text": "Pneumocystis carinii pneumonia", "start": 0, "end": 3}, {"entity_id": "1792646_1_Ent1", "role": "Treatment", "text": "methotrexate", "start": 7, "end": 8}, {"entity_id": "1792646_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 7, "end": 8}, {"entity_id": "1792646_1_Ent3", "role": "Treatment_Disorder", "text": "asthma", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "1792646_1_Ent0", "text": "Pneumocystis carinii pneumonia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1792646_1_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1792646_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1792646_1_Ent3", "text": "asthma", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17931455_1", "wnd_id": "17931455_1_1", "text": "CASE REPORT : A six - year - old boy with transfusion - dependent beta - thalassaemia developed a unilateral hearing loss shortly after commencing desferrioxamine therapy .", "tokens": ["CASE", "REPORT", ":", "A", "six", "-", "year", "-", "old", "boy", "with", "transfusion", "-", "dependent", "beta", "-", "thalassaemia", "developed", "a", "unilateral", "hearing", "loss", "shortly", "after", "commencing", "desferrioxamine", "therapy", "."], "event_mentions": [{"id": "17931455_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "17931455_1_Ent0", "role": "Subject", "text": "A six - year - old boy with transfusion - dependent beta - thalassaemia", "start": 3, "end": 17}, {"entity_id": "17931455_1_Ent1", "role": "Subject_Age", "text": "six - year - old", "start": 4, "end": 9}, {"entity_id": "17931455_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 9, "end": 10}, {"entity_id": "17931455_1_Ent5", "role": "Treatment_Disorder", "text": "transfusion - dependent beta - thalassaemia", "start": 11, "end": 17}, {"entity_id": "17931455_1_Ent3", "role": "Effect", "text": "a unilateral hearing loss", "start": 18, "end": 22}, {"entity_id": "17931455_1_Ent6", "role": "Treatment_Time_elapsed", "text": "shortly after", "start": 22, "end": 24}, {"entity_id": "17931455_1_Ent4", "role": "Treatment", "text": "commencing desferrioxamine therapy", "start": 24, "end": 27}, {"entity_id": "17931455_1_Ent7", "role": "Treatment_Drug", "text": "desferrioxamine", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "17931455_1_Ent0", "text": "A six - year - old boy with transfusion - dependent beta - thalassaemia", "entity_type": "Entity", "start": 3, "end": 17}, {"id": "17931455_1_Ent1", "text": "six - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "17931455_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17931455_1_Ent5", "text": "transfusion - dependent beta - thalassaemia", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "17931455_1_Ent3", "text": "a unilateral hearing loss", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "17931455_1_Ent6", "text": "shortly after", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "17931455_1_Ent4", "text": "commencing desferrioxamine therapy", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "17931455_1_Ent7", "text": "desferrioxamine", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "17937473_2", "wnd_id": "17937473_2_1", "text": "Leflunomide - associated infections in rheumatoid arthritis .", "tokens": ["Leflunomide", "-", "associated", "infections", "in", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "17937473_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "17937473_2_Ent1", "role": "Treatment", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "17937473_2_Ent2", "role": "Treatment_Drug", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "17937473_2_Ent0", "role": "Effect", "text": "infections", "start": 3, "end": 4}, {"entity_id": "17937473_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "17937473_2_Ent1", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17937473_2_Ent2", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17937473_2_Ent0", "text": "infections", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17937473_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "17937473_3", "wnd_id": "17937473_3_1", "text": "The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide .", "tokens": ["The", "NZ", "Pharmacovigilance", "Centre", "has", "received", "7", "additional", "reports", "of", "severe", "infections", "in", "patients", "with", "RA", "taking", "leflunomide", "."], "event_mentions": [{"id": "17937473_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 16, "end": 17}, "arguments": [{"entity_id": "17937473_3_Ent1", "role": "Effect", "text": "severe infections", "start": 10, "end": 12}, {"entity_id": "17937473_3_Ent0", "role": "Subject", "text": "patients with RA", "start": 13, "end": 16}, {"entity_id": "17937473_3_Ent3", "role": "Treatment_Disorder", "text": "RA", "start": 15, "end": 16}, {"entity_id": "17937473_3_Ent2", "role": "Treatment", "text": "leflunomide", "start": 17, "end": 18}, {"entity_id": "17937473_3_Ent4", "role": "Treatment_Drug", "text": "leflunomide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17937473_3_Ent1", "text": "severe infections", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17937473_3_Ent0", "text": "patients with RA", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17937473_3_Ent3", "text": "RA", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17937473_3_Ent2", "text": "leflunomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17937473_3_Ent4", "text": "leflunomide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "18006091_2", "wnd_id": "18006091_2_1", "text": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion .", "tokens": ["We", "present", "a", "case", "of", "a", "sustained", "monomorphic", "ventricular", "tachycardia", "following", "adenosine", "infusion", "."], "event_mentions": [{"id": "18006091_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 10, "end": 11}, "arguments": [{"entity_id": "18006091_2_Ent0", "role": "Effect", "text": "sustained monomorphic ventricular tachycardia", "start": 6, "end": 10}, {"entity_id": "18006091_2_Ent2", "role": "Treatment_Drug", "text": "adenosine", "start": 11, "end": 12}, {"entity_id": "18006091_2_Ent1", "role": "Treatment", "text": "adenosine infusion", "start": 11, "end": 13}, {"entity_id": "18006091_2_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "18006091_2_Ent0", "text": "sustained monomorphic ventricular tachycardia", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "18006091_2_Ent2", "text": "adenosine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18006091_2_Ent1", "text": "adenosine infusion", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18006091_2_Ent3", "text": "infusion", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "18020545_1", "wnd_id": "18020545_1_1", "text": "Surprisingly , we found that three patients appeared to develop tardive OGC while taking clozapine .", "tokens": ["Surprisingly", ",", "we", "found", "that", "three", "patients", "appeared", "to", "develop", "tardive", "OGC", "while", "taking", "clozapine", "."], "event_mentions": [{"id": "18020545_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 9, "end": 10}, "arguments": [{"entity_id": "18020545_1_Ent1", "role": "Subject_Population", "text": "three", "start": 5, "end": 6}, {"entity_id": "18020545_1_Ent0", "role": "Subject", "text": "three patients", "start": 5, "end": 7}, {"entity_id": "18020545_1_Ent2", "role": "Effect", "text": "tardive OGC", "start": 10, "end": 12}, {"entity_id": "18020545_1_Ent3", "role": "Treatment", "text": "clozapine", "start": 14, "end": 15}, {"entity_id": "18020545_1_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "18020545_1_Ent1", "text": "three", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18020545_1_Ent0", "text": "three patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18020545_1_Ent2", "text": "tardive OGC", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18020545_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18020545_1_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "18020545_2", "wnd_id": "18020545_2_1", "text": "Tardive oculogyric crisis during treatment with clozapine : report of three cases .", "tokens": ["Tardive", "oculogyric", "crisis", "during", "treatment", "with", "clozapine", ":", "report", "of", "three", "cases", "."], "event_mentions": [{"id": "18020545_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 5, "end": 6}, "arguments": [{"entity_id": "18020545_2_Ent2", "role": "Effect", "text": "Tardive oculogyric crisis", "start": 0, "end": 3}, {"entity_id": "18020545_2_Ent3", "role": "Treatment", "text": "clozapine", "start": 6, "end": 7}, {"entity_id": "18020545_2_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 6, "end": 7}, {"entity_id": "18020545_2_Ent1", "role": "Subject_Population", "text": "three", "start": 10, "end": 11}, {"entity_id": "18020545_2_Ent0", "role": "Subject", "text": "three cases", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18020545_2_Ent2", "text": "Tardive oculogyric crisis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18020545_2_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18020545_2_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18020545_2_Ent1", "text": "three", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18020545_2_Ent0", "text": "three cases", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18071101_2", "wnd_id": "18071101_2_1", "text": "Quetiapine - induced leucopenia and thrombocytopenia .", "tokens": ["Quetiapine", "-", "induced", "leucopenia", "and", "thrombocytopenia", "."], "event_mentions": [{"id": "18071101_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18071101_2_Ent1", "role": "Treatment", "text": "Quetiapine", "start": 0, "end": 1}, {"entity_id": "18071101_2_Ent2", "role": "Treatment_Drug", "text": "Quetiapine", "start": 0, "end": 1}, {"entity_id": "18071101_2_Ent0", "role": "Effect", "text": "leucopenia and thrombocytopenia .", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "18071101_2_Ent1", "text": "Quetiapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18071101_2_Ent2", "text": "Quetiapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18071101_2_Ent0", "text": "leucopenia and thrombocytopenia .", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "18076602_3", "wnd_id": "18076602_3_1", "text": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor .", "tokens": ["We", "present", "a", "case", "of", "cutaneous", "leucocytoclastic", "vasculitis", "in", "which", "amphotericin", "B", "might", "presumably", "be", "the", "aetiological", "factor", "."], "event_mentions": [{"id": "18076602_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "be", "start": 14, "end": 15}, "arguments": [{"entity_id": "18076602_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "18076602_3_Ent1", "role": "Effect", "text": "cutaneous leucocytoclastic vasculitis", "start": 5, "end": 8}, {"entity_id": "18076602_3_Ent2", "role": "Treatment", "text": "amphotericin B", "start": 10, "end": 12}, {"entity_id": "18076602_3_Ent3", "role": "Treatment_Drug", "text": "amphotericin B", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18076602_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18076602_3_Ent1", "text": "cutaneous leucocytoclastic vasculitis", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18076602_3_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18076602_3_Ent3", "text": "amphotericin B", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18176653_4", "wnd_id": "18176653_4_1", "text": "CASE REPORT : A 29 - year - old black man , HIV - infected since 1996 , began highly active antiretroviral therapy ( HAART ) with zidovudine , lamivudine , and indinavir .", "tokens": ["CASE", "REPORT", ":", "A", "29", "-", "year", "-", "old", "black", "man", ",", "HIV", "-", "infected", "since", "1996", ",", "began", "highly", "active", "antiretroviral", "therapy", "(", "HAART", ")", "with", "zidovudine", ",", "lamivudine", ",", "and", "indinavir", "."], "event_mentions": [{"id": "18176653_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "began", "start": 18, "end": 19}, "arguments": [{"entity_id": "18176653_4_Ent0", "role": "Subject", "text": "A 29 - year - old black man , HIV - infected since 1996", "start": 3, "end": 17}, {"entity_id": "18176653_4_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 4, "end": 9}, {"entity_id": "18176653_4_Ent2", "role": "Subject_Race", "text": "black", "start": 9, "end": 10}, {"entity_id": "18176653_4_Ent3", "role": "Subject_Gender", "text": "man", "start": 10, "end": 11}, {"entity_id": "18176653_4_Ent8", "role": "Treatment_Disorder", "text": "HIV", "start": 12, "end": 13}, {"entity_id": "18176653_4_Ent4", "role": "Treatment", "text": "highly active antiretroviral therapy ( HAART ) with zidovudine , lamivudine , and indinavir", "start": 19, "end": 33}, {"entity_id": "18176653_4_Ent5", "role": "Treatment_Drug", "text": "zidovudine", "start": 27, "end": 28}, {"entity_id": "18176653_4_Ent9", "role": "Combination_Drug", "text": "zidovudine", "start": 27, "end": 28}, {"entity_id": "18176653_4_Ent6", "role": "Treatment_Drug", "text": "lamivudine", "start": 29, "end": 30}, {"entity_id": "18176653_4_Ent10", "role": "Combination_Drug", "text": "lamivudine", "start": 29, "end": 30}, {"entity_id": "18176653_4_Ent7", "role": "Treatment_Drug", "text": "indinavir", "start": 32, "end": 33}, {"entity_id": "18176653_4_Ent11", "role": "Combination_Drug", "text": "indinavir", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "18176653_4_Ent0", "text": "A 29 - year - old black man , HIV - infected since 1996", "entity_type": "Entity", "start": 3, "end": 17}, {"id": "18176653_4_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "18176653_4_Ent2", "text": "black", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18176653_4_Ent3", "text": "man", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18176653_4_Ent8", "text": "HIV", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18176653_4_Ent4", "text": "highly active antiretroviral therapy ( HAART ) with zidovudine , lamivudine , and indinavir", "entity_type": "Entity", "start": 19, "end": 33}, {"id": "18176653_4_Ent5", "text": "zidovudine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "18176653_4_Ent9", "text": "zidovudine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "18176653_4_Ent6", "text": "lamivudine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "18176653_4_Ent10", "text": "lamivudine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "18176653_4_Ent7", "text": "indinavir", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18176653_4_Ent11", "text": "indinavir", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "18191947_2", "wnd_id": "18191947_2_1", "text": "This case demonstrates the value of DWI in evaluation and diagnosis of sub - acute toxic leukoencephalopathy in patients being treated with methotrexate .", "tokens": ["This", "case", "demonstrates", "the", "value", "of", "DWI", "in", "evaluation", "and", "diagnosis", "of", "sub", "-", "acute", "toxic", "leukoencephalopathy", "in", "patients", "being", "treated", "with", "methotrexate", "."], "event_mentions": [{"id": "18191947_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 17, "end": 18}, "arguments": [{"entity_id": "18191947_2_Ent1", "role": "Effect", "text": "sub - acute toxic leukoencephalopathy", "start": 12, "end": 17}, {"entity_id": "18191947_2_Ent0", "role": "Subject", "text": "patients", "start": 18, "end": 19}, {"entity_id": "18191947_2_Ent2", "role": "Treatment", "text": "methotrexate", "start": 22, "end": 23}, {"entity_id": "18191947_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "18191947_2_Ent1", "text": "sub - acute toxic leukoencephalopathy", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "18191947_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18191947_2_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "18191947_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "18203308_1", "wnd_id": "18203308_1_1", "text": "New onset of CD may be considered as an immune - mediated injury induced by etanercept .", "tokens": ["New", "onset", "of", "CD", "may", "be", "considered", "as", "an", "immune", "-", "mediated", "injury", "induced", "by", "etanercept", "."], "event_mentions": [{"id": "18203308_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "18203308_1_Ent0", "role": "Effect", "text": "CD", "start": 3, "end": 4}, {"entity_id": "18203308_1_Ent1", "role": "Effect", "text": "immune - mediated injury", "start": 9, "end": 13}, {"entity_id": "18203308_1_Ent2", "role": "Treatment", "text": "etanercept", "start": 15, "end": 16}, {"entity_id": "18203308_1_Ent3", "role": "Treatment_Drug", "text": "etanercept", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "18203308_1_Ent0", "text": "CD", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18203308_1_Ent1", "text": "immune - mediated injury", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "18203308_1_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18203308_1_Ent3", "text": "etanercept", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "18262450_7", "wnd_id": "18262450_7_1", "text": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin , had oral prolonged - release oxycodone or placebo tablets added to their therapy for up to 12 weeks .", "tokens": ["Three", "hundred", "and", "thirty", "eight", "patients", "with", "moderate", "to", "severe", "painful", "diabetic", "neuropathy", "despite", "receiving", "their", "maximum", "tolerated", "dose", "of", "gabapentin", ",", "had", "oral", "prolonged", "-", "release", "oxycodone", "or", "placebo", "tablets", "added", "to", "their", "therapy", "for", "up", "to", "12", "weeks", "."], "event_mentions": [{"id": "18262450_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 14, "end": 15}, "arguments": [{"entity_id": "18262450_7_Ent1", "role": "Subject_Population", "text": "Three hundred and thirty eight", "start": 0, "end": 5}, {"entity_id": "18262450_7_Ent0", "role": "Subject", "text": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy", "start": 0, "end": 13}, {"entity_id": "18262450_7_Ent11", "role": "Treatment_Disorder", "text": "painful diabetic neuropathy", "start": 10, "end": 13}, {"entity_id": "18262450_7_Ent7", "role": "Treatment_Dosage", "text": "maximum tolerated dose", "start": 16, "end": 19}, {"entity_id": "18262450_7_Ent2", "role": "Treatment", "text": "gabapentin", "start": 20, "end": 21}, {"entity_id": "18262450_7_Ent4", "role": "Treatment_Drug", "text": "gabapentin", "start": 20, "end": 21}, {"entity_id": "18262450_7_Ent8", "role": "Treatment_Route", "text": "oral", "start": 23, "end": 24}, {"entity_id": "18262450_7_Ent3", "role": "Treatment", "text": "oral prolonged - release oxycodone or placebo tablets added to their therapy for up to 12 weeks", "start": 23, "end": 40}, {"entity_id": "18262450_7_Ent5", "role": "Treatment_Drug", "text": "prolonged - release oxycodone", "start": 24, "end": 28}, {"entity_id": "18262450_7_Ent6", "role": "Treatment_Drug", "text": "placebo", "start": 29, "end": 30}, {"entity_id": "18262450_7_Ent9", "role": "Treatment_Route", "text": "tablets", "start": 30, "end": 31}, {"entity_id": "18262450_7_Ent10", "role": "Treatment_Time_elapsed", "text": "for up to 12 weeks", "start": 35, "end": 40}]}], "entity_mentions": [{"id": "18262450_7_Ent1", "text": "Three hundred and thirty eight", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "18262450_7_Ent0", "text": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "18262450_7_Ent11", "text": "painful diabetic neuropathy", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18262450_7_Ent7", "text": "maximum tolerated dose", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "18262450_7_Ent2", "text": "gabapentin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "18262450_7_Ent4", "text": "gabapentin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "18262450_7_Ent8", "text": "oral", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "18262450_7_Ent3", "text": "oral prolonged - release oxycodone or placebo tablets added to their therapy for up to 12 weeks", "entity_type": "Entity", "start": 23, "end": 40}, {"id": "18262450_7_Ent5", "text": "prolonged - release oxycodone", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "18262450_7_Ent6", "text": "placebo", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "18262450_7_Ent9", "text": "tablets", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "18262450_7_Ent10", "text": "for up to 12 weeks", "entity_type": "Entity", "start": 35, "end": 40}], "lang": "en"}
{"doc_id": "18294121_4", "wnd_id": "18294121_4_1", "text": "Temozolomide - induced desquamative skin rash in a patient with metastatic melanoma .", "tokens": ["Temozolomide", "-", "induced", "desquamative", "skin", "rash", "in", "a", "patient", "with", "metastatic", "melanoma", "."], "event_mentions": [{"id": "18294121_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18294121_4_Ent2", "role": "Treatment", "text": "Temozolomide", "start": 0, "end": 1}, {"entity_id": "18294121_4_Ent3", "role": "Treatment_Drug", "text": "Temozolomide", "start": 0, "end": 1}, {"entity_id": "18294121_4_Ent1", "role": "Effect", "text": "desquamative skin rash", "start": 3, "end": 6}, {"entity_id": "18294121_4_Ent0", "role": "Subject", "text": "a patient with metastatic melanoma", "start": 7, "end": 12}, {"entity_id": "18294121_4_Ent4", "role": "Treatment_Disorder", "text": "metastatic melanoma", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18294121_4_Ent2", "text": "Temozolomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18294121_4_Ent3", "text": "Temozolomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18294121_4_Ent1", "text": "desquamative skin rash", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18294121_4_Ent0", "text": "a patient with metastatic melanoma", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18294121_4_Ent4", "text": "metastatic melanoma", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18294121_5", "wnd_id": "18294121_5_1", "text": "Temozolomide was restarted 2 months later ; the patient again developed a fever .", "tokens": ["Temozolomide", "was", "restarted", "2", "months", "later", ";", "the", "patient", "again", "developed", "a", "fever", "."], "event_mentions": [{"id": "18294121_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "18294121_5_Ent2", "role": "Treatment", "text": "Temozolomide", "start": 0, "end": 1}, {"entity_id": "18294121_5_Ent3", "role": "Treatment_Drug", "text": "Temozolomide", "start": 0, "end": 1}, {"entity_id": "18294121_5_Ent0", "role": "Subject", "text": "the patient", "start": 7, "end": 9}, {"entity_id": "18294121_5_Ent1", "role": "Effect", "text": "fever", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "18294121_5_Ent2", "text": "Temozolomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18294121_5_Ent3", "text": "Temozolomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18294121_5_Ent0", "text": "the patient", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18294121_5_Ent1", "text": "fever", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "1834424_1", "wnd_id": "1834424_1_1", "text": "A 30 - year - old pharmacist suffered from acute allergic contact dermatitis due to 4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl ) .", "tokens": ["A", "30", "-", "year", "-", "old", "pharmacist", "suffered", "from", "acute", "allergic", "contact", "dermatitis", "due", "to", "4", "-", "chloro", "-", "7", "-", "nitrobenzofurazan", "(", "NBD", "-", "Cl", ")", "."], "event_mentions": [{"id": "1834424_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 7, "end": 8}, "arguments": [{"entity_id": "1834424_1_Ent0", "role": "Subject", "text": "A 30 - year - old pharmacist", "start": 0, "end": 7}, {"entity_id": "1834424_1_Ent1", "role": "Subject_Age", "text": "30 - year - old", "start": 1, "end": 6}, {"entity_id": "1834424_1_Ent2", "role": "Effect", "text": "acute allergic contact dermatitis", "start": 9, "end": 13}, {"entity_id": "1834424_1_Ent4", "role": "Treatment_Drug", "text": "4 - chloro - 7 - nitrobenzofurazan", "start": 15, "end": 22}, {"entity_id": "1834424_1_Ent3", "role": "Treatment", "text": "4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl )", "start": 15, "end": 27}]}], "entity_mentions": [{"id": "1834424_1_Ent0", "text": "A 30 - year - old pharmacist", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "1834424_1_Ent1", "text": "30 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1834424_1_Ent2", "text": "acute allergic contact dermatitis", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "1834424_1_Ent4", "text": "4 - chloro - 7 - nitrobenzofurazan", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "1834424_1_Ent3", "text": "4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl )", "entity_type": "Entity", "start": 15, "end": 27}], "lang": "en"}
{"doc_id": "18344455_1", "wnd_id": "18344455_1_1", "text": "Simultaneous toxicities in a child on multiple anticonvulsants .", "tokens": ["Simultaneous", "toxicities", "in", "a", "child", "on", "multiple", "anticonvulsants", "."], "event_mentions": [{"id": "18344455_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 5, "end": 6}, "arguments": [{"entity_id": "18344455_1_Ent2", "role": "Effect", "text": "Simultaneous toxicities", "start": 0, "end": 2}, {"entity_id": "18344455_1_Ent0", "role": "Subject", "text": "a child", "start": 3, "end": 5}, {"entity_id": "18344455_1_Ent1", "role": "Subject_Age", "text": "child", "start": 4, "end": 5}, {"entity_id": "18344455_1_Ent3", "role": "Treatment", "text": "multiple anticonvulsants .", "start": 6, "end": 9}, {"entity_id": "18344455_1_Ent4", "role": "Treatment_Drug", "text": "anticonvulsants", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "18344455_1_Ent2", "text": "Simultaneous toxicities", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18344455_1_Ent0", "text": "a child", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18344455_1_Ent1", "text": "child", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18344455_1_Ent3", "text": "multiple anticonvulsants .", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "18344455_1_Ent4", "text": "anticonvulsants", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "18344455_4", "wnd_id": "18344455_4_1", "text": "These toxicities resolved after the cessation of anticonvulsants , and her seizures were managed acutely with scheduled lorazepam .", "tokens": ["These", "toxicities", "resolved", "after", "the", "cessation", "of", "anticonvulsants", ",", "and", "her", "seizures", "were", "managed", "acutely", "with", "scheduled", "lorazepam", "."], "event_mentions": [{"id": "18344455_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "managed", "start": 13, "end": 14}, "arguments": [{"entity_id": "18344455_4_Ent1", "role": "Treatment_Disorder", "text": "seizures", "start": 11, "end": 12}, {"entity_id": "18344455_4_Ent0", "role": "Treatment", "text": "lorazepam", "start": 17, "end": 18}, {"entity_id": "18344455_4_Ent2", "role": "Treatment_Drug", "text": "lorazepam", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "18344455_4_Ent1", "text": "seizures", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18344455_4_Ent0", "text": "lorazepam", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18344455_4_Ent2", "text": "lorazepam", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "18362995_1", "wnd_id": "18362995_1_1", "text": "A short review on imatinib - related hepatotoxicity is also presented .", "tokens": ["A", "short", "review", "on", "imatinib", "-", "related", "hepatotoxicity", "is", "also", "presented", "."], "event_mentions": [{"id": "18362995_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 6, "end": 7}, "arguments": [{"entity_id": "18362995_1_Ent1", "role": "Treatment", "text": "imatinib", "start": 4, "end": 5}, {"entity_id": "18362995_1_Ent2", "role": "Treatment_Drug", "text": "imatinib", "start": 4, "end": 5}, {"entity_id": "18362995_1_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "18362995_1_Ent1", "text": "imatinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18362995_1_Ent2", "text": "imatinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18362995_1_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "18364401_4", "wnd_id": "18364401_4_1", "text": "Subsequently , he developed hyperglycemia ( fasting blood glucose 138 mg / dL ) that resolved when olanzapine was stopped and recurred ( fasting blood glucose 150 mg / dL ) after 2 days of rechallenge with olanzapine 2.5 mg twice daily .", "tokens": ["Subsequently", ",", "he", "developed", "hyperglycemia", "(", "fasting", "blood", "glucose", "138", "mg", "/", "dL", ")", "that", "resolved", "when", "olanzapine", "was", "stopped", "and", "recurred", "(", "fasting", "blood", "glucose", "150", "mg", "/", "dL", ")", "after", "2", "days", "of", "rechallenge", "with", "olanzapine", "2.5", "mg", "twice", "daily", "."], "event_mentions": [{"id": "18364401_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 15, "end": 16}, "arguments": [{"entity_id": "18364401_4_Ent1", "role": "Treatment_Disorder", "text": "hyperglycemia ( fasting blood glucose 138 mg / dL )", "start": 4, "end": 14}, {"entity_id": "18364401_4_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 17, "end": 18}, {"entity_id": "18364401_4_Ent0", "role": "Treatment", "text": "olanzapine was stopped", "start": 17, "end": 20}]}, {"id": "18364401_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 31, "end": 32}, "arguments": [{"entity_id": "18364401_4_Ent3", "role": "Effect", "text": "hyperglycemia", "start": 4, "end": 5}, {"entity_id": "18364401_4_Ent4", "role": "Effect", "text": "recurred ( fasting blood glucose 150 mg / dL )", "start": 21, "end": 31}, {"entity_id": "18364401_4_Ent6", "role": "Treatment_Time_elapsed", "text": "2 days", "start": 32, "end": 34}, {"entity_id": "18364401_4_Ent5", "role": "Treatment", "text": "2 days of rechallenge with olanzapine 2.5 mg twice daily", "start": 32, "end": 42}, {"entity_id": "18364401_4_Ent7", "role": "Treatment_Drug", "text": "olanzapine", "start": 37, "end": 38}, {"entity_id": "18364401_4_Ent8", "role": "Treatment_Dosage", "text": "2.5 mg", "start": 38, "end": 40}, {"entity_id": "18364401_4_Ent9", "role": "Treatment_Freq", "text": "twice daily", "start": 40, "end": 42}]}], "entity_mentions": [{"id": "18364401_4_Ent3", "text": "hyperglycemia", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18364401_4_Ent1", "text": "hyperglycemia ( fasting blood glucose 138 mg / dL )", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "18364401_4_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18364401_4_Ent0", "text": "olanzapine was stopped", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "18364401_4_Ent4", "text": "recurred ( fasting blood glucose 150 mg / dL )", "entity_type": "Entity", "start": 21, "end": 31}, {"id": "18364401_4_Ent6", "text": "2 days", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "18364401_4_Ent5", "text": "2 days of rechallenge with olanzapine 2.5 mg twice daily", "entity_type": "Entity", "start": 32, "end": 42}, {"id": "18364401_4_Ent7", "text": "olanzapine", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "18364401_4_Ent8", "text": "2.5 mg", "entity_type": "Entity", "start": 38, "end": 40}, {"id": "18364401_4_Ent9", "text": "twice daily", "entity_type": "Entity", "start": 40, "end": 42}], "lang": "en"}
{"doc_id": "18371508_2", "wnd_id": "18371508_2_1", "text": "We report the first case of fulminant adult respiratory distress syndrome ( ARDS ) associated with pegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and ribavirin use for hepatitis C , complicated by subsequent and ultimately fatal sepsis and multiorgan failure .", "tokens": ["We", "report", "the", "first", "case", "of", "fulminant", "adult", "respiratory", "distress", "syndrome", "(", "ARDS", ")", "associated", "with", "pegylated", "interferon", "alpha", "-", "2a", "(", "pegIFNalpha", "-", "2a", ")", "and", "ribavirin", "use", "for", "hepatitis", "C", ",", "complicated", "by", "subsequent", "and", "ultimately", "fatal", "sepsis", "and", "multiorgan", "failure", "."], "event_mentions": [{"id": "18371508_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 14, "end": 15}, "arguments": [{"entity_id": "18371508_2_Ent0", "role": "Effect", "text": "adult respiratory distress syndrome ( ARDS )", "start": 7, "end": 14}, {"entity_id": "18371508_2_Ent2", "role": "Treatment_Drug", "text": "pegylated interferon alpha - 2a", "start": 16, "end": 21}, {"entity_id": "18371508_2_Ent1", "role": "Treatment", "text": "pegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and ribavirin", "start": 16, "end": 28}, {"entity_id": "18371508_2_Ent3", "role": "Treatment_Drug", "text": "ribavirin", "start": 27, "end": 28}, {"entity_id": "18371508_2_Ent4", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 30, "end": 32}]}], "entity_mentions": [{"id": "18371508_2_Ent0", "text": "adult respiratory distress syndrome ( ARDS )", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "18371508_2_Ent2", "text": "pegylated interferon alpha - 2a", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "18371508_2_Ent1", "text": "pegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and ribavirin", "entity_type": "Entity", "start": 16, "end": 28}, {"id": "18371508_2_Ent3", "text": "ribavirin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "18371508_2_Ent4", "text": "hepatitis C", "entity_type": "Entity", "start": 30, "end": 32}], "lang": "en"}
{"doc_id": "18453852_4", "wnd_id": "18453852_4_1", "text": "A total of 40 healthy volunteers were planned to start with 600 mg rifampicin once daily from days 1 - 5 .", "tokens": ["A", "total", "of", "40", "healthy", "volunteers", "were", "planned", "to", "start", "with", "600", "mg", "rifampicin", "once", "daily", "from", "days", "1", "-", "5", "."], "event_mentions": [{"id": "18453852_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "start", "start": 9, "end": 10}, "arguments": [{"entity_id": "18453852_4_Ent1", "role": "Subject_Population", "text": "40", "start": 3, "end": 4}, {"entity_id": "18453852_4_Ent0", "role": "Subject", "text": "40 healthy volunteers", "start": 3, "end": 6}, {"entity_id": "18453852_4_Ent3", "role": "Treatment_Dosage", "text": "600 mg", "start": 11, "end": 13}, {"entity_id": "18453852_4_Ent2", "role": "Treatment", "text": "600 mg rifampicin once daily from days 1 - 5", "start": 11, "end": 21}, {"entity_id": "18453852_4_Ent4", "role": "Treatment_Drug", "text": "rifampicin", "start": 13, "end": 14}, {"entity_id": "18453852_4_Ent5", "role": "Treatment_Freq", "text": "once daily", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "18453852_4_Ent1", "text": "40", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18453852_4_Ent0", "text": "40 healthy volunteers", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18453852_4_Ent3", "text": "600 mg", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18453852_4_Ent2", "text": "600 mg rifampicin once daily from days 1 - 5", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "18453852_4_Ent4", "text": "rifampicin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18453852_4_Ent5", "text": "once daily", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "18459568_1", "wnd_id": "18459568_1_1", "text": "Gastric tumor , endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer .", "tokens": ["Gastric", "tumor", ",", "endometrial", "carcinoma", "and", "cervical", "adenocarcinoma", "in", "situ", "were", "detected", "after", "treatment", "with", "tamoxifen", "for", "breast", "cancer", "."], "event_mentions": [{"id": "18459568_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "detected", "start": 11, "end": 12}, "arguments": [{"entity_id": "18459568_1_Ent0", "role": "Effect", "text": "Gastric tumor , endometrial carcinoma and cervical adenocarcinoma in situ", "start": 0, "end": 10}, {"entity_id": "18459568_1_Ent1", "role": "Treatment", "text": "tamoxifen", "start": 15, "end": 16}, {"entity_id": "18459568_1_Ent3", "role": "Treatment_Drug", "text": "tamoxifen", "start": 15, "end": 16}, {"entity_id": "18459568_1_Ent2", "role": "Treatment_Disorder", "text": "breast cancer", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "18459568_1_Ent0", "text": "Gastric tumor , endometrial carcinoma and cervical adenocarcinoma in situ", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "18459568_1_Ent1", "text": "tamoxifen", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18459568_1_Ent3", "text": "tamoxifen", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18459568_1_Ent2", "text": "breast cancer", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "18465737_1", "wnd_id": "18465737_1_1", "text": "Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema .", "tokens": ["Incomplete", "posterior", "hyaloid", "detachment", "after", "intravitreal", "pegaptanib", "injection", "in", "diabetic", "macular", "edema", "."], "event_mentions": [{"id": "18465737_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "18465737_1_Ent0", "role": "Effect", "text": "Incomplete posterior hyaloid detachment", "start": 0, "end": 4}, {"entity_id": "18465737_1_Ent4", "role": "Treatment_Route", "text": "intravitreal", "start": 5, "end": 6}, {"entity_id": "18465737_1_Ent1", "role": "Treatment", "text": "intravitreal pegaptanib injection in diabetic macular edema", "start": 5, "end": 12}, {"entity_id": "18465737_1_Ent3", "role": "Treatment_Drug", "text": "pegaptanib", "start": 6, "end": 7}, {"entity_id": "18465737_1_Ent5", "role": "Treatment_Route", "text": "injection", "start": 7, "end": 8}, {"entity_id": "18465737_1_Ent2", "role": "Treatment_Disorder", "text": "diabetic macular edema", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "18465737_1_Ent0", "text": "Incomplete posterior hyaloid detachment", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18465737_1_Ent4", "text": "intravitreal", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18465737_1_Ent1", "text": "intravitreal pegaptanib injection in diabetic macular edema", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "18465737_1_Ent3", "text": "pegaptanib", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18465737_1_Ent5", "text": "injection", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18465737_1_Ent2", "text": "diabetic macular edema", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "18465737_2", "wnd_id": "18465737_2_1", "text": "The authors report one case of incomplete posterior hyaloid detachment ( PHD ) following intravitreal pegaptanib to treat DME .", "tokens": ["The", "authors", "report", "one", "case", "of", "incomplete", "posterior", "hyaloid", "detachment", "(", "PHD", ")", "following", "intravitreal", "pegaptanib", "to", "treat", "DME", "."], "event_mentions": [{"id": "18465737_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 13, "end": 14}, "arguments": [{"entity_id": "18465737_2_Ent0", "role": "Subject", "text": "one case", "start": 3, "end": 5}, {"entity_id": "18465737_2_Ent1", "role": "Effect", "text": "incomplete posterior hyaloid detachment ( PHD )", "start": 6, "end": 13}, {"entity_id": "18465737_2_Ent3", "role": "Treatment_Route", "text": "intravitreal", "start": 14, "end": 15}, {"entity_id": "18465737_2_Ent2", "role": "Treatment", "text": "intravitreal pegaptanib", "start": 14, "end": 16}, {"entity_id": "18465737_2_Ent4", "role": "Treatment_Drug", "text": "pegaptanib", "start": 15, "end": 16}, {"entity_id": "18465737_2_Ent5", "role": "Treatment_Disorder", "text": "DME", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "18465737_2_Ent0", "text": "one case", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18465737_2_Ent1", "text": "incomplete posterior hyaloid detachment ( PHD )", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "18465737_2_Ent3", "text": "intravitreal", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18465737_2_Ent2", "text": "intravitreal pegaptanib", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "18465737_2_Ent4", "text": "pegaptanib", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18465737_2_Ent5", "text": "DME", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "18472517_1", "wnd_id": "18472517_1_1", "text": "Enalaprilat induced acute parotitis .", "tokens": ["Enalaprilat", "induced", "acute", "parotitis", "."], "event_mentions": [{"id": "18472517_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "18472517_1_Ent1", "role": "Treatment", "text": "Enalaprilat", "start": 0, "end": 1}, {"entity_id": "18472517_1_Ent2", "role": "Treatment_Drug", "text": "Enalaprilat", "start": 0, "end": 1}, {"entity_id": "18472517_1_Ent0", "role": "Effect", "text": "acute parotitis", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "18472517_1_Ent1", "text": "Enalaprilat", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18472517_1_Ent2", "text": "Enalaprilat", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18472517_1_Ent0", "text": "acute parotitis", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "18477279_3", "wnd_id": "18477279_3_1", "text": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis .", "tokens": ["He", "had", "been", "commenced", "on", "a", "course", "of", "fusidic", "acid", "at", "discharge", "in", "addition", "to", "his", "ongoing", "statin", "prescription", "and", "presented", "4", "weeks", "later", "with", "symptoms", "consistent", "with", "rhabdomyolysis", "."], "event_mentions": [{"id": "18477279_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 20, "end": 21}, "arguments": [{"entity_id": "18477279_3_Ent1", "role": "Treatment", "text": "a course of fusidic acid at discharge in addition to his ongoing statin prescription", "start": 5, "end": 19}, {"entity_id": "18477279_3_Ent3", "role": "Treatment_Drug", "text": "fusidic acid", "start": 8, "end": 10}, {"entity_id": "18477279_3_Ent5", "role": "Combination_Drug", "text": "fusidic acid", "start": 8, "end": 10}, {"entity_id": "18477279_3_Ent2", "role": "Treatment_Drug", "text": "statin", "start": 17, "end": 18}, {"entity_id": "18477279_3_Ent6", "role": "Combination_Drug", "text": "statin", "start": 17, "end": 18}, {"entity_id": "18477279_3_Ent4", "role": "Treatment_Time_elapsed", "text": "4 weeks later", "start": 21, "end": 24}, {"entity_id": "18477279_3_Ent0", "role": "Effect", "text": "symptoms consistent with rhabdomyolysis", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "18477279_3_Ent1", "text": "a course of fusidic acid at discharge in addition to his ongoing statin prescription", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "18477279_3_Ent3", "text": "fusidic acid", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18477279_3_Ent5", "text": "fusidic acid", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18477279_3_Ent2", "text": "statin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18477279_3_Ent6", "text": "statin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18477279_3_Ent4", "text": "4 weeks later", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "18477279_3_Ent0", "text": "symptoms consistent with rhabdomyolysis", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "18505911_1", "wnd_id": "18505911_1_1", "text": "Azathioprine - induced warfarin resistance .", "tokens": ["Azathioprine", "-", "induced", "warfarin", "resistance", "."], "event_mentions": [{"id": "18505911_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18505911_1_Ent1", "role": "Treatment", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "18505911_1_Ent2", "role": "Treatment_Drug", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "18505911_1_Ent0", "role": "Effect", "text": "warfarin resistance .", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "18505911_1_Ent1", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18505911_1_Ent2", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18505911_1_Ent0", "text": "warfarin resistance .", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "18515982_2", "wnd_id": "18515982_2_1", "text": "CONCLUSIONS : Anastrozole may be the causative factor in patients with sclerosing glomerulonephritis .", "tokens": ["CONCLUSIONS", ":", "Anastrozole", "may", "be", "the", "causative", "factor", "in", "patients", "with", "sclerosing", "glomerulonephritis", "."], "event_mentions": [{"id": "18515982_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causative", "start": 6, "end": 7}, "arguments": [{"entity_id": "18515982_2_Ent2", "role": "Treatment", "text": "Anastrozole", "start": 2, "end": 3}, {"entity_id": "18515982_2_Ent3", "role": "Treatment_Drug", "text": "Anastrozole", "start": 2, "end": 3}, {"entity_id": "18515982_2_Ent0", "role": "Subject", "text": "patients", "start": 9, "end": 10}, {"entity_id": "18515982_2_Ent1", "role": "Effect", "text": "sclerosing glomerulonephritis", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "18515982_2_Ent2", "text": "Anastrozole", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18515982_2_Ent3", "text": "Anastrozole", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18515982_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18515982_2_Ent1", "text": "sclerosing glomerulonephritis", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "18515982_4", "wnd_id": "18515982_4_1", "text": "Renal injury due to anastrozole has not been published in the English literature .", "tokens": ["Renal", "injury", "due", "to", "anastrozole", "has", "not", "been", "published", "in", "the", "English", "literature", "."], "event_mentions": [{"id": "18515982_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "18515982_4_Ent0", "role": "Effect", "text": "Renal injury", "start": 0, "end": 2}, {"entity_id": "18515982_4_Ent1", "role": "Treatment", "text": "anastrozole", "start": 4, "end": 5}, {"entity_id": "18515982_4_Ent2", "role": "Treatment_Drug", "text": "anastrozole", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "18515982_4_Ent0", "text": "Renal injury", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18515982_4_Ent1", "text": "anastrozole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18515982_4_Ent2", "text": "anastrozole", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "18533420_1", "wnd_id": "18533420_1_1", "text": "CONCLUSIONS : Intrathecal baclofen can impair sexual function and ejaculation in some patients .", "tokens": ["CONCLUSIONS", ":", "Intrathecal", "baclofen", "can", "impair", "sexual", "function", "and", "ejaculation", "in", "some", "patients", "."], "event_mentions": [{"id": "18533420_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "impair", "start": 5, "end": 6}, "arguments": [{"entity_id": "18533420_1_Ent3", "role": "Treatment_Route", "text": "Intrathecal", "start": 2, "end": 3}, {"entity_id": "18533420_1_Ent2", "role": "Treatment", "text": "Intrathecal baclofen", "start": 2, "end": 4}, {"entity_id": "18533420_1_Ent4", "role": "Treatment_Drug", "text": "baclofen", "start": 3, "end": 4}, {"entity_id": "18533420_1_Ent1", "role": "Effect", "text": "impair sexual function and ejaculation", "start": 5, "end": 10}, {"entity_id": "18533420_1_Ent0", "role": "Subject", "text": "some patients", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "18533420_1_Ent3", "text": "Intrathecal", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18533420_1_Ent2", "text": "Intrathecal baclofen", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18533420_1_Ent4", "text": "baclofen", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18533420_1_Ent1", "text": "impair sexual function and ejaculation", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18533420_1_Ent0", "text": "some patients", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "18533420_3", "wnd_id": "18533420_3_1", "text": "Sexual dysfunction associated with intrathecal baclofen use : a report of two cases .", "tokens": ["Sexual", "dysfunction", "associated", "with", "intrathecal", "baclofen", "use", ":", "a", "report", "of", "two", "cases", "."], "event_mentions": [{"id": "18533420_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "18533420_3_Ent2", "role": "Effect", "text": "Sexual dysfunction", "start": 0, "end": 2}, {"entity_id": "18533420_3_Ent4", "role": "Treatment_Route", "text": "intrathecal", "start": 4, "end": 5}, {"entity_id": "18533420_3_Ent3", "role": "Treatment", "text": "intrathecal baclofen", "start": 4, "end": 6}, {"entity_id": "18533420_3_Ent5", "role": "Treatment_Drug", "text": "baclofen", "start": 5, "end": 6}, {"entity_id": "18533420_3_Ent1", "role": "Subject_Population", "text": "two", "start": 11, "end": 12}, {"entity_id": "18533420_3_Ent0", "role": "Subject", "text": "two cases", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "18533420_3_Ent2", "text": "Sexual dysfunction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18533420_3_Ent4", "text": "intrathecal", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18533420_3_Ent3", "text": "intrathecal baclofen", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18533420_3_Ent5", "text": "baclofen", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18533420_3_Ent1", "text": "two", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18533420_3_Ent0", "text": "two cases", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "18569796_3", "wnd_id": "18569796_3_1", "text": "PURPOSE : To report a case of nodular scleritis following alendronate sodium .", "tokens": ["PURPOSE", ":", "To", "report", "a", "case", "of", "nodular", "scleritis", "following", "alendronate", "sodium", "."], "event_mentions": [{"id": "18569796_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "18569796_3_Ent0", "role": "Effect", "text": "nodular scleritis", "start": 7, "end": 9}, {"entity_id": "18569796_3_Ent1", "role": "Treatment", "text": "alendronate sodium", "start": 10, "end": 12}, {"entity_id": "18569796_3_Ent2", "role": "Treatment_Drug", "text": "alendronate sodium", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18569796_3_Ent0", "text": "nodular scleritis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18569796_3_Ent1", "text": "alendronate sodium", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18569796_3_Ent2", "text": "alendronate sodium", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18569796_4", "wnd_id": "18569796_4_1", "text": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis .", "tokens": ["Two", "weeks", "following", "rechallenge", "with", "alendronate", "sodium", "resulted", "in", "recurrence", "of", "his", "scleritis", "."], "event_mentions": [{"id": "18569796_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 7, "end": 8}, "arguments": [{"entity_id": "18569796_4_Ent2", "role": "Treatment", "text": "Two weeks following", "start": 0, "end": 3}, {"entity_id": "18569796_4_Ent4", "role": "Treatment_Time_elapsed", "text": "Two weeks following", "start": 0, "end": 3}, {"entity_id": "18569796_4_Ent1", "role": "Treatment", "text": "alendronate sodium", "start": 5, "end": 7}, {"entity_id": "18569796_4_Ent3", "role": "Treatment_Drug", "text": "alendronate sodium", "start": 5, "end": 7}, {"entity_id": "18569796_4_Ent0", "role": "Effect", "text": "scleritis", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "18569796_4_Ent2", "text": "Two weeks following", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18569796_4_Ent4", "text": "Two weeks following", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18569796_4_Ent1", "text": "alendronate sodium", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18569796_4_Ent3", "text": "alendronate sodium", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18569796_4_Ent0", "text": "scleritis", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "18585545_1", "wnd_id": "18585545_1_1", "text": "Acute delirium resulting from levofloxacin therapy is an exceedingly rare complication that has been thought to occur more commonly in elderly patients .", "tokens": ["Acute", "delirium", "resulting", "from", "levofloxacin", "therapy", "is", "an", "exceedingly", "rare", "complication", "that", "has", "been", "thought", "to", "occur", "more", "commonly", "in", "elderly", "patients", "."], "event_mentions": [{"id": "18585545_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 2, "end": 3}, "arguments": [{"entity_id": "18585545_1_Ent2", "role": "Effect", "text": "Acute delirium", "start": 0, "end": 2}, {"entity_id": "18585545_1_Ent3", "role": "Treatment", "text": "levofloxacin", "start": 4, "end": 5}, {"entity_id": "18585545_1_Ent4", "role": "Treatment_Drug", "text": "levofloxacin", "start": 4, "end": 5}, {"entity_id": "18585545_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 20, "end": 21}, {"entity_id": "18585545_1_Ent0", "role": "Subject", "text": "elderly patients", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "18585545_1_Ent2", "text": "Acute delirium", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18585545_1_Ent3", "text": "levofloxacin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18585545_1_Ent4", "text": "levofloxacin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18585545_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "18585545_1_Ent0", "text": "elderly patients", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "18585545_2", "wnd_id": "18585545_2_1", "text": "CONCLUSION : The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system - related adverse effects , including headache , dizziness and insomnia .", "tokens": ["CONCLUSION", ":", "The", "new", "quinolone", "derivatives", "(", "levofloxacin", ",", "sparfloxacin", ",", "grepafloxacin", ",", "trovafloxacin", ",", "gatifloxacin", "and", "moxifloxacin", ")", ",", "also", "called", "gyrase", "inhibitors", ",", "are", "known", "for", "their", "potential", "to", "cause", "central", "nervous", "system", "-", "related", "adverse", "effects", ",", "including", "headache", ",", "dizziness", "and", "insomnia", "."], "event_mentions": [{"id": "18585545_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 31, "end": 32}, "arguments": [{"entity_id": "18585545_2_Ent1", "role": "Treatment", "text": "The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors", "start": 2, "end": 24}, {"entity_id": "18585545_2_Ent2", "role": "Treatment_Drug", "text": "levofloxacin", "start": 7, "end": 8}, {"entity_id": "18585545_2_Ent3", "role": "Treatment_Drug", "text": "sparfloxacin", "start": 9, "end": 10}, {"entity_id": "18585545_2_Ent4", "role": "Treatment_Drug", "text": "grepafloxacin", "start": 11, "end": 12}, {"entity_id": "18585545_2_Ent5", "role": "Treatment_Drug", "text": "trovafloxacin", "start": 13, "end": 14}, {"entity_id": "18585545_2_Ent6", "role": "Treatment_Drug", "text": "gatifloxacin", "start": 15, "end": 16}, {"entity_id": "18585545_2_Ent7", "role": "Treatment_Drug", "text": "moxifloxacin", "start": 17, "end": 18}, {"entity_id": "18585545_2_Ent0", "role": "Effect", "text": "central nervous system - related adverse effects , including headache , dizziness and insomnia", "start": 32, "end": 46}]}], "entity_mentions": [{"id": "18585545_2_Ent1", "text": "The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors", "entity_type": "Entity", "start": 2, "end": 24}, {"id": "18585545_2_Ent2", "text": "levofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18585545_2_Ent3", "text": "sparfloxacin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18585545_2_Ent4", "text": "grepafloxacin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18585545_2_Ent5", "text": "trovafloxacin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18585545_2_Ent6", "text": "gatifloxacin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18585545_2_Ent7", "text": "moxifloxacin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18585545_2_Ent0", "text": "central nervous system - related adverse effects , including headache , dizziness and insomnia", "entity_type": "Entity", "start": 32, "end": 46}], "lang": "en"}
{"doc_id": "18585545_4", "wnd_id": "18585545_4_1", "text": "Levofloxacin - induced delirium with psychotic features .", "tokens": ["Levofloxacin", "-", "induced", "delirium", "with", "psychotic", "features", "."], "event_mentions": [{"id": "18585545_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18585545_4_Ent1", "role": "Treatment", "text": "Levofloxacin", "start": 0, "end": 1}, {"entity_id": "18585545_4_Ent2", "role": "Treatment_Drug", "text": "Levofloxacin", "start": 0, "end": 1}, {"entity_id": "18585545_4_Ent0", "role": "Effect", "text": "delirium with psychotic features", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "18585545_4_Ent1", "text": "Levofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18585545_4_Ent2", "text": "Levofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18585545_4_Ent0", "text": "delirium with psychotic features", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "18609153_2", "wnd_id": "18609153_2_1", "text": "During intravenous treatment with terlipressin for recurrent gastrointestinal ( GI ) bleeding , a 50 - year - old male with no history of heart disease developed a newly prolonged QT interval and torsade de pointes .", "tokens": ["During", "intravenous", "treatment", "with", "terlipressin", "for", "recurrent", "gastrointestinal", "(", "GI", ")", "bleeding", ",", "a", "50", "-", "year", "-", "old", "male", "with", "no", "history", "of", "heart", "disease", "developed", "a", "newly", "prolonged", "QT", "interval", "and", "torsade", "de", "pointes", "."], "event_mentions": [{"id": "18609153_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 26, "end": 27}, "arguments": [{"entity_id": "18609153_2_Ent4", "role": "Treatment", "text": "During intravenous treatment with terlipressin for recurrent gastrointestinal ( GI ) bleeding", "start": 0, "end": 12}, {"entity_id": "18609153_2_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 1, "end": 2}, {"entity_id": "18609153_2_Ent6", "role": "Treatment_Drug", "text": "terlipressin", "start": 4, "end": 5}, {"entity_id": "18609153_2_Ent7", "role": "Treatment_Disorder", "text": "recurrent gastrointestinal", "start": 6, "end": 8}, {"entity_id": "18609153_2_Ent0", "role": "Subject", "text": "a 50 - year - old male with no history of heart disease", "start": 13, "end": 26}, {"entity_id": "18609153_2_Ent1", "role": "Subject_Age", "text": "50 - year - old", "start": 14, "end": 19}, {"entity_id": "18609153_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 19, "end": 20}, {"entity_id": "18609153_2_Ent3", "role": "Effect", "text": "a newly prolonged QT interval and torsade de pointes", "start": 27, "end": 36}]}], "entity_mentions": [{"id": "18609153_2_Ent4", "text": "During intravenous treatment with terlipressin for recurrent gastrointestinal ( GI ) bleeding", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "18609153_2_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18609153_2_Ent6", "text": "terlipressin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18609153_2_Ent7", "text": "recurrent gastrointestinal", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "18609153_2_Ent0", "text": "a 50 - year - old male with no history of heart disease", "entity_type": "Entity", "start": 13, "end": 26}, {"id": "18609153_2_Ent1", "text": "50 - year - old", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "18609153_2_Ent2", "text": "male", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18609153_2_Ent3", "text": "a newly prolonged QT interval and torsade de pointes", "entity_type": "Entity", "start": 27, "end": 36}], "lang": "en"}
{"doc_id": "18622319_1", "wnd_id": "18622319_1_1", "text": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy .", "tokens": ["Spontaneous", "nasal", "septal", "perforation", "with", "antiangiogenic", "bevacizumab", "therapy", "."], "event_mentions": [{"id": "18622319_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 4, "end": 5}, "arguments": [{"entity_id": "18622319_1_Ent0", "role": "Effect", "text": "Spontaneous nasal septal perforation", "start": 0, "end": 4}, {"entity_id": "18622319_1_Ent1", "role": "Treatment", "text": "antiangiogenic bevacizumab therapy", "start": 5, "end": 8}, {"entity_id": "18622319_1_Ent2", "role": "Treatment_Drug", "text": "bevacizumab", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "18622319_1_Ent0", "text": "Spontaneous nasal septal perforation", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18622319_1_Ent1", "text": "antiangiogenic bevacizumab therapy", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18622319_1_Ent2", "text": "bevacizumab", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "18661248_2", "wnd_id": "18661248_2_1", "text": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis ( collapsing FGS ) with complete recovery after withdrawal of cyclosporine ( CSA ) .", "tokens": ["We", "describe", "a", "case", "of", "PRES", "in", "a", "patient", "with", "collapsing", "focal", "glomeruloesclerosis", "(", "collapsing", "FGS", ")", "with", "complete", "recovery", "after", "withdrawal", "of", "cyclosporine", "(", "CSA", ")", "."], "event_mentions": [{"id": "18661248_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "complete recovery", "start": 18, "end": 20}, "arguments": [{"entity_id": "18661248_2_Ent3", "role": "Treatment_Disorder", "text": "PRES", "start": 5, "end": 6}, {"entity_id": "18661248_2_Ent0", "role": "Subject", "text": "a patient with collapsing focal glomeruloesclerosis ( collapsing FGS )", "start": 7, "end": 17}, {"entity_id": "18661248_2_Ent1", "role": "Subject_Disorder", "text": "collapsing focal glomeruloesclerosis", "start": 10, "end": 13}, {"entity_id": "18661248_2_Ent2", "role": "Treatment", "text": "withdrawal of cyclosporine ( CSA )", "start": 21, "end": 27}, {"entity_id": "18661248_2_Ent4", "role": "Treatment_Drug", "text": "cyclosporine", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "18661248_2_Ent3", "text": "PRES", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18661248_2_Ent0", "text": "a patient with collapsing focal glomeruloesclerosis ( collapsing FGS )", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "18661248_2_Ent1", "text": "collapsing focal glomeruloesclerosis", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18661248_2_Ent2", "text": "withdrawal of cyclosporine ( CSA )", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "18661248_2_Ent4", "text": "cyclosporine", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "18665833_1", "wnd_id": "18665833_1_1", "text": "Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency .", "tokens": ["Stuttering", "priapism", "complicating", "warfarin", "therapy", "in", "a", "patient", "with", "protein", "C", "deficiency", "."], "event_mentions": [{"id": "18665833_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "18665833_1_Ent1", "role": "Effect", "text": "Stuttering priapism", "start": 0, "end": 2}, {"entity_id": "18665833_1_Ent2", "role": "Treatment", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "18665833_1_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "18665833_1_Ent0", "role": "Subject", "text": "a patient with protein C deficiency", "start": 6, "end": 12}, {"entity_id": "18665833_1_Ent3", "role": "Treatment_Disorder", "text": "protein C deficiency", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "18665833_1_Ent1", "text": "Stuttering priapism", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18665833_1_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18665833_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18665833_1_Ent0", "text": "a patient with protein C deficiency", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "18665833_1_Ent3", "text": "protein C deficiency", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "18665833_2", "wnd_id": "18665833_2_1", "text": "This therapy was also complicated by Warfarin - induced skin necrosis .", "tokens": ["This", "therapy", "was", "also", "complicated", "by", "Warfarin", "-", "induced", "skin", "necrosis", "."], "event_mentions": [{"id": "18665833_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "18665833_2_Ent1", "role": "Treatment", "text": "Warfarin", "start": 6, "end": 7}, {"entity_id": "18665833_2_Ent2", "role": "Treatment_Drug", "text": "Warfarin", "start": 6, "end": 7}, {"entity_id": "18665833_2_Ent0", "role": "Effect", "text": "skin necrosis", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "18665833_2_Ent1", "text": "Warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18665833_2_Ent2", "text": "Warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18665833_2_Ent0", "text": "skin necrosis", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "18675768_15", "wnd_id": "18675768_15_1", "text": "CONCLUSIONS : This is the first report of a possible interaction between propafenone and citalopram , which caused propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease .", "tokens": ["CONCLUSIONS", ":", "This", "is", "the", "first", "report", "of", "a", "possible", "interaction", "between", "propafenone", "and", "citalopram", ",", "which", "caused", "propafenone", "adverse", "effects", "(", "eg", ",", "dizziness", ",", "falls", ")", "and", "mimicked", "coronary", "artery", "disease", "."], "event_mentions": [{"id": "18675768_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 17, "end": 18}, "arguments": [{"entity_id": "18675768_15_Ent1", "role": "Treatment", "text": "propafenone", "start": 12, "end": 13}, {"entity_id": "18675768_15_Ent3", "role": "Treatment_Drug", "text": "propafenone", "start": 12, "end": 13}, {"entity_id": "18675768_15_Ent5", "role": "Combination_Drug", "text": "propafenone", "start": 12, "end": 13}, {"entity_id": "18675768_15_Ent2", "role": "Treatment", "text": "citalopram", "start": 14, "end": 15}, {"entity_id": "18675768_15_Ent4", "role": "Treatment_Drug", "text": "citalopram", "start": 14, "end": 15}, {"entity_id": "18675768_15_Ent6", "role": "Combination_Drug", "text": "citalopram", "start": 14, "end": 15}, {"entity_id": "18675768_15_Ent0", "role": "Effect", "text": "adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease", "start": 19, "end": 33}]}], "entity_mentions": [{"id": "18675768_15_Ent1", "text": "propafenone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_15_Ent3", "text": "propafenone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_15_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_15_Ent2", "text": "citalopram", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18675768_15_Ent4", "text": "citalopram", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18675768_15_Ent6", "text": "citalopram", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18675768_15_Ent0", "text": "adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease", "entity_type": "Entity", "start": 19, "end": 33}], "lang": "en"}
{"doc_id": "18675768_4", "wnd_id": "18675768_4_1", "text": "The goal of this article was to describe a potential drug - drug interaction between propafenone and citalopram , which caused symptoms of propafenone adverse effects .", "tokens": ["The", "goal", "of", "this", "article", "was", "to", "describe", "a", "potential", "drug", "-", "drug", "interaction", "between", "propafenone", "and", "citalopram", ",", "which", "caused", "symptoms", "of", "propafenone", "adverse", "effects", "."], "event_mentions": [{"id": "18675768_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 20, "end": 21}, "arguments": [{"entity_id": "18675768_4_Ent1", "role": "Treatment", "text": "drug - drug interaction between propafenone and citalopram", "start": 10, "end": 18}, {"entity_id": "18675768_4_Ent2", "role": "Treatment_Drug", "text": "propafenone", "start": 15, "end": 16}, {"entity_id": "18675768_4_Ent5", "role": "Combination_Drug", "text": "propafenone", "start": 15, "end": 16}, {"entity_id": "18675768_4_Ent3", "role": "Treatment_Drug", "text": "citalopram", "start": 17, "end": 18}, {"entity_id": "18675768_4_Ent6", "role": "Combination_Drug", "text": "citalopram", "start": 17, "end": 18}, {"entity_id": "18675768_4_Ent0", "role": "Effect", "text": "symptoms of propafenone adverse effects", "start": 21, "end": 26}, {"entity_id": "18675768_4_Ent4", "role": "Treatment_Drug", "text": "propafenone", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "18675768_4_Ent1", "text": "drug - drug interaction between propafenone and citalopram", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "18675768_4_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18675768_4_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18675768_4_Ent3", "text": "citalopram", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18675768_4_Ent6", "text": "citalopram", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18675768_4_Ent0", "text": "symptoms of propafenone adverse effects", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "18675768_4_Ent4", "text": "propafenone", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "18676387_2", "wnd_id": "18676387_2_1", "text": "To report a case of serotonin toxicity , presenting in the postoperative period , caused by an interaction between paroxetine ( a selective serotonin reuptake inhibitor , SSRI ) and fentanyl ( a phenylpiperidine opioid ) .", "tokens": ["To", "report", "a", "case", "of", "serotonin", "toxicity", ",", "presenting", "in", "the", "postoperative", "period", ",", "caused", "by", "an", "interaction", "between", "paroxetine", "(", "a", "selective", "serotonin", "reuptake", "inhibitor", ",", "SSRI", ")", "and", "fentanyl", "(", "a", "phenylpiperidine", "opioid", ")", "."], "event_mentions": [{"id": "18676387_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 14, "end": 15}, "arguments": [{"entity_id": "18676387_2_Ent0", "role": "Effect", "text": "serotonin toxicity", "start": 5, "end": 7}, {"entity_id": "18676387_2_Ent1", "role": "Treatment", "text": "paroxetine", "start": 19, "end": 20}, {"entity_id": "18676387_2_Ent3", "role": "Treatment_Drug", "text": "paroxetine", "start": 19, "end": 20}, {"entity_id": "18676387_2_Ent5", "role": "Combination_Drug", "text": "paroxetine", "start": 19, "end": 20}, {"entity_id": "18676387_2_Ent2", "role": "Treatment", "text": "fentanyl", "start": 30, "end": 31}, {"entity_id": "18676387_2_Ent4", "role": "Treatment_Drug", "text": "fentanyl", "start": 30, "end": 31}, {"entity_id": "18676387_2_Ent6", "role": "Combination_Drug", "text": "fentanyl", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "18676387_2_Ent0", "text": "serotonin toxicity", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18676387_2_Ent1", "text": "paroxetine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18676387_2_Ent3", "text": "paroxetine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18676387_2_Ent5", "text": "paroxetine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18676387_2_Ent2", "text": "fentanyl", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "18676387_2_Ent4", "text": "fentanyl", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "18676387_2_Ent6", "text": "fentanyl", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "18676387_8", "wnd_id": "18676387_8_1", "text": "The co - administration of SSRIs and fentanyl may precipitate serotonin toxicity .", "tokens": ["The", "co", "-", "administration", "of", "SSRIs", "and", "fentanyl", "may", "precipitate", "serotonin", "toxicity", "."], "event_mentions": [{"id": "18676387_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitate", "start": 9, "end": 10}, "arguments": [{"entity_id": "18676387_8_Ent1", "role": "Treatment", "text": "co - administration of SSRIs and fentanyl", "start": 1, "end": 8}, {"entity_id": "18676387_8_Ent2", "role": "Treatment_Drug", "text": "SSRIs", "start": 5, "end": 6}, {"entity_id": "18676387_8_Ent4", "role": "Combination_Drug", "text": "SSRIs", "start": 5, "end": 6}, {"entity_id": "18676387_8_Ent3", "role": "Treatment_Drug", "text": "fentanyl", "start": 7, "end": 8}, {"entity_id": "18676387_8_Ent5", "role": "Combination_Drug", "text": "fentanyl", "start": 7, "end": 8}, {"entity_id": "18676387_8_Ent0", "role": "Effect", "text": "serotonin toxicity", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18676387_8_Ent1", "text": "co - administration of SSRIs and fentanyl", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "18676387_8_Ent2", "text": "SSRIs", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18676387_8_Ent4", "text": "SSRIs", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18676387_8_Ent3", "text": "fentanyl", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18676387_8_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18676387_8_Ent0", "text": "serotonin toxicity", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "1868481_1", "wnd_id": "1868481_1_1", "text": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis .", "tokens": ["Seizures", "and", "transient", "blindness", "following", "intravenous", "pulse", "methylprednisolone", "in", "children", "with", "primary", "glomerulonephritis", "."], "event_mentions": [{"id": "1868481_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "1868481_1_Ent2", "role": "Effect", "text": "Seizures and transient blindness", "start": 0, "end": 4}, {"entity_id": "1868481_1_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 5, "end": 6}, {"entity_id": "1868481_1_Ent3", "role": "Treatment", "text": "intravenous pulse methylprednisolone", "start": 5, "end": 8}, {"entity_id": "1868481_1_Ent5", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 7, "end": 8}, {"entity_id": "1868481_1_Ent1", "role": "Subject_Age", "text": "children", "start": 9, "end": 10}, {"entity_id": "1868481_1_Ent0", "role": "Subject", "text": "children with primary glomerulonephritis", "start": 9, "end": 13}, {"entity_id": "1868481_1_Ent6", "role": "Treatment_Disorder", "text": "primary glomerulonephritis", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "1868481_1_Ent2", "text": "Seizures and transient blindness", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "1868481_1_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1868481_1_Ent3", "text": "intravenous pulse methylprednisolone", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1868481_1_Ent5", "text": "methylprednisolone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1868481_1_Ent1", "text": "children", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1868481_1_Ent0", "text": "children with primary glomerulonephritis", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "1868481_1_Ent6", "text": "primary glomerulonephritis", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "18691992_4", "wnd_id": "18691992_4_1", "text": "CONCLUSIONS : We report this case of the concomitant appearance of multiple skin cancers and nail changes associated with hydroxyurea use .", "tokens": ["CONCLUSIONS", ":", "We", "report", "this", "case", "of", "the", "concomitant", "appearance", "of", "multiple", "skin", "cancers", "and", "nail", "changes", "associated", "with", "hydroxyurea", "use", "."], "event_mentions": [{"id": "18691992_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 17, "end": 18}, "arguments": [{"entity_id": "18691992_4_Ent0", "role": "Subject", "text": "case", "start": 5, "end": 6}, {"entity_id": "18691992_4_Ent1", "role": "Effect", "text": "multiple skin cancers and nail changes", "start": 11, "end": 17}, {"entity_id": "18691992_4_Ent2", "role": "Treatment", "text": "hydroxyurea", "start": 19, "end": 20}, {"entity_id": "18691992_4_Ent3", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "18691992_4_Ent0", "text": "case", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18691992_4_Ent1", "text": "multiple skin cancers and nail changes", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "18691992_4_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18691992_4_Ent3", "text": "hydroxyurea", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "18715650_2", "wnd_id": "18715650_2_1", "text": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide .", "tokens": ["We", "describe", "the", "first", "case", "of", "disseminated", "salmonellosis", "in", "a", "patient", "treated", "with", "temozolomide", "."], "event_mentions": [{"id": "18715650_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 8, "end": 9}, "arguments": [{"entity_id": "18715650_2_Ent1", "role": "Effect", "text": "disseminated salmonellosis", "start": 6, "end": 8}, {"entity_id": "18715650_2_Ent0", "role": "Subject", "text": "a patient", "start": 9, "end": 11}, {"entity_id": "18715650_2_Ent2", "role": "Treatment", "text": "temozolomide", "start": 13, "end": 14}, {"entity_id": "18715650_2_Ent3", "role": "Treatment_Drug", "text": "temozolomide", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "18715650_2_Ent1", "text": "disseminated salmonellosis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "18715650_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18715650_2_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18715650_2_Ent3", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "18717612_1", "wnd_id": "18717612_1_1", "text": "Ceftriaxone - induced fixed drug eruption : first report .", "tokens": ["Ceftriaxone", "-", "induced", "fixed", "drug", "eruption", ":", "first", "report", "."], "event_mentions": [{"id": "18717612_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18717612_1_Ent1", "role": "Treatment", "text": "Ceftriaxone", "start": 0, "end": 1}, {"entity_id": "18717612_1_Ent2", "role": "Treatment_Drug", "text": "Ceftriaxone", "start": 0, "end": 1}, {"entity_id": "18717612_1_Ent0", "role": "Effect", "text": "fixed drug eruption", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "18717612_1_Ent1", "text": "Ceftriaxone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18717612_1_Ent2", "text": "Ceftriaxone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18717612_1_Ent0", "text": "fixed drug eruption", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "18717612_2", "wnd_id": "18717612_2_1", "text": "FDE from cephalosporins has been rarely reported , and to the best of our knowledge there is no published report of ceftriaxone - induced FDE in the literature .", "tokens": ["FDE", "from", "cephalosporins", "has", "been", "rarely", "reported", ",", "and", "to", "the", "best", "of", "our", "knowledge", "there", "is", "no", "published", "report", "of", "ceftriaxone", "-", "induced", "FDE", "in", "the", "literature", "."], "event_mentions": [{"id": "18717612_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 1, "end": 2}, "arguments": [{"entity_id": "18717612_2_Ent0", "role": "Effect", "text": "FDE", "start": 0, "end": 1}, {"entity_id": "18717612_2_Ent1", "role": "Treatment", "text": "cephalosporins", "start": 2, "end": 3}, {"entity_id": "18717612_2_Ent2", "role": "Treatment_Drug", "text": "cephalosporins", "start": 2, "end": 3}]}, {"id": "18717612_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 23, "end": 24}, "arguments": [{"entity_id": "18717612_2_Ent4", "role": "Treatment", "text": "ceftriaxone", "start": 21, "end": 22}, {"entity_id": "18717612_2_Ent5", "role": "Treatment_Drug", "text": "ceftriaxone", "start": 21, "end": 22}, {"entity_id": "18717612_2_Ent3", "role": "Effect", "text": "FDE", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "18717612_2_Ent0", "text": "FDE", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18717612_2_Ent1", "text": "cephalosporins", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18717612_2_Ent2", "text": "cephalosporins", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18717612_2_Ent4", "text": "ceftriaxone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18717612_2_Ent5", "text": "ceftriaxone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18717612_2_Ent3", "text": "FDE", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "18751717_2", "wnd_id": "18751717_2_1", "text": "BACKGROUND : We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis ( ASPPC ) that developed after intravitreal triamcinolone acetonide ( IVTA ) injection .", "tokens": ["BACKGROUND", ":", "We", "describe", "the", "ophthalmic", "features", "and", "clinical", "course", "of", "two", "cases", "of", "acute", "syphilitic", "posterior", "placoid", "chorioretinitis", "(", "ASPPC", ")", "that", "developed", "after", "intravitreal", "triamcinolone", "acetonide", "(", "IVTA", ")", "injection", "."], "event_mentions": [{"id": "18751717_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 23, "end": 24}, "arguments": [{"entity_id": "18751717_2_Ent0", "role": "Effect", "text": "acute syphilitic posterior placoid chorioretinitis", "start": 14, "end": 19}, {"entity_id": "18751717_2_Ent1", "role": "Treatment", "text": "intravitreal triamcinolone acetonide ( IVTA ) injection", "start": 25, "end": 32}, {"entity_id": "18751717_2_Ent2", "role": "Treatment_Drug", "text": "triamcinolone acetonide ( IVTA )", "start": 26, "end": 31}, {"entity_id": "18751717_2_Ent3", "role": "Treatment_Route", "text": "injection", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "18751717_2_Ent0", "text": "acute syphilitic posterior placoid chorioretinitis", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "18751717_2_Ent1", "text": "intravitreal triamcinolone acetonide ( IVTA ) injection", "entity_type": "Entity", "start": 25, "end": 32}, {"id": "18751717_2_Ent2", "text": "triamcinolone acetonide ( IVTA )", "entity_type": "Entity", "start": 26, "end": 31}, {"id": "18751717_2_Ent3", "text": "injection", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "18755414_1", "wnd_id": "18755414_1_1", "text": "Hemorrhage from a falx meningioma after internal use of low - dose aspirin .", "tokens": ["Hemorrhage", "from", "a", "falx", "meningioma", "after", "internal", "use", "of", "low", "-", "dose", "aspirin", "."], "event_mentions": [{"id": "18755414_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "18755414_1_Ent0", "role": "Effect", "text": "Hemorrhage from a falx meningioma", "start": 0, "end": 5}, {"entity_id": "18755414_1_Ent5", "role": "Treatment_Disorder", "text": "falx meningioma", "start": 3, "end": 5}, {"entity_id": "18755414_1_Ent4", "role": "Treatment_Route", "text": "internal", "start": 6, "end": 7}, {"entity_id": "18755414_1_Ent1", "role": "Treatment", "text": "internal use of low - dose aspirin", "start": 6, "end": 13}, {"entity_id": "18755414_1_Ent3", "role": "Treatment_Dosage", "text": "low - dose", "start": 9, "end": 12}, {"entity_id": "18755414_1_Ent2", "role": "Treatment_Drug", "text": "aspirin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "18755414_1_Ent0", "text": "Hemorrhage from a falx meningioma", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "18755414_1_Ent5", "text": "falx meningioma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18755414_1_Ent4", "text": "internal", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18755414_1_Ent1", "text": "internal use of low - dose aspirin", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "18755414_1_Ent3", "text": "low - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18755414_1_Ent2", "text": "aspirin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "18765315_1", "wnd_id": "18765315_1_1", "text": "Acute coronary syndromes can be associated with the infusion of rituximab .", "tokens": ["Acute", "coronary", "syndromes", "can", "be", "associated", "with", "the", "infusion", "of", "rituximab", "."], "event_mentions": [{"id": "18765315_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "18765315_1_Ent0", "role": "Effect", "text": "Acute coronary syndromes", "start": 0, "end": 3}, {"entity_id": "18765315_1_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 8, "end": 9}, {"entity_id": "18765315_1_Ent1", "role": "Treatment", "text": "infusion of rituximab", "start": 8, "end": 11}, {"entity_id": "18765315_1_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "18765315_1_Ent0", "text": "Acute coronary syndromes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18765315_1_Ent3", "text": "infusion", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18765315_1_Ent1", "text": "infusion of rituximab", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "18765315_1_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "18765315_2", "wnd_id": "18765315_2_1", "text": "Acute coronary syndromes complicating the first infusion of rituximab .", "tokens": ["Acute", "coronary", "syndromes", "complicating", "the", "first", "infusion", "of", "rituximab", "."], "event_mentions": [{"id": "18765315_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicating", "start": 3, "end": 4}, "arguments": [{"entity_id": "18765315_2_Ent0", "role": "Effect", "text": "Acute coronary syndromes", "start": 0, "end": 3}, {"entity_id": "18765315_2_Ent1", "role": "Treatment", "text": "the first infusion of rituximab", "start": 4, "end": 9}, {"entity_id": "18765315_2_Ent2", "role": "Treatment_Route", "text": "infusion", "start": 6, "end": 7}, {"entity_id": "18765315_2_Ent3", "role": "Treatment_Drug", "text": "rituximab", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18765315_2_Ent0", "text": "Acute coronary syndromes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18765315_2_Ent1", "text": "the first infusion of rituximab", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "18765315_2_Ent2", "text": "infusion", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18765315_2_Ent3", "text": "rituximab", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18775393_1", "wnd_id": "18775393_1_1", "text": "CONCLUSION : This report describes a case of a probable interaction between topical econazole lotion 1 % and acenocoumarol that resulted in overanticoagulation and a life - threatening laryngeal hematoma in this elderly patient .", "tokens": ["CONCLUSION", ":", "This", "report", "describes", "a", "case", "of", "a", "probable", "interaction", "between", "topical", "econazole", "lotion", "1", "%", "and", "acenocoumarol", "that", "resulted", "in", "overanticoagulation", "and", "a", "life", "-", "threatening", "laryngeal", "hematoma", "in", "this", "elderly", "patient", "."], "event_mentions": [{"id": "18775393_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 20, "end": 21}, "arguments": [{"entity_id": "18775393_1_Ent3", "role": "Treatment", "text": "a probable interaction between topical econazole lotion 1 % and acenocoumarol", "start": 8, "end": 19}, {"entity_id": "18775393_1_Ent6", "role": "Treatment_Route", "text": "topical", "start": 12, "end": 13}, {"entity_id": "18775393_1_Ent4", "role": "Treatment_Drug", "text": "econazole", "start": 13, "end": 14}, {"entity_id": "18775393_1_Ent8", "role": "Combination_Drug", "text": "econazole", "start": 13, "end": 14}, {"entity_id": "18775393_1_Ent7", "role": "Treatment_Route", "text": "lotion", "start": 14, "end": 15}, {"entity_id": "18775393_1_Ent5", "role": "Treatment_Drug", "text": "acenocoumarol", "start": 18, "end": 19}, {"entity_id": "18775393_1_Ent9", "role": "Combination_Drug", "text": "acenocoumarol", "start": 18, "end": 19}, {"entity_id": "18775393_1_Ent2", "role": "Effect", "text": "overanticoagulation and a life - threatening laryngeal hematoma", "start": 22, "end": 30}, {"entity_id": "18775393_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 32, "end": 33}, {"entity_id": "18775393_1_Ent0", "role": "Subject", "text": "elderly patient", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "18775393_1_Ent3", "text": "a probable interaction between topical econazole lotion 1 % and acenocoumarol", "entity_type": "Entity", "start": 8, "end": 19}, {"id": "18775393_1_Ent6", "text": "topical", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18775393_1_Ent4", "text": "econazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18775393_1_Ent8", "text": "econazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18775393_1_Ent7", "text": "lotion", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18775393_1_Ent5", "text": "acenocoumarol", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18775393_1_Ent9", "text": "acenocoumarol", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18775393_1_Ent2", "text": "overanticoagulation and a life - threatening laryngeal hematoma", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "18775393_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18775393_1_Ent0", "text": "elderly patient", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "18795_3", "wnd_id": "18795_3_1", "text": "When DSCG was withdrawn , urticaria vanished and the child remained symptom - free .", "tokens": ["When", "DSCG", "was", "withdrawn", ",", "urticaria", "vanished", "and", "the", "child", "remained", "symptom", "-", "free", "."], "event_mentions": [{"id": "18795_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "remained", "start": 10, "end": 11}, "arguments": [{"entity_id": "18795_3_Ent5", "role": "Treatment_Drug", "text": "DSCG", "start": 1, "end": 2}, {"entity_id": "18795_3_Ent4", "role": "Treatment", "text": "DSCG was withdrawn", "start": 1, "end": 4}, {"entity_id": "18795_3_Ent2", "role": "Effect", "text": "urticaria vanished", "start": 5, "end": 7}, {"entity_id": "18795_3_Ent0", "role": "Subject", "text": "the child", "start": 8, "end": 10}, {"entity_id": "18795_3_Ent1", "role": "Subject_Age", "text": "child", "start": 9, "end": 10}, {"entity_id": "18795_3_Ent3", "role": "Effect", "text": "symptom - free", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "18795_3_Ent5", "text": "DSCG", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18795_3_Ent4", "text": "DSCG was withdrawn", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "18795_3_Ent2", "text": "urticaria vanished", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18795_3_Ent0", "text": "the child", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18795_3_Ent1", "text": "child", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18795_3_Ent3", "text": "symptom - free", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "18801826_3", "wnd_id": "18801826_3_1", "text": "We report a case of a 35 - year old female who developed new onset type II diabetes mellitus with hyperosmolar hyperglycaemic coma and acute renal failure following treatment with a SGA for a first manic episode .", "tokens": ["We", "report", "a", "case", "of", "a", "35", "-", "year", "old", "female", "who", "developed", "new", "onset", "type", "II", "diabetes", "mellitus", "with", "hyperosmolar", "hyperglycaemic", "coma", "and", "acute", "renal", "failure", "following", "treatment", "with", "a", "SGA", "for", "a", "first", "manic", "episode", "."], "event_mentions": [{"id": "18801826_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "18801826_3_Ent1", "role": "Subject_Age", "text": "35 - year old", "start": 6, "end": 10}, {"entity_id": "18801826_3_Ent0", "role": "Subject", "text": "35 - year old female", "start": 6, "end": 11}, {"entity_id": "18801826_3_Ent2", "role": "Subject_Gender", "text": "female", "start": 10, "end": 11}, {"entity_id": "18801826_3_Ent3", "role": "Effect", "text": "type II diabetes mellitus with hyperosmolar hyperglycaemic coma and acute renal failure", "start": 15, "end": 27}, {"entity_id": "18801826_3_Ent4", "role": "Treatment", "text": "treatment with a SGA", "start": 28, "end": 32}, {"entity_id": "18801826_3_Ent5", "role": "Treatment_Drug", "text": "SGA", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "18801826_3_Ent1", "text": "35 - year old", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "18801826_3_Ent0", "text": "35 - year old female", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "18801826_3_Ent2", "text": "female", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18801826_3_Ent3", "text": "type II diabetes mellitus with hyperosmolar hyperglycaemic coma and acute renal failure", "entity_type": "Entity", "start": 15, "end": 27}, {"id": "18801826_3_Ent4", "text": "treatment with a SGA", "entity_type": "Entity", "start": 28, "end": 32}, {"id": "18801826_3_Ent5", "text": "SGA", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "18855892_3", "wnd_id": "18855892_3_1", "text": "In patients with methotrexate - induced anaphylaxis , discontinuation of treatment may increase the risk of death due to cancer progression .", "tokens": ["In", "patients", "with", "methotrexate", "-", "induced", "anaphylaxis", ",", "discontinuation", "of", "treatment", "may", "increase", "the", "risk", "of", "death", "due", "to", "cancer", "progression", "."], "event_mentions": [{"id": "18855892_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "18855892_3_Ent5", "role": "Treatment", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "18855892_3_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "18855892_3_Ent4", "role": "Effect", "text": "anaphylaxis", "start": 6, "end": 7}]}, {"id": "18855892_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "discontinuation", "start": 8, "end": 9}, "arguments": [{"entity_id": "18855892_3_Ent0", "role": "Subject", "text": "In patients with methotrexate - induced anaphylaxis", "start": 0, "end": 7}, {"entity_id": "18855892_3_Ent3", "role": "Treatment_Disorder", "text": "methotrexate - induced anaphylaxis", "start": 3, "end": 7}, {"entity_id": "18855892_3_Ent2", "role": "Treatment", "text": "treatment", "start": 10, "end": 11}, {"entity_id": "18855892_3_Ent1", "role": "Effect", "text": "death due to cancer progression", "start": 16, "end": 21}]}], "entity_mentions": [{"id": "18855892_3_Ent0", "text": "In patients with methotrexate - induced anaphylaxis", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "18855892_3_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18855892_3_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18855892_3_Ent3", "text": "methotrexate - induced anaphylaxis", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "18855892_3_Ent4", "text": "anaphylaxis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18855892_3_Ent2", "text": "treatment", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18855892_3_Ent1", "text": "death due to cancer progression", "entity_type": "Entity", "start": 16, "end": 21}], "lang": "en"}
{"doc_id": "18957000_3", "wnd_id": "18957000_3_1", "text": "Heparin - dependent antibodies and thrombosis without heparin - induced thrombocytopenia .", "tokens": ["Heparin", "-", "dependent", "antibodies", "and", "thrombosis", "without", "heparin", "-", "induced", "thrombocytopenia", "."], "event_mentions": [{"id": "18957000_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "18957000_3_Ent1", "role": "Treatment", "text": "heparin", "start": 7, "end": 8}, {"entity_id": "18957000_3_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 7, "end": 8}, {"entity_id": "18957000_3_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "18957000_3_Ent1", "text": "heparin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18957000_3_Ent2", "text": "heparin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18957000_3_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "18983414_1", "wnd_id": "18983414_1_1", "text": "Four months after receiving an orthotopic liver transplant , a 51 - year - old man was admitted for progressive liver failure and severe hepatocellular necrosis thought to be due to tacrolimus .", "tokens": ["Four", "months", "after", "receiving", "an", "orthotopic", "liver", "transplant", ",", "a", "51", "-", "year", "-", "old", "man", "was", "admitted", "for", "progressive", "liver", "failure", "and", "severe", "hepatocellular", "necrosis", "thought", "to", "be", "due", "to", "tacrolimus", "."], "event_mentions": [{"id": "18983414_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 29, "end": 31}, "arguments": [{"entity_id": "18983414_1_Ent5", "role": "Treatment_Time_elapsed", "text": "Four months", "start": 0, "end": 2}, {"entity_id": "18983414_1_Ent0", "role": "Subject", "text": "Four months after receiving an orthotopic liver transplant , a 51 - year - old man", "start": 0, "end": 16}, {"entity_id": "18983414_1_Ent1", "role": "Subject_Age", "text": "a 51 - year - old", "start": 9, "end": 15}, {"entity_id": "18983414_1_Ent2", "role": "Effect", "text": "progressive liver failure and severe hepatocellular necrosis", "start": 19, "end": 26}, {"entity_id": "18983414_1_Ent3", "role": "Treatment", "text": "tacrolimus", "start": 31, "end": 32}, {"entity_id": "18983414_1_Ent4", "role": "Treatment_Drug", "text": "tacrolimus", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "18983414_1_Ent5", "text": "Four months", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18983414_1_Ent0", "text": "Four months after receiving an orthotopic liver transplant , a 51 - year - old man", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "18983414_1_Ent1", "text": "a 51 - year - old", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "18983414_1_Ent2", "text": "progressive liver failure and severe hepatocellular necrosis", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "18983414_1_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "18983414_1_Ent4", "text": "tacrolimus", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "18991509_1", "wnd_id": "18991509_1_1", "text": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1 - infected patient receiving therapy with ritonavir - lopinavir .", "tokens": ["Iatrogenic", "Cushing", "syndrome", "after", "epidural", "triamcinolone", "injections", "in", "an", "HIV", "type", "1", "-", "infected", "patient", "receiving", "therapy", "with", "ritonavir", "-", "lopinavir", "."], "event_mentions": [{"id": "18991509_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "18991509_1_Ent1", "role": "Effect", "text": "Iatrogenic Cushing syndrome", "start": 0, "end": 3}, {"entity_id": "18991509_1_Ent5", "role": "Treatment_Drug", "text": "epidural triamcinolone", "start": 4, "end": 6}, {"entity_id": "18991509_1_Ent8", "role": "Combination_Drug", "text": "epidural triamcinolone", "start": 4, "end": 6}, {"entity_id": "18991509_1_Ent3", "role": "Treatment", "text": "epidural triamcinolone injections", "start": 4, "end": 7}, {"entity_id": "18991509_1_Ent7", "role": "Treatment_Route", "text": "injections", "start": 6, "end": 7}, {"entity_id": "18991509_1_Ent0", "role": "Subject", "text": "an HIV type 1 - infected patient", "start": 8, "end": 15}, {"entity_id": "18991509_1_Ent4", "role": "Treatment_Disorder", "text": "HIV type 1", "start": 9, "end": 12}, {"entity_id": "18991509_1_Ent2", "role": "Treatment", "text": "receiving therapy with ritonavir - lopinavir", "start": 15, "end": 21}, {"entity_id": "18991509_1_Ent6", "role": "Treatment_Drug", "text": "ritonavir - lopinavir", "start": 18, "end": 21}, {"entity_id": "18991509_1_Ent9", "role": "Combination_Drug", "text": "ritonavir - lopinavir", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "18991509_1_Ent1", "text": "Iatrogenic Cushing syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18991509_1_Ent5", "text": "epidural triamcinolone", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18991509_1_Ent8", "text": "epidural triamcinolone", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18991509_1_Ent3", "text": "epidural triamcinolone injections", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "18991509_1_Ent7", "text": "injections", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18991509_1_Ent0", "text": "an HIV type 1 - infected patient", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "18991509_1_Ent4", "text": "HIV type 1", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18991509_1_Ent2", "text": "receiving therapy with ritonavir - lopinavir", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "18991509_1_Ent6", "text": "ritonavir - lopinavir", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "18991509_1_Ent9", "text": "ritonavir - lopinavir", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "19003750_1", "wnd_id": "19003750_1_1", "text": "A 22 - year - old drug - abuser injected flunitrazepam tablets dissolved in tap water into her left femoral artery and presented with clinical signs of acute ischaemia of the left leg .", "tokens": ["A", "22", "-", "year", "-", "old", "drug", "-", "abuser", "injected", "flunitrazepam", "tablets", "dissolved", "in", "tap", "water", "into", "her", "left", "femoral", "artery", "and", "presented", "with", "clinical", "signs", "of", "acute", "ischaemia", "of", "the", "left", "leg", "."], "event_mentions": [{"id": "19003750_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 22, "end": 23}, "arguments": [{"entity_id": "19003750_1_Ent0", "role": "Subject", "text": "A 22 - year - old drug - abuser", "start": 0, "end": 9}, {"entity_id": "19003750_1_Ent1", "role": "Subject_Age", "text": "22 - year - old", "start": 1, "end": 6}, {"entity_id": "19003750_1_Ent2", "role": "Subject_Disorder", "text": "drug - abuser", "start": 6, "end": 9}, {"entity_id": "19003750_1_Ent6", "role": "Treatment_Route", "text": "injected", "start": 9, "end": 10}, {"entity_id": "19003750_1_Ent4", "role": "Treatment", "text": "injected flunitrazepam tablets dissolved in tap water into her left femoral artery", "start": 9, "end": 21}, {"entity_id": "19003750_1_Ent5", "role": "Treatment_Drug", "text": "flunitrazepam", "start": 10, "end": 11}, {"entity_id": "19003750_1_Ent7", "role": "Treatment_Route", "text": "tablets dissolved in tap water", "start": 11, "end": 16}, {"entity_id": "19003750_1_Ent3", "role": "Effect", "text": "acute ischaemia of the left leg", "start": 27, "end": 33}]}], "entity_mentions": [{"id": "19003750_1_Ent0", "text": "A 22 - year - old drug - abuser", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "19003750_1_Ent1", "text": "22 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19003750_1_Ent2", "text": "drug - abuser", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19003750_1_Ent6", "text": "injected", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19003750_1_Ent4", "text": "injected flunitrazepam tablets dissolved in tap water into her left femoral artery", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "19003750_1_Ent5", "text": "flunitrazepam", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19003750_1_Ent7", "text": "tablets dissolved in tap water", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19003750_1_Ent3", "text": "acute ischaemia of the left leg", "entity_type": "Entity", "start": 27, "end": 33}], "lang": "en"}
{"doc_id": "19018868_2", "wnd_id": "19018868_2_1", "text": "Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidomide , aplastic anemia has not previously been reported to be associated with this agent .", "tokens": ["Although", "moderate", "myelosuppression", "is", "not", "uncommonly", "seen", "in", "patients", "treated", "with", "lenalidomide", ",", "aplastic", "anemia", "has", "not", "previously", "been", "reported", "to", "be", "associated", "with", "this", "agent", "."], "event_mentions": [{"id": "19018868_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 22, "end": 23}, "arguments": [{"entity_id": "19018868_2_Ent1", "role": "Treatment", "text": "lenalidomide", "start": 11, "end": 12}, {"entity_id": "19018868_2_Ent2", "role": "Treatment_Drug", "text": "lenalidomide", "start": 11, "end": 12}, {"entity_id": "19018868_2_Ent0", "role": "Effect", "text": "aplastic anemia", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "19018868_2_Ent1", "text": "lenalidomide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19018868_2_Ent2", "text": "lenalidomide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19018868_2_Ent0", "text": "aplastic anemia", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "19034138_1", "wnd_id": "19034138_1_1", "text": "After cessation of amantadine , the edema resolved , and the endothelial cell densities were < or=600/mm .", "tokens": ["After", "cessation", "of", "amantadine", ",", "the", "edema", "resolved", ",", "and", "the", "endothelial", "cell", "densities", "were", "<", "or=600/mm", "."], "event_mentions": [{"id": "19034138_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "19034138_1_Ent1", "role": "Treatment", "text": "cessation of amantadine", "start": 1, "end": 4}, {"entity_id": "19034138_1_Ent2", "role": "Treatment_Drug", "text": "amantadine", "start": 3, "end": 4}, {"entity_id": "19034138_1_Ent0", "role": "Effect", "text": "the edema resolved , and the endothelial cell densities were < or=600/mm", "start": 5, "end": 17}, {"entity_id": "19034138_1_Ent3", "role": "Treatment_Dosage", "text": "< or=600/mm", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "19034138_1_Ent1", "text": "cessation of amantadine", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "19034138_1_Ent2", "text": "amantadine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19034138_1_Ent0", "text": "the edema resolved , and the endothelial cell densities were < or=600/mm", "entity_type": "Entity", "start": 5, "end": 17}, {"id": "19034138_1_Ent3", "text": "< or=600/mm", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "19034138_2", "wnd_id": "19034138_2_1", "text": "CONCLUSIONS : Amantadine can cause reversible corneal edema but can irreversibly reduce the density of endothelial cells .", "tokens": ["CONCLUSIONS", ":", "Amantadine", "can", "cause", "reversible", "corneal", "edema", "but", "can", "irreversibly", "reduce", "the", "density", "of", "endothelial", "cells", "."], "event_mentions": [{"id": "19034138_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "19034138_2_Ent1", "role": "Treatment", "text": "Amantadine", "start": 2, "end": 3}, {"entity_id": "19034138_2_Ent2", "role": "Treatment_Drug", "text": "Amantadine", "start": 2, "end": 3}, {"entity_id": "19034138_2_Ent0", "role": "Effect", "text": "reversible corneal edema", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "19034138_2_Ent1", "text": "Amantadine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19034138_2_Ent2", "text": "Amantadine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19034138_2_Ent0", "text": "reversible corneal edema", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "19097599_2", "wnd_id": "19097599_2_1", "text": "We herein described an additional patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10 - day treatment with imatinib .", "tokens": ["We", "herein", "described", "an", "additional", "patient", "with", "BCR", "-", "ABL", "(", "ela2", ")", "positive", "acute", "lymphoblastic", "leukemia", "who", "developed", "tumor", "lysis", "syndrome", "after", "10", "-", "day", "treatment", "with", "imatinib", "."], "event_mentions": [{"id": "19097599_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "19097599_2_Ent0", "role": "Subject", "text": "patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "start": 5, "end": 17}, {"entity_id": "19097599_2_Ent5", "role": "Treatment_Disorder", "text": "BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "start": 7, "end": 17}, {"entity_id": "19097599_2_Ent1", "role": "Effect", "text": "tumor lysis syndrome", "start": 19, "end": 22}, {"entity_id": "19097599_2_Ent4", "role": "Treatment_Time_elapsed", "text": "10 - day", "start": 23, "end": 26}, {"entity_id": "19097599_2_Ent2", "role": "Treatment", "text": "10 - day treatment with imatinib", "start": 23, "end": 29}, {"entity_id": "19097599_2_Ent3", "role": "Treatment_Drug", "text": "imatinib", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "19097599_2_Ent0", "text": "patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "entity_type": "Entity", "start": 5, "end": 17}, {"id": "19097599_2_Ent5", "text": "BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "19097599_2_Ent1", "text": "tumor lysis syndrome", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "19097599_2_Ent4", "text": "10 - day", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "19097599_2_Ent2", "text": "10 - day treatment with imatinib", "entity_type": "Entity", "start": 23, "end": 29}, {"id": "19097599_2_Ent3", "text": "imatinib", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "19104709_1", "wnd_id": "19104709_1_1", "text": "IFNalpha - induced recurrence of Graves ' disease ten years after thyroidectomy in chronic viral hepatitis C.", "tokens": ["IFNalpha", "-", "induced", "recurrence", "of", "Graves", "'", "disease", "ten", "years", "after", "thyroidectomy", "in", "chronic", "viral", "hepatitis", "C."], "event_mentions": [{"id": "19104709_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19104709_1_Ent1", "role": "Treatment", "text": "IFNalpha", "start": 0, "end": 1}, {"entity_id": "19104709_1_Ent4", "role": "Treatment_Drug", "text": "IFNalpha", "start": 0, "end": 1}, {"entity_id": "19104709_1_Ent0", "role": "Effect", "text": "recurrence of Graves ' disease", "start": 3, "end": 8}, {"entity_id": "19104709_1_Ent2", "role": "Treatment", "text": "ten years after thyroidectomy", "start": 8, "end": 12}, {"entity_id": "19104709_1_Ent3", "role": "Treatment_Disorder", "text": "chronic viral hepatitis C.", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "19104709_1_Ent1", "text": "IFNalpha", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19104709_1_Ent4", "text": "IFNalpha", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19104709_1_Ent0", "text": "recurrence of Graves ' disease", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19104709_1_Ent2", "text": "ten years after thyroidectomy", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "19104709_1_Ent3", "text": "chronic viral hepatitis C.", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "19104709_2", "wnd_id": "19104709_2_1", "text": "In contrast to chronic or subacute thyroiditis , Graves ' disease rarely complicates IFN - alpha therapy for chronic viral C hepatitis .", "tokens": ["In", "contrast", "to", "chronic", "or", "subacute", "thyroiditis", ",", "Graves", "'", "disease", "rarely", "complicates", "IFN", "-", "alpha", "therapy", "for", "chronic", "viral", "C", "hepatitis", "."], "event_mentions": [{"id": "19104709_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 17, "end": 18}, "arguments": [{"entity_id": "19104709_2_Ent0", "role": "Subject", "text": "Graves ' disease", "start": 8, "end": 11}, {"entity_id": "19104709_2_Ent1", "role": "Subject_Disorder", "text": "Graves ' disease", "start": 8, "end": 11}, {"entity_id": "19104709_2_Ent2", "role": "Treatment", "text": "IFN - alpha", "start": 13, "end": 16}, {"entity_id": "19104709_2_Ent4", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 13, "end": 16}, {"entity_id": "19104709_2_Ent3", "role": "Treatment_Disorder", "text": "chronic viral C hepatitis", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "19104709_2_Ent0", "text": "Graves ' disease", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "19104709_2_Ent1", "text": "Graves ' disease", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "19104709_2_Ent2", "text": "IFN - alpha", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "19104709_2_Ent4", "text": "IFN - alpha", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "19104709_2_Ent3", "text": "chronic viral C hepatitis", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "19112808_2", "wnd_id": "19112808_2_1", "text": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin .", "tokens": ["The", "authors", "describe", "a", "case", "of", "interstitial", "granulomatous", "dermatitis", "associated", "with", "darifenacin", "."], "event_mentions": [{"id": "19112808_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "19112808_2_Ent0", "role": "Effect", "text": "interstitial granulomatous dermatitis", "start": 6, "end": 9}, {"entity_id": "19112808_2_Ent1", "role": "Treatment", "text": "darifenacin", "start": 11, "end": 12}, {"entity_id": "19112808_2_Ent2", "role": "Treatment_Drug", "text": "darifenacin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "19112808_2_Ent0", "text": "interstitial granulomatous dermatitis", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19112808_2_Ent1", "text": "darifenacin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19112808_2_Ent2", "text": "darifenacin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "19122478_6", "wnd_id": "19122478_6_1", "text": "He developed recurrent skin rash , fever , hypereosinophilia , and acute renal failure after rechallenge with chlorambucil .", "tokens": ["He", "developed", "recurrent", "skin", "rash", ",", "fever", ",", "hypereosinophilia", ",", "and", "acute", "renal", "failure", "after", "rechallenge", "with", "chlorambucil", "."], "event_mentions": [{"id": "19122478_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "19122478_6_Ent0", "role": "Effect", "text": "recurrent skin rash , fever , hypereosinophilia , and acute renal failure", "start": 2, "end": 14}, {"entity_id": "19122478_6_Ent1", "role": "Treatment", "text": "rechallenge with chlorambucil", "start": 15, "end": 18}, {"entity_id": "19122478_6_Ent2", "role": "Treatment_Drug", "text": "chlorambucil", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "19122478_6_Ent0", "text": "recurrent skin rash , fever , hypereosinophilia , and acute renal failure", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "19122478_6_Ent1", "text": "rechallenge with chlorambucil", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "19122478_6_Ent2", "text": "chlorambucil", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "19131789_2", "wnd_id": "19131789_2_1", "text": "Although his renal function recovered completely with high - dose leucovorin , hemodialysis , charcoal hemoperfusion , and carboxypeptidase G2 , we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4 - hour MTX infusion , and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4 - hour MTX infusion .", "tokens": ["Although", "his", "renal", "function", "recovered", "completely", "with", "high", "-", "dose", "leucovorin", ",", "hemodialysis", ",", "charcoal", "hemoperfusion", ",", "and", "carboxypeptidase", "G2", ",", "we", "present", "this", "case", "to", "emphasize", "that", "signs", "of", "renal", "toxicity", "may", "be", "present", "as", "early", "as", "2", "hours", "after", "the", "completion", "of", "a", "4", "-", "hour", "MTX", "infusion", ",", "and", "to", "suggest", "that", "monitoring", "for", "MTX", "toxicity", "should", "perhaps", "begin", "within", "a", "few", "hours", "after", "the", "completion", "of", "4", "-", "hour", "MTX", "infusion", "."], "event_mentions": [{"id": "19131789_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "recovered", "start": 4, "end": 5}, "arguments": [{"entity_id": "19131789_2_Ent8", "role": "Treatment_Dosage", "text": "high - dose", "start": 7, "end": 10}, {"entity_id": "19131789_2_Ent6", "role": "Treatment", "text": "high - dose leucovorin , hemodialysis , charcoal hemoperfusion , and carboxypeptidase G2", "start": 7, "end": 20}, {"entity_id": "19131789_2_Ent9", "role": "Treatment_Drug", "text": "leucovorin", "start": 10, "end": 11}, {"entity_id": "19131789_2_Ent14", "role": "Combination_Drug", "text": "leucovorin", "start": 10, "end": 11}, {"entity_id": "19131789_2_Ent10", "role": "Treatment_Drug", "text": "hemodialysis", "start": 12, "end": 13}, {"entity_id": "19131789_2_Ent15", "role": "Combination_Drug", "text": "hemodialysis", "start": 12, "end": 13}, {"entity_id": "19131789_2_Ent11", "role": "Treatment_Drug", "text": "charcoal", "start": 14, "end": 15}, {"entity_id": "19131789_2_Ent16", "role": "Combination_Drug", "text": "charcoal", "start": 14, "end": 15}, {"entity_id": "19131789_2_Ent13", "role": "Treatment_Route", "text": "hemoperfusion", "start": 15, "end": 16}, {"entity_id": "19131789_2_Ent12", "role": "Treatment_Drug", "text": "carboxypeptidase G2", "start": 18, "end": 20}, {"entity_id": "19131789_2_Ent17", "role": "Combination_Drug", "text": "carboxypeptidase G2", "start": 18, "end": 20}, {"entity_id": "19131789_2_Ent7", "role": "Treatment_Disorder", "text": "renal toxicity", "start": 30, "end": 32}]}, {"id": "19131789_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 40, "end": 41}, "arguments": [{"entity_id": "19131789_2_Ent0", "role": "Effect", "text": "renal toxicity", "start": 30, "end": 32}, {"entity_id": "19131789_2_Ent5", "role": "Treatment_Time_elapsed", "text": "2 hours", "start": 38, "end": 40}, {"entity_id": "19131789_2_Ent1", "role": "Treatment", "text": "2 hours after the completion of a 4 - hour MTX infusion", "start": 38, "end": 50}, {"entity_id": "19131789_2_Ent2", "role": "Treatment_Duration", "text": "4 - hour", "start": 45, "end": 48}, {"entity_id": "19131789_2_Ent3", "role": "Treatment_Drug", "text": "MTX", "start": 48, "end": 49}, {"entity_id": "19131789_2_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 49, "end": 50}]}], "entity_mentions": [{"id": "19131789_2_Ent8", "text": "high - dose", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "19131789_2_Ent6", "text": "high - dose leucovorin , hemodialysis , charcoal hemoperfusion , and carboxypeptidase G2", "entity_type": "Entity", "start": 7, "end": 20}, {"id": "19131789_2_Ent9", "text": "leucovorin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19131789_2_Ent14", "text": "leucovorin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19131789_2_Ent10", "text": "hemodialysis", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19131789_2_Ent15", "text": "hemodialysis", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19131789_2_Ent11", "text": "charcoal", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19131789_2_Ent16", "text": "charcoal", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19131789_2_Ent13", "text": "hemoperfusion", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19131789_2_Ent12", "text": "carboxypeptidase G2", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "19131789_2_Ent17", "text": "carboxypeptidase G2", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "19131789_2_Ent0", "text": "renal toxicity", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "19131789_2_Ent7", "text": "renal toxicity", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "19131789_2_Ent5", "text": "2 hours", "entity_type": "Entity", "start": 38, "end": 40}, {"id": "19131789_2_Ent1", "text": "2 hours after the completion of a 4 - hour MTX infusion", "entity_type": "Entity", "start": 38, "end": 50}, {"id": "19131789_2_Ent2", "text": "4 - hour", "entity_type": "Entity", "start": 45, "end": 48}, {"id": "19131789_2_Ent3", "text": "MTX", "entity_type": "Entity", "start": 48, "end": 49}, {"id": "19131789_2_Ent4", "text": "infusion", "entity_type": "Entity", "start": 49, "end": 50}], "lang": "en"}
{"doc_id": "19131789_3", "wnd_id": "19131789_3_1", "text": "Early recognition of renal toxicity of high - dose methotrexate therapy : a case report .", "tokens": ["Early", "recognition", "of", "renal", "toxicity", "of", "high", "-", "dose", "methotrexate", "therapy", ":", "a", "case", "report", "."], "event_mentions": [{"id": "19131789_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "recognition", "start": 1, "end": 2}, "arguments": [{"entity_id": "19131789_3_Ent0", "role": "Effect", "text": "renal toxicity", "start": 3, "end": 5}, {"entity_id": "19131789_3_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 6, "end": 9}, {"entity_id": "19131789_3_Ent1", "role": "Treatment", "text": "high - dose methotrexate therapy", "start": 6, "end": 11}, {"entity_id": "19131789_3_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19131789_3_Ent0", "text": "renal toxicity", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19131789_3_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19131789_3_Ent1", "text": "high - dose methotrexate therapy", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19131789_3_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19145124_1", "wnd_id": "19145124_1_1", "text": "Multifocal electroretinographic abnormalities in ethambutol - induced visual loss .", "tokens": ["Multifocal", "electroretinographic", "abnormalities", "in", "ethambutol", "-", "induced", "visual", "loss", "."], "event_mentions": [{"id": "19145124_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "19145124_1_Ent1", "role": "Treatment", "text": "ethambutol", "start": 4, "end": 5}, {"entity_id": "19145124_1_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 4, "end": 5}, {"entity_id": "19145124_1_Ent0", "role": "Effect", "text": "visual loss", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "19145124_1_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19145124_1_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19145124_1_Ent0", "text": "visual loss", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "19151423_1", "wnd_id": "19151423_1_1", "text": "Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin .", "tokens": ["Rhabdomyolysis", "due", "to", "an", "uncommon", "interaction", "of", "ciprofloxacin", "with", "simvastatin", "."], "event_mentions": [{"id": "19151423_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 1, "end": 2}, "arguments": [{"entity_id": "19151423_1_Ent0", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "19151423_1_Ent1", "role": "Treatment", "text": "interaction of ciprofloxacin with simvastatin", "start": 5, "end": 10}, {"entity_id": "19151423_1_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "19151423_1_Ent4", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "19151423_1_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 9, "end": 10}, {"entity_id": "19151423_1_Ent5", "role": "Combination_Drug", "text": "simvastatin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19151423_1_Ent0", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19151423_1_Ent1", "text": "interaction of ciprofloxacin with simvastatin", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19151423_1_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19151423_1_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19151423_1_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19151423_1_Ent5", "text": "simvastatin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19183077_2", "wnd_id": "19183077_2_1", "text": "To our knowledge , these cases represent the first reports of TDF - associated irreversible renal failure and rickets in pediatric patients .", "tokens": ["To", "our", "knowledge", ",", "these", "cases", "represent", "the", "first", "reports", "of", "TDF", "-", "associated", "irreversible", "renal", "failure", "and", "rickets", "in", "pediatric", "patients", "."], "event_mentions": [{"id": "19183077_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "19183077_2_Ent3", "role": "Treatment", "text": "TDF", "start": 11, "end": 12}, {"entity_id": "19183077_2_Ent4", "role": "Treatment_Drug", "text": "TDF", "start": 11, "end": 12}, {"entity_id": "19183077_2_Ent2", "role": "Effect", "text": "irreversible renal failure and rickets", "start": 14, "end": 19}, {"entity_id": "19183077_2_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 20, "end": 21}, {"entity_id": "19183077_2_Ent0", "role": "Subject", "text": "pediatric patients", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "19183077_2_Ent3", "text": "TDF", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19183077_2_Ent4", "text": "TDF", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19183077_2_Ent2", "text": "irreversible renal failure and rickets", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "19183077_2_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "19183077_2_Ent0", "text": "pediatric patients", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "19183077_3", "wnd_id": "19183077_3_1", "text": "We report two cases of tenofovir ( TDF) - associated nephrotoxicity in perinatally HIV - infected adolescents .", "tokens": ["We", "report", "two", "cases", "of", "tenofovir", "(", "TDF)", "-", "associated", "nephrotoxicity", "in", "perinatally", "HIV", "-", "infected", "adolescents", "."], "event_mentions": [{"id": "19183077_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "19183077_3_Ent4", "role": "Treatment_Drug", "text": "tenofovir", "start": 5, "end": 6}, {"entity_id": "19183077_3_Ent3", "role": "Treatment", "text": "tenofovir ( TDF)", "start": 5, "end": 8}, {"entity_id": "19183077_3_Ent2", "role": "Effect", "text": "nephrotoxicity", "start": 10, "end": 11}, {"entity_id": "19183077_3_Ent0", "role": "Subject", "text": "perinatally HIV - infected adolescents", "start": 12, "end": 17}, {"entity_id": "19183077_3_Ent5", "role": "Treatment_Disorder", "text": "HIV", "start": 13, "end": 14}, {"entity_id": "19183077_3_Ent1", "role": "Subject_Age", "text": "adolescents", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "19183077_3_Ent4", "text": "tenofovir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19183077_3_Ent3", "text": "tenofovir ( TDF)", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "19183077_3_Ent2", "text": "nephrotoxicity", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19183077_3_Ent0", "text": "perinatally HIV - infected adolescents", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "19183077_3_Ent5", "text": "HIV", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19183077_3_Ent1", "text": "adolescents", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "1918672_1", "wnd_id": "1918672_1_1", "text": "In this case , discontinuing piroxicam , a nonsteroidal anti - inflammatory drug , and starting a palliative treatment plan helped resolve a patient 's ulcers .", "tokens": ["In", "this", "case", ",", "discontinuing", "piroxicam", ",", "a", "nonsteroidal", "anti", "-", "inflammatory", "drug", ",", "and", "starting", "a", "palliative", "treatment", "plan", "helped", "resolve", "a", "patient", "'s", "ulcers", "."], "event_mentions": [{"id": "1918672_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolve", "start": 21, "end": 22}, "arguments": [{"entity_id": "1918672_1_Ent1", "role": "Treatment", "text": "discontinuing piroxicam , a nonsteroidal anti - inflammatory drug , and starting a palliative treatment", "start": 4, "end": 19}, {"entity_id": "1918672_1_Ent3", "role": "Treatment_Drug", "text": "piroxicam", "start": 5, "end": 6}, {"entity_id": "1918672_1_Ent0", "role": "Subject", "text": "a patient 's", "start": 22, "end": 25}, {"entity_id": "1918672_1_Ent2", "role": "Treatment_Disorder", "text": "ulcers", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "1918672_1_Ent1", "text": "discontinuing piroxicam , a nonsteroidal anti - inflammatory drug , and starting a palliative treatment", "entity_type": "Entity", "start": 4, "end": 19}, {"id": "1918672_1_Ent3", "text": "piroxicam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1918672_1_Ent0", "text": "a patient 's", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "1918672_1_Ent2", "text": "ulcers", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "19203515_3", "wnd_id": "19203515_3_1", "text": "The exact mechanism of IVIG - associated acute renal failure remains unclear .", "tokens": ["The", "exact", "mechanism", "of", "IVIG", "-", "associated", "acute", "renal", "failure", "remains", "unclear", "."], "event_mentions": [{"id": "19203515_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "19203515_3_Ent1", "role": "Treatment", "text": "IVIG", "start": 4, "end": 5}, {"entity_id": "19203515_3_Ent2", "role": "Treatment_Drug", "text": "IVIG", "start": 4, "end": 5}, {"entity_id": "19203515_3_Ent0", "role": "Effect", "text": "acute renal failure", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "19203515_3_Ent1", "text": "IVIG", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19203515_3_Ent2", "text": "IVIG", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19203515_3_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "19212144_1", "wnd_id": "19212144_1_1", "text": "A 58 - year - old man with advanced renal cell carcinoma developed grade 3 proteinuria ( 8.5 g/24 h ) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion .", "tokens": ["A", "58", "-", "year", "-", "old", "man", "with", "advanced", "renal", "cell", "carcinoma", "developed", "grade", "3", "proteinuria", "(", "8.5", "g/24", "h", ")", "without", "microscopic", "hematuria", "or", "renal", "insufficiency", "five", "days", "after", "temsirolimus", "infusion", "."], "event_mentions": [{"id": "19212144_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "19212144_1_Ent0", "role": "Subject", "text": "A 58 - year - old man with advanced renal cell carcinoma", "start": 0, "end": 12}, {"entity_id": "19212144_1_Ent1", "role": "Subject_Age", "text": "58 - year - old", "start": 1, "end": 6}, {"entity_id": "19212144_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "19212144_1_Ent5", "role": "Treatment_Disorder", "text": "renal cell carcinoma", "start": 9, "end": 12}, {"entity_id": "19212144_1_Ent3", "role": "Effect", "text": "grade 3 proteinuria ( 8.5 g/24 h ) without microscopic hematuria or renal insufficiency", "start": 13, "end": 27}, {"entity_id": "19212144_1_Ent6", "role": "Treatment_Time_elapsed", "text": "five days", "start": 27, "end": 29}, {"entity_id": "19212144_1_Ent4", "role": "Treatment", "text": "five days after temsirolimus infusion", "start": 27, "end": 32}, {"entity_id": "19212144_1_Ent7", "role": "Treatment_Drug", "text": "temsirolimus", "start": 30, "end": 31}, {"entity_id": "19212144_1_Ent8", "role": "Treatment_Route", "text": "infusion", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "19212144_1_Ent0", "text": "A 58 - year - old man with advanced renal cell carcinoma", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "19212144_1_Ent1", "text": "58 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19212144_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19212144_1_Ent5", "text": "renal cell carcinoma", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "19212144_1_Ent3", "text": "grade 3 proteinuria ( 8.5 g/24 h ) without microscopic hematuria or renal insufficiency", "entity_type": "Entity", "start": 13, "end": 27}, {"id": "19212144_1_Ent6", "text": "five days", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "19212144_1_Ent4", "text": "five days after temsirolimus infusion", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "19212144_1_Ent7", "text": "temsirolimus", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "19212144_1_Ent8", "text": "infusion", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "19217693_2", "wnd_id": "19217693_2_1", "text": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis .", "tokens": ["Persistent", "hypoglycemia", "in", "a", "patient", "with", "diabetes", "taking", "etanercept", "for", "the", "treatment", "of", "psoriasis", "."], "event_mentions": [{"id": "19217693_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 7, "end": 8}, "arguments": [{"entity_id": "19217693_2_Ent2", "role": "Effect", "text": "Persistent hypoglycemia", "start": 0, "end": 2}, {"entity_id": "19217693_2_Ent0", "role": "Subject", "text": "a patient with diabetes", "start": 3, "end": 7}, {"entity_id": "19217693_2_Ent1", "role": "Subject_Disorder", "text": "diabetes", "start": 6, "end": 7}, {"entity_id": "19217693_2_Ent3", "role": "Treatment", "text": "etanercept", "start": 8, "end": 9}, {"entity_id": "19217693_2_Ent4", "role": "Treatment_Drug", "text": "etanercept", "start": 8, "end": 9}, {"entity_id": "19217693_2_Ent5", "role": "Treatment_Disorder", "text": "psoriasis", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "19217693_2_Ent2", "text": "Persistent hypoglycemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19217693_2_Ent0", "text": "a patient with diabetes", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "19217693_2_Ent1", "text": "diabetes", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19217693_2_Ent3", "text": "etanercept", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19217693_2_Ent4", "text": "etanercept", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19217693_2_Ent5", "text": "psoriasis", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "19249953_1", "wnd_id": "19249953_1_1", "text": "Rhabdomyolysis caused by a potential sitagliptin - lovastatin interaction .", "tokens": ["Rhabdomyolysis", "caused", "by", "a", "potential", "sitagliptin", "-", "lovastatin", "interaction", "."], "event_mentions": [{"id": "19249953_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 1, "end": 2}, "arguments": [{"entity_id": "19249953_1_Ent0", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "19249953_1_Ent1", "role": "Treatment", "text": "potential sitagliptin - lovastatin interaction", "start": 4, "end": 9}, {"entity_id": "19249953_1_Ent2", "role": "Treatment_Drug", "text": "sitagliptin", "start": 5, "end": 6}, {"entity_id": "19249953_1_Ent5", "role": "Combination_Drug", "text": "sitagliptin", "start": 5, "end": 6}, {"entity_id": "19249953_1_Ent3", "role": "Treatment_Drug", "text": "lovastatin", "start": 7, "end": 8}, {"entity_id": "19249953_1_Ent4", "role": "Combination_Drug", "text": "lovastatin", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "19249953_1_Ent0", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19249953_1_Ent1", "text": "potential sitagliptin - lovastatin interaction", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "19249953_1_Ent2", "text": "sitagliptin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19249953_1_Ent5", "text": "sitagliptin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19249953_1_Ent3", "text": "lovastatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19249953_1_Ent4", "text": "lovastatin", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "19249953_7", "wnd_id": "19249953_7_1", "text": "As it had been 10 months since her last dosage adjustment of diltiazem , it was unlikely that the statin - induced rhabdomyolysis was precipitated by diltiazem .", "tokens": ["As", "it", "had", "been", "10", "months", "since", "her", "last", "dosage", "adjustment", "of", "diltiazem", ",", "it", "was", "unlikely", "that", "the", "statin", "-", "induced", "rhabdomyolysis", "was", "precipitated", "by", "diltiazem", "."], "event_mentions": [{"id": "19249953_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitated", "start": 24, "end": 25}, "arguments": [{"entity_id": "19249953_7_Ent0", "role": "Effect", "text": "statin - induced rhabdomyolysis", "start": 19, "end": 23}, {"entity_id": "19249953_7_Ent1", "role": "Treatment", "text": "diltiazem", "start": 26, "end": 27}, {"entity_id": "19249953_7_Ent2", "role": "Treatment_Drug", "text": "diltiazem", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "19249953_7_Ent0", "text": "statin - induced rhabdomyolysis", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "19249953_7_Ent1", "text": "diltiazem", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "19249953_7_Ent2", "text": "diltiazem", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "19307676_1", "wnd_id": "19307676_1_1", "text": "Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity : conventional magnetic resonance and diffusion - weighted imaging findings .", "tokens": ["Posterior", "reversible", "encephalopathy", "syndrome", "associated", "with", "methotrexate", "neurotoxicity", ":", "conventional", "magnetic", "resonance", "and", "diffusion", "-", "weighted", "imaging", "findings", "."], "event_mentions": [{"id": "19307676_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "19307676_1_Ent0", "role": "Effect", "text": "Posterior reversible encephalopathy syndrome", "start": 0, "end": 4}, {"entity_id": "19307676_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 6, "end": 7}, {"entity_id": "19307676_1_Ent1", "role": "Treatment", "text": "methotrexate neurotoxicity", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "19307676_1_Ent0", "text": "Posterior reversible encephalopathy syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19307676_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19307676_1_Ent1", "text": "methotrexate neurotoxicity", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "19318596_2", "wnd_id": "19318596_2_1", "text": "In this case , CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale .", "tokens": ["In", "this", "case", ",", "CIPS", "was", "considered", "to", "be", "probably", "associated", "with", "cyclosporine", "according", "to", "the", "Naranjo", "probability", "scale", "."], "event_mentions": [{"id": "19318596_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "19318596_2_Ent0", "role": "Effect", "text": "CIPS", "start": 4, "end": 5}, {"entity_id": "19318596_2_Ent1", "role": "Treatment", "text": "cyclosporine", "start": 12, "end": 13}, {"entity_id": "19318596_2_Ent2", "role": "Treatment_Drug", "text": "cyclosporine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19318596_2_Ent0", "text": "CIPS", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19318596_2_Ent1", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19318596_2_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19331262_3", "wnd_id": "19331262_3_1", "text": "Neuroleptic malignant syndrome is an uncommon and potentially fatal idiosynchratic reaction of antipsychotic drugs , in which the clinical scenario encompass muscular rigidity , hyperthermia , autonomic dysfunction , altered consciousness , high creatinine phosphokinase levels , and leukocytosis .", "tokens": ["Neuroleptic", "malignant", "syndrome", "is", "an", "uncommon", "and", "potentially", "fatal", "idiosynchratic", "reaction", "of", "antipsychotic", "drugs", ",", "in", "which", "the", "clinical", "scenario", "encompass", "muscular", "rigidity", ",", "hyperthermia", ",", "autonomic", "dysfunction", ",", "altered", "consciousness", ",", "high", "creatinine", "phosphokinase", "levels", ",", "and", "leukocytosis", "."], "event_mentions": [{"id": "19331262_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reaction", "start": 10, "end": 11}, "arguments": [{"entity_id": "19331262_3_Ent0", "role": "Effect", "text": "Neuroleptic malignant syndrome", "start": 0, "end": 3}, {"entity_id": "19331262_3_Ent3", "role": "Treatment_Drug", "text": "antipsychotic", "start": 12, "end": 13}, {"entity_id": "19331262_3_Ent2", "role": "Treatment", "text": "antipsychotic drugs", "start": 12, "end": 14}, {"entity_id": "19331262_3_Ent1", "role": "Effect", "text": "muscular rigidity , hyperthermia , autonomic dysfunction , altered consciousness , high creatinine phosphokinase levels , and leukocytosis", "start": 21, "end": 39}]}], "entity_mentions": [{"id": "19331262_3_Ent0", "text": "Neuroleptic malignant syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19331262_3_Ent3", "text": "antipsychotic", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19331262_3_Ent2", "text": "antipsychotic drugs", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "19331262_3_Ent1", "text": "muscular rigidity , hyperthermia , autonomic dysfunction , altered consciousness , high creatinine phosphokinase levels , and leukocytosis", "entity_type": "Entity", "start": 21, "end": 39}], "lang": "en"}
{"doc_id": "19365885_2", "wnd_id": "19365885_2_1", "text": "Hypoglycemia induced by long - acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor .", "tokens": ["Hypoglycemia", "induced", "by", "long", "-", "acting", "somatostatin", "analogues", "in", "a", "patient", "with", "nonfunctional", "neuroendocrine", "tumor", "."], "event_mentions": [{"id": "19365885_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "19365885_2_Ent1", "role": "Effect", "text": "Hypoglycemia", "start": 0, "end": 1}, {"entity_id": "19365885_2_Ent2", "role": "Treatment", "text": "long - acting somatostatin analogues", "start": 3, "end": 8}, {"entity_id": "19365885_2_Ent4", "role": "Treatment_Drug", "text": "long - acting somatostatin analogues", "start": 3, "end": 8}, {"entity_id": "19365885_2_Ent0", "role": "Subject", "text": "a patient with nonfunctional neuroendocrine tumor", "start": 9, "end": 15}, {"entity_id": "19365885_2_Ent3", "role": "Treatment_Disorder", "text": "nonfunctional neuroendocrine tumor", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "19365885_2_Ent1", "text": "Hypoglycemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19365885_2_Ent2", "text": "long - acting somatostatin analogues", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19365885_2_Ent4", "text": "long - acting somatostatin analogues", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19365885_2_Ent0", "text": "a patient with nonfunctional neuroendocrine tumor", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "19365885_2_Ent3", "text": "nonfunctional neuroendocrine tumor", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "19365885_3", "wnd_id": "19365885_3_1", "text": "In these patients , long - acting octreotide may trigger serious hypoglycemia .", "tokens": ["In", "these", "patients", ",", "long", "-", "acting", "octreotide", "may", "trigger", "serious", "hypoglycemia", "."], "event_mentions": [{"id": "19365885_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "trigger", "start": 9, "end": 10}, "arguments": [{"entity_id": "19365885_3_Ent0", "role": "Subject", "text": "these patients", "start": 1, "end": 3}, {"entity_id": "19365885_3_Ent2", "role": "Treatment", "text": "long - acting octreotide", "start": 4, "end": 8}, {"entity_id": "19365885_3_Ent3", "role": "Treatment_Drug", "text": "octreotide", "start": 7, "end": 8}, {"entity_id": "19365885_3_Ent1", "role": "Effect", "text": "serious hypoglycemia", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "19365885_3_Ent0", "text": "these patients", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "19365885_3_Ent2", "text": "long - acting octreotide", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19365885_3_Ent3", "text": "octreotide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19365885_3_Ent1", "text": "serious hypoglycemia", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "19390192_1", "wnd_id": "19390192_1_1", "text": "Leukopenia due to parvovirus B19 in a Crohn 's disease patient using azathioprine .", "tokens": ["Leukopenia", "due", "to", "parvovirus", "B19", "in", "a", "Crohn", "'s", "disease", "patient", "using", "azathioprine", "."], "event_mentions": [{"id": "19390192_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 1, "end": 2}, "arguments": [{"entity_id": "19390192_1_Ent2", "role": "Effect", "text": "Leukopenia", "start": 0, "end": 1}, {"entity_id": "19390192_1_Ent1", "role": "Subject_Disorder", "text": "parvovirus B19", "start": 3, "end": 5}, {"entity_id": "19390192_1_Ent0", "role": "Subject", "text": "parvovirus B19 in a Crohn 's disease patient", "start": 3, "end": 11}, {"entity_id": "19390192_1_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 7, "end": 10}, {"entity_id": "19390192_1_Ent3", "role": "Treatment", "text": "azathioprine", "start": 12, "end": 13}, {"entity_id": "19390192_1_Ent5", "role": "Treatment_Drug", "text": "azathioprine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19390192_1_Ent2", "text": "Leukopenia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19390192_1_Ent1", "text": "parvovirus B19", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19390192_1_Ent0", "text": "parvovirus B19 in a Crohn 's disease patient", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "19390192_1_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "19390192_1_Ent3", "text": "azathioprine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19390192_1_Ent5", "text": "azathioprine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19423476_1", "wnd_id": "19423476_1_1", "text": "Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab : case report and review of the literature .", "tokens": ["Cryptococcus", "neoformans", "fatal", "sepsis", "in", "a", "chronic", "lymphocytic", "leukemia", "patient", "treated", "with", "alemtuzumab", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "19423476_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 4, "end": 5}, "arguments": [{"entity_id": "19423476_1_Ent1", "role": "Effect", "text": "Cryptococcus neoformans fatal sepsis", "start": 0, "end": 4}, {"entity_id": "19423476_1_Ent0", "role": "Subject", "text": "a chronic lymphocytic leukemia patient", "start": 5, "end": 10}, {"entity_id": "19423476_1_Ent3", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia", "start": 6, "end": 9}, {"entity_id": "19423476_1_Ent2", "role": "Treatment", "text": "alemtuzumab", "start": 12, "end": 13}, {"entity_id": "19423476_1_Ent4", "role": "Treatment_Drug", "text": "alemtuzumab", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19423476_1_Ent1", "text": "Cryptococcus neoformans fatal sepsis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19423476_1_Ent0", "text": "a chronic lymphocytic leukemia patient", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19423476_1_Ent3", "text": "chronic lymphocytic leukemia", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19423476_1_Ent2", "text": "alemtuzumab", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19423476_1_Ent4", "text": "alemtuzumab", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19423476_4", "wnd_id": "19423476_4_1", "text": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab .", "tokens": ["We", "report", "a", "case", "of", "fatal", "C.", "neoformans", "fungemia", "in", "a", "neutropenic", "patient", "with", "a", "history", "of", "chronic", "lymphocytic", "leukemia", "treated", "with", "alemtuzumab", "."], "event_mentions": [{"id": "19423476_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 20, "end": 22}, "arguments": [{"entity_id": "19423476_4_Ent1", "role": "Effect", "text": "fatal C. neoformans fungemia", "start": 5, "end": 9}, {"entity_id": "19423476_4_Ent0", "role": "Subject", "text": "a neutropenic patient with a history of chronic lymphocytic leukemia", "start": 10, "end": 20}, {"entity_id": "19423476_4_Ent4", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia", "start": 17, "end": 20}, {"entity_id": "19423476_4_Ent2", "role": "Treatment", "text": "alemtuzumab", "start": 22, "end": 23}, {"entity_id": "19423476_4_Ent3", "role": "Treatment_Drug", "text": "alemtuzumab", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "19423476_4_Ent1", "text": "fatal C. neoformans fungemia", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19423476_4_Ent0", "text": "a neutropenic patient with a history of chronic lymphocytic leukemia", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "19423476_4_Ent4", "text": "chronic lymphocytic leukemia", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "19423476_4_Ent2", "text": "alemtuzumab", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "19423476_4_Ent3", "text": "alemtuzumab", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "19423610_1", "wnd_id": "19423610_1_1", "text": "Risk of severe serotonin toxicity following co - administration of methylene blue and serotonin reuptake inhibitors : an update on a case report of post - operative delirium .", "tokens": ["Risk", "of", "severe", "serotonin", "toxicity", "following", "co", "-", "administration", "of", "methylene", "blue", "and", "serotonin", "reuptake", "inhibitors", ":", "an", "update", "on", "a", "case", "report", "of", "post", "-", "operative", "delirium", "."], "event_mentions": [{"id": "19423610_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "19423610_1_Ent0", "role": "Effect", "text": "serotonin toxicity", "start": 3, "end": 5}, {"entity_id": "19423610_1_Ent2", "role": "Treatment", "text": "co - administration of methylene blue and serotonin reuptake inhibitors", "start": 6, "end": 16}, {"entity_id": "19423610_1_Ent3", "role": "Treatment_Drug", "text": "methylene blue", "start": 10, "end": 12}, {"entity_id": "19423610_1_Ent5", "role": "Combination_Drug", "text": "methylene blue", "start": 10, "end": 12}, {"entity_id": "19423610_1_Ent4", "role": "Treatment_Drug", "text": "serotonin reuptake inhibitors", "start": 13, "end": 16}, {"entity_id": "19423610_1_Ent6", "role": "Combination_Drug", "text": "serotonin reuptake inhibitors", "start": 13, "end": 16}, {"entity_id": "19423610_1_Ent1", "role": "Effect", "text": "post - operative delirium", "start": 24, "end": 28}]}], "entity_mentions": [{"id": "19423610_1_Ent0", "text": "serotonin toxicity", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19423610_1_Ent2", "text": "co - administration of methylene blue and serotonin reuptake inhibitors", "entity_type": "Entity", "start": 6, "end": 16}, {"id": "19423610_1_Ent3", "text": "methylene blue", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19423610_1_Ent5", "text": "methylene blue", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19423610_1_Ent4", "text": "serotonin reuptake inhibitors", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "19423610_1_Ent6", "text": "serotonin reuptake inhibitors", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "19423610_1_Ent1", "text": "post - operative delirium", "entity_type": "Entity", "start": 24, "end": 28}], "lang": "en"}
{"doc_id": "19423610_7", "wnd_id": "19423610_7_1", "text": "Methylene blue has been found to be a potent inhibitor of monoamine oxidase ( MAO ) , and several cases of serotonin toxicity have been reported recently following its administration .", "tokens": ["Methylene", "blue", "has", "been", "found", "to", "be", "a", "potent", "inhibitor", "of", "monoamine", "oxidase", "(", "MAO", ")", ",", "and", "several", "cases", "of", "serotonin", "toxicity", "have", "been", "reported", "recently", "following", "its", "administration", "."], "event_mentions": [{"id": "19423610_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 27, "end": 28}, "arguments": [{"entity_id": "19423610_7_Ent2", "role": "Treatment", "text": "Methylene blue", "start": 0, "end": 2}, {"entity_id": "19423610_7_Ent3", "role": "Treatment_Drug", "text": "Methylene blue", "start": 0, "end": 2}, {"entity_id": "19423610_7_Ent0", "role": "Subject", "text": "several cases", "start": 18, "end": 20}, {"entity_id": "19423610_7_Ent1", "role": "Effect", "text": "serotonin toxicity", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "19423610_7_Ent2", "text": "Methylene blue", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19423610_7_Ent3", "text": "Methylene blue", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19423610_7_Ent0", "text": "several cases", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "19423610_7_Ent1", "text": "serotonin toxicity", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "19499966_3", "wnd_id": "19499966_3_1", "text": "Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma .", "tokens": ["Onset", "of", "male", "gynaecomastia", "in", "a", "patient", "treated", "with", "sunitinib", "for", "metastatic", "renal", "cell", "carcinoma", "."], "event_mentions": [{"id": "19499966_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Onset", "start": 0, "end": 1}, "arguments": [{"entity_id": "19499966_3_Ent0", "role": "Subject", "text": "male", "start": 2, "end": 3}, {"entity_id": "19499966_3_Ent2", "role": "Subject_Gender", "text": "male", "start": 2, "end": 3}, {"entity_id": "19499966_3_Ent3", "role": "Effect", "text": "gynaecomastia", "start": 3, "end": 4}, {"entity_id": "19499966_3_Ent1", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "19499966_3_Ent6", "role": "Treatment_Drug", "text": "sunitinib", "start": 9, "end": 10}, {"entity_id": "19499966_3_Ent4", "role": "Treatment", "text": "sunitinib for metastatic renal cell carcinoma", "start": 9, "end": 15}, {"entity_id": "19499966_3_Ent5", "role": "Treatment_Disorder", "text": "metastatic renal cell carcinoma", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "19499966_3_Ent0", "text": "male", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19499966_3_Ent2", "text": "male", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19499966_3_Ent3", "text": "gynaecomastia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19499966_3_Ent1", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19499966_3_Ent6", "text": "sunitinib", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19499966_3_Ent4", "text": "sunitinib for metastatic renal cell carcinoma", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "19499966_3_Ent5", "text": "metastatic renal cell carcinoma", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "19512997_2", "wnd_id": "19512997_2_1", "text": "We report a case of 48 - year - old woman with seizure disorder on divalproex sodium ( Depakote ) who presented with dyspnea .", "tokens": ["We", "report", "a", "case", "of", "48", "-", "year", "-", "old", "woman", "with", "seizure", "disorder", "on", "divalproex", "sodium", "(", "Depakote", ")", "who", "presented", "with", "dyspnea", "."], "event_mentions": [{"id": "19512997_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 21, "end": 22}, "arguments": [{"entity_id": "19512997_2_Ent0", "role": "Subject", "text": "a case of 48 - year - old woman with seizure disorder", "start": 2, "end": 14}, {"entity_id": "19512997_2_Ent1", "role": "Subject_Age", "text": "48 - year - old", "start": 5, "end": 10}, {"entity_id": "19512997_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "19512997_2_Ent5", "role": "Treatment_Disorder", "text": "seizure disorder", "start": 12, "end": 14}, {"entity_id": "19512997_2_Ent6", "role": "Treatment_Drug", "text": "divalproex sodium", "start": 15, "end": 17}, {"entity_id": "19512997_2_Ent4", "role": "Treatment", "text": "divalproex sodium ( Depakote )", "start": 15, "end": 20}, {"entity_id": "19512997_2_Ent3", "role": "Effect", "text": "dyspnea", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "19512997_2_Ent0", "text": "a case of 48 - year - old woman with seizure disorder", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "19512997_2_Ent1", "text": "48 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19512997_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19512997_2_Ent5", "text": "seizure disorder", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "19512997_2_Ent6", "text": "divalproex sodium", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "19512997_2_Ent4", "text": "divalproex sodium ( Depakote )", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "19512997_2_Ent3", "text": "dyspnea", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "19512997_3", "wnd_id": "19512997_3_1", "text": "Withdrawal of Depakote resulted in resolution of the effusion .", "tokens": ["Withdrawal", "of", "Depakote", "resulted", "in", "resolution", "of", "the", "effusion", "."], "event_mentions": [{"id": "19512997_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 3, "end": 4}, "arguments": [{"entity_id": "19512997_3_Ent1", "role": "Treatment", "text": "Withdrawal of Depakote", "start": 0, "end": 3}, {"entity_id": "19512997_3_Ent2", "role": "Treatment_Drug", "text": "Depakote", "start": 2, "end": 3}, {"entity_id": "19512997_3_Ent0", "role": "Effect", "text": "resolution of the effusion", "start": 5, "end": 9}]}], "entity_mentions": [{"id": "19512997_3_Ent1", "text": "Withdrawal of Depakote", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19512997_3_Ent2", "text": "Depakote", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19512997_3_Ent0", "text": "resolution of the effusion", "entity_type": "Entity", "start": 5, "end": 9}], "lang": "en"}
{"doc_id": "1951476_2", "wnd_id": "1951476_2_1", "text": "We report a case of biopsy - proven acute tubulointerstitial nephritis associated with a second course of flurbiprofen , a nonsteroidal anti - inflammatory drug of the propionic acid class .", "tokens": ["We", "report", "a", "case", "of", "biopsy", "-", "proven", "acute", "tubulointerstitial", "nephritis", "associated", "with", "a", "second", "course", "of", "flurbiprofen", ",", "a", "nonsteroidal", "anti", "-", "inflammatory", "drug", "of", "the", "propionic", "acid", "class", "."], "event_mentions": [{"id": "1951476_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "1951476_2_Ent0", "role": "Effect", "text": "biopsy - proven acute tubulointerstitial nephritis", "start": 5, "end": 11}, {"entity_id": "1951476_2_Ent1", "role": "Treatment", "text": "a second course of flurbiprofen", "start": 13, "end": 18}, {"entity_id": "1951476_2_Ent3", "role": "Treatment_Freq", "text": "second course", "start": 14, "end": 16}, {"entity_id": "1951476_2_Ent2", "role": "Treatment_Drug", "text": "flurbiprofen", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "1951476_2_Ent0", "text": "biopsy - proven acute tubulointerstitial nephritis", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "1951476_2_Ent1", "text": "a second course of flurbiprofen", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "1951476_2_Ent3", "text": "second course", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "1951476_2_Ent2", "text": "flurbiprofen", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "19520277_1", "wnd_id": "19520277_1_1", "text": "Stupor and fast activity on electroencephalography in a child treated with valproate .", "tokens": ["Stupor", "and", "fast", "activity", "on", "electroencephalography", "in", "a", "child", "treated", "with", "valproate", "."], "event_mentions": [{"id": "19520277_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "19520277_1_Ent2", "role": "Effect", "text": "Stupor", "start": 0, "end": 1}, {"entity_id": "19520277_1_Ent3", "role": "Effect", "text": "fast activity on electroencephalography", "start": 2, "end": 6}, {"entity_id": "19520277_1_Ent0", "role": "Subject", "text": "a child", "start": 7, "end": 9}, {"entity_id": "19520277_1_Ent1", "role": "Subject_Age", "text": "child", "start": 8, "end": 9}, {"entity_id": "19520277_1_Ent4", "role": "Treatment", "text": "valproate", "start": 11, "end": 12}, {"entity_id": "19520277_1_Ent5", "role": "Treatment_Drug", "text": "valproate", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "19520277_1_Ent2", "text": "Stupor", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19520277_1_Ent3", "text": "fast activity on electroencephalography", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "19520277_1_Ent0", "text": "a child", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19520277_1_Ent1", "text": "child", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19520277_1_Ent4", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19520277_1_Ent5", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "19531695_11", "wnd_id": "19531695_11_1", "text": "A MEDLINE search ( 1966 - January 2009 ) revealed one in vivo pharmacokinetic study on the interaction between flecainide , a CYP2D6 substrate , and paroxetine , a CYP2D6 inhibitor , as well as 3 case reports of flecainide - induced delirium .", "tokens": ["A", "MEDLINE", "search", "(", "1966", "-", "January", "2009", ")", "revealed", "one", "in", "vivo", "pharmacokinetic", "study", "on", "the", "interaction", "between", "flecainide", ",", "a", "CYP2D6", "substrate", ",", "and", "paroxetine", ",", "a", "CYP2D6", "inhibitor", ",", "as", "well", "as", "3", "case", "reports", "of", "flecainide", "-", "induced", "delirium", "."], "event_mentions": [{"id": "19531695_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 41, "end": 42}, "arguments": [{"entity_id": "19531695_11_Ent1", "role": "Subject_Population", "text": "3", "start": 35, "end": 36}, {"entity_id": "19531695_11_Ent0", "role": "Subject", "text": "3 case reports", "start": 35, "end": 38}, {"entity_id": "19531695_11_Ent3", "role": "Treatment", "text": "flecainide", "start": 39, "end": 40}, {"entity_id": "19531695_11_Ent4", "role": "Treatment_Drug", "text": "flecainide", "start": 39, "end": 40}, {"entity_id": "19531695_11_Ent2", "role": "Effect", "text": "delirium", "start": 42, "end": 43}]}], "entity_mentions": [{"id": "19531695_11_Ent1", "text": "3", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "19531695_11_Ent0", "text": "3 case reports", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "19531695_11_Ent3", "text": "flecainide", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "19531695_11_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "19531695_11_Ent2", "text": "delirium", "entity_type": "Entity", "start": 42, "end": 43}], "lang": "en"}
{"doc_id": "19540093_4", "wnd_id": "19540093_4_1", "text": "Tigecycline - induced acute pancreatitis : case report and literature review .", "tokens": ["Tigecycline", "-", "induced", "acute", "pancreatitis", ":", "case", "report", "and", "literature", "review", "."], "event_mentions": [{"id": "19540093_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19540093_4_Ent1", "role": "Treatment", "text": "Tigecycline", "start": 0, "end": 1}, {"entity_id": "19540093_4_Ent2", "role": "Treatment_Drug", "text": "Tigecycline", "start": 0, "end": 1}, {"entity_id": "19540093_4_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "19540093_4_Ent1", "text": "Tigecycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19540093_4_Ent2", "text": "Tigecycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19540093_4_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "19567656_3", "wnd_id": "19567656_3_1", "text": "OBJECTIVE : To describe a case of sertraline - induced rhabdomyolysis in an elderly patient with dementia and comorbidities .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "case", "of", "sertraline", "-", "induced", "rhabdomyolysis", "in", "an", "elderly", "patient", "with", "dementia", "and", "comorbidities", "."], "event_mentions": [{"id": "19567656_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "19567656_3_Ent3", "role": "Treatment", "text": "sertraline", "start": 7, "end": 8}, {"entity_id": "19567656_3_Ent6", "role": "Treatment_Drug", "text": "sertraline", "start": 7, "end": 8}, {"entity_id": "19567656_3_Ent2", "role": "Effect", "text": "rhabdomyolysis", "start": 10, "end": 11}, {"entity_id": "19567656_3_Ent0", "role": "Subject", "text": "an elderly patient with dementia and comorbidities", "start": 12, "end": 19}, {"entity_id": "19567656_3_Ent1", "role": "Subject_Age", "text": "elderly", "start": 13, "end": 14}, {"entity_id": "19567656_3_Ent5", "role": "Treatment_Disorder", "text": "dementia", "start": 16, "end": 17}, {"entity_id": "19567656_3_Ent4", "role": "Treatment_Disorder", "text": "comorbidities", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "19567656_3_Ent3", "text": "sertraline", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19567656_3_Ent6", "text": "sertraline", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19567656_3_Ent2", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19567656_3_Ent0", "text": "an elderly patient with dementia and comorbidities", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "19567656_3_Ent1", "text": "elderly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19567656_3_Ent5", "text": "dementia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19567656_3_Ent4", "text": "comorbidities", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "19570088_1", "wnd_id": "19570088_1_1", "text": "Tumor lysis syndrome after transcatheter arterial infusion of cisplatin and embolization therapy for liver metastases of melanoma .", "tokens": ["Tumor", "lysis", "syndrome", "after", "transcatheter", "arterial", "infusion", "of", "cisplatin", "and", "embolization", "therapy", "for", "liver", "metastases", "of", "melanoma", "."], "event_mentions": [{"id": "19570088_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "19570088_1_Ent0", "role": "Effect", "text": "Tumor lysis syndrome", "start": 0, "end": 3}, {"entity_id": "19570088_1_Ent3", "role": "Treatment_Route", "text": "transcatheter arterial infusion", "start": 4, "end": 7}, {"entity_id": "19570088_1_Ent1", "role": "Treatment", "text": "transcatheter arterial infusion of cisplatin and embolization", "start": 4, "end": 11}, {"entity_id": "19570088_1_Ent4", "role": "Treatment_Drug", "text": "cisplatin", "start": 8, "end": 9}, {"entity_id": "19570088_1_Ent2", "role": "Treatment_Disorder", "text": "liver metastases of melanoma", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "19570088_1_Ent0", "text": "Tumor lysis syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19570088_1_Ent3", "text": "transcatheter arterial infusion", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "19570088_1_Ent1", "text": "transcatheter arterial infusion of cisplatin and embolization", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "19570088_1_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19570088_1_Ent2", "text": "liver metastases of melanoma", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "19579947_1", "wnd_id": "19579947_1_1", "text": "He had priapism following the use of olanzapine .", "tokens": ["He", "had", "priapism", "following", "the", "use", "of", "olanzapine", "."], "event_mentions": [{"id": "19579947_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "19579947_1_Ent0", "role": "Effect", "text": "priapism", "start": 2, "end": 3}, {"entity_id": "19579947_1_Ent1", "role": "Treatment", "text": "olanzapine", "start": 7, "end": 8}, {"entity_id": "19579947_1_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "19579947_1_Ent0", "text": "priapism", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19579947_1_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19579947_1_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "19667003_3", "wnd_id": "19667003_3_1", "text": "SUMMARY : A 26 - year - old man with bipolar disorder , seizures , and mild mental retardation secondary to a traumatic brain injury began treatment with carbamazepine for aggression and seizure control .", "tokens": ["SUMMARY", ":", "A", "26", "-", "year", "-", "old", "man", "with", "bipolar", "disorder", ",", "seizures", ",", "and", "mild", "mental", "retardation", "secondary", "to", "a", "traumatic", "brain", "injury", "began", "treatment", "with", "carbamazepine", "for", "aggression", "and", "seizure", "control", "."], "event_mentions": [{"id": "19667003_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 26, "end": 27}, "arguments": [{"entity_id": "19667003_3_Ent0", "role": "Subject", "text": "A 26 - year - old man with bipolar disorder , seizures , and mild mental retardation secondary to a traumatic brain injury", "start": 2, "end": 25}, {"entity_id": "19667003_3_Ent4", "role": "Subject_Age", "text": "26 - year - old", "start": 3, "end": 8}, {"entity_id": "19667003_3_Ent5", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "19667003_3_Ent1", "role": "Subject_Disorder", "text": "bipolar disorder", "start": 10, "end": 12}, {"entity_id": "19667003_3_Ent2", "role": "Subject_Disorder", "text": "seizures", "start": 13, "end": 14}, {"entity_id": "19667003_3_Ent3", "role": "Subject_Disorder", "text": "mild mental retardation secondary to a traumatic brain injury", "start": 16, "end": 25}, {"entity_id": "19667003_3_Ent6", "role": "Treatment", "text": "carbamazepine", "start": 28, "end": 29}, {"entity_id": "19667003_3_Ent7", "role": "Treatment_Drug", "text": "carbamazepine", "start": 28, "end": 29}, {"entity_id": "19667003_3_Ent8", "role": "Treatment_Disorder", "text": "aggression", "start": 30, "end": 31}, {"entity_id": "19667003_3_Ent9", "role": "Treatment_Disorder", "text": "seizure", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "19667003_3_Ent0", "text": "A 26 - year - old man with bipolar disorder , seizures , and mild mental retardation secondary to a traumatic brain injury", "entity_type": "Entity", "start": 2, "end": 25}, {"id": "19667003_3_Ent4", "text": "26 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19667003_3_Ent5", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19667003_3_Ent1", "text": "bipolar disorder", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19667003_3_Ent2", "text": "seizures", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19667003_3_Ent3", "text": "mild mental retardation secondary to a traumatic brain injury", "entity_type": "Entity", "start": 16, "end": 25}, {"id": "19667003_3_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "19667003_3_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "19667003_3_Ent8", "text": "aggression", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "19667003_3_Ent9", "text": "seizure", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "19669617_3", "wnd_id": "19669617_3_1", "text": "Acute bilateral phrenic neuropathy following treatment with adalimumab .", "tokens": ["Acute", "bilateral", "phrenic", "neuropathy", "following", "treatment", "with", "adalimumab", "."], "event_mentions": [{"id": "19669617_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "19669617_3_Ent0", "role": "Effect", "text": "Acute bilateral phrenic neuropathy", "start": 0, "end": 4}, {"entity_id": "19669617_3_Ent1", "role": "Treatment", "text": "adalimumab", "start": 7, "end": 8}, {"entity_id": "19669617_3_Ent2", "role": "Treatment_Drug", "text": "adalimumab", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "19669617_3_Ent0", "text": "Acute bilateral phrenic neuropathy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19669617_3_Ent1", "text": "adalimumab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19669617_3_Ent2", "text": "adalimumab", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "19687711_3", "wnd_id": "19687711_3_1", "text": "Although the association between SJS / TEN and the sulfonamide class of antibiotics is well established , the increasing prevalence of CA - MRSA has left practitioners with limited regimens to effectively treat skin and soft tissue infections ( SSTIs ) in the outpatient setting .", "tokens": ["Although", "the", "association", "between", "SJS", "/", "TEN", "and", "the", "sulfonamide", "class", "of", "antibiotics", "is", "well", "established", ",", "the", "increasing", "prevalence", "of", "CA", "-", "MRSA", "has", "left", "practitioners", "with", "limited", "regimens", "to", "effectively", "treat", "skin", "and", "soft", "tissue", "infections", "(", "SSTIs", ")", "in", "the", "outpatient", "setting", "."], "event_mentions": [{"id": "19687711_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 2, "end": 3}, "arguments": [{"entity_id": "19687711_3_Ent2", "role": "Effect", "text": "SJS / TEN", "start": 4, "end": 7}, {"entity_id": "19687711_3_Ent3", "role": "Treatment", "text": "sulfonamide class of antibiotics", "start": 9, "end": 13}, {"entity_id": "19687711_3_Ent4", "role": "Treatment_Drug", "text": "sulfonamide class of antibiotics", "start": 9, "end": 13}, {"entity_id": "19687711_3_Ent0", "role": "Subject", "text": "CA - MRSA", "start": 21, "end": 24}, {"entity_id": "19687711_3_Ent1", "role": "Subject_Disorder", "text": "CA - MRSA", "start": 21, "end": 24}, {"entity_id": "19687711_3_Ent5", "role": "Treatment_Disorder", "text": "skin and soft tissue infections ( SSTIs )", "start": 33, "end": 41}]}], "entity_mentions": [{"id": "19687711_3_Ent2", "text": "SJS / TEN", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "19687711_3_Ent3", "text": "sulfonamide class of antibiotics", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "19687711_3_Ent4", "text": "sulfonamide class of antibiotics", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "19687711_3_Ent0", "text": "CA - MRSA", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "19687711_3_Ent1", "text": "CA - MRSA", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "19687711_3_Ent5", "text": "skin and soft tissue infections ( SSTIs )", "entity_type": "Entity", "start": 33, "end": 41}], "lang": "en"}
{"doc_id": "19707032_2", "wnd_id": "19707032_2_1", "text": "Acute vision loss after intravitreal injection of bevacizumab ( avastin ) associated with ocular ischemic syndrome .", "tokens": ["Acute", "vision", "loss", "after", "intravitreal", "injection", "of", "bevacizumab", "(", "avastin", ")", "associated", "with", "ocular", "ischemic", "syndrome", "."], "event_mentions": [{"id": "19707032_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "19707032_2_Ent0", "role": "Effect", "text": "Acute vision loss", "start": 0, "end": 3}, {"entity_id": "19707032_2_Ent3", "role": "Treatment_Route", "text": "intravitreal injection", "start": 4, "end": 6}, {"entity_id": "19707032_2_Ent2", "role": "Treatment", "text": "intravitreal injection of bevacizumab ( avastin )", "start": 4, "end": 11}, {"entity_id": "19707032_2_Ent4", "role": "Treatment_Drug", "text": "bevacizumab", "start": 7, "end": 8}, {"entity_id": "19707032_2_Ent1", "role": "Effect", "text": "ocular ischemic syndrome", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "19707032_2_Ent0", "text": "Acute vision loss", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19707032_2_Ent3", "text": "intravitreal injection", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19707032_2_Ent2", "text": "intravitreal injection of bevacizumab ( avastin )", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "19707032_2_Ent4", "text": "bevacizumab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19707032_2_Ent1", "text": "ocular ischemic syndrome", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "19733945_2", "wnd_id": "19733945_2_1", "text": "On day 7 of linezolid treatment , the patient developed severe pruritus , macular rash , facial edema , eosinophilia , marked increase in serum creatinine level , and mild hepatitis .", "tokens": ["On", "day", "7", "of", "linezolid", "treatment", ",", "the", "patient", "developed", "severe", "pruritus", ",", "macular", "rash", ",", "facial", "edema", ",", "eosinophilia", ",", "marked", "increase", "in", "serum", "creatinine", "level", ",", "and", "mild", "hepatitis", "."], "event_mentions": [{"id": "19733945_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "19733945_2_Ent3", "role": "Treatment", "text": "linezolid", "start": 4, "end": 5}, {"entity_id": "19733945_2_Ent4", "role": "Treatment_Drug", "text": "linezolid", "start": 4, "end": 5}, {"entity_id": "19733945_2_Ent0", "role": "Subject", "text": "the patient", "start": 7, "end": 9}, {"entity_id": "19733945_2_Ent1", "role": "Effect", "text": "pruritus , macular rash , facial edema , eosinophilia , marked increase in serum creatinine level", "start": 11, "end": 27}, {"entity_id": "19733945_2_Ent2", "role": "Effect", "text": "hepatitis", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "19733945_2_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19733945_2_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19733945_2_Ent0", "text": "the patient", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19733945_2_Ent1", "text": "pruritus , macular rash , facial edema , eosinophilia , marked increase in serum creatinine level", "entity_type": "Entity", "start": 11, "end": 27}, {"id": "19733945_2_Ent2", "text": "hepatitis", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "19754002_2", "wnd_id": "19754002_2_1", "text": "We report on a serious side effect in a severely depressed 55 - year - old woman , who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants , atypical antipsychotic drugs , the mood stabilizer lithium and the lipid - lowering drug pravastatin .", "tokens": ["We", "report", "on", "a", "serious", "side", "effect", "in", "a", "severely", "depressed", "55", "-", "year", "-", "old", "woman", ",", "who", "presented", "an", "erythematous", "pigmented", "skin", "rash", "on", "the", "whole", "body", "under", "combination", "treatment", "with", "antidepressants", ",", "atypical", "antipsychotic", "drugs", ",", "the", "mood", "stabilizer", "lithium", "and", "the", "lipid", "-", "lowering", "drug", "pravastatin", "."], "event_mentions": [{"id": "19754002_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 19, "end": 20}, "arguments": [{"entity_id": "19754002_2_Ent5", "role": "Treatment_Disorder", "text": "depressed", "start": 10, "end": 11}, {"entity_id": "19754002_2_Ent0", "role": "Subject", "text": "depressed 55 - year - old woman", "start": 10, "end": 17}, {"entity_id": "19754002_2_Ent1", "role": "Subject_Age", "text": "55 - year - old", "start": 11, "end": 16}, {"entity_id": "19754002_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 16, "end": 17}, {"entity_id": "19754002_2_Ent3", "role": "Effect", "text": "erythematous pigmented skin rash on the whole body", "start": 21, "end": 29}, {"entity_id": "19754002_2_Ent4", "role": "Treatment", "text": "combination treatment with antidepressants , atypical antipsychotic drugs , the mood stabilizer lithium and the lipid - lowering drug pravastatin", "start": 30, "end": 50}, {"entity_id": "19754002_2_Ent6", "role": "Treatment_Drug", "text": "antidepressants", "start": 33, "end": 34}, {"entity_id": "19754002_2_Ent10", "role": "Combination_Drug", "text": "antidepressants", "start": 33, "end": 34}, {"entity_id": "19754002_2_Ent7", "role": "Treatment_Drug", "text": "atypical antipsychotic", "start": 35, "end": 37}, {"entity_id": "19754002_2_Ent11", "role": "Combination_Drug", "text": "atypical antipsychotic", "start": 35, "end": 37}, {"entity_id": "19754002_2_Ent8", "role": "Treatment_Drug", "text": "lithium", "start": 42, "end": 43}, {"entity_id": "19754002_2_Ent12", "role": "Combination_Drug", "text": "lithium", "start": 42, "end": 43}, {"entity_id": "19754002_2_Ent9", "role": "Treatment_Drug", "text": "pravastatin", "start": 49, "end": 50}, {"entity_id": "19754002_2_Ent13", "role": "Combination_Drug", "text": "pravastatin", "start": 49, "end": 50}]}], "entity_mentions": [{"id": "19754002_2_Ent5", "text": "depressed", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19754002_2_Ent0", "text": "depressed 55 - year - old woman", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "19754002_2_Ent1", "text": "55 - year - old", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19754002_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19754002_2_Ent3", "text": "erythematous pigmented skin rash on the whole body", "entity_type": "Entity", "start": 21, "end": 29}, {"id": "19754002_2_Ent4", "text": "combination treatment with antidepressants , atypical antipsychotic drugs , the mood stabilizer lithium and the lipid - lowering drug pravastatin", "entity_type": "Entity", "start": 30, "end": 50}, {"id": "19754002_2_Ent6", "text": "antidepressants", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "19754002_2_Ent10", "text": "antidepressants", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "19754002_2_Ent7", "text": "atypical antipsychotic", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "19754002_2_Ent11", "text": "atypical antipsychotic", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "19754002_2_Ent8", "text": "lithium", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "19754002_2_Ent12", "text": "lithium", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "19754002_2_Ent9", "text": "pravastatin", "entity_type": "Entity", "start": 49, "end": 50}, {"id": "19754002_2_Ent13", "text": "pravastatin", "entity_type": "Entity", "start": 49, "end": 50}], "lang": "en"}
{"doc_id": "19764104_2", "wnd_id": "19764104_2_1", "text": "Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient .", "tokens": ["Sorafenib", "induced", "tumor", "lysis", "syndrome", "in", "an", "advanced", "hepatocellular", "carcinoma", "patient", "."], "event_mentions": [{"id": "19764104_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "19764104_2_Ent2", "role": "Treatment", "text": "Sorafenib", "start": 0, "end": 1}, {"entity_id": "19764104_2_Ent3", "role": "Treatment_Drug", "text": "Sorafenib", "start": 0, "end": 1}, {"entity_id": "19764104_2_Ent1", "role": "Effect", "text": "tumor lysis syndrome", "start": 2, "end": 5}, {"entity_id": "19764104_2_Ent0", "role": "Subject", "text": "an advanced hepatocellular carcinoma patient", "start": 6, "end": 11}, {"entity_id": "19764104_2_Ent4", "role": "Treatment_Disorder", "text": "hepatocellular carcinoma", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "19764104_2_Ent2", "text": "Sorafenib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19764104_2_Ent3", "text": "Sorafenib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19764104_2_Ent1", "text": "tumor lysis syndrome", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "19764104_2_Ent0", "text": "an advanced hepatocellular carcinoma patient", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19764104_2_Ent4", "text": "hepatocellular carcinoma", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "19775485_1", "wnd_id": "19775485_1_1", "text": "Are nasal decongestants safer than rhinitis ? A case of oxymetazoline - induced syncope .", "tokens": ["Are", "nasal", "decongestants", "safer", "than", "rhinitis", "?", "A", "case", "of", "oxymetazoline", "-", "induced", "syncope", "."], "event_mentions": [{"id": "19775485_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "19775485_1_Ent1", "role": "Treatment", "text": "oxymetazoline", "start": 10, "end": 11}, {"entity_id": "19775485_1_Ent2", "role": "Treatment_Drug", "text": "oxymetazoline", "start": 10, "end": 11}, {"entity_id": "19775485_1_Ent0", "role": "Effect", "text": "syncope", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "19775485_1_Ent1", "text": "oxymetazoline", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19775485_1_Ent2", "text": "oxymetazoline", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19775485_1_Ent0", "text": "syncope", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "19782276_10", "wnd_id": "19782276_10_1", "text": "Concomitant administration of cytarabine might have affected his liver function and there might have been interaction between the drugs .", "tokens": ["Concomitant", "administration", "of", "cytarabine", "might", "have", "affected", "his", "liver", "function", "and", "there", "might", "have", "been", "interaction", "between", "the", "drugs", "."], "event_mentions": [{"id": "19782276_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "affected", "start": 6, "end": 7}, "arguments": [{"entity_id": "19782276_10_Ent1", "role": "Treatment", "text": "cytarabine", "start": 3, "end": 4}, {"entity_id": "19782276_10_Ent2", "role": "Treatment_Drug", "text": "cytarabine", "start": 3, "end": 4}, {"entity_id": "19782276_10_Ent0", "role": "Effect", "text": "liver function", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "19782276_10_Ent1", "text": "cytarabine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19782276_10_Ent2", "text": "cytarabine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19782276_10_Ent0", "text": "liver function", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "19782276_9", "wnd_id": "19782276_9_1", "text": "Cyclophosphamide - induced cardiotoxicity occurred , even though the patient had both shown normal cardiac function before high - dose chemotherapy and had received a lower dose of cyclophosphamide .", "tokens": ["Cyclophosphamide", "-", "induced", "cardiotoxicity", "occurred", ",", "even", "though", "the", "patient", "had", "both", "shown", "normal", "cardiac", "function", "before", "high", "-", "dose", "chemotherapy", "and", "had", "received", "a", "lower", "dose", "of", "cyclophosphamide", "."], "event_mentions": [{"id": "19782276_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19782276_9_Ent2", "role": "Treatment", "text": "Cyclophosphamide", "start": 0, "end": 1}, {"entity_id": "19782276_9_Ent4", "role": "Treatment_Drug", "text": "Cyclophosphamide", "start": 0, "end": 1}, {"entity_id": "19782276_9_Ent1", "role": "Effect", "text": "cardiotoxicity", "start": 3, "end": 4}, {"entity_id": "19782276_9_Ent0", "role": "Subject", "text": "the patient had both shown normal cardiac function", "start": 8, "end": 16}, {"entity_id": "19782276_9_Ent3", "role": "Treatment", "text": "high - dose chemotherapy and had received a lower dose of cyclophosphamide", "start": 17, "end": 29}, {"entity_id": "19782276_9_Ent5", "role": "Treatment_Dosage", "text": "lower dose", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "19782276_9_Ent2", "text": "Cyclophosphamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19782276_9_Ent4", "text": "Cyclophosphamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19782276_9_Ent1", "text": "cardiotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19782276_9_Ent0", "text": "the patient had both shown normal cardiac function", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "19782276_9_Ent3", "text": "high - dose chemotherapy and had received a lower dose of cyclophosphamide", "entity_type": "Entity", "start": 17, "end": 29}, {"id": "19782276_9_Ent5", "text": "lower dose", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "19798640_2", "wnd_id": "19798640_2_1", "text": "Primary central nervous system lymphoma in a patient treated with natalizumab .", "tokens": ["Primary", "central", "nervous", "system", "lymphoma", "in", "a", "patient", "treated", "with", "natalizumab", "."], "event_mentions": [{"id": "19798640_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "19798640_2_Ent1", "role": "Effect", "text": "Primary central nervous system lymphoma", "start": 0, "end": 5}, {"entity_id": "19798640_2_Ent0", "role": "Subject", "text": "a patient", "start": 6, "end": 8}, {"entity_id": "19798640_2_Ent2", "role": "Treatment", "text": "natalizumab", "start": 10, "end": 11}, {"entity_id": "19798640_2_Ent3", "role": "Treatment_Drug", "text": "natalizumab", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "19798640_2_Ent1", "text": "Primary central nervous system lymphoma", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "19798640_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19798640_2_Ent2", "text": "natalizumab", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19798640_2_Ent3", "text": "natalizumab", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "19815480_1", "wnd_id": "19815480_1_1", "text": "The first patient is undergoing hemodialysis and , though responding to sunitinib , is having significant fatigue and hypertension .", "tokens": ["The", "first", "patient", "is", "undergoing", "hemodialysis", "and", ",", "though", "responding", "to", "sunitinib", ",", "is", "having", "significant", "fatigue", "and", "hypertension", "."], "event_mentions": [{"id": "19815480_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "having", "start": 14, "end": 15}, "arguments": [{"entity_id": "19815480_1_Ent0", "role": "Subject", "text": "The first patient", "start": 0, "end": 3}, {"entity_id": "19815480_1_Ent2", "role": "Treatment", "text": "sunitinib", "start": 11, "end": 12}, {"entity_id": "19815480_1_Ent3", "role": "Treatment_Drug", "text": "sunitinib", "start": 11, "end": 12}, {"entity_id": "19815480_1_Ent1", "role": "Effect", "text": "significant fatigue and hypertension", "start": 15, "end": 19}]}], "entity_mentions": [{"id": "19815480_1_Ent0", "text": "The first patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19815480_1_Ent2", "text": "sunitinib", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19815480_1_Ent3", "text": "sunitinib", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19815480_1_Ent1", "text": "significant fatigue and hypertension", "entity_type": "Entity", "start": 15, "end": 19}], "lang": "en"}
{"doc_id": "19826099_1", "wnd_id": "19826099_1_1", "text": "OBJECTIVE : To report a case of severe apnea in an infant exposed to lamotrigine through breast - feeding .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "severe", "apnea", "in", "an", "infant", "exposed", "to", "lamotrigine", "through", "breast", "-", "feeding", "."], "event_mentions": [{"id": "19826099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 9, "end": 10}, "arguments": [{"entity_id": "19826099_1_Ent2", "role": "Effect", "text": "severe apnea", "start": 7, "end": 9}, {"entity_id": "19826099_1_Ent0", "role": "Subject", "text": "an infant", "start": 10, "end": 12}, {"entity_id": "19826099_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 11, "end": 12}, {"entity_id": "19826099_1_Ent3", "role": "Treatment", "text": "exposed to lamotrigine through breast - feeding", "start": 12, "end": 19}, {"entity_id": "19826099_1_Ent4", "role": "Treatment_Drug", "text": "lamotrigine", "start": 14, "end": 15}, {"entity_id": "19826099_1_Ent5", "role": "Treatment_Route", "text": "breast - feeding", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "19826099_1_Ent2", "text": "severe apnea", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19826099_1_Ent0", "text": "an infant", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19826099_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19826099_1_Ent3", "text": "exposed to lamotrigine through breast - feeding", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "19826099_1_Ent4", "text": "lamotrigine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19826099_1_Ent5", "text": "breast - feeding", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "19875411_2", "wnd_id": "19875411_2_1", "text": "Severe cardiomyopathy following treatment with the tumour necrosis factor - alpha inhibitor adalimumab for Crohn 's disease .", "tokens": ["Severe", "cardiomyopathy", "following", "treatment", "with", "the", "tumour", "necrosis", "factor", "-", "alpha", "inhibitor", "adalimumab", "for", "Crohn", "'s", "disease", "."], "event_mentions": [{"id": "19875411_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "19875411_2_Ent0", "role": "Effect", "text": "cardiomyopathy", "start": 1, "end": 2}, {"entity_id": "19875411_2_Ent1", "role": "Treatment", "text": "treatment with the tumour necrosis factor - alpha inhibitor adalimumab", "start": 3, "end": 13}, {"entity_id": "19875411_2_Ent2", "role": "Treatment_Drug", "text": "adalimumab", "start": 12, "end": 13}, {"entity_id": "19875411_2_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "19875411_2_Ent0", "text": "cardiomyopathy", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19875411_2_Ent1", "text": "treatment with the tumour necrosis factor - alpha inhibitor adalimumab", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "19875411_2_Ent2", "text": "adalimumab", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19875411_2_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "19884751_3", "wnd_id": "19884751_3_1", "text": "We discuss a patient who developed severe renal tubular dysfunction secondary to short - term therapy with Amikacin , resulting in refractory hypokalemia , hypocalcemia , hypomagnesemia , metabolic alkalosis , and polyuria .", "tokens": ["We", "discuss", "a", "patient", "who", "developed", "severe", "renal", "tubular", "dysfunction", "secondary", "to", "short", "-", "term", "therapy", "with", "Amikacin", ",", "resulting", "in", "refractory", "hypokalemia", ",", "hypocalcemia", ",", "hypomagnesemia", ",", "metabolic", "alkalosis", ",", "and", "polyuria", "."], "event_mentions": [{"id": "19884751_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "19884751_3_Ent0", "role": "Effect", "text": "severe renal tubular dysfunction", "start": 6, "end": 10}, {"entity_id": "19884751_3_Ent4", "role": "Treatment_Duration", "text": "short - term", "start": 12, "end": 15}, {"entity_id": "19884751_3_Ent2", "role": "Treatment", "text": "short - term therapy with Amikacin", "start": 12, "end": 18}, {"entity_id": "19884751_3_Ent3", "role": "Treatment_Drug", "text": "Amikacin", "start": 17, "end": 18}, {"entity_id": "19884751_3_Ent1", "role": "Effect", "text": "resulting in refractory hypokalemia , hypocalcemia , hypomagnesemia , metabolic alkalosis , and polyuria", "start": 19, "end": 33}]}], "entity_mentions": [{"id": "19884751_3_Ent0", "text": "severe renal tubular dysfunction", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "19884751_3_Ent4", "text": "short - term", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "19884751_3_Ent2", "text": "short - term therapy with Amikacin", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "19884751_3_Ent3", "text": "Amikacin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19884751_3_Ent1", "text": "resulting in refractory hypokalemia , hypocalcemia , hypomagnesemia , metabolic alkalosis , and polyuria", "entity_type": "Entity", "start": 19, "end": 33}], "lang": "en"}
{"doc_id": "19892516_4", "wnd_id": "19892516_4_1", "text": "In one patient the vasculitis resolved after termination of the ciprofloxacin therapy ; in the other patient the ciprofloxacin - induced hemorrhagic vasculitis was superimposed on a severe forefoot infection , leading to progressive gangrene and a below - knee amputation .", "tokens": ["In", "one", "patient", "the", "vasculitis", "resolved", "after", "termination", "of", "the", "ciprofloxacin", "therapy", ";", "in", "the", "other", "patient", "the", "ciprofloxacin", "-", "induced", "hemorrhagic", "vasculitis", "was", "superimposed", "on", "a", "severe", "forefoot", "infection", ",", "leading", "to", "progressive", "gangrene", "and", "a", "below", "-", "knee", "amputation", "."], "event_mentions": [{"id": "19892516_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 5, "end": 6}, "arguments": [{"entity_id": "19892516_4_Ent5", "role": "Subject_Population", "text": "one", "start": 1, "end": 2}, {"entity_id": "19892516_4_Ent4", "role": "Subject", "text": "one patient the vasculitis", "start": 1, "end": 5}, {"entity_id": "19892516_4_Ent8", "role": "Treatment_Disorder", "text": "vasculitis", "start": 4, "end": 5}, {"entity_id": "19892516_4_Ent6", "role": "Treatment", "text": "termination of the ciprofloxacin therapy", "start": 7, "end": 12}, {"entity_id": "19892516_4_Ent7", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 10, "end": 11}]}, {"id": "19892516_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 20, "end": 21}, "arguments": [{"entity_id": "19892516_4_Ent0", "role": "Subject", "text": "patient", "start": 16, "end": 17}, {"entity_id": "19892516_4_Ent2", "role": "Treatment", "text": "ciprofloxacin", "start": 18, "end": 19}, {"entity_id": "19892516_4_Ent3", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 18, "end": 19}, {"entity_id": "19892516_4_Ent1", "role": "Effect", "text": "hemorrhagic vasculitis was superimposed on a severe forefoot infection , leading to progressive gangrene and a below - knee amputation", "start": 21, "end": 41}]}], "entity_mentions": [{"id": "19892516_4_Ent5", "text": "one", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19892516_4_Ent4", "text": "one patient the vasculitis", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "19892516_4_Ent8", "text": "vasculitis", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19892516_4_Ent6", "text": "termination of the ciprofloxacin therapy", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "19892516_4_Ent7", "text": "ciprofloxacin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19892516_4_Ent0", "text": "patient", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19892516_4_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "19892516_4_Ent3", "text": "ciprofloxacin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "19892516_4_Ent1", "text": "hemorrhagic vasculitis was superimposed on a severe forefoot infection , leading to progressive gangrene and a below - knee amputation", "entity_type": "Entity", "start": 21, "end": 41}], "lang": "en"}
{"doc_id": "19897274_2", "wnd_id": "19897274_2_1", "text": "Interstitial pneumonia probably associated with sorafenib treatment : An alert of an adverse event .", "tokens": ["Interstitial", "pneumonia", "probably", "associated", "with", "sorafenib", "treatment", ":", "An", "alert", "of", "an", "adverse", "event", "."], "event_mentions": [{"id": "19897274_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "19897274_2_Ent0", "role": "Effect", "text": "Interstitial pneumonia", "start": 0, "end": 2}, {"entity_id": "19897274_2_Ent2", "role": "Treatment_Drug", "text": "sorafenib", "start": 5, "end": 6}, {"entity_id": "19897274_2_Ent1", "role": "Treatment", "text": "sorafenib treatment :", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "19897274_2_Ent0", "text": "Interstitial pneumonia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19897274_2_Ent2", "text": "sorafenib", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19897274_2_Ent1", "text": "sorafenib treatment :", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "19904536_13", "wnd_id": "19904536_13_1", "text": "Gemcitabine - induced pulmonary toxicity is usually a dramatic condition .", "tokens": ["Gemcitabine", "-", "induced", "pulmonary", "toxicity", "is", "usually", "a", "dramatic", "condition", "."], "event_mentions": [{"id": "19904536_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19904536_13_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19904536_13_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19904536_13_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "19904536_13_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19904536_13_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19904536_13_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "19904536_2", "wnd_id": "19904536_2_1", "text": "Gemcitabine is a chemotherapy agent that may cause unpredictable side effects .", "tokens": ["Gemcitabine", "is", "a", "chemotherapy", "agent", "that", "may", "cause", "unpredictable", "side", "effects", "."], "event_mentions": [{"id": "19904536_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "19904536_2_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19904536_2_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19904536_2_Ent0", "role": "Effect", "text": "unpredictable side effects", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "19904536_2_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19904536_2_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19904536_2_Ent0", "text": "unpredictable side effects", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "1993143_1", "wnd_id": "1993143_1_1", "text": "Of 371 patients treated with 8MOP , three ( 0.8 % ) developed an acute dermatitis in the PUVA - treated areas .", "tokens": ["Of", "371", "patients", "treated", "with", "8MOP", ",", "three", "(", "0.8", "%", ")", "developed", "an", "acute", "dermatitis", "in", "the", "PUVA", "-", "treated", "areas", "."], "event_mentions": [{"id": "1993143_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "1993143_1_Ent0", "role": "Subject", "text": "Of 371 patients", "start": 0, "end": 3}, {"entity_id": "1993143_1_Ent2", "role": "Subject_Population", "text": "371", "start": 1, "end": 2}, {"entity_id": "1993143_1_Ent5", "role": "Treatment", "text": "treated with 8MOP", "start": 3, "end": 6}, {"entity_id": "1993143_1_Ent6", "role": "Treatment_Drug", "text": "8MOP", "start": 5, "end": 6}, {"entity_id": "1993143_1_Ent1", "role": "Subject", "text": "three ( 0.8 % )", "start": 7, "end": 12}, {"entity_id": "1993143_1_Ent3", "role": "Subject_Population", "text": "three ( 0.8 % )", "start": 7, "end": 12}, {"entity_id": "1993143_1_Ent4", "role": "Effect", "text": "acute dermatitis", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "1993143_1_Ent0", "text": "Of 371 patients", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1993143_1_Ent2", "text": "371", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1993143_1_Ent5", "text": "treated with 8MOP", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1993143_1_Ent6", "text": "8MOP", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1993143_1_Ent1", "text": "three ( 0.8 % )", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "1993143_1_Ent3", "text": "three ( 0.8 % )", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "1993143_1_Ent4", "text": "acute dermatitis", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19949685_1", "wnd_id": "19949685_1_1", "text": "Colonic mucosal necrosis following administration of calcium polystryrene sulfonate ( Kalimate ) in a uremic patient .", "tokens": ["Colonic", "mucosal", "necrosis", "following", "administration", "of", "calcium", "polystryrene", "sulfonate", "(", "Kalimate", ")", "in", "a", "uremic", "patient", "."], "event_mentions": [{"id": "19949685_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 4, "end": 5}, "arguments": [{"entity_id": "19949685_1_Ent1", "role": "Effect", "text": "Colonic mucosal necrosis", "start": 0, "end": 3}, {"entity_id": "19949685_1_Ent3", "role": "Treatment_Drug", "text": "calcium polystryrene sulfonate", "start": 6, "end": 9}, {"entity_id": "19949685_1_Ent2", "role": "Treatment", "text": "calcium polystryrene sulfonate ( Kalimate )", "start": 6, "end": 12}, {"entity_id": "19949685_1_Ent4", "role": "Treatment_Disorder", "text": "uremic", "start": 14, "end": 15}, {"entity_id": "19949685_1_Ent0", "role": "Subject", "text": "uremic patient", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19949685_1_Ent1", "text": "Colonic mucosal necrosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19949685_1_Ent3", "text": "calcium polystryrene sulfonate", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19949685_1_Ent2", "text": "calcium polystryrene sulfonate ( Kalimate )", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "19949685_1_Ent4", "text": "uremic", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19949685_1_Ent0", "text": "uremic patient", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19949685_2", "wnd_id": "19949685_2_1", "text": "Colonic necrosis is known as a rare complication following the administration of Kayexalate ( sodium polystryrene sulfonate ) in sorbitol .", "tokens": ["Colonic", "necrosis", "is", "known", "as", "a", "rare", "complication", "following", "the", "administration", "of", "Kayexalate", "(", "sodium", "polystryrene", "sulfonate", ")", "in", "sorbitol", "."], "event_mentions": [{"id": "19949685_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "19949685_2_Ent0", "role": "Effect", "text": "Colonic necrosis", "start": 0, "end": 2}, {"entity_id": "19949685_2_Ent2", "role": "Treatment_Drug", "text": "Kayexalate", "start": 12, "end": 13}, {"entity_id": "19949685_2_Ent5", "role": "Combination_Drug", "text": "Kayexalate", "start": 12, "end": 13}, {"entity_id": "19949685_2_Ent1", "role": "Treatment", "text": "Kayexalate ( sodium polystryrene sulfonate ) in sorbitol", "start": 12, "end": 20}, {"entity_id": "19949685_2_Ent3", "role": "Treatment_Drug", "text": "sorbitol", "start": 19, "end": 20}, {"entity_id": "19949685_2_Ent4", "role": "Combination_Drug", "text": "sorbitol", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "19949685_2_Ent0", "text": "Colonic necrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19949685_2_Ent2", "text": "Kayexalate", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19949685_2_Ent5", "text": "Kayexalate", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19949685_2_Ent1", "text": "Kayexalate ( sodium polystryrene sulfonate ) in sorbitol", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "19949685_2_Ent3", "text": "sorbitol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19949685_2_Ent4", "text": "sorbitol", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "19995222_1", "wnd_id": "19995222_1_1", "text": "Clozapine - induced tardive dyskinesia in schizophrenic patients taking clozapine as a first - line antipsychotic drug .", "tokens": ["Clozapine", "-", "induced", "tardive", "dyskinesia", "in", "schizophrenic", "patients", "taking", "clozapine", "as", "a", "first", "-", "line", "antipsychotic", "drug", "."], "event_mentions": [{"id": "19995222_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19995222_1_Ent2", "role": "Treatment", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "19995222_1_Ent3", "role": "Treatment_Drug", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "19995222_1_Ent1", "role": "Effect", "text": "tardive dyskinesia", "start": 3, "end": 5}, {"entity_id": "19995222_1_Ent4", "role": "Treatment_Disorder", "text": "schizophrenic", "start": 6, "end": 7}, {"entity_id": "19995222_1_Ent0", "role": "Subject", "text": "schizophrenic patients", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "19995222_1_Ent2", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19995222_1_Ent3", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19995222_1_Ent1", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19995222_1_Ent4", "text": "schizophrenic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19995222_1_Ent0", "text": "schizophrenic patients", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "19995222_2", "wnd_id": "19995222_2_1", "text": "CONCLUSIONS : These results suggest that clozapine may cause TD ; however , the prevalence is low and the severity is relatively mild , with no or mild self - reported discomfort .", "tokens": ["CONCLUSIONS", ":", "These", "results", "suggest", "that", "clozapine", "may", "cause", "TD", ";", "however", ",", "the", "prevalence", "is", "low", "and", "the", "severity", "is", "relatively", "mild", ",", "with", "no", "or", "mild", "self", "-", "reported", "discomfort", "."], "event_mentions": [{"id": "19995222_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 8, "end": 9}, "arguments": [{"entity_id": "19995222_2_Ent1", "role": "Treatment", "text": "clozapine", "start": 6, "end": 7}, {"entity_id": "19995222_2_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 6, "end": 7}, {"entity_id": "19995222_2_Ent0", "role": "Effect", "text": "TD", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19995222_2_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19995222_2_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19995222_2_Ent0", "text": "TD", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19995222_3", "wnd_id": "19995222_3_1", "text": "However , several case reports have suggested that clozapine could also cause TD .", "tokens": ["However", ",", "several", "case", "reports", "have", "suggested", "that", "clozapine", "could", "also", "cause", "TD", "."], "event_mentions": [{"id": "19995222_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "19995222_3_Ent1", "role": "Treatment", "text": "clozapine", "start": 8, "end": 9}, {"entity_id": "19995222_3_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 8, "end": 9}, {"entity_id": "19995222_3_Ent0", "role": "Effect", "text": "TD", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19995222_3_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19995222_3_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19995222_3_Ent0", "text": "TD", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19995690_4", "wnd_id": "19995690_4_1", "text": "We report a case of a 34 - year - old man on carbamazepine for complex partial seizures who developed acute liver and renal failure on less than 2.5 grams a day of acetaminophen .", "tokens": ["We", "report", "a", "case", "of", "a", "34", "-", "year", "-", "old", "man", "on", "carbamazepine", "for", "complex", "partial", "seizures", "who", "developed", "acute", "liver", "and", "renal", "failure", "on", "less", "than", "2.5", "grams", "a", "day", "of", "acetaminophen", "."], "event_mentions": [{"id": "19995690_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 12, "end": 13}, "arguments": [{"entity_id": "19995690_4_Ent0", "role": "Subject", "text": "a 34 - year - old man", "start": 5, "end": 12}, {"entity_id": "19995690_4_Ent1", "role": "Subject_Age", "text": "34 - year - old", "start": 6, "end": 11}, {"entity_id": "19995690_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "19995690_4_Ent4", "role": "Treatment", "text": "carbamazepine", "start": 13, "end": 14}, {"entity_id": "19995690_4_Ent6", "role": "Treatment_Drug", "text": "carbamazepine", "start": 13, "end": 14}, {"entity_id": "19995690_4_Ent12", "role": "Combination_Drug", "text": "carbamazepine", "start": 13, "end": 14}, {"entity_id": "19995690_4_Ent8", "role": "Treatment_Disorder", "text": "complex partial seizures", "start": 15, "end": 18}, {"entity_id": "19995690_4_Ent3", "role": "Effect", "text": "acute liver and renal failure", "start": 20, "end": 25}, {"entity_id": "19995690_4_Ent9", "role": "Treatment_Dosage", "text": "less than 2.5 grams", "start": 26, "end": 30}, {"entity_id": "19995690_4_Ent5", "role": "Treatment", "text": "less than 2.5 grams a day of acetaminophen", "start": 26, "end": 34}, {"entity_id": "19995690_4_Ent10", "role": "Treatment_Freq", "text": "a day", "start": 30, "end": 32}, {"entity_id": "19995690_4_Ent7", "role": "Treatment_Drug", "text": "acetaminophen", "start": 33, "end": 34}, {"entity_id": "19995690_4_Ent11", "role": "Combination_Drug", "text": "acetaminophen", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "19995690_4_Ent0", "text": "a 34 - year - old man", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "19995690_4_Ent1", "text": "34 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19995690_4_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19995690_4_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19995690_4_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19995690_4_Ent12", "text": "carbamazepine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19995690_4_Ent8", "text": "complex partial seizures", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "19995690_4_Ent3", "text": "acute liver and renal failure", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "19995690_4_Ent9", "text": "less than 2.5 grams", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "19995690_4_Ent5", "text": "less than 2.5 grams a day of acetaminophen", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "19995690_4_Ent10", "text": "a day", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "19995690_4_Ent7", "text": "acetaminophen", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "19995690_4_Ent11", "text": "acetaminophen", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "20038831_3", "wnd_id": "20038831_3_1", "text": "Prick tests and intradermal tests with a series of dilutions of carboplatin and cisplatin were performed on three patients who had exhibited medium and severe hypersensitivity reactions to carboplatin .", "tokens": ["Prick", "tests", "and", "intradermal", "tests", "with", "a", "series", "of", "dilutions", "of", "carboplatin", "and", "cisplatin", "were", "performed", "on", "three", "patients", "who", "had", "exhibited", "medium", "and", "severe", "hypersensitivity", "reactions", "to", "carboplatin", "."], "event_mentions": [{"id": "20038831_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exhibited", "start": 21, "end": 22}, "arguments": [{"entity_id": "20038831_3_Ent0", "role": "Subject", "text": "three patients", "start": 17, "end": 19}, {"entity_id": "20038831_3_Ent1", "role": "Effect", "text": "medium and severe hypersensitivity reactions", "start": 22, "end": 27}, {"entity_id": "20038831_3_Ent2", "role": "Treatment", "text": "carboplatin", "start": 28, "end": 29}, {"entity_id": "20038831_3_Ent3", "role": "Treatment_Drug", "text": "carboplatin", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "20038831_3_Ent0", "text": "three patients", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "20038831_3_Ent1", "text": "medium and severe hypersensitivity reactions", "entity_type": "Entity", "start": 22, "end": 27}, {"id": "20038831_3_Ent2", "text": "carboplatin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "20038831_3_Ent3", "text": "carboplatin", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "20065266_2", "wnd_id": "20065266_2_1", "text": "CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed hemolytic anemia , hepatitis , orthostatic hypotension , and aseptic meningitis simultaneously after using trimethoprim - sulfamethoxazole .", "tokens": ["CONCLUSION", ":", "A", "37", "-", "year", "-", "old", "African", "-", "American", "man", "with", "G6PD", "deficiency", "developed", "hemolytic", "anemia", ",", "hepatitis", ",", "orthostatic", "hypotension", ",", "and", "aseptic", "meningitis", "simultaneously", "after", "using", "trimethoprim", "-", "sulfamethoxazole", "."], "event_mentions": [{"id": "20065266_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "20065266_2_Ent0", "role": "Subject", "text": "A 37 - year - old African - American man with G6PD deficiency", "start": 2, "end": 15}, {"entity_id": "20065266_2_Ent2", "role": "Subject_Age", "text": "37 - year - old", "start": 3, "end": 8}, {"entity_id": "20065266_2_Ent3", "role": "Subject_Race", "text": "African - American", "start": 8, "end": 11}, {"entity_id": "20065266_2_Ent4", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "20065266_2_Ent1", "role": "Subject_Disorder", "text": "G6PD deficiency", "start": 13, "end": 15}, {"entity_id": "20065266_2_Ent5", "role": "Effect", "text": "hemolytic anemia , hepatitis , orthostatic hypotension , and aseptic meningitis", "start": 16, "end": 27}, {"entity_id": "20065266_2_Ent6", "role": "Treatment", "text": "trimethoprim - sulfamethoxazole", "start": 30, "end": 33}, {"entity_id": "20065266_2_Ent7", "role": "Treatment_Drug", "text": "trimethoprim - sulfamethoxazole", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "20065266_2_Ent0", "text": "A 37 - year - old African - American man with G6PD deficiency", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "20065266_2_Ent2", "text": "37 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "20065266_2_Ent3", "text": "African - American", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "20065266_2_Ent4", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20065266_2_Ent1", "text": "G6PD deficiency", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "20065266_2_Ent5", "text": "hemolytic anemia , hepatitis , orthostatic hypotension , and aseptic meningitis", "entity_type": "Entity", "start": 16, "end": 27}, {"id": "20065266_2_Ent6", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 30, "end": 33}, {"id": "20065266_2_Ent7", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "20118434_2", "wnd_id": "20118434_2_1", "text": "Interferon - induced psychosis as a \" psychiatric contraindication \" to hepatitis C treatment : a review and case - based discussion .", "tokens": ["Interferon", "-", "induced", "psychosis", "as", "a", "\"", "psychiatric", "contraindication", "\"", "to", "hepatitis", "C", "treatment", ":", "a", "review", "and", "case", "-", "based", "discussion", "."], "event_mentions": [{"id": "20118434_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "20118434_2_Ent1", "role": "Treatment", "text": "Interferon", "start": 0, "end": 1}, {"entity_id": "20118434_2_Ent2", "role": "Treatment_Drug", "text": "Interferon", "start": 0, "end": 1}, {"entity_id": "20118434_2_Ent0", "role": "Effect", "text": "psychosis", "start": 3, "end": 4}, {"entity_id": "20118434_2_Ent3", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "20118434_2_Ent1", "text": "Interferon", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20118434_2_Ent2", "text": "Interferon", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20118434_2_Ent0", "text": "psychosis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20118434_2_Ent3", "text": "hepatitis C", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "2016556_1", "wnd_id": "2016556_1_1", "text": "We describe a patient who experienced chronic nausea and an episode of confusion while treated with a small , stable dose of oral morphine in the setting of mild renal insufficiency .", "tokens": ["We", "describe", "a", "patient", "who", "experienced", "chronic", "nausea", "and", "an", "episode", "of", "confusion", "while", "treated", "with", "a", "small", ",", "stable", "dose", "of", "oral", "morphine", "in", "the", "setting", "of", "mild", "renal", "insufficiency", "."], "event_mentions": [{"id": "2016556_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 5, "end": 6}, "arguments": [{"entity_id": "2016556_1_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "2016556_1_Ent2", "role": "Effect", "text": "chronic nausea and an episode of confusion", "start": 6, "end": 13}, {"entity_id": "2016556_1_Ent3", "role": "Treatment", "text": "a small , stable dose of oral morphine", "start": 16, "end": 24}, {"entity_id": "2016556_1_Ent4", "role": "Treatment_Dosage", "text": "small , stable dose", "start": 17, "end": 21}, {"entity_id": "2016556_1_Ent5", "role": "Treatment_Route", "text": "oral", "start": 22, "end": 23}, {"entity_id": "2016556_1_Ent6", "role": "Treatment_Drug", "text": "morphine", "start": 23, "end": 24}, {"entity_id": "2016556_1_Ent1", "role": "Subject_Disorder", "text": "mild renal insufficiency", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "2016556_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "2016556_1_Ent2", "text": "chronic nausea and an episode of confusion", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "2016556_1_Ent3", "text": "a small , stable dose of oral morphine", "entity_type": "Entity", "start": 16, "end": 24}, {"id": "2016556_1_Ent4", "text": "small , stable dose", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "2016556_1_Ent5", "text": "oral", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2016556_1_Ent6", "text": "morphine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "2016556_1_Ent1", "text": "mild renal insufficiency", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "20178709_1", "wnd_id": "20178709_1_1", "text": "A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy .", "tokens": ["A", "case", "of", "aseptic", "pleuropericarditis", "in", "a", "patient", "with", "chronic", "plaque", "psoriasis", "under", "methotrexate", "therapy", "."], "event_mentions": [{"id": "20178709_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "20178709_1_Ent1", "role": "Effect", "text": "aseptic pleuropericarditis", "start": 3, "end": 5}, {"entity_id": "20178709_1_Ent0", "role": "Subject", "text": "a patient with chronic plaque psoriasis", "start": 6, "end": 12}, {"entity_id": "20178709_1_Ent4", "role": "Treatment_Disorder", "text": "chronic plaque psoriasis", "start": 9, "end": 12}, {"entity_id": "20178709_1_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 13, "end": 14}, {"entity_id": "20178709_1_Ent2", "role": "Treatment", "text": "methotrexate therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "20178709_1_Ent1", "text": "aseptic pleuropericarditis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "20178709_1_Ent0", "text": "a patient with chronic plaque psoriasis", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "20178709_1_Ent4", "text": "chronic plaque psoriasis", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "20178709_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "20178709_1_Ent2", "text": "methotrexate therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "20180933_2", "wnd_id": "20180933_2_1", "text": "Artemether - lumefantrine ( AL ) is first - line treatment for uncomplicated malaria in many African countries .", "tokens": ["Artemether", "-", "lumefantrine", "(", "AL", ")", "is", "first", "-", "line", "treatment", "for", "uncomplicated", "malaria", "in", "many", "African", "countries", "."], "event_mentions": [{"id": "20180933_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "first - line treatment", "start": 7, "end": 11}, "arguments": [{"entity_id": "20180933_2_Ent2", "role": "Treatment_Drug", "text": "Artemether - lumefantrine", "start": 0, "end": 3}, {"entity_id": "20180933_2_Ent0", "role": "Treatment", "text": "Artemether - lumefantrine ( AL )", "start": 0, "end": 6}, {"entity_id": "20180933_2_Ent1", "role": "Treatment_Disorder", "text": "uncomplicated malaria", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "20180933_2_Ent2", "text": "Artemether - lumefantrine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "20180933_2_Ent0", "text": "Artemether - lumefantrine ( AL )", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "20180933_2_Ent1", "text": "uncomplicated malaria", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "20234160_3", "wnd_id": "20234160_3_1", "text": "We report a case of a 23 - year - old man who developed a vancomycin - induced anaphylactic reaction in the treatment of methicillin - resistant Staphylococcus aureus infection .", "tokens": ["We", "report", "a", "case", "of", "a", "23", "-", "year", "-", "old", "man", "who", "developed", "a", "vancomycin", "-", "induced", "anaphylactic", "reaction", "in", "the", "treatment", "of", "methicillin", "-", "resistant", "Staphylococcus", "aureus", "infection", "."], "event_mentions": [{"id": "20234160_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "20234160_3_Ent0", "role": "Subject", "text": "a 23 - year - old man", "start": 5, "end": 12}, {"entity_id": "20234160_3_Ent1", "role": "Subject_Age", "text": "23 - year - old", "start": 6, "end": 11}, {"entity_id": "20234160_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "20234160_3_Ent3", "role": "Effect", "text": "a vancomycin - induced anaphylactic reaction", "start": 14, "end": 20}, {"entity_id": "20234160_3_Ent4", "role": "Treatment", "text": "vancomycin", "start": 15, "end": 16}, {"entity_id": "20234160_3_Ent5", "role": "Treatment_Drug", "text": "vancomycin", "start": 15, "end": 16}, {"entity_id": "20234160_3_Ent6", "role": "Treatment_Disorder", "text": "methicillin - resistant Staphylococcus aureus infection", "start": 24, "end": 30}]}], "entity_mentions": [{"id": "20234160_3_Ent0", "text": "a 23 - year - old man", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "20234160_3_Ent1", "text": "23 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "20234160_3_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20234160_3_Ent3", "text": "a vancomycin - induced anaphylactic reaction", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "20234160_3_Ent4", "text": "vancomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "20234160_3_Ent5", "text": "vancomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "20234160_3_Ent6", "text": "methicillin - resistant Staphylococcus aureus infection", "entity_type": "Entity", "start": 24, "end": 30}], "lang": "en"}
{"doc_id": "20298401_1", "wnd_id": "20298401_1_1", "text": "Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis .", "tokens": ["Fatal", "interstitial", "lung", "disease", "after", "erlotinib", "administration", "in", "a", "patient", "with", "radiation", "fibrosis", "."], "event_mentions": [{"id": "20298401_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "20298401_1_Ent2", "role": "Effect", "text": "interstitial lung disease", "start": 1, "end": 4}, {"entity_id": "20298401_1_Ent3", "role": "Treatment", "text": "erlotinib", "start": 5, "end": 6}, {"entity_id": "20298401_1_Ent4", "role": "Treatment_Drug", "text": "erlotinib", "start": 5, "end": 6}, {"entity_id": "20298401_1_Ent0", "role": "Subject", "text": "a patient with radiation fibrosis", "start": 8, "end": 13}, {"entity_id": "20298401_1_Ent1", "role": "Subject_Disorder", "text": "radiation fibrosis", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "20298401_1_Ent2", "text": "interstitial lung disease", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "20298401_1_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20298401_1_Ent4", "text": "erlotinib", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20298401_1_Ent0", "text": "a patient with radiation fibrosis", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "20298401_1_Ent1", "text": "radiation fibrosis", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "20298401_2", "wnd_id": "20298401_2_1", "text": "INTRODUCTION : Although gefitinib used for the treatment of non - small - cell lung cancer is a well - known cause of interstitial lung disease ( ILD ) , few case reports on erlotinib - induced ILD have been issued .", "tokens": ["INTRODUCTION", ":", "Although", "gefitinib", "used", "for", "the", "treatment", "of", "non", "-", "small", "-", "cell", "lung", "cancer", "is", "a", "well", "-", "known", "cause", "of", "interstitial", "lung", "disease", "(", "ILD", ")", ",", "few", "case", "reports", "on", "erlotinib", "-", "induced", "ILD", "have", "been", "issued", "."], "event_mentions": [{"id": "20298401_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 21, "end": 22}, "arguments": [{"entity_id": "20298401_2_Ent1", "role": "Treatment", "text": "gefitinib", "start": 3, "end": 4}, {"entity_id": "20298401_2_Ent3", "role": "Treatment_Drug", "text": "gefitinib", "start": 3, "end": 4}, {"entity_id": "20298401_2_Ent2", "role": "Treatment_Disorder", "text": "non - small - cell lung cancer", "start": 9, "end": 16}, {"entity_id": "20298401_2_Ent0", "role": "Effect", "text": "interstitial lung disease ( ILD )", "start": 23, "end": 29}]}, {"id": "20298401_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 36, "end": 37}, "arguments": [{"entity_id": "20298401_2_Ent5", "role": "Treatment", "text": "erlotinib", "start": 34, "end": 35}, {"entity_id": "20298401_2_Ent6", "role": "Treatment_Drug", "text": "erlotinib", "start": 34, "end": 35}, {"entity_id": "20298401_2_Ent4", "role": "Effect", "text": "ILD", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "20298401_2_Ent1", "text": "gefitinib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20298401_2_Ent3", "text": "gefitinib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20298401_2_Ent2", "text": "non - small - cell lung cancer", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "20298401_2_Ent0", "text": "interstitial lung disease ( ILD )", "entity_type": "Entity", "start": 23, "end": 29}, {"id": "20298401_2_Ent5", "text": "erlotinib", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "20298401_2_Ent6", "text": "erlotinib", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "20298401_2_Ent4", "text": "ILD", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "20298401_9", "wnd_id": "20298401_9_1", "text": "The patient died of respiratory failure after 8 days of steroid infusion and erlotinib discontinuation .", "tokens": ["The", "patient", "died", "of", "respiratory", "failure", "after", "8", "days", "of", "steroid", "infusion", "and", "erlotinib", "discontinuation", "."], "event_mentions": [{"id": "20298401_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "20298401_9_Ent1", "role": "Subject", "text": "The", "start": 0, "end": 1}, {"entity_id": "20298401_9_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "20298401_9_Ent2", "role": "Effect", "text": "died of respiratory failure", "start": 2, "end": 6}, {"entity_id": "20298401_9_Ent4", "role": "Treatment_Time_elapsed", "text": "after 8 days", "start": 6, "end": 9}, {"entity_id": "20298401_9_Ent3", "role": "Treatment", "text": "8 days of steroid infusion and erlotinib discontinuation .", "start": 7, "end": 16}, {"entity_id": "20298401_9_Ent5", "role": "Treatment_Drug", "text": "steroid", "start": 10, "end": 11}, {"entity_id": "20298401_9_Ent7", "role": "Treatment_Route", "text": "infusion", "start": 11, "end": 12}, {"entity_id": "20298401_9_Ent6", "role": "Treatment_Drug", "text": "erlotinib", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "20298401_9_Ent1", "text": "The", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20298401_9_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20298401_9_Ent2", "text": "died of respiratory failure", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "20298401_9_Ent4", "text": "after 8 days", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "20298401_9_Ent3", "text": "8 days of steroid infusion and erlotinib discontinuation .", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "20298401_9_Ent5", "text": "steroid", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20298401_9_Ent7", "text": "infusion", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20298401_9_Ent6", "text": "erlotinib", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "20338114_2", "wnd_id": "20338114_2_1", "text": "The other patient developed transient intraoperative hypertension immediately after inadvertent submucosal injection of concentrated epinephrine .", "tokens": ["The", "other", "patient", "developed", "transient", "intraoperative", "hypertension", "immediately", "after", "inadvertent", "submucosal", "injection", "of", "concentrated", "epinephrine", "."], "event_mentions": [{"id": "20338114_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "20338114_2_Ent0", "role": "Subject", "text": "The other patient", "start": 0, "end": 3}, {"entity_id": "20338114_2_Ent1", "role": "Effect", "text": "transient intraoperative hypertension immediately", "start": 4, "end": 8}, {"entity_id": "20338114_2_Ent2", "role": "Treatment", "text": "inadvertent submucosal injection of concentrated epinephrine", "start": 9, "end": 15}, {"entity_id": "20338114_2_Ent4", "role": "Treatment_Route", "text": "injection", "start": 11, "end": 12}, {"entity_id": "20338114_2_Ent3", "role": "Treatment_Drug", "text": "epinephrine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "20338114_2_Ent0", "text": "The other patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "20338114_2_Ent1", "text": "transient intraoperative hypertension immediately", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "20338114_2_Ent2", "text": "inadvertent submucosal injection of concentrated epinephrine", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "20338114_2_Ent4", "text": "injection", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20338114_2_Ent3", "text": "epinephrine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "20349794_1", "wnd_id": "20349794_1_1", "text": "Cisplatin - induced syndrome of inappropriate antidiuretic hormone ( SIADH ) in a patient with neuroendocrine tumor of the cervix : a case report and review of the literature .", "tokens": ["Cisplatin", "-", "induced", "syndrome", "of", "inappropriate", "antidiuretic", "hormone", "(", "SIADH", ")", "in", "a", "patient", "with", "neuroendocrine", "tumor", "of", "the", "cervix", ":", "a", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "20349794_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "20349794_1_Ent2", "role": "Treatment", "text": "Cisplatin", "start": 0, "end": 1}, {"entity_id": "20349794_1_Ent3", "role": "Treatment_Drug", "text": "Cisplatin", "start": 0, "end": 1}, {"entity_id": "20349794_1_Ent1", "role": "Effect", "text": "syndrome of inappropriate antidiuretic hormone ( SIADH )", "start": 3, "end": 11}, {"entity_id": "20349794_1_Ent0", "role": "Subject", "text": "a patient with neuroendocrine tumor of the cervix", "start": 12, "end": 20}, {"entity_id": "20349794_1_Ent4", "role": "Treatment_Disorder", "text": "neuroendocrine tumor of the cervix", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "20349794_1_Ent2", "text": "Cisplatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20349794_1_Ent3", "text": "Cisplatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20349794_1_Ent1", "text": "syndrome of inappropriate antidiuretic hormone ( SIADH )", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "20349794_1_Ent0", "text": "a patient with neuroendocrine tumor of the cervix", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "20349794_1_Ent4", "text": "neuroendocrine tumor of the cervix", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "20378385_2", "wnd_id": "20378385_2_1", "text": "Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab .", "tokens": ["Visceral", "leishmaniasis", "and", "macrophagic", "activation", "syndrome", "in", "a", "patient", "with", "rheumatoid", "arthritis", "under", "treatment", "with", "adalimumab", "."], "event_mentions": [{"id": "20378385_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "under", "start": 12, "end": 13}, "arguments": [{"entity_id": "20378385_2_Ent1", "role": "Effect", "text": "Visceral leishmaniasis and macrophagic activation syndrome", "start": 0, "end": 6}, {"entity_id": "20378385_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 7, "end": 12}, {"entity_id": "20378385_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 10, "end": 12}, {"entity_id": "20378385_2_Ent2", "role": "Treatment", "text": "adalimumab", "start": 15, "end": 16}, {"entity_id": "20378385_2_Ent4", "role": "Treatment_Drug", "text": "adalimumab", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "20378385_2_Ent1", "text": "Visceral leishmaniasis and macrophagic activation syndrome", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "20378385_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "20378385_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "20378385_2_Ent2", "text": "adalimumab", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "20378385_2_Ent4", "text": "adalimumab", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "20412003_1", "wnd_id": "20412003_1_1", "text": "After other potential causes of liver toxicity were excluded , TMP - SMX was determined to be the cause of his acute liver toxicity .", "tokens": ["After", "other", "potential", "causes", "of", "liver", "toxicity", "were", "excluded", ",", "TMP", "-", "SMX", "was", "determined", "to", "be", "the", "cause", "of", "his", "acute", "liver", "toxicity", "."], "event_mentions": [{"id": "20412003_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "determined", "start": 14, "end": 15}, "arguments": [{"entity_id": "20412003_1_Ent2", "role": "Treatment_Drug", "text": "TMP", "start": 10, "end": 11}, {"entity_id": "20412003_1_Ent4", "role": "Combination_Drug", "text": "TMP", "start": 10, "end": 11}, {"entity_id": "20412003_1_Ent1", "role": "Treatment", "text": "TMP - SMX", "start": 10, "end": 13}, {"entity_id": "20412003_1_Ent3", "role": "Treatment_Drug", "text": "SMX", "start": 12, "end": 13}, {"entity_id": "20412003_1_Ent5", "role": "Combination_Drug", "text": "SMX", "start": 12, "end": 13}, {"entity_id": "20412003_1_Ent0", "role": "Effect", "text": "acute liver toxicity", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "20412003_1_Ent2", "text": "TMP", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20412003_1_Ent4", "text": "TMP", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20412003_1_Ent1", "text": "TMP - SMX", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "20412003_1_Ent3", "text": "SMX", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20412003_1_Ent5", "text": "SMX", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20412003_1_Ent0", "text": "acute liver toxicity", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "20412003_4", "wnd_id": "20412003_4_1", "text": "Trimethoprim - sulfamethoxazole - induced hepatotoxicity in a pediatric patient .", "tokens": ["Trimethoprim", "-", "sulfamethoxazole", "-", "induced", "hepatotoxicity", "in", "a", "pediatric", "patient", "."], "event_mentions": [{"id": "20412003_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "20412003_4_Ent4", "role": "Treatment_Drug", "text": "Trimethoprim", "start": 0, "end": 1}, {"entity_id": "20412003_4_Ent6", "role": "Combination_Drug", "text": "Trimethoprim", "start": 0, "end": 1}, {"entity_id": "20412003_4_Ent3", "role": "Treatment", "text": "Trimethoprim - sulfamethoxazole", "start": 0, "end": 3}, {"entity_id": "20412003_4_Ent5", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 2, "end": 3}, {"entity_id": "20412003_4_Ent7", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 2, "end": 3}, {"entity_id": "20412003_4_Ent2", "role": "Effect", "text": "hepatotoxicity", "start": 5, "end": 6}, {"entity_id": "20412003_4_Ent0", "role": "Subject", "text": "a pediatric patient", "start": 7, "end": 10}, {"entity_id": "20412003_4_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "20412003_4_Ent4", "text": "Trimethoprim", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20412003_4_Ent6", "text": "Trimethoprim", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20412003_4_Ent3", "text": "Trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "20412003_4_Ent5", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20412003_4_Ent7", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20412003_4_Ent2", "text": "hepatotoxicity", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20412003_4_Ent0", "text": "a pediatric patient", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "20412003_4_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "20412003_6", "wnd_id": "20412003_6_1", "text": "We describe a relatively healthy , 9 - year - old boy who developed a CA - MRSA skin and soft tissue infection and was treated with TMP - SMX .", "tokens": ["We", "describe", "a", "relatively", "healthy", ",", "9", "-", "year", "-", "old", "boy", "who", "developed", "a", "CA", "-", "MRSA", "skin", "and", "soft", "tissue", "infection", "and", "was", "treated", "with", "TMP", "-", "SMX", "."], "event_mentions": [{"id": "20412003_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 25, "end": 26}, "arguments": [{"entity_id": "20412003_6_Ent0", "role": "Subject", "text": "a relatively healthy , 9 - year - old boy", "start": 2, "end": 12}, {"entity_id": "20412003_6_Ent1", "role": "Subject_Age", "text": "9 - year - old", "start": 6, "end": 11}, {"entity_id": "20412003_6_Ent2", "role": "Subject_Gender", "text": "boy", "start": 11, "end": 12}, {"entity_id": "20412003_6_Ent4", "role": "Treatment_Disorder", "text": "CA - MRSA skin and soft tissue infection", "start": 15, "end": 23}, {"entity_id": "20412003_6_Ent3", "role": "Treatment", "text": "TMP - SMX", "start": 27, "end": 30}, {"entity_id": "20412003_6_Ent5", "role": "Treatment_Drug", "text": "TMP - SMX", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "20412003_6_Ent0", "text": "a relatively healthy , 9 - year - old boy", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "20412003_6_Ent1", "text": "9 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "20412003_6_Ent2", "text": "boy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20412003_6_Ent4", "text": "CA - MRSA skin and soft tissue infection", "entity_type": "Entity", "start": 15, "end": 23}, {"id": "20412003_6_Ent3", "text": "TMP - SMX", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "20412003_6_Ent5", "text": "TMP - SMX", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "20465622_4", "wnd_id": "20465622_4_1", "text": "CASE : We present an 11 - year old male with Budd - Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus .", "tokens": ["CASE", ":", "We", "present", "an", "11", "-", "year", "old", "male", "with", "Budd", "-", "Chiari", "syndrome", "who", "experienced", "profound", "worsening", "of", "chronic", "aphthous", "ulcers", "after", "immunosuppressive", "therapy", "was", "changed", "from", "tacrolimus", "to", "sirolimus", "."], "event_mentions": [{"id": "20465622_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 16, "end": 17}, "arguments": [{"entity_id": "20465622_4_Ent0", "role": "Subject", "text": "an 11 - year old male with Budd - Chiari syndrome", "start": 4, "end": 15}, {"entity_id": "20465622_4_Ent1", "role": "Subject_Age", "text": "11 - year old", "start": 5, "end": 9}, {"entity_id": "20465622_4_Ent2", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "20465622_4_Ent3", "role": "Subject_Disorder", "text": "Budd - Chiari syndrome", "start": 11, "end": 15}, {"entity_id": "20465622_4_Ent4", "role": "Effect", "text": "profound worsening of chronic aphthous ulcers", "start": 17, "end": 23}, {"entity_id": "20465622_4_Ent5", "role": "Treatment", "text": "immunosuppressive therapy was changed from tacrolimus to sirolimus", "start": 24, "end": 32}, {"entity_id": "20465622_4_Ent6", "role": "Treatment_Drug", "text": "tacrolimus", "start": 29, "end": 30}, {"entity_id": "20465622_4_Ent7", "role": "Treatment_Drug", "text": "sirolimus", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "20465622_4_Ent0", "text": "an 11 - year old male with Budd - Chiari syndrome", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "20465622_4_Ent1", "text": "11 - year old", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "20465622_4_Ent2", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20465622_4_Ent3", "text": "Budd - Chiari syndrome", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "20465622_4_Ent4", "text": "profound worsening of chronic aphthous ulcers", "entity_type": "Entity", "start": 17, "end": 23}, {"id": "20465622_4_Ent5", "text": "immunosuppressive therapy was changed from tacrolimus to sirolimus", "entity_type": "Entity", "start": 24, "end": 32}, {"id": "20465622_4_Ent6", "text": "tacrolimus", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "20465622_4_Ent7", "text": "sirolimus", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "20666169_9", "wnd_id": "20666169_9_1", "text": "We presume the cause for multiple organ failure could be the result of drug - drug interaction , atorvastatin and verapamil , as verapamil is known to increase the serum concentration of atorvastatin significantly .", "tokens": ["We", "presume", "the", "cause", "for", "multiple", "organ", "failure", "could", "be", "the", "result", "of", "drug", "-", "drug", "interaction", ",", "atorvastatin", "and", "verapamil", ",", "as", "verapamil", "is", "known", "to", "increase", "the", "serum", "concentration", "of", "atorvastatin", "significantly", "."], "event_mentions": [{"id": "20666169_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "20666169_9_Ent0", "role": "Effect", "text": "multiple organ failure", "start": 5, "end": 8}, {"entity_id": "20666169_9_Ent1", "role": "Treatment", "text": "interaction , atorvastatin and verapamil", "start": 16, "end": 21}, {"entity_id": "20666169_9_Ent2", "role": "Treatment_Drug", "text": "atorvastatin", "start": 18, "end": 19}, {"entity_id": "20666169_9_Ent4", "role": "Combination_Drug", "text": "atorvastatin", "start": 18, "end": 19}, {"entity_id": "20666169_9_Ent3", "role": "Treatment_Drug", "text": "verapamil", "start": 20, "end": 21}, {"entity_id": "20666169_9_Ent5", "role": "Combination_Drug", "text": "verapamil", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "20666169_9_Ent0", "text": "multiple organ failure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "20666169_9_Ent1", "text": "interaction , atorvastatin and verapamil", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "20666169_9_Ent2", "text": "atorvastatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20666169_9_Ent4", "text": "atorvastatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20666169_9_Ent3", "text": "verapamil", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "20666169_9_Ent5", "text": "verapamil", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "2076372_2", "wnd_id": "2076372_2_1", "text": "The photosensitivity is still present 3 years after the withdrawal of quinine .", "tokens": ["The", "photosensitivity", "is", "still", "present", "3", "years", "after", "the", "withdrawal", "of", "quinine", "."], "event_mentions": [{"id": "2076372_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "2076372_2_Ent0", "role": "Effect", "text": "photosensitivity is still present 3 years", "start": 1, "end": 7}, {"entity_id": "2076372_2_Ent1", "role": "Treatment", "text": "withdrawal of quinine", "start": 9, "end": 12}, {"entity_id": "2076372_2_Ent2", "role": "Treatment_Drug", "text": "quinine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "2076372_2_Ent0", "text": "photosensitivity is still present 3 years", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "2076372_2_Ent1", "text": "withdrawal of quinine", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2076372_2_Ent2", "text": "quinine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "20925534_13", "wnd_id": "20925534_13_1", "text": "The two groups did not differ significantly in the rate of serious adverse events , though the risk of diarrhea was increased with omeprazole .", "tokens": ["The", "two", "groups", "did", "not", "differ", "significantly", "in", "the", "rate", "of", "serious", "adverse", "events", ",", "though", "the", "risk", "of", "diarrhea", "was", "increased", "with", "omeprazole", "."], "event_mentions": [{"id": "20925534_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 21, "end": 22}, "arguments": [{"entity_id": "20925534_13_Ent0", "role": "Effect", "text": "risk of diarrhea was increased", "start": 17, "end": 22}, {"entity_id": "20925534_13_Ent1", "role": "Treatment", "text": "omeprazole", "start": 23, "end": 24}, {"entity_id": "20925534_13_Ent2", "role": "Treatment_Drug", "text": "omeprazole", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "20925534_13_Ent0", "text": "risk of diarrhea was increased", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "20925534_13_Ent1", "text": "omeprazole", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "20925534_13_Ent2", "text": "omeprazole", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "20925534_15", "wnd_id": "20925534_15_1", "text": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole , but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI .", "tokens": ["There", "was", "no", "apparent", "cardiovascular", "interaction", "between", "clopidogrel", "and", "omeprazole", ",", "but", "our", "results", "do", "not", "rule", "out", "a", "clinically", "meaningful", "difference", "in", "cardiovascular", "events", "due", "to", "use", "of", "a", "PPI", "."], "event_mentions": [{"id": "20925534_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 25, "end": 26}, "arguments": [{"entity_id": "20925534_15_Ent0", "role": "Effect", "text": "cardiovascular", "start": 23, "end": 24}, {"entity_id": "20925534_15_Ent1", "role": "Treatment", "text": "PPI", "start": 30, "end": 31}, {"entity_id": "20925534_15_Ent2", "role": "Treatment_Drug", "text": "PPI", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "20925534_15_Ent0", "text": "cardiovascular", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "20925534_15_Ent1", "text": "PPI", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "20925534_15_Ent2", "text": "PPI", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "20925534_3", "wnd_id": "20925534_3_1", "text": "Proton - pump inhibitors ( PPIs ) are believed to decrease the risk of such complications , though no randomized trial has proved this in patients receiving dual antiplatelet therapy .", "tokens": ["Proton", "-", "pump", "inhibitors", "(", "PPIs", ")", "are", "believed", "to", "decrease", "the", "risk", "of", "such", "complications", ",", "though", "no", "randomized", "trial", "has", "proved", "this", "in", "patients", "receiving", "dual", "antiplatelet", "therapy", "."], "event_mentions": [{"id": "20925534_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "believed", "start": 8, "end": 9}, "arguments": [{"entity_id": "20925534_3_Ent0", "role": "Treatment", "text": "Proton - pump inhibitors ( PPIs )", "start": 0, "end": 7}, {"entity_id": "20925534_3_Ent1", "role": "Treatment_Drug", "text": "Proton - pump inhibitors ( PPIs )", "start": 0, "end": 7}, {"entity_id": "20925534_3_Ent2", "role": "Treatment_Drug", "text": "antiplatelet", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "20925534_3_Ent0", "text": "Proton - pump inhibitors ( PPIs )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "20925534_3_Ent1", "text": "Proton - pump inhibitors ( PPIs )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "20925534_3_Ent2", "text": "antiplatelet", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "21045170_9", "wnd_id": "21045170_9_1", "text": "When these cells are exposed to nicotinic acid , an exaggerated immune response is produced that may lead to pain , redness , and swelling at the injection site .", "tokens": ["When", "these", "cells", "are", "exposed", "to", "nicotinic", "acid", ",", "an", "exaggerated", "immune", "response", "is", "produced", "that", "may", "lead", "to", "pain", ",", "redness", ",", "and", "swelling", "at", "the", "injection", "site", "."], "event_mentions": [{"id": "21045170_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produced", "start": 14, "end": 15}, "arguments": [{"entity_id": "21045170_9_Ent2", "role": "Treatment", "text": "nicotinic acid", "start": 6, "end": 8}, {"entity_id": "21045170_9_Ent3", "role": "Treatment_Drug", "text": "nicotinic acid", "start": 6, "end": 8}, {"entity_id": "21045170_9_Ent0", "role": "Effect", "text": "exaggerated immune response", "start": 10, "end": 13}, {"entity_id": "21045170_9_Ent1", "role": "Effect", "text": "pain , redness , and swelling at the injection site", "start": 19, "end": 29}]}], "entity_mentions": [{"id": "21045170_9_Ent2", "text": "nicotinic acid", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "21045170_9_Ent3", "text": "nicotinic acid", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "21045170_9_Ent0", "text": "exaggerated immune response", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "21045170_9_Ent1", "text": "pain , redness , and swelling at the injection site", "entity_type": "Entity", "start": 19, "end": 29}], "lang": "en"}
{"doc_id": "2113320_1", "wnd_id": "2113320_1_1", "text": "A patient with Wegener 's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates .", "tokens": ["A", "patient", "with", "Wegener", "'s", "granulomatosis", "rapidly", "developed", "a", "circumferential", "subglottic", "stenosis", "while", "on", "a", "cyclophosphamide", "regimen", "that", "had", "caused", "resolution", "of", "systemic", "symptoms", "and", "pulmonary", "infiltrates", "."], "event_mentions": [{"id": "2113320_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "2113320_1_Ent0", "role": "Subject", "text": "A patient with Wegener 's granulomatosis", "start": 0, "end": 6}, {"entity_id": "2113320_1_Ent5", "role": "Treatment_Disorder", "text": "Wegener 's granulomatosis", "start": 3, "end": 6}, {"entity_id": "2113320_1_Ent1", "role": "Effect", "text": "circumferential subglottic stenosis", "start": 9, "end": 12}, {"entity_id": "2113320_1_Ent4", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 15, "end": 16}, {"entity_id": "2113320_1_Ent3", "role": "Treatment", "text": "cyclophosphamide regimen", "start": 15, "end": 17}, {"entity_id": "2113320_1_Ent2", "role": "Effect", "text": "resolution of systemic symptoms and pulmonary infiltrates", "start": 20, "end": 27}]}], "entity_mentions": [{"id": "2113320_1_Ent0", "text": "A patient with Wegener 's granulomatosis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "2113320_1_Ent5", "text": "Wegener 's granulomatosis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "2113320_1_Ent1", "text": "circumferential subglottic stenosis", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2113320_1_Ent4", "text": "cyclophosphamide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2113320_1_Ent3", "text": "cyclophosphamide regimen", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "2113320_1_Ent2", "text": "resolution of systemic symptoms and pulmonary infiltrates", "entity_type": "Entity", "start": 20, "end": 27}], "lang": "en"}
{"doc_id": "21330680_13", "wnd_id": "21330680_13_1", "text": "A 73 - year - old woman receiving high - dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation .", "tokens": ["A", "73", "-", "year", "-", "old", "woman", "receiving", "high", "-", "dosage", "olanzapine", "for", "bipolar", "disorder", "developed", "parkinsonism", "after", "smoking", "cessation", "."], "event_mentions": [{"id": "21330680_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 17, "end": 18}, "arguments": [{"entity_id": "21330680_13_Ent0", "role": "Subject", "text": "A 73 - year - old woman", "start": 0, "end": 7}, {"entity_id": "21330680_13_Ent1", "role": "Subject_Age", "text": "73 - year - old", "start": 1, "end": 6}, {"entity_id": "21330680_13_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "21330680_13_Ent9", "role": "Treatment_Dosage", "text": "high - dosage", "start": 8, "end": 11}, {"entity_id": "21330680_13_Ent4", "role": "Treatment", "text": "high - dosage olanzapine", "start": 8, "end": 12}, {"entity_id": "21330680_13_Ent7", "role": "Treatment_Drug", "text": "olanzapine", "start": 11, "end": 12}, {"entity_id": "21330680_13_Ent6", "role": "Treatment_Disorder", "text": "bipolar disorder", "start": 13, "end": 15}, {"entity_id": "21330680_13_Ent3", "role": "Effect", "text": "parkinsonism", "start": 16, "end": 17}, {"entity_id": "21330680_13_Ent8", "role": "Treatment_Drug", "text": "smoking", "start": 18, "end": 19}, {"entity_id": "21330680_13_Ent5", "role": "Treatment", "text": "smoking cessation", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "21330680_13_Ent0", "text": "A 73 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "21330680_13_Ent1", "text": "73 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "21330680_13_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21330680_13_Ent9", "text": "high - dosage", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "21330680_13_Ent4", "text": "high - dosage olanzapine", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "21330680_13_Ent7", "text": "olanzapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "21330680_13_Ent6", "text": "bipolar disorder", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "21330680_13_Ent3", "text": "parkinsonism", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "21330680_13_Ent8", "text": "smoking", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "21330680_13_Ent5", "text": "smoking cessation", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "21350204_10", "wnd_id": "21350204_10_1", "text": "Preadmission warfarin use was not associated with any secondary intracerebral hemorrhage ( OR , 1.2 ; 95 % CI , 0.7 to 2.2 ) , symptomatic intracerebral hemorrhage ( OR , 1.1 ; 95 % CI , 0.5 to 2.3 ) , or gastrointestinal hemorrhage ( OR , 1.1 ; 95 % CI , 0.2 to 5.6 ) .", "tokens": ["Preadmission", "warfarin", "use", "was", "not", "associated", "with", "any", "secondary", "intracerebral", "hemorrhage", "(", "OR", ",", "1.2", ";", "95", "%", "CI", ",", "0.7", "to", "2.2", ")", ",", "symptomatic", "intracerebral", "hemorrhage", "(", "OR", ",", "1.1", ";", "95", "%", "CI", ",", "0.5", "to", "2.3", ")", ",", "or", "gastrointestinal", "hemorrhage", "(", "OR", ",", "1.1", ";", "95", "%", "CI", ",", "0.2", "to", "5.6", ")", "."], "event_mentions": [{"id": "21350204_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "21350204_10_Ent1", "role": "Treatment", "text": "Preadmission warfarin", "start": 0, "end": 2}, {"entity_id": "21350204_10_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 1, "end": 2}, {"entity_id": "21350204_10_Ent0", "role": "Effect", "text": "any secondary intracerebral hemorrhage ( OR , 1.2 ; 95 % CI , 0.7 to 2.2 ) , symptomatic intracerebral hemorrhage ( OR , 1.1 ; 95 % CI , 0.5 to 2.3 ) , or gastrointestinal hemorrhage ( OR , 1.1 ; 95 % CI , 0.2 to 5.6 )", "start": 7, "end": 58}]}], "entity_mentions": [{"id": "21350204_10_Ent1", "text": "Preadmission warfarin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21350204_10_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "21350204_10_Ent0", "text": "any secondary intracerebral hemorrhage ( OR , 1.2 ; 95 % CI , 0.7 to 2.2 ) , symptomatic intracerebral hemorrhage ( OR , 1.1 ; 95 % CI , 0.5 to 2.3 ) , or gastrointestinal hemorrhage ( OR , 1.1 ; 95 % CI , 0.2 to 5.6 )", "entity_type": "Entity", "start": 7, "end": 58}], "lang": "en"}
{"doc_id": "21515865_1", "wnd_id": "21515865_1_1", "text": "Moxifloxacin - acetaminophen - warfarin interaction during bacille Calmette - Guerin treatment for bladder cancer .", "tokens": ["Moxifloxacin", "-", "acetaminophen", "-", "warfarin", "interaction", "during", "bacille", "Calmette", "-", "Guerin", "treatment", "for", "bladder", "cancer", "."], "event_mentions": [{"id": "21515865_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 6, "end": 7}, "arguments": [{"entity_id": "21515865_1_Ent2", "role": "Treatment_Drug", "text": "Moxifloxacin", "start": 0, "end": 1}, {"entity_id": "21515865_1_Ent9", "role": "Combination_Drug", "text": "Moxifloxacin", "start": 0, "end": 1}, {"entity_id": "21515865_1_Ent0", "role": "Treatment", "text": "Moxifloxacin - acetaminophen - warfarin interaction", "start": 0, "end": 6}, {"entity_id": "21515865_1_Ent3", "role": "Treatment_Drug", "text": "acetaminophen", "start": 2, "end": 3}, {"entity_id": "21515865_1_Ent8", "role": "Combination_Drug", "text": "acetaminophen", "start": 2, "end": 3}, {"entity_id": "21515865_1_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 4, "end": 5}, {"entity_id": "21515865_1_Ent7", "role": "Combination_Drug", "text": "warfarin", "start": 4, "end": 5}, {"entity_id": "21515865_1_Ent5", "role": "Treatment_Drug", "text": "bacille Calmette - Guerin", "start": 7, "end": 11}, {"entity_id": "21515865_1_Ent10", "role": "Combination_Drug", "text": "bacille Calmette - Guerin", "start": 7, "end": 11}, {"entity_id": "21515865_1_Ent1", "role": "Treatment", "text": "bacille Calmette - Guerin treatment", "start": 7, "end": 12}, {"entity_id": "21515865_1_Ent6", "role": "Treatment_Disorder", "text": "bladder cancer", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "21515865_1_Ent2", "text": "Moxifloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21515865_1_Ent9", "text": "Moxifloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21515865_1_Ent0", "text": "Moxifloxacin - acetaminophen - warfarin interaction", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "21515865_1_Ent3", "text": "acetaminophen", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "21515865_1_Ent8", "text": "acetaminophen", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "21515865_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21515865_1_Ent7", "text": "warfarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21515865_1_Ent5", "text": "bacille Calmette - Guerin", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "21515865_1_Ent10", "text": "bacille Calmette - Guerin", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "21515865_1_Ent1", "text": "bacille Calmette - Guerin treatment", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "21515865_1_Ent6", "text": "bladder cancer", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "21515865_11", "wnd_id": "21515865_11_1", "text": "According to the Drug Interaction Probability Scale , the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use .", "tokens": ["According", "to", "the", "Drug", "Interaction", "Probability", "Scale", ",", "the", "development", "of", "supratherapeutic", "INRs", "was", "probably", "associated", "with", "concomitant", "acetaminophen", "and", "moxifloxacin", "use", "."], "event_mentions": [{"id": "21515865_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "21515865_11_Ent0", "role": "Effect", "text": "development of supratherapeutic INRs", "start": 9, "end": 13}, {"entity_id": "21515865_11_Ent1", "role": "Treatment", "text": "concomitant acetaminophen and moxifloxacin use", "start": 17, "end": 22}, {"entity_id": "21515865_11_Ent3", "role": "Treatment_Drug", "text": "acetaminophen", "start": 18, "end": 19}, {"entity_id": "21515865_11_Ent4", "role": "Combination_Drug", "text": "acetaminophen", "start": 18, "end": 19}, {"entity_id": "21515865_11_Ent2", "role": "Treatment_Drug", "text": "moxifloxacin", "start": 20, "end": 21}, {"entity_id": "21515865_11_Ent5", "role": "Combination_Drug", "text": "moxifloxacin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "21515865_11_Ent0", "text": "development of supratherapeutic INRs", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "21515865_11_Ent1", "text": "concomitant acetaminophen and moxifloxacin use", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "21515865_11_Ent3", "text": "acetaminophen", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "21515865_11_Ent4", "text": "acetaminophen", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "21515865_11_Ent2", "text": "moxifloxacin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21515865_11_Ent5", "text": "moxifloxacin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "21515865_3", "wnd_id": "21515865_3_1", "text": "An 89 - year - old man receiving long - term anticoagulation with warfarin sodium ( total weekly dosage of 19 mg ) arrived at the anticoagulation clinic for his monthly visit .", "tokens": ["An", "89", "-", "year", "-", "old", "man", "receiving", "long", "-", "term", "anticoagulation", "with", "warfarin", "sodium", "(", "total", "weekly", "dosage", "of", "19", "mg", ")", "arrived", "at", "the", "anticoagulation", "clinic", "for", "his", "monthly", "visit", "."], "event_mentions": [{"id": "21515865_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 7, "end": 8}, "arguments": [{"entity_id": "21515865_3_Ent0", "role": "Subject", "text": "An 89 - year - old man", "start": 0, "end": 7}, {"entity_id": "21515865_3_Ent1", "role": "Subject_Age", "text": "89 - year - old", "start": 1, "end": 6}, {"entity_id": "21515865_3_Ent6", "role": "Treatment_Duration", "text": "long - term", "start": 8, "end": 11}, {"entity_id": "21515865_3_Ent2", "role": "Treatment", "text": "long - term anticoagulation with warfarin sodium ( total weekly dosage of 19 mg )", "start": 8, "end": 23}, {"entity_id": "21515865_3_Ent3", "role": "Treatment_Drug", "text": "warfarin sodium", "start": 13, "end": 15}, {"entity_id": "21515865_3_Ent4", "role": "Treatment_Freq", "text": "weekly", "start": 17, "end": 18}, {"entity_id": "21515865_3_Ent5", "role": "Treatment_Dosage", "text": "19 mg", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "21515865_3_Ent0", "text": "An 89 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "21515865_3_Ent1", "text": "89 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "21515865_3_Ent6", "text": "long - term", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "21515865_3_Ent2", "text": "long - term anticoagulation with warfarin sodium ( total weekly dosage of 19 mg )", "entity_type": "Entity", "start": 8, "end": 23}, {"id": "21515865_3_Ent3", "text": "warfarin sodium", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "21515865_3_Ent4", "text": "weekly", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "21515865_3_Ent5", "text": "19 mg", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "2154663_2", "wnd_id": "2154663_2_1", "text": "Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient .", "tokens": ["Concomitant", "irradiation", "apparently", "enhanced", "the", "skin", "toxicity", "of", "aminoglutethimide", "or", "possibly", "aminoglutethimide", "had", "a", "radiosensitizing", "role", "in", "this", "patient", "."], "event_mentions": [{"id": "2154663_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "enhanced", "start": 3, "end": 4}, "arguments": [{"entity_id": "2154663_2_Ent2", "role": "Treatment", "text": "Concomitant irradiation", "start": 0, "end": 2}, {"entity_id": "2154663_2_Ent5", "role": "Treatment_Drug", "text": "irradiation", "start": 1, "end": 2}, {"entity_id": "2154663_2_Ent6", "role": "Combination_Drug", "text": "irradiation", "start": 1, "end": 2}, {"entity_id": "2154663_2_Ent1", "role": "Effect", "text": "skin toxicity", "start": 5, "end": 7}, {"entity_id": "2154663_2_Ent3", "role": "Treatment", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "2154663_2_Ent4", "role": "Treatment_Drug", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "2154663_2_Ent7", "role": "Combination_Drug", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "2154663_2_Ent0", "role": "Subject", "text": "this patient", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "2154663_2_Ent2", "text": "Concomitant irradiation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2154663_2_Ent5", "text": "irradiation", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2154663_2_Ent6", "text": "irradiation", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2154663_2_Ent1", "text": "skin toxicity", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2154663_2_Ent3", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2154663_2_Ent4", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2154663_2_Ent7", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2154663_2_Ent0", "text": "this patient", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "21658326_2", "wnd_id": "21658326_2_1", "text": "Topical imiquimod and tumor necrosis factor ( TNF) - alpha inhibitors have gained wide acceptance as safe and effective treatments for non - melanoma skin cancer ( NMSC ) and moderate to severe psoriasis , respectively .", "tokens": ["Topical", "imiquimod", "and", "tumor", "necrosis", "factor", "(", "TNF)", "-", "alpha", "inhibitors", "have", "gained", "wide", "acceptance", "as", "safe", "and", "effective", "treatments", "for", "non", "-", "melanoma", "skin", "cancer", "(", "NMSC", ")", "and", "moderate", "to", "severe", "psoriasis", ",", "respectively", "."], "event_mentions": [{"id": "21658326_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatments", "start": 19, "end": 20}, "arguments": [{"entity_id": "21658326_2_Ent2", "role": "Treatment_Route", "text": "Topical", "start": 0, "end": 1}, {"entity_id": "21658326_2_Ent0", "role": "Treatment", "text": "Topical imiquimod", "start": 0, "end": 2}, {"entity_id": "21658326_2_Ent3", "role": "Treatment_Drug", "text": "imiquimod", "start": 1, "end": 2}, {"entity_id": "21658326_2_Ent1", "role": "Treatment_Disorder", "text": "non - melanoma skin cancer ( NMSC )", "start": 21, "end": 29}]}, {"id": "21658326_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatments", "start": 19, "end": 20}, "arguments": [{"entity_id": "21658326_2_Ent4", "role": "Treatment", "text": "tumor necrosis factor ( TNF) - alpha", "start": 3, "end": 10}, {"entity_id": "21658326_2_Ent6", "role": "Treatment_Drug", "text": "tumor necrosis factor ( TNF) - alpha", "start": 3, "end": 10}, {"entity_id": "21658326_2_Ent5", "role": "Treatment_Disorder", "text": "moderate to severe psoriasis", "start": 30, "end": 34}]}], "entity_mentions": [{"id": "21658326_2_Ent2", "text": "Topical", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21658326_2_Ent0", "text": "Topical imiquimod", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21658326_2_Ent3", "text": "imiquimod", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "21658326_2_Ent4", "text": "tumor necrosis factor ( TNF) - alpha", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "21658326_2_Ent6", "text": "tumor necrosis factor ( TNF) - alpha", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "21658326_2_Ent1", "text": "non - melanoma skin cancer ( NMSC )", "entity_type": "Entity", "start": 21, "end": 29}, {"id": "21658326_2_Ent5", "text": "moderate to severe psoriasis", "entity_type": "Entity", "start": 30, "end": 34}], "lang": "en"}
{"doc_id": "21658326_3", "wnd_id": "21658326_3_1", "text": "While mild to moderate application site reactions ( ASRs ) are a well - known and common phenomenon associated with imiquimod , the potential of TNF - alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized .", "tokens": ["While", "mild", "to", "moderate", "application", "site", "reactions", "(", "ASRs", ")", "are", "a", "well", "-", "known", "and", "common", "phenomenon", "associated", "with", "imiquimod", ",", "the", "potential", "of", "TNF", "-", "alpha", "blockers", "to", "elicit", "cutaneous", "inflammatory", "reactions", "has", "only", "recently", "been", "recognized", "."], "event_mentions": [{"id": "21658326_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 18, "end": 19}, "arguments": [{"entity_id": "21658326_3_Ent3", "role": "Effect", "text": "application site reactions ( ASRs )", "start": 4, "end": 10}, {"entity_id": "21658326_3_Ent4", "role": "Treatment", "text": "imiquimod", "start": 20, "end": 21}, {"entity_id": "21658326_3_Ent5", "role": "Treatment_Drug", "text": "imiquimod", "start": 20, "end": 21}]}, {"id": "21658326_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "elicit", "start": 30, "end": 31}, "arguments": [{"entity_id": "21658326_3_Ent1", "role": "Treatment", "text": "TNF - alpha blockers", "start": 25, "end": 29}, {"entity_id": "21658326_3_Ent2", "role": "Treatment_Drug", "text": "TNF - alpha blockers", "start": 25, "end": 29}, {"entity_id": "21658326_3_Ent0", "role": "Effect", "text": "cutaneous inflammatory reactions", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "21658326_3_Ent3", "text": "application site reactions ( ASRs )", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "21658326_3_Ent4", "text": "imiquimod", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21658326_3_Ent5", "text": "imiquimod", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21658326_3_Ent1", "text": "TNF - alpha blockers", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "21658326_3_Ent2", "text": "TNF - alpha blockers", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "21658326_3_Ent0", "text": "cutaneous inflammatory reactions", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "21658326_4", "wnd_id": "21658326_4_1", "text": "We present two cases of severe , atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis , and consider the grounds supporting a non - fortuitous association .", "tokens": ["We", "present", "two", "cases", "of", "severe", ",", "atypical", "ASRs", "which", "occurred", "during", "NMSC", "treatment", "with", "imiquimod", "in", "the", "context", "of", "infliximab", "administration", "for", "psoriasis", ",", "and", "consider", "the", "grounds", "supporting", "a", "non", "-", "fortuitous", "association", "."], "event_mentions": [{"id": "21658326_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 10, "end": 11}, "arguments": [{"entity_id": "21658326_4_Ent0", "role": "Effect", "text": "atypical ASRs", "start": 7, "end": 9}, {"entity_id": "21658326_4_Ent2", "role": "Treatment_Disorder", "text": "NMSC", "start": 12, "end": 13}, {"entity_id": "21658326_4_Ent4", "role": "Treatment_Drug", "text": "NMSC", "start": 12, "end": 13}, {"entity_id": "21658326_4_Ent5", "role": "Treatment_Drug", "text": "imiquimod", "start": 15, "end": 16}, {"entity_id": "21658326_4_Ent7", "role": "Combination_Drug", "text": "imiquimod", "start": 15, "end": 16}, {"entity_id": "21658326_4_Ent1", "role": "Treatment", "text": "imiquimod in the context of infliximab administration", "start": 15, "end": 22}, {"entity_id": "21658326_4_Ent6", "role": "Treatment_Drug", "text": "infliximab", "start": 20, "end": 21}, {"entity_id": "21658326_4_Ent8", "role": "Combination_Drug", "text": "infliximab", "start": 20, "end": 21}, {"entity_id": "21658326_4_Ent3", "role": "Treatment_Disorder", "text": "psoriasis", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "21658326_4_Ent0", "text": "atypical ASRs", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "21658326_4_Ent2", "text": "NMSC", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21658326_4_Ent4", "text": "NMSC", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21658326_4_Ent5", "text": "imiquimod", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21658326_4_Ent7", "text": "imiquimod", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21658326_4_Ent1", "text": "imiquimod in the context of infliximab administration", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "21658326_4_Ent6", "text": "infliximab", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21658326_4_Ent8", "text": "infliximab", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21658326_4_Ent3", "text": "psoriasis", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "21712512_5", "wnd_id": "21712512_5_1", "text": "Seven weeks after the initiation of inhaled fluticasone , she developed vaginal candidiasis and was prescribed fluconazole 100 mg / day , a CYP3A4 inhibitor .", "tokens": ["Seven", "weeks", "after", "the", "initiation", "of", "inhaled", "fluticasone", ",", "she", "developed", "vaginal", "candidiasis", "and", "was", "prescribed", "fluconazole", "100", "mg", "/", "day", ",", "a", "CYP3A4", "inhibitor", "."], "event_mentions": [{"id": "21712512_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "21712512_5_Ent4", "role": "Treatment_Time_elapsed", "text": "Seven weeks", "start": 0, "end": 2}, {"entity_id": "21712512_5_Ent1", "role": "Treatment", "text": "Seven weeks after the initiation of inhaled fluticasone", "start": 0, "end": 8}, {"entity_id": "21712512_5_Ent2", "role": "Treatment_Route", "text": "inhaled", "start": 6, "end": 7}, {"entity_id": "21712512_5_Ent3", "role": "Treatment_Drug", "text": "fluticasone", "start": 7, "end": 8}, {"entity_id": "21712512_5_Ent0", "role": "Effect", "text": "vaginal candidiasis", "start": 11, "end": 13}]}, {"id": "21712512_5_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 15, "end": 16}, "arguments": [{"entity_id": "21712512_5_Ent6", "role": "Treatment_Disorder", "text": "vaginal candidiasis", "start": 11, "end": 13}, {"entity_id": "21712512_5_Ent7", "role": "Treatment_Drug", "text": "fluconazole", "start": 16, "end": 17}, {"entity_id": "21712512_5_Ent5", "role": "Treatment", "text": "fluconazole 100 mg / day , a CYP3A4 inhibitor", "start": 16, "end": 25}, {"entity_id": "21712512_5_Ent8", "role": "Treatment_Dosage", "text": "100 mg / day", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "21712512_5_Ent4", "text": "Seven weeks", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21712512_5_Ent1", "text": "Seven weeks after the initiation of inhaled fluticasone", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "21712512_5_Ent2", "text": "inhaled", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21712512_5_Ent3", "text": "fluticasone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21712512_5_Ent0", "text": "vaginal candidiasis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "21712512_5_Ent6", "text": "vaginal candidiasis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "21712512_5_Ent7", "text": "fluconazole", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "21712512_5_Ent5", "text": "fluconazole 100 mg / day , a CYP3A4 inhibitor", "entity_type": "Entity", "start": 16, "end": 25}, {"id": "21712512_5_Ent8", "text": "100 mg / day", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "21729965_1", "wnd_id": "21729965_1_1", "text": "Implanon    failure in an HIV - positive woman on antiretroviral therapy resulting in two ectopic pregnancies .", "tokens": ["Implanon", "  ", "failure", "in", "an", "HIV", "-", "positive", "woman", "on", "antiretroviral", "therapy", "resulting", "in", "two", "ectopic", "pregnancies", "."], "event_mentions": [{"id": "21729965_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 12, "end": 13}, "arguments": [{"entity_id": "21729965_1_Ent3", "role": "Treatment", "text": "Implanon    failure", "start": 0, "end": 3}, {"entity_id": "21729965_1_Ent0", "role": "Subject", "text": "an HIV - positive woman", "start": 4, "end": 9}, {"entity_id": "21729965_1_Ent5", "role": "Treatment_Disorder", "text": "HIV - positive", "start": 5, "end": 8}, {"entity_id": "21729965_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "21729965_1_Ent4", "role": "Treatment", "text": "on antiretroviral therapy", "start": 9, "end": 12}, {"entity_id": "21729965_1_Ent2", "role": "Effect", "text": "two ectopic pregnancies", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "21729965_1_Ent3", "text": "Implanon    failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "21729965_1_Ent0", "text": "an HIV - positive woman", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "21729965_1_Ent5", "text": "HIV - positive", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "21729965_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21729965_1_Ent4", "text": "on antiretroviral therapy", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "21729965_1_Ent2", "text": "two ectopic pregnancies", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "21729965_4", "wnd_id": "21729965_4_1", "text": "We present an interesting case of an HIV - positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place .", "tokens": ["We", "present", "an", "interesting", "case", "of", "an", "HIV", "-", "positive", "woman", "on", "antiretroviral", "therapy", "having", "tubal", "pregnancies", "on", "two", "separate", "occasions", "with", "Implanon", "in", "place", "."], "event_mentions": [{"id": "21729965_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "having", "start": 14, "end": 15}, "arguments": [{"entity_id": "21729965_4_Ent0", "role": "Subject", "text": "an HIV - positive woman", "start": 6, "end": 11}, {"entity_id": "21729965_4_Ent4", "role": "Treatment_Disorder", "text": "HIV - positive", "start": 7, "end": 10}, {"entity_id": "21729965_4_Ent1", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "21729965_4_Ent3", "role": "Treatment", "text": "antiretroviral", "start": 12, "end": 13}, {"entity_id": "21729965_4_Ent5", "role": "Treatment_Drug", "text": "antiretroviral", "start": 12, "end": 13}, {"entity_id": "21729965_4_Ent2", "role": "Effect", "text": "tubal pregnancies", "start": 15, "end": 17}, {"entity_id": "21729965_4_Ent6", "role": "Treatment_Drug", "text": "Implanon", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "21729965_4_Ent0", "text": "an HIV - positive woman", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "21729965_4_Ent4", "text": "HIV - positive", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "21729965_4_Ent1", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "21729965_4_Ent3", "text": "antiretroviral", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21729965_4_Ent5", "text": "antiretroviral", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21729965_4_Ent2", "text": "tubal pregnancies", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "21729965_4_Ent6", "text": "Implanon", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "21751666_1", "wnd_id": "21751666_1_1", "text": "Post - exposure prophylaxis for H1N1 with oseltamivir in renal allograft recipient -- safe and effective without any immunosuppresive drug interaction .", "tokens": ["Post", "-", "exposure", "prophylaxis", "for", "H1N1", "with", "oseltamivir", "in", "renal", "allograft", "recipient", "--", "safe", "and", "effective", "without", "any", "immunosuppresive", "drug", "interaction", "."], "event_mentions": [{"id": "21751666_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Post - exposure prophylaxis", "start": 0, "end": 4}, "arguments": [{"entity_id": "21751666_1_Ent4", "role": "Treatment_Disorder", "text": "H1N1", "start": 5, "end": 6}, {"entity_id": "21751666_1_Ent3", "role": "Treatment", "text": "oseltamivir", "start": 7, "end": 8}, {"entity_id": "21751666_1_Ent5", "role": "Treatment_Drug", "text": "oseltamivir", "start": 7, "end": 8}, {"entity_id": "21751666_1_Ent1", "role": "Subject_Disorder", "text": "renal allograft", "start": 9, "end": 11}, {"entity_id": "21751666_1_Ent0", "role": "Subject", "text": "renal allograft recipient", "start": 9, "end": 12}, {"entity_id": "21751666_1_Ent2", "role": "Effect", "text": "safe and effective without any immunosuppresive drug interaction", "start": 13, "end": 21}]}], "entity_mentions": [{"id": "21751666_1_Ent4", "text": "H1N1", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21751666_1_Ent3", "text": "oseltamivir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21751666_1_Ent5", "text": "oseltamivir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21751666_1_Ent1", "text": "renal allograft", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "21751666_1_Ent0", "text": "renal allograft recipient", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "21751666_1_Ent2", "text": "safe and effective without any immunosuppresive drug interaction", "entity_type": "Entity", "start": 13, "end": 21}], "lang": "en"}
{"doc_id": "21751692_4", "wnd_id": "21751692_4_1", "text": "EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low - dose ketamine was added to propofol .", "tokens": ["EA", "signs", "were", "observed", "in", "all", "7", "patients", "in", "association", "with", "propofol", "TIVA", "but", "did", "not", "recur", "in", "any", "of", "123", "subsequent", "anesthetics", "sessions", "during", "which", "low", "-", "dose", "ketamine", "was", "added", "to", "propofol", "."], "event_mentions": [{"id": "21751692_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 3, "end": 4}, "arguments": [{"entity_id": "21751692_4_Ent2", "role": "Effect", "text": "EA signs", "start": 0, "end": 2}, {"entity_id": "21751692_4_Ent0", "role": "Subject", "text": "all 7 patients", "start": 5, "end": 8}, {"entity_id": "21751692_4_Ent1", "role": "Subject_Population", "text": "7", "start": 6, "end": 7}, {"entity_id": "21751692_4_Ent5", "role": "Treatment_Drug", "text": "propofol", "start": 11, "end": 12}, {"entity_id": "21751692_4_Ent3", "role": "Treatment", "text": "propofol TIVA", "start": 11, "end": 13}, {"entity_id": "21751692_4_Ent8", "role": "Treatment_Route", "text": "TIVA", "start": 12, "end": 13}, {"entity_id": "21751692_4_Ent9", "role": "Treatment_Dosage", "text": "low - dose", "start": 26, "end": 29}, {"entity_id": "21751692_4_Ent4", "role": "Treatment", "text": "low - dose ketamine was added to propofol", "start": 26, "end": 34}, {"entity_id": "21751692_4_Ent6", "role": "Treatment_Drug", "text": "ketamine", "start": 29, "end": 30}, {"entity_id": "21751692_4_Ent11", "role": "Combination_Drug", "text": "ketamine", "start": 29, "end": 30}, {"entity_id": "21751692_4_Ent7", "role": "Treatment_Drug", "text": "propofol", "start": 33, "end": 34}, {"entity_id": "21751692_4_Ent10", "role": "Combination_Drug", "text": "propofol", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "21751692_4_Ent2", "text": "EA signs", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21751692_4_Ent0", "text": "all 7 patients", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "21751692_4_Ent1", "text": "7", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21751692_4_Ent5", "text": "propofol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "21751692_4_Ent3", "text": "propofol TIVA", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "21751692_4_Ent8", "text": "TIVA", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21751692_4_Ent9", "text": "low - dose", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "21751692_4_Ent4", "text": "low - dose ketamine was added to propofol", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "21751692_4_Ent6", "text": "ketamine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "21751692_4_Ent11", "text": "ketamine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "21751692_4_Ent7", "text": "propofol", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "21751692_4_Ent10", "text": "propofol", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "21789791_2", "wnd_id": "21789791_2_1", "text": "The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL - induced apoptosis in several human cancers .", "tokens": ["The", "proteasome", "inhibitor", "Bortezomib", "has", "been", "identified", "as", "a", "potent", "enhancer", "of", "TRAIL", "-", "induced", "apoptosis", "in", "several", "human", "cancers", "."], "event_mentions": [{"id": "21789791_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "21789791_2_Ent1", "role": "Treatment", "text": "proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL", "start": 1, "end": 13}, {"entity_id": "21789791_2_Ent2", "role": "Treatment_Drug", "text": "Bortezomib", "start": 3, "end": 4}, {"entity_id": "21789791_2_Ent0", "role": "Effect", "text": "apoptosis in several human cancers", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "21789791_2_Ent1", "text": "proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL", "entity_type": "Entity", "start": 1, "end": 13}, {"id": "21789791_2_Ent2", "text": "Bortezomib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21789791_2_Ent0", "text": "apoptosis in several human cancers", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "21881031_11", "wnd_id": "21881031_11_1", "text": "Cisplatin was the common drug in the cases presented and therefore could be related to the INR elevations .", "tokens": ["Cisplatin", "was", "the", "common", "drug", "in", "the", "cases", "presented", "and", "therefore", "could", "be", "related", "to", "the", "INR", "elevations", "."], "event_mentions": [{"id": "21881031_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 13, "end": 14}, "arguments": [{"entity_id": "21881031_11_Ent2", "role": "Treatment", "text": "Cisplatin", "start": 0, "end": 1}, {"entity_id": "21881031_11_Ent3", "role": "Treatment_Drug", "text": "Cisplatin", "start": 0, "end": 1}, {"entity_id": "21881031_11_Ent0", "role": "Subject", "text": "the cases", "start": 6, "end": 8}, {"entity_id": "21881031_11_Ent1", "role": "Effect", "text": "INR elevations", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "21881031_11_Ent2", "text": "Cisplatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21881031_11_Ent3", "text": "Cisplatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21881031_11_Ent0", "text": "the cases", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "21881031_11_Ent1", "text": "INR elevations", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "21881031_5", "wnd_id": "21881031_5_1", "text": "Granisetron hydrochloride ( 3 mg on days 1 , 8 , and 15 ) and dexamethasone ( 13.2 mg on day 1 and 6.6 mg on days 2 , 3 , 8 , and 15 ) were used prior to irinotecan administration in both patients .", "tokens": ["Granisetron", "hydrochloride", "(", "3", "mg", "on", "days", "1", ",", "8", ",", "and", "15", ")", "and", "dexamethasone", "(", "13.2", "mg", "on", "day", "1", "and", "6.6", "mg", "on", "days", "2", ",", "3", ",", "8", ",", "and", "15", ")", "were", "used", "prior", "to", "irinotecan", "administration", "in", "both", "patients", "."], "event_mentions": [{"id": "21881031_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 37, "end": 38}, "arguments": [{"entity_id": "21881031_5_Ent3", "role": "Treatment_Drug", "text": "Granisetron hydrochloride", "start": 0, "end": 2}, {"entity_id": "21881031_5_Ent12", "role": "Combination_Drug", "text": "Granisetron hydrochloride", "start": 0, "end": 2}, {"entity_id": "21881031_5_Ent1", "role": "Treatment", "text": "Granisetron hydrochloride ( 3 mg on days 1 , 8 , and 15 ) and dexamethasone ( 13.2 mg on day 1 and 6.6 mg on days 2 , 3 , 8 , and 15 )", "start": 0, "end": 36}, {"entity_id": "21881031_5_Ent5", "role": "Treatment_Dosage", "text": "3 mg", "start": 3, "end": 5}, {"entity_id": "21881031_5_Ent9", "role": "Treatment_Freq", "text": "on days 1 , 8 , and 15", "start": 5, "end": 13}, {"entity_id": "21881031_5_Ent4", "role": "Treatment_Drug", "text": "dexamethasone", "start": 15, "end": 16}, {"entity_id": "21881031_5_Ent11", "role": "Combination_Drug", "text": "dexamethasone", "start": 15, "end": 16}, {"entity_id": "21881031_5_Ent6", "role": "Treatment_Dosage", "text": "13.2 mg", "start": 17, "end": 19}, {"entity_id": "21881031_5_Ent8", "role": "Treatment_Freq", "text": "on day 1", "start": 19, "end": 22}, {"entity_id": "21881031_5_Ent7", "role": "Treatment_Dosage", "text": "6.6 mg", "start": 23, "end": 25}, {"entity_id": "21881031_5_Ent10", "role": "Treatment_Freq", "text": "on days 2 , 3 , 8 , and 15", "start": 25, "end": 35}, {"entity_id": "21881031_5_Ent2", "role": "Treatment", "text": "irinotecan", "start": 40, "end": 41}, {"entity_id": "21881031_5_Ent0", "role": "Subject", "text": "both patients", "start": 43, "end": 45}]}], "entity_mentions": [{"id": "21881031_5_Ent3", "text": "Granisetron hydrochloride", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21881031_5_Ent12", "text": "Granisetron hydrochloride", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21881031_5_Ent1", "text": "Granisetron hydrochloride ( 3 mg on days 1 , 8 , and 15 ) and dexamethasone ( 13.2 mg on day 1 and 6.6 mg on days 2 , 3 , 8 , and 15 )", "entity_type": "Entity", "start": 0, "end": 36}, {"id": "21881031_5_Ent5", "text": "3 mg", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "21881031_5_Ent9", "text": "on days 1 , 8 , and 15", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "21881031_5_Ent4", "text": "dexamethasone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21881031_5_Ent11", "text": "dexamethasone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21881031_5_Ent6", "text": "13.2 mg", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "21881031_5_Ent8", "text": "on day 1", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "21881031_5_Ent7", "text": "6.6 mg", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "21881031_5_Ent10", "text": "on days 2 , 3 , 8 , and 15", "entity_type": "Entity", "start": 25, "end": 35}, {"id": "21881031_5_Ent2", "text": "irinotecan", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "21881031_5_Ent0", "text": "both patients", "entity_type": "Entity", "start": 43, "end": 45}], "lang": "en"}
{"doc_id": "22010004_3", "wnd_id": "22010004_3_1", "text": "A 69 - year - old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily ( 17.5 mg / wk ) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended - release niacin ( Niaspan ) from 500 mg to 1000 mg daily the previous week .", "tokens": ["A", "69", "-", "year", "-", "old", "white", "female", "whose", "anticoagulation", "treatment", "had", "been", "stable", "for", "18", "months", "with", "warfarin", "2.5", "mg", "daily", "(", "17.5", "mg", "/", "wk", ")", "presented", "to", "an", "anticoagulation", "clinic", "with", "a", "critically", "elevated", "INR", "of", "greater", "than", "12.3", "after", "a", "dose", "increase", "in", "extended", "-", "release", "niacin", "(", "Niaspan", ")", "from", "500", "mg", "to", "1000", "mg", "daily", "the", "previous", "week", "."], "event_mentions": [{"id": "22010004_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 42, "end": 43}, "arguments": [{"entity_id": "22010004_3_Ent1", "role": "Subject_Age", "text": "69 - year - old", "start": 1, "end": 6}, {"entity_id": "22010004_3_Ent0", "role": "Subject", "text": "69 - year - old white female", "start": 1, "end": 8}, {"entity_id": "22010004_3_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "22010004_3_Ent3", "role": "Subject_Gender", "text": "female", "start": 7, "end": 8}, {"entity_id": "22010004_3_Ent5", "role": "Treatment", "text": "anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily ( 17.5 mg / wk )", "start": 9, "end": 28}, {"entity_id": "22010004_3_Ent8", "role": "Treatment_Drug", "text": "warfarin", "start": 18, "end": 19}, {"entity_id": "22010004_3_Ent14", "role": "Combination_Drug", "text": "warfarin", "start": 18, "end": 19}, {"entity_id": "22010004_3_Ent10", "role": "Treatment_Dosage", "text": "2.5 mg", "start": 19, "end": 21}, {"entity_id": "22010004_3_Ent12", "role": "Treatment_Freq", "text": "daily", "start": 21, "end": 22}, {"entity_id": "22010004_3_Ent4", "role": "Effect", "text": "elevated INR of greater than 12.3", "start": 36, "end": 42}, {"entity_id": "22010004_3_Ent6", "role": "Treatment", "text": "dose increase in extended - release niacin ( Niaspan ) from 500 mg to 1000 mg daily the previous week", "start": 44, "end": 64}, {"entity_id": "22010004_3_Ent7", "role": "Treatment_Drug", "text": "extended - release niacin", "start": 47, "end": 51}, {"entity_id": "22010004_3_Ent13", "role": "Combination_Drug", "text": "extended - release niacin", "start": 47, "end": 51}, {"entity_id": "22010004_3_Ent9", "role": "Treatment_Dosage", "text": "1000 mg", "start": 58, "end": 60}, {"entity_id": "22010004_3_Ent11", "role": "Treatment_Freq", "text": "daily", "start": 60, "end": 61}]}], "entity_mentions": [{"id": "22010004_3_Ent1", "text": "69 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "22010004_3_Ent0", "text": "69 - year - old white female", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "22010004_3_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22010004_3_Ent3", "text": "female", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "22010004_3_Ent5", "text": "anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily ( 17.5 mg / wk )", "entity_type": "Entity", "start": 9, "end": 28}, {"id": "22010004_3_Ent8", "text": "warfarin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "22010004_3_Ent14", "text": "warfarin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "22010004_3_Ent10", "text": "2.5 mg", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "22010004_3_Ent12", "text": "daily", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "22010004_3_Ent4", "text": "elevated INR of greater than 12.3", "entity_type": "Entity", "start": 36, "end": 42}, {"id": "22010004_3_Ent6", "text": "dose increase in extended - release niacin ( Niaspan ) from 500 mg to 1000 mg daily the previous week", "entity_type": "Entity", "start": 44, "end": 64}, {"id": "22010004_3_Ent7", "text": "extended - release niacin", "entity_type": "Entity", "start": 47, "end": 51}, {"id": "22010004_3_Ent13", "text": "extended - release niacin", "entity_type": "Entity", "start": 47, "end": 51}, {"id": "22010004_3_Ent9", "text": "1000 mg", "entity_type": "Entity", "start": 58, "end": 60}, {"id": "22010004_3_Ent11", "text": "daily", "entity_type": "Entity", "start": 60, "end": 61}], "lang": "en"}
{"doc_id": "22293514_5", "wnd_id": "22293514_5_1", "text": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite , N - desmethylclobazam , causing neurotoxic symptoms .", "tokens": ["We", "report", "a", "case", "in", "which", "a", "potential", "drug", "interaction", "between", "clobazam", "and", "etravirine", "may", "have", "led", "to", "increased", "concentrations", "of", "clobazam", "and", "its", "pharmacologically", "active", "metabolite", ",", "N", "-", "desmethylclobazam", ",", "causing", "neurotoxic", "symptoms", "."], "event_mentions": [{"id": "22293514_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "led", "start": 16, "end": 17}, "arguments": [{"entity_id": "22293514_5_Ent2", "role": "Treatment", "text": "interaction between clobazam and etravirine", "start": 9, "end": 14}, {"entity_id": "22293514_5_Ent4", "role": "Treatment_Drug", "text": "clobazam", "start": 11, "end": 12}, {"entity_id": "22293514_5_Ent5", "role": "Combination_Drug", "text": "clobazam", "start": 11, "end": 12}, {"entity_id": "22293514_5_Ent3", "role": "Treatment_Drug", "text": "etravirine", "start": 13, "end": 14}, {"entity_id": "22293514_5_Ent6", "role": "Combination_Drug", "text": "etravirine", "start": 13, "end": 14}, {"entity_id": "22293514_5_Ent0", "role": "Effect", "text": "increased concentrations of clobazam and its pharmacologically active metabolite , N - desmethylclobazam", "start": 18, "end": 31}, {"entity_id": "22293514_5_Ent1", "role": "Effect", "text": "neurotoxic symptoms", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "22293514_5_Ent2", "text": "interaction between clobazam and etravirine", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "22293514_5_Ent4", "text": "clobazam", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "22293514_5_Ent5", "text": "clobazam", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "22293514_5_Ent3", "text": "etravirine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "22293514_5_Ent6", "text": "etravirine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "22293514_5_Ent0", "text": "increased concentrations of clobazam and its pharmacologically active metabolite , N - desmethylclobazam", "entity_type": "Entity", "start": 18, "end": 31}, {"id": "22293514_5_Ent1", "text": "neurotoxic symptoms", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "2241449_2", "wnd_id": "2241449_2_1", "text": "Sulfadiazine crystalluria revisited .", "tokens": ["Sulfadiazine", "crystalluria", "revisited", "."], "event_mentions": [{"id": "2241449_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "revisited", "start": 2, "end": 3}, "arguments": [{"entity_id": "2241449_2_Ent1", "role": "Treatment", "text": "Sulfadiazine", "start": 0, "end": 1}, {"entity_id": "2241449_2_Ent2", "role": "Treatment_Drug", "text": "Sulfadiazine", "start": 0, "end": 1}, {"entity_id": "2241449_2_Ent0", "role": "Effect", "text": "crystalluria", "start": 1, "end": 2}]}], "entity_mentions": [{"id": "2241449_2_Ent1", "text": "Sulfadiazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2241449_2_Ent2", "text": "Sulfadiazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2241449_2_Ent0", "text": "crystalluria", "entity_type": "Entity", "start": 1, "end": 2}], "lang": "en"}
{"doc_id": "2250853_2", "wnd_id": "2250853_2_1", "text": "We report a case of secondary glaucoma caused by epithelial downgrowth in which filtration surgery was performed with adjunctive use of subconjunctival 5 - fluorouracil .", "tokens": ["We", "report", "a", "case", "of", "secondary", "glaucoma", "caused", "by", "epithelial", "downgrowth", "in", "which", "filtration", "surgery", "was", "performed", "with", "adjunctive", "use", "of", "subconjunctival", "5", "-", "fluorouracil", "."], "event_mentions": [{"id": "2250853_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 7, "end": 8}, "arguments": [{"entity_id": "2250853_2_Ent0", "role": "Effect", "text": "secondary glaucoma", "start": 5, "end": 7}, {"entity_id": "2250853_2_Ent1", "role": "Effect", "text": "epithelial downgrowth", "start": 9, "end": 11}, {"entity_id": "2250853_2_Ent2", "role": "Treatment", "text": "filtration surgery was performed with adjunctive use of subconjunctival 5 - fluorouracil", "start": 13, "end": 25}, {"entity_id": "2250853_2_Ent3", "role": "Treatment_Route", "text": "subconjunctival", "start": 21, "end": 22}, {"entity_id": "2250853_2_Ent4", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "2250853_2_Ent0", "text": "secondary glaucoma", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2250853_2_Ent1", "text": "epithelial downgrowth", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2250853_2_Ent2", "text": "filtration surgery was performed with adjunctive use of subconjunctival 5 - fluorouracil", "entity_type": "Entity", "start": 13, "end": 25}, {"id": "2250853_2_Ent3", "text": "subconjunctival", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "2250853_2_Ent4", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "22550162_9", "wnd_id": "22550162_9_1", "text": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship ( score of 6 ) between the patient 's development of methotrexate toxicity and omeprazole use , we believe this was a drug - drug interaction case consistent with previous reports in the literature .", "tokens": ["Although", "use", "of", "the", "Naranjo", "adverse", "reaction", "probability", "scale", "indicated", "a", "probable", "relationship", "(", "score", "of", "6", ")", "between", "the", "patient", "'s", "development", "of", "methotrexate", "toxicity", "and", "omeprazole", "use", ",", "we", "believe", "this", "was", "a", "drug", "-", "drug", "interaction", "case", "consistent", "with", "previous", "reports", "in", "the", "literature", "."], "event_mentions": [{"id": "22550162_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 12, "end": 13}, "arguments": [{"entity_id": "22550162_9_Ent0", "role": "Subject", "text": "the patient", "start": 19, "end": 21}, {"entity_id": "22550162_9_Ent2", "role": "Treatment", "text": "methotrexate", "start": 24, "end": 25}, {"entity_id": "22550162_9_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 24, "end": 25}, {"entity_id": "22550162_9_Ent6", "role": "Combination_Drug", "text": "methotrexate", "start": 24, "end": 25}, {"entity_id": "22550162_9_Ent1", "role": "Effect", "text": "methotrexate toxicity", "start": 24, "end": 26}, {"entity_id": "22550162_9_Ent3", "role": "Treatment", "text": "and omeprazole use", "start": 26, "end": 29}, {"entity_id": "22550162_9_Ent5", "role": "Treatment_Drug", "text": "omeprazole", "start": 27, "end": 28}, {"entity_id": "22550162_9_Ent7", "role": "Combination_Drug", "text": "omeprazole", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "22550162_9_Ent0", "text": "the patient", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "22550162_9_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "22550162_9_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "22550162_9_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "22550162_9_Ent1", "text": "methotrexate toxicity", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "22550162_9_Ent3", "text": "and omeprazole use", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "22550162_9_Ent5", "text": "omeprazole", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "22550162_9_Ent7", "text": "omeprazole", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "22552763_4", "wnd_id": "22552763_4_1", "text": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate , with and without concomitant NSAID or ASA .", "tokens": ["We", "assessed", "the", "bleeding", "risk", "in", "patients", "treated", "with", "thromboprophylactic", "dabigatran", "etexilate", ",", "with", "and", "without", "concomitant", "NSAID", "or", "ASA", "."], "event_mentions": [{"id": "22552763_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "22552763_4_Ent1", "role": "Effect", "text": "bleeding", "start": 3, "end": 4}, {"entity_id": "22552763_4_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "22552763_4_Ent2", "role": "Treatment", "text": "thromboprophylactic dabigatran etexilate , with and without concomitant NSAID or ASA", "start": 9, "end": 20}, {"entity_id": "22552763_4_Ent5", "role": "Treatment_Drug", "text": "dabigatran etexilate", "start": 10, "end": 12}, {"entity_id": "22552763_4_Ent6", "role": "Combination_Drug", "text": "dabigatran etexilate", "start": 10, "end": 12}, {"entity_id": "22552763_4_Ent4", "role": "Treatment_Drug", "text": "NSAID", "start": 17, "end": 18}, {"entity_id": "22552763_4_Ent7", "role": "Combination_Drug", "text": "NSAID", "start": 17, "end": 18}, {"entity_id": "22552763_4_Ent3", "role": "Treatment_Drug", "text": "ASA", "start": 19, "end": 20}, {"entity_id": "22552763_4_Ent8", "role": "Combination_Drug", "text": "ASA", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "22552763_4_Ent1", "text": "bleeding", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "22552763_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22552763_4_Ent2", "text": "thromboprophylactic dabigatran etexilate , with and without concomitant NSAID or ASA", "entity_type": "Entity", "start": 9, "end": 20}, {"id": "22552763_4_Ent5", "text": "dabigatran etexilate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "22552763_4_Ent6", "text": "dabigatran etexilate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "22552763_4_Ent4", "text": "NSAID", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "22552763_4_Ent7", "text": "NSAID", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "22552763_4_Ent3", "text": "ASA", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "22552763_4_Ent8", "text": "ASA", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "2257522_1", "wnd_id": "2257522_1_1", "text": "Antacid and sucralfate - induced hypophosphatemic osteomalacia : a case report and review of the literature .", "tokens": ["Antacid", "and", "sucralfate", "-", "induced", "hypophosphatemic", "osteomalacia", ":", "a", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "2257522_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "2257522_1_Ent4", "role": "Treatment_Drug", "text": "Antacid", "start": 0, "end": 1}, {"entity_id": "2257522_1_Ent2", "role": "Treatment", "text": "Antacid and sucralfate", "start": 0, "end": 3}, {"entity_id": "2257522_1_Ent3", "role": "Treatment_Drug", "text": "sucralfate", "start": 2, "end": 3}, {"entity_id": "2257522_1_Ent1", "role": "Effect", "text": "hypophosphatemic osteomalacia", "start": 5, "end": 7}, {"entity_id": "2257522_1_Ent0", "role": "Subject", "text": "a case", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "2257522_1_Ent4", "text": "Antacid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2257522_1_Ent2", "text": "Antacid and sucralfate", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2257522_1_Ent3", "text": "sucralfate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "2257522_1_Ent1", "text": "hypophosphatemic osteomalacia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2257522_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "22677303_11", "wnd_id": "22677303_11_1", "text": "According to the Drug Interaction Probability Scale , a causal relationship between the warfarin - cloxacillin interaction and increased INR value was rated \" probable \" .", "tokens": ["According", "to", "the", "Drug", "Interaction", "Probability", "Scale", ",", "a", "causal", "relationship", "between", "the", "warfarin", "-", "cloxacillin", "interaction", "and", "increased", "INR", "value", "was", "rated", "\"", "probable", "\"", "."], "event_mentions": [{"id": "22677303_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 10, "end": 11}, "arguments": [{"entity_id": "22677303_11_Ent1", "role": "Treatment", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "22677303_11_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "22677303_11_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "22677303_11_Ent2", "role": "Treatment", "text": "cloxacillin", "start": 15, "end": 16}, {"entity_id": "22677303_11_Ent4", "role": "Treatment_Drug", "text": "cloxacillin", "start": 15, "end": 16}, {"entity_id": "22677303_11_Ent6", "role": "Combination_Drug", "text": "cloxacillin", "start": 15, "end": 16}, {"entity_id": "22677303_11_Ent0", "role": "Effect", "text": "increased INR value", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "22677303_11_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "22677303_11_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "22677303_11_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "22677303_11_Ent2", "text": "cloxacillin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "22677303_11_Ent4", "text": "cloxacillin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "22677303_11_Ent6", "text": "cloxacillin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "22677303_11_Ent0", "text": "increased INR value", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "22791547_4", "wnd_id": "22791547_4_1", "text": "Orofacial dyskinesia appeared 5 hours after methylphenidate administration , persisted for 10 hours , and had completely resolved within 2 days .", "tokens": ["Orofacial", "dyskinesia", "appeared", "5", "hours", "after", "methylphenidate", "administration", ",", "persisted", "for", "10", "hours", ",", "and", "had", "completely", "resolved", "within", "2", "days", "."], "event_mentions": [{"id": "22791547_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared", "start": 2, "end": 3}, "arguments": [{"entity_id": "22791547_4_Ent0", "role": "Effect", "text": "Orofacial dyskinesia", "start": 0, "end": 2}, {"entity_id": "22791547_4_Ent3", "role": "Treatment_Time_elapsed", "text": "5 hours after", "start": 3, "end": 6}, {"entity_id": "22791547_4_Ent1", "role": "Treatment", "text": "5 hours after methylphenidate", "start": 3, "end": 7}, {"entity_id": "22791547_4_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "22791547_4_Ent0", "text": "Orofacial dyskinesia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "22791547_4_Ent3", "text": "5 hours after", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "22791547_4_Ent1", "text": "5 hours after methylphenidate", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "22791547_4_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "228648_1", "wnd_id": "228648_1_1", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE ) .", "tokens": ["Prenatal", "cytomegalovirus", "(", "CMV", ")", "infection", "associated", "with", "severe", "brain", "damage", "was", "detected", "in", "an", "infant", "whose", "mother", "had", "been", "treated", "with", "prednisolone", "and", "azathioprine", "for", "systemic", "lupus", "erythematosus", "(", "SLE", ")", "."], "event_mentions": [{"id": "228648_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 20, "end": 21}, "arguments": [{"entity_id": "228648_1_Ent2", "role": "Effect", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage", "start": 0, "end": 11}, {"entity_id": "228648_1_Ent0", "role": "Subject", "text": "an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE )", "start": 14, "end": 32}, {"entity_id": "228648_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 15, "end": 16}, {"entity_id": "228648_1_Ent4", "role": "Treatment_Drug", "text": "prednisolone", "start": 22, "end": 23}, {"entity_id": "228648_1_Ent6", "role": "Combination_Drug", "text": "prednisolone", "start": 22, "end": 23}, {"entity_id": "228648_1_Ent3", "role": "Treatment", "text": "prednisolone and azathioprine", "start": 22, "end": 25}, {"entity_id": "228648_1_Ent5", "role": "Treatment_Drug", "text": "azathioprine", "start": 24, "end": 25}, {"entity_id": "228648_1_Ent7", "role": "Combination_Drug", "text": "azathioprine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "228648_1_Ent2", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "228648_1_Ent0", "text": "an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE )", "entity_type": "Entity", "start": 14, "end": 32}, {"id": "228648_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "228648_1_Ent4", "text": "prednisolone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "228648_1_Ent6", "text": "prednisolone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "228648_1_Ent3", "text": "prednisolone and azathioprine", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "228648_1_Ent5", "text": "azathioprine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "228648_1_Ent7", "text": "azathioprine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "2302898_1", "wnd_id": "2302898_1_1", "text": "Diazepam use by pregnant women can be associated with a later presentation of withdrawal symptoms in the neonate than that induced by the use of other drugs .", "tokens": ["Diazepam", "use", "by", "pregnant", "women", "can", "be", "associated", "with", "a", "later", "presentation", "of", "withdrawal", "symptoms", "in", "the", "neonate", "than", "that", "induced", "by", "the", "use", "of", "other", "drugs", "."], "event_mentions": [{"id": "2302898_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "2302898_1_Ent3", "role": "Treatment", "text": "Diazepam", "start": 0, "end": 1}, {"entity_id": "2302898_1_Ent4", "role": "Treatment_Drug", "text": "Diazepam", "start": 0, "end": 1}, {"entity_id": "2302898_1_Ent2", "role": "Effect", "text": "later presentation of withdrawal symptoms in the neonate", "start": 10, "end": 18}, {"entity_id": "2302898_1_Ent0", "role": "Subject", "text": "neonate", "start": 17, "end": 18}, {"entity_id": "2302898_1_Ent1", "role": "Subject_Age", "text": "neonate", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "2302898_1_Ent3", "text": "Diazepam", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2302898_1_Ent4", "text": "Diazepam", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2302898_1_Ent2", "text": "later presentation of withdrawal symptoms in the neonate", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "2302898_1_Ent0", "text": "neonate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2302898_1_Ent1", "text": "neonate", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "2309833_3", "wnd_id": "2309833_3_1", "text": "Insulin - dependent diabetes mellitus developed in a young woman 8 weeks after the initiation of danazol for treatment of pelvic endometriosis .", "tokens": ["Insulin", "-", "dependent", "diabetes", "mellitus", "developed", "in", "a", "young", "woman", "8", "weeks", "after", "the", "initiation", "of", "danazol", "for", "treatment", "of", "pelvic", "endometriosis", "."], "event_mentions": [{"id": "2309833_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "2309833_3_Ent3", "role": "Effect", "text": "Insulin - dependent diabetes mellitus", "start": 0, "end": 5}, {"entity_id": "2309833_3_Ent0", "role": "Subject", "text": "a young woman", "start": 7, "end": 10}, {"entity_id": "2309833_3_Ent1", "role": "Subject_Age", "text": "young", "start": 8, "end": 9}, {"entity_id": "2309833_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "2309833_3_Ent6", "role": "Treatment_Time_elapsed", "text": "8 weeks", "start": 10, "end": 12}, {"entity_id": "2309833_3_Ent4", "role": "Treatment", "text": "8 weeks after the initiation of danazol", "start": 10, "end": 17}, {"entity_id": "2309833_3_Ent7", "role": "Treatment_Drug", "text": "danazol", "start": 16, "end": 17}, {"entity_id": "2309833_3_Ent5", "role": "Treatment_Disorder", "text": "pelvic endometriosis", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "2309833_3_Ent3", "text": "Insulin - dependent diabetes mellitus", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "2309833_3_Ent0", "text": "a young woman", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "2309833_3_Ent1", "text": "young", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2309833_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2309833_3_Ent6", "text": "8 weeks", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "2309833_3_Ent4", "text": "8 weeks after the initiation of danazol", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "2309833_3_Ent7", "text": "danazol", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "2309833_3_Ent5", "text": "pelvic endometriosis", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "23115227_6", "wnd_id": "23115227_6_1", "text": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg ( 95 % CI 12.7 to 13.8 ) , with a mean international normalized ratio ( INR ) of 2.8 ( 95 % CI 2.5 to 3.1 ) .", "tokens": ["The", "mean", "weekly", "warfarin", "dose", "while", "the", "patient", "was", "receiving", "emtricitabine", "monotherapy", "was", "13.3", "mg", "(", "95", "%", "CI", "12.7", "to", "13.8", ")", ",", "with", "a", "mean", "international", "normalized", "ratio", "(", "INR", ")", "of", "2.8", "(", "95", "%", "CI", "2.5", "to", "3.1", ")", "."], "event_mentions": [{"id": "23115227_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 9, "end": 10}, "arguments": [{"entity_id": "23115227_6_Ent1", "role": "Treatment", "text": "The mean weekly warfarin dose", "start": 0, "end": 5}, {"entity_id": "23115227_6_Ent3", "role": "Treatment_Freq", "text": "weekly", "start": 2, "end": 3}, {"entity_id": "23115227_6_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "23115227_6_Ent0", "role": "Subject", "text": "the patient", "start": 6, "end": 8}, {"entity_id": "23115227_6_Ent5", "role": "Treatment_Drug", "text": "emtricitabine", "start": 10, "end": 11}, {"entity_id": "23115227_6_Ent2", "role": "Treatment", "text": "emtricitabine monotherapy was 13.3 mg ( 95 % CI 12.7 to 13.8 )", "start": 10, "end": 23}, {"entity_id": "23115227_6_Ent6", "role": "Treatment_Dosage", "text": "13.3 mg", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "23115227_6_Ent1", "text": "The mean weekly warfarin dose", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "23115227_6_Ent3", "text": "weekly", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "23115227_6_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "23115227_6_Ent0", "text": "the patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "23115227_6_Ent5", "text": "emtricitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "23115227_6_Ent2", "text": "emtricitabine monotherapy was 13.3 mg ( 95 % CI 12.7 to 13.8 )", "entity_type": "Entity", "start": 10, "end": 23}, {"id": "23115227_6_Ent6", "text": "13.3 mg", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "2320800_7", "wnd_id": "2320800_7_1", "text": "We strongly suspect that this lethal anuria was mainly due to ifosfamide , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension .", "tokens": ["We", "strongly", "suspect", "that", "this", "lethal", "anuria", "was", "mainly", "due", "to", "ifosfamide", ",", "occurring", "in", "a", "patient", "having", "received", "previous", "cisplatin", "chemotherapy", "and", "with", "poor", "kidney", "perfusion", "due", "to", "transient", "hypotension", "."], "event_mentions": [{"id": "2320800_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 13, "end": 14}, "arguments": [{"entity_id": "2320800_7_Ent2", "role": "Effect", "text": "lethal anuria", "start": 5, "end": 7}, {"entity_id": "2320800_7_Ent3", "role": "Treatment", "text": "ifosfamide", "start": 11, "end": 12}, {"entity_id": "2320800_7_Ent5", "role": "Treatment_Drug", "text": "ifosfamide", "start": 11, "end": 12}, {"entity_id": "2320800_7_Ent7", "role": "Combination_Drug", "text": "ifosfamide", "start": 11, "end": 12}, {"entity_id": "2320800_7_Ent0", "role": "Subject", "text": "a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension", "start": 15, "end": 31}, {"entity_id": "2320800_7_Ent4", "role": "Treatment", "text": "having received previous cisplatin chemotherapy", "start": 17, "end": 22}, {"entity_id": "2320800_7_Ent6", "role": "Treatment_Drug", "text": "cisplatin", "start": 20, "end": 21}, {"entity_id": "2320800_7_Ent8", "role": "Combination_Drug", "text": "cisplatin", "start": 20, "end": 21}, {"entity_id": "2320800_7_Ent1", "role": "Subject_Disorder", "text": "poor kidney perfusion", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "2320800_7_Ent2", "text": "lethal anuria", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2320800_7_Ent3", "text": "ifosfamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2320800_7_Ent5", "text": "ifosfamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2320800_7_Ent7", "text": "ifosfamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2320800_7_Ent0", "text": "a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension", "entity_type": "Entity", "start": 15, "end": 31}, {"id": "2320800_7_Ent4", "text": "having received previous cisplatin chemotherapy", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "2320800_7_Ent6", "text": "cisplatin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "2320800_7_Ent8", "text": "cisplatin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "2320800_7_Ent1", "text": "poor kidney perfusion", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "2327115_2", "wnd_id": "2327115_2_1", "text": "Renal toxicities have been reported in less than one percent of the patients receiving ciprofloxacin therapy .", "tokens": ["Renal", "toxicities", "have", "been", "reported", "in", "less", "than", "one", "percent", "of", "the", "patients", "receiving", "ciprofloxacin", "therapy", "."], "event_mentions": [{"id": "2327115_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 4, "end": 5}, "arguments": [{"entity_id": "2327115_2_Ent2", "role": "Effect", "text": "Renal toxicities", "start": 0, "end": 2}, {"entity_id": "2327115_2_Ent1", "role": "Subject_Population", "text": "less than one percent", "start": 6, "end": 10}, {"entity_id": "2327115_2_Ent0", "role": "Subject", "text": "less than one percent of the patients", "start": 6, "end": 13}, {"entity_id": "2327115_2_Ent4", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 14, "end": 15}, {"entity_id": "2327115_2_Ent3", "role": "Treatment", "text": "ciprofloxacin therapy .", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "2327115_2_Ent2", "text": "Renal toxicities", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2327115_2_Ent1", "text": "less than one percent", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "2327115_2_Ent0", "text": "less than one percent of the patients", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "2327115_2_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "2327115_2_Ent3", "text": "ciprofloxacin therapy .", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "2327115_3", "wnd_id": "2327115_3_1", "text": "Suspected ciprofloxacin - induced interstitial nephritis .", "tokens": ["Suspected", "ciprofloxacin", "-", "induced", "interstitial", "nephritis", "."], "event_mentions": [{"id": "2327115_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "2327115_3_Ent1", "role": "Treatment", "text": "ciprofloxacin", "start": 1, "end": 2}, {"entity_id": "2327115_3_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 1, "end": 2}, {"entity_id": "2327115_3_Ent0", "role": "Effect", "text": "interstitial nephritis", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "2327115_3_Ent1", "text": "ciprofloxacin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2327115_3_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2327115_3_Ent0", "text": "interstitial nephritis", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "2332596_1", "wnd_id": "2332596_1_1", "text": "Phenobarbital hepatotoxicity in an 8 - month - old infant .", "tokens": ["Phenobarbital", "hepatotoxicity", "in", "an", "8", "-", "month", "-", "old", "infant", "."], "event_mentions": [{"id": "2332596_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "2332596_1_Ent3", "role": "Treatment", "text": "Phenobarbital", "start": 0, "end": 1}, {"entity_id": "2332596_1_Ent4", "role": "Treatment_Drug", "text": "Phenobarbital", "start": 0, "end": 1}, {"entity_id": "2332596_1_Ent2", "role": "Effect", "text": "hepatotoxicity", "start": 1, "end": 2}, {"entity_id": "2332596_1_Ent0", "role": "Subject", "text": "an 8 - month - old infant", "start": 3, "end": 10}, {"entity_id": "2332596_1_Ent1", "role": "Subject_Age", "text": "8 - month - old infant", "start": 4, "end": 10}]}], "entity_mentions": [{"id": "2332596_1_Ent3", "text": "Phenobarbital", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2332596_1_Ent4", "text": "Phenobarbital", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2332596_1_Ent2", "text": "hepatotoxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2332596_1_Ent0", "text": "an 8 - month - old infant", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "2332596_1_Ent1", "text": "8 - month - old infant", "entity_type": "Entity", "start": 4, "end": 10}], "lang": "en"}
{"doc_id": "2332596_2", "wnd_id": "2332596_2_1", "text": "Severe hepatotoxicity from phenobarbital occurred in an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis .", "tokens": ["Severe", "hepatotoxicity", "from", "phenobarbital", "occurred", "in", "an", "infant", "boy", "who", "had", "a", "complicated", "illness", "with", "chronic", "bilateral", "subdural", "hematomas", "and", "sepsis", "."], "event_mentions": [{"id": "2332596_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "2332596_2_Ent3", "role": "Effect", "text": "Severe hepatotoxicity", "start": 0, "end": 2}, {"entity_id": "2332596_2_Ent4", "role": "Treatment", "text": "phenobarbital", "start": 3, "end": 4}, {"entity_id": "2332596_2_Ent5", "role": "Treatment_Drug", "text": "phenobarbital", "start": 3, "end": 4}, {"entity_id": "2332596_2_Ent0", "role": "Subject", "text": "an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis .", "start": 6, "end": 22}, {"entity_id": "2332596_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 7, "end": 8}, {"entity_id": "2332596_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 8, "end": 9}, {"entity_id": "2332596_2_Ent6", "role": "Treatment_Disorder", "text": "chronic bilateral subdural hematomas", "start": 15, "end": 19}, {"entity_id": "2332596_2_Ent7", "role": "Treatment_Disorder", "text": "sepsis", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "2332596_2_Ent3", "text": "Severe hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2332596_2_Ent4", "text": "phenobarbital", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2332596_2_Ent5", "text": "phenobarbital", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2332596_2_Ent0", "text": "an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis .", "entity_type": "Entity", "start": 6, "end": 22}, {"id": "2332596_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2332596_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2332596_2_Ent6", "text": "chronic bilateral subdural hematomas", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "2332596_2_Ent7", "text": "sepsis", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "23471710_2", "wnd_id": "23471710_2_1", "text": "Two drugs commonly used in triple - drug therapy for treatment of a Helicobacter pylori infection , clarithromycin and omeprazole , have rarely been associated with hypoglycemia when given alone .", "tokens": ["Two", "drugs", "commonly", "used", "in", "triple", "-", "drug", "therapy", "for", "treatment", "of", "a", "Helicobacter", "pylori", "infection", ",", "clarithromycin", "and", "omeprazole", ",", "have", "rarely", "been", "associated", "with", "hypoglycemia", "when", "given", "alone", "."], "event_mentions": [{"id": "23471710_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 24, "end": 25}, "arguments": [{"entity_id": "23471710_2_Ent4", "role": "Treatment_Disorder", "text": "a Helicobacter pylori infection", "start": 12, "end": 16}, {"entity_id": "23471710_2_Ent2", "role": "Treatment_Drug", "text": "clarithromycin", "start": 17, "end": 18}, {"entity_id": "23471710_2_Ent5", "role": "Combination_Drug", "text": "clarithromycin", "start": 17, "end": 18}, {"entity_id": "23471710_2_Ent1", "role": "Treatment", "text": "clarithromycin and omeprazole", "start": 17, "end": 20}, {"entity_id": "23471710_2_Ent3", "role": "Treatment_Drug", "text": "omeprazole", "start": 19, "end": 20}, {"entity_id": "23471710_2_Ent6", "role": "Combination_Drug", "text": "omeprazole", "start": 19, "end": 20}, {"entity_id": "23471710_2_Ent0", "role": "Effect", "text": "hypoglycemia", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "23471710_2_Ent4", "text": "a Helicobacter pylori infection", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "23471710_2_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "23471710_2_Ent5", "text": "clarithromycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "23471710_2_Ent1", "text": "clarithromycin and omeprazole", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "23471710_2_Ent3", "text": "omeprazole", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "23471710_2_Ent6", "text": "omeprazole", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "23471710_2_Ent0", "text": "hypoglycemia", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "2357706_1", "wnd_id": "2357706_1_1", "text": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents , it was only rarely reported in association with sulpiride , a selective D2 - receptor antagonist .", "tokens": ["Although", "tardive", "dyskinesia", "is", "a", "known", "adverse", "reaction", "of", "sustained", "treatment", "with", "traditional", "neuroleptic", "agents", ",", "it", "was", "only", "rarely", "reported", "in", "association", "with", "sulpiride", ",", "a", "selective", "D2", "-", "receptor", "antagonist", "."], "event_mentions": [{"id": "2357706_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 22, "end": 23}, "arguments": [{"entity_id": "2357706_1_Ent0", "role": "Effect", "text": "tardive dyskinesia", "start": 1, "end": 3}, {"entity_id": "2357706_1_Ent1", "role": "Treatment", "text": "sulpiride", "start": 24, "end": 25}, {"entity_id": "2357706_1_Ent2", "role": "Treatment_Drug", "text": "sulpiride", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "2357706_1_Ent0", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "2357706_1_Ent1", "text": "sulpiride", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "2357706_1_Ent2", "text": "sulpiride", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "23624139_10", "wnd_id": "23624139_10_1", "text": "Risks and benefits of co - treatment should be carefully considered and therapeutic alternatives to NSAIDs should be recommended to patients with central DI in order to improve DDAVP safety .", "tokens": ["Risks", "and", "benefits", "of", "co", "-", "treatment", "should", "be", "carefully", "considered", "and", "therapeutic", "alternatives", "to", "NSAIDs", "should", "be", "recommended", "to", "patients", "with", "central", "DI", "in", "order", "to", "improve", "DDAVP", "safety", "."], "event_mentions": [{"id": "23624139_10_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "recommended", "start": 18, "end": 19}, "arguments": [{"entity_id": "23624139_10_Ent2", "role": "Treatment", "text": "therapeutic alternatives to NSAIDs", "start": 12, "end": 16}, {"entity_id": "23624139_10_Ent4", "role": "Treatment_Drug", "text": "NSAIDs", "start": 15, "end": 16}, {"entity_id": "23624139_10_Ent0", "role": "Subject", "text": "patients with central DI", "start": 20, "end": 24}, {"entity_id": "23624139_10_Ent3", "role": "Treatment_Disorder", "text": "central DI", "start": 22, "end": 24}, {"entity_id": "23624139_10_Ent1", "role": "Effect", "text": "in order to improve DDAVP safety", "start": 24, "end": 30}]}], "entity_mentions": [{"id": "23624139_10_Ent2", "text": "therapeutic alternatives to NSAIDs", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "23624139_10_Ent4", "text": "NSAIDs", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "23624139_10_Ent0", "text": "patients with central DI", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "23624139_10_Ent3", "text": "central DI", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "23624139_10_Ent1", "text": "in order to improve DDAVP safety", "entity_type": "Entity", "start": 24, "end": 30}], "lang": "en"}
{"doc_id": "2378415_3", "wnd_id": "2378415_3_1", "text": "Transtentorial herniation caused by an intracranial mass lesion following high - dose methotrexate .", "tokens": ["Transtentorial", "herniation", "caused", "by", "an", "intracranial", "mass", "lesion", "following", "high", "-", "dose", "methotrexate", "."], "event_mentions": [{"id": "2378415_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "2378415_3_Ent1", "role": "Effect", "text": "Transtentorial herniation", "start": 0, "end": 2}, {"entity_id": "2378415_3_Ent0", "role": "Effect", "text": "an intracranial mass lesion", "start": 4, "end": 8}, {"entity_id": "2378415_3_Ent4", "role": "Treatment_Dosage", "text": "high - dose", "start": 9, "end": 12}, {"entity_id": "2378415_3_Ent2", "role": "Treatment", "text": "high - dose methotrexate", "start": 9, "end": 13}, {"entity_id": "2378415_3_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "2378415_3_Ent1", "text": "Transtentorial herniation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2378415_3_Ent0", "text": "an intracranial mass lesion", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "2378415_3_Ent4", "text": "high - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2378415_3_Ent2", "text": "high - dose methotrexate", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "2378415_3_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "23970584_8", "wnd_id": "23970584_8_1", "text": "Clinicians should be aware of raltegravir - induced DRESS syndrome as well as the potential for drug - drug interactions due to protease inhibitor - based therapy .", "tokens": ["Clinicians", "should", "be", "aware", "of", "raltegravir", "-", "induced", "DRESS", "syndrome", "as", "well", "as", "the", "potential", "for", "drug", "-", "drug", "interactions", "due", "to", "protease", "inhibitor", "-", "based", "therapy", "."], "event_mentions": [{"id": "23970584_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "23970584_8_Ent1", "role": "Treatment", "text": "raltegravir", "start": 5, "end": 6}, {"entity_id": "23970584_8_Ent2", "role": "Treatment_Drug", "text": "raltegravir", "start": 5, "end": 6}, {"entity_id": "23970584_8_Ent0", "role": "Effect", "text": "DRESS syndrome", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "23970584_8_Ent1", "text": "raltegravir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "23970584_8_Ent2", "text": "raltegravir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "23970584_8_Ent0", "text": "DRESS syndrome", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "2406680_1", "wnd_id": "2406680_1_1", "text": "Quinine - induced hearing loss .", "tokens": ["Quinine", "-", "induced", "hearing", "loss", "."], "event_mentions": [{"id": "2406680_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2406680_1_Ent1", "role": "Treatment", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "2406680_1_Ent2", "role": "Treatment_Drug", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "2406680_1_Ent0", "role": "Effect", "text": "hearing loss", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "2406680_1_Ent1", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2406680_1_Ent2", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2406680_1_Ent0", "text": "hearing loss", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "2406680_3", "wnd_id": "2406680_3_1", "text": "The case of a 29 - year - old man suffering from falciparum malaria disease who got a reversible hearing loss from quinine therapy is presented .", "tokens": ["The", "case", "of", "a", "29", "-", "year", "-", "old", "man", "suffering", "from", "falciparum", "malaria", "disease", "who", "got", "a", "reversible", "hearing", "loss", "from", "quinine", "therapy", "is", "presented", "."], "event_mentions": [{"id": "2406680_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "got", "start": 16, "end": 17}, "arguments": [{"entity_id": "2406680_3_Ent0", "role": "Subject", "text": "a 29 - year - old man suffering from falciparum malaria disease", "start": 3, "end": 15}, {"entity_id": "2406680_3_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 4, "end": 9}, {"entity_id": "2406680_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "2406680_3_Ent5", "role": "Treatment_Disorder", "text": "falciparum malaria disease", "start": 12, "end": 15}, {"entity_id": "2406680_3_Ent3", "role": "Effect", "text": "reversible hearing loss", "start": 18, "end": 21}, {"entity_id": "2406680_3_Ent4", "role": "Treatment", "text": "quinine", "start": 22, "end": 23}, {"entity_id": "2406680_3_Ent6", "role": "Treatment_Drug", "text": "quinine", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "2406680_3_Ent0", "text": "a 29 - year - old man suffering from falciparum malaria disease", "entity_type": "Entity", "start": 3, "end": 15}, {"id": "2406680_3_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "2406680_3_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2406680_3_Ent5", "text": "falciparum malaria disease", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "2406680_3_Ent3", "text": "reversible hearing loss", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "2406680_3_Ent4", "text": "quinine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2406680_3_Ent6", "text": "quinine", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "24163322_1", "wnd_id": "24163322_1_1", "text": "Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy .", "tokens": ["Inadvertent", "exaggerated", "anticoagulation", "following", "use", "of", "bismuth", "subsalicylate", "in", "an", "enterally", "fed", "patient", "receiving", "warfarin", "therapy", "."], "event_mentions": [{"id": "24163322_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "24163322_1_Ent1", "role": "Effect", "text": "Inadvertent exaggerated anticoagulation", "start": 0, "end": 3}, {"entity_id": "24163322_1_Ent2", "role": "Treatment", "text": "bismuth subsalicylate", "start": 6, "end": 8}, {"entity_id": "24163322_1_Ent5", "role": "Treatment_Drug", "text": "bismuth subsalicylate", "start": 6, "end": 8}, {"entity_id": "24163322_1_Ent0", "role": "Subject", "text": "an enterally fed patient", "start": 9, "end": 13}, {"entity_id": "24163322_1_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 14, "end": 15}, {"entity_id": "24163322_1_Ent3", "role": "Treatment", "text": "warfarin therapy", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "24163322_1_Ent1", "text": "Inadvertent exaggerated anticoagulation", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "24163322_1_Ent2", "text": "bismuth subsalicylate", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "24163322_1_Ent5", "text": "bismuth subsalicylate", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "24163322_1_Ent0", "text": "an enterally fed patient", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "24163322_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "24163322_1_Ent3", "text": "warfarin therapy", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "2429270_2", "wnd_id": "2429270_2_1", "text": "Escape atrial complexes , which occurred following junctional premature complexes , failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide .", "tokens": ["Escape", "atrial", "complexes", ",", "which", "occurred", "following", "junctional", "premature", "complexes", ",", "failed", "to", "initiate", "tachycardia", "in", "the", "control", "state", "but", "tachycardia", "was", "always", "reinitiated", "by", "an", "identical", "escape", "sequence", "after", "procainamide", "."], "event_mentions": [{"id": "2429270_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reinitiated", "start": 23, "end": 24}, "arguments": [{"entity_id": "2429270_2_Ent0", "role": "Effect", "text": "tachycardia", "start": 20, "end": 21}, {"entity_id": "2429270_2_Ent1", "role": "Treatment", "text": "procainamide", "start": 30, "end": 31}, {"entity_id": "2429270_2_Ent2", "role": "Treatment_Drug", "text": "procainamide", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "2429270_2_Ent0", "text": "tachycardia", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "2429270_2_Ent1", "text": "procainamide", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "2429270_2_Ent2", "text": "procainamide", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "2429270_3", "wnd_id": "2429270_3_1", "text": "In addition , the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide .", "tokens": ["In", "addition", ",", "the", "tachycardia", "persisted", "and", "was", "repeatedly", "spontaneously", "reinitiated", "for", "prolonged", "periods", "after", "procainamide", "."], "event_mentions": [{"id": "2429270_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 14, "end": 15}, "arguments": [{"entity_id": "2429270_3_Ent0", "role": "Effect", "text": "tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods", "start": 4, "end": 14}, {"entity_id": "2429270_3_Ent1", "role": "Treatment", "text": "procainamide", "start": 15, "end": 16}, {"entity_id": "2429270_3_Ent2", "role": "Treatment_Drug", "text": "procainamide", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2429270_3_Ent0", "text": "tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "2429270_3_Ent1", "text": "procainamide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2429270_3_Ent2", "text": "procainamide", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "24429012_1", "wnd_id": "24429012_1_1", "text": "Elevated International Normalized Ratio in a patient concurrently using warfarin and vismodegib .", "tokens": ["Elevated", "International", "Normalized", "Ratio", "in", "a", "patient", "concurrently", "using", "warfarin", "and", "vismodegib", "."], "event_mentions": [{"id": "24429012_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "using", "start": 8, "end": 9}, "arguments": [{"entity_id": "24429012_1_Ent1", "role": "Effect", "text": "Elevated International Normalized Ratio", "start": 0, "end": 4}, {"entity_id": "24429012_1_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "24429012_1_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 9, "end": 10}, {"entity_id": "24429012_1_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 9, "end": 10}, {"entity_id": "24429012_1_Ent2", "role": "Treatment", "text": "warfarin and vismodegib", "start": 9, "end": 12}, {"entity_id": "24429012_1_Ent4", "role": "Treatment_Drug", "text": "vismodegib", "start": 11, "end": 12}, {"entity_id": "24429012_1_Ent6", "role": "Combination_Drug", "text": "vismodegib", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "24429012_1_Ent1", "text": "Elevated International Normalized Ratio", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "24429012_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "24429012_1_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "24429012_1_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "24429012_1_Ent2", "text": "warfarin and vismodegib", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "24429012_1_Ent4", "text": "vismodegib", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "24429012_1_Ent6", "text": "vismodegib", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "2445709_1", "wnd_id": "2445709_1_1", "text": "A 52 - year - old woman developed symmetric sensorimotor polyneuropathy and cerebellar syndrome after 24 months of amiodarone treatment .", "tokens": ["A", "52", "-", "year", "-", "old", "woman", "developed", "symmetric", "sensorimotor", "polyneuropathy", "and", "cerebellar", "syndrome", "after", "24", "months", "of", "amiodarone", "treatment", "."], "event_mentions": [{"id": "2445709_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "2445709_1_Ent0", "role": "Subject", "text": "A 52 - year - old woman", "start": 0, "end": 7}, {"entity_id": "2445709_1_Ent1", "role": "Subject_Age", "text": "52 - year - old", "start": 1, "end": 6}, {"entity_id": "2445709_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "2445709_1_Ent3", "role": "Effect", "text": "symmetric sensorimotor polyneuropathy", "start": 8, "end": 11}, {"entity_id": "2445709_1_Ent4", "role": "Effect", "text": "cerebellar syndrome", "start": 12, "end": 14}, {"entity_id": "2445709_1_Ent6", "role": "Treatment_Time_elapsed", "text": "24 months", "start": 15, "end": 17}, {"entity_id": "2445709_1_Ent5", "role": "Treatment", "text": "amiodarone", "start": 18, "end": 19}, {"entity_id": "2445709_1_Ent7", "role": "Treatment_Drug", "text": "amiodarone", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "2445709_1_Ent0", "text": "A 52 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "2445709_1_Ent1", "text": "52 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "2445709_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2445709_1_Ent3", "text": "symmetric sensorimotor polyneuropathy", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "2445709_1_Ent4", "text": "cerebellar syndrome", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2445709_1_Ent6", "text": "24 months", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "2445709_1_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "2445709_1_Ent7", "text": "amiodarone", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "2445709_2", "wnd_id": "2445709_2_1", "text": "Peripheral neuropathy and cerebellar syndrome associated with amiodarone therapy .", "tokens": ["Peripheral", "neuropathy", "and", "cerebellar", "syndrome", "associated", "with", "amiodarone", "therapy", "."], "event_mentions": [{"id": "2445709_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "2445709_2_Ent0", "role": "Effect", "text": "Peripheral neuropathy and cerebellar syndrome", "start": 0, "end": 5}, {"entity_id": "2445709_2_Ent1", "role": "Treatment", "text": "amiodarone", "start": 7, "end": 8}, {"entity_id": "2445709_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "2445709_2_Ent0", "text": "Peripheral neuropathy and cerebellar syndrome", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "2445709_2_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2445709_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "24477376_4", "wnd_id": "24477376_4_1", "text": "The patient was previously on phenytoin and was initiated on ticagrelor for antiplatelet therapy following stent placement .", "tokens": ["The", "patient", "was", "previously", "on", "phenytoin", "and", "was", "initiated", "on", "ticagrelor", "for", "antiplatelet", "therapy", "following", "stent", "placement", "."], "event_mentions": [{"id": "24477376_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 11, "end": 12}, "arguments": [{"entity_id": "24477376_4_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "24477376_4_Ent1", "role": "Treatment", "text": "previously on phenytoin", "start": 3, "end": 6}, {"entity_id": "24477376_4_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 5, "end": 6}, {"entity_id": "24477376_4_Ent2", "role": "Treatment", "text": "initiated on ticagrelor", "start": 8, "end": 11}, {"entity_id": "24477376_4_Ent6", "role": "Treatment_Drug", "text": "ticagrelor", "start": 10, "end": 11}, {"entity_id": "24477376_4_Ent4", "role": "Treatment_Disorder", "text": "antiplatelet therapy", "start": 12, "end": 14}, {"entity_id": "24477376_4_Ent3", "role": "Treatment", "text": "following stent placement", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "24477376_4_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "24477376_4_Ent1", "text": "previously on phenytoin", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "24477376_4_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "24477376_4_Ent2", "text": "initiated on ticagrelor", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "24477376_4_Ent6", "text": "ticagrelor", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "24477376_4_Ent4", "text": "antiplatelet therapy", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "24477376_4_Ent3", "text": "following stent placement", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "24679099_7", "wnd_id": "24679099_7_1", "text": "Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed .", "tokens": ["Because", "of", "further", "progression", "combination", "treatment", "of", "bevacizumab", "and", "irinotecan", "was", "started", "and", "again", "no", "liver", "toxicity", "was", "observed", "."], "event_mentions": [{"id": "24679099_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 18, "end": 19}, "arguments": [{"entity_id": "24679099_7_Ent2", "role": "Treatment_Drug", "text": "bevacizumab", "start": 7, "end": 8}, {"entity_id": "24679099_7_Ent4", "role": "Combination_Drug", "text": "bevacizumab", "start": 7, "end": 8}, {"entity_id": "24679099_7_Ent1", "role": "Treatment", "text": "bevacizumab and irinotecan", "start": 7, "end": 10}, {"entity_id": "24679099_7_Ent3", "role": "Treatment_Drug", "text": "irinotecan", "start": 9, "end": 10}, {"entity_id": "24679099_7_Ent5", "role": "Combination_Drug", "text": "irinotecan", "start": 9, "end": 10}, {"entity_id": "24679099_7_Ent0", "role": "Effect", "text": "liver toxicity", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "24679099_7_Ent2", "text": "bevacizumab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "24679099_7_Ent4", "text": "bevacizumab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "24679099_7_Ent1", "text": "bevacizumab and irinotecan", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "24679099_7_Ent3", "text": "irinotecan", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "24679099_7_Ent5", "text": "irinotecan", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "24679099_7_Ent0", "text": "liver toxicity", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "24679099_8", "wnd_id": "24679099_8_1", "text": "We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide .", "tokens": ["We", "conclude", "that", "the", "observed", "toxicity", "with", "jaundice", "was", "probably", "caused", "by", "an", "interaction", "of", "this", "popular", "Chinese", "formula", "and", "temozolomide", "."], "event_mentions": [{"id": "24679099_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 10, "end": 11}, "arguments": [{"entity_id": "24679099_8_Ent0", "role": "Effect", "text": "toxicity with jaundice", "start": 5, "end": 8}, {"entity_id": "24679099_8_Ent1", "role": "Treatment", "text": "temozolomide", "start": 20, "end": 21}, {"entity_id": "24679099_8_Ent2", "role": "Treatment_Drug", "text": "temozolomide", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "24679099_8_Ent0", "text": "toxicity with jaundice", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "24679099_8_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "24679099_8_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "24801976_1", "wnd_id": "24801976_1_1", "text": "Pain management discussion forum : serious interaction among frequently used drugs for chronic pain .", "tokens": ["Pain", "management", "discussion", "forum", ":", "serious", "interaction", "among", "frequently", "used", "drugs", "for", "chronic", "pain", "."], "event_mentions": [{"id": "24801976_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "among", "start": 7, "end": 8}, "arguments": [{"entity_id": "24801976_1_Ent0", "role": "Effect", "text": "serious interaction", "start": 5, "end": 7}, {"entity_id": "24801976_1_Ent3", "role": "Treatment_Freq", "text": "frequently", "start": 8, "end": 9}, {"entity_id": "24801976_1_Ent1", "role": "Treatment", "text": "frequently used drugs", "start": 8, "end": 11}, {"entity_id": "24801976_1_Ent4", "role": "Treatment_Drug", "text": "drugs", "start": 10, "end": 11}, {"entity_id": "24801976_1_Ent2", "role": "Treatment_Disorder", "text": "chronic pain", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "24801976_1_Ent0", "text": "serious interaction", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "24801976_1_Ent3", "text": "frequently", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "24801976_1_Ent1", "text": "frequently used drugs", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "24801976_1_Ent4", "text": "drugs", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "24801976_1_Ent2", "text": "chronic pain", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "2483959_3", "wnd_id": "2483959_3_1", "text": "Several possible explanations of the mechanism of renal failure associated with the use of dextran - 40 are discussed .", "tokens": ["Several", "possible", "explanations", "of", "the", "mechanism", "of", "renal", "failure", "associated", "with", "the", "use", "of", "dextran", "-", "40", "are", "discussed", "."], "event_mentions": [{"id": "2483959_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "2483959_3_Ent0", "role": "Effect", "text": "renal failure", "start": 7, "end": 9}, {"entity_id": "2483959_3_Ent1", "role": "Treatment", "text": "dextran - 40", "start": 14, "end": 17}, {"entity_id": "2483959_3_Ent2", "role": "Treatment_Drug", "text": "dextran - 40", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "2483959_3_Ent0", "text": "renal failure", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "2483959_3_Ent1", "text": "dextran - 40", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "2483959_3_Ent2", "text": "dextran - 40", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "2483959_4", "wnd_id": "2483959_4_1", "text": "While the mechanism of dextran - associated renal failure remains unsolved , plasma exchange seems to be effective therapy .", "tokens": ["While", "the", "mechanism", "of", "dextran", "-", "associated", "renal", "failure", "remains", "unsolved", ",", "plasma", "exchange", "seems", "to", "be", "effective", "therapy", "."], "event_mentions": [{"id": "2483959_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "2483959_4_Ent1", "role": "Treatment", "text": "dextran", "start": 4, "end": 5}, {"entity_id": "2483959_4_Ent2", "role": "Treatment_Drug", "text": "dextran", "start": 4, "end": 5}, {"entity_id": "2483959_4_Ent0", "role": "Effect", "text": "renal failure", "start": 7, "end": 9}]}, {"id": "2483959_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "effective", "start": 17, "end": 18}, "arguments": [{"entity_id": "2483959_4_Ent5", "role": "Treatment_Disorder", "text": "dextran - associated renal failure", "start": 4, "end": 9}, {"entity_id": "2483959_4_Ent3", "role": "Treatment", "text": "plasma exchange", "start": 12, "end": 14}, {"entity_id": "2483959_4_Ent4", "role": "Treatment_Drug", "text": "plasma exchange", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "2483959_4_Ent1", "text": "dextran", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2483959_4_Ent2", "text": "dextran", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2483959_4_Ent5", "text": "dextran - associated renal failure", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "2483959_4_Ent0", "text": "renal failure", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "2483959_4_Ent3", "text": "plasma exchange", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2483959_4_Ent4", "text": "plasma exchange", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "24918555_1", "wnd_id": "24918555_1_1", "text": "Results of a Phase III , double - blind , randomized , parallel - group , non - inferiority study evaluating the safety and efficacy of isotretinoin - Lidose in patients with severe recalcitrant nodular acne .", "tokens": ["Results", "of", "a", "Phase", "III", ",", "double", "-", "blind", ",", "randomized", ",", "parallel", "-", "group", ",", "non", "-", "inferiority", "study", "evaluating", "the", "safety", "and", "efficacy", "of", "isotretinoin", "-", "Lidose", "in", "patients", "with", "severe", "recalcitrant", "nodular", "acne", "."], "event_mentions": [{"id": "24918555_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "of", "start": 25, "end": 26}, "arguments": [{"entity_id": "24918555_1_Ent1", "role": "Effect", "text": "evaluating the safety and efficacy", "start": 20, "end": 25}, {"entity_id": "24918555_1_Ent2", "role": "Treatment", "text": "isotretinoin - Lidose", "start": 26, "end": 29}, {"entity_id": "24918555_1_Ent4", "role": "Treatment_Drug", "text": "isotretinoin - Lidose", "start": 26, "end": 29}, {"entity_id": "24918555_1_Ent0", "role": "Subject", "text": "patients with severe recalcitrant nodular acne", "start": 30, "end": 36}, {"entity_id": "24918555_1_Ent3", "role": "Treatment_Disorder", "text": "severe recalcitrant nodular acne", "start": 32, "end": 36}]}], "entity_mentions": [{"id": "24918555_1_Ent1", "text": "evaluating the safety and efficacy", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "24918555_1_Ent2", "text": "isotretinoin - Lidose", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "24918555_1_Ent4", "text": "isotretinoin - Lidose", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "24918555_1_Ent0", "text": "patients with severe recalcitrant nodular acne", "entity_type": "Entity", "start": 30, "end": 36}, {"id": "24918555_1_Ent3", "text": "severe recalcitrant nodular acne", "entity_type": "Entity", "start": 32, "end": 36}], "lang": "en"}
{"doc_id": "24927617_1", "wnd_id": "24927617_1_1", "text": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin .", "tokens": ["Rhabdomyolysis", "in", "a", "hepatitis", "C", "virus", "infected", "patient", "treated", "with", "telaprevir", "and", "simvastatin", "."], "event_mentions": [{"id": "24927617_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "24927617_1_Ent1", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "24927617_1_Ent5", "role": "Treatment_Disorder", "text": "hepatitis C virus", "start": 3, "end": 6}, {"entity_id": "24927617_1_Ent0", "role": "Subject", "text": "hepatitis C virus infected patient", "start": 3, "end": 8}, {"entity_id": "24927617_1_Ent3", "role": "Treatment_Drug", "text": "telaprevir", "start": 10, "end": 11}, {"entity_id": "24927617_1_Ent6", "role": "Combination_Drug", "text": "telaprevir", "start": 10, "end": 11}, {"entity_id": "24927617_1_Ent2", "role": "Treatment", "text": "telaprevir and simvastatin", "start": 10, "end": 13}, {"entity_id": "24927617_1_Ent4", "role": "Treatment_Drug", "text": "simvastatin", "start": 12, "end": 13}, {"entity_id": "24927617_1_Ent7", "role": "Combination_Drug", "text": "simvastatin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "24927617_1_Ent1", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24927617_1_Ent5", "text": "hepatitis C virus", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "24927617_1_Ent0", "text": "hepatitis C virus infected patient", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "24927617_1_Ent3", "text": "telaprevir", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "24927617_1_Ent6", "text": "telaprevir", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "24927617_1_Ent2", "text": "telaprevir and simvastatin", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "24927617_1_Ent4", "text": "simvastatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "24927617_1_Ent7", "text": "simvastatin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "25295553_2", "wnd_id": "25295553_2_1", "text": "Pregabalin is an antiepileptic drug with anti - anxiety properties and is approved for treatment of generalized anxiety disorder .", "tokens": ["Pregabalin", "is", "an", "antiepileptic", "drug", "with", "anti", "-", "anxiety", "properties", "and", "is", "approved", "for", "treatment", "of", "generalized", "anxiety", "disorder", "."], "event_mentions": [{"id": "25295553_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 14, "end": 15}, "arguments": [{"entity_id": "25295553_2_Ent1", "role": "Treatment_Drug", "text": "Pregabalin", "start": 0, "end": 1}, {"entity_id": "25295553_2_Ent0", "role": "Treatment", "text": "Pregabalin is an antiepileptic drug with anti - anxiety properties", "start": 0, "end": 10}, {"entity_id": "25295553_2_Ent2", "role": "Treatment_Disorder", "text": "generalized anxiety disorder", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "25295553_2_Ent1", "text": "Pregabalin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25295553_2_Ent0", "text": "Pregabalin is an antiepileptic drug with anti - anxiety properties", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "25295553_2_Ent2", "text": "generalized anxiety disorder", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "25407257_3", "wnd_id": "25407257_3_1", "text": "The seizures were suspected to be caused by a reduced concentration of VPA in the blood .", "tokens": ["The", "seizures", "were", "suspected", "to", "be", "caused", "by", "a", "reduced", "concentration", "of", "VPA", "in", "the", "blood", "."], "event_mentions": [{"id": "25407257_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 6, "end": 7}, "arguments": [{"entity_id": "25407257_3_Ent0", "role": "Effect", "text": "seizures", "start": 1, "end": 2}, {"entity_id": "25407257_3_Ent2", "role": "Treatment_Dosage", "text": "reduced concentration", "start": 9, "end": 11}, {"entity_id": "25407257_3_Ent1", "role": "Treatment", "text": "reduced concentration of VPA in the blood", "start": 9, "end": 16}, {"entity_id": "25407257_3_Ent3", "role": "Treatment_Drug", "text": "VPA", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "25407257_3_Ent0", "text": "seizures", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "25407257_3_Ent2", "text": "reduced concentration", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "25407257_3_Ent1", "text": "reduced concentration of VPA in the blood", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "25407257_3_Ent3", "text": "VPA", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "25407257_6", "wnd_id": "25407257_6_1", "text": "In December , he was prescribed 160 mg / day tebipenem pivoxil by an otolaryngologist for inflammation of the tympanic membrane .", "tokens": ["In", "December", ",", "he", "was", "prescribed", "160", "mg", "/", "day", "tebipenem", "pivoxil", "by", "an", "otolaryngologist", "for", "inflammation", "of", "the", "tympanic", "membrane", "."], "event_mentions": [{"id": "25407257_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 15, "end": 16}, "arguments": [{"entity_id": "25407257_6_Ent0", "role": "Subject", "text": "he", "start": 3, "end": 4}, {"entity_id": "25407257_6_Ent1", "role": "Subject_Gender", "text": "he", "start": 3, "end": 4}, {"entity_id": "25407257_6_Ent4", "role": "Treatment_Dosage", "text": "160 mg / day", "start": 6, "end": 10}, {"entity_id": "25407257_6_Ent2", "role": "Treatment", "text": "160 mg / day tebipenem pivoxil", "start": 6, "end": 12}, {"entity_id": "25407257_6_Ent5", "role": "Treatment_Drug", "text": "tebipenem pivoxil", "start": 10, "end": 12}, {"entity_id": "25407257_6_Ent3", "role": "Treatment_Disorder", "text": "inflammation of the tympanic membrane", "start": 16, "end": 21}]}], "entity_mentions": [{"id": "25407257_6_Ent0", "text": "he", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "25407257_6_Ent1", "text": "he", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "25407257_6_Ent4", "text": "160 mg / day", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "25407257_6_Ent2", "text": "160 mg / day tebipenem pivoxil", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "25407257_6_Ent5", "text": "tebipenem pivoxil", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "25407257_6_Ent3", "text": "inflammation of the tympanic membrane", "entity_type": "Entity", "start": 16, "end": 21}], "lang": "en"}
{"doc_id": "25515435_8", "wnd_id": "25515435_8_1", "text": "A liver biopsy in 2012 revealed marked fibrosis , leading the patient to start hepatitis C treatment with peginterferon alfa - 2a , ribavirin and boceprevir .", "tokens": ["A", "liver", "biopsy", "in", "2012", "revealed", "marked", "fibrosis", ",", "leading", "the", "patient", "to", "start", "hepatitis", "C", "treatment", "with", "peginterferon", "alfa", "-", "2a", ",", "ribavirin", "and", "boceprevir", "."], "event_mentions": [{"id": "25515435_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 16, "end": 17}, "arguments": [{"entity_id": "25515435_8_Ent2", "role": "Treatment_Disorder", "text": "fibrosis", "start": 7, "end": 8}, {"entity_id": "25515435_8_Ent0", "role": "Subject", "text": "fibrosis , leading the patient", "start": 7, "end": 12}, {"entity_id": "25515435_8_Ent3", "role": "Treatment_Drug", "text": "peginterferon alfa - 2a", "start": 18, "end": 22}, {"entity_id": "25515435_8_Ent8", "role": "Combination_Drug", "text": "peginterferon alfa - 2a", "start": 18, "end": 22}, {"entity_id": "25515435_8_Ent1", "role": "Treatment", "text": "peginterferon alfa - 2a , ribavirin and boceprevir", "start": 18, "end": 26}, {"entity_id": "25515435_8_Ent4", "role": "Treatment_Drug", "text": "ribavirin", "start": 23, "end": 24}, {"entity_id": "25515435_8_Ent6", "role": "Combination_Drug", "text": "ribavirin", "start": 23, "end": 24}, {"entity_id": "25515435_8_Ent5", "role": "Treatment_Drug", "text": "boceprevir", "start": 25, "end": 26}, {"entity_id": "25515435_8_Ent7", "role": "Combination_Drug", "text": "boceprevir", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "25515435_8_Ent2", "text": "fibrosis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "25515435_8_Ent0", "text": "fibrosis , leading the patient", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "25515435_8_Ent3", "text": "peginterferon alfa - 2a", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "25515435_8_Ent8", "text": "peginterferon alfa - 2a", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "25515435_8_Ent1", "text": "peginterferon alfa - 2a , ribavirin and boceprevir", "entity_type": "Entity", "start": 18, "end": 26}, {"id": "25515435_8_Ent4", "text": "ribavirin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "25515435_8_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "25515435_8_Ent5", "text": "boceprevir", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "25515435_8_Ent7", "text": "boceprevir", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "2554727_2", "wnd_id": "2554727_2_1", "text": "High - dose cytosine arabinoside may benefit patients with refractory acute leukemia .", "tokens": ["High", "-", "dose", "cytosine", "arabinoside", "may", "benefit", "patients", "with", "refractory", "acute", "leukemia", "."], "event_mentions": [{"id": "2554727_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "benefit", "start": 6, "end": 7}, "arguments": [{"entity_id": "2554727_2_Ent3", "role": "Treatment_Dosage", "text": "High - dose", "start": 0, "end": 3}, {"entity_id": "2554727_2_Ent1", "role": "Treatment", "text": "High - dose cytosine arabinoside", "start": 0, "end": 5}, {"entity_id": "2554727_2_Ent4", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 3, "end": 5}, {"entity_id": "2554727_2_Ent0", "role": "Subject", "text": "patients with refractory acute leukemia", "start": 7, "end": 12}, {"entity_id": "2554727_2_Ent2", "role": "Treatment_Disorder", "text": "refractory acute leukemia", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "2554727_2_Ent3", "text": "High - dose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2554727_2_Ent1", "text": "High - dose cytosine arabinoside", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "2554727_2_Ent4", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2554727_2_Ent0", "text": "patients with refractory acute leukemia", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "2554727_2_Ent2", "text": "refractory acute leukemia", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "2554727_4", "wnd_id": "2554727_4_1", "text": "We describe a patient with acute leukemia who developed Horner 's syndrome and a severe demyelinating peripheral neuropathy leading to death after receiving high - dose cytosine arabinoside .", "tokens": ["We", "describe", "a", "patient", "with", "acute", "leukemia", "who", "developed", "Horner", "'s", "syndrome", "and", "a", "severe", "demyelinating", "peripheral", "neuropathy", "leading", "to", "death", "after", "receiving", "high", "-", "dose", "cytosine", "arabinoside", "."], "event_mentions": [{"id": "2554727_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "2554727_4_Ent0", "role": "Subject", "text": "a patient with acute leukemia", "start": 2, "end": 7}, {"entity_id": "2554727_4_Ent3", "role": "Treatment_Disorder", "text": "acute leukemia", "start": 5, "end": 7}, {"entity_id": "2554727_4_Ent1", "role": "Effect", "text": "Horner 's syndrome and a severe demyelinating peripheral neuropathy leading to death", "start": 9, "end": 21}, {"entity_id": "2554727_4_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 23, "end": 26}, {"entity_id": "2554727_4_Ent2", "role": "Treatment", "text": "high - dose cytosine arabinoside .", "start": 23, "end": 29}, {"entity_id": "2554727_4_Ent4", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "2554727_4_Ent0", "text": "a patient with acute leukemia", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "2554727_4_Ent3", "text": "acute leukemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2554727_4_Ent1", "text": "Horner 's syndrome and a severe demyelinating peripheral neuropathy leading to death", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "2554727_4_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "2554727_4_Ent2", "text": "high - dose cytosine arabinoside .", "entity_type": "Entity", "start": 23, "end": 29}, {"id": "2554727_4_Ent4", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "2568058_4", "wnd_id": "2568058_4_1", "text": "Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail - changes .", "tokens": ["Reinstitution", "of", "penicillamine", "treatment", "caused", "a", "recurrence", "thus", "proving", "a", "causal", "relationship", "between", "penicillamine", "and", "the", "described", "nail", "-", "changes", "."], "event_mentions": [{"id": "2568058_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causal relationship", "start": 10, "end": 12}, "arguments": [{"entity_id": "2568058_4_Ent3", "role": "Treatment_Drug", "text": "penicillamine", "start": 2, "end": 3}, {"entity_id": "2568058_4_Ent1", "role": "Treatment", "text": "penicillamine", "start": 13, "end": 14}, {"entity_id": "2568058_4_Ent2", "role": "Treatment_Drug", "text": "penicillamine", "start": 13, "end": 14}, {"entity_id": "2568058_4_Ent0", "role": "Effect", "text": "nail - changes", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "2568058_4_Ent3", "text": "penicillamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "2568058_4_Ent1", "text": "penicillamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2568058_4_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2568058_4_Ent0", "text": "nail - changes", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "25842648_7", "wnd_id": "25842648_7_1", "text": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl , a commonly used opioid in anesthesia practice .", "tokens": ["This", "article", "discusses", "the", "clinical", "manifestations", "of", "the", "serotonin", "syndrome", "and", "highlights", "reported", "cases", "of", "serotonin", "syndrome", "specifically", "related", "to", "an", "interaction", "between", "SSRIs", "and", "fentanyl", ",", "a", "commonly", "used", "opioid", "in", "anesthesia", "practice", "."], "event_mentions": [{"id": "25842648_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 18, "end": 19}, "arguments": [{"entity_id": "25842648_7_Ent0", "role": "Subject", "text": "cases", "start": 13, "end": 14}, {"entity_id": "25842648_7_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 15, "end": 17}, {"entity_id": "25842648_7_Ent3", "role": "Treatment_Drug", "text": "SSRIs", "start": 23, "end": 24}, {"entity_id": "25842648_7_Ent5", "role": "Combination_Drug", "text": "SSRIs", "start": 23, "end": 24}, {"entity_id": "25842648_7_Ent2", "role": "Treatment", "text": "SSRIs and fentanyl", "start": 23, "end": 26}, {"entity_id": "25842648_7_Ent4", "role": "Treatment_Drug", "text": "fentanyl", "start": 25, "end": 26}, {"entity_id": "25842648_7_Ent6", "role": "Combination_Drug", "text": "fentanyl", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "25842648_7_Ent0", "text": "cases", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "25842648_7_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "25842648_7_Ent3", "text": "SSRIs", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "25842648_7_Ent5", "text": "SSRIs", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "25842648_7_Ent2", "text": "SSRIs and fentanyl", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "25842648_7_Ent4", "text": "fentanyl", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "25842648_7_Ent6", "text": "fentanyl", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "25957434_4", "wnd_id": "25957434_4_1", "text": "The same symptoms recurred few days after taking nitrendipine .", "tokens": ["The", "same", "symptoms", "recurred", "few", "days", "after", "taking", "nitrendipine", "."], "event_mentions": [{"id": "25957434_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 7, "end": 8}, "arguments": [{"entity_id": "25957434_4_Ent0", "role": "Effect", "text": "same symptoms", "start": 1, "end": 3}, {"entity_id": "25957434_4_Ent2", "role": "Treatment", "text": "few days after", "start": 4, "end": 7}, {"entity_id": "25957434_4_Ent3", "role": "Treatment_Time_elapsed", "text": "few days after", "start": 4, "end": 7}, {"entity_id": "25957434_4_Ent1", "role": "Treatment", "text": "nitrendipine", "start": 8, "end": 9}, {"entity_id": "25957434_4_Ent4", "role": "Treatment_Drug", "text": "nitrendipine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "25957434_4_Ent0", "text": "same symptoms", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "25957434_4_Ent2", "text": "few days after", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "25957434_4_Ent3", "text": "few days after", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "25957434_4_Ent1", "text": "nitrendipine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "25957434_4_Ent4", "text": "nitrendipine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "2643458_1", "wnd_id": "2643458_1_1", "text": "Attenuation of asparaginase - induced hyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation .", "tokens": ["Attenuation", "of", "asparaginase", "-", "induced", "hyperglycemia", "after", "substitution", "of", "the", "Erwinia", "carotovora", "for", "the", "Escherichia", "coli", "enzyme", "preparation", "."], "event_mentions": [{"id": "2643458_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "2643458_1_Ent0", "role": "Effect", "text": "Attenuation of asparaginase - induced hyperglycemia", "start": 0, "end": 6}, {"entity_id": "2643458_1_Ent1", "role": "Treatment", "text": "substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation", "start": 7, "end": 18}, {"entity_id": "2643458_1_Ent2", "role": "Treatment_Drug", "text": "Erwinia carotovora", "start": 10, "end": 12}, {"entity_id": "2643458_1_Ent3", "role": "Treatment_Drug", "text": "Escherichia coli enzyme preparation", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "2643458_1_Ent0", "text": "Attenuation of asparaginase - induced hyperglycemia", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "2643458_1_Ent1", "text": "substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation", "entity_type": "Entity", "start": 7, "end": 18}, {"id": "2643458_1_Ent2", "text": "Erwinia carotovora", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "2643458_1_Ent3", "text": "Escherichia coli enzyme preparation", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "267281_1", "wnd_id": "267281_1_1", "text": "A patient with chronic myeloid leukaemia treated with busulphan for 4 - 5 years , developed signs of busulphan toxicity and portal hypertension with ascites , oesophageal varices and jaundice .", "tokens": ["A", "patient", "with", "chronic", "myeloid", "leukaemia", "treated", "with", "busulphan", "for", "4", "-", "5", "years", ",", "developed", "signs", "of", "busulphan", "toxicity", "and", "portal", "hypertension", "with", "ascites", ",", "oesophageal", "varices", "and", "jaundice", "."], "event_mentions": [{"id": "267281_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "267281_1_Ent0", "role": "Subject", "text": "A patient with chronic myeloid leukaemia", "start": 0, "end": 6}, {"entity_id": "267281_1_Ent5", "role": "Treatment_Disorder", "text": "chronic myeloid leukaemia", "start": 3, "end": 6}, {"entity_id": "267281_1_Ent4", "role": "Treatment_Drug", "text": "busulphan", "start": 8, "end": 9}, {"entity_id": "267281_1_Ent2", "role": "Treatment", "text": "busulphan for 4 - 5 years", "start": 8, "end": 14}, {"entity_id": "267281_1_Ent3", "role": "Treatment_Duration", "text": "4 - 5 years", "start": 10, "end": 14}, {"entity_id": "267281_1_Ent1", "role": "Effect", "text": "busulphan toxicity and portal hypertension with ascites , oesophageal varices and jaundice", "start": 18, "end": 30}]}], "entity_mentions": [{"id": "267281_1_Ent0", "text": "A patient with chronic myeloid leukaemia", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "267281_1_Ent5", "text": "chronic myeloid leukaemia", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "267281_1_Ent4", "text": "busulphan", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "267281_1_Ent2", "text": "busulphan for 4 - 5 years", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "267281_1_Ent3", "text": "4 - 5 years", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "267281_1_Ent1", "text": "busulphan toxicity and portal hypertension with ascites , oesophageal varices and jaundice", "entity_type": "Entity", "start": 18, "end": 30}], "lang": "en"}
{"doc_id": "2690546_3", "wnd_id": "2690546_3_1", "text": "We report three cases of amiodarone - induced torsades de pointe .", "tokens": ["We", "report", "three", "cases", "of", "amiodarone", "-", "induced", "torsades", "de", "pointe", "."], "event_mentions": [{"id": "2690546_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "2690546_3_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "2690546_3_Ent0", "role": "Subject", "text": "three cases", "start": 2, "end": 4}, {"entity_id": "2690546_3_Ent3", "role": "Treatment", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "2690546_3_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "2690546_3_Ent2", "role": "Effect", "text": "torsades de pointe", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "2690546_3_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "2690546_3_Ent0", "text": "three cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "2690546_3_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2690546_3_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2690546_3_Ent2", "text": "torsades de pointe", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "2728526_2", "wnd_id": "2728526_2_1", "text": "Rifampin can be associated with severe adverse effects such as hepatitis , acute renal failure , hemolytic anemia , and thrombocytopenia .", "tokens": ["Rifampin", "can", "be", "associated", "with", "severe", "adverse", "effects", "such", "as", "hepatitis", ",", "acute", "renal", "failure", ",", "hemolytic", "anemia", ",", "and", "thrombocytopenia", "."], "event_mentions": [{"id": "2728526_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "2728526_2_Ent1", "role": "Treatment", "text": "Rifampin", "start": 0, "end": 1}, {"entity_id": "2728526_2_Ent2", "role": "Treatment_Drug", "text": "Rifampin", "start": 0, "end": 1}, {"entity_id": "2728526_2_Ent0", "role": "Effect", "text": "hepatitis , acute renal failure , hemolytic anemia , and thrombocytopenia", "start": 10, "end": 21}]}], "entity_mentions": [{"id": "2728526_2_Ent1", "text": "Rifampin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2728526_2_Ent2", "text": "Rifampin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2728526_2_Ent0", "text": "hepatitis , acute renal failure , hemolytic anemia , and thrombocytopenia", "entity_type": "Entity", "start": 10, "end": 21}], "lang": "en"}
{"doc_id": "2728526_4", "wnd_id": "2728526_4_1", "text": "This article reports the occurrence of rifampin - associated thrombocytopenia in an indigent patient after a four - month lapse in therapy for pulmonary tuberculosis .", "tokens": ["This", "article", "reports", "the", "occurrence", "of", "rifampin", "-", "associated", "thrombocytopenia", "in", "an", "indigent", "patient", "after", "a", "four", "-", "month", "lapse", "in", "therapy", "for", "pulmonary", "tuberculosis", "."], "event_mentions": [{"id": "2728526_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "2728526_4_Ent2", "role": "Treatment", "text": "rifampin", "start": 6, "end": 7}, {"entity_id": "2728526_4_Ent4", "role": "Treatment_Drug", "text": "rifampin", "start": 6, "end": 7}, {"entity_id": "2728526_4_Ent1", "role": "Effect", "text": "thrombocytopenia", "start": 9, "end": 10}, {"entity_id": "2728526_4_Ent0", "role": "Subject", "text": "an indigent patient", "start": 11, "end": 14}, {"entity_id": "2728526_4_Ent3", "role": "Treatment", "text": "after a four - month lapse in therapy for pulmonary tuberculosis", "start": 14, "end": 25}, {"entity_id": "2728526_4_Ent5", "role": "Treatment_Time_elapsed", "text": "four - month", "start": 16, "end": 19}, {"entity_id": "2728526_4_Ent6", "role": "Treatment_Disorder", "text": "pulmonary tuberculosis", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "2728526_4_Ent2", "text": "rifampin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2728526_4_Ent4", "text": "rifampin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2728526_4_Ent1", "text": "thrombocytopenia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2728526_4_Ent0", "text": "an indigent patient", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "2728526_4_Ent3", "text": "after a four - month lapse in therapy for pulmonary tuberculosis", "entity_type": "Entity", "start": 14, "end": 25}, {"id": "2728526_4_Ent5", "text": "four - month", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "2728526_4_Ent6", "text": "pulmonary tuberculosis", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "2746565_3", "wnd_id": "2746565_3_1", "text": "We describe a case of ulcerative proctitis after ibuprofen treatment in a girl with juvenile systemic lupus erythematosus .", "tokens": ["We", "describe", "a", "case", "of", "ulcerative", "proctitis", "after", "ibuprofen", "treatment", "in", "a", "girl", "with", "juvenile", "systemic", "lupus", "erythematosus", "."], "event_mentions": [{"id": "2746565_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "2746565_3_Ent2", "role": "Effect", "text": "ulcerative proctitis", "start": 5, "end": 7}, {"entity_id": "2746565_3_Ent4", "role": "Treatment_Drug", "text": "ibuprofen", "start": 8, "end": 9}, {"entity_id": "2746565_3_Ent3", "role": "Treatment", "text": "ibuprofen treatment", "start": 8, "end": 10}, {"entity_id": "2746565_3_Ent0", "role": "Subject", "text": "a girl with juvenile systemic lupus erythematosus", "start": 11, "end": 18}, {"entity_id": "2746565_3_Ent1", "role": "Subject_Gender", "text": "girl", "start": 12, "end": 13}, {"entity_id": "2746565_3_Ent5", "role": "Treatment_Disorder", "text": "juvenile systemic lupus erythematosus", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "2746565_3_Ent2", "text": "ulcerative proctitis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2746565_3_Ent4", "text": "ibuprofen", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2746565_3_Ent3", "text": "ibuprofen treatment", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "2746565_3_Ent0", "text": "a girl with juvenile systemic lupus erythematosus", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "2746565_3_Ent1", "text": "girl", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2746565_3_Ent5", "text": "juvenile systemic lupus erythematosus", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "2796025_1", "wnd_id": "2796025_1_1", "text": "Panic anxiety after abrupt discontinuation of mianserin .", "tokens": ["Panic", "anxiety", "after", "abrupt", "discontinuation", "of", "mianserin", "."], "event_mentions": [{"id": "2796025_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "2796025_1_Ent0", "role": "Effect", "text": "Panic anxiety", "start": 0, "end": 2}, {"entity_id": "2796025_1_Ent1", "role": "Treatment", "text": "abrupt discontinuation of mianserin", "start": 3, "end": 7}, {"entity_id": "2796025_1_Ent2", "role": "Treatment_Drug", "text": "mianserin", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "2796025_1_Ent0", "text": "Panic anxiety", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2796025_1_Ent1", "text": "abrupt discontinuation of mianserin", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "2796025_1_Ent2", "text": "mianserin", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "2830062_4", "wnd_id": "2830062_4_1", "text": "The hypoadrenalism was overcome by increasing steroid replacement therapy .", "tokens": ["The", "hypoadrenalism", "was", "overcome", "by", "increasing", "steroid", "replacement", "therapy", "."], "event_mentions": [{"id": "2830062_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "overcome", "start": 3, "end": 4}, "arguments": [{"entity_id": "2830062_4_Ent1", "role": "Treatment_Disorder", "text": "The hypoadrenalism", "start": 0, "end": 2}, {"entity_id": "2830062_4_Ent3", "role": "Treatment_Dosage", "text": "increasing", "start": 5, "end": 6}, {"entity_id": "2830062_4_Ent0", "role": "Treatment", "text": "increasing steroid replacement therapy", "start": 5, "end": 9}, {"entity_id": "2830062_4_Ent2", "role": "Treatment_Drug", "text": "steroid", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "2830062_4_Ent1", "text": "The hypoadrenalism", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2830062_4_Ent3", "text": "increasing", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2830062_4_Ent0", "text": "increasing steroid replacement therapy", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "2830062_4_Ent2", "text": "steroid", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "2857534_2", "wnd_id": "2857534_2_1", "text": "The authors caution that treatment with alprazolam may be complicated by the induction of mania .", "tokens": ["The", "authors", "caution", "that", "treatment", "with", "alprazolam", "may", "be", "complicated", "by", "the", "induction", "of", "mania", "."], "event_mentions": [{"id": "2857534_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induction of", "start": 12, "end": 14}, "arguments": [{"entity_id": "2857534_2_Ent1", "role": "Treatment", "text": "treatment with alprazolam", "start": 4, "end": 7}, {"entity_id": "2857534_2_Ent2", "role": "Treatment_Drug", "text": "alprazolam", "start": 6, "end": 7}, {"entity_id": "2857534_2_Ent0", "role": "Effect", "text": "mania", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "2857534_2_Ent1", "text": "treatment with alprazolam", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "2857534_2_Ent2", "text": "alprazolam", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2857534_2_Ent0", "text": "mania", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "2924444_8", "wnd_id": "2924444_8_1", "text": "We believe this is the first report of myocardial infarction due to coronary spasm , demonstrated by angiography associated with L - thyroxine therapy .", "tokens": ["We", "believe", "this", "is", "the", "first", "report", "of", "myocardial", "infarction", "due", "to", "coronary", "spasm", ",", "demonstrated", "by", "angiography", "associated", "with", "L", "-", "thyroxine", "therapy", "."], "event_mentions": [{"id": "2924444_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 18, "end": 19}, "arguments": [{"entity_id": "2924444_8_Ent0", "role": "Effect", "text": "myocardial infarction", "start": 8, "end": 10}, {"entity_id": "2924444_8_Ent1", "role": "Effect", "text": "coronary spasm", "start": 12, "end": 14}, {"entity_id": "2924444_8_Ent2", "role": "Treatment", "text": "L - thyroxine", "start": 20, "end": 23}, {"entity_id": "2924444_8_Ent3", "role": "Treatment_Drug", "text": "L - thyroxine", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "2924444_8_Ent0", "text": "myocardial infarction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "2924444_8_Ent1", "text": "coronary spasm", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2924444_8_Ent2", "text": "L - thyroxine", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "2924444_8_Ent3", "text": "L - thyroxine", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "2931445_2", "wnd_id": "2931445_2_1", "text": "A study of in vitro reactivity to L - T4 , as assessed by peripheral blood lymphocyte transformation , was carried out in a patient with Hashimoto 's disease who developed leukopenia during treatment with L - T4 .", "tokens": ["A", "study", "of", "in", "vitro", "reactivity", "to", "L", "-", "T4", ",", "as", "assessed", "by", "peripheral", "blood", "lymphocyte", "transformation", ",", "was", "carried", "out", "in", "a", "patient", "with", "Hashimoto", "'s", "disease", "who", "developed", "leukopenia", "during", "treatment", "with", "L", "-", "T4", "."], "event_mentions": [{"id": "2931445_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 30, "end": 31}, "arguments": [{"entity_id": "2931445_2_Ent0", "role": "Subject", "text": "a patient with Hashimoto 's disease", "start": 23, "end": 29}, {"entity_id": "2931445_2_Ent3", "role": "Treatment_Disorder", "text": "Hashimoto 's disease", "start": 26, "end": 29}, {"entity_id": "2931445_2_Ent1", "role": "Effect", "text": "leukopenia", "start": 31, "end": 32}, {"entity_id": "2931445_2_Ent2", "role": "Treatment", "text": "L - T4", "start": 35, "end": 38}, {"entity_id": "2931445_2_Ent4", "role": "Treatment_Drug", "text": "L - T4", "start": 35, "end": 38}]}], "entity_mentions": [{"id": "2931445_2_Ent0", "text": "a patient with Hashimoto 's disease", "entity_type": "Entity", "start": 23, "end": 29}, {"id": "2931445_2_Ent3", "text": "Hashimoto 's disease", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "2931445_2_Ent1", "text": "leukopenia", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "2931445_2_Ent2", "text": "L - T4", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "2931445_2_Ent4", "text": "L - T4", "entity_type": "Entity", "start": 35, "end": 38}], "lang": "en"}
{"doc_id": "2931445_3", "wnd_id": "2931445_3_1", "text": "L - T4 stimulated lymphocyte transformation in this patient .", "tokens": ["L", "-", "T4", "stimulated", "lymphocyte", "transformation", "in", "this", "patient", "."], "event_mentions": [{"id": "2931445_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "stimulated", "start": 3, "end": 4}, "arguments": [{"entity_id": "2931445_3_Ent2", "role": "Treatment", "text": "L - T4", "start": 0, "end": 3}, {"entity_id": "2931445_3_Ent3", "role": "Treatment_Drug", "text": "L - T4", "start": 0, "end": 3}, {"entity_id": "2931445_3_Ent1", "role": "Effect", "text": "lymphocyte transformation", "start": 4, "end": 6}, {"entity_id": "2931445_3_Ent0", "role": "Subject", "text": "this patient", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "2931445_3_Ent2", "text": "L - T4", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2931445_3_Ent3", "text": "L - T4", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2931445_3_Ent1", "text": "lymphocyte transformation", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2931445_3_Ent0", "text": "this patient", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "2935070_1", "wnd_id": "2935070_1_1", "text": "Ampicillin - induced interstitial nephritis with generalised exfoliative dermatitis .", "tokens": ["Ampicillin", "-", "induced", "interstitial", "nephritis", "with", "generalised", "exfoliative", "dermatitis", "."], "event_mentions": [{"id": "2935070_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2935070_1_Ent1", "role": "Treatment", "text": "Ampicillin", "start": 0, "end": 1}, {"entity_id": "2935070_1_Ent2", "role": "Treatment_Drug", "text": "Ampicillin", "start": 0, "end": 1}, {"entity_id": "2935070_1_Ent0", "role": "Effect", "text": "interstitial nephritis with generalised exfoliative dermatitis", "start": 3, "end": 9}]}], "entity_mentions": [{"id": "2935070_1_Ent1", "text": "Ampicillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2935070_1_Ent2", "text": "Ampicillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2935070_1_Ent0", "text": "interstitial nephritis with generalised exfoliative dermatitis", "entity_type": "Entity", "start": 3, "end": 9}], "lang": "en"}
{"doc_id": "2979256_2", "wnd_id": "2979256_2_1", "text": "Gastro - oesophageal reflux associated with nifedipine .", "tokens": ["Gastro", "-", "oesophageal", "reflux", "associated", "with", "nifedipine", "."], "event_mentions": [{"id": "2979256_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "2979256_2_Ent0", "role": "Effect", "text": "Gastro - oesophageal reflux", "start": 0, "end": 4}, {"entity_id": "2979256_2_Ent1", "role": "Treatment", "text": "nifedipine", "start": 6, "end": 7}, {"entity_id": "2979256_2_Ent2", "role": "Treatment_Drug", "text": "nifedipine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "2979256_2_Ent0", "text": "Gastro - oesophageal reflux", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "2979256_2_Ent1", "text": "nifedipine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2979256_2_Ent2", "text": "nifedipine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "3003260_1", "wnd_id": "3003260_1_1", "text": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five - drug antiemetic regimen for cisplatin - associated nausea .", "tokens": ["A", "young", "diamond", "dealer", "developed", "visual", "impairment", "attributed", "to", "bilateral", "posterior", "subcapsular", "cataracts", "following", "only", "four", "courses", "of", "intermittent", "Decadron", "used", "as", "part", "of", "a", "five", "-", "drug", "antiemetic", "regimen", "for", "cisplatin", "-", "associated", "nausea", "."], "event_mentions": [{"id": "3003260_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 13, "end": 14}, "arguments": [{"entity_id": "3003260_1_Ent0", "role": "Subject", "text": "A young diamond dealer", "start": 0, "end": 4}, {"entity_id": "3003260_1_Ent1", "role": "Subject_Age", "text": "young", "start": 1, "end": 2}, {"entity_id": "3003260_1_Ent2", "role": "Effect", "text": "visual impairment attributed to bilateral posterior subcapsular cataracts", "start": 5, "end": 13}, {"entity_id": "3003260_1_Ent3", "role": "Treatment", "text": "only four courses of intermittent Decadron used as part of a five - drug antiemetic regimen", "start": 14, "end": 30}, {"entity_id": "3003260_1_Ent7", "role": "Treatment_Dosage", "text": "four courses", "start": 15, "end": 17}, {"entity_id": "3003260_1_Ent5", "role": "Treatment_Drug", "text": "Decadron", "start": 19, "end": 20}, {"entity_id": "3003260_1_Ent8", "role": "Combination_Drug", "text": "Decadron", "start": 19, "end": 20}, {"entity_id": "3003260_1_Ent6", "role": "Treatment_Drug", "text": "five - drug antiemetic regimen", "start": 25, "end": 30}, {"entity_id": "3003260_1_Ent9", "role": "Combination_Drug", "text": "five - drug antiemetic regimen", "start": 25, "end": 30}, {"entity_id": "3003260_1_Ent4", "role": "Treatment_Disorder", "text": "cisplatin - associated nausea", "start": 31, "end": 35}]}], "entity_mentions": [{"id": "3003260_1_Ent0", "text": "A young diamond dealer", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3003260_1_Ent1", "text": "young", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3003260_1_Ent2", "text": "visual impairment attributed to bilateral posterior subcapsular cataracts", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "3003260_1_Ent3", "text": "only four courses of intermittent Decadron used as part of a five - drug antiemetic regimen", "entity_type": "Entity", "start": 14, "end": 30}, {"id": "3003260_1_Ent7", "text": "four courses", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "3003260_1_Ent5", "text": "Decadron", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3003260_1_Ent8", "text": "Decadron", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3003260_1_Ent6", "text": "five - drug antiemetic regimen", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "3003260_1_Ent9", "text": "five - drug antiemetic regimen", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "3003260_1_Ent4", "text": "cisplatin - associated nausea", "entity_type": "Entity", "start": 31, "end": 35}], "lang": "en"}
{"doc_id": "3003260_2", "wnd_id": "3003260_2_1", "text": "Cataracts induced by intermittent Decadron used as an antiemetic .", "tokens": ["Cataracts", "induced", "by", "intermittent", "Decadron", "used", "as", "an", "antiemetic", "."], "event_mentions": [{"id": "3003260_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "3003260_2_Ent0", "role": "Effect", "text": "Cataracts", "start": 0, "end": 1}, {"entity_id": "3003260_2_Ent1", "role": "Treatment", "text": "Decadron", "start": 4, "end": 5}, {"entity_id": "3003260_2_Ent2", "role": "Treatment_Drug", "text": "Decadron", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "3003260_2_Ent0", "text": "Cataracts", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3003260_2_Ent1", "text": "Decadron", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3003260_2_Ent2", "text": "Decadron", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "3084231_3", "wnd_id": "3084231_3_1", "text": "Reversible valproic acid - induced dementia was documented in a 21 - year - old man with epilepsy who had a 3 - year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies .", "tokens": ["Reversible", "valproic", "acid", "-", "induced", "dementia", "was", "documented", "in", "a", "21", "-", "year", "-", "old", "man", "with", "epilepsy", "who", "had", "a", "3", "-", "year", "history", "of", "insidious", "progressive", "decline", "in", "global", "cognitive", "abilities", "documented", "by", "serial", "neuropsychological", "studies", "."], "event_mentions": [{"id": "3084231_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "3084231_3_Ent4", "role": "Effect", "text": "Reversible", "start": 0, "end": 1}, {"entity_id": "3084231_3_Ent6", "role": "Treatment", "text": "valproic acid", "start": 1, "end": 3}, {"entity_id": "3084231_3_Ent7", "role": "Treatment_Drug", "text": "valproic acid", "start": 1, "end": 3}, {"entity_id": "3084231_3_Ent5", "role": "Effect", "text": "dementia", "start": 5, "end": 6}, {"entity_id": "3084231_3_Ent0", "role": "Subject", "text": "a 21 - year - old man with epilepsy who had a 3 - year history of insidious progressive decline in global cognitive abilities", "start": 9, "end": 33}, {"entity_id": "3084231_3_Ent1", "role": "Subject_Age", "text": "21 - year - old", "start": 10, "end": 15}, {"entity_id": "3084231_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 15, "end": 16}, {"entity_id": "3084231_3_Ent8", "role": "Treatment_Disorder", "text": "epilepsy", "start": 17, "end": 18}, {"entity_id": "3084231_3_Ent3", "role": "Subject_Disorder", "text": "insidious progressive decline in global cognitive abilities", "start": 26, "end": 33}]}], "entity_mentions": [{"id": "3084231_3_Ent4", "text": "Reversible", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3084231_3_Ent6", "text": "valproic acid", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "3084231_3_Ent7", "text": "valproic acid", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "3084231_3_Ent5", "text": "dementia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3084231_3_Ent0", "text": "a 21 - year - old man with epilepsy who had a 3 - year history of insidious progressive decline in global cognitive abilities", "entity_type": "Entity", "start": 9, "end": 33}, {"id": "3084231_3_Ent1", "text": "21 - year - old", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "3084231_3_Ent2", "text": "man", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "3084231_3_Ent8", "text": "epilepsy", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "3084231_3_Ent3", "text": "insidious progressive decline in global cognitive abilities", "entity_type": "Entity", "start": 26, "end": 33}], "lang": "en"}
{"doc_id": "3115809_1", "wnd_id": "3115809_1_1", "text": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol .", "tokens": ["A", "patient", "developed", "optic", "neuropathy", "while", "being", "treated", "with", "isoniazid", "and", "ethambutol", "."], "event_mentions": [{"id": "3115809_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "3115809_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "3115809_1_Ent1", "role": "Effect", "text": "optic neuropathy", "start": 3, "end": 5}, {"entity_id": "3115809_1_Ent3", "role": "Treatment_Drug", "text": "isoniazid", "start": 9, "end": 10}, {"entity_id": "3115809_1_Ent5", "role": "Combination_Drug", "text": "isoniazid", "start": 9, "end": 10}, {"entity_id": "3115809_1_Ent2", "role": "Treatment", "text": "isoniazid and ethambutol", "start": 9, "end": 12}, {"entity_id": "3115809_1_Ent4", "role": "Treatment_Drug", "text": "ethambutol", "start": 11, "end": 12}, {"entity_id": "3115809_1_Ent6", "role": "Combination_Drug", "text": "ethambutol", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "3115809_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3115809_1_Ent1", "text": "optic neuropathy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3115809_1_Ent3", "text": "isoniazid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3115809_1_Ent5", "text": "isoniazid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3115809_1_Ent2", "text": "isoniazid and ethambutol", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "3115809_1_Ent4", "text": "ethambutol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3115809_1_Ent6", "text": "ethambutol", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "3124393_2", "wnd_id": "3124393_2_1", "text": "Calcification and ossification of the spinal arachnoid after intrathecal administration of Depo - Medrol .", "tokens": ["Calcification", "and", "ossification", "of", "the", "spinal", "arachnoid", "after", "intrathecal", "administration", "of", "Depo", "-", "Medrol", "."], "event_mentions": [{"id": "3124393_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "3124393_2_Ent0", "role": "Effect", "text": "Calcification and ossification of the spinal arachnoid", "start": 0, "end": 7}, {"entity_id": "3124393_2_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 8, "end": 9}, {"entity_id": "3124393_2_Ent1", "role": "Treatment", "text": "intrathecal administration of Depo - Medrol", "start": 8, "end": 14}, {"entity_id": "3124393_2_Ent3", "role": "Treatment_Drug", "text": "Depo - Medrol", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "3124393_2_Ent0", "text": "Calcification and ossification of the spinal arachnoid", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "3124393_2_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3124393_2_Ent1", "text": "intrathecal administration of Depo - Medrol", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "3124393_2_Ent3", "text": "Depo - Medrol", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "3152997_1", "wnd_id": "3152997_1_1", "text": "Atrial fibrillation following methylprednisolone pulse therapy .", "tokens": ["Atrial", "fibrillation", "following", "methylprednisolone", "pulse", "therapy", "."], "event_mentions": [{"id": "3152997_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3152997_1_Ent0", "role": "Effect", "text": "Atrial fibrillation", "start": 0, "end": 2}, {"entity_id": "3152997_1_Ent2", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 3, "end": 4}, {"entity_id": "3152997_1_Ent1", "role": "Treatment", "text": "methylprednisolone pulse therapy", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "3152997_1_Ent0", "text": "Atrial fibrillation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3152997_1_Ent2", "text": "methylprednisolone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3152997_1_Ent1", "text": "methylprednisolone pulse therapy", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "3156465_1", "wnd_id": "3156465_1_1", "text": "Isotretinoin , a drug used for the treatment of acne , has been shown to have teratogenic effects .", "tokens": ["Isotretinoin", ",", "a", "drug", "used", "for", "the", "treatment", "of", "acne", ",", "has", "been", "shown", "to", "have", "teratogenic", "effects", "."], "event_mentions": [{"id": "3156465_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 15, "end": 16}, "arguments": [{"entity_id": "3156465_1_Ent1", "role": "Treatment", "text": "Isotretinoin", "start": 0, "end": 1}, {"entity_id": "3156465_1_Ent2", "role": "Treatment_Drug", "text": "Isotretinoin", "start": 0, "end": 1}, {"entity_id": "3156465_1_Ent3", "role": "Treatment_Disorder", "text": "acne", "start": 9, "end": 10}, {"entity_id": "3156465_1_Ent0", "role": "Effect", "text": "teratogenic effects", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "3156465_1_Ent1", "text": "Isotretinoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3156465_1_Ent2", "text": "Isotretinoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3156465_1_Ent3", "text": "acne", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3156465_1_Ent0", "text": "teratogenic effects", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "3156465_3", "wnd_id": "3156465_3_1", "text": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis , multiple leptomeningeal neuroglial heterotopias , hydrocephalus , and abnormalities of the corticospinal tracts .", "tokens": ["We", "report", "an", "additional", "case", "of", "isotretinoin", "teratogenicity", "in", "which", "the", "patient", "had", "agenesis", "of", "the", "cerebellar", "vermis", ",", "multiple", "leptomeningeal", "neuroglial", "heterotopias", ",", "hydrocephalus", ",", "and", "abnormalities", "of", "the", "corticospinal", "tracts", "."], "event_mentions": [{"id": "3156465_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "teratogenicity", "start": 7, "end": 8}, "arguments": [{"entity_id": "3156465_3_Ent2", "role": "Treatment", "text": "isotretinoin", "start": 6, "end": 7}, {"entity_id": "3156465_3_Ent3", "role": "Treatment_Drug", "text": "isotretinoin", "start": 6, "end": 7}, {"entity_id": "3156465_3_Ent0", "role": "Subject", "text": "patient", "start": 11, "end": 12}, {"entity_id": "3156465_3_Ent1", "role": "Effect", "text": "agenesis of the cerebellar vermis , multiple leptomeningeal neuroglial heterotopias , hydrocephalus , and abnormalities of the corticospinal tracts", "start": 13, "end": 32}]}], "entity_mentions": [{"id": "3156465_3_Ent2", "text": "isotretinoin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3156465_3_Ent3", "text": "isotretinoin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3156465_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3156465_3_Ent1", "text": "agenesis of the cerebellar vermis , multiple leptomeningeal neuroglial heterotopias , hydrocephalus , and abnormalities of the corticospinal tracts", "entity_type": "Entity", "start": 13, "end": 32}], "lang": "en"}
{"doc_id": "3159106_1", "wnd_id": "3159106_1_1", "text": "A case of allopurinol hypersensitivity , possibly the first in a black African , is reported .", "tokens": ["A", "case", "of", "allopurinol", "hypersensitivity", ",", "possibly", "the", "first", "in", "a", "black", "African", ",", "is", "reported", "."], "event_mentions": [{"id": "3159106_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 2, "end": 3}, "arguments": [{"entity_id": "3159106_1_Ent3", "role": "Treatment", "text": "allopurinol", "start": 3, "end": 4}, {"entity_id": "3159106_1_Ent4", "role": "Treatment_Drug", "text": "allopurinol", "start": 3, "end": 4}, {"entity_id": "3159106_1_Ent2", "role": "Effect", "text": "hypersensitivity", "start": 4, "end": 5}, {"entity_id": "3159106_1_Ent0", "role": "Subject", "text": "a black African", "start": 10, "end": 13}, {"entity_id": "3159106_1_Ent1", "role": "Subject_Race", "text": "black African", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "3159106_1_Ent3", "text": "allopurinol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3159106_1_Ent4", "text": "allopurinol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3159106_1_Ent2", "text": "hypersensitivity", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3159106_1_Ent0", "text": "a black African", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3159106_1_Ent1", "text": "black African", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "3171334_2", "wnd_id": "3171334_2_1", "text": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients .", "tokens": ["Although", "differential", "diagnostic", "alternatives", "can", "be", "considered", "in", "all", "described", "cases", "it", "is", "very", "likely", "that", "vincristine", "does", "cause", "severe", "visual", "loss", "in", "a", "small", "number", "of", "patients", "."], "event_mentions": [{"id": "3171334_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 18, "end": 19}, "arguments": [{"entity_id": "3171334_2_Ent3", "role": "Treatment", "text": "vincristine", "start": 16, "end": 17}, {"entity_id": "3171334_2_Ent4", "role": "Treatment_Drug", "text": "vincristine", "start": 16, "end": 17}, {"entity_id": "3171334_2_Ent2", "role": "Effect", "text": "severe visual loss", "start": 19, "end": 22}, {"entity_id": "3171334_2_Ent1", "role": "Subject_Population", "text": "a small number", "start": 23, "end": 26}, {"entity_id": "3171334_2_Ent0", "role": "Subject", "text": "a small number of patients", "start": 23, "end": 28}]}], "entity_mentions": [{"id": "3171334_2_Ent3", "text": "vincristine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "3171334_2_Ent4", "text": "vincristine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "3171334_2_Ent2", "text": "severe visual loss", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "3171334_2_Ent1", "text": "a small number", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "3171334_2_Ent0", "text": "a small number of patients", "entity_type": "Entity", "start": 23, "end": 28}], "lang": "en"}
{"doc_id": "3259776_2", "wnd_id": "3259776_2_1", "text": "Thrombo - embolic complication after streptokinase therapy of pulmonary emboli .", "tokens": ["Thrombo", "-", "embolic", "complication", "after", "streptokinase", "therapy", "of", "pulmonary", "emboli", "."], "event_mentions": [{"id": "3259776_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "3259776_2_Ent0", "role": "Effect", "text": "Thrombo - embolic complication", "start": 0, "end": 4}, {"entity_id": "3259776_2_Ent1", "role": "Treatment", "text": "streptokinase", "start": 5, "end": 6}, {"entity_id": "3259776_2_Ent2", "role": "Treatment_Drug", "text": "streptokinase", "start": 5, "end": 6}, {"entity_id": "3259776_2_Ent3", "role": "Treatment_Disorder", "text": "pulmonary emboli .", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "3259776_2_Ent0", "text": "Thrombo - embolic complication", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3259776_2_Ent1", "text": "streptokinase", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3259776_2_Ent2", "text": "streptokinase", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3259776_2_Ent3", "text": "pulmonary emboli .", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "3301251_2", "wnd_id": "3301251_2_1", "text": "Hepatotoxicity associated with choline magnesium trisalicylate : case report and review of salicylate - induced hepatotoxicity .", "tokens": ["Hepatotoxicity", "associated", "with", "choline", "magnesium", "trisalicylate", ":", "case", "report", "and", "review", "of", "salicylate", "-", "induced", "hepatotoxicity", "."], "event_mentions": [{"id": "3301251_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "3301251_2_Ent1", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "3301251_2_Ent2", "role": "Treatment", "text": "choline magnesium trisalicylate", "start": 3, "end": 6}, {"entity_id": "3301251_2_Ent3", "role": "Treatment_Drug", "text": "choline magnesium trisalicylate", "start": 3, "end": 6}, {"entity_id": "3301251_2_Ent0", "role": "Subject", "text": "case", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "3301251_2_Ent1", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3301251_2_Ent2", "text": "choline magnesium trisalicylate", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3301251_2_Ent3", "text": "choline magnesium trisalicylate", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3301251_2_Ent0", "text": "case", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "3318771_1", "wnd_id": "3318771_1_1", "text": "We also describe a case of timolol - induced ocular pemphigoid .", "tokens": ["We", "also", "describe", "a", "case", "of", "timolol", "-", "induced", "ocular", "pemphigoid", "."], "event_mentions": [{"id": "3318771_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "3318771_1_Ent0", "role": "Subject", "text": "a case", "start": 3, "end": 5}, {"entity_id": "3318771_1_Ent2", "role": "Treatment", "text": "timolol", "start": 6, "end": 7}, {"entity_id": "3318771_1_Ent3", "role": "Treatment_Drug", "text": "timolol", "start": 6, "end": 7}, {"entity_id": "3318771_1_Ent1", "role": "Effect", "text": "ocular pemphigoid", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3318771_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3318771_1_Ent2", "text": "timolol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3318771_1_Ent3", "text": "timolol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3318771_1_Ent1", "text": "ocular pemphigoid", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "3335488_2", "wnd_id": "3335488_2_1", "text": "Two patients are described who developed testicular swelling and pain during treatment with desipramine .", "tokens": ["Two", "patients", "are", "described", "who", "developed", "testicular", "swelling", "and", "pain", "during", "treatment", "with", "desipramine", "."], "event_mentions": [{"id": "3335488_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "3335488_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "3335488_2_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "3335488_2_Ent2", "role": "Effect", "text": "testicular swelling and pain", "start": 6, "end": 10}, {"entity_id": "3335488_2_Ent3", "role": "Treatment", "text": "desipramine", "start": 13, "end": 14}, {"entity_id": "3335488_2_Ent4", "role": "Treatment_Drug", "text": "desipramine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "3335488_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3335488_2_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3335488_2_Ent2", "text": "testicular swelling and pain", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "3335488_2_Ent3", "text": "desipramine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3335488_2_Ent4", "text": "desipramine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "3343188_2", "wnd_id": "3343188_2_1", "text": "Benzocaine - induced methemoglobinemia has been reported in man , dogs , and cats .", "tokens": ["Benzocaine", "-", "induced", "methemoglobinemia", "has", "been", "reported", "in", "man", ",", "dogs", ",", "and", "cats", "."], "event_mentions": [{"id": "3343188_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3343188_2_Ent2", "role": "Treatment", "text": "Benzocaine", "start": 0, "end": 1}, {"entity_id": "3343188_2_Ent3", "role": "Treatment_Drug", "text": "Benzocaine", "start": 0, "end": 1}, {"entity_id": "3343188_2_Ent1", "role": "Effect", "text": "methemoglobinemia", "start": 3, "end": 4}, {"entity_id": "3343188_2_Ent0", "role": "Subject", "text": "man , dogs , and cats", "start": 8, "end": 14}]}], "entity_mentions": [{"id": "3343188_2_Ent2", "text": "Benzocaine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3343188_2_Ent3", "text": "Benzocaine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3343188_2_Ent1", "text": "methemoglobinemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3343188_2_Ent0", "text": "man , dogs , and cats", "entity_type": "Entity", "start": 8, "end": 14}], "lang": "en"}
{"doc_id": "3370103_1", "wnd_id": "3370103_1_1", "text": "Cardiopulmonary arrest following intravenous phenytoin loading .", "tokens": ["Cardiopulmonary", "arrest", "following", "intravenous", "phenytoin", "loading", "."], "event_mentions": [{"id": "3370103_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3370103_1_Ent0", "role": "Effect", "text": "Cardiopulmonary arrest", "start": 0, "end": 2}, {"entity_id": "3370103_1_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 3, "end": 4}, {"entity_id": "3370103_1_Ent1", "role": "Treatment", "text": "intravenous phenytoin loading", "start": 3, "end": 6}, {"entity_id": "3370103_1_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "3370103_1_Ent0", "text": "Cardiopulmonary arrest", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3370103_1_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3370103_1_Ent1", "text": "intravenous phenytoin loading", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3370103_1_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "3379435_1", "wnd_id": "3379435_1_1", "text": "Evidence obtained indicated that the Reye - like syndrome might be caused by calcium hopantenate possibly due to the induction of pantothenic acid deficiency .", "tokens": ["Evidence", "obtained", "indicated", "that", "the", "Reye", "-", "like", "syndrome", "might", "be", "caused", "by", "calcium", "hopantenate", "possibly", "due", "to", "the", "induction", "of", "pantothenic", "acid", "deficiency", "."], "event_mentions": [{"id": "3379435_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 11, "end": 12}, "arguments": [{"entity_id": "3379435_1_Ent0", "role": "Effect", "text": "Reye - like syndrome", "start": 5, "end": 9}, {"entity_id": "3379435_1_Ent1", "role": "Treatment", "text": "calcium hopantenate", "start": 13, "end": 15}, {"entity_id": "3379435_1_Ent2", "role": "Treatment_Drug", "text": "calcium hopantenate", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "3379435_1_Ent0", "text": "Reye - like syndrome", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "3379435_1_Ent1", "text": "calcium hopantenate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "3379435_1_Ent2", "text": "calcium hopantenate", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "3430507_1", "wnd_id": "3430507_1_1", "text": "D - penicillamine induced crescentic glomerulonephritis : report and review of the literature .", "tokens": ["D", "-", "penicillamine", "induced", "crescentic", "glomerulonephritis", ":", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "3430507_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "3430507_1_Ent1", "role": "Treatment", "text": "D - penicillamine", "start": 0, "end": 3}, {"entity_id": "3430507_1_Ent2", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 0, "end": 3}, {"entity_id": "3430507_1_Ent0", "role": "Effect", "text": "crescentic glomerulonephritis", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "3430507_1_Ent1", "text": "D - penicillamine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3430507_1_Ent2", "text": "D - penicillamine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3430507_1_Ent0", "text": "crescentic glomerulonephritis", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "3438585_6", "wnd_id": "3438585_6_1", "text": "This case supports the view that in gold - induced pneumonitis a prolonged treatment with corticosteroids may be necessary , as lung function continued to improve .", "tokens": ["This", "case", "supports", "the", "view", "that", "in", "gold", "-", "induced", "pneumonitis", "a", "prolonged", "treatment", "with", "corticosteroids", "may", "be", "necessary", ",", "as", "lung", "function", "continued", "to", "improve", "."], "event_mentions": [{"id": "3438585_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "as", "start": 20, "end": 21}, "arguments": [{"entity_id": "3438585_6_Ent1", "role": "Treatment_Disorder", "text": "in gold - induced pneumonitis", "start": 6, "end": 11}, {"entity_id": "3438585_6_Ent2", "role": "Treatment_Drug", "text": "gold", "start": 7, "end": 8}, {"entity_id": "3438585_6_Ent0", "role": "Treatment", "text": "a prolonged treatment with corticosteroids", "start": 11, "end": 16}, {"entity_id": "3438585_6_Ent3", "role": "Treatment_Drug", "text": "corticosteroids", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "3438585_6_Ent1", "text": "in gold - induced pneumonitis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "3438585_6_Ent2", "text": "gold", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3438585_6_Ent0", "text": "a prolonged treatment with corticosteroids", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "3438585_6_Ent3", "text": "corticosteroids", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "3470173_1", "wnd_id": "3470173_1_1", "text": "Because the cerebellar toxicity may be worsened by continuation of therapy after initial onset of symptoms , prompt termination of HDARAC is recommended .", "tokens": ["Because", "the", "cerebellar", "toxicity", "may", "be", "worsened", "by", "continuation", "of", "therapy", "after", "initial", "onset", "of", "symptoms", ",", "prompt", "termination", "of", "HDARAC", "is", "recommended", "."], "event_mentions": [{"id": "3470173_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 19, "end": 20}, "arguments": [{"entity_id": "3470173_1_Ent0", "role": "Effect", "text": "cerebellar toxicity", "start": 2, "end": 4}, {"entity_id": "3470173_1_Ent1", "role": "Treatment", "text": "HDARAC", "start": 20, "end": 21}, {"entity_id": "3470173_1_Ent2", "role": "Treatment_Drug", "text": "HDARAC", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "3470173_1_Ent0", "text": "cerebellar toxicity", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "3470173_1_Ent1", "text": "HDARAC", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "3470173_1_Ent2", "text": "HDARAC", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "3470173_3", "wnd_id": "3470173_3_1", "text": "During the first treatment , dysarthria and ataxia were seen after completion of the patient 's eighth and final dose of HDARAC .", "tokens": ["During", "the", "first", "treatment", ",", "dysarthria", "and", "ataxia", "were", "seen", "after", "completion", "of", "the", "patient", "'s", "eighth", "and", "final", "dose", "of", "HDARAC", "."], "event_mentions": [{"id": "3470173_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 9, "end": 10}, "arguments": [{"entity_id": "3470173_3_Ent1", "role": "Effect", "text": "dysarthria and ataxia", "start": 5, "end": 8}, {"entity_id": "3470173_3_Ent0", "role": "Subject", "text": "the patient 's", "start": 13, "end": 16}, {"entity_id": "3470173_3_Ent2", "role": "Treatment", "text": "HDARAC", "start": 21, "end": 22}, {"entity_id": "3470173_3_Ent3", "role": "Treatment_Drug", "text": "HDARAC", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "3470173_3_Ent1", "text": "dysarthria and ataxia", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "3470173_3_Ent0", "text": "the patient 's", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "3470173_3_Ent2", "text": "HDARAC", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "3470173_3_Ent3", "text": "HDARAC", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "3485422_2", "wnd_id": "3485422_2_1", "text": "We are concerned that the macular lesion was a retinal toxic effect of gentamicin because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug .", "tokens": ["We", "are", "concerned", "that", "the", "macular", "lesion", "was", "a", "retinal", "toxic", "effect", "of", "gentamicin", "because", "of", "the", "recent", "description", "of", "similar", "lesions", "occurring", "after", "the", "inadvertent", "intraocular", "injection", "of", "massive", "doses", "of", "this", "drug", "."], "event_mentions": [{"id": "3485422_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 12, "end": 13}, "arguments": [{"entity_id": "3485422_2_Ent0", "role": "Effect", "text": "macular lesion", "start": 5, "end": 7}, {"entity_id": "3485422_2_Ent1", "role": "Treatment", "text": "gentamicin", "start": 13, "end": 14}, {"entity_id": "3485422_2_Ent2", "role": "Treatment_Drug", "text": "gentamicin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "3485422_2_Ent0", "text": "macular lesion", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3485422_2_Ent1", "text": "gentamicin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3485422_2_Ent2", "text": "gentamicin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "3513544_1", "wnd_id": "3513544_1_1", "text": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A : a case report .", "tokens": ["Herpes", "simplex", "esophagitis", "in", "a", "renal", "transplant", "patient", "treated", "with", "cyclosporine", "A", ":", "a", "case", "report", "."], "event_mentions": [{"id": "3513544_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "3513544_1_Ent1", "role": "Effect", "text": "Herpes simplex esophagitis", "start": 0, "end": 3}, {"entity_id": "3513544_1_Ent4", "role": "Treatment_Disorder", "text": "renal transplant", "start": 5, "end": 7}, {"entity_id": "3513544_1_Ent0", "role": "Subject", "text": "renal transplant patient", "start": 5, "end": 8}, {"entity_id": "3513544_1_Ent2", "role": "Treatment", "text": "cyclosporine", "start": 10, "end": 11}, {"entity_id": "3513544_1_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "3513544_1_Ent1", "text": "Herpes simplex esophagitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3513544_1_Ent4", "text": "renal transplant", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3513544_1_Ent0", "text": "renal transplant patient", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "3513544_1_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3513544_1_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "3549808_1", "wnd_id": "3549808_1_1", "text": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction .", "tokens": ["One", "of", "the", "subjects", "who", "was", "using", "extemporaneous", "topical", "minoxidil", "had", "hypertension", "and", "arteriosclerotic", "disease", "and", "the", "other", "died", "of", "a", "myocardial", "infarction", "."], "event_mentions": [{"id": "3549808_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 10, "end": 11}, "arguments": [{"entity_id": "3549808_1_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "3549808_1_Ent0", "role": "Subject", "text": "One of the subjects", "start": 0, "end": 4}, {"entity_id": "3549808_1_Ent3", "role": "Treatment", "text": "extemporaneous topical minoxidil", "start": 7, "end": 10}, {"entity_id": "3549808_1_Ent4", "role": "Treatment_Route", "text": "topical", "start": 8, "end": 9}, {"entity_id": "3549808_1_Ent5", "role": "Treatment_Drug", "text": "minoxidil", "start": 9, "end": 10}, {"entity_id": "3549808_1_Ent2", "role": "Effect", "text": "hypertension and arteriosclerotic disease", "start": 11, "end": 15}]}, {"id": "3549808_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "died", "start": 18, "end": 19}, "arguments": [{"entity_id": "3549808_1_Ent8", "role": "Treatment", "text": "extemporaneous topical minoxidil", "start": 7, "end": 10}, {"entity_id": "3549808_1_Ent9", "role": "Treatment_Route", "text": "topical", "start": 8, "end": 9}, {"entity_id": "3549808_1_Ent10", "role": "Treatment_Drug", "text": "minoxidil", "start": 9, "end": 10}, {"entity_id": "3549808_1_Ent6", "role": "Subject", "text": "the other", "start": 16, "end": 18}, {"entity_id": "3549808_1_Ent7", "role": "Effect", "text": "died of a myocardial infarction", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "3549808_1_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3549808_1_Ent0", "text": "One of the subjects", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3549808_1_Ent3", "text": "extemporaneous topical minoxidil", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "3549808_1_Ent8", "text": "extemporaneous topical minoxidil", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "3549808_1_Ent4", "text": "topical", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3549808_1_Ent9", "text": "topical", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3549808_1_Ent5", "text": "minoxidil", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3549808_1_Ent10", "text": "minoxidil", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3549808_1_Ent2", "text": "hypertension and arteriosclerotic disease", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "3549808_1_Ent6", "text": "the other", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "3549808_1_Ent7", "text": "died of a myocardial infarction", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "3579660_1", "wnd_id": "3579660_1_1", "text": "Replicate brain magnetic resonance imaging examinations after six weeks and 11 months of penicillamine therapy documented the development of new brain lesions during this period , while liver biopsy specimen data disclosed that excellent hepatic decoppering had occurred .", "tokens": ["Replicate", "brain", "magnetic", "resonance", "imaging", "examinations", "after", "six", "weeks", "and", "11", "months", "of", "penicillamine", "therapy", "documented", "the", "development", "of", "new", "brain", "lesions", "during", "this", "period", ",", "while", "liver", "biopsy", "specimen", "data", "disclosed", "that", "excellent", "hepatic", "decoppering", "had", "occurred", "."], "event_mentions": [{"id": "3579660_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 17, "end": 18}, "arguments": [{"entity_id": "3579660_1_Ent2", "role": "Treatment_Duration", "text": "six weeks and 11 months", "start": 7, "end": 12}, {"entity_id": "3579660_1_Ent1", "role": "Treatment", "text": "six weeks and 11 months of penicillamine therapy", "start": 7, "end": 15}, {"entity_id": "3579660_1_Ent3", "role": "Treatment_Drug", "text": "penicillamine", "start": 13, "end": 14}, {"entity_id": "3579660_1_Ent0", "role": "Effect", "text": "new brain lesions", "start": 19, "end": 22}]}, {"id": "3579660_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "occurred", "start": 37, "end": 38}, "arguments": [{"entity_id": "3579660_1_Ent6", "role": "Treatment_Duration", "text": "six weeks and 11 months", "start": 7, "end": 12}, {"entity_id": "3579660_1_Ent5", "role": "Treatment", "text": "six weeks and 11 months of penicillamine therapy", "start": 7, "end": 15}, {"entity_id": "3579660_1_Ent7", "role": "Treatment_Drug", "text": "penicillamine", "start": 13, "end": 14}, {"entity_id": "3579660_1_Ent4", "role": "Effect", "text": "excellent hepatic decoppering", "start": 33, "end": 36}]}], "entity_mentions": [{"id": "3579660_1_Ent2", "text": "six weeks and 11 months", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "3579660_1_Ent6", "text": "six weeks and 11 months", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "3579660_1_Ent1", "text": "six weeks and 11 months of penicillamine therapy", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "3579660_1_Ent5", "text": "six weeks and 11 months of penicillamine therapy", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "3579660_1_Ent3", "text": "penicillamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3579660_1_Ent7", "text": "penicillamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3579660_1_Ent0", "text": "new brain lesions", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "3579660_1_Ent4", "text": "excellent hepatic decoppering", "entity_type": "Entity", "start": 33, "end": 36}], "lang": "en"}
{"doc_id": "3579660_3", "wnd_id": "3579660_3_1", "text": "We describe a patient with Wilson 's disease who presented with neurologic disease , was treated with D - penicillamine , and suffered sudden neurologic deterioration coincident with therapy .", "tokens": ["We", "describe", "a", "patient", "with", "Wilson", "'s", "disease", "who", "presented", "with", "neurologic", "disease", ",", "was", "treated", "with", "D", "-", "penicillamine", ",", "and", "suffered", "sudden", "neurologic", "deterioration", "coincident", "with", "therapy", "."], "event_mentions": [{"id": "3579660_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 22, "end": 23}, "arguments": [{"entity_id": "3579660_3_Ent0", "role": "Subject", "text": "a patient with Wilson 's disease who presented with neurologic disease", "start": 2, "end": 13}, {"entity_id": "3579660_3_Ent4", "role": "Treatment_Disorder", "text": "Wilson 's disease", "start": 5, "end": 8}, {"entity_id": "3579660_3_Ent1", "role": "Subject_Disorder", "text": "neurologic disease", "start": 11, "end": 13}, {"entity_id": "3579660_3_Ent3", "role": "Treatment", "text": "D - penicillamine", "start": 17, "end": 20}, {"entity_id": "3579660_3_Ent5", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 17, "end": 20}, {"entity_id": "3579660_3_Ent2", "role": "Effect", "text": "sudden neurologic deterioration", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "3579660_3_Ent0", "text": "a patient with Wilson 's disease who presented with neurologic disease", "entity_type": "Entity", "start": 2, "end": 13}, {"id": "3579660_3_Ent4", "text": "Wilson 's disease", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "3579660_3_Ent1", "text": "neurologic disease", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "3579660_3_Ent3", "text": "D - penicillamine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "3579660_3_Ent5", "text": "D - penicillamine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "3579660_3_Ent2", "text": "sudden neurologic deterioration", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "3609047_3", "wnd_id": "3609047_3_1", "text": "We report a case of torsade de pointes following a single oral dose of amiodarone ( 1400 mg or 30 mg kg - 1 ) administered after short intravenous loading for prevention of paroxysmal atrial flutter .", "tokens": ["We", "report", "a", "case", "of", "torsade", "de", "pointes", "following", "a", "single", "oral", "dose", "of", "amiodarone", "(", "1400", "mg", "or", "30", "mg", "kg", "-", "1", ")", "administered", "after", "short", "intravenous", "loading", "for", "prevention", "of", "paroxysmal", "atrial", "flutter", "."], "event_mentions": [{"id": "3609047_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "3609047_3_Ent0", "role": "Effect", "text": "torsade de pointes", "start": 5, "end": 8}, {"entity_id": "3609047_3_Ent1", "role": "Treatment", "text": "a single oral dose of amiodarone ( 1400 mg or 30 mg kg - 1 )", "start": 9, "end": 25}, {"entity_id": "3609047_3_Ent2", "role": "Treatment_Dosage", "text": "single oral dose", "start": 10, "end": 13}, {"entity_id": "3609047_3_Ent5", "role": "Treatment_Drug", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "3609047_3_Ent3", "role": "Treatment_Dosage", "text": "1400 mg", "start": 16, "end": 18}, {"entity_id": "3609047_3_Ent4", "role": "Treatment_Dosage", "text": "30 mg kg - 1", "start": 19, "end": 24}, {"entity_id": "3609047_3_Ent6", "role": "Treatment_Disorder", "text": "prevention of paroxysmal atrial flutter", "start": 31, "end": 36}]}], "entity_mentions": [{"id": "3609047_3_Ent0", "text": "torsade de pointes", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "3609047_3_Ent1", "text": "a single oral dose of amiodarone ( 1400 mg or 30 mg kg - 1 )", "entity_type": "Entity", "start": 9, "end": 25}, {"id": "3609047_3_Ent2", "text": "single oral dose", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3609047_3_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3609047_3_Ent3", "text": "1400 mg", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "3609047_3_Ent4", "text": "30 mg kg - 1", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "3609047_3_Ent6", "text": "prevention of paroxysmal atrial flutter", "entity_type": "Entity", "start": 31, "end": 36}], "lang": "en"}
{"doc_id": "3628148_1", "wnd_id": "3628148_1_1", "text": "Rupture of a cerebral aneurysm associated with nifedipine treatment .", "tokens": ["Rupture", "of", "a", "cerebral", "aneurysm", "associated", "with", "nifedipine", "treatment", "."], "event_mentions": [{"id": "3628148_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "3628148_1_Ent0", "role": "Effect", "text": "Rupture of a cerebral aneurysm", "start": 0, "end": 5}, {"entity_id": "3628148_1_Ent1", "role": "Treatment", "text": "nifedipine", "start": 7, "end": 8}, {"entity_id": "3628148_1_Ent2", "role": "Treatment_Drug", "text": "nifedipine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "3628148_1_Ent0", "text": "Rupture of a cerebral aneurysm", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "3628148_1_Ent1", "text": "nifedipine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3628148_1_Ent2", "text": "nifedipine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "3628148_2", "wnd_id": "3628148_2_1", "text": "We describe rupture of a cerebral arterial aneurysm in a 32 year old hypertensive woman following the introduction of nifedipine treatment .", "tokens": ["We", "describe", "rupture", "of", "a", "cerebral", "arterial", "aneurysm", "in", "a", "32", "year", "old", "hypertensive", "woman", "following", "the", "introduction", "of", "nifedipine", "treatment", "."], "event_mentions": [{"id": "3628148_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 15, "end": 16}, "arguments": [{"entity_id": "3628148_2_Ent3", "role": "Effect", "text": "rupture of a cerebral arterial aneurysm", "start": 2, "end": 8}, {"entity_id": "3628148_2_Ent0", "role": "Subject", "text": "a 32 year old hypertensive woman", "start": 9, "end": 15}, {"entity_id": "3628148_2_Ent1", "role": "Subject_Age", "text": "32 year old", "start": 10, "end": 13}, {"entity_id": "3628148_2_Ent5", "role": "Treatment_Disorder", "text": "hypertensive", "start": 13, "end": 14}, {"entity_id": "3628148_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 14, "end": 15}, {"entity_id": "3628148_2_Ent6", "role": "Treatment_Drug", "text": "nifedipine", "start": 19, "end": 20}, {"entity_id": "3628148_2_Ent4", "role": "Treatment", "text": "nifedipine treatment", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "3628148_2_Ent3", "text": "rupture of a cerebral arterial aneurysm", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "3628148_2_Ent0", "text": "a 32 year old hypertensive woman", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "3628148_2_Ent1", "text": "32 year old", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3628148_2_Ent5", "text": "hypertensive", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3628148_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3628148_2_Ent6", "text": "nifedipine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3628148_2_Ent4", "text": "nifedipine treatment", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "3680913_3", "wnd_id": "3680913_3_1", "text": "We suggest that nicotinic acid was the cause of his liver disease , that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure , and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity .", "tokens": ["We", "suggest", "that", "nicotinic", "acid", "was", "the", "cause", "of", "his", "liver", "disease", ",", "that", "this", "case", "is", "of", "particular", "note", "because", "of", "the", "rather", "short", "period", "of", "therapy", "before", "the", "onset", "of", "liver", "injury", "and", "the", "severity", "of", "the", "hepatic", "failure", ",", "and", "that", "the", "probable", "increased", "use", "of", "nicotinic", "acid", "for", "serum", "cholesterol", "control", "makes", "it", "especially", "important", "for", "physicians", "and", "their", "patients", "to", "be", "alert", "to", "the", "signs", "of", "hepatotoxicity", "."], "event_mentions": [{"id": "3680913_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "3680913_3_Ent1", "role": "Treatment", "text": "nicotinic acid", "start": 3, "end": 5}, {"entity_id": "3680913_3_Ent2", "role": "Treatment_Drug", "text": "nicotinic acid", "start": 3, "end": 5}, {"entity_id": "3680913_3_Ent0", "role": "Effect", "text": "liver disease", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "3680913_3_Ent1", "text": "nicotinic acid", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3680913_3_Ent2", "text": "nicotinic acid", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3680913_3_Ent0", "text": "liver disease", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "3688031_1", "wnd_id": "3688031_1_1", "text": "An infant girl with choanal atresia , athelia , minor anomalies , and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and propranolol .", "tokens": ["An", "infant", "girl", "with", "choanal", "atresia", ",", "athelia", ",", "minor", "anomalies", ",", "and", "mild", "to", "moderate", "mental", "retardation", "was", "born", "to", "a", "woman", "treated", "for", "hyperthyroidism", "throughout", "pregnancy", "with", "methimazole", "and", "propranolol", "."], "event_mentions": [{"id": "3688031_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 28, "end": 29}, "arguments": [{"entity_id": "3688031_1_Ent2", "role": "Effect", "text": "An infant girl with choanal atresia , athelia , minor anomalies , and mild to moderate mental retardation", "start": 0, "end": 18}, {"entity_id": "3688031_1_Ent0", "role": "Subject", "text": "a woman", "start": 21, "end": 23}, {"entity_id": "3688031_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 22, "end": 23}, {"entity_id": "3688031_1_Ent6", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 25, "end": 26}, {"entity_id": "3688031_1_Ent4", "role": "Treatment_Drug", "text": "methimazole", "start": 29, "end": 30}, {"entity_id": "3688031_1_Ent7", "role": "Combination_Drug", "text": "methimazole", "start": 29, "end": 30}, {"entity_id": "3688031_1_Ent3", "role": "Treatment", "text": "methimazole and propranolol", "start": 29, "end": 32}, {"entity_id": "3688031_1_Ent5", "role": "Treatment_Drug", "text": "propranolol", "start": 31, "end": 32}, {"entity_id": "3688031_1_Ent8", "role": "Combination_Drug", "text": "propranolol", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "3688031_1_Ent2", "text": "An infant girl with choanal atresia , athelia , minor anomalies , and mild to moderate mental retardation", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "3688031_1_Ent0", "text": "a woman", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "3688031_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "3688031_1_Ent6", "text": "hyperthyroidism", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "3688031_1_Ent4", "text": "methimazole", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "3688031_1_Ent7", "text": "methimazole", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "3688031_1_Ent3", "text": "methimazole and propranolol", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "3688031_1_Ent5", "text": "propranolol", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "3688031_1_Ent8", "text": "propranolol", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "3732375_1", "wnd_id": "3732375_1_1", "text": "Theophylline intoxication following viloxazine induced decrease in clearance .", "tokens": ["Theophylline", "intoxication", "following", "viloxazine", "induced", "decrease", "in", "clearance", "."], "event_mentions": [{"id": "3732375_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3732375_1_Ent3", "role": "Treatment_Drug", "text": "Theophylline", "start": 0, "end": 1}, {"entity_id": "3732375_1_Ent5", "role": "Combination_Drug", "text": "Theophylline", "start": 0, "end": 1}, {"entity_id": "3732375_1_Ent0", "role": "Effect", "text": "Theophylline intoxication", "start": 0, "end": 2}, {"entity_id": "3732375_1_Ent1", "role": "Treatment", "text": "viloxazine", "start": 3, "end": 4}, {"entity_id": "3732375_1_Ent2", "role": "Treatment_Drug", "text": "viloxazine", "start": 3, "end": 4}, {"entity_id": "3732375_1_Ent4", "role": "Combination_Drug", "text": "viloxazine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "3732375_1_Ent3", "text": "Theophylline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3732375_1_Ent5", "text": "Theophylline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3732375_1_Ent0", "text": "Theophylline intoxication", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3732375_1_Ent1", "text": "viloxazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3732375_1_Ent2", "text": "viloxazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3732375_1_Ent4", "text": "viloxazine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "3753891_1", "wnd_id": "3753891_1_1", "text": "Acute myocardial necrosis during administration of amsacrine .", "tokens": ["Acute", "myocardial", "necrosis", "during", "administration", "of", "amsacrine", "."], "event_mentions": [{"id": "3753891_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "3753891_1_Ent0", "role": "Effect", "text": "Acute myocardial necrosis", "start": 0, "end": 3}, {"entity_id": "3753891_1_Ent1", "role": "Treatment", "text": "amsacrine", "start": 6, "end": 7}, {"entity_id": "3753891_1_Ent2", "role": "Treatment_Drug", "text": "amsacrine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "3753891_1_Ent0", "text": "Acute myocardial necrosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3753891_1_Ent1", "text": "amsacrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3753891_1_Ent2", "text": "amsacrine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "3763264_1", "wnd_id": "3763264_1_1", "text": "Graft versus host - like illness in a child with phenobarbital hypersensitivity .", "tokens": ["Graft", "versus", "host", "-", "like", "illness", "in", "a", "child", "with", "phenobarbital", "hypersensitivity", "."], "event_mentions": [{"id": "3763264_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "hypersensitivity", "start": 11, "end": 12}, "arguments": [{"entity_id": "3763264_1_Ent2", "role": "Effect", "text": "Graft versus host - like illness", "start": 0, "end": 6}, {"entity_id": "3763264_1_Ent0", "role": "Subject", "text": "a child", "start": 7, "end": 9}, {"entity_id": "3763264_1_Ent1", "role": "Subject_Age", "text": "child", "start": 8, "end": 9}, {"entity_id": "3763264_1_Ent4", "role": "Treatment", "text": "phenobarbital", "start": 10, "end": 11}, {"entity_id": "3763264_1_Ent5", "role": "Treatment_Drug", "text": "phenobarbital", "start": 10, "end": 11}, {"entity_id": "3763264_1_Ent3", "role": "Effect", "text": "hypersensitivity", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "3763264_1_Ent2", "text": "Graft versus host - like illness", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "3763264_1_Ent0", "text": "a child", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "3763264_1_Ent1", "text": "child", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3763264_1_Ent4", "text": "phenobarbital", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3763264_1_Ent5", "text": "phenobarbital", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3763264_1_Ent3", "text": "hypersensitivity", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "3773837_1", "wnd_id": "3773837_1_1", "text": "The latter form ( Macrodantin ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form -- liver damage , acute and chronic pulmonary reactions , peripheral neuropathy , blood dyscrasias and allergic reactions -- and does so just as rapidly and floridly ; one such case is reported here .", "tokens": ["The", "latter", "form", "(", "Macrodantin", ")", "is", "reported", "to", "engender", "less", "gastrointestinal", "intolerance", "but", "it", "can", "produce", "the", "same", "adverse", "effects", "as", "the", "conventional", "form", "--", "liver", "damage", ",", "acute", "and", "chronic", "pulmonary", "reactions", ",", "peripheral", "neuropathy", ",", "blood", "dyscrasias", "and", "allergic", "reactions", "--", "and", "does", "so", "just", "as", "rapidly", "and", "floridly", ";", "one", "such", "case", "is", "reported", "here", "."], "event_mentions": [{"id": "3773837_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effects", "start": 19, "end": 21}, "arguments": [{"entity_id": "3773837_1_Ent4", "role": "Treatment", "text": "Macrodantin", "start": 4, "end": 5}, {"entity_id": "3773837_1_Ent5", "role": "Treatment_Drug", "text": "Macrodantin", "start": 4, "end": 5}, {"entity_id": "3773837_1_Ent2", "role": "Effect", "text": "less gastrointestinal intolerance", "start": 10, "end": 13}, {"entity_id": "3773837_1_Ent3", "role": "Effect", "text": "liver damage , acute and chronic pulmonary reactions , peripheral neuropathy , blood dyscrasias and allergic reactions", "start": 26, "end": 43}, {"entity_id": "3773837_1_Ent1", "role": "Subject_Population", "text": "one", "start": 53, "end": 54}, {"entity_id": "3773837_1_Ent0", "role": "Subject", "text": "one such case", "start": 53, "end": 56}]}], "entity_mentions": [{"id": "3773837_1_Ent4", "text": "Macrodantin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3773837_1_Ent5", "text": "Macrodantin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3773837_1_Ent2", "text": "less gastrointestinal intolerance", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3773837_1_Ent3", "text": "liver damage , acute and chronic pulmonary reactions , peripheral neuropathy , blood dyscrasias and allergic reactions", "entity_type": "Entity", "start": 26, "end": 43}, {"id": "3773837_1_Ent1", "text": "one", "entity_type": "Entity", "start": 53, "end": 54}, {"id": "3773837_1_Ent0", "text": "one such case", "entity_type": "Entity", "start": 53, "end": 56}], "lang": "en"}
{"doc_id": "3790438_2", "wnd_id": "3790438_2_1", "text": "We report a patient in whom the anti - depressant trazodone hydrochloride ( Molipaxin , Roussel ) , a serotonin antagonist , provoked generalized pustular psoriasis ( GPP ) .", "tokens": ["We", "report", "a", "patient", "in", "whom", "the", "anti", "-", "depressant", "trazodone", "hydrochloride", "(", "Molipaxin", ",", "Roussel", ")", ",", "a", "serotonin", "antagonist", ",", "provoked", "generalized", "pustular", "psoriasis", "(", "GPP", ")", "."], "event_mentions": [{"id": "3790438_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 22, "end": 23}, "arguments": [{"entity_id": "3790438_2_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "3790438_2_Ent3", "role": "Treatment_Drug", "text": "trazodone hydrochloride", "start": 10, "end": 12}, {"entity_id": "3790438_2_Ent2", "role": "Treatment", "text": "trazodone hydrochloride ( Molipaxin , Roussel )", "start": 10, "end": 17}, {"entity_id": "3790438_2_Ent1", "role": "Effect", "text": "generalized pustular psoriasis ( GPP )", "start": 23, "end": 29}]}], "entity_mentions": [{"id": "3790438_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "3790438_2_Ent3", "text": "trazodone hydrochloride", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3790438_2_Ent2", "text": "trazodone hydrochloride ( Molipaxin , Roussel )", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "3790438_2_Ent1", "text": "generalized pustular psoriasis ( GPP )", "entity_type": "Entity", "start": 23, "end": 29}], "lang": "en"}
{"doc_id": "3873709_1", "wnd_id": "3873709_1_1", "text": "Antibiotic - associated colitis ( pseudomembranous colitis ) developed in four patients with spinal cord injury and taking oral trimethoprim - sulfamethoxazole .", "tokens": ["Antibiotic", "-", "associated", "colitis", "(", "pseudomembranous", "colitis", ")", "developed", "in", "four", "patients", "with", "spinal", "cord", "injury", "and", "taking", "oral", "trimethoprim", "-", "sulfamethoxazole", "."], "event_mentions": [{"id": "3873709_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "3873709_1_Ent2", "role": "Effect", "text": "Antibiotic - associated colitis ( pseudomembranous colitis )", "start": 0, "end": 8}, {"entity_id": "3873709_1_Ent1", "role": "Subject_Population", "text": "four", "start": 10, "end": 11}, {"entity_id": "3873709_1_Ent0", "role": "Subject", "text": "four patients with spinal cord injury", "start": 10, "end": 16}, {"entity_id": "3873709_1_Ent7", "role": "Treatment_Disorder", "text": "spinal cord injury", "start": 13, "end": 16}, {"entity_id": "3873709_1_Ent6", "role": "Treatment_Route", "text": "oral", "start": 18, "end": 19}, {"entity_id": "3873709_1_Ent3", "role": "Treatment", "text": "oral trimethoprim - sulfamethoxazole", "start": 18, "end": 22}, {"entity_id": "3873709_1_Ent5", "role": "Treatment_Drug", "text": "trimethoprim", "start": 19, "end": 20}, {"entity_id": "3873709_1_Ent8", "role": "Combination_Drug", "text": "trimethoprim", "start": 19, "end": 20}, {"entity_id": "3873709_1_Ent4", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 21, "end": 22}, {"entity_id": "3873709_1_Ent9", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "3873709_1_Ent2", "text": "Antibiotic - associated colitis ( pseudomembranous colitis )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "3873709_1_Ent1", "text": "four", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3873709_1_Ent0", "text": "four patients with spinal cord injury", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "3873709_1_Ent7", "text": "spinal cord injury", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "3873709_1_Ent6", "text": "oral", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "3873709_1_Ent3", "text": "oral trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "3873709_1_Ent5", "text": "trimethoprim", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3873709_1_Ent8", "text": "trimethoprim", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3873709_1_Ent4", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "3873709_1_Ent9", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "3878320_2", "wnd_id": "3878320_2_1", "text": "The condition should be suspected in patients who develop unexplained abdominal pain or collapse following vasopressin treatment .", "tokens": ["The", "condition", "should", "be", "suspected", "in", "patients", "who", "develop", "unexplained", "abdominal", "pain", "or", "collapse", "following", "vasopressin", "treatment", "."], "event_mentions": [{"id": "3878320_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 8, "end": 9}, "arguments": [{"entity_id": "3878320_2_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "3878320_2_Ent1", "role": "Effect", "text": "unexplained abdominal pain or collapse", "start": 9, "end": 14}, {"entity_id": "3878320_2_Ent2", "role": "Treatment", "text": "vasopressin", "start": 15, "end": 16}, {"entity_id": "3878320_2_Ent3", "role": "Treatment_Drug", "text": "vasopressin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "3878320_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3878320_2_Ent1", "text": "unexplained abdominal pain or collapse", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "3878320_2_Ent2", "text": "vasopressin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "3878320_2_Ent3", "text": "vasopressin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "3892171_4", "wnd_id": "3892171_4_1", "text": "Although adverse reactions to protamine are reported infrequently and are usually mild , we recently observed the first fatal case of type I anaphylaxis resulting from protamine .", "tokens": ["Although", "adverse", "reactions", "to", "protamine", "are", "reported", "infrequently", "and", "are", "usually", "mild", ",", "we", "recently", "observed", "the", "first", "fatal", "case", "of", "type", "I", "anaphylaxis", "resulting", "from", "protamine", "."], "event_mentions": [{"id": "3892171_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 24, "end": 25}, "arguments": [{"entity_id": "3892171_4_Ent0", "role": "Effect", "text": "fatal case of type I anaphylaxis", "start": 18, "end": 24}, {"entity_id": "3892171_4_Ent1", "role": "Treatment", "text": "protamine", "start": 26, "end": 27}, {"entity_id": "3892171_4_Ent2", "role": "Treatment_Drug", "text": "protamine", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "3892171_4_Ent0", "text": "fatal case of type I anaphylaxis", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "3892171_4_Ent1", "text": "protamine", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3892171_4_Ent2", "text": "protamine", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "3947272_4", "wnd_id": "3947272_4_1", "text": "One patient had severe temporary weakness after an ampicillin sodium challenge .", "tokens": ["One", "patient", "had", "severe", "temporary", "weakness", "after", "an", "ampicillin", "sodium", "challenge", "."], "event_mentions": [{"id": "3947272_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "3947272_4_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "3947272_4_Ent0", "role": "Subject", "text": "One patient", "start": 0, "end": 2}, {"entity_id": "3947272_4_Ent2", "role": "Effect", "text": "temporary weakness", "start": 4, "end": 6}, {"entity_id": "3947272_4_Ent3", "role": "Treatment", "text": "an ampicillin sodium challenge", "start": 7, "end": 11}, {"entity_id": "3947272_4_Ent4", "role": "Treatment_Drug", "text": "ampicillin sodium", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "3947272_4_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3947272_4_Ent0", "text": "One patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3947272_4_Ent2", "text": "temporary weakness", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "3947272_4_Ent3", "text": "an ampicillin sodium challenge", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "3947272_4_Ent4", "text": "ampicillin sodium", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "3954165_1", "wnd_id": "3954165_1_1", "text": "A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma .", "tokens": ["A", "study", "following", "large", "patient", "groups", "on", "theophylline", "and", "a", "combination", "of", "theophylline", "and", "steroids", "might", "clarify", "the", "risk", "of", "ulcer", "formation", "in", "patients", "being", "treated", "with", "these", "medications", "for", "asthma", "."], "event_mentions": [{"id": "3954165_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 18, "end": 19}, "arguments": [{"entity_id": "3954165_1_Ent0", "role": "Subject", "text": "large patient groups", "start": 3, "end": 6}, {"entity_id": "3954165_1_Ent3", "role": "Treatment_Drug", "text": "theophylline", "start": 7, "end": 8}, {"entity_id": "3954165_1_Ent2", "role": "Treatment", "text": "theophylline and a combination of theophylline and steroids", "start": 7, "end": 15}, {"entity_id": "3954165_1_Ent4", "role": "Treatment_Drug", "text": "theophylline", "start": 12, "end": 13}, {"entity_id": "3954165_1_Ent7", "role": "Combination_Drug", "text": "theophylline", "start": 12, "end": 13}, {"entity_id": "3954165_1_Ent5", "role": "Treatment_Drug", "text": "steroids", "start": 14, "end": 15}, {"entity_id": "3954165_1_Ent8", "role": "Combination_Drug", "text": "steroids", "start": 14, "end": 15}, {"entity_id": "3954165_1_Ent1", "role": "Effect", "text": "ulcer", "start": 20, "end": 21}, {"entity_id": "3954165_1_Ent6", "role": "Treatment_Disorder", "text": "asthma", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "3954165_1_Ent0", "text": "large patient groups", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3954165_1_Ent3", "text": "theophylline", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3954165_1_Ent2", "text": "theophylline and a combination of theophylline and steroids", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "3954165_1_Ent4", "text": "theophylline", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3954165_1_Ent7", "text": "theophylline", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3954165_1_Ent5", "text": "steroids", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3954165_1_Ent8", "text": "steroids", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3954165_1_Ent1", "text": "ulcer", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "3954165_1_Ent6", "text": "asthma", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "3967572_5", "wnd_id": "3967572_5_1", "text": "With combined use , clinicians should be aware , when phenytoin is added , of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations .", "tokens": ["With", "combined", "use", ",", "clinicians", "should", "be", "aware", ",", "when", "phenytoin", "is", "added", ",", "of", "the", "potential", "for", "reexacerbation", "of", "pulmonary", "symptomatology", "due", "to", "lowered", "serum", "theophylline", "concentrations", "."], "event_mentions": [{"id": "3967572_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 22, "end": 23}, "arguments": [{"entity_id": "3967572_5_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 10, "end": 11}, {"entity_id": "3967572_5_Ent5", "role": "Combination_Drug", "text": "phenytoin", "start": 10, "end": 11}, {"entity_id": "3967572_5_Ent1", "role": "Treatment", "text": "phenytoin is added", "start": 10, "end": 13}, {"entity_id": "3967572_5_Ent0", "role": "Effect", "text": "reexacerbation of pulmonary symptomatology", "start": 18, "end": 22}, {"entity_id": "3967572_5_Ent2", "role": "Treatment", "text": "theophylline", "start": 26, "end": 27}, {"entity_id": "3967572_5_Ent4", "role": "Treatment_Drug", "text": "theophylline", "start": 26, "end": 27}, {"entity_id": "3967572_5_Ent6", "role": "Combination_Drug", "text": "theophylline", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "3967572_5_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3967572_5_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3967572_5_Ent1", "text": "phenytoin is added", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3967572_5_Ent0", "text": "reexacerbation of pulmonary symptomatology", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "3967572_5_Ent2", "text": "theophylline", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3967572_5_Ent4", "text": "theophylline", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3967572_5_Ent6", "text": "theophylline", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "3997294_2", "wnd_id": "3997294_2_1", "text": "Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis , immediate withdrawal of amiodarone , and prompt but continued steroid therapy to ensure full recovery .", "tokens": ["Review", "of", "this", "and", "previously", "reported", "cases", "indicates", "the", "need", "for", "early", "diagnosis", "of", "amiodarone", "pneumonitis", ",", "immediate", "withdrawal", "of", "amiodarone", ",", "and", "prompt", "but", "continued", "steroid", "therapy", "to", "ensure", "full", "recovery", "."], "event_mentions": [{"id": "3997294_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 13, "end": 14}, "arguments": [{"entity_id": "3997294_2_Ent1", "role": "Treatment", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "3997294_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "3997294_2_Ent0", "role": "Effect", "text": "pneumonitis", "start": 15, "end": 16}]}, {"id": "3997294_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "recovery", "start": 31, "end": 32}, "arguments": [{"entity_id": "3997294_2_Ent4", "role": "Treatment_Disorder", "text": "pneumonitis", "start": 15, "end": 16}, {"entity_id": "3997294_2_Ent3", "role": "Treatment", "text": "immediate withdrawal of amiodarone , and prompt but continued steroid therapy", "start": 17, "end": 28}, {"entity_id": "3997294_2_Ent6", "role": "Treatment_Drug", "text": "amiodarone", "start": 20, "end": 21}, {"entity_id": "3997294_2_Ent5", "role": "Treatment_Drug", "text": "steroid", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "3997294_2_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3997294_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3997294_2_Ent0", "text": "pneumonitis", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "3997294_2_Ent4", "text": "pneumonitis", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "3997294_2_Ent3", "text": "immediate withdrawal of amiodarone , and prompt but continued steroid therapy", "entity_type": "Entity", "start": 17, "end": 28}, {"id": "3997294_2_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "3997294_2_Ent5", "text": "steroid", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "4014301_1", "wnd_id": "4014301_1_1", "text": "Insulin - induced cardiac failure .", "tokens": ["Insulin", "-", "induced", "cardiac", "failure", "."], "event_mentions": [{"id": "4014301_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "4014301_1_Ent1", "role": "Treatment", "text": "Insulin", "start": 0, "end": 1}, {"entity_id": "4014301_1_Ent2", "role": "Treatment_Drug", "text": "Insulin", "start": 0, "end": 1}, {"entity_id": "4014301_1_Ent0", "role": "Effect", "text": "cardiac failure", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "4014301_1_Ent1", "text": "Insulin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4014301_1_Ent2", "text": "Insulin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4014301_1_Ent0", "text": "cardiac failure", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "4018433_2", "wnd_id": "4018433_2_1", "text": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia .", "tokens": ["Administration", "of", "pyridoxine", "to", "an", "infant", "after", "a", "long", "period", "of", "convulsions", "was", "followed", "by", "acute", "hypotonia", "."], "event_mentions": [{"id": "4018433_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 13, "end": 14}, "arguments": [{"entity_id": "4018433_2_Ent3", "role": "Treatment", "text": "pyridoxine", "start": 2, "end": 3}, {"entity_id": "4018433_2_Ent4", "role": "Treatment_Drug", "text": "pyridoxine", "start": 2, "end": 3}, {"entity_id": "4018433_2_Ent0", "role": "Subject", "text": "an infant", "start": 4, "end": 6}, {"entity_id": "4018433_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 5, "end": 6}, {"entity_id": "4018433_2_Ent5", "role": "Treatment_Disorder", "text": "convulsions", "start": 11, "end": 12}, {"entity_id": "4018433_2_Ent2", "role": "Effect", "text": "acute hypotonia", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "4018433_2_Ent3", "text": "pyridoxine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "4018433_2_Ent4", "text": "pyridoxine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "4018433_2_Ent0", "text": "an infant", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "4018433_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "4018433_2_Ent5", "text": "convulsions", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4018433_2_Ent2", "text": "acute hypotonia", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "4038510_3", "wnd_id": "4038510_3_1", "text": "Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage .", "tokens": ["Sodium", "thiosulfate", "is", "a", "neutralizing", "agent", "for", "cisplatin", "that", "protects", "against", "renal", "damage", "."], "event_mentions": [{"id": "4038510_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "protects", "start": 9, "end": 10}, "arguments": [{"entity_id": "4038510_3_Ent3", "role": "Treatment_Drug", "text": "Sodium thiosulfate", "start": 0, "end": 2}, {"entity_id": "4038510_3_Ent5", "role": "Combination_Drug", "text": "Sodium thiosulfate", "start": 0, "end": 2}, {"entity_id": "4038510_3_Ent1", "role": "Treatment", "text": "Sodium thiosulfate is a neutralizing agent for cisplatin", "start": 0, "end": 8}, {"entity_id": "4038510_3_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 7, "end": 8}, {"entity_id": "4038510_3_Ent6", "role": "Combination_Drug", "text": "cisplatin", "start": 7, "end": 8}, {"entity_id": "4038510_3_Ent0", "role": "Effect", "text": "protects against renal damage", "start": 9, "end": 13}, {"entity_id": "4038510_3_Ent4", "role": "Treatment_Disorder", "text": "renal damage", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "4038510_3_Ent3", "text": "Sodium thiosulfate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "4038510_3_Ent5", "text": "Sodium thiosulfate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "4038510_3_Ent1", "text": "Sodium thiosulfate is a neutralizing agent for cisplatin", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "4038510_3_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "4038510_3_Ent6", "text": "cisplatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "4038510_3_Ent0", "text": "protects against renal damage", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "4038510_3_Ent4", "text": "renal damage", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "4044222_1", "wnd_id": "4044222_1_1", "text": "A 54 - year - old man , treated with amiodarone , developed thyrotoxicosis .", "tokens": ["A", "54", "-", "year", "-", "old", "man", ",", "treated", "with", "amiodarone", ",", "developed", "thyrotoxicosis", "."], "event_mentions": [{"id": "4044222_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "4044222_1_Ent0", "role": "Subject", "text": "A 54 - year - old man", "start": 0, "end": 7}, {"entity_id": "4044222_1_Ent1", "role": "Subject_Age", "text": "54 - year - old", "start": 1, "end": 6}, {"entity_id": "4044222_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "4044222_1_Ent4", "role": "Treatment", "text": "amiodarone", "start": 10, "end": 11}, {"entity_id": "4044222_1_Ent5", "role": "Treatment_Drug", "text": "amiodarone", "start": 10, "end": 11}, {"entity_id": "4044222_1_Ent3", "role": "Effect", "text": "thyrotoxicosis", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "4044222_1_Ent0", "text": "A 54 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "4044222_1_Ent1", "text": "54 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "4044222_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "4044222_1_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "4044222_1_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "4044222_1_Ent3", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "4054170_1", "wnd_id": "4054170_1_1", "text": "According to the literature , chlorambucil central nervous toxicity is found almost exclusively in childhood nephrotic syndrome .", "tokens": ["According", "to", "the", "literature", ",", "chlorambucil", "central", "nervous", "toxicity", "is", "found", "almost", "exclusively", "in", "childhood", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "4054170_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "found", "start": 10, "end": 11}, "arguments": [{"entity_id": "4054170_1_Ent4", "role": "Treatment", "text": "chlorambucil", "start": 5, "end": 6}, {"entity_id": "4054170_1_Ent5", "role": "Treatment_Drug", "text": "chlorambucil", "start": 5, "end": 6}, {"entity_id": "4054170_1_Ent3", "role": "Effect", "text": "central nervous toxicity", "start": 6, "end": 9}, {"entity_id": "4054170_1_Ent1", "role": "Subject_Age", "text": "childhood", "start": 14, "end": 15}, {"entity_id": "4054170_1_Ent0", "role": "Subject", "text": "childhood nephrotic syndrome", "start": 14, "end": 17}, {"entity_id": "4054170_1_Ent2", "role": "Subject_Disorder", "text": "nephrotic syndrome", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "4054170_1_Ent4", "text": "chlorambucil", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "4054170_1_Ent5", "text": "chlorambucil", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "4054170_1_Ent3", "text": "central nervous toxicity", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "4054170_1_Ent1", "text": "childhood", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "4054170_1_Ent0", "text": "childhood nephrotic syndrome", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "4054170_1_Ent2", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "4063627_1", "wnd_id": "4063627_1_1", "text": "A 35 - year - old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac .", "tokens": ["A", "35", "-", "year", "-", "old", "man", "with", "seropositive", "rheumatoid", "arthritis", "developed", "selective", "IgA", "deficiency", "during", "treatment", "with", "fenclofenac", "."], "event_mentions": [{"id": "4063627_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 15, "end": 16}, "arguments": [{"entity_id": "4063627_1_Ent0", "role": "Subject", "text": "A 35 - year - old man with seropositive rheumatoid arthritis", "start": 0, "end": 11}, {"entity_id": "4063627_1_Ent1", "role": "Subject_Age", "text": "35 - year - old", "start": 1, "end": 6}, {"entity_id": "4063627_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "4063627_1_Ent6", "role": "Treatment_Disorder", "text": "seropositive rheumatoid arthritis", "start": 8, "end": 11}, {"entity_id": "4063627_1_Ent3", "role": "Effect", "text": "selective IgA deficiency", "start": 12, "end": 15}, {"entity_id": "4063627_1_Ent4", "role": "Treatment", "text": "fenclofenac", "start": 18, "end": 19}, {"entity_id": "4063627_1_Ent5", "role": "Treatment_Drug", "text": "fenclofenac", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "4063627_1_Ent0", "text": "A 35 - year - old man with seropositive rheumatoid arthritis", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "4063627_1_Ent1", "text": "35 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "4063627_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "4063627_1_Ent6", "text": "seropositive rheumatoid arthritis", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "4063627_1_Ent3", "text": "selective IgA deficiency", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "4063627_1_Ent4", "text": "fenclofenac", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "4063627_1_Ent5", "text": "fenclofenac", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "4075534_2", "wnd_id": "4075534_2_1", "text": "Spindle coma in benzodiazepine toxicity : case report .", "tokens": ["Spindle", "coma", "in", "benzodiazepine", "toxicity", ":", "case", "report", "."], "event_mentions": [{"id": "4075534_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "4075534_2_Ent0", "role": "Effect", "text": "Spindle coma", "start": 0, "end": 2}, {"entity_id": "4075534_2_Ent1", "role": "Treatment", "text": "benzodiazepine", "start": 3, "end": 4}, {"entity_id": "4075534_2_Ent2", "role": "Treatment_Drug", "text": "benzodiazepine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "4075534_2_Ent0", "text": "Spindle coma", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "4075534_2_Ent1", "text": "benzodiazepine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "4075534_2_Ent2", "text": "benzodiazepine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "4082283_6", "wnd_id": "4082283_6_1", "text": "A literature review revealed 83 other reported cases of rifampicin - induced renal insufficiency .", "tokens": ["A", "literature", "review", "revealed", "83", "other", "reported", "cases", "of", "rifampicin", "-", "induced", "renal", "insufficiency", "."], "event_mentions": [{"id": "4082283_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "4082283_6_Ent1", "role": "Subject_Population", "text": "83", "start": 4, "end": 5}, {"entity_id": "4082283_6_Ent0", "role": "Subject", "text": "83 other reported cases", "start": 4, "end": 8}, {"entity_id": "4082283_6_Ent3", "role": "Treatment", "text": "rifampicin", "start": 9, "end": 10}, {"entity_id": "4082283_6_Ent4", "role": "Treatment_Drug", "text": "rifampicin", "start": 9, "end": 10}, {"entity_id": "4082283_6_Ent2", "role": "Effect", "text": "renal insufficiency", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "4082283_6_Ent1", "text": "83", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "4082283_6_Ent0", "text": "83 other reported cases", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "4082283_6_Ent3", "text": "rifampicin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4082283_6_Ent4", "text": "rifampicin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4082283_6_Ent2", "text": "renal insufficiency", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "412488_2", "wnd_id": "412488_2_1", "text": "Three patients developed proteinuria following gold therapy for rheumatoid arthritis .", "tokens": ["Three", "patients", "developed", "proteinuria", "following", "gold", "therapy", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "412488_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "412488_2_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "412488_2_Ent0", "role": "Subject", "text": "Three patients", "start": 0, "end": 2}, {"entity_id": "412488_2_Ent2", "role": "Effect", "text": "proteinuria", "start": 3, "end": 4}, {"entity_id": "412488_2_Ent3", "role": "Treatment", "text": "gold", "start": 5, "end": 6}, {"entity_id": "412488_2_Ent5", "role": "Treatment_Drug", "text": "gold", "start": 5, "end": 6}, {"entity_id": "412488_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "412488_2_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "412488_2_Ent0", "text": "Three patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "412488_2_Ent2", "text": "proteinuria", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "412488_2_Ent3", "text": "gold", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "412488_2_Ent5", "text": "gold", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "412488_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "417679_1", "wnd_id": "417679_1_1", "text": "Four cases of fat embolism are described in infants receiving prolonged intravenous infusion of fat ( Intralipid 20 % ) .", "tokens": ["Four", "cases", "of", "fat", "embolism", "are", "described", "in", "infants", "receiving", "prolonged", "intravenous", "infusion", "of", "fat", "(", "Intralipid", "20", "%", ")", "."], "event_mentions": [{"id": "417679_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 9, "end": 10}, "arguments": [{"entity_id": "417679_1_Ent3", "role": "Subject_Age", "text": "Four", "start": 0, "end": 1}, {"entity_id": "417679_1_Ent0", "role": "Subject", "text": "Four cases", "start": 0, "end": 2}, {"entity_id": "417679_1_Ent4", "role": "Effect", "text": "fat embolism", "start": 3, "end": 5}, {"entity_id": "417679_1_Ent1", "role": "Subject", "text": "infants", "start": 8, "end": 9}, {"entity_id": "417679_1_Ent2", "role": "Subject_Age", "text": "infants", "start": 8, "end": 9}, {"entity_id": "417679_1_Ent5", "role": "Treatment", "text": "prolonged intravenous infusion of fat ( Intralipid 20 % )", "start": 10, "end": 20}, {"entity_id": "417679_1_Ent6", "role": "Treatment_Route", "text": "intravenous infusion", "start": 11, "end": 13}, {"entity_id": "417679_1_Ent7", "role": "Treatment_Drug", "text": "Intralipid", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "417679_1_Ent3", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "417679_1_Ent0", "text": "Four cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "417679_1_Ent4", "text": "fat embolism", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "417679_1_Ent1", "text": "infants", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "417679_1_Ent2", "text": "infants", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "417679_1_Ent5", "text": "prolonged intravenous infusion of fat ( Intralipid 20 % )", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "417679_1_Ent6", "text": "intravenous infusion", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "417679_1_Ent7", "text": "Intralipid", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "424824_3", "wnd_id": "424824_3_1", "text": "It is suggested therefore that methotrexate be added to the list of agents capable of inducing diffuse interstitial pulmonary fibrosis .", "tokens": ["It", "is", "suggested", "therefore", "that", "methotrexate", "be", "added", "to", "the", "list", "of", "agents", "capable", "of", "inducing", "diffuse", "interstitial", "pulmonary", "fibrosis", "."], "event_mentions": [{"id": "424824_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inducing", "start": 15, "end": 16}, "arguments": [{"entity_id": "424824_3_Ent1", "role": "Treatment", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "424824_3_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "424824_3_Ent0", "role": "Effect", "text": "diffuse interstitial pulmonary fibrosis", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "424824_3_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "424824_3_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "424824_3_Ent0", "text": "diffuse interstitial pulmonary fibrosis", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "448845_4", "wnd_id": "448845_4_1", "text": "This article describes two cases of aplastic anemia , at least one of which was almost certainly induced by the use of methazolamide , and one case of agranulocytosis related to the use of methazolamide .", "tokens": ["This", "article", "describes", "two", "cases", "of", "aplastic", "anemia", ",", "at", "least", "one", "of", "which", "was", "almost", "certainly", "induced", "by", "the", "use", "of", "methazolamide", ",", "and", "one", "case", "of", "agranulocytosis", "related", "to", "the", "use", "of", "methazolamide", "."], "event_mentions": [{"id": "448845_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 17, "end": 18}, "arguments": [{"entity_id": "448845_4_Ent0", "role": "Subject", "text": "two cases", "start": 3, "end": 5}, {"entity_id": "448845_4_Ent1", "role": "Effect", "text": "aplastic anemia", "start": 6, "end": 8}, {"entity_id": "448845_4_Ent2", "role": "Treatment", "text": "methazolamide", "start": 22, "end": 23}, {"entity_id": "448845_4_Ent3", "role": "Treatment_Drug", "text": "methazolamide", "start": 22, "end": 23}]}, {"id": "448845_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 29, "end": 30}, "arguments": [{"entity_id": "448845_4_Ent4", "role": "Effect", "text": "agranulocytosis", "start": 28, "end": 29}, {"entity_id": "448845_4_Ent5", "role": "Treatment", "text": "methazolamide", "start": 34, "end": 35}, {"entity_id": "448845_4_Ent6", "role": "Treatment_Drug", "text": "methazolamide", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "448845_4_Ent0", "text": "two cases", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "448845_4_Ent1", "text": "aplastic anemia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "448845_4_Ent2", "text": "methazolamide", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "448845_4_Ent3", "text": "methazolamide", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "448845_4_Ent4", "text": "agranulocytosis", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "448845_4_Ent5", "text": "methazolamide", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "448845_4_Ent6", "text": "methazolamide", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "515777_1", "wnd_id": "515777_1_1", "text": "Hyperglycemia and diabetic coma : possible relationship to diuretic - propranolol therapy .", "tokens": ["Hyperglycemia", "and", "diabetic", "coma", ":", "possible", "relationship", "to", "diuretic", "-", "propranolol", "therapy", "."], "event_mentions": [{"id": "515777_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 7, "end": 8}, "arguments": [{"entity_id": "515777_1_Ent0", "role": "Effect", "text": "Hyperglycemia and diabetic coma", "start": 0, "end": 4}, {"entity_id": "515777_1_Ent1", "role": "Treatment", "text": "propranolol", "start": 10, "end": 11}, {"entity_id": "515777_1_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "515777_1_Ent0", "text": "Hyperglycemia and diabetic coma", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "515777_1_Ent1", "text": "propranolol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "515777_1_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "53128_3", "wnd_id": "53128_3_1", "text": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain .", "tokens": ["This", "progressed", "to", "tracheal", "compression", "with", "stridor", "after", "he", "had", "taken", "some", "aspirin", "for", "relief", "of", "the", "neck", "pain", "."], "event_mentions": [{"id": "53128_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "progressed", "start": 1, "end": 2}, "arguments": [{"entity_id": "53128_3_Ent2", "role": "Effect", "text": "tracheal compression with stridor", "start": 3, "end": 7}, {"entity_id": "53128_3_Ent0", "role": "Subject", "text": "he", "start": 8, "end": 9}, {"entity_id": "53128_3_Ent1", "role": "Subject_Gender", "text": "he", "start": 8, "end": 9}, {"entity_id": "53128_3_Ent3", "role": "Treatment", "text": "aspirin", "start": 12, "end": 13}, {"entity_id": "53128_3_Ent4", "role": "Treatment_Drug", "text": "aspirin", "start": 12, "end": 13}, {"entity_id": "53128_3_Ent5", "role": "Treatment_Disorder", "text": "neck pain", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "53128_3_Ent2", "text": "tracheal compression with stridor", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "53128_3_Ent0", "text": "he", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "53128_3_Ent1", "text": "he", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "53128_3_Ent3", "text": "aspirin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "53128_3_Ent4", "text": "aspirin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "53128_3_Ent5", "text": "neck pain", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "566977_3", "wnd_id": "566977_3_1", "text": "Intravenous sodium bicarbonate appears to be indicated prophylactically in combating the associated metabolic acidosis due to absorbed formic acid .", "tokens": ["Intravenous", "sodium", "bicarbonate", "appears", "to", "be", "indicated", "prophylactically", "in", "combating", "the", "associated", "metabolic", "acidosis", "due", "to", "absorbed", "formic", "acid", "."], "event_mentions": [{"id": "566977_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "combating", "start": 9, "end": 10}, "arguments": [{"entity_id": "566977_3_Ent5", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "566977_3_Ent3", "role": "Treatment", "text": "Intravenous sodium bicarbonate", "start": 0, "end": 3}, {"entity_id": "566977_3_Ent6", "role": "Treatment_Drug", "text": "sodium bicarbonate", "start": 1, "end": 3}, {"entity_id": "566977_3_Ent4", "role": "Treatment_Disorder", "text": "metabolic acidosis due to absorbed formic acid", "start": 12, "end": 19}]}, {"id": "566977_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 14, "end": 15}, "arguments": [{"entity_id": "566977_3_Ent0", "role": "Effect", "text": "metabolic acidosis", "start": 12, "end": 14}, {"entity_id": "566977_3_Ent1", "role": "Treatment", "text": "absorbed formic acid", "start": 16, "end": 19}, {"entity_id": "566977_3_Ent2", "role": "Treatment_Drug", "text": "formic acid", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "566977_3_Ent5", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "566977_3_Ent3", "text": "Intravenous sodium bicarbonate", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "566977_3_Ent6", "text": "sodium bicarbonate", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "566977_3_Ent0", "text": "metabolic acidosis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "566977_3_Ent4", "text": "metabolic acidosis due to absorbed formic acid", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "566977_3_Ent1", "text": "absorbed formic acid", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "566977_3_Ent2", "text": "formic acid", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "578255_2", "wnd_id": "578255_2_1", "text": "Telescoped digits of the hands and feet developed in a 69 - year - old male with severe chronic tophaceous gout during allopurinol treatment .", "tokens": ["Telescoped", "digits", "of", "the", "hands", "and", "feet", "developed", "in", "a", "69", "-", "year", "-", "old", "male", "with", "severe", "chronic", "tophaceous", "gout", "during", "allopurinol", "treatment", "."], "event_mentions": [{"id": "578255_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "578255_2_Ent3", "role": "Effect", "text": "Telescoped digits of the hands and feet", "start": 0, "end": 7}, {"entity_id": "578255_2_Ent0", "role": "Subject", "text": "a 69 - year - old male with severe chronic tophaceous gout", "start": 9, "end": 21}, {"entity_id": "578255_2_Ent1", "role": "Subject_Age", "text": "69 - year - old", "start": 10, "end": 15}, {"entity_id": "578255_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 15, "end": 16}, {"entity_id": "578255_2_Ent5", "role": "Treatment_Disorder", "text": "severe chronic tophaceous gout", "start": 17, "end": 21}, {"entity_id": "578255_2_Ent6", "role": "Treatment_Drug", "text": "allopurinol", "start": 22, "end": 23}, {"entity_id": "578255_2_Ent4", "role": "Treatment", "text": "allopurinol treatment", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "578255_2_Ent3", "text": "Telescoped digits of the hands and feet", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "578255_2_Ent0", "text": "a 69 - year - old male with severe chronic tophaceous gout", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "578255_2_Ent1", "text": "69 - year - old", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "578255_2_Ent2", "text": "male", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "578255_2_Ent5", "text": "severe chronic tophaceous gout", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "578255_2_Ent6", "text": "allopurinol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "578255_2_Ent4", "text": "allopurinol treatment", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "582099_1", "wnd_id": "582099_1_1", "text": "A patient with coccidioidal meningitis was treated with intrathecally administered amphotericin B , and an acute toxic delirium with EEG abnormalities developed .", "tokens": ["A", "patient", "with", "coccidioidal", "meningitis", "was", "treated", "with", "intrathecally", "administered", "amphotericin", "B", ",", "and", "an", "acute", "toxic", "delirium", "with", "EEG", "abnormalities", "developed", "."], "event_mentions": [{"id": "582099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 6, "end": 8}, "arguments": [{"entity_id": "582099_1_Ent0", "role": "Subject", "text": "A patient with coccidioidal meningitis", "start": 0, "end": 5}, {"entity_id": "582099_1_Ent3", "role": "Treatment_Disorder", "text": "coccidioidal meningitis", "start": 3, "end": 5}, {"entity_id": "582099_1_Ent5", "role": "Treatment_Route", "text": "intrathecally", "start": 8, "end": 9}, {"entity_id": "582099_1_Ent2", "role": "Treatment", "text": "intrathecally administered amphotericin B", "start": 8, "end": 12}, {"entity_id": "582099_1_Ent4", "role": "Treatment_Drug", "text": "amphotericin B", "start": 10, "end": 12}, {"entity_id": "582099_1_Ent1", "role": "Effect", "text": "an acute toxic delirium with EEG abnormalities", "start": 14, "end": 21}]}], "entity_mentions": [{"id": "582099_1_Ent0", "text": "A patient with coccidioidal meningitis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "582099_1_Ent3", "text": "coccidioidal meningitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "582099_1_Ent5", "text": "intrathecally", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "582099_1_Ent2", "text": "intrathecally administered amphotericin B", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "582099_1_Ent4", "text": "amphotericin B", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "582099_1_Ent1", "text": "an acute toxic delirium with EEG abnormalities", "entity_type": "Entity", "start": 14, "end": 21}], "lang": "en"}
{"doc_id": "58443_1", "wnd_id": "58443_1_1", "text": "In keeping with findings in the literature , the aortic wall in this case was damaged by secondary changes following irradiation and Bleomycin treatment .", "tokens": ["In", "keeping", "with", "findings", "in", "the", "literature", ",", "the", "aortic", "wall", "in", "this", "case", "was", "damaged", "by", "secondary", "changes", "following", "irradiation", "and", "Bleomycin", "treatment", "."], "event_mentions": [{"id": "58443_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 19, "end": 20}, "arguments": [{"entity_id": "58443_1_Ent0", "role": "Effect", "text": "aortic wall in this case was damaged", "start": 9, "end": 16}, {"entity_id": "58443_1_Ent1", "role": "Treatment", "text": "irradiation and Bleomycin treatment .", "start": 20, "end": 25}, {"entity_id": "58443_1_Ent2", "role": "Treatment_Drug", "text": "Bleomycin", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "58443_1_Ent0", "text": "aortic wall in this case was damaged", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "58443_1_Ent1", "text": "irradiation and Bleomycin treatment .", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "58443_1_Ent2", "text": "Bleomycin", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "6108450_2", "wnd_id": "6108450_2_1", "text": "Two patients with imminent gangrene of the extremities caused by ergot - induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation , vasodilation , and sympathetic blockade produced no improvement .", "tokens": ["Two", "patients", "with", "imminent", "gangrene", "of", "the", "extremities", "caused", "by", "ergot", "-", "induced", "arteriospasm", "underwent", "mechanical", "dilatation", "of", "the", "arteries", "when", "conventional", "measures", "such", "as", "anticoagulation", ",", "vasodilation", ",", "and", "sympathetic", "blockade", "produced", "no", "improvement", "."], "event_mentions": [{"id": "6108450_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 8, "end": 9}, "arguments": [{"entity_id": "6108450_2_Ent5", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "6108450_2_Ent3", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "6108450_2_Ent6", "role": "Effect", "text": "imminent gangrene of the extremities", "start": 3, "end": 8}, {"entity_id": "6108450_2_Ent7", "role": "Treatment", "text": "ergot", "start": 10, "end": 11}, {"entity_id": "6108450_2_Ent8", "role": "Treatment_Drug", "text": "ergot", "start": 10, "end": 11}, {"entity_id": "6108450_2_Ent4", "role": "Subject_Disorder", "text": "ergot - induced arteriospasm", "start": 10, "end": 14}]}, {"id": "6108450_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "6108450_2_Ent1", "role": "Treatment", "text": "ergot", "start": 10, "end": 11}, {"entity_id": "6108450_2_Ent2", "role": "Treatment_Drug", "text": "ergot", "start": 10, "end": 11}, {"entity_id": "6108450_2_Ent0", "role": "Effect", "text": "arteriospasm", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "6108450_2_Ent5", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6108450_2_Ent3", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6108450_2_Ent6", "text": "imminent gangrene of the extremities", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "6108450_2_Ent1", "text": "ergot", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6108450_2_Ent2", "text": "ergot", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6108450_2_Ent7", "text": "ergot", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6108450_2_Ent8", "text": "ergot", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6108450_2_Ent4", "text": "ergot - induced arteriospasm", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "6108450_2_Ent0", "text": "arteriospasm", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "6149250_4", "wnd_id": "6149250_4_1", "text": "The second patient suffered from high blood pressure , which was controlled with beta - blocker drugs .", "tokens": ["The", "second", "patient", "suffered", "from", "high", "blood", "pressure", ",", "which", "was", "controlled", "with", "beta", "-", "blocker", "drugs", "."], "event_mentions": [{"id": "6149250_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "controlled", "start": 11, "end": 12}, "arguments": [{"entity_id": "6149250_4_Ent0", "role": "Subject", "text": "The second patient suffered from high blood pressure", "start": 0, "end": 8}, {"entity_id": "6149250_4_Ent2", "role": "Treatment_Disorder", "text": "high blood pressure", "start": 5, "end": 8}, {"entity_id": "6149250_4_Ent1", "role": "Treatment", "text": "beta - blocker drugs", "start": 13, "end": 17}, {"entity_id": "6149250_4_Ent3", "role": "Treatment_Drug", "text": "beta - blocker drugs", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "6149250_4_Ent0", "text": "The second patient suffered from high blood pressure", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "6149250_4_Ent2", "text": "high blood pressure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6149250_4_Ent1", "text": "beta - blocker drugs", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "6149250_4_Ent3", "text": "beta - blocker drugs", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "6149250_5", "wnd_id": "6149250_5_1", "text": "Both patients developed severe complications when treated with aminoglutethimide as a cancer hormonal therapy .", "tokens": ["Both", "patients", "developed", "severe", "complications", "when", "treated", "with", "aminoglutethimide", "as", "a", "cancer", "hormonal", "therapy", "."], "event_mentions": [{"id": "6149250_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "6149250_5_Ent0", "role": "Subject", "text": "Both patients", "start": 0, "end": 2}, {"entity_id": "6149250_5_Ent1", "role": "Effect", "text": "severe complications", "start": 3, "end": 5}, {"entity_id": "6149250_5_Ent2", "role": "Treatment", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "6149250_5_Ent4", "role": "Treatment_Drug", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "6149250_5_Ent3", "role": "Treatment_Disorder", "text": "cancer", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6149250_5_Ent0", "text": "Both patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6149250_5_Ent1", "text": "severe complications", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6149250_5_Ent2", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6149250_5_Ent4", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6149250_5_Ent3", "text": "cancer", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6159523_6", "wnd_id": "6159523_6_1", "text": "We suggest that the treatment of hypoglycaemia with 50 % solution of dextrose is associated with a significant risk factor in those diabetic individuals who are either allergic or are receiving beta - adrenoreceptor blocking drugs .", "tokens": ["We", "suggest", "that", "the", "treatment", "of", "hypoglycaemia", "with", "50", "%", "solution", "of", "dextrose", "is", "associated", "with", "a", "significant", "risk", "factor", "in", "those", "diabetic", "individuals", "who", "are", "either", "allergic", "or", "are", "receiving", "beta", "-", "adrenoreceptor", "blocking", "drugs", "."], "event_mentions": [{"id": "6159523_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 14, "end": 15}, "arguments": [{"entity_id": "6159523_6_Ent4", "role": "Treatment_Disorder", "text": "hypoglycaemia", "start": 6, "end": 7}, {"entity_id": "6159523_6_Ent6", "role": "Treatment_Route", "text": "50 % solution", "start": 8, "end": 11}, {"entity_id": "6159523_6_Ent3", "role": "Treatment", "text": "50 % solution of dextrose", "start": 8, "end": 13}, {"entity_id": "6159523_6_Ent5", "role": "Treatment_Drug", "text": "dextrose", "start": 12, "end": 13}, {"entity_id": "6159523_6_Ent2", "role": "Effect", "text": "a significant risk factor", "start": 16, "end": 20}, {"entity_id": "6159523_6_Ent1", "role": "Subject_Disorder", "text": "diabetic", "start": 22, "end": 23}, {"entity_id": "6159523_6_Ent0", "role": "Subject", "text": "diabetic individuals who are either allergic or are receiving beta - adrenoreceptor blocking drugs", "start": 22, "end": 36}]}], "entity_mentions": [{"id": "6159523_6_Ent4", "text": "hypoglycaemia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6159523_6_Ent6", "text": "50 % solution", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "6159523_6_Ent3", "text": "50 % solution of dextrose", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "6159523_6_Ent5", "text": "dextrose", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6159523_6_Ent2", "text": "a significant risk factor", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "6159523_6_Ent1", "text": "diabetic", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6159523_6_Ent0", "text": "diabetic individuals who are either allergic or are receiving beta - adrenoreceptor blocking drugs", "entity_type": "Entity", "start": 22, "end": 36}], "lang": "en"}
{"doc_id": "6303138_1", "wnd_id": "6303138_1_1", "text": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline .", "tokens": ["Marked", "sinus", "tachycardia", "resulting", "from", "the", "synergistic", "effects", "of", "marijuana", "and", "nortriptyline", "."], "event_mentions": [{"id": "6303138_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 3, "end": 4}, "arguments": [{"entity_id": "6303138_1_Ent0", "role": "Effect", "text": "Marked sinus tachycardia", "start": 0, "end": 3}, {"entity_id": "6303138_1_Ent2", "role": "Treatment_Drug", "text": "marijuana", "start": 9, "end": 10}, {"entity_id": "6303138_1_Ent4", "role": "Combination_Drug", "text": "marijuana", "start": 9, "end": 10}, {"entity_id": "6303138_1_Ent1", "role": "Treatment", "text": "marijuana and nortriptyline", "start": 9, "end": 12}, {"entity_id": "6303138_1_Ent3", "role": "Treatment_Drug", "text": "nortriptyline", "start": 11, "end": 12}, {"entity_id": "6303138_1_Ent5", "role": "Combination_Drug", "text": "nortriptyline", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6303138_1_Ent0", "text": "Marked sinus tachycardia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6303138_1_Ent2", "text": "marijuana", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6303138_1_Ent4", "text": "marijuana", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6303138_1_Ent1", "text": "marijuana and nortriptyline", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "6303138_1_Ent3", "text": "nortriptyline", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6303138_1_Ent5", "text": "nortriptyline", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6324592_1", "wnd_id": "6324592_1_1", "text": "Disulfiram - like reactions with newer cephalosporins : cefmenoxime .", "tokens": ["Disulfiram", "-", "like", "reactions", "with", "newer", "cephalosporins", ":", "cefmenoxime", "."], "event_mentions": [{"id": "6324592_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 4, "end": 5}, "arguments": [{"entity_id": "6324592_1_Ent0", "role": "Effect", "text": "Disulfiram - like reactions", "start": 0, "end": 4}, {"entity_id": "6324592_1_Ent1", "role": "Treatment", "text": "cefmenoxime", "start": 8, "end": 9}, {"entity_id": "6324592_1_Ent2", "role": "Treatment_Drug", "text": "cefmenoxime", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "6324592_1_Ent0", "text": "Disulfiram - like reactions", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "6324592_1_Ent1", "text": "cefmenoxime", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6324592_1_Ent2", "text": "cefmenoxime", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "6405633_2", "wnd_id": "6405633_2_1", "text": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy .", "tokens": ["Two", "patients", "with", "bipolar", "affective", "disorder", "and", "a", "history", "of", "bronchospastic", "phenomena", "experienced", "tremor", "during", "lithium", "carbonate", "therapy", "."], "event_mentions": [{"id": "6405633_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 12, "end": 13}, "arguments": [{"entity_id": "6405633_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "6405633_2_Ent0", "role": "Subject", "text": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena", "start": 0, "end": 12}, {"entity_id": "6405633_2_Ent6", "role": "Treatment_Disorder", "text": "bipolar affective disorder", "start": 3, "end": 6}, {"entity_id": "6405633_2_Ent2", "role": "Subject_Disorder", "text": "a history of bronchospastic phenomena", "start": 7, "end": 12}, {"entity_id": "6405633_2_Ent3", "role": "Effect", "text": "tremor", "start": 13, "end": 14}, {"entity_id": "6405633_2_Ent5", "role": "Treatment_Drug", "text": "lithium carbonate", "start": 15, "end": 17}, {"entity_id": "6405633_2_Ent4", "role": "Treatment", "text": "lithium carbonate therapy", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "6405633_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6405633_2_Ent0", "text": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "6405633_2_Ent6", "text": "bipolar affective disorder", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6405633_2_Ent2", "text": "a history of bronchospastic phenomena", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "6405633_2_Ent3", "text": "tremor", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6405633_2_Ent5", "text": "lithium carbonate", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6405633_2_Ent4", "text": "lithium carbonate therapy", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "6453500_1", "wnd_id": "6453500_1_1", "text": "A reversible toxic liver damage was observed in a non - alcoholic woman treated with disulfiram .", "tokens": ["A", "reversible", "toxic", "liver", "damage", "was", "observed", "in", "a", "non", "-", "alcoholic", "woman", "treated", "with", "disulfiram", "."], "event_mentions": [{"id": "6453500_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "damage", "start": 4, "end": 5}, "arguments": [{"entity_id": "6453500_1_Ent3", "role": "Effect", "text": "reversible toxic liver damage", "start": 1, "end": 5}, {"entity_id": "6453500_1_Ent0", "role": "Subject", "text": "a non - alcoholic woman", "start": 8, "end": 13}, {"entity_id": "6453500_1_Ent1", "role": "Subject_Disorder", "text": "non - alcoholic", "start": 9, "end": 12}, {"entity_id": "6453500_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 12, "end": 13}, {"entity_id": "6453500_1_Ent4", "role": "Treatment", "text": "disulfiram", "start": 15, "end": 16}, {"entity_id": "6453500_1_Ent5", "role": "Treatment_Drug", "text": "disulfiram", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "6453500_1_Ent3", "text": "reversible toxic liver damage", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "6453500_1_Ent0", "text": "a non - alcoholic woman", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "6453500_1_Ent1", "text": "non - alcoholic", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "6453500_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6453500_1_Ent4", "text": "disulfiram", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6453500_1_Ent5", "text": "disulfiram", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "6460590_1", "wnd_id": "6460590_1_1", "text": "One type of SMON is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of clioquinol .", "tokens": ["One", "type", "of", "SMON", "is", "associated", "with", "acrodermatitis", "enteropathica", "which", "has", "a", "very", "high", "frequency", "of", "occurrence", "in", "association", "with", "administration", "of", "clioquinol", "."], "event_mentions": [{"id": "6460590_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 18, "end": 19}, "arguments": [{"entity_id": "6460590_1_Ent0", "role": "Effect", "text": "SMON", "start": 3, "end": 4}, {"entity_id": "6460590_1_Ent1", "role": "Effect", "text": "acrodermatitis enteropathica", "start": 7, "end": 9}, {"entity_id": "6460590_1_Ent2", "role": "Treatment", "text": "clioquinol", "start": 22, "end": 23}, {"entity_id": "6460590_1_Ent3", "role": "Treatment_Drug", "text": "clioquinol", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "6460590_1_Ent0", "text": "SMON", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6460590_1_Ent1", "text": "acrodermatitis enteropathica", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6460590_1_Ent2", "text": "clioquinol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6460590_1_Ent3", "text": "clioquinol", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "647693_1", "wnd_id": "647693_1_1", "text": "Four patients receiving high - dose tamoxifen for greater than 1 year have demonstrated similar retinal changes .", "tokens": ["Four", "patients", "receiving", "high", "-", "dose", "tamoxifen", "for", "greater", "than", "1", "year", "have", "demonstrated", "similar", "retinal", "changes", "."], "event_mentions": [{"id": "647693_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 2, "end": 3}, "arguments": [{"entity_id": "647693_1_Ent1", "role": "Subject_Population", "text": "Four", "start": 0, "end": 1}, {"entity_id": "647693_1_Ent0", "role": "Subject", "text": "Four patients", "start": 0, "end": 2}, {"entity_id": "647693_1_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 3, "end": 6}, {"entity_id": "647693_1_Ent3", "role": "Treatment", "text": "high - dose tamoxifen for greater than 1 year", "start": 3, "end": 12}, {"entity_id": "647693_1_Ent6", "role": "Treatment_Drug", "text": "tamoxifen", "start": 6, "end": 7}, {"entity_id": "647693_1_Ent4", "role": "Treatment_Duration", "text": "1 year", "start": 10, "end": 12}, {"entity_id": "647693_1_Ent2", "role": "Effect", "text": "retinal changes", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "647693_1_Ent1", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "647693_1_Ent0", "text": "Four patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "647693_1_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "647693_1_Ent3", "text": "high - dose tamoxifen for greater than 1 year", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "647693_1_Ent6", "text": "tamoxifen", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "647693_1_Ent4", "text": "1 year", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "647693_1_Ent2", "text": "retinal changes", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "647693_3", "wnd_id": "647693_3_1", "text": "These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described .", "tokens": ["These", "findings", "suggest", "that", "the", "corneal", "and", "retinal", "changes", "are", "the", "result", "of", "a", "toxic", "effect", "of", "tamoxifen", "when", "used", "in", "the", "doses", "and", "duration", "described", "."], "event_mentions": [{"id": "647693_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 11, "end": 12}, "arguments": [{"entity_id": "647693_3_Ent0", "role": "Effect", "text": "corneal and retinal changes", "start": 5, "end": 9}, {"entity_id": "647693_3_Ent1", "role": "Treatment", "text": "tamoxifen", "start": 17, "end": 18}, {"entity_id": "647693_3_Ent2", "role": "Treatment_Drug", "text": "tamoxifen", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "647693_3_Ent0", "text": "corneal and retinal changes", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "647693_3_Ent1", "text": "tamoxifen", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "647693_3_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "6498095_3", "wnd_id": "6498095_3_1", "text": "Pemphigus foliaceus was seen in a patient with pulmonary tuberculosis during rifampicin therapy .", "tokens": ["Pemphigus", "foliaceus", "was", "seen", "in", "a", "patient", "with", "pulmonary", "tuberculosis", "during", "rifampicin", "therapy", "."], "event_mentions": [{"id": "6498095_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 3, "end": 4}, "arguments": [{"entity_id": "6498095_3_Ent1", "role": "Effect", "text": "Pemphigus foliaceus", "start": 0, "end": 2}, {"entity_id": "6498095_3_Ent0", "role": "Subject", "text": "a patient with pulmonary tuberculosis", "start": 5, "end": 10}, {"entity_id": "6498095_3_Ent3", "role": "Treatment_Disorder", "text": "pulmonary tuberculosis", "start": 8, "end": 10}, {"entity_id": "6498095_3_Ent2", "role": "Treatment", "text": "rifampicin", "start": 11, "end": 12}, {"entity_id": "6498095_3_Ent4", "role": "Treatment_Drug", "text": "rifampicin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6498095_3_Ent1", "text": "Pemphigus foliaceus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6498095_3_Ent0", "text": "a patient with pulmonary tuberculosis", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "6498095_3_Ent3", "text": "pulmonary tuberculosis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "6498095_3_Ent2", "text": "rifampicin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6498095_3_Ent4", "text": "rifampicin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6510223_4", "wnd_id": "6510223_4_1", "text": "This case demonstrates that there is no cross reactivity between glyburide and chlorpropamide in producing hemolytic anemia .", "tokens": ["This", "case", "demonstrates", "that", "there", "is", "no", "cross", "reactivity", "between", "glyburide", "and", "chlorpropamide", "in", "producing", "hemolytic", "anemia", "."], "event_mentions": [{"id": "6510223_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "producing", "start": 14, "end": 15}, "arguments": [{"entity_id": "6510223_4_Ent2", "role": "Treatment_Drug", "text": "glyburide", "start": 10, "end": 11}, {"entity_id": "6510223_4_Ent4", "role": "Combination_Drug", "text": "glyburide", "start": 10, "end": 11}, {"entity_id": "6510223_4_Ent1", "role": "Treatment", "text": "glyburide and chlorpropamide", "start": 10, "end": 13}, {"entity_id": "6510223_4_Ent3", "role": "Treatment_Drug", "text": "chlorpropamide", "start": 12, "end": 13}, {"entity_id": "6510223_4_Ent5", "role": "Combination_Drug", "text": "chlorpropamide", "start": 12, "end": 13}, {"entity_id": "6510223_4_Ent0", "role": "Effect", "text": "hemolytic anemia", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "6510223_4_Ent2", "text": "glyburide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6510223_4_Ent4", "text": "glyburide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6510223_4_Ent1", "text": "glyburide and chlorpropamide", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "6510223_4_Ent3", "text": "chlorpropamide", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6510223_4_Ent5", "text": "chlorpropamide", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6510223_4_Ent0", "text": "hemolytic anemia", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "6529939_2", "wnd_id": "6529939_2_1", "text": "Alternating sinus rhythm and intermittent sinoatrial ( S - A ) block was observed in a 57 - year - old woman , under treatment for angina with 80 mg propranolol daily .", "tokens": ["Alternating", "sinus", "rhythm", "and", "intermittent", "sinoatrial", "(", "S", "-", "A", ")", "block", "was", "observed", "in", "a", "57", "-", "year", "-", "old", "woman", ",", "under", "treatment", "for", "angina", "with", "80", "mg", "propranolol", "daily", "."], "event_mentions": [{"id": "6529939_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 24, "end": 25}, "arguments": [{"entity_id": "6529939_2_Ent3", "role": "Effect", "text": "Alternating sinus rhythm and intermittent sinoatrial ( S - A ) block", "start": 0, "end": 12}, {"entity_id": "6529939_2_Ent0", "role": "Subject", "text": "a 57 - year - old woman", "start": 15, "end": 22}, {"entity_id": "6529939_2_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 16, "end": 21}, {"entity_id": "6529939_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 21, "end": 22}, {"entity_id": "6529939_2_Ent8", "role": "Treatment_Disorder", "text": "angina", "start": 26, "end": 27}, {"entity_id": "6529939_2_Ent5", "role": "Treatment_Dosage", "text": "80 mg", "start": 28, "end": 30}, {"entity_id": "6529939_2_Ent4", "role": "Treatment", "text": "80 mg propranolol daily .", "start": 28, "end": 33}, {"entity_id": "6529939_2_Ent6", "role": "Treatment_Drug", "text": "propranolol", "start": 30, "end": 31}, {"entity_id": "6529939_2_Ent7", "role": "Treatment_Freq", "text": "daily", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "6529939_2_Ent3", "text": "Alternating sinus rhythm and intermittent sinoatrial ( S - A ) block", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "6529939_2_Ent0", "text": "a 57 - year - old woman", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "6529939_2_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "6529939_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6529939_2_Ent8", "text": "angina", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "6529939_2_Ent5", "text": "80 mg", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "6529939_2_Ent4", "text": "80 mg propranolol daily .", "entity_type": "Entity", "start": 28, "end": 33}, {"id": "6529939_2_Ent6", "text": "propranolol", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "6529939_2_Ent7", "text": "daily", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "6529939_3", "wnd_id": "6529939_3_1", "text": "The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2/1 S - A block was seen .", "tokens": ["The", "abnormal", "rhythm", "disappeared", "with", "the", "withdrawal", "of", "propranolol", "and", "when", "the", "drug", "was", "restarted", "a", "2/1", "S", "-", "A", "block", "was", "seen", "."], "event_mentions": [{"id": "6529939_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 22, "end": 23}, "arguments": [{"entity_id": "6529939_3_Ent1", "role": "Treatment", "text": "propranolol", "start": 8, "end": 9}, {"entity_id": "6529939_3_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 8, "end": 9}, {"entity_id": "6529939_3_Ent0", "role": "Effect", "text": "2/1 S - A block", "start": 16, "end": 21}]}], "entity_mentions": [{"id": "6529939_3_Ent1", "text": "propranolol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6529939_3_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6529939_3_Ent0", "text": "2/1 S - A block", "entity_type": "Entity", "start": 16, "end": 21}], "lang": "en"}
{"doc_id": "6540393_1", "wnd_id": "6540393_1_1", "text": "A further case of anaphylactoid reaction to methylprednisolone is reported .", "tokens": ["A", "further", "case", "of", "anaphylactoid", "reaction", "to", "methylprednisolone", "is", "reported", "."], "event_mentions": [{"id": "6540393_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 6, "end": 7}, "arguments": [{"entity_id": "6540393_1_Ent0", "role": "Effect", "text": "anaphylactoid reaction", "start": 4, "end": 6}, {"entity_id": "6540393_1_Ent1", "role": "Treatment", "text": "methylprednisolone", "start": 7, "end": 8}, {"entity_id": "6540393_1_Ent2", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "6540393_1_Ent0", "text": "anaphylactoid reaction", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "6540393_1_Ent1", "text": "methylprednisolone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6540393_1_Ent2", "text": "methylprednisolone", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "6540393_2", "wnd_id": "6540393_2_1", "text": "Anaphylactoid reaction to methylprednisolone pulsed therapy for multiple sclerosis .", "tokens": ["Anaphylactoid", "reaction", "to", "methylprednisolone", "pulsed", "therapy", "for", "multiple", "sclerosis", "."], "event_mentions": [{"id": "6540393_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 2, "end": 3}, "arguments": [{"entity_id": "6540393_2_Ent0", "role": "Effect", "text": "Anaphylactoid reaction", "start": 0, "end": 2}, {"entity_id": "6540393_2_Ent3", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 3, "end": 4}, {"entity_id": "6540393_2_Ent1", "role": "Treatment", "text": "methylprednisolone pulsed therapy", "start": 3, "end": 6}, {"entity_id": "6540393_2_Ent2", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "6540393_2_Ent0", "text": "Anaphylactoid reaction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6540393_2_Ent3", "text": "methylprednisolone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6540393_2_Ent1", "text": "methylprednisolone pulsed therapy", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6540393_2_Ent2", "text": "multiple sclerosis", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "6578007_2", "wnd_id": "6578007_2_1", "text": "We report a 59 - year - old patient with chronic myeloid leukemia , who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan .", "tokens": ["We", "report", "a", "59", "-", "year", "-", "old", "patient", "with", "chronic", "myeloid", "leukemia", ",", "who", "developed", "severe", "interstitial", "lung", "fibrosis", "after", "short", "term", "and", "sequential", "treatment", "with", "melphalan", "and", "busulfan", "."], "event_mentions": [{"id": "6578007_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "6578007_2_Ent0", "role": "Subject", "text": "a 59 - year - old patient with chronic myeloid leukemia", "start": 2, "end": 13}, {"entity_id": "6578007_2_Ent1", "role": "Subject_Age", "text": "59 - year - old", "start": 3, "end": 8}, {"entity_id": "6578007_2_Ent4", "role": "Treatment_Disorder", "text": "chronic myeloid leukemia", "start": 10, "end": 13}, {"entity_id": "6578007_2_Ent2", "role": "Effect", "text": "interstitial lung fibrosis", "start": 17, "end": 20}, {"entity_id": "6578007_2_Ent5", "role": "Treatment_Time_elapsed", "text": "short term", "start": 21, "end": 23}, {"entity_id": "6578007_2_Ent3", "role": "Treatment", "text": "short term and sequential treatment with melphalan and busulfan", "start": 21, "end": 30}, {"entity_id": "6578007_2_Ent6", "role": "Treatment_Drug", "text": "melphalan", "start": 27, "end": 28}, {"entity_id": "6578007_2_Ent8", "role": "Combination_Drug", "text": "melphalan", "start": 27, "end": 28}, {"entity_id": "6578007_2_Ent7", "role": "Treatment_Drug", "text": "busulfan", "start": 29, "end": 30}, {"entity_id": "6578007_2_Ent9", "role": "Combination_Drug", "text": "busulfan", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "6578007_2_Ent0", "text": "a 59 - year - old patient with chronic myeloid leukemia", "entity_type": "Entity", "start": 2, "end": 13}, {"id": "6578007_2_Ent1", "text": "59 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "6578007_2_Ent4", "text": "chronic myeloid leukemia", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "6578007_2_Ent2", "text": "interstitial lung fibrosis", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "6578007_2_Ent5", "text": "short term", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "6578007_2_Ent3", "text": "short term and sequential treatment with melphalan and busulfan", "entity_type": "Entity", "start": 21, "end": 30}, {"id": "6578007_2_Ent6", "text": "melphalan", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "6578007_2_Ent8", "text": "melphalan", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "6578007_2_Ent7", "text": "busulfan", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "6578007_2_Ent9", "text": "busulfan", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "6608139_1", "wnd_id": "6608139_1_1", "text": "Although myelosuppression is mild , immunosuppression and superinfection are potential hazards of treatment with DCF .", "tokens": ["Although", "myelosuppression", "is", "mild", ",", "immunosuppression", "and", "superinfection", "are", "potential", "hazards", "of", "treatment", "with", "DCF", "."], "event_mentions": [{"id": "6608139_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "hazards", "start": 10, "end": 11}, "arguments": [{"entity_id": "6608139_1_Ent0", "role": "Effect", "text": "myelosuppression", "start": 1, "end": 2}, {"entity_id": "6608139_1_Ent1", "role": "Effect", "text": "immunosuppression and superinfection", "start": 5, "end": 8}, {"entity_id": "6608139_1_Ent2", "role": "Treatment", "text": "DCF", "start": 14, "end": 15}, {"entity_id": "6608139_1_Ent3", "role": "Treatment_Drug", "text": "DCF", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6608139_1_Ent0", "text": "myelosuppression", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6608139_1_Ent1", "text": "immunosuppression and superinfection", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6608139_1_Ent2", "text": "DCF", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6608139_1_Ent3", "text": "DCF", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6610943_1", "wnd_id": "6610943_1_1", "text": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion .", "tokens": ["Myoglobinuria", "and", "acute", "renal", "failure", "associated", "with", "intravenous", "vasopressin", "infusion", "."], "event_mentions": [{"id": "6610943_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "6610943_1_Ent0", "role": "Effect", "text": "Myoglobinuria and acute renal failure", "start": 0, "end": 5}, {"entity_id": "6610943_1_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 7, "end": 8}, {"entity_id": "6610943_1_Ent1", "role": "Treatment", "text": "intravenous vasopressin infusion", "start": 7, "end": 10}, {"entity_id": "6610943_1_Ent4", "role": "Treatment_Drug", "text": "vasopressin", "start": 8, "end": 9}, {"entity_id": "6610943_1_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "6610943_1_Ent0", "text": "Myoglobinuria and acute renal failure", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6610943_1_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6610943_1_Ent1", "text": "intravenous vasopressin infusion", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "6610943_1_Ent4", "text": "vasopressin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6610943_1_Ent3", "text": "infusion", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "6610943_4", "wnd_id": "6610943_4_1", "text": "This association should be considered in the period after vasopressin - treated gastrointestinal hemorrhage .", "tokens": ["This", "association", "should", "be", "considered", "in", "the", "period", "after", "vasopressin", "-", "treated", "gastrointestinal", "hemorrhage", "."], "event_mentions": [{"id": "6610943_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "6610943_4_Ent1", "role": "Treatment", "text": "vasopressin", "start": 9, "end": 10}, {"entity_id": "6610943_4_Ent2", "role": "Treatment_Drug", "text": "vasopressin", "start": 9, "end": 10}, {"entity_id": "6610943_4_Ent0", "role": "Effect", "text": "gastrointestinal hemorrhage", "start": 12, "end": 14}, {"entity_id": "6610943_4_Ent3", "role": "Treatment_Disorder", "text": "gastrointestinal hemorrhage", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "6610943_4_Ent1", "text": "vasopressin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6610943_4_Ent2", "text": "vasopressin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6610943_4_Ent0", "text": "gastrointestinal hemorrhage", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "6610943_4_Ent3", "text": "gastrointestinal hemorrhage", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "6625005_1", "wnd_id": "6625005_1_1", "text": "Case report of withdrawal dyskinesia associated with amoxapine .", "tokens": ["Case", "report", "of", "withdrawal", "dyskinesia", "associated", "with", "amoxapine", "."], "event_mentions": [{"id": "6625005_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "6625005_1_Ent0", "role": "Subject", "text": "Case", "start": 0, "end": 1}, {"entity_id": "6625005_1_Ent1", "role": "Effect", "text": "withdrawal dyskinesia", "start": 3, "end": 5}, {"entity_id": "6625005_1_Ent2", "role": "Treatment", "text": "amoxapine", "start": 7, "end": 8}, {"entity_id": "6625005_1_Ent3", "role": "Treatment_Drug", "text": "amoxapine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "6625005_1_Ent0", "text": "Case", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6625005_1_Ent1", "text": "withdrawal dyskinesia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6625005_1_Ent2", "text": "amoxapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6625005_1_Ent3", "text": "amoxapine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "665845_1", "wnd_id": "665845_1_1", "text": "A case history of a 15 - year - old boy who developed incapacitating tardive dyskinesia that resolved during treatment with deanol is presented .", "tokens": ["A", "case", "history", "of", "a", "15", "-", "year", "-", "old", "boy", "who", "developed", "incapacitating", "tardive", "dyskinesia", "that", "resolved", "during", "treatment", "with", "deanol", "is", "presented", "."], "event_mentions": [{"id": "665845_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 17, "end": 18}, "arguments": [{"entity_id": "665845_1_Ent0", "role": "Subject", "text": "a 15 - year - old boy", "start": 4, "end": 11}, {"entity_id": "665845_1_Ent1", "role": "Subject_Age", "text": "15 - year - old", "start": 5, "end": 10}, {"entity_id": "665845_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 10, "end": 11}, {"entity_id": "665845_1_Ent3", "role": "Effect", "text": "incapacitating tardive dyskinesia", "start": 13, "end": 16}, {"entity_id": "665845_1_Ent4", "role": "Treatment", "text": "deanol", "start": 21, "end": 22}, {"entity_id": "665845_1_Ent5", "role": "Treatment_Drug", "text": "deanol", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "665845_1_Ent0", "text": "a 15 - year - old boy", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "665845_1_Ent1", "text": "15 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "665845_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "665845_1_Ent3", "text": "incapacitating tardive dyskinesia", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "665845_1_Ent4", "text": "deanol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "665845_1_Ent5", "text": "deanol", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "6671350_2", "wnd_id": "6671350_2_1", "text": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure .", "tokens": ["Coagulopathy", "associated", "with", "the", "use", "of", "cephalosporin", "or", "moxalactam", "antibiotics", "in", "acute", "and", "chronic", "renal", "failure", "."], "event_mentions": [{"id": "6671350_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "6671350_2_Ent0", "role": "Effect", "text": "Coagulopathy", "start": 0, "end": 1}, {"entity_id": "6671350_2_Ent3", "role": "Treatment_Drug", "text": "cephalosporin", "start": 6, "end": 7}, {"entity_id": "6671350_2_Ent1", "role": "Treatment", "text": "cephalosporin or moxalactam antibiotics", "start": 6, "end": 10}, {"entity_id": "6671350_2_Ent4", "role": "Treatment_Drug", "text": "moxalactam", "start": 8, "end": 9}, {"entity_id": "6671350_2_Ent2", "role": "Treatment_Disorder", "text": "acute and chronic renal failure", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "6671350_2_Ent0", "text": "Coagulopathy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6671350_2_Ent3", "text": "cephalosporin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6671350_2_Ent1", "text": "cephalosporin or moxalactam antibiotics", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "6671350_2_Ent4", "text": "moxalactam", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6671350_2_Ent2", "text": "acute and chronic renal failure", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "6671350_3", "wnd_id": "6671350_3_1", "text": "Moxalactam is more likely to be associated with platelet dysfunction .", "tokens": ["Moxalactam", "is", "more", "likely", "to", "be", "associated", "with", "platelet", "dysfunction", "."], "event_mentions": [{"id": "6671350_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "6671350_3_Ent1", "role": "Treatment", "text": "Moxalactam", "start": 0, "end": 1}, {"entity_id": "6671350_3_Ent2", "role": "Treatment_Drug", "text": "Moxalactam", "start": 0, "end": 1}, {"entity_id": "6671350_3_Ent0", "role": "Effect", "text": "platelet dysfunction", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "6671350_3_Ent1", "text": "Moxalactam", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6671350_3_Ent2", "text": "Moxalactam", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6671350_3_Ent0", "text": "platelet dysfunction", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "6671350_5", "wnd_id": "6671350_5_1", "text": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported .", "tokens": ["Nine", "azotemic", "patients", "who", "developed", "a", "coagulopathy", "associated", "with", "the", "use", "of", "either", "cephalosporin", "or", "moxalactam", "antibiotics", "are", "reported", "."], "event_mentions": [{"id": "6671350_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "6671350_5_Ent1", "role": "Subject_Population", "text": "Nine", "start": 0, "end": 1}, {"entity_id": "6671350_5_Ent0", "role": "Subject", "text": "Nine azotemic patients", "start": 0, "end": 3}, {"entity_id": "6671350_5_Ent2", "role": "Subject_Disorder", "text": "azotemic", "start": 1, "end": 2}, {"entity_id": "6671350_5_Ent3", "role": "Effect", "text": "coagulopathy", "start": 6, "end": 7}, {"entity_id": "6671350_5_Ent5", "role": "Treatment_Drug", "text": "cephalosporin", "start": 13, "end": 14}, {"entity_id": "6671350_5_Ent4", "role": "Treatment", "text": "cephalosporin or moxalactam antibiotics", "start": 13, "end": 17}, {"entity_id": "6671350_5_Ent6", "role": "Treatment_Drug", "text": "moxalactam", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "6671350_5_Ent1", "text": "Nine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6671350_5_Ent0", "text": "Nine azotemic patients", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6671350_5_Ent2", "text": "azotemic", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6671350_5_Ent3", "text": "coagulopathy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6671350_5_Ent5", "text": "cephalosporin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6671350_5_Ent4", "text": "cephalosporin or moxalactam antibiotics", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "6671350_5_Ent6", "text": "moxalactam", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "667809_1", "wnd_id": "667809_1_1", "text": "A case is reported of a child with fatal pulmonary fibrosis following BCNU therapy .", "tokens": ["A", "case", "is", "reported", "of", "a", "child", "with", "fatal", "pulmonary", "fibrosis", "following", "BCNU", "therapy", "."], "event_mentions": [{"id": "667809_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 11, "end": 12}, "arguments": [{"entity_id": "667809_1_Ent1", "role": "Subject_Age", "text": "child", "start": 6, "end": 7}, {"entity_id": "667809_1_Ent0", "role": "Subject", "text": "child with fatal pulmonary fibrosis", "start": 6, "end": 11}, {"entity_id": "667809_1_Ent2", "role": "Effect", "text": "fatal pulmonary fibrosis", "start": 8, "end": 11}, {"entity_id": "667809_1_Ent4", "role": "Treatment_Drug", "text": "BCNU", "start": 12, "end": 13}, {"entity_id": "667809_1_Ent3", "role": "Treatment", "text": "BCNU therapy", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "667809_1_Ent1", "text": "child", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "667809_1_Ent0", "text": "child with fatal pulmonary fibrosis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "667809_1_Ent2", "text": "fatal pulmonary fibrosis", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "667809_1_Ent4", "text": "BCNU", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "667809_1_Ent3", "text": "BCNU therapy", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "6683487_4", "wnd_id": "6683487_4_1", "text": "To our knowledge , no prior cases of penicillamine - induced TTP in RA have been reported .", "tokens": ["To", "our", "knowledge", ",", "no", "prior", "cases", "of", "penicillamine", "-", "induced", "TTP", "in", "RA", "have", "been", "reported", "."], "event_mentions": [{"id": "6683487_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "6683487_4_Ent1", "role": "Treatment", "text": "penicillamine", "start": 8, "end": 9}, {"entity_id": "6683487_4_Ent2", "role": "Treatment_Drug", "text": "penicillamine", "start": 8, "end": 9}, {"entity_id": "6683487_4_Ent0", "role": "Effect", "text": "TTP", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6683487_4_Ent1", "text": "penicillamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6683487_4_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6683487_4_Ent0", "text": "TTP", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6697887_2", "wnd_id": "6697887_2_1", "text": "The incidence of oral - verapamil - induced hypotension in the presence of concomitant beta - adrenergic blockade by the oral route is quite rare .", "tokens": ["The", "incidence", "of", "oral", "-", "verapamil", "-", "induced", "hypotension", "in", "the", "presence", "of", "concomitant", "beta", "-", "adrenergic", "blockade", "by", "the", "oral", "route", "is", "quite", "rare", "."], "event_mentions": [{"id": "6697887_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "6697887_2_Ent4", "role": "Treatment_Route", "text": "oral", "start": 3, "end": 4}, {"entity_id": "6697887_2_Ent1", "role": "Treatment", "text": "oral - verapamil", "start": 3, "end": 6}, {"entity_id": "6697887_2_Ent3", "role": "Treatment_Drug", "text": "verapamil", "start": 5, "end": 6}, {"entity_id": "6697887_2_Ent0", "role": "Effect", "text": "hypotension", "start": 8, "end": 9}, {"entity_id": "6697887_2_Ent2", "role": "Treatment", "text": "in the presence of concomitant beta - adrenergic blockade", "start": 9, "end": 18}, {"entity_id": "6697887_2_Ent5", "role": "Treatment_Route", "text": "oral", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "6697887_2_Ent4", "text": "oral", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6697887_2_Ent1", "text": "oral - verapamil", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6697887_2_Ent3", "text": "verapamil", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6697887_2_Ent0", "text": "hypotension", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6697887_2_Ent2", "text": "in the presence of concomitant beta - adrenergic blockade", "entity_type": "Entity", "start": 9, "end": 18}, {"id": "6697887_2_Ent5", "text": "oral", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "6702890_1", "wnd_id": "6702890_1_1", "text": "A 69 - year - old man developed pure red cell aplasia after taking fenoprofen for ten months .", "tokens": ["A", "69", "-", "year", "-", "old", "man", "developed", "pure", "red", "cell", "aplasia", "after", "taking", "fenoprofen", "for", "ten", "months", "."], "event_mentions": [{"id": "6702890_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "6702890_1_Ent0", "role": "Subject", "text": "A 69 - year - old man", "start": 0, "end": 7}, {"entity_id": "6702890_1_Ent1", "role": "Subject_Age", "text": "69 - year - old", "start": 1, "end": 6}, {"entity_id": "6702890_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "6702890_1_Ent3", "role": "Effect", "text": "pure red cell aplasia", "start": 8, "end": 12}, {"entity_id": "6702890_1_Ent4", "role": "Treatment", "text": "taking fenoprofen for ten months", "start": 13, "end": 18}, {"entity_id": "6702890_1_Ent5", "role": "Treatment_Drug", "text": "fenoprofen", "start": 14, "end": 15}, {"entity_id": "6702890_1_Ent6", "role": "Treatment_Time_elapsed", "text": "ten months", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "6702890_1_Ent0", "text": "A 69 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "6702890_1_Ent1", "text": "69 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6702890_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6702890_1_Ent3", "text": "pure red cell aplasia", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "6702890_1_Ent4", "text": "taking fenoprofen for ten months", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "6702890_1_Ent5", "text": "fenoprofen", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6702890_1_Ent6", "text": "ten months", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "6721543_1", "wnd_id": "6721543_1_1", "text": "Drug - induced psychosis resulted from the administration of quinacrine hydrochloride at a dosage of 100 mg twice daily for the treatment of discoid lupus .", "tokens": ["Drug", "-", "induced", "psychosis", "resulted", "from", "the", "administration", "of", "quinacrine", "hydrochloride", "at", "a", "dosage", "of", "100", "mg", "twice", "daily", "for", "the", "treatment", "of", "discoid", "lupus", "."], "event_mentions": [{"id": "6721543_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6721543_1_Ent0", "role": "Effect", "text": "psychosis resulted", "start": 3, "end": 5}, {"entity_id": "6721543_1_Ent1", "role": "Treatment", "text": "administration of quinacrine hydrochloride at a dosage of 100 mg twice daily", "start": 7, "end": 19}, {"entity_id": "6721543_1_Ent5", "role": "Treatment_Drug", "text": "quinacrine hydrochloride", "start": 9, "end": 11}, {"entity_id": "6721543_1_Ent2", "role": "Treatment_Dosage", "text": "100 mg", "start": 15, "end": 17}, {"entity_id": "6721543_1_Ent3", "role": "Treatment_Freq", "text": "twice daily", "start": 17, "end": 19}, {"entity_id": "6721543_1_Ent4", "role": "Treatment_Disorder", "text": "discoid lupus", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "6721543_1_Ent0", "text": "psychosis resulted", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6721543_1_Ent1", "text": "administration of quinacrine hydrochloride at a dosage of 100 mg twice daily", "entity_type": "Entity", "start": 7, "end": 19}, {"id": "6721543_1_Ent5", "text": "quinacrine hydrochloride", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "6721543_1_Ent2", "text": "100 mg", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6721543_1_Ent3", "text": "twice daily", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "6721543_1_Ent4", "text": "discoid lupus", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "6731466_6", "wnd_id": "6731466_6_1", "text": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti - inflammatory agents , especially zomepirac .", "tokens": ["This", "observation", "adds", "another", "dimension", "to", "the", "previously", "reported", "renal", "complications", "of", "nonsteroidal", "anti", "-", "inflammatory", "agents", ",", "especially", "zomepirac", "."], "event_mentions": [{"id": "6731466_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 8, "end": 9}, "arguments": [{"entity_id": "6731466_6_Ent0", "role": "Effect", "text": "renal complications", "start": 9, "end": 11}, {"entity_id": "6731466_6_Ent2", "role": "Treatment_Drug", "text": "nonsteroidal anti - inflammatory", "start": 12, "end": 16}, {"entity_id": "6731466_6_Ent1", "role": "Treatment", "text": "nonsteroidal anti - inflammatory agents , especially zomepirac", "start": 12, "end": 20}, {"entity_id": "6731466_6_Ent3", "role": "Treatment_Drug", "text": "zomepirac", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "6731466_6_Ent0", "text": "renal complications", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "6731466_6_Ent2", "text": "nonsteroidal anti - inflammatory", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "6731466_6_Ent1", "text": "nonsteroidal anti - inflammatory agents , especially zomepirac", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "6731466_6_Ent3", "text": "zomepirac", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "6733633_1", "wnd_id": "6733633_1_1", "text": "Cimetidine - induced fever .", "tokens": ["Cimetidine", "-", "induced", "fever", "."], "event_mentions": [{"id": "6733633_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6733633_1_Ent1", "role": "Treatment", "text": "Cimetidine", "start": 0, "end": 1}, {"entity_id": "6733633_1_Ent2", "role": "Treatment_Drug", "text": "Cimetidine", "start": 0, "end": 1}, {"entity_id": "6733633_1_Ent0", "role": "Effect", "text": "fever", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "6733633_1_Ent1", "text": "Cimetidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6733633_1_Ent2", "text": "Cimetidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6733633_1_Ent0", "text": "fever", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "6744146_1", "wnd_id": "6744146_1_1", "text": "A 65 - year - old woman , in the intensive care unit because of septic shock and acute renal failure , had a small - bowel obstruction due to Amphojel concretions .", "tokens": ["A", "65", "-", "year", "-", "old", "woman", ",", "in", "the", "intensive", "care", "unit", "because", "of", "septic", "shock", "and", "acute", "renal", "failure", ",", "had", "a", "small", "-", "bowel", "obstruction", "due", "to", "Amphojel", "concretions", "."], "event_mentions": [{"id": "6744146_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 28, "end": 29}, "arguments": [{"entity_id": "6744146_1_Ent0", "role": "Subject", "text": "A 65 - year - old woman , in the intensive care unit because of septic shock and acute renal failure", "start": 0, "end": 21}, {"entity_id": "6744146_1_Ent3", "role": "Subject_Age", "text": "65 - year - old", "start": 1, "end": 6}, {"entity_id": "6744146_1_Ent4", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "6744146_1_Ent1", "role": "Subject_Disorder", "text": "septic shock", "start": 15, "end": 17}, {"entity_id": "6744146_1_Ent2", "role": "Subject_Disorder", "text": "acute renal failure", "start": 18, "end": 21}, {"entity_id": "6744146_1_Ent5", "role": "Effect", "text": "small - bowel obstruction", "start": 24, "end": 28}, {"entity_id": "6744146_1_Ent7", "role": "Treatment", "text": "Amphojel", "start": 30, "end": 31}, {"entity_id": "6744146_1_Ent8", "role": "Treatment_Drug", "text": "Amphojel", "start": 30, "end": 31}, {"entity_id": "6744146_1_Ent6", "role": "Effect", "text": "concretions", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "6744146_1_Ent0", "text": "A 65 - year - old woman , in the intensive care unit because of septic shock and acute renal failure", "entity_type": "Entity", "start": 0, "end": 21}, {"id": "6744146_1_Ent3", "text": "65 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6744146_1_Ent4", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6744146_1_Ent1", "text": "septic shock", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6744146_1_Ent2", "text": "acute renal failure", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "6744146_1_Ent5", "text": "small - bowel obstruction", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "6744146_1_Ent7", "text": "Amphojel", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "6744146_1_Ent8", "text": "Amphojel", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "6744146_1_Ent6", "text": "concretions", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "6788011_4", "wnd_id": "6788011_4_1", "text": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis .", "tokens": ["The", "nephrotic", "syndrome", "developed", "in", "a", "patient", "receiving", "therapy", "with", "gold", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "6788011_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "6788011_4_Ent1", "role": "Effect", "text": "nephrotic syndrome", "start": 1, "end": 3}, {"entity_id": "6788011_4_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "6788011_4_Ent2", "role": "Treatment", "text": "therapy with gold", "start": 8, "end": 11}, {"entity_id": "6788011_4_Ent4", "role": "Treatment_Drug", "text": "gold", "start": 10, "end": 11}, {"entity_id": "6788011_4_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "6788011_4_Ent1", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "6788011_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "6788011_4_Ent2", "text": "therapy with gold", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "6788011_4_Ent4", "text": "gold", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6788011_4_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "6794018_1", "wnd_id": "6794018_1_1", "text": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61 - year - old diabetic patient who presented wit hypoglycaemic coma .", "tokens": ["Intrahepatic", "cholestasis", "and", "cutaneous", "bullae", "associated", "with", "glibenclamide", "therapy", "are", "described", "in", "a", "61", "-", "year", "-", "old", "diabetic", "patient", "who", "presented", "wit", "hypoglycaemic", "coma", "."], "event_mentions": [{"id": "6794018_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "6794018_1_Ent3", "role": "Effect", "text": "Intrahepatic cholestasis and cutaneous bullae", "start": 0, "end": 5}, {"entity_id": "6794018_1_Ent4", "role": "Treatment", "text": "glibenclamide", "start": 7, "end": 8}, {"entity_id": "6794018_1_Ent5", "role": "Treatment_Drug", "text": "glibenclamide", "start": 7, "end": 8}, {"entity_id": "6794018_1_Ent0", "role": "Subject", "text": "a 61 - year - old diabetic patient who presented wit hypoglycaemic coma", "start": 12, "end": 25}, {"entity_id": "6794018_1_Ent2", "role": "Subject_Age", "text": "61 - year - old", "start": 13, "end": 18}, {"entity_id": "6794018_1_Ent6", "role": "Treatment_Disorder", "text": "diabetic", "start": 18, "end": 19}, {"entity_id": "6794018_1_Ent1", "role": "Subject_Disorder", "text": "hypoglycaemic coma", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "6794018_1_Ent3", "text": "Intrahepatic cholestasis and cutaneous bullae", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6794018_1_Ent4", "text": "glibenclamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6794018_1_Ent5", "text": "glibenclamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6794018_1_Ent0", "text": "a 61 - year - old diabetic patient who presented wit hypoglycaemic coma", "entity_type": "Entity", "start": 12, "end": 25}, {"id": "6794018_1_Ent2", "text": "61 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "6794018_1_Ent6", "text": "diabetic", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "6794018_1_Ent1", "text": "hypoglycaemic coma", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "6810714_1", "wnd_id": "6810714_1_1", "text": "The authors describe a woman with chronic schizophrenia who experienced delirium , grand mal seizure , and photosensitivity after the addition of propranolol to her neuroleptic regimen .", "tokens": ["The", "authors", "describe", "a", "woman", "with", "chronic", "schizophrenia", "who", "experienced", "delirium", ",", "grand", "mal", "seizure", ",", "and", "photosensitivity", "after", "the", "addition", "of", "propranolol", "to", "her", "neuroleptic", "regimen", "."], "event_mentions": [{"id": "6810714_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 18, "end": 19}, "arguments": [{"entity_id": "6810714_1_Ent0", "role": "Subject", "text": "a woman with chronic schizophrenia", "start": 3, "end": 8}, {"entity_id": "6810714_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "6810714_1_Ent5", "role": "Treatment_Disorder", "text": "chronic schizophrenia", "start": 6, "end": 8}, {"entity_id": "6810714_1_Ent2", "role": "Effect", "text": "delirium , grand mal seizure , and photosensitivity", "start": 10, "end": 18}, {"entity_id": "6810714_1_Ent3", "role": "Treatment", "text": "propranolol", "start": 22, "end": 23}, {"entity_id": "6810714_1_Ent4", "role": "Treatment_Drug", "text": "propranolol", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "6810714_1_Ent0", "text": "a woman with chronic schizophrenia", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "6810714_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6810714_1_Ent5", "text": "chronic schizophrenia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "6810714_1_Ent2", "text": "delirium , grand mal seizure , and photosensitivity", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "6810714_1_Ent3", "text": "propranolol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6810714_1_Ent4", "text": "propranolol", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "681921_1", "wnd_id": "681921_1_1", "text": "Catatonia associated with disulfiram therapy .", "tokens": ["Catatonia", "associated", "with", "disulfiram", "therapy", "."], "event_mentions": [{"id": "681921_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "681921_1_Ent0", "role": "Effect", "text": "Catatonia", "start": 0, "end": 1}, {"entity_id": "681921_1_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 3, "end": 4}, {"entity_id": "681921_1_Ent1", "role": "Treatment", "text": "disulfiram therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "681921_1_Ent0", "text": "Catatonia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "681921_1_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "681921_1_Ent1", "text": "disulfiram therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "6830388_1", "wnd_id": "6830388_1_1", "text": "Since early symptoms of the toxic effects of theophylline can mimic peptic ulcer disease , cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of theophylline poisoning .", "tokens": ["Since", "early", "symptoms", "of", "the", "toxic", "effects", "of", "theophylline", "can", "mimic", "peptic", "ulcer", "disease", ",", "cimetidine", "might", "be", "prescribed", "for", "the", "gastrointestinal", "symptoms", "with", "subsequent", "worsening", "of", "theophylline", "poisoning", "."], "event_mentions": [{"id": "6830388_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 18, "end": 19}, "arguments": [{"entity_id": "6830388_1_Ent0", "role": "Treatment", "text": "cimetidine", "start": 15, "end": 16}, {"entity_id": "6830388_1_Ent2", "role": "Treatment_Drug", "text": "cimetidine", "start": 15, "end": 16}, {"entity_id": "6830388_1_Ent1", "role": "Treatment_Disorder", "text": "gastrointestinal symptoms", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "6830388_1_Ent0", "text": "cimetidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6830388_1_Ent2", "text": "cimetidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6830388_1_Ent1", "text": "gastrointestinal symptoms", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "6837655_1", "wnd_id": "6837655_1_1", "text": "Prior reports have emphasized the tubular and interstitial lesions associated with intermittent or discontinuous rifampin therapy for tuberculosis .", "tokens": ["Prior", "reports", "have", "emphasized", "the", "tubular", "and", "interstitial", "lesions", "associated", "with", "intermittent", "or", "discontinuous", "rifampin", "therapy", "for", "tuberculosis", "."], "event_mentions": [{"id": "6837655_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "6837655_1_Ent0", "role": "Effect", "text": "tubular and interstitial lesions", "start": 5, "end": 9}, {"entity_id": "6837655_1_Ent1", "role": "Treatment", "text": "intermittent or discontinuous rifampin therapy", "start": 11, "end": 16}, {"entity_id": "6837655_1_Ent2", "role": "Treatment_Drug", "text": "rifampin", "start": 14, "end": 15}, {"entity_id": "6837655_1_Ent3", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "6837655_1_Ent0", "text": "tubular and interstitial lesions", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "6837655_1_Ent1", "text": "intermittent or discontinuous rifampin therapy", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "6837655_1_Ent2", "text": "rifampin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6837655_1_Ent3", "text": "tuberculosis", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "6837655_2", "wnd_id": "6837655_2_1", "text": "The spectrum of renal lesions occurring during antituberculous therapy , particularly in association with rifampin , may be wider than previously suspected .", "tokens": ["The", "spectrum", "of", "renal", "lesions", "occurring", "during", "antituberculous", "therapy", ",", "particularly", "in", "association", "with", "rifampin", ",", "may", "be", "wider", "than", "previously", "suspected", "."], "event_mentions": [{"id": "6837655_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 6, "end": 7}, "arguments": [{"entity_id": "6837655_2_Ent0", "role": "Effect", "text": "The spectrum of renal lesions occurring", "start": 0, "end": 6}, {"entity_id": "6837655_2_Ent3", "role": "Treatment_Drug", "text": "antituberculous therapy", "start": 7, "end": 9}, {"entity_id": "6837655_2_Ent5", "role": "Combination_Drug", "text": "antituberculous therapy", "start": 7, "end": 9}, {"entity_id": "6837655_2_Ent1", "role": "Treatment", "text": "antituberculous therapy , particularly in association with rifampin", "start": 7, "end": 15}, {"entity_id": "6837655_2_Ent2", "role": "Treatment_Drug", "text": "rifampin", "start": 14, "end": 15}, {"entity_id": "6837655_2_Ent4", "role": "Combination_Drug", "text": "rifampin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6837655_2_Ent0", "text": "The spectrum of renal lesions occurring", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "6837655_2_Ent3", "text": "antituberculous therapy", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6837655_2_Ent5", "text": "antituberculous therapy", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6837655_2_Ent1", "text": "antituberculous therapy , particularly in association with rifampin", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "6837655_2_Ent2", "text": "rifampin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6837655_2_Ent4", "text": "rifampin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6837655_3", "wnd_id": "6837655_3_1", "text": "Within 3 weeks of beginning continuous daily isoniazid and rifampin therapy for pulmonary tuberculosis , a patient developed acute renal failure .", "tokens": ["Within", "3", "weeks", "of", "beginning", "continuous", "daily", "isoniazid", "and", "rifampin", "therapy", "for", "pulmonary", "tuberculosis", ",", "a", "patient", "developed", "acute", "renal", "failure", "."], "event_mentions": [{"id": "6837655_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "6837655_3_Ent4", "role": "Treatment_Time_elapsed", "text": "Within 3 weeks of beginning", "start": 0, "end": 5}, {"entity_id": "6837655_3_Ent2", "role": "Treatment", "text": "Within 3 weeks of beginning continuous daily isoniazid and rifampin", "start": 0, "end": 10}, {"entity_id": "6837655_3_Ent5", "role": "Treatment_Freq", "text": "daily", "start": 6, "end": 7}, {"entity_id": "6837655_3_Ent6", "role": "Treatment_Drug", "text": "isoniazid", "start": 7, "end": 8}, {"entity_id": "6837655_3_Ent8", "role": "Combination_Drug", "text": "isoniazid", "start": 7, "end": 8}, {"entity_id": "6837655_3_Ent7", "role": "Treatment_Drug", "text": "rifampin", "start": 9, "end": 10}, {"entity_id": "6837655_3_Ent9", "role": "Combination_Drug", "text": "rifampin", "start": 9, "end": 10}, {"entity_id": "6837655_3_Ent3", "role": "Treatment_Disorder", "text": "pulmonary tuberculosis", "start": 12, "end": 14}, {"entity_id": "6837655_3_Ent0", "role": "Subject", "text": "a patient", "start": 15, "end": 17}, {"entity_id": "6837655_3_Ent1", "role": "Effect", "text": "acute renal failure", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "6837655_3_Ent4", "text": "Within 3 weeks of beginning", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6837655_3_Ent2", "text": "Within 3 weeks of beginning continuous daily isoniazid and rifampin", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "6837655_3_Ent5", "text": "daily", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6837655_3_Ent6", "text": "isoniazid", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6837655_3_Ent8", "text": "isoniazid", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6837655_3_Ent7", "text": "rifampin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6837655_3_Ent9", "text": "rifampin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6837655_3_Ent3", "text": "pulmonary tuberculosis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "6837655_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6837655_3_Ent1", "text": "acute renal failure", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "6851259_1", "wnd_id": "6851259_1_1", "text": "Nephrotic range pseudoproteinuria in a tolmetin - treated patient .", "tokens": ["Nephrotic", "range", "pseudoproteinuria", "in", "a", "tolmetin", "-", "treated", "patient", "."], "event_mentions": [{"id": "6851259_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "6851259_1_Ent1", "role": "Effect", "text": "Nephrotic range pseudoproteinuria", "start": 0, "end": 3}, {"entity_id": "6851259_1_Ent2", "role": "Treatment", "text": "tolmetin", "start": 5, "end": 6}, {"entity_id": "6851259_1_Ent3", "role": "Treatment_Drug", "text": "tolmetin", "start": 5, "end": 6}, {"entity_id": "6851259_1_Ent0", "role": "Subject", "text": "patient", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "6851259_1_Ent1", "text": "Nephrotic range pseudoproteinuria", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6851259_1_Ent2", "text": "tolmetin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6851259_1_Ent3", "text": "tolmetin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6851259_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "6865827_1", "wnd_id": "6865827_1_1", "text": "A 45 - year - old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil .", "tokens": ["A", "45", "-", "year", "-", "old", "woman", "with", "thyrotoxicosis", "developed", "agranulocytosis", "after", "treatment", "with", "propylthiouracil", "."], "event_mentions": [{"id": "6865827_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "6865827_1_Ent0", "role": "Subject", "text": "A 45 - year - old woman with thyrotoxicosis", "start": 0, "end": 9}, {"entity_id": "6865827_1_Ent1", "role": "Subject_Age", "text": "45 - year - old", "start": 1, "end": 6}, {"entity_id": "6865827_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "6865827_1_Ent5", "role": "Treatment_Disorder", "text": "thyrotoxicosis", "start": 8, "end": 9}, {"entity_id": "6865827_1_Ent3", "role": "Effect", "text": "agranulocytosis", "start": 10, "end": 11}, {"entity_id": "6865827_1_Ent4", "role": "Treatment", "text": "propylthiouracil", "start": 14, "end": 15}, {"entity_id": "6865827_1_Ent6", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6865827_1_Ent0", "text": "A 45 - year - old woman with thyrotoxicosis", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "6865827_1_Ent1", "text": "45 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6865827_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6865827_1_Ent5", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6865827_1_Ent3", "text": "agranulocytosis", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6865827_1_Ent4", "text": "propylthiouracil", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6865827_1_Ent6", "text": "propylthiouracil", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6873616_1", "wnd_id": "6873616_1_1", "text": "A 55 - yr - old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy .", "tokens": ["A", "55", "-", "yr", "-", "old", "man", "developed", "prolonged", "jaundice", "and", "sicca", "complex", "after", "a", "course", "of", "thiabendazole", "therapy", "."], "event_mentions": [{"id": "6873616_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "6873616_1_Ent0", "role": "Subject", "text": "A 55 - yr - old man", "start": 0, "end": 7}, {"entity_id": "6873616_1_Ent1", "role": "Subject_Age", "text": "55 - yr - old", "start": 1, "end": 6}, {"entity_id": "6873616_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "6873616_1_Ent3", "role": "Effect", "text": "prolonged jaundice and sicca complex", "start": 8, "end": 13}, {"entity_id": "6873616_1_Ent4", "role": "Treatment", "text": "a course of thiabendazole", "start": 14, "end": 18}, {"entity_id": "6873616_1_Ent5", "role": "Treatment_Drug", "text": "thiabendazole", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "6873616_1_Ent0", "text": "A 55 - yr - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "6873616_1_Ent1", "text": "55 - yr - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6873616_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6873616_1_Ent3", "text": "prolonged jaundice and sicca complex", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "6873616_1_Ent4", "text": "a course of thiabendazole", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "6873616_1_Ent5", "text": "thiabendazole", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "6873616_3", "wnd_id": "6873616_3_1", "text": "The literature on thiabendazole - induced cholestasis and its association with sicca complex is reviewed .", "tokens": ["The", "literature", "on", "thiabendazole", "-", "induced", "cholestasis", "and", "its", "association", "with", "sicca", "complex", "is", "reviewed", "."], "event_mentions": [{"id": "6873616_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "6873616_3_Ent1", "role": "Treatment", "text": "thiabendazole", "start": 3, "end": 4}, {"entity_id": "6873616_3_Ent2", "role": "Treatment_Drug", "text": "thiabendazole", "start": 3, "end": 4}, {"entity_id": "6873616_3_Ent0", "role": "Effect", "text": "cholestasis", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6873616_3_Ent1", "text": "thiabendazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6873616_3_Ent2", "text": "thiabendazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6873616_3_Ent0", "text": "cholestasis", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6947095_2", "wnd_id": "6947095_2_1", "text": "The cause is presumed to be secondary to hypercoagulability due to asparaginase - induced antithrombin III deficiency .", "tokens": ["The", "cause", "is", "presumed", "to", "be", "secondary", "to", "hypercoagulability", "due", "to", "asparaginase", "-", "induced", "antithrombin", "III", "deficiency", "."], "event_mentions": [{"id": "6947095_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "6947095_2_Ent1", "role": "Treatment", "text": "asparaginase", "start": 11, "end": 12}, {"entity_id": "6947095_2_Ent2", "role": "Treatment_Drug", "text": "asparaginase", "start": 11, "end": 12}, {"entity_id": "6947095_2_Ent0", "role": "Effect", "text": "antithrombin III deficiency", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "6947095_2_Ent1", "text": "asparaginase", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6947095_2_Ent2", "text": "asparaginase", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6947095_2_Ent0", "text": "antithrombin III deficiency", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "6958210_2", "wnd_id": "6958210_2_1", "text": "Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis .", "tokens": ["Systemic", "lupus", "erythematosus", "during", "penicillamine", "therapy", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "6958210_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "6958210_2_Ent0", "role": "Effect", "text": "Systemic lupus erythematosus", "start": 0, "end": 3}, {"entity_id": "6958210_2_Ent2", "role": "Treatment_Drug", "text": "penicillamine", "start": 4, "end": 5}, {"entity_id": "6958210_2_Ent1", "role": "Treatment", "text": "penicillamine therapy", "start": 4, "end": 6}, {"entity_id": "6958210_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis .", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "6958210_2_Ent0", "text": "Systemic lupus erythematosus", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6958210_2_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6958210_2_Ent1", "text": "penicillamine therapy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "6958210_2_Ent3", "text": "rheumatoid arthritis .", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "6998294_1", "wnd_id": "6998294_1_1", "text": "Clinicians should be aware of fasting hypoglycemia as an unusual but potentially serious complication of disopyramide therapy .", "tokens": ["Clinicians", "should", "be", "aware", "of", "fasting", "hypoglycemia", "as", "an", "unusual", "but", "potentially", "serious", "complication", "of", "disopyramide", "therapy", "."], "event_mentions": [{"id": "6998294_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 13, "end": 14}, "arguments": [{"entity_id": "6998294_1_Ent0", "role": "Effect", "text": "fasting hypoglycemia", "start": 5, "end": 7}, {"entity_id": "6998294_1_Ent1", "role": "Treatment", "text": "disopyramide", "start": 15, "end": 16}, {"entity_id": "6998294_1_Ent2", "role": "Treatment_Drug", "text": "disopyramide", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "6998294_1_Ent0", "text": "fasting hypoglycemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "6998294_1_Ent1", "text": "disopyramide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6998294_1_Ent2", "text": "disopyramide", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "7019786_1", "wnd_id": "7019786_1_1", "text": "Cefoxitin - associated renal failure .", "tokens": ["Cefoxitin", "-", "associated", "renal", "failure", "."], "event_mentions": [{"id": "7019786_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7019786_1_Ent1", "role": "Treatment", "text": "Cefoxitin", "start": 0, "end": 1}, {"entity_id": "7019786_1_Ent2", "role": "Treatment_Drug", "text": "Cefoxitin", "start": 0, "end": 1}, {"entity_id": "7019786_1_Ent0", "role": "Effect", "text": "renal failure", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "7019786_1_Ent1", "text": "Cefoxitin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7019786_1_Ent2", "text": "Cefoxitin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7019786_1_Ent0", "text": "renal failure", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "7019786_3", "wnd_id": "7019786_3_1", "text": "Two elderly women suffered an acute deterioration of renal function after treatment with cefoxitin sodium .", "tokens": ["Two", "elderly", "women", "suffered", "an", "acute", "deterioration", "of", "renal", "function", "after", "treatment", "with", "cefoxitin", "sodium", "."], "event_mentions": [{"id": "7019786_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "7019786_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "7019786_3_Ent0", "role": "Subject", "text": "Two elderly women", "start": 0, "end": 3}, {"entity_id": "7019786_3_Ent2", "role": "Subject_Age", "text": "elderly", "start": 1, "end": 2}, {"entity_id": "7019786_3_Ent3", "role": "Subject_Gender", "text": "women", "start": 2, "end": 3}, {"entity_id": "7019786_3_Ent4", "role": "Effect", "text": "acute deterioration of renal function", "start": 5, "end": 10}, {"entity_id": "7019786_3_Ent5", "role": "Treatment", "text": "treatment with cefoxitin sodium", "start": 11, "end": 15}, {"entity_id": "7019786_3_Ent6", "role": "Treatment_Drug", "text": "cefoxitin sodium", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "7019786_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7019786_3_Ent0", "text": "Two elderly women", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7019786_3_Ent2", "text": "elderly", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7019786_3_Ent3", "text": "women", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7019786_3_Ent4", "text": "acute deterioration of renal function", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "7019786_3_Ent5", "text": "treatment with cefoxitin sodium", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7019786_3_Ent6", "text": "cefoxitin sodium", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "7035691_3", "wnd_id": "7035691_3_1", "text": "Although inhibition of the angiotensin - converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure , care should be taken when captopril is administered initially to a patient with decreased renal function , under the conditions of sodium and water depletion .", "tokens": ["Although", "inhibition", "of", "the", "angiotensin", "-", "converting", "enzyme", "is", "considered", "to", "be", "efficient", "treatment", "for", "hypertension", "associated", "with", "chronic", "renal", "failure", ",", "care", "should", "be", "taken", "when", "captopril", "is", "administered", "initially", "to", "a", "patient", "with", "decreased", "renal", "function", ",", "under", "the", "conditions", "of", "sodium", "and", "water", "depletion", "."], "event_mentions": [{"id": "7035691_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 13, "end": 14}, "arguments": [{"entity_id": "7035691_3_Ent3", "role": "Treatment_Disorder", "text": "hypertension associated with chronic renal failure", "start": 15, "end": 21}, {"entity_id": "7035691_3_Ent2", "role": "Treatment", "text": "captopril", "start": 27, "end": 28}, {"entity_id": "7035691_3_Ent4", "role": "Treatment_Drug", "text": "captopril", "start": 27, "end": 28}, {"entity_id": "7035691_3_Ent0", "role": "Subject", "text": "a patient with decreased renal function", "start": 32, "end": 38}, {"entity_id": "7035691_3_Ent1", "role": "Subject_Disorder", "text": "decreased renal function", "start": 35, "end": 38}]}], "entity_mentions": [{"id": "7035691_3_Ent3", "text": "hypertension associated with chronic renal failure", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "7035691_3_Ent2", "text": "captopril", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "7035691_3_Ent4", "text": "captopril", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "7035691_3_Ent0", "text": "a patient with decreased renal function", "entity_type": "Entity", "start": 32, "end": 38}, {"id": "7035691_3_Ent1", "text": "decreased renal function", "entity_type": "Entity", "start": 35, "end": 38}], "lang": "en"}
{"doc_id": "7056119_3", "wnd_id": "7056119_3_1", "text": "Following a closed mitral valvotomy , she received quinidine , 1.2 g / day , without interruption for 17 years .", "tokens": ["Following", "a", "closed", "mitral", "valvotomy", ",", "she", "received", "quinidine", ",", "1.2", "g", "/", "day", ",", "without", "interruption", "for", "17", "years", "."], "event_mentions": [{"id": "7056119_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 7, "end": 8}, "arguments": [{"entity_id": "7056119_3_Ent1", "role": "Treatment_Drug", "text": "quinidine", "start": 8, "end": 9}, {"entity_id": "7056119_3_Ent0", "role": "Treatment", "text": "quinidine , 1.2 g / day", "start": 8, "end": 14}, {"entity_id": "7056119_3_Ent2", "role": "Treatment_Dosage", "text": "1.2 g / day", "start": 10, "end": 14}, {"entity_id": "7056119_3_Ent3", "role": "Treatment_Duration", "text": "17 years", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "7056119_3_Ent1", "text": "quinidine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7056119_3_Ent0", "text": "quinidine , 1.2 g / day", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "7056119_3_Ent2", "text": "1.2 g / day", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "7056119_3_Ent3", "text": "17 years", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "7056119_6", "wnd_id": "7056119_6_1", "text": "Amiodarone was the third drug to induce AVT in this patient ; she received 200 mg / day six days per week for six months .", "tokens": ["Amiodarone", "was", "the", "third", "drug", "to", "induce", "AVT", "in", "this", "patient", ";", "she", "received", "200", "mg", "/", "day", "six", "days", "per", "week", "for", "six", "months", "."], "event_mentions": [{"id": "7056119_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 6, "end": 7}, "arguments": [{"entity_id": "7056119_6_Ent4", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "7056119_6_Ent6", "role": "Treatment_Drug", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "7056119_6_Ent3", "role": "Effect", "text": "AVT", "start": 7, "end": 8}, {"entity_id": "7056119_6_Ent0", "role": "Subject", "text": "patient", "start": 10, "end": 11}, {"entity_id": "7056119_6_Ent1", "role": "Subject", "text": "she", "start": 12, "end": 13}, {"entity_id": "7056119_6_Ent2", "role": "Subject_Gender", "text": "she", "start": 12, "end": 13}, {"entity_id": "7056119_6_Ent7", "role": "Treatment_Dosage", "text": "200 mg / day", "start": 14, "end": 18}, {"entity_id": "7056119_6_Ent5", "role": "Treatment", "text": "200 mg / day six days per week for six months", "start": 14, "end": 25}, {"entity_id": "7056119_6_Ent8", "role": "Treatment_Freq", "text": "six days per week", "start": 18, "end": 22}, {"entity_id": "7056119_6_Ent9", "role": "Treatment_Freq", "text": "six months", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "7056119_6_Ent4", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7056119_6_Ent6", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7056119_6_Ent3", "text": "AVT", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7056119_6_Ent0", "text": "patient", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7056119_6_Ent1", "text": "she", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7056119_6_Ent2", "text": "she", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7056119_6_Ent7", "text": "200 mg / day", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "7056119_6_Ent5", "text": "200 mg / day six days per week for six months", "entity_type": "Entity", "start": 14, "end": 25}, {"id": "7056119_6_Ent8", "text": "six days per week", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "7056119_6_Ent9", "text": "six months", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "7098384_1", "wnd_id": "7098384_1_1", "text": "A 66 - year - old mand suffering from severe coronary heart disease took digoxin with suicidal intent an was treated for the ensuing complete atrioventricular block with digoxin - specific antibody fragments .", "tokens": ["A", "66", "-", "year", "-", "old", "mand", "suffering", "from", "severe", "coronary", "heart", "disease", "took", "digoxin", "with", "suicidal", "intent", "an", "was", "treated", "for", "the", "ensuing", "complete", "atrioventricular", "block", "with", "digoxin", "-", "specific", "antibody", "fragments", "."], "event_mentions": [{"id": "7098384_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "took", "start": 13, "end": 14}, "arguments": [{"entity_id": "7098384_1_Ent0", "role": "Subject", "text": "A 66 - year - old mand suffering from severe coronary heart disease", "start": 0, "end": 13}, {"entity_id": "7098384_1_Ent1", "role": "Subject_Age", "text": "66 - year - old", "start": 1, "end": 6}, {"entity_id": "7098384_1_Ent2", "role": "Subject_Gender", "text": "mand", "start": 6, "end": 7}, {"entity_id": "7098384_1_Ent3", "role": "Subject_Disorder", "text": "coronary heart disease", "start": 10, "end": 13}, {"entity_id": "7098384_1_Ent5", "role": "Treatment", "text": "digoxin", "start": 14, "end": 15}, {"entity_id": "7098384_1_Ent6", "role": "Treatment_Drug", "text": "digoxin", "start": 14, "end": 15}, {"entity_id": "7098384_1_Ent4", "role": "Effect", "text": "complete atrioventricular block", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "7098384_1_Ent0", "text": "A 66 - year - old mand suffering from severe coronary heart disease", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "7098384_1_Ent1", "text": "66 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7098384_1_Ent2", "text": "mand", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7098384_1_Ent3", "text": "coronary heart disease", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "7098384_1_Ent5", "text": "digoxin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7098384_1_Ent6", "text": "digoxin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7098384_1_Ent4", "text": "complete atrioventricular block", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "7139589_1", "wnd_id": "7139589_1_1", "text": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L - asparaginase .", "tokens": ["An", "adolescent", "male", "developed", "acute", "pancreatitis", "and", "pseudocyst", "of", "the", "pancreas", "16", "weeks", "after", "cessation", "of", "intramuscular", "L", "-", "asparaginase", "."], "event_mentions": [{"id": "7139589_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "7139589_1_Ent0", "role": "Subject", "text": "An adolescent male", "start": 0, "end": 3}, {"entity_id": "7139589_1_Ent1", "role": "Subject_Age", "text": "adolescent", "start": 1, "end": 2}, {"entity_id": "7139589_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 2, "end": 3}, {"entity_id": "7139589_1_Ent3", "role": "Effect", "text": "acute pancreatitis and pseudocyst of the pancreas", "start": 4, "end": 11}, {"entity_id": "7139589_1_Ent7", "role": "Treatment_Time_elapsed", "text": "16 weeks", "start": 11, "end": 13}, {"entity_id": "7139589_1_Ent4", "role": "Treatment", "text": "cessation of intramuscular L - asparaginase", "start": 14, "end": 20}, {"entity_id": "7139589_1_Ent6", "role": "Treatment_Route", "text": "intramuscular", "start": 16, "end": 17}, {"entity_id": "7139589_1_Ent5", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "7139589_1_Ent0", "text": "An adolescent male", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7139589_1_Ent1", "text": "adolescent", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7139589_1_Ent2", "text": "male", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7139589_1_Ent3", "text": "acute pancreatitis and pseudocyst of the pancreas", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "7139589_1_Ent7", "text": "16 weeks", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "7139589_1_Ent4", "text": "cessation of intramuscular L - asparaginase", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "7139589_1_Ent6", "text": "intramuscular", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7139589_1_Ent5", "text": "L - asparaginase", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "717931_2", "wnd_id": "717931_2_1", "text": "Marked hyperkalemia was observed during and immediately after an infusion of arginine monohydrochloride in two patients with severe hepatic disease and moderate renal insufficiency .", "tokens": ["Marked", "hyperkalemia", "was", "observed", "during", "and", "immediately", "after", "an", "infusion", "of", "arginine", "monohydrochloride", "in", "two", "patients", "with", "severe", "hepatic", "disease", "and", "moderate", "renal", "insufficiency", "."], "event_mentions": [{"id": "717931_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 3, "end": 4}, "arguments": [{"entity_id": "717931_2_Ent3", "role": "Effect", "text": "Marked hyperkalemia", "start": 0, "end": 2}, {"entity_id": "717931_2_Ent4", "role": "Treatment", "text": "during and immediately after an infusion of arginine monohydrochloride", "start": 4, "end": 13}, {"entity_id": "717931_2_Ent7", "role": "Treatment_Time_elapsed", "text": "immediately", "start": 6, "end": 7}, {"entity_id": "717931_2_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 9, "end": 10}, {"entity_id": "717931_2_Ent5", "role": "Treatment_Drug", "text": "arginine monohydrochloride", "start": 11, "end": 13}, {"entity_id": "717931_2_Ent1", "role": "Subject_Population", "text": "two", "start": 14, "end": 15}, {"entity_id": "717931_2_Ent0", "role": "Subject", "text": "two patients with severe hepatic disease and moderate renal insufficiency", "start": 14, "end": 24}, {"entity_id": "717931_2_Ent8", "role": "Treatment_Disorder", "text": "hepatic disease", "start": 18, "end": 20}, {"entity_id": "717931_2_Ent2", "role": "Subject_Disorder", "text": "moderate renal insufficiency", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "717931_2_Ent3", "text": "Marked hyperkalemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "717931_2_Ent4", "text": "during and immediately after an infusion of arginine monohydrochloride", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "717931_2_Ent7", "text": "immediately", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "717931_2_Ent6", "text": "infusion", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "717931_2_Ent5", "text": "arginine monohydrochloride", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "717931_2_Ent1", "text": "two", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "717931_2_Ent0", "text": "two patients with severe hepatic disease and moderate renal insufficiency", "entity_type": "Entity", "start": 14, "end": 24}, {"id": "717931_2_Ent8", "text": "hepatic disease", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "717931_2_Ent2", "text": "moderate renal insufficiency", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "71813_2", "wnd_id": "71813_2_1", "text": "Acne provoked by gold seems not to have been described elsewhere .", "tokens": ["Acne", "provoked", "by", "gold", "seems", "not", "to", "have", "been", "described", "elsewhere", "."], "event_mentions": [{"id": "71813_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 1, "end": 2}, "arguments": [{"entity_id": "71813_2_Ent0", "role": "Effect", "text": "Acne", "start": 0, "end": 1}, {"entity_id": "71813_2_Ent1", "role": "Treatment", "text": "gold", "start": 3, "end": 4}, {"entity_id": "71813_2_Ent2", "role": "Treatment_Drug", "text": "gold", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "71813_2_Ent0", "text": "Acne", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "71813_2_Ent1", "text": "gold", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "71813_2_Ent2", "text": "gold", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "7212107_1", "wnd_id": "7212107_1_1", "text": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible .", "tokens": ["Secondary", "hyperparathyroidism", "in", "certain", "patients", "with", "lithium", "nephrotoxicity", "is", "also", "possible", "."], "event_mentions": [{"id": "7212107_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "7212107_1_Ent2", "role": "Effect", "text": "Secondary hyperparathyroidism", "start": 0, "end": 2}, {"entity_id": "7212107_1_Ent0", "role": "Subject", "text": "certain patients", "start": 3, "end": 5}, {"entity_id": "7212107_1_Ent3", "role": "Treatment", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "7212107_1_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "7212107_1_Ent1", "role": "Effect", "text": "nephrotoxicity", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "7212107_1_Ent2", "text": "Secondary hyperparathyroidism", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7212107_1_Ent0", "text": "certain patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7212107_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7212107_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7212107_1_Ent1", "text": "nephrotoxicity", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "7235792_4", "wnd_id": "7235792_4_1", "text": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy .", "tokens": ["Paradoxical", "ventricular", "tachycardia", "and", "fibrillation", "after", "intravenous", "bretylium", "therapy", "."], "event_mentions": [{"id": "7235792_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "7235792_4_Ent0", "role": "Effect", "text": "Paradoxical ventricular tachycardia and fibrillation", "start": 0, "end": 5}, {"entity_id": "7235792_4_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 6, "end": 7}, {"entity_id": "7235792_4_Ent1", "role": "Treatment", "text": "intravenous bretylium", "start": 6, "end": 8}, {"entity_id": "7235792_4_Ent3", "role": "Treatment_Drug", "text": "bretylium", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "7235792_4_Ent0", "text": "Paradoxical ventricular tachycardia and fibrillation", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7235792_4_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7235792_4_Ent1", "text": "intravenous bretylium", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7235792_4_Ent3", "text": "bretylium", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "7258204_1", "wnd_id": "7258204_1_1", "text": "A 67 - year - old man developed diarrhea shortly after a 10 - day course of oral ampicillin .", "tokens": ["A", "67", "-", "year", "-", "old", "man", "developed", "diarrhea", "shortly", "after", "a", "10", "-", "day", "course", "of", "oral", "ampicillin", "."], "event_mentions": [{"id": "7258204_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "7258204_1_Ent0", "role": "Subject", "text": "A 67 - year - old man", "start": 0, "end": 7}, {"entity_id": "7258204_1_Ent1", "role": "Subject_Age", "text": "67 - year - old", "start": 1, "end": 6}, {"entity_id": "7258204_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "7258204_1_Ent3", "role": "Effect", "text": "diarrhea", "start": 8, "end": 9}, {"entity_id": "7258204_1_Ent4", "role": "Treatment", "text": "a 10 - day course of oral ampicillin", "start": 11, "end": 19}, {"entity_id": "7258204_1_Ent5", "role": "Treatment_Duration", "text": "10 - day", "start": 12, "end": 15}, {"entity_id": "7258204_1_Ent7", "role": "Treatment_Route", "text": "oral", "start": 17, "end": 18}, {"entity_id": "7258204_1_Ent6", "role": "Treatment_Drug", "text": "ampicillin", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "7258204_1_Ent0", "text": "A 67 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "7258204_1_Ent1", "text": "67 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7258204_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7258204_1_Ent3", "text": "diarrhea", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7258204_1_Ent4", "text": "a 10 - day course of oral ampicillin", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "7258204_1_Ent5", "text": "10 - day", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "7258204_1_Ent7", "text": "oral", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7258204_1_Ent6", "text": "ampicillin", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "736591_1", "wnd_id": "736591_1_1", "text": "Interstitial fibrosis of the lung is a potential complication of methotrexate therapy for psoriasis .", "tokens": ["Interstitial", "fibrosis", "of", "the", "lung", "is", "a", "potential", "complication", "of", "methotrexate", "therapy", "for", "psoriasis", "."], "event_mentions": [{"id": "736591_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 8, "end": 9}, "arguments": [{"entity_id": "736591_1_Ent0", "role": "Effect", "text": "Interstitial fibrosis of the lung", "start": 0, "end": 5}, {"entity_id": "736591_1_Ent1", "role": "Treatment", "text": "methotrexate", "start": 10, "end": 11}, {"entity_id": "736591_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 10, "end": 11}, {"entity_id": "736591_1_Ent3", "role": "Treatment_Disorder", "text": "psoriasis", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "736591_1_Ent0", "text": "Interstitial fibrosis of the lung", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "736591_1_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "736591_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "736591_1_Ent3", "text": "psoriasis", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "7428724_1", "wnd_id": "7428724_1_1", "text": "Four cases of oesophageal damage associated with ingestion of the urinary anti - spasmodic agent emepronium bromide are described .", "tokens": ["Four", "cases", "of", "oesophageal", "damage", "associated", "with", "ingestion", "of", "the", "urinary", "anti", "-", "spasmodic", "agent", "emepronium", "bromide", "are", "described", "."], "event_mentions": [{"id": "7428724_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "7428724_1_Ent1", "role": "Subject_Population", "text": "Four", "start": 0, "end": 1}, {"entity_id": "7428724_1_Ent0", "role": "Subject", "text": "Four cases", "start": 0, "end": 2}, {"entity_id": "7428724_1_Ent2", "role": "Effect", "text": "oesophageal damage", "start": 3, "end": 5}, {"entity_id": "7428724_1_Ent4", "role": "Treatment_Route", "text": "ingestion", "start": 7, "end": 8}, {"entity_id": "7428724_1_Ent3", "role": "Treatment", "text": "ingestion of the urinary anti - spasmodic agent emepronium bromide", "start": 7, "end": 17}, {"entity_id": "7428724_1_Ent5", "role": "Treatment_Drug", "text": "emepronium bromide", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "7428724_1_Ent1", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7428724_1_Ent0", "text": "Four cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7428724_1_Ent2", "text": "oesophageal damage", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7428724_1_Ent4", "text": "ingestion", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7428724_1_Ent3", "text": "ingestion of the urinary anti - spasmodic agent emepronium bromide", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "7428724_1_Ent5", "text": "emepronium bromide", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "7459812_1", "wnd_id": "7459812_1_1", "text": "Fatal interstitial pneumonitis following high - dose intermittent chlorambucil therapy for chronic lymphocyte leukemia .", "tokens": ["Fatal", "interstitial", "pneumonitis", "following", "high", "-", "dose", "intermittent", "chlorambucil", "therapy", "for", "chronic", "lymphocyte", "leukemia", "."], "event_mentions": [{"id": "7459812_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "7459812_1_Ent0", "role": "Effect", "text": "Fatal interstitial pneumonitis", "start": 0, "end": 3}, {"entity_id": "7459812_1_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 4, "end": 7}, {"entity_id": "7459812_1_Ent1", "role": "Treatment", "text": "high - dose intermittent chlorambucil therapy", "start": 4, "end": 10}, {"entity_id": "7459812_1_Ent3", "role": "Treatment_Drug", "text": "chlorambucil", "start": 8, "end": 9}, {"entity_id": "7459812_1_Ent4", "role": "Treatment_Disorder", "text": "chronic lymphocyte leukemia", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "7459812_1_Ent0", "text": "Fatal interstitial pneumonitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7459812_1_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "7459812_1_Ent1", "text": "high - dose intermittent chlorambucil therapy", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "7459812_1_Ent3", "text": "chlorambucil", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7459812_1_Ent4", "text": "chronic lymphocyte leukemia", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "7459812_2", "wnd_id": "7459812_2_1", "text": "Following several of these courses of therapy , respiratory distress occurred 9 to 12 days after the chlorambucil was given .", "tokens": ["Following", "several", "of", "these", "courses", "of", "therapy", ",", "respiratory", "distress", "occurred", "9", "to", "12", "days", "after", "the", "chlorambucil", "was", "given", "."], "event_mentions": [{"id": "7459812_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 15, "end": 16}, "arguments": [{"entity_id": "7459812_2_Ent0", "role": "Effect", "text": "respiratory distress", "start": 8, "end": 10}, {"entity_id": "7459812_2_Ent2", "role": "Treatment_Time_elapsed", "text": "9 to 12 days", "start": 11, "end": 15}, {"entity_id": "7459812_2_Ent1", "role": "Treatment", "text": "the chlorambucil", "start": 16, "end": 18}, {"entity_id": "7459812_2_Ent3", "role": "Treatment_Drug", "text": "chlorambucil", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "7459812_2_Ent0", "text": "respiratory distress", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7459812_2_Ent2", "text": "9 to 12 days", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7459812_2_Ent1", "text": "the chlorambucil", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "7459812_2_Ent3", "text": "chlorambucil", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "7468565_3", "wnd_id": "7468565_3_1", "text": "A case of barbiturate - induced submassive hepatic necrosis is presented and the literature is reviewed .", "tokens": ["A", "case", "of", "barbiturate", "-", "induced", "submassive", "hepatic", "necrosis", "is", "presented", "and", "the", "literature", "is", "reviewed", "."], "event_mentions": [{"id": "7468565_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "7468565_3_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "7468565_3_Ent2", "role": "Treatment", "text": "barbiturate", "start": 3, "end": 4}, {"entity_id": "7468565_3_Ent3", "role": "Treatment_Drug", "text": "barbiturate", "start": 3, "end": 4}, {"entity_id": "7468565_3_Ent1", "role": "Effect", "text": "submassive hepatic necrosis", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "7468565_3_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7468565_3_Ent2", "text": "barbiturate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7468565_3_Ent3", "text": "barbiturate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7468565_3_Ent1", "text": "submassive hepatic necrosis", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "748238_2", "wnd_id": "748238_2_1", "text": "The development of an IgG lambda - type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin ( DILANTIN ) therapy for 20 years is reported .", "tokens": ["The", "development", "of", "an", "IgG", "lambda", "-", "type", "monoclonal", "gammopathy", "and", "subsequent", "multiple", "myeloma", "in", "an", "epilepsy", "patient", "on", "diphenylhydantoin", "(", "DILANTIN", ")", "therapy", "for", "20", "years", "is", "reported", "."], "event_mentions": [{"id": "748238_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 1, "end": 2}, "arguments": [{"entity_id": "748238_2_Ent1", "role": "Effect", "text": "an IgG lambda - type monoclonal gammopathy and subsequent multiple myeloma", "start": 3, "end": 14}, {"entity_id": "748238_2_Ent0", "role": "Subject", "text": "an epilepsy patient", "start": 15, "end": 18}, {"entity_id": "748238_2_Ent3", "role": "Treatment_Disorder", "text": "epilepsy", "start": 16, "end": 17}, {"entity_id": "748238_2_Ent4", "role": "Treatment_Drug", "text": "diphenylhydantoin", "start": 19, "end": 20}, {"entity_id": "748238_2_Ent2", "role": "Treatment", "text": "diphenylhydantoin ( DILANTIN ) therapy for 20 years", "start": 19, "end": 27}, {"entity_id": "748238_2_Ent5", "role": "Treatment_Duration", "text": "for 20 years", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "748238_2_Ent1", "text": "an IgG lambda - type monoclonal gammopathy and subsequent multiple myeloma", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "748238_2_Ent0", "text": "an epilepsy patient", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "748238_2_Ent3", "text": "epilepsy", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "748238_2_Ent4", "text": "diphenylhydantoin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "748238_2_Ent2", "text": "diphenylhydantoin ( DILANTIN ) therapy for 20 years", "entity_type": "Entity", "start": 19, "end": 27}, {"id": "748238_2_Ent5", "text": "for 20 years", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "7485371_1", "wnd_id": "7485371_1_1", "text": "CONCLUSION : Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium .", "tokens": ["CONCLUSION", ":", "Atovaquone", "should", "be", "added", "to", "the", "list", "of", "agents", "causing", "vortex", "keratopathy", "involving", "the", "corneal", "epithelium", "."], "event_mentions": [{"id": "7485371_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 11, "end": 12}, "arguments": [{"entity_id": "7485371_1_Ent1", "role": "Treatment", "text": "Atovaquone", "start": 2, "end": 3}, {"entity_id": "7485371_1_Ent2", "role": "Treatment_Drug", "text": "Atovaquone", "start": 2, "end": 3}, {"entity_id": "7485371_1_Ent0", "role": "Effect", "text": "vortex keratopathy involving the corneal epithelium", "start": 12, "end": 18}]}], "entity_mentions": [{"id": "7485371_1_Ent1", "text": "Atovaquone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7485371_1_Ent2", "text": "Atovaquone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7485371_1_Ent0", "text": "vortex keratopathy involving the corneal epithelium", "entity_type": "Entity", "start": 12, "end": 18}], "lang": "en"}
{"doc_id": "7496198_6", "wnd_id": "7496198_6_1", "text": "The incidence of ARE suddenly exceeded 10 % of the patients treated by melarsoprol during August 1992 and September 1993 .", "tokens": ["The", "incidence", "of", "ARE", "suddenly", "exceeded", "10", "%", "of", "the", "patients", "treated", "by", "melarsoprol", "during", "August", "1992", "and", "September", "1993", "."], "event_mentions": [{"id": "7496198_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 12, "end": 13}, "arguments": [{"entity_id": "7496198_6_Ent1", "role": "Effect", "text": "ARE", "start": 3, "end": 4}, {"entity_id": "7496198_6_Ent0", "role": "Subject", "text": "patients", "start": 10, "end": 11}, {"entity_id": "7496198_6_Ent2", "role": "Treatment", "text": "melarsoprol", "start": 13, "end": 14}, {"entity_id": "7496198_6_Ent3", "role": "Treatment_Drug", "text": "melarsoprol", "start": 13, "end": 14}, {"entity_id": "7496198_6_Ent4", "role": "Treatment_Duration", "text": "August 1992 and September 1993", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "7496198_6_Ent1", "text": "ARE", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7496198_6_Ent0", "text": "patients", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7496198_6_Ent2", "text": "melarsoprol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7496198_6_Ent3", "text": "melarsoprol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7496198_6_Ent4", "text": "August 1992 and September 1993", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "7519913_1", "wnd_id": "7519913_1_1", "text": "However , there remain questions concerning whether these drugs , especially methimazole ( MMI ) , may be associated with aplasia cutis congenita ( ACC ) and how best to avoid impairment of fetal thyroid function during their use .", "tokens": ["However", ",", "there", "remain", "questions", "concerning", "whether", "these", "drugs", ",", "especially", "methimazole", "(", "MMI", ")", ",", "may", "be", "associated", "with", "aplasia", "cutis", "congenita", "(", "ACC", ")", "and", "how", "best", "to", "avoid", "impairment", "of", "fetal", "thyroid", "function", "during", "their", "use", "."], "event_mentions": [{"id": "7519913_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 18, "end": 19}, "arguments": [{"entity_id": "7519913_1_Ent1", "role": "Treatment", "text": "methimazole", "start": 11, "end": 12}, {"entity_id": "7519913_1_Ent2", "role": "Treatment_Drug", "text": "methimazole ( MMI )", "start": 11, "end": 15}, {"entity_id": "7519913_1_Ent0", "role": "Effect", "text": "aplasia cutis congenita", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "7519913_1_Ent1", "text": "methimazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7519913_1_Ent2", "text": "methimazole ( MMI )", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7519913_1_Ent0", "text": "aplasia cutis congenita", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "7582710_2", "wnd_id": "7582710_2_1", "text": "The first patient developed mild nitritoid symptoms and pain in a band - like distribution , corresponding to T10 - T12 dermatomes , shortly after gold sodium thiomalate ( GSTM ) injection .", "tokens": ["The", "first", "patient", "developed", "mild", "nitritoid", "symptoms", "and", "pain", "in", "a", "band", "-", "like", "distribution", ",", "corresponding", "to", "T10", "-", "T12", "dermatomes", ",", "shortly", "after", "gold", "sodium", "thiomalate", "(", "GSTM", ")", "injection", "."], "event_mentions": [{"id": "7582710_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "7582710_2_Ent0", "role": "Subject", "text": "The first patient", "start": 0, "end": 3}, {"entity_id": "7582710_2_Ent1", "role": "Effect", "text": "mild nitritoid symptoms and pain in a band - like distribution", "start": 4, "end": 15}, {"entity_id": "7582710_2_Ent3", "role": "Treatment_Drug", "text": "gold sodium thiomalate", "start": 25, "end": 28}, {"entity_id": "7582710_2_Ent2", "role": "Treatment", "text": "gold sodium thiomalate ( GSTM ) injection", "start": 25, "end": 32}, {"entity_id": "7582710_2_Ent4", "role": "Treatment_Route", "text": "injection", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "7582710_2_Ent0", "text": "The first patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7582710_2_Ent1", "text": "mild nitritoid symptoms and pain in a band - like distribution", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "7582710_2_Ent3", "text": "gold sodium thiomalate", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "7582710_2_Ent2", "text": "gold sodium thiomalate ( GSTM ) injection", "entity_type": "Entity", "start": 25, "end": 32}, {"id": "7582710_2_Ent4", "text": "injection", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "7606071_1", "wnd_id": "7606071_1_1", "text": "Anaphylactoid reactions with intraperitoneal cisplatin .", "tokens": ["Anaphylactoid", "reactions", "with", "intraperitoneal", "cisplatin", "."], "event_mentions": [{"id": "7606071_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "7606071_1_Ent0", "role": "Effect", "text": "Anaphylactoid reactions", "start": 0, "end": 2}, {"entity_id": "7606071_1_Ent2", "role": "Treatment_Route", "text": "intraperitoneal", "start": 3, "end": 4}, {"entity_id": "7606071_1_Ent1", "role": "Treatment", "text": "intraperitoneal cisplatin", "start": 3, "end": 5}, {"entity_id": "7606071_1_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "7606071_1_Ent0", "text": "Anaphylactoid reactions", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7606071_1_Ent2", "text": "intraperitoneal", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7606071_1_Ent1", "text": "intraperitoneal cisplatin", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7606071_1_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "7606071_4", "wnd_id": "7606071_4_1", "text": "DISCUSSION : Anaphylactoid reactions have been described previously with cisplatin administration .", "tokens": ["DISCUSSION", ":", "Anaphylactoid", "reactions", "have", "been", "described", "previously", "with", "cisplatin", "administration", "."], "event_mentions": [{"id": "7606071_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 8, "end": 9}, "arguments": [{"entity_id": "7606071_4_Ent0", "role": "Effect", "text": "Anaphylactoid reactions", "start": 2, "end": 4}, {"entity_id": "7606071_4_Ent1", "role": "Treatment", "text": "cisplatin", "start": 9, "end": 10}, {"entity_id": "7606071_4_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7606071_4_Ent0", "text": "Anaphylactoid reactions", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7606071_4_Ent1", "text": "cisplatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7606071_4_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7632529_2", "wnd_id": "7632529_2_1", "text": "Acute renal failure in a child associated with acyclovir .", "tokens": ["Acute", "renal", "failure", "in", "a", "child", "associated", "with", "acyclovir", "."], "event_mentions": [{"id": "7632529_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "7632529_2_Ent2", "role": "Effect", "text": "Acute renal failure", "start": 0, "end": 3}, {"entity_id": "7632529_2_Ent0", "role": "Subject", "text": "a child", "start": 4, "end": 6}, {"entity_id": "7632529_2_Ent1", "role": "Subject_Age", "text": "child", "start": 5, "end": 6}, {"entity_id": "7632529_2_Ent3", "role": "Treatment", "text": "acyclovir", "start": 8, "end": 9}, {"entity_id": "7632529_2_Ent4", "role": "Treatment_Drug", "text": "acyclovir", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "7632529_2_Ent2", "text": "Acute renal failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7632529_2_Ent0", "text": "a child", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7632529_2_Ent1", "text": "child", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7632529_2_Ent3", "text": "acyclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7632529_2_Ent4", "text": "acyclovir", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "7639655_2", "wnd_id": "7639655_2_1", "text": "CONCLUSION : Anterior ischemic optic neuropathy may complicate treatment with interferon alfa .", "tokens": ["CONCLUSION", ":", "Anterior", "ischemic", "optic", "neuropathy", "may", "complicate", "treatment", "with", "interferon", "alfa", "."], "event_mentions": [{"id": "7639655_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicate", "start": 7, "end": 8}, "arguments": [{"entity_id": "7639655_2_Ent0", "role": "Effect", "text": "Anterior ischemic optic neuropathy", "start": 2, "end": 6}, {"entity_id": "7639655_2_Ent1", "role": "Treatment", "text": "interferon alfa", "start": 10, "end": 12}, {"entity_id": "7639655_2_Ent2", "role": "Treatment_Drug", "text": "interferon alfa", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7639655_2_Ent0", "text": "Anterior ischemic optic neuropathy", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "7639655_2_Ent1", "text": "interferon alfa", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7639655_2_Ent2", "text": "interferon alfa", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7639655_3", "wnd_id": "7639655_3_1", "text": "OBJECTIVE : To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "occurrence", "of", "anterior", "ischemic", "optic", "neuropathy", "as", "a", "complication", "of", "treatment", "with", "interferon", "alfa", "and", "to", "consider", "the", "possible", "underlying", "mechanisms", "for", "this", "association", "."], "event_mentions": [{"id": "7639655_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 13, "end": 14}, "arguments": [{"entity_id": "7639655_3_Ent0", "role": "Effect", "text": "anterior ischemic optic neuropathy", "start": 7, "end": 11}, {"entity_id": "7639655_3_Ent1", "role": "Treatment", "text": "interferon alfa", "start": 17, "end": 19}, {"entity_id": "7639655_3_Ent2", "role": "Treatment_Drug", "text": "interferon alfa", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "7639655_3_Ent0", "text": "anterior ischemic optic neuropathy", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "7639655_3_Ent1", "text": "interferon alfa", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "7639655_3_Ent2", "text": "interferon alfa", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "7663030_12", "wnd_id": "7663030_12_1", "text": "Propafenone 's distribution , clearance , and structural similarity to propranolol contribute to its central nervous system effects .", "tokens": ["Propafenone", "'s", "distribution", ",", "clearance", ",", "and", "structural", "similarity", "to", "propranolol", "contribute", "to", "its", "central", "nervous", "system", "effects", "."], "event_mentions": [{"id": "7663030_12_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "contribute", "start": 11, "end": 12}, "arguments": [{"entity_id": "7663030_12_Ent1", "role": "Treatment", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "7663030_12_Ent3", "role": "Treatment_Drug", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "7663030_12_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 10, "end": 11}, {"entity_id": "7663030_12_Ent0", "role": "Effect", "text": "central nervous system effects", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "7663030_12_Ent1", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7663030_12_Ent3", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7663030_12_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7663030_12_Ent0", "text": "central nervous system effects", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "7668127_3", "wnd_id": "7668127_3_1", "text": "To the best of our knowledge no comparable case and no discussion of possible complications of aspirin prophylaxis in patients with brain tumours have been published .", "tokens": ["To", "the", "best", "of", "our", "knowledge", "no", "comparable", "case", "and", "no", "discussion", "of", "possible", "complications", "of", "aspirin", "prophylaxis", "in", "patients", "with", "brain", "tumours", "have", "been", "published", "."], "event_mentions": [{"id": "7668127_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complications", "start": 14, "end": 15}, "arguments": [{"entity_id": "7668127_3_Ent3", "role": "Treatment_Drug", "text": "aspirin", "start": 16, "end": 17}, {"entity_id": "7668127_3_Ent2", "role": "Treatment", "text": "aspirin prophylaxis", "start": 16, "end": 18}, {"entity_id": "7668127_3_Ent0", "role": "Subject", "text": "patients with brain tumours", "start": 19, "end": 23}, {"entity_id": "7668127_3_Ent1", "role": "Subject_Disorder", "text": "brain tumours", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "7668127_3_Ent3", "text": "aspirin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7668127_3_Ent2", "text": "aspirin prophylaxis", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "7668127_3_Ent0", "text": "patients with brain tumours", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "7668127_3_Ent1", "text": "brain tumours", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "7685228_2", "wnd_id": "7685228_2_1", "text": "We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .", "tokens": ["We", "have", "successfully", "overcome", "severe", "neutropenia", "in", "an", "RA", "patient", "treated", "with", "gold", "salts", ",", "using", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", ",", "reducing", "the", "duration", "of", "neutropenia", "and", "risk", "of", "infection", "."], "event_mentions": [{"id": "7685228_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "overcome", "start": 3, "end": 4}, "arguments": [{"entity_id": "7685228_2_Ent4", "role": "Treatment_Disorder", "text": "severe neutropenia", "start": 4, "end": 6}, {"entity_id": "7685228_2_Ent0", "role": "Subject", "text": "an RA patient treated with gold salts", "start": 7, "end": 14}, {"entity_id": "7685228_2_Ent1", "role": "Subject_Disorder", "text": "RA", "start": 8, "end": 9}, {"entity_id": "7685228_2_Ent5", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 16, "end": 21}, {"entity_id": "7685228_2_Ent3", "role": "Treatment", "text": "granulocyte colony - stimulating factor ( G - CSF )", "start": 16, "end": 26}, {"entity_id": "7685228_2_Ent2", "role": "Effect", "text": "reducing the duration of neutropenia and risk of infection", "start": 27, "end": 36}]}, {"id": "7685228_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 6, "end": 7}, "arguments": [{"entity_id": "7685228_2_Ent6", "role": "Effect", "text": "severe neutropenia", "start": 4, "end": 6}, {"entity_id": "7685228_2_Ent8", "role": "Treatment_Disorder", "text": "RA", "start": 8, "end": 9}, {"entity_id": "7685228_2_Ent7", "role": "Treatment", "text": "gold salts", "start": 12, "end": 14}, {"entity_id": "7685228_2_Ent9", "role": "Treatment_Drug", "text": "gold salts", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "7685228_2_Ent4", "text": "severe neutropenia", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7685228_2_Ent6", "text": "severe neutropenia", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7685228_2_Ent0", "text": "an RA patient treated with gold salts", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "7685228_2_Ent1", "text": "RA", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7685228_2_Ent8", "text": "RA", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7685228_2_Ent7", "text": "gold salts", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7685228_2_Ent9", "text": "gold salts", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7685228_2_Ent5", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "7685228_2_Ent3", "text": "granulocyte colony - stimulating factor ( G - CSF )", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "7685228_2_Ent2", "text": "reducing the duration of neutropenia and risk of infection", "entity_type": "Entity", "start": 27, "end": 36}], "lang": "en"}
{"doc_id": "7696938_1", "wnd_id": "7696938_1_1", "text": "Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .", "tokens": ["Arrhythmias", "and", "cardiac", "arrest", "have", "been", "reported", "during", "amphotericin", "B", "administration", "but", "no", "effective", "technique", "has", "been", "described", "to", "prevent", "them", "."], "event_mentions": [{"id": "7696938_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 7, "end": 8}, "arguments": [{"entity_id": "7696938_1_Ent0", "role": "Effect", "text": "Arrhythmias and cardiac arrest", "start": 0, "end": 4}, {"entity_id": "7696938_1_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 8, "end": 10}, {"entity_id": "7696938_1_Ent1", "role": "Treatment", "text": "amphotericin B administration", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "7696938_1_Ent0", "text": "Arrhythmias and cardiac arrest", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7696938_1_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7696938_1_Ent1", "text": "amphotericin B administration", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "7712052_6", "wnd_id": "7712052_6_1", "text": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD .", "tokens": ["These", "findings", "should", "lead", "to", "further", "study", "of", "the", "role", "of", "lithium", "in", "the", "treatment", "of", "this", "symptom", "complex", "in", "patients", "with", "PTSD", "."], "event_mentions": [{"id": "7712052_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 14, "end": 15}, "arguments": [{"entity_id": "7712052_6_Ent1", "role": "Treatment", "text": "lithium", "start": 11, "end": 12}, {"entity_id": "7712052_6_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 11, "end": 12}, {"entity_id": "7712052_6_Ent0", "role": "Subject", "text": "patients with PTSD", "start": 20, "end": 23}, {"entity_id": "7712052_6_Ent3", "role": "Treatment_Disorder", "text": "PTSD", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "7712052_6_Ent1", "text": "lithium", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7712052_6_Ent2", "text": "lithium", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7712052_6_Ent0", "text": "patients with PTSD", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "7712052_6_Ent3", "text": "PTSD", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "7718983_3", "wnd_id": "7718983_3_1", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C.", "tokens": ["Graves", "'", "hyperthyroidism", "following", "transient", "thyrotoxicosis", "during", "interferon", "therapy", "for", "chronic", "hepatitis", "type", "C."], "event_mentions": [{"id": "7718983_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 6, "end": 7}, "arguments": [{"entity_id": "7718983_3_Ent0", "role": "Effect", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis", "start": 0, "end": 6}, {"entity_id": "7718983_3_Ent1", "role": "Treatment", "text": "interferon therapy", "start": 7, "end": 9}, {"entity_id": "7718983_3_Ent2", "role": "Treatment_Drug", "text": "interferon therapy", "start": 7, "end": 9}, {"entity_id": "7718983_3_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis type C.", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "7718983_3_Ent0", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "7718983_3_Ent1", "text": "interferon therapy", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7718983_3_Ent2", "text": "interferon therapy", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7718983_3_Ent3", "text": "chronic hepatitis type C.", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "7718983_4", "wnd_id": "7718983_4_1", "text": "This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .", "tokens": ["This", "case", "showed", "sequential", "manifestation", "from", "transient", "thyrotoxicosis", "to", "the", "appearance", "of", "TSH", "-", "receptor", "autoantibodies", ",", "and", "then", "the", "occurrence", "of", "Graves", "'", "hyperthyroidism", "during", "IFN", "therapy", "."], "event_mentions": [{"id": "7718983_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 20, "end": 21}, "arguments": [{"entity_id": "7718983_4_Ent0", "role": "Subject", "text": "This case", "start": 0, "end": 2}, {"entity_id": "7718983_4_Ent1", "role": "Effect", "text": "Graves ' hyperthyroidism", "start": 22, "end": 25}, {"entity_id": "7718983_4_Ent3", "role": "Treatment_Drug", "text": "IFN", "start": 26, "end": 27}, {"entity_id": "7718983_4_Ent2", "role": "Treatment", "text": "IFN therapy", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "7718983_4_Ent0", "text": "This case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7718983_4_Ent1", "text": "Graves ' hyperthyroidism", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "7718983_4_Ent3", "text": "IFN", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "7718983_4_Ent2", "text": "IFN therapy", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "7724306_4", "wnd_id": "7724306_4_1", "text": "In patients with a known access to INH , seizures should be considered to be caused by INH toxicity unless proved otherwise .", "tokens": ["In", "patients", "with", "a", "known", "access", "to", "INH", ",", "seizures", "should", "be", "considered", "to", "be", "caused", "by", "INH", "toxicity", "unless", "proved", "otherwise", "."], "event_mentions": [{"id": "7724306_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 15, "end": 16}, "arguments": [{"entity_id": "7724306_4_Ent1", "role": "Treatment", "text": "INH", "start": 7, "end": 8}, {"entity_id": "7724306_4_Ent2", "role": "Treatment_Drug", "text": "INH", "start": 7, "end": 8}, {"entity_id": "7724306_4_Ent0", "role": "Effect", "text": "seizures", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7724306_4_Ent1", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7724306_4_Ent2", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7724306_4_Ent0", "text": "seizures", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7724306_5", "wnd_id": "7724306_5_1", "text": "OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .", "tokens": ["OBJECTIVES", ":", "To", "describe", "the", "presentation", "and", "treatment", "of", "acute", "isoniazid", "(", "INH", ")", "neurotoxicity", "appearing", "at", "an", "inner", "-", "city", "municipal", "hospital", "."], "event_mentions": [{"id": "7724306_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "neurotoxicity", "start": 14, "end": 15}, "arguments": [{"entity_id": "7724306_5_Ent2", "role": "Treatment_Drug", "text": "isoniazid", "start": 10, "end": 11}, {"entity_id": "7724306_5_Ent1", "role": "Treatment", "text": "isoniazid ( INH )", "start": 10, "end": 14}, {"entity_id": "7724306_5_Ent0", "role": "Effect", "text": "isoniazid ( INH ) neurotoxicity", "start": 10, "end": 15}]}], "entity_mentions": [{"id": "7724306_5_Ent2", "text": "isoniazid", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7724306_5_Ent1", "text": "isoniazid ( INH )", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "7724306_5_Ent0", "text": "isoniazid ( INH ) neurotoxicity", "entity_type": "Entity", "start": 10, "end": 15}], "lang": "en"}
{"doc_id": "7724306_6", "wnd_id": "7724306_6_1", "text": "Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .", "tokens": ["Parenteral", "pyridoxine", ",", "the", "specific", "antidote", "for", "INH", "-", "induced", "refractory", "seizures", ",", "should", "be", "readily", "available", "in", "every", "emergency", "department", "in", "the", "areas", "similarly", "experiencing", "increasing", "trends", "of", "TB", "."], "event_mentions": [{"id": "7724306_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "7724306_6_Ent1", "role": "Treatment", "text": "INH", "start": 7, "end": 8}, {"entity_id": "7724306_6_Ent2", "role": "Treatment_Drug", "text": "INH", "start": 7, "end": 8}, {"entity_id": "7724306_6_Ent0", "role": "Effect", "text": "refractory seizures", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7724306_6_Ent1", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7724306_6_Ent2", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7724306_6_Ent0", "text": "refractory seizures", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7748076_3", "wnd_id": "7748076_3_1", "text": "RESULTS : Extensive squamous metaplasia was found in endometrial glands following progestin therapy .", "tokens": ["RESULTS", ":", "Extensive", "squamous", "metaplasia", "was", "found", "in", "endometrial", "glands", "following", "progestin", "therapy", "."], "event_mentions": [{"id": "7748076_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 10, "end": 11}, "arguments": [{"entity_id": "7748076_3_Ent0", "role": "Effect", "text": "Extensive squamous metaplasia was found in endometrial glands", "start": 2, "end": 10}, {"entity_id": "7748076_3_Ent2", "role": "Treatment_Drug", "text": "progestin", "start": 11, "end": 12}, {"entity_id": "7748076_3_Ent1", "role": "Treatment", "text": "progestin therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "7748076_3_Ent0", "text": "Extensive squamous metaplasia was found in endometrial glands", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "7748076_3_Ent2", "text": "progestin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7748076_3_Ent1", "text": "progestin therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "7761316_1", "wnd_id": "7761316_1_1", "text": "Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .", "tokens": ["Musculoskeletal", "complaints", "were", "the", "presenting", "symptoms", "in", "four", "of", "44", "children", "(", "9", "%", ")", "treated", "for", "relapsed", "Wilms", "'", "tumors", "with", "ifosfamide", ",", "a", "derivative", "of", "cyclophosphamide", "."], "event_mentions": [{"id": "7761316_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 21, "end": 22}, "arguments": [{"entity_id": "7761316_1_Ent3", "role": "Effect", "text": "Musculoskeletal complaints", "start": 0, "end": 2}, {"entity_id": "7761316_1_Ent1", "role": "Subject_Population", "text": "four of 44", "start": 7, "end": 10}, {"entity_id": "7761316_1_Ent0", "role": "Subject", "text": "four of 44 children ( 9 % )", "start": 7, "end": 15}, {"entity_id": "7761316_1_Ent2", "role": "Subject_Age", "text": "children", "start": 10, "end": 11}, {"entity_id": "7761316_1_Ent5", "role": "Treatment_Disorder", "text": "relapsed Wilms ' tumors", "start": 17, "end": 21}, {"entity_id": "7761316_1_Ent4", "role": "Treatment", "text": "ifosfamide", "start": 22, "end": 23}, {"entity_id": "7761316_1_Ent6", "role": "Treatment_Drug", "text": "ifosfamide", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "7761316_1_Ent3", "text": "Musculoskeletal complaints", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7761316_1_Ent1", "text": "four of 44", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "7761316_1_Ent0", "text": "four of 44 children ( 9 % )", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "7761316_1_Ent2", "text": "children", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7761316_1_Ent5", "text": "relapsed Wilms ' tumors", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "7761316_1_Ent4", "text": "ifosfamide", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "7761316_1_Ent6", "text": "ifosfamide", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "7761316_2", "wnd_id": "7761316_2_1", "text": "Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide .", "tokens": ["Recognition", "of", "a", "potential", "drug", "-", "induced", "Fanconi", "syndrome", "is", "important", "when", "managing", "pediatric", "oncology", "patients", "previously", "treated", "with", "ifosfamide", "."], "event_mentions": [{"id": "7761316_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 17, "end": 18}, "arguments": [{"entity_id": "7761316_2_Ent2", "role": "Effect", "text": "drug - induced Fanconi syndrome", "start": 4, "end": 9}, {"entity_id": "7761316_2_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 13, "end": 14}, {"entity_id": "7761316_2_Ent0", "role": "Subject", "text": "pediatric oncology patients", "start": 13, "end": 16}, {"entity_id": "7761316_2_Ent4", "role": "Treatment_Disorder", "text": "oncology", "start": 14, "end": 15}, {"entity_id": "7761316_2_Ent3", "role": "Treatment", "text": "ifosfamide", "start": 19, "end": 20}, {"entity_id": "7761316_2_Ent5", "role": "Treatment_Drug", "text": "ifosfamide", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "7761316_2_Ent2", "text": "drug - induced Fanconi syndrome", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "7761316_2_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7761316_2_Ent0", "text": "pediatric oncology patients", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "7761316_2_Ent4", "text": "oncology", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7761316_2_Ent3", "text": "ifosfamide", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "7761316_2_Ent5", "text": "ifosfamide", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "7776854_4", "wnd_id": "7776854_4_1", "text": "We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .", "tokens": ["We", "stress", "the", "potential", "of", "benzarone", "to", "cause", "hepatotoxicity", ",", "which", "usually", "resembles", "severe", "chronic", "active", "hepatitis", "."], "event_mentions": [{"id": "7776854_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "7776854_4_Ent2", "role": "Treatment", "text": "benzarone", "start": 5, "end": 6}, {"entity_id": "7776854_4_Ent3", "role": "Treatment_Drug", "text": "benzarone", "start": 5, "end": 6}, {"entity_id": "7776854_4_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 8, "end": 9}, {"entity_id": "7776854_4_Ent1", "role": "Effect", "text": "severe chronic active hepatitis", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "7776854_4_Ent2", "text": "benzarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7776854_4_Ent3", "text": "benzarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7776854_4_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7776854_4_Ent1", "text": "severe chronic active hepatitis", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "7781845_11", "wnd_id": "7781845_11_1", "text": "Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .", "tokens": ["Clinicians", "who", "manage", "cachectic", "patients", ",", "particularly", "those", "with", "protracted", "diarrhoea", "and/or", "receiving", "anti", "-", "malarial", "drugs", "including", "mefloquine", ",", "should", "be", "aware", "of", "the", "risk", "of", "severe", "hypoglycaemia", "."], "event_mentions": [{"id": "7781845_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 25, "end": 26}, "arguments": [{"entity_id": "7781845_11_Ent5", "role": "Treatment_Disorder", "text": "cachectic", "start": 3, "end": 4}, {"entity_id": "7781845_11_Ent0", "role": "Subject", "text": "cachectic patients", "start": 3, "end": 5}, {"entity_id": "7781845_11_Ent1", "role": "Subject", "text": "with protracted diarrhoea", "start": 8, "end": 11}, {"entity_id": "7781845_11_Ent6", "role": "Treatment_Disorder", "text": "protracted diarrhoea", "start": 9, "end": 11}, {"entity_id": "7781845_11_Ent3", "role": "Treatment", "text": "anti - malarial drugs including mefloquine", "start": 13, "end": 19}, {"entity_id": "7781845_11_Ent4", "role": "Treatment_Drug", "text": "mefloquine", "start": 18, "end": 19}, {"entity_id": "7781845_11_Ent2", "role": "Effect", "text": "severe hypoglycaemia", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "7781845_11_Ent5", "text": "cachectic", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7781845_11_Ent0", "text": "cachectic patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7781845_11_Ent1", "text": "with protracted diarrhoea", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "7781845_11_Ent6", "text": "protracted diarrhoea", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "7781845_11_Ent3", "text": "anti - malarial drugs including mefloquine", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "7781845_11_Ent4", "text": "mefloquine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "7781845_11_Ent2", "text": "severe hypoglycaemia", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "7783891_1", "wnd_id": "7783891_1_1", "text": "Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .", "tokens": ["Because", "sumatriptan", "can", "cause", "coronary", "artery", "vasospasm", ",", "patients", "with", "significant", "risk", "factors", "for", "coronary", "artery", "disease", "should", "be", "carefully", "evaluated", "for", "cardiovascular", "disease", "prior", "to", "the", "use", "of", "sumatriptan", "."], "event_mentions": [{"id": "7783891_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "7783891_1_Ent1", "role": "Treatment", "text": "sumatriptan", "start": 1, "end": 2}, {"entity_id": "7783891_1_Ent2", "role": "Treatment_Drug", "text": "sumatriptan", "start": 1, "end": 2}, {"entity_id": "7783891_1_Ent0", "role": "Effect", "text": "coronary artery vasospasm", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "7783891_1_Ent1", "text": "sumatriptan", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7783891_1_Ent2", "text": "sumatriptan", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7783891_1_Ent0", "text": "coronary artery vasospasm", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "7831179_2", "wnd_id": "7831179_2_1", "text": "There is a dose - effect relationship between doxorubicin and the incidence of symptomatic cardiac failure .", "tokens": ["There", "is", "a", "dose", "-", "effect", "relationship", "between", "doxorubicin", "and", "the", "incidence", "of", "symptomatic", "cardiac", "failure", "."], "event_mentions": [{"id": "7831179_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 6, "end": 7}, "arguments": [{"entity_id": "7831179_2_Ent1", "role": "Treatment", "text": "doxorubicin", "start": 8, "end": 9}, {"entity_id": "7831179_2_Ent2", "role": "Treatment_Drug", "text": "doxorubicin", "start": 8, "end": 9}, {"entity_id": "7831179_2_Ent0", "role": "Effect", "text": "symptomatic cardiac failure", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "7831179_2_Ent1", "text": "doxorubicin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7831179_2_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7831179_2_Ent0", "text": "symptomatic cardiac failure", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "7865488_3", "wnd_id": "7865488_3_1", "text": "We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix .", "tokens": ["We", "report", "a", "case", "of", "noncardiogenic", "pulmonary", "edema", "developed", "after", "therapeutic", "trial", "of", "EO", "as", "sclerosing", "agent", "for", "esophageal", "varix", "."], "event_mentions": [{"id": "7865488_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "7865488_3_Ent0", "role": "Effect", "text": "noncardiogenic pulmonary edema", "start": 5, "end": 8}, {"entity_id": "7865488_3_Ent1", "role": "Treatment", "text": "EO", "start": 13, "end": 14}, {"entity_id": "7865488_3_Ent2", "role": "Treatment_Drug", "text": "EO", "start": 13, "end": 14}, {"entity_id": "7865488_3_Ent3", "role": "Treatment_Disorder", "text": "esophageal varix", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "7865488_3_Ent0", "text": "noncardiogenic pulmonary edema", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7865488_3_Ent1", "text": "EO", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7865488_3_Ent2", "text": "EO", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7865488_3_Ent3", "text": "esophageal varix", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "7900744_4", "wnd_id": "7900744_4_1", "text": "Mannitol - induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure .", "tokens": ["Mannitol", "-", "induced", "ARF", "responds", "promptly", "to", "hemodialysis", "with", "rapid", "resolution", "of", "anuria", "and", "recovery", "of", "renal", "failure", "."], "event_mentions": [{"id": "7900744_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "7900744_4_Ent3", "role": "Treatment", "text": "Mannitol", "start": 0, "end": 1}, {"entity_id": "7900744_4_Ent4", "role": "Treatment_Drug", "text": "Mannitol", "start": 0, "end": 1}, {"entity_id": "7900744_4_Ent0", "role": "Effect", "text": "ARF", "start": 3, "end": 4}, {"entity_id": "7900744_4_Ent1", "role": "Effect", "text": "anuria", "start": 12, "end": 13}, {"entity_id": "7900744_4_Ent2", "role": "Effect", "text": "renal failure", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "7900744_4_Ent3", "text": "Mannitol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7900744_4_Ent4", "text": "Mannitol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7900744_4_Ent0", "text": "ARF", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7900744_4_Ent1", "text": "anuria", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7900744_4_Ent2", "text": "renal failure", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "7900744_6", "wnd_id": "7900744_6_1", "text": "This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .", "tokens": ["This", "is", "a", "report", "of", "a", "case", "of", "anuric", "ARF", "after", "high", "-", "dose", "mannitol", "infusion", "for", "treatment", "of", "narrow", "-", "angle", "glaucoma", "that", "readily", "responded", "to", "acute", "hemodialysis", "."], "event_mentions": [{"id": "7900744_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "7900744_6_Ent0", "role": "Subject", "text": "a case", "start": 5, "end": 7}, {"entity_id": "7900744_6_Ent1", "role": "Effect", "text": "anuric ARF", "start": 8, "end": 10}, {"entity_id": "7900744_6_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 11, "end": 14}, {"entity_id": "7900744_6_Ent2", "role": "Treatment", "text": "high - dose mannitol infusion", "start": 11, "end": 16}, {"entity_id": "7900744_6_Ent3", "role": "Treatment_Drug", "text": "mannitol", "start": 14, "end": 15}, {"entity_id": "7900744_6_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 15, "end": 16}, {"entity_id": "7900744_6_Ent6", "role": "Treatment_Disorder", "text": "narrow - angle glaucoma", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "7900744_6_Ent0", "text": "a case", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7900744_6_Ent1", "text": "anuric ARF", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7900744_6_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "7900744_6_Ent2", "text": "high - dose mannitol infusion", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "7900744_6_Ent3", "text": "mannitol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7900744_6_Ent4", "text": "infusion", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7900744_6_Ent6", "text": "narrow - angle glaucoma", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "7914463_1", "wnd_id": "7914463_1_1", "text": "Flumazenil reversal of benzodiazepine - induced sedation for a patient with severe pre - ECT anxiety .", "tokens": ["Flumazenil", "reversal", "of", "benzodiazepine", "-", "induced", "sedation", "for", "a", "patient", "with", "severe", "pre", "-", "ECT", "anxiety", "."], "event_mentions": [{"id": "7914463_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reversal", "start": 1, "end": 2}, "arguments": [{"entity_id": "7914463_1_Ent7", "role": "Treatment", "text": "Flumazenil", "start": 0, "end": 1}, {"entity_id": "7914463_1_Ent9", "role": "Treatment_Drug", "text": "Flumazenil", "start": 0, "end": 1}, {"entity_id": "7914463_1_Ent8", "role": "Treatment_Disorder", "text": "benzodiazepine - induced sedation", "start": 3, "end": 7}, {"entity_id": "7914463_1_Ent5", "role": "Subject", "text": "a patient with severe pre - ECT anxiety", "start": 8, "end": 16}, {"entity_id": "7914463_1_Ent6", "role": "Subject_Disorder", "text": "severe pre - ECT anxiety", "start": 11, "end": 16}]}, {"id": "7914463_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "7914463_1_Ent3", "role": "Treatment", "text": "benzodiazepine", "start": 3, "end": 4}, {"entity_id": "7914463_1_Ent4", "role": "Treatment_Drug", "text": "benzodiazepine", "start": 3, "end": 4}, {"entity_id": "7914463_1_Ent2", "role": "Effect", "text": "sedation", "start": 6, "end": 7}, {"entity_id": "7914463_1_Ent0", "role": "Subject", "text": "a patient with severe pre - ECT anxiety", "start": 8, "end": 16}, {"entity_id": "7914463_1_Ent1", "role": "Subject_Disorder", "text": "severe pre - ECT anxiety", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "7914463_1_Ent7", "text": "Flumazenil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7914463_1_Ent9", "text": "Flumazenil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7914463_1_Ent3", "text": "benzodiazepine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7914463_1_Ent4", "text": "benzodiazepine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7914463_1_Ent8", "text": "benzodiazepine - induced sedation", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "7914463_1_Ent2", "text": "sedation", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7914463_1_Ent0", "text": "a patient with severe pre - ECT anxiety", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "7914463_1_Ent5", "text": "a patient with severe pre - ECT anxiety", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "7914463_1_Ent1", "text": "severe pre - ECT anxiety", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "7914463_1_Ent6", "text": "severe pre - ECT anxiety", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "7937287_10", "wnd_id": "7937287_10_1", "text": "This is the first reported case of suspected DIAN due to cefuroxime .", "tokens": ["This", "is", "the", "first", "reported", "case", "of", "suspected", "DIAN", "due", "to", "cefuroxime", "."], "event_mentions": [{"id": "7937287_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 9, "end": 11}, "arguments": [{"entity_id": "7937287_10_Ent0", "role": "Subject", "text": "first reported case", "start": 3, "end": 6}, {"entity_id": "7937287_10_Ent1", "role": "Effect", "text": "DIAN", "start": 8, "end": 9}, {"entity_id": "7937287_10_Ent2", "role": "Treatment", "text": "cefuroxime", "start": 11, "end": 12}, {"entity_id": "7937287_10_Ent3", "role": "Treatment_Drug", "text": "cefuroxime", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "7937287_10_Ent0", "text": "first reported case", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "7937287_10_Ent1", "text": "DIAN", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7937287_10_Ent2", "text": "cefuroxime", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7937287_10_Ent3", "text": "cefuroxime", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "7973922_1", "wnd_id": "7973922_1_1", "text": "Acyclovir neurotoxicity : clinical experience and review of the literature .", "tokens": ["Acyclovir", "neurotoxicity", ":", "clinical", "experience", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "7973922_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experience", "start": 4, "end": 5}, "arguments": [{"entity_id": "7973922_1_Ent1", "role": "Treatment", "text": "Acyclovir", "start": 0, "end": 1}, {"entity_id": "7973922_1_Ent2", "role": "Treatment_Drug", "text": "Acyclovir", "start": 0, "end": 1}, {"entity_id": "7973922_1_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 1, "end": 2}]}], "entity_mentions": [{"id": "7973922_1_Ent1", "text": "Acyclovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7973922_1_Ent2", "text": "Acyclovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7973922_1_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 1, "end": 2}], "lang": "en"}
{"doc_id": "8002140_4", "wnd_id": "8002140_4_1", "text": "RESULTS : Budesonide use can cause contact dermatitis .", "tokens": ["RESULTS", ":", "Budesonide", "use", "can", "cause", "contact", "dermatitis", "."], "event_mentions": [{"id": "8002140_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 5, "end": 6}, "arguments": [{"entity_id": "8002140_4_Ent1", "role": "Treatment", "text": "Budesonide", "start": 2, "end": 3}, {"entity_id": "8002140_4_Ent2", "role": "Treatment_Drug", "text": "Budesonide", "start": 2, "end": 3}, {"entity_id": "8002140_4_Ent0", "role": "Effect", "text": "contact dermatitis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "8002140_4_Ent1", "text": "Budesonide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8002140_4_Ent2", "text": "Budesonide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8002140_4_Ent0", "text": "contact dermatitis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "8007037_1", "wnd_id": "8007037_1_1", "text": "Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .", "tokens": ["Although", "other", "nitrites", "induce", "methemoglobinemia", ",", "exposure", "to", "methyl", "nitrite", "during", "phenylpropanolamine", "production", "appears", "to", "be", "a", "new", "cause", "of", "occupational", "methemoglobinemia", "."], "event_mentions": [{"id": "8007037_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 18, "end": 19}, "arguments": [{"entity_id": "8007037_1_Ent1", "role": "Treatment", "text": "methyl nitrite", "start": 8, "end": 10}, {"entity_id": "8007037_1_Ent2", "role": "Treatment_Drug", "text": "methyl nitrite", "start": 8, "end": 10}, {"entity_id": "8007037_1_Ent0", "role": "Effect", "text": "occupational methemoglobinemia", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "8007037_1_Ent1", "text": "methyl nitrite", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8007037_1_Ent2", "text": "methyl nitrite", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8007037_1_Ent0", "text": "occupational methemoglobinemia", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "8007037_2", "wnd_id": "8007037_2_1", "text": "Methemoglobinemia : an occupational hazard of phenylpropanolamine production .", "tokens": ["Methemoglobinemia", ":", "an", "occupational", "hazard", "of", "phenylpropanolamine", "production", "."], "event_mentions": [{"id": "8007037_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "production", "start": 7, "end": 8}, "arguments": [{"entity_id": "8007037_2_Ent0", "role": "Effect", "text": "Methemoglobinemia", "start": 0, "end": 1}, {"entity_id": "8007037_2_Ent1", "role": "Treatment", "text": "phenylpropanolamine", "start": 6, "end": 7}, {"entity_id": "8007037_2_Ent2", "role": "Treatment_Drug", "text": "phenylpropanolamine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8007037_2_Ent0", "text": "Methemoglobinemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8007037_2_Ent1", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8007037_2_Ent2", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8013261_3", "wnd_id": "8013261_3_1", "text": "Occurrence of IDDM during interferon therapy for chronic viral hepatitis .", "tokens": ["Occurrence", "of", "IDDM", "during", "interferon", "therapy", "for", "chronic", "viral", "hepatitis", "."], "event_mentions": [{"id": "8013261_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "8013261_3_Ent0", "role": "Effect", "text": "IDDM", "start": 2, "end": 3}, {"entity_id": "8013261_3_Ent2", "role": "Treatment_Drug", "text": "interferon", "start": 4, "end": 5}, {"entity_id": "8013261_3_Ent1", "role": "Treatment", "text": "interferon therapy", "start": 4, "end": 6}, {"entity_id": "8013261_3_Ent3", "role": "Treatment_Disorder", "text": "chronic viral hepatitis", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "8013261_3_Ent0", "text": "IDDM", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8013261_3_Ent2", "text": "interferon", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8013261_3_Ent1", "text": "interferon therapy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8013261_3_Ent3", "text": "chronic viral hepatitis", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "8024670_1", "wnd_id": "8024670_1_1", "text": "Four patients who manifested symptoms of the antiepileptic drug ( AED ) hypersensitivity syndrome during therapy with carbamazepine are reported .", "tokens": ["Four", "patients", "who", "manifested", "symptoms", "of", "the", "antiepileptic", "drug", "(", "AED", ")", "hypersensitivity", "syndrome", "during", "therapy", "with", "carbamazepine", "are", "reported", "."], "event_mentions": [{"id": "8024670_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "symptoms of", "start": 4, "end": 6}, "arguments": [{"entity_id": "8024670_1_Ent1", "role": "Subject_Population", "text": "Four", "start": 0, "end": 1}, {"entity_id": "8024670_1_Ent0", "role": "Subject", "text": "Four patients", "start": 0, "end": 2}, {"entity_id": "8024670_1_Ent3", "role": "Treatment", "text": "antiepileptic drug ( AED )", "start": 7, "end": 12}, {"entity_id": "8024670_1_Ent5", "role": "Treatment_Drug", "text": "antiepileptic drug ( AED )", "start": 7, "end": 12}, {"entity_id": "8024670_1_Ent2", "role": "Effect", "text": "hypersensitivity syndrome", "start": 12, "end": 14}, {"entity_id": "8024670_1_Ent4", "role": "Treatment", "text": "during therapy with carbamazepine", "start": 14, "end": 18}, {"entity_id": "8024670_1_Ent6", "role": "Treatment_Drug", "text": "carbamazepine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8024670_1_Ent1", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8024670_1_Ent0", "text": "Four patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8024670_1_Ent3", "text": "antiepileptic drug ( AED )", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "8024670_1_Ent5", "text": "antiepileptic drug ( AED )", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "8024670_1_Ent2", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "8024670_1_Ent4", "text": "during therapy with carbamazepine", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "8024670_1_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8038468_1", "wnd_id": "8038468_1_1", "text": "CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5 - FU to a previous regimen of warfarin alone .", "tokens": ["CONCLUSIONS", ":", "This", "case", "describes", "the", "clinically", "significant", "increase", "of", "INR", "in", "an", "elderly", "patient", "after", "adding", "a", "chemotherapy", "regimen", "of", "levamisole", "and", "5", "-", "FU", "to", "a", "previous", "regimen", "of", "warfarin", "alone", "."], "event_mentions": [{"id": "8038468_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 11, "end": 12}, "arguments": [{"entity_id": "8038468_1_Ent2", "role": "Effect", "text": "increase of INR", "start": 8, "end": 11}, {"entity_id": "8038468_1_Ent0", "role": "Subject", "text": "an elderly patient", "start": 12, "end": 15}, {"entity_id": "8038468_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 13, "end": 14}, {"entity_id": "8038468_1_Ent5", "role": "Treatment_Drug", "text": "levamisole", "start": 21, "end": 22}, {"entity_id": "8038468_1_Ent8", "role": "Combination_Drug", "text": "levamisole", "start": 21, "end": 22}, {"entity_id": "8038468_1_Ent3", "role": "Treatment", "text": "levamisole and 5 - FU", "start": 21, "end": 26}, {"entity_id": "8038468_1_Ent6", "role": "Treatment_Drug", "text": "5 - FU", "start": 23, "end": 26}, {"entity_id": "8038468_1_Ent9", "role": "Combination_Drug", "text": "5 - FU", "start": 23, "end": 26}, {"entity_id": "8038468_1_Ent4", "role": "Treatment", "text": "warfarin", "start": 31, "end": 32}, {"entity_id": "8038468_1_Ent7", "role": "Treatment_Drug", "text": "warfarin", "start": 31, "end": 32}, {"entity_id": "8038468_1_Ent10", "role": "Combination_Drug", "text": "warfarin", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "8038468_1_Ent2", "text": "increase of INR", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8038468_1_Ent0", "text": "an elderly patient", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "8038468_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8038468_1_Ent5", "text": "levamisole", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8038468_1_Ent8", "text": "levamisole", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8038468_1_Ent3", "text": "levamisole and 5 - FU", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "8038468_1_Ent6", "text": "5 - FU", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "8038468_1_Ent9", "text": "5 - FU", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "8038468_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "8038468_1_Ent7", "text": "warfarin", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "8038468_1_Ent10", "text": "warfarin", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "8053440_3", "wnd_id": "8053440_3_1", "text": "The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .", "tokens": ["The", "second", "patient", ",", "who", "developed", "cholestasis", "after", "receiving", "trimethoprim", "-", "sulfamethoxazole", ",", "had", "marked", "duct", "paucity", "in", "the", "liver", "biopsy", "."], "event_mentions": [{"id": "8053440_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "8053440_3_Ent0", "role": "Subject", "text": "The second patient", "start": 0, "end": 3}, {"entity_id": "8053440_3_Ent1", "role": "Effect", "text": "cholestasis", "start": 6, "end": 7}, {"entity_id": "8053440_3_Ent3", "role": "Treatment", "text": "trimethoprim - sulfamethoxazole", "start": 9, "end": 12}, {"entity_id": "8053440_3_Ent4", "role": "Treatment_Drug", "text": "trimethoprim - sulfamethoxazole", "start": 9, "end": 12}, {"entity_id": "8053440_3_Ent2", "role": "Effect", "text": "duct paucity", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "8053440_3_Ent0", "text": "The second patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8053440_3_Ent1", "text": "cholestasis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8053440_3_Ent3", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8053440_3_Ent4", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8053440_3_Ent2", "text": "duct paucity", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "8104147_1", "wnd_id": "8104147_1_1", "text": "Ibopamine - induced reversible leukopenia during treatment for congestive heart failure .", "tokens": ["Ibopamine", "-", "induced", "reversible", "leukopenia", "during", "treatment", "for", "congestive", "heart", "failure", "."], "event_mentions": [{"id": "8104147_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8104147_1_Ent1", "role": "Treatment", "text": "Ibopamine", "start": 0, "end": 1}, {"entity_id": "8104147_1_Ent3", "role": "Treatment_Drug", "text": "Ibopamine", "start": 0, "end": 1}, {"entity_id": "8104147_1_Ent0", "role": "Effect", "text": "leukopenia", "start": 4, "end": 5}, {"entity_id": "8104147_1_Ent2", "role": "Treatment_Disorder", "text": "congestive heart failure", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "8104147_1_Ent1", "text": "Ibopamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8104147_1_Ent3", "text": "Ibopamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8104147_1_Ent0", "text": "leukopenia", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8104147_1_Ent2", "text": "congestive heart failure", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "812008_2", "wnd_id": "812008_2_1", "text": "Significant clinical improvement of the porphyria followed withdrawal of the diphenylhydantoin .", "tokens": ["Significant", "clinical", "improvement", "of", "the", "porphyria", "followed", "withdrawal", "of", "the", "diphenylhydantoin", "."], "event_mentions": [{"id": "812008_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improvement", "start": 2, "end": 3}, "arguments": [{"entity_id": "812008_2_Ent1", "role": "Treatment_Disorder", "text": "porphyria", "start": 5, "end": 6}, {"entity_id": "812008_2_Ent0", "role": "Treatment", "text": "withdrawal of the diphenylhydantoin", "start": 7, "end": 11}, {"entity_id": "812008_2_Ent2", "role": "Treatment_Drug", "text": "diphenylhydantoin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "812008_2_Ent1", "text": "porphyria", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "812008_2_Ent0", "text": "withdrawal of the diphenylhydantoin", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "812008_2_Ent2", "text": "diphenylhydantoin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "8149366_1", "wnd_id": "8149366_1_1", "text": "In two patients , apomorphine remained effective in the morning , but increased the intensity of the dyskinesias in the afternoon .", "tokens": ["In", "two", "patients", ",", "apomorphine", "remained", "effective", "in", "the", "morning", ",", "but", "increased", "the", "intensity", "of", "the", "dyskinesias", "in", "the", "afternoon", "."], "event_mentions": [{"id": "8149366_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 12, "end": 13}, "arguments": [{"entity_id": "8149366_1_Ent0", "role": "Subject", "text": "In two patients", "start": 0, "end": 3}, {"entity_id": "8149366_1_Ent1", "role": "Subject_Population", "text": "two", "start": 1, "end": 2}, {"entity_id": "8149366_1_Ent3", "role": "Treatment", "text": "apomorphine", "start": 4, "end": 5}, {"entity_id": "8149366_1_Ent4", "role": "Treatment_Drug", "text": "apomorphine", "start": 4, "end": 5}, {"entity_id": "8149366_1_Ent2", "role": "Effect", "text": "intensity of the dyskinesias in the afternoon", "start": 14, "end": 21}]}], "entity_mentions": [{"id": "8149366_1_Ent0", "text": "In two patients", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8149366_1_Ent1", "text": "two", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8149366_1_Ent3", "text": "apomorphine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8149366_1_Ent4", "text": "apomorphine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8149366_1_Ent2", "text": "intensity of the dyskinesias in the afternoon", "entity_type": "Entity", "start": 14, "end": 21}], "lang": "en"}
{"doc_id": "8162401_2", "wnd_id": "8162401_2_1", "text": "Seizures associated with fluoxetine therapy are uncommon .", "tokens": ["Seizures", "associated", "with", "fluoxetine", "therapy", "are", "uncommon", "."], "event_mentions": [{"id": "8162401_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "8162401_2_Ent0", "role": "Effect", "text": "Seizures", "start": 0, "end": 1}, {"entity_id": "8162401_2_Ent2", "role": "Treatment_Drug", "text": "fluoxetine", "start": 3, "end": 4}, {"entity_id": "8162401_2_Ent1", "role": "Treatment", "text": "fluoxetine therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "8162401_2_Ent0", "text": "Seizures", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8162401_2_Ent2", "text": "fluoxetine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8162401_2_Ent1", "text": "fluoxetine therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8181372_1", "wnd_id": "8181372_1_1", "text": "Severe diffuse interstitial pneumonitis induced by carmustine ( BCNU ) .", "tokens": ["Severe", "diffuse", "interstitial", "pneumonitis", "induced", "by", "carmustine", "(", "BCNU", ")", "."], "event_mentions": [{"id": "8181372_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "8181372_1_Ent0", "role": "Effect", "text": "diffuse interstitial pneumonitis", "start": 1, "end": 4}, {"entity_id": "8181372_1_Ent2", "role": "Treatment_Drug", "text": "carmustine", "start": 6, "end": 7}, {"entity_id": "8181372_1_Ent1", "role": "Treatment", "text": "carmustine ( BCNU )", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "8181372_1_Ent0", "text": "diffuse interstitial pneumonitis", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "8181372_1_Ent2", "text": "carmustine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8181372_1_Ent1", "text": "carmustine ( BCNU )", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "8186884_2", "wnd_id": "8186884_2_1", "text": "Electrical proarrhythmia with procainamide : a new ICD - drug interaction .", "tokens": ["Electrical", "proarrhythmia", "with", "procainamide", ":", "a", "new", "ICD", "-", "drug", "interaction", "."], "event_mentions": [{"id": "8186884_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "8186884_2_Ent0", "role": "Effect", "text": "Electrical proarrhythmia", "start": 0, "end": 2}, {"entity_id": "8186884_2_Ent1", "role": "Treatment", "text": "procainamide", "start": 3, "end": 4}, {"entity_id": "8186884_2_Ent2", "role": "Treatment_Drug", "text": "procainamide", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "8186884_2_Ent0", "text": "Electrical proarrhythmia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8186884_2_Ent1", "text": "procainamide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8186884_2_Ent2", "text": "procainamide", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "8222875_1", "wnd_id": "8222875_1_1", "text": "Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .", "tokens": ["Mitomycin", "C", "(", "MMC", ")", "is", "an", "alkylating", "agent", "that", "has", "been", "recently", "associated", "with", "the", "hemolytic", "-", "uremic", "syndrome", "(", "HUS", ")", "."], "event_mentions": [{"id": "8222875_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "8222875_1_Ent2", "role": "Treatment_Drug", "text": "Mitomycin C", "start": 0, "end": 2}, {"entity_id": "8222875_1_Ent1", "role": "Treatment", "text": "Mitomycin C ( MMC )", "start": 0, "end": 5}, {"entity_id": "8222875_1_Ent0", "role": "Effect", "text": "the hemolytic - uremic syndrome ( HUS )", "start": 15, "end": 23}]}], "entity_mentions": [{"id": "8222875_1_Ent2", "text": "Mitomycin C", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8222875_1_Ent1", "text": "Mitomycin C ( MMC )", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8222875_1_Ent0", "text": "the hemolytic - uremic syndrome ( HUS )", "entity_type": "Entity", "start": 15, "end": 23}], "lang": "en"}
{"doc_id": "8292513_1", "wnd_id": "8292513_1_1", "text": "Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .", "tokens": ["Cerebrovascular", "complications", "of", "L", "-", "asparaginase", "therapy", "in", "children", "with", "leukemia", ":", "aphasia", "and", "other", "neuropsychological", "deficits", "."], "event_mentions": [{"id": "8292513_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complications", "start": 1, "end": 2}, "arguments": [{"entity_id": "8292513_1_Ent2", "role": "Effect", "text": "Cerebrovascular complications", "start": 0, "end": 2}, {"entity_id": "8292513_1_Ent4", "role": "Treatment", "text": "L - asparaginase", "start": 3, "end": 6}, {"entity_id": "8292513_1_Ent5", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 3, "end": 6}, {"entity_id": "8292513_1_Ent1", "role": "Subject_Age", "text": "children", "start": 8, "end": 9}, {"entity_id": "8292513_1_Ent0", "role": "Subject", "text": "children with leukemia", "start": 8, "end": 11}, {"entity_id": "8292513_1_Ent6", "role": "Treatment_Disorder", "text": "leukemia", "start": 10, "end": 11}, {"entity_id": "8292513_1_Ent3", "role": "Effect", "text": "aphasia and other neuropsychological deficits", "start": 12, "end": 17}]}], "entity_mentions": [{"id": "8292513_1_Ent2", "text": "Cerebrovascular complications", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8292513_1_Ent4", "text": "L - asparaginase", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "8292513_1_Ent5", "text": "L - asparaginase", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "8292513_1_Ent1", "text": "children", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8292513_1_Ent0", "text": "children with leukemia", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8292513_1_Ent6", "text": "leukemia", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8292513_1_Ent3", "text": "aphasia and other neuropsychological deficits", "entity_type": "Entity", "start": 12, "end": 17}], "lang": "en"}
{"doc_id": "8301877_2", "wnd_id": "8301877_2_1", "text": "Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .", "tokens": ["Myoclonus", "and", "seizures", "in", "a", "patient", "with", "parkinsonism", ":", "induction", "by", "levodopa", "and", "its", "confirmation", "on", "SEPs", "."], "event_mentions": [{"id": "8301877_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induction", "start": 9, "end": 10}, "arguments": [{"entity_id": "8301877_2_Ent1", "role": "Effect", "text": "Myoclonus and seizures", "start": 0, "end": 3}, {"entity_id": "8301877_2_Ent0", "role": "Subject", "text": "a patient with parkinsonism", "start": 4, "end": 8}, {"entity_id": "8301877_2_Ent3", "role": "Treatment_Disorder", "text": "parkinsonism", "start": 7, "end": 8}, {"entity_id": "8301877_2_Ent2", "role": "Treatment", "text": "levodopa", "start": 11, "end": 12}, {"entity_id": "8301877_2_Ent4", "role": "Treatment_Drug", "text": "levodopa", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8301877_2_Ent1", "text": "Myoclonus and seizures", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8301877_2_Ent0", "text": "a patient with parkinsonism", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "8301877_2_Ent3", "text": "parkinsonism", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8301877_2_Ent2", "text": "levodopa", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8301877_2_Ent4", "text": "levodopa", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8301877_3", "wnd_id": "8301877_3_1", "text": "Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .", "tokens": ["Myoclonus", "was", "induced", "and", "enhanced", "by", "L", "-", "dopa", ",", "developing", "into", "generalized", "seizures", "."], "event_mentions": [{"id": "8301877_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced and enhanced", "start": 2, "end": 5}, "arguments": [{"entity_id": "8301877_3_Ent1", "role": "Effect", "text": "Myoclonus", "start": 0, "end": 1}, {"entity_id": "8301877_3_Ent2", "role": "Treatment", "text": "L - dopa", "start": 6, "end": 9}, {"entity_id": "8301877_3_Ent3", "role": "Treatment_Drug", "text": "L - dopa", "start": 6, "end": 9}, {"entity_id": "8301877_3_Ent0", "role": "Effect", "text": "developing into generalized seizures", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "8301877_3_Ent1", "text": "Myoclonus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8301877_3_Ent2", "text": "L - dopa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8301877_3_Ent3", "text": "L - dopa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8301877_3_Ent0", "text": "developing into generalized seizures", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "8305778_9", "wnd_id": "8305778_9_1", "text": "Hypothyroidism , occurring in up to 11 percent of patients treated with amiodarone , can also alter drug metabolism and sensitize the central nervous system , thus increasing the potential for toxicity .", "tokens": ["Hypothyroidism", ",", "occurring", "in", "up", "to", "11", "percent", "of", "patients", "treated", "with", "amiodarone", ",", "can", "also", "alter", "drug", "metabolism", "and", "sensitize", "the", "central", "nervous", "system", ",", "thus", "increasing", "the", "potential", "for", "toxicity", "."], "event_mentions": [{"id": "8305778_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 2, "end": 3}, "arguments": [{"entity_id": "8305778_9_Ent2", "role": "Effect", "text": "Hypothyroidism", "start": 0, "end": 1}, {"entity_id": "8305778_9_Ent1", "role": "Subject_Population", "text": "11 percent", "start": 6, "end": 8}, {"entity_id": "8305778_9_Ent0", "role": "Subject", "text": "11 percent of patients", "start": 6, "end": 10}, {"entity_id": "8305778_9_Ent3", "role": "Treatment", "text": "amiodarone", "start": 12, "end": 13}, {"entity_id": "8305778_9_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "8305778_9_Ent2", "text": "Hypothyroidism", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8305778_9_Ent1", "text": "11 percent", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8305778_9_Ent0", "text": "11 percent of patients", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "8305778_9_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8305778_9_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "8308511_1", "wnd_id": "8308511_1_1", "text": "Unintended exposure to acyclovir early in pregnancy , which is not uncommon , may cause excessive maternal and physician anxiety .", "tokens": ["Unintended", "exposure", "to", "acyclovir", "early", "in", "pregnancy", ",", "which", "is", "not", "uncommon", ",", "may", "cause", "excessive", "maternal", "and", "physician", "anxiety", "."], "event_mentions": [{"id": "8308511_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 14, "end": 15}, "arguments": [{"entity_id": "8308511_1_Ent1", "role": "Treatment", "text": "Unintended exposure to acyclovir", "start": 0, "end": 4}, {"entity_id": "8308511_1_Ent2", "role": "Treatment_Drug", "text": "acyclovir", "start": 3, "end": 4}, {"entity_id": "8308511_1_Ent0", "role": "Effect", "text": "excessive maternal and physician anxiety", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "8308511_1_Ent1", "text": "Unintended exposure to acyclovir", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8308511_1_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8308511_1_Ent0", "text": "excessive maternal and physician anxiety", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "8329789_12", "wnd_id": "8329789_12_1", "text": "INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B.", "tokens": ["INTERVENTIONS", "AND", "RESULTS", ":", "Cardiac", "complications", "were", "observed", "in", "five", "pediatric", "patients", "who", "received", "between", "4.6", "and", "40.8", "mg", "/", "kg", "/", "d", "of", "amphotericin", "B."], "event_mentions": [{"id": "8329789_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "received", "start": 13, "end": 14}, "arguments": [{"entity_id": "8329789_12_Ent3", "role": "Effect", "text": "Cardiac complications", "start": 4, "end": 6}, {"entity_id": "8329789_12_Ent1", "role": "Subject_Population", "text": "five", "start": 9, "end": 10}, {"entity_id": "8329789_12_Ent0", "role": "Subject", "text": "five pediatric patients", "start": 9, "end": 12}, {"entity_id": "8329789_12_Ent2", "role": "Subject_Age", "text": "pediatric", "start": 10, "end": 11}, {"entity_id": "8329789_12_Ent4", "role": "Treatment", "text": "between 4.6 and 40.8 mg / kg / d of amphotericin B.", "start": 14, "end": 26}, {"entity_id": "8329789_12_Ent5", "role": "Treatment_Dosage", "text": "4.6 and 40.8 mg / kg / d", "start": 15, "end": 23}, {"entity_id": "8329789_12_Ent6", "role": "Treatment_Drug", "text": "amphotericin B.", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "8329789_12_Ent3", "text": "Cardiac complications", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8329789_12_Ent1", "text": "five", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8329789_12_Ent0", "text": "five pediatric patients", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8329789_12_Ent2", "text": "pediatric", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8329789_12_Ent4", "text": "between 4.6 and 40.8 mg / kg / d of amphotericin B.", "entity_type": "Entity", "start": 14, "end": 26}, {"id": "8329789_12_Ent5", "text": "4.6 and 40.8 mg / kg / d", "entity_type": "Entity", "start": 15, "end": 23}, {"id": "8329789_12_Ent6", "text": "amphotericin B.", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "834512_1", "wnd_id": "834512_1_1", "text": "Sudden death in an infant from methemoglobinemia after administration of \" sweet spirits of nitre \" .", "tokens": ["Sudden", "death", "in", "an", "infant", "from", "methemoglobinemia", "after", "administration", "of", "\"", "sweet", "spirits", "of", "nitre", "\"", "."], "event_mentions": [{"id": "834512_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "834512_1_Ent2", "role": "Effect", "text": "Sudden death", "start": 0, "end": 2}, {"entity_id": "834512_1_Ent0", "role": "Subject", "text": "an infant", "start": 3, "end": 5}, {"entity_id": "834512_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 4, "end": 5}, {"entity_id": "834512_1_Ent3", "role": "Effect", "text": "methemoglobinemia", "start": 6, "end": 7}, {"entity_id": "834512_1_Ent4", "role": "Treatment", "text": "sweet spirits of nitre", "start": 11, "end": 15}, {"entity_id": "834512_1_Ent5", "role": "Treatment_Drug", "text": "sweet spirits of nitre", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "834512_1_Ent2", "text": "Sudden death", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "834512_1_Ent0", "text": "an infant", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "834512_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "834512_1_Ent3", "text": "methemoglobinemia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "834512_1_Ent4", "text": "sweet spirits of nitre", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "834512_1_Ent5", "text": "sweet spirits of nitre", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "834512_2", "wnd_id": "834512_2_1", "text": "The administration of \" sweet spirits of nitre \" ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .", "tokens": ["The", "administration", "of", "\"", "sweet", "spirits", "of", "nitre", "\"", "(", "4", "%", "ethyl", "nitrite", "CH3CH2ONO", "in", "70", "%", "ethyl", "alcohol", ")", "was", "followed", "by", "acute", "methemoglobinemia", "and", "severe", "anoxic", "metabolic", "acidosis", "in", "infant", "twins", ",", "Methylene", "blue", "administration", "reversed", "methemoglobinemia", "in", "both", ",", "but", "one", "twin", "died", "from", "the", "consequences", "of", "hypoxemia", "."], "event_mentions": [{"id": "834512_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 22, "end": 23}, "arguments": [{"entity_id": "834512_2_Ent3", "role": "Treatment", "text": "\" sweet spirits of nitre \" ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol )", "start": 3, "end": 21}, {"entity_id": "834512_2_Ent4", "role": "Treatment_Drug", "text": "sweet spirits of nitre", "start": 4, "end": 8}, {"entity_id": "834512_2_Ent2", "role": "Effect", "text": "acute methemoglobinemia and severe anoxic metabolic acidosis", "start": 24, "end": 31}, {"entity_id": "834512_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 32, "end": 33}, {"entity_id": "834512_2_Ent0", "role": "Subject", "text": "infant twins", "start": 32, "end": 34}]}, {"id": "834512_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reversed", "start": 38, "end": 39}, "arguments": [{"entity_id": "834512_2_Ent6", "role": "Subject_Age", "text": "infant", "start": 32, "end": 33}, {"entity_id": "834512_2_Ent5", "role": "Subject", "text": "infant twins", "start": 32, "end": 34}, {"entity_id": "834512_2_Ent7", "role": "Treatment", "text": "Methylene blue", "start": 35, "end": 37}, {"entity_id": "834512_2_Ent9", "role": "Treatment_Drug", "text": "Methylene blue", "start": 35, "end": 37}, {"entity_id": "834512_2_Ent8", "role": "Treatment_Disorder", "text": "methemoglobinemia", "start": 39, "end": 40}]}, {"id": "834512_2_Evt2", "event_type": "Adverse_event", "trigger": {"text": "died", "start": 46, "end": 47}, "arguments": [{"entity_id": "834512_2_Ent12", "role": "Treatment", "text": "\" sweet spirits of nitre \" ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol )", "start": 3, "end": 21}, {"entity_id": "834512_2_Ent13", "role": "Treatment_Drug", "text": "sweet spirits of nitre", "start": 4, "end": 8}, {"entity_id": "834512_2_Ent10", "role": "Subject", "text": "one twin", "start": 44, "end": 46}, {"entity_id": "834512_2_Ent11", "role": "Effect", "text": "died from the consequences of hypoxemia", "start": 46, "end": 52}]}], "entity_mentions": [{"id": "834512_2_Ent3", "text": "\" sweet spirits of nitre \" ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol )", "entity_type": "Entity", "start": 3, "end": 21}, {"id": "834512_2_Ent12", "text": "\" sweet spirits of nitre \" ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol )", "entity_type": "Entity", "start": 3, "end": 21}, {"id": "834512_2_Ent4", "text": "sweet spirits of nitre", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "834512_2_Ent13", "text": "sweet spirits of nitre", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "834512_2_Ent2", "text": "acute methemoglobinemia and severe anoxic metabolic acidosis", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "834512_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "834512_2_Ent6", "text": "infant", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "834512_2_Ent0", "text": "infant twins", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "834512_2_Ent5", "text": "infant twins", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "834512_2_Ent7", "text": "Methylene blue", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "834512_2_Ent9", "text": "Methylene blue", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "834512_2_Ent8", "text": "methemoglobinemia", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "834512_2_Ent10", "text": "one twin", "entity_type": "Entity", "start": 44, "end": 46}, {"id": "834512_2_Ent11", "text": "died from the consequences of hypoxemia", "entity_type": "Entity", "start": 46, "end": 52}], "lang": "en"}
{"doc_id": "8384030_3", "wnd_id": "8384030_3_1", "text": "Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .", "tokens": ["Foscarnet", "-", "induced", "severe", "hypomagnesemia", "and", "other", "electrolyte", "disorders", "."], "event_mentions": [{"id": "8384030_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8384030_3_Ent1", "role": "Treatment", "text": "Foscarnet", "start": 0, "end": 1}, {"entity_id": "8384030_3_Ent2", "role": "Treatment_Drug", "text": "Foscarnet", "start": 0, "end": 1}, {"entity_id": "8384030_3_Ent0", "role": "Effect", "text": "hypomagnesemia and other electrolyte disorders", "start": 4, "end": 9}]}], "entity_mentions": [{"id": "8384030_3_Ent1", "text": "Foscarnet", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8384030_3_Ent2", "text": "Foscarnet", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8384030_3_Ent0", "text": "hypomagnesemia and other electrolyte disorders", "entity_type": "Entity", "start": 4, "end": 9}], "lang": "en"}
{"doc_id": "8384030_4", "wnd_id": "8384030_4_1", "text": "OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "possible", "foscarnet", "-", "induced", "severe", "hypomagnesemia", "and", "other", "electrolyte", "disorders", "."], "event_mentions": [{"id": "8384030_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "8384030_4_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "8384030_4_Ent2", "role": "Treatment", "text": "foscarnet", "start": 8, "end": 9}, {"entity_id": "8384030_4_Ent3", "role": "Treatment_Drug", "text": "foscarnet", "start": 8, "end": 9}, {"entity_id": "8384030_4_Ent1", "role": "Effect", "text": "severe hypomagnesemia and other electrolyte disorders", "start": 11, "end": 17}]}], "entity_mentions": [{"id": "8384030_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8384030_4_Ent2", "text": "foscarnet", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8384030_4_Ent3", "text": "foscarnet", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8384030_4_Ent1", "text": "severe hypomagnesemia and other electrolyte disorders", "entity_type": "Entity", "start": 11, "end": 17}], "lang": "en"}
{"doc_id": "8384030_5", "wnd_id": "8384030_5_1", "text": "The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .", "tokens": ["The", "patient", "experienced", "muscle", "twitches", ",", "tremulousness", ",", "and", "anxiety", "on", "day", "17", "of", "foscarnet", "therapy", "."], "event_mentions": [{"id": "8384030_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8384030_5_Ent0", "role": "Subject", "text": "patient", "start": 1, "end": 2}, {"entity_id": "8384030_5_Ent1", "role": "Effect", "text": "muscle twitches , tremulousness , and anxiety", "start": 3, "end": 10}, {"entity_id": "8384030_5_Ent4", "role": "Treatment_Time_elapsed", "text": "on day 17", "start": 10, "end": 13}, {"entity_id": "8384030_5_Ent3", "role": "Treatment_Drug", "text": "foscarnet", "start": 14, "end": 15}, {"entity_id": "8384030_5_Ent2", "role": "Treatment", "text": "foscarnet therapy", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "8384030_5_Ent0", "text": "patient", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8384030_5_Ent1", "text": "muscle twitches , tremulousness , and anxiety", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "8384030_5_Ent4", "text": "on day 17", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "8384030_5_Ent3", "text": "foscarnet", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8384030_5_Ent2", "text": "foscarnet therapy", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "8391300_3", "wnd_id": "8391300_3_1", "text": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36 - year - old woman .", "tokens": ["In", "this", "case", "report", "we", "present", "a", "rare", "drug", "interaction", "between", "erythromycin", "and", "ergotamine", "at", "normal", "doses", "causing", "lower", "extremity", "ischemia", "in", "a", "36", "-", "year", "-", "old", "woman", "."], "event_mentions": [{"id": "8391300_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 17, "end": 18}, "arguments": [{"entity_id": "8391300_3_Ent4", "role": "Treatment", "text": "a rare drug interaction between erythromycin and ergotamine at normal doses", "start": 6, "end": 17}, {"entity_id": "8391300_3_Ent5", "role": "Treatment_Drug", "text": "erythromycin", "start": 11, "end": 12}, {"entity_id": "8391300_3_Ent8", "role": "Combination_Drug", "text": "erythromycin", "start": 11, "end": 12}, {"entity_id": "8391300_3_Ent6", "role": "Treatment_Drug", "text": "ergotamine", "start": 13, "end": 14}, {"entity_id": "8391300_3_Ent9", "role": "Combination_Drug", "text": "ergotamine", "start": 13, "end": 14}, {"entity_id": "8391300_3_Ent7", "role": "Treatment_Dosage", "text": "normal doses", "start": 15, "end": 17}, {"entity_id": "8391300_3_Ent3", "role": "Effect", "text": "lower extremity ischemia", "start": 18, "end": 21}, {"entity_id": "8391300_3_Ent0", "role": "Subject", "text": "a 36 - year - old woman", "start": 22, "end": 29}, {"entity_id": "8391300_3_Ent1", "role": "Subject_Age", "text": "36 - year - old", "start": 23, "end": 28}, {"entity_id": "8391300_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "8391300_3_Ent4", "text": "a rare drug interaction between erythromycin and ergotamine at normal doses", "entity_type": "Entity", "start": 6, "end": 17}, {"id": "8391300_3_Ent5", "text": "erythromycin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8391300_3_Ent8", "text": "erythromycin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8391300_3_Ent6", "text": "ergotamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8391300_3_Ent9", "text": "ergotamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8391300_3_Ent7", "text": "normal doses", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "8391300_3_Ent3", "text": "lower extremity ischemia", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8391300_3_Ent0", "text": "a 36 - year - old woman", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "8391300_3_Ent1", "text": "36 - year - old", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "8391300_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "8404753_1", "wnd_id": "8404753_1_1", "text": "Carbamazepine - induced tics .", "tokens": ["Carbamazepine", "-", "induced", "tics", "."], "event_mentions": [{"id": "8404753_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8404753_1_Ent1", "role": "Treatment", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "8404753_1_Ent2", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "8404753_1_Ent0", "role": "Effect", "text": "tics", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "8404753_1_Ent1", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8404753_1_Ent2", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8404753_1_Ent0", "text": "tics", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "8438851_1", "wnd_id": "8438851_1_1", "text": "A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin .", "tokens": ["A", "patient", "with", "acute", "esophageal", "variceal", "bleeding", "developed", "fatal", "rhabdomyolysis", "during", "treatment", "with", "a", "continuous", "intravenous", "infusion", "of", "vasopressin", "."], "event_mentions": [{"id": "8438851_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "8438851_1_Ent0", "role": "Subject", "text": "A patient with acute esophageal variceal bleeding", "start": 0, "end": 7}, {"entity_id": "8438851_1_Ent5", "role": "Treatment_Disorder", "text": "acute esophageal variceal bleeding", "start": 3, "end": 7}, {"entity_id": "8438851_1_Ent1", "role": "Effect", "text": "fatal rhabdomyolysis", "start": 8, "end": 10}, {"entity_id": "8438851_1_Ent3", "role": "Treatment_Route", "text": "continuous intravenous infusion", "start": 14, "end": 17}, {"entity_id": "8438851_1_Ent2", "role": "Treatment", "text": "continuous intravenous infusion of vasopressin", "start": 14, "end": 19}, {"entity_id": "8438851_1_Ent4", "role": "Treatment_Drug", "text": "vasopressin", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8438851_1_Ent0", "text": "A patient with acute esophageal variceal bleeding", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "8438851_1_Ent5", "text": "acute esophageal variceal bleeding", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8438851_1_Ent1", "text": "fatal rhabdomyolysis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8438851_1_Ent3", "text": "continuous intravenous infusion", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "8438851_1_Ent2", "text": "continuous intravenous infusion of vasopressin", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "8438851_1_Ent4", "text": "vasopressin", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "8438851_4", "wnd_id": "8438851_4_1", "text": "These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving vasopressin infusion .", "tokens": ["These", "multiple", "overlapping", "factors", "probably", "lead", "to", "rhabdomyolysis", "in", "a", "minority", "of", "patients", "receiving", "vasopressin", "infusion", "."], "event_mentions": [{"id": "8438851_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 5, "end": 6}, "arguments": [{"entity_id": "8438851_4_Ent1", "role": "Effect", "text": "rhabdomyolysis", "start": 7, "end": 8}, {"entity_id": "8438851_4_Ent0", "role": "Subject", "text": "patients", "start": 12, "end": 13}, {"entity_id": "8438851_4_Ent2", "role": "Treatment", "text": "vasopressin", "start": 14, "end": 15}, {"entity_id": "8438851_4_Ent3", "role": "Treatment_Drug", "text": "vasopressin", "start": 14, "end": 15}, {"entity_id": "8438851_4_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "8438851_4_Ent1", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8438851_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8438851_4_Ent2", "text": "vasopressin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8438851_4_Ent3", "text": "vasopressin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8438851_4_Ent4", "text": "infusion", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "8442800_10", "wnd_id": "8442800_10_1", "text": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted .", "tokens": ["This", "report", "suggests", "that", "the", "poor", "prognosis", "previously", "given", "to", "fetuses", "exposed", "to", "disulfiram", "in", "the", "first", "trimester", "may", "not", "be", "warranted", "."], "event_mentions": [{"id": "8442800_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exposed", "start": 11, "end": 12}, "arguments": [{"entity_id": "8442800_10_Ent2", "role": "Effect", "text": "poor prognosis", "start": 5, "end": 7}, {"entity_id": "8442800_10_Ent0", "role": "Subject", "text": "fetuses", "start": 10, "end": 11}, {"entity_id": "8442800_10_Ent1", "role": "Subject_Age", "text": "fetuses", "start": 10, "end": 11}, {"entity_id": "8442800_10_Ent3", "role": "Treatment", "text": "disulfiram", "start": 13, "end": 14}, {"entity_id": "8442800_10_Ent4", "role": "Treatment_Drug", "text": "disulfiram", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "8442800_10_Ent2", "text": "poor prognosis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8442800_10_Ent0", "text": "fetuses", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8442800_10_Ent1", "text": "fetuses", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8442800_10_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8442800_10_Ent4", "text": "disulfiram", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8445549_2", "wnd_id": "8445549_2_1", "text": "Pemphigus vulgaris precipitated by glibenclamide therapy .", "tokens": ["Pemphigus", "vulgaris", "precipitated", "by", "glibenclamide", "therapy", "."], "event_mentions": [{"id": "8445549_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8445549_2_Ent0", "role": "Effect", "text": "Pemphigus vulgaris", "start": 0, "end": 2}, {"entity_id": "8445549_2_Ent1", "role": "Treatment", "text": "glibenclamide", "start": 4, "end": 5}, {"entity_id": "8445549_2_Ent2", "role": "Treatment_Drug", "text": "glibenclamide", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "8445549_2_Ent0", "text": "Pemphigus vulgaris", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8445549_2_Ent1", "text": "glibenclamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8445549_2_Ent2", "text": "glibenclamide", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "85289_1", "wnd_id": "85289_1_1", "text": "Anterior spinal artery syndrome -- a complication of cervical intrathecal phenol injection .", "tokens": ["Anterior", "spinal", "artery", "syndrome", "--", "a", "complication", "of", "cervical", "intrathecal", "phenol", "injection", "."], "event_mentions": [{"id": "85289_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 6, "end": 7}, "arguments": [{"entity_id": "85289_1_Ent0", "role": "Effect", "text": "Anterior spinal artery syndrome", "start": 0, "end": 4}, {"entity_id": "85289_1_Ent1", "role": "Treatment", "text": "cervical intrathecal phenol injection", "start": 8, "end": 12}, {"entity_id": "85289_1_Ent2", "role": "Treatment_Drug", "text": "phenol", "start": 10, "end": 11}, {"entity_id": "85289_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "85289_1_Ent0", "text": "Anterior spinal artery syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "85289_1_Ent1", "text": "cervical intrathecal phenol injection", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "85289_1_Ent2", "text": "phenol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "85289_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8530331_2", "wnd_id": "8530331_2_1", "text": "BACKGROUND : We report six cases of psychosis in patients with akinetic - rigid syndromes who were treated with risperidone .", "tokens": ["BACKGROUND", ":", "We", "report", "six", "cases", "of", "psychosis", "in", "patients", "with", "akinetic", "-", "rigid", "syndromes", "who", "were", "treated", "with", "risperidone", "."], "event_mentions": [{"id": "8530331_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 17, "end": 18}, "arguments": [{"entity_id": "8530331_2_Ent2", "role": "Subject_Population", "text": "six", "start": 4, "end": 5}, {"entity_id": "8530331_2_Ent0", "role": "Subject", "text": "six cases", "start": 4, "end": 6}, {"entity_id": "8530331_2_Ent5", "role": "Treatment_Disorder", "text": "psychosis", "start": 7, "end": 8}, {"entity_id": "8530331_2_Ent1", "role": "Subject", "text": "patients with akinetic - rigid syndromes", "start": 9, "end": 15}, {"entity_id": "8530331_2_Ent3", "role": "Subject_Disorder", "text": "akinetic - rigid syndromes", "start": 11, "end": 15}, {"entity_id": "8530331_2_Ent4", "role": "Treatment", "text": "risperidone", "start": 19, "end": 20}, {"entity_id": "8530331_2_Ent6", "role": "Treatment_Drug", "text": "risperidone", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "8530331_2_Ent2", "text": "six", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8530331_2_Ent0", "text": "six cases", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8530331_2_Ent5", "text": "psychosis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8530331_2_Ent1", "text": "patients with akinetic - rigid syndromes", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "8530331_2_Ent3", "text": "akinetic - rigid syndromes", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "8530331_2_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8530331_2_Ent6", "text": "risperidone", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "8530331_8", "wnd_id": "8530331_8_1", "text": "CONCLUSION : We believe that risperidone is not a substitute for clozapine in treating psychosis in parkinsonian patients and should be used with caution .", "tokens": ["CONCLUSION", ":", "We", "believe", "that", "risperidone", "is", "not", "a", "substitute", "for", "clozapine", "in", "treating", "psychosis", "in", "parkinsonian", "patients", "and", "should", "be", "used", "with", "caution", "."], "event_mentions": [{"id": "8530331_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treating", "start": 13, "end": 14}, "arguments": [{"entity_id": "8530331_8_Ent2", "role": "Treatment", "text": "risperidone", "start": 5, "end": 6}, {"entity_id": "8530331_8_Ent4", "role": "Treatment_Drug", "text": "risperidone", "start": 5, "end": 6}, {"entity_id": "8530331_8_Ent3", "role": "Treatment_Disorder", "text": "psychosis", "start": 14, "end": 15}, {"entity_id": "8530331_8_Ent1", "role": "Subject_Disorder", "text": "parkinsonian", "start": 16, "end": 17}, {"entity_id": "8530331_8_Ent0", "role": "Subject", "text": "parkinsonian patients", "start": 16, "end": 18}]}, {"id": "8530331_8_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treating", "start": 13, "end": 14}, "arguments": [{"entity_id": "8530331_8_Ent7", "role": "Treatment", "text": "clozapine", "start": 11, "end": 12}, {"entity_id": "8530331_8_Ent8", "role": "Treatment_Drug", "text": "clozapine", "start": 11, "end": 12}, {"entity_id": "8530331_8_Ent6", "role": "Subject_Disorder", "text": "parkinsonian", "start": 16, "end": 17}, {"entity_id": "8530331_8_Ent5", "role": "Subject", "text": "parkinsonian patients", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "8530331_8_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8530331_8_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8530331_8_Ent7", "text": "clozapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8530331_8_Ent8", "text": "clozapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8530331_8_Ent3", "text": "psychosis", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8530331_8_Ent1", "text": "parkinsonian", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8530331_8_Ent6", "text": "parkinsonian", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8530331_8_Ent0", "text": "parkinsonian patients", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "8530331_8_Ent5", "text": "parkinsonian patients", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "8551001_3", "wnd_id": "8551001_3_1", "text": "The azathioprine dose was low ( 1 mg / kg ) and pancytopenia occurred after 56 days therapy .", "tokens": ["The", "azathioprine", "dose", "was", "low", "(", "1", "mg", "/", "kg", ")", "and", "pancytopenia", "occurred", "after", "56", "days", "therapy", "."], "event_mentions": [{"id": "8551001_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 13, "end": 14}, "arguments": [{"entity_id": "8551001_3_Ent2", "role": "Treatment", "text": "The azathioprine dose was low ( 1 mg / kg )", "start": 0, "end": 11}, {"entity_id": "8551001_3_Ent4", "role": "Treatment_Drug", "text": "azathioprine", "start": 1, "end": 2}, {"entity_id": "8551001_3_Ent5", "role": "Treatment_Dosage", "text": "1 mg / kg", "start": 6, "end": 10}, {"entity_id": "8551001_3_Ent0", "role": "Effect", "text": "pancytopenia", "start": 12, "end": 13}, {"entity_id": "8551001_3_Ent3", "role": "Treatment_Time_elapsed", "text": "56 days", "start": 15, "end": 17}, {"entity_id": "8551001_3_Ent1", "role": "Treatment", "text": "56 days therapy", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "8551001_3_Ent2", "text": "The azathioprine dose was low ( 1 mg / kg )", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "8551001_3_Ent4", "text": "azathioprine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8551001_3_Ent5", "text": "1 mg / kg", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "8551001_3_Ent0", "text": "pancytopenia", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8551001_3_Ent3", "text": "56 days", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "8551001_3_Ent1", "text": "56 days therapy", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "8551001_4", "wnd_id": "8551001_4_1", "text": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine .", "tokens": ["Thiopurine", "methyltransferase", "deficiency", "occurs", "at", "a", "frequency", "of", "one", "in", "300", "and", "is", "associated", "with", "profound", "myelosuppression", "after", "a", "short", "course", "of", "azathioprine", "."], "event_mentions": [{"id": "8551001_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 17, "end": 18}, "arguments": [{"entity_id": "8551001_4_Ent0", "role": "Effect", "text": "profound myelosuppression", "start": 15, "end": 17}, {"entity_id": "8551001_4_Ent3", "role": "Treatment_Time_elapsed", "text": "a short course", "start": 18, "end": 21}, {"entity_id": "8551001_4_Ent1", "role": "Treatment", "text": "a short course of azathioprine", "start": 18, "end": 23}, {"entity_id": "8551001_4_Ent2", "role": "Treatment_Drug", "text": "azathioprine", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "8551001_4_Ent0", "text": "profound myelosuppression", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "8551001_4_Ent3", "text": "a short course", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8551001_4_Ent1", "text": "a short course of azathioprine", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "8551001_4_Ent2", "text": "azathioprine", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "8579054_1", "wnd_id": "8579054_1_1", "text": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea .", "tokens": ["Acute", "myeloid", "leukemia", "evolving", "from", "essential", "thrombocythemia", "in", "two", "patients", "treated", "with", "hydroxyurea", "."], "event_mentions": [{"id": "8579054_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 10, "end": 11}, "arguments": [{"entity_id": "8579054_1_Ent2", "role": "Effect", "text": "Acute myeloid leukemia", "start": 0, "end": 3}, {"entity_id": "8579054_1_Ent4", "role": "Treatment_Disorder", "text": "essential thrombocythemia", "start": 5, "end": 7}, {"entity_id": "8579054_1_Ent1", "role": "Subject_Population", "text": "two", "start": 8, "end": 9}, {"entity_id": "8579054_1_Ent0", "role": "Subject", "text": "two patients", "start": 8, "end": 10}, {"entity_id": "8579054_1_Ent3", "role": "Treatment", "text": "hydroxyurea", "start": 12, "end": 13}, {"entity_id": "8579054_1_Ent5", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "8579054_1_Ent2", "text": "Acute myeloid leukemia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8579054_1_Ent4", "text": "essential thrombocythemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8579054_1_Ent1", "text": "two", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8579054_1_Ent0", "text": "two patients", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8579054_1_Ent3", "text": "hydroxyurea", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8579054_1_Ent5", "text": "hydroxyurea", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "8586895_2", "wnd_id": "8586895_2_1", "text": "In the present paper , we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with halofantrine .", "tokens": ["In", "the", "present", "paper", ",", "we", "discuss", "the", "first", "Japanese", "vivax", "malaria", "patient", "whose", "QT", "interval", "was", "prolonged", "after", "treatment", "with", "halofantrine", "."], "event_mentions": [{"id": "8586895_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 18, "end": 19}, "arguments": [{"entity_id": "8586895_2_Ent1", "role": "Subject_Race", "text": "Japanese", "start": 9, "end": 10}, {"entity_id": "8586895_2_Ent0", "role": "Subject", "text": "Japanese vivax malaria patient", "start": 9, "end": 13}, {"entity_id": "8586895_2_Ent4", "role": "Treatment_Disorder", "text": "vivax malaria", "start": 10, "end": 12}, {"entity_id": "8586895_2_Ent2", "role": "Effect", "text": "QT interval was prolonged", "start": 14, "end": 18}, {"entity_id": "8586895_2_Ent3", "role": "Treatment", "text": "halofantrine", "start": 21, "end": 22}, {"entity_id": "8586895_2_Ent5", "role": "Treatment_Drug", "text": "halofantrine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "8586895_2_Ent1", "text": "Japanese", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8586895_2_Ent0", "text": "Japanese vivax malaria patient", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "8586895_2_Ent4", "text": "vivax malaria", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "8586895_2_Ent2", "text": "QT interval was prolonged", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "8586895_2_Ent3", "text": "halofantrine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8586895_2_Ent5", "text": "halofantrine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "8610807_1", "wnd_id": "8610807_1_1", "text": "Choroidal hemorrhage associated with systemic tissue plasminogen activator .", "tokens": ["Choroidal", "hemorrhage", "associated", "with", "systemic", "tissue", "plasminogen", "activator", "."], "event_mentions": [{"id": "8610807_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8610807_1_Ent0", "role": "Effect", "text": "Choroidal hemorrhage", "start": 0, "end": 2}, {"entity_id": "8610807_1_Ent1", "role": "Treatment", "text": "systemic tissue plasminogen activator", "start": 4, "end": 8}, {"entity_id": "8610807_1_Ent2", "role": "Treatment_Drug", "text": "systemic tissue plasminogen activator", "start": 4, "end": 8}]}], "entity_mentions": [{"id": "8610807_1_Ent0", "text": "Choroidal hemorrhage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8610807_1_Ent1", "text": "systemic tissue plasminogen activator", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "8610807_1_Ent2", "text": "systemic tissue plasminogen activator", "entity_type": "Entity", "start": 4, "end": 8}], "lang": "en"}
{"doc_id": "8641617_4", "wnd_id": "8641617_4_1", "text": "Clostridium difficile colitis associated with cisplatin - based chemotherapy in ovarian cancer patients .", "tokens": ["Clostridium", "difficile", "colitis", "associated", "with", "cisplatin", "-", "based", "chemotherapy", "in", "ovarian", "cancer", "patients", "."], "event_mentions": [{"id": "8641617_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "8641617_4_Ent1", "role": "Effect", "text": "Clostridium difficile colitis", "start": 0, "end": 3}, {"entity_id": "8641617_4_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 5, "end": 6}, {"entity_id": "8641617_4_Ent2", "role": "Treatment", "text": "cisplatin - based chemotherapy", "start": 5, "end": 9}, {"entity_id": "8641617_4_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 8, "end": 9}, {"entity_id": "8641617_4_Ent4", "role": "Treatment_Disorder", "text": "ovarian cancer", "start": 10, "end": 12}, {"entity_id": "8641617_4_Ent0", "role": "Subject", "text": "ovarian cancer patients .", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "8641617_4_Ent1", "text": "Clostridium difficile colitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8641617_4_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8641617_4_Ent2", "text": "cisplatin - based chemotherapy", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "8641617_4_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8641617_4_Ent4", "text": "ovarian cancer", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "8641617_4_Ent0", "text": "ovarian cancer patients .", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "8641617_5", "wnd_id": "8641617_5_1", "text": "Severe C. difficile colitis occurred in 2 patients ( 6.1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies .", "tokens": ["Severe", "C.", "difficile", "colitis", "occurred", "in", "2", "patients", "(", "6.1", "%", ")", "after", "receiving", "cisplatin", "-", "based", "combination", "chemotherapy", "for", "ovarian", "malignancies", "."], "event_mentions": [{"id": "8641617_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 4, "end": 5}, "arguments": [{"entity_id": "8641617_5_Ent3", "role": "Effect", "text": "Severe C. difficile colitis", "start": 0, "end": 4}, {"entity_id": "8641617_5_Ent1", "role": "Subject_Population", "text": "2", "start": 6, "end": 7}, {"entity_id": "8641617_5_Ent0", "role": "Subject", "text": "2 patients ( 6.1 % )", "start": 6, "end": 12}, {"entity_id": "8641617_5_Ent2", "role": "Subject_Population", "text": "( 6.1 % )", "start": 8, "end": 12}, {"entity_id": "8641617_5_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 14, "end": 15}, {"entity_id": "8641617_5_Ent4", "role": "Treatment", "text": "cisplatin - based combination chemotherapy", "start": 14, "end": 19}, {"entity_id": "8641617_5_Ent7", "role": "Treatment_Route", "text": "chemotherapy", "start": 18, "end": 19}, {"entity_id": "8641617_5_Ent6", "role": "Treatment_Disorder", "text": "ovarian malignancies", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "8641617_5_Ent3", "text": "Severe C. difficile colitis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8641617_5_Ent1", "text": "2", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8641617_5_Ent0", "text": "2 patients ( 6.1 % )", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "8641617_5_Ent2", "text": "( 6.1 % )", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "8641617_5_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8641617_5_Ent4", "text": "cisplatin - based combination chemotherapy", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "8641617_5_Ent7", "text": "chemotherapy", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "8641617_5_Ent6", "text": "ovarian malignancies", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "8672829_5", "wnd_id": "8672829_5_1", "text": "OBJECTIVE : To describe a patient with ifosfamide - induced nonconvulsive status epilepticus .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "patient", "with", "ifosfamide", "-", "induced", "nonconvulsive", "status", "epilepticus", "."], "event_mentions": [{"id": "8672829_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "8672829_5_Ent0", "role": "Subject", "text": "patient", "start": 5, "end": 6}, {"entity_id": "8672829_5_Ent2", "role": "Treatment", "text": "ifosfamide", "start": 7, "end": 8}, {"entity_id": "8672829_5_Ent3", "role": "Treatment_Drug", "text": "ifosfamide", "start": 7, "end": 8}, {"entity_id": "8672829_5_Ent1", "role": "Effect", "text": "nonconvulsive status epilepticus", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "8672829_5_Ent0", "text": "patient", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8672829_5_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8672829_5_Ent3", "text": "ifosfamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8672829_5_Ent1", "text": "nonconvulsive status epilepticus", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "8672829_6", "wnd_id": "8672829_6_1", "text": "This represents the first report of nonconvulsive status epilepticus induced by ifosfamide .", "tokens": ["This", "represents", "the", "first", "report", "of", "nonconvulsive", "status", "epilepticus", "induced", "by", "ifosfamide", "."], "event_mentions": [{"id": "8672829_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "8672829_6_Ent0", "role": "Effect", "text": "nonconvulsive status epilepticus", "start": 6, "end": 9}, {"entity_id": "8672829_6_Ent1", "role": "Treatment", "text": "ifosfamide", "start": 11, "end": 12}, {"entity_id": "8672829_6_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8672829_6_Ent0", "text": "nonconvulsive status epilepticus", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8672829_6_Ent1", "text": "ifosfamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8672829_6_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8678015_3", "wnd_id": "8678015_3_1", "text": "While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .", "tokens": ["While", "undergoing", "treatment", "with", "albendazole", ",", "he", "developed", "worsening", "diarrhea", "with", "abdominal", "pain", "and", "fever", "."], "event_mentions": [{"id": "8678015_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "8678015_3_Ent3", "role": "Treatment", "text": "albendazole", "start": 4, "end": 5}, {"entity_id": "8678015_3_Ent4", "role": "Treatment_Drug", "text": "albendazole", "start": 4, "end": 5}, {"entity_id": "8678015_3_Ent0", "role": "Subject", "text": "he", "start": 6, "end": 7}, {"entity_id": "8678015_3_Ent1", "role": "Subject_Gender", "text": "he", "start": 6, "end": 7}, {"entity_id": "8678015_3_Ent2", "role": "Effect", "text": "worsening diarrhea with abdominal pain and fever", "start": 8, "end": 15}]}], "entity_mentions": [{"id": "8678015_3_Ent3", "text": "albendazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8678015_3_Ent4", "text": "albendazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8678015_3_Ent0", "text": "he", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8678015_3_Ent1", "text": "he", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8678015_3_Ent2", "text": "worsening diarrhea with abdominal pain and fever", "entity_type": "Entity", "start": 8, "end": 15}], "lang": "en"}
{"doc_id": "8691927_5", "wnd_id": "8691927_5_1", "text": "METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .", "tokens": ["METHODS", ":", "Growth", "retardation", "was", "observed", "in", "six", "severely", "asthmatic", "children", "after", "introduction", "of", "high", "-", "dose", "fluticasone", "propionate", "treatment", "(", "dry", "powder", ")", "."], "event_mentions": [{"id": "8691927_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "8691927_5_Ent3", "role": "Effect", "text": "Growth retardation", "start": 2, "end": 4}, {"entity_id": "8691927_5_Ent1", "role": "Subject_Population", "text": "six", "start": 7, "end": 8}, {"entity_id": "8691927_5_Ent0", "role": "Subject", "text": "six severely asthmatic children", "start": 7, "end": 11}, {"entity_id": "8691927_5_Ent5", "role": "Treatment_Disorder", "text": "severely asthmatic", "start": 8, "end": 10}, {"entity_id": "8691927_5_Ent2", "role": "Subject_Age", "text": "children", "start": 10, "end": 11}, {"entity_id": "8691927_5_Ent4", "role": "Treatment", "text": "introduction of high - dose fluticasone propionate treatment ( dry powder )", "start": 12, "end": 24}, {"entity_id": "8691927_5_Ent6", "role": "Treatment_Dosage", "text": "high - dose", "start": 14, "end": 17}, {"entity_id": "8691927_5_Ent7", "role": "Treatment_Drug", "text": "fluticasone propionate", "start": 17, "end": 19}, {"entity_id": "8691927_5_Ent8", "role": "Treatment_Route", "text": "dry powder", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "8691927_5_Ent3", "text": "Growth retardation", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8691927_5_Ent1", "text": "six", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8691927_5_Ent0", "text": "six severely asthmatic children", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "8691927_5_Ent5", "text": "severely asthmatic", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8691927_5_Ent2", "text": "children", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8691927_5_Ent4", "text": "introduction of high - dose fluticasone propionate treatment ( dry powder )", "entity_type": "Entity", "start": 12, "end": 24}, {"id": "8691927_5_Ent6", "text": "high - dose", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "8691927_5_Ent7", "text": "fluticasone propionate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8691927_5_Ent8", "text": "dry powder", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "8700794_1", "wnd_id": "8700794_1_1", "text": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .", "tokens": ["A", "review", "of", "the", "literature", "found", "11", "children", "and", "2", "adults", "in", "whom", "intranasal", "desmopressin", "was", "associated", "with", "hyponatremia", ",", "all", "of", "whom", "experienced", "seizures", "or", "altered", "mental", "status", "."], "event_mentions": [{"id": "8700794_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 16, "end": 17}, "arguments": [{"entity_id": "8700794_1_Ent1", "role": "Subject_Population", "text": "11", "start": 6, "end": 7}, {"entity_id": "8700794_1_Ent0", "role": "Subject", "text": "11 children and 2 adults", "start": 6, "end": 11}, {"entity_id": "8700794_1_Ent3", "role": "Subject_Age", "text": "children", "start": 7, "end": 8}, {"entity_id": "8700794_1_Ent2", "role": "Subject_Population", "text": "2", "start": 9, "end": 10}, {"entity_id": "8700794_1_Ent4", "role": "Subject_Age", "text": "adults", "start": 10, "end": 11}, {"entity_id": "8700794_1_Ent9", "role": "Treatment_Route", "text": "intranasal", "start": 13, "end": 14}, {"entity_id": "8700794_1_Ent7", "role": "Treatment", "text": "intranasal desmopressin", "start": 13, "end": 15}, {"entity_id": "8700794_1_Ent8", "role": "Treatment_Drug", "text": "desmopressin", "start": 14, "end": 15}, {"entity_id": "8700794_1_Ent5", "role": "Effect", "text": "hyponatremia", "start": 18, "end": 19}, {"entity_id": "8700794_1_Ent6", "role": "Effect", "text": "seizures or altered mental status", "start": 24, "end": 29}]}], "entity_mentions": [{"id": "8700794_1_Ent1", "text": "11", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8700794_1_Ent0", "text": "11 children and 2 adults", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "8700794_1_Ent3", "text": "children", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8700794_1_Ent2", "text": "2", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8700794_1_Ent4", "text": "adults", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8700794_1_Ent9", "text": "intranasal", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8700794_1_Ent7", "text": "intranasal desmopressin", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8700794_1_Ent8", "text": "desmopressin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8700794_1_Ent5", "text": "hyponatremia", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "8700794_1_Ent6", "text": "seizures or altered mental status", "entity_type": "Entity", "start": 24, "end": 29}], "lang": "en"}
{"doc_id": "8700794_2", "wnd_id": "8700794_2_1", "text": "Intranasal desmopressin - induced hyponatremia .", "tokens": ["Intranasal", "desmopressin", "-", "induced", "hyponatremia", "."], "event_mentions": [{"id": "8700794_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "8700794_2_Ent2", "role": "Treatment_Route", "text": "Intranasal", "start": 0, "end": 1}, {"entity_id": "8700794_2_Ent1", "role": "Treatment", "text": "Intranasal desmopressin", "start": 0, "end": 2}, {"entity_id": "8700794_2_Ent3", "role": "Treatment_Drug", "text": "desmopressin", "start": 1, "end": 2}, {"entity_id": "8700794_2_Ent0", "role": "Effect", "text": "hyponatremia", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "8700794_2_Ent2", "text": "Intranasal", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8700794_2_Ent1", "text": "Intranasal desmopressin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8700794_2_Ent3", "text": "desmopressin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8700794_2_Ent0", "text": "hyponatremia", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "8726608_3", "wnd_id": "8726608_3_1", "text": "This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .", "tokens": ["This", "case", "suggests", "that", "acyclovir", "when", "given", "intravenously", "in", "doses", "of", "10", "mg", "/", "kg", "may", "result", "in", "increased", "serum", "lithium", "concentrations", "."], "event_mentions": [{"id": "8726608_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 16, "end": 17}, "arguments": [{"entity_id": "8726608_3_Ent1", "role": "Treatment", "text": "acyclovir", "start": 4, "end": 5}, {"entity_id": "8726608_3_Ent2", "role": "Treatment_Drug", "text": "acyclovir", "start": 4, "end": 5}, {"entity_id": "8726608_3_Ent3", "role": "Treatment_Dosage", "text": "10 mg / kg", "start": 11, "end": 15}, {"entity_id": "8726608_3_Ent0", "role": "Effect", "text": "increased serum lithium concentrations", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "8726608_3_Ent1", "text": "acyclovir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8726608_3_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8726608_3_Ent3", "text": "10 mg / kg", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "8726608_3_Ent0", "text": "increased serum lithium concentrations", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "8730143_3", "wnd_id": "8730143_3_1", "text": "We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .", "tokens": ["We", "describe", "2", "patients", "with", "cutaneous", "lupus", "erythematosus", "who", "developed", "severe", "dapsone", "reaction", "after", "low", "dose", "therapy", ",", "with", "a", "fatal", "outcome", "in", "one", "."], "event_mentions": [{"id": "8730143_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "8730143_3_Ent1", "role": "Subject_Population", "text": "2", "start": 2, "end": 3}, {"entity_id": "8730143_3_Ent0", "role": "Subject", "text": "2 patients with cutaneous lupus erythematosus", "start": 2, "end": 8}, {"entity_id": "8730143_3_Ent5", "role": "Treatment_Disorder", "text": "cutaneous lupus erythematosus", "start": 5, "end": 8}, {"entity_id": "8730143_3_Ent2", "role": "Effect", "text": "severe dapsone reaction", "start": 10, "end": 13}, {"entity_id": "8730143_3_Ent7", "role": "Treatment_Drug", "text": "dapsone", "start": 11, "end": 12}, {"entity_id": "8730143_3_Ent6", "role": "Treatment_Dosage", "text": "low dose", "start": 14, "end": 16}, {"entity_id": "8730143_3_Ent4", "role": "Treatment", "text": "low dose therapy", "start": 14, "end": 17}, {"entity_id": "8730143_3_Ent3", "role": "Effect", "text": "with a fatal outcome in one", "start": 18, "end": 24}]}], "entity_mentions": [{"id": "8730143_3_Ent1", "text": "2", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8730143_3_Ent0", "text": "2 patients with cutaneous lupus erythematosus", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "8730143_3_Ent5", "text": "cutaneous lupus erythematosus", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8730143_3_Ent2", "text": "severe dapsone reaction", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "8730143_3_Ent7", "text": "dapsone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8730143_3_Ent6", "text": "low dose", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8730143_3_Ent4", "text": "low dose therapy", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "8730143_3_Ent3", "text": "with a fatal outcome in one", "entity_type": "Entity", "start": 18, "end": 24}], "lang": "en"}
{"doc_id": "8739289_2", "wnd_id": "8739289_2_1", "text": "Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .", "tokens": ["Nephrogenic", "diabetes", "insipidus", "(", "NDI", ")", "is", "a", "well", "-", "documented", "complication", "of", "lithium", "use", "."], "event_mentions": [{"id": "8739289_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 11, "end": 12}, "arguments": [{"entity_id": "8739289_2_Ent0", "role": "Effect", "text": "Nephrogenic diabetes insipidus ( NDI )", "start": 0, "end": 6}, {"entity_id": "8739289_2_Ent1", "role": "Treatment", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8739289_2_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "8739289_2_Ent0", "text": "Nephrogenic diabetes insipidus ( NDI )", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "8739289_2_Ent1", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8739289_2_Ent2", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8739289_4", "wnd_id": "8739289_4_1", "text": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI .", "tokens": ["We", "report", "a", "patient", "receiving", "chronic", "lithium", "therapy", "who", "presented", "with", "a", "transient", "CDI", "occurring", "in", "the", "setting", "of", "underlying", "chronic", "NDI", "."], "event_mentions": [{"id": "8739289_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 9, "end": 10}, "arguments": [{"entity_id": "8739289_4_Ent0", "role": "Subject", "text": "patient", "start": 3, "end": 4}, {"entity_id": "8739289_4_Ent5", "role": "Treatment_Duration", "text": "chronic", "start": 5, "end": 6}, {"entity_id": "8739289_4_Ent3", "role": "Treatment", "text": "chronic lithium therapy", "start": 5, "end": 8}, {"entity_id": "8739289_4_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "8739289_4_Ent2", "role": "Effect", "text": "transient CDI", "start": 12, "end": 14}, {"entity_id": "8739289_4_Ent1", "role": "Subject_Disorder", "text": "underlying chronic NDI", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "8739289_4_Ent0", "text": "patient", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8739289_4_Ent5", "text": "chronic", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8739289_4_Ent3", "text": "chronic lithium therapy", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8739289_4_Ent4", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8739289_4_Ent2", "text": "transient CDI", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "8739289_4_Ent1", "text": "underlying chronic NDI", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "8742573_3", "wnd_id": "8742573_3_1", "text": "Human insulin - induced lipoatrophy .", "tokens": ["Human", "insulin", "-", "induced", "lipoatrophy", "."], "event_mentions": [{"id": "8742573_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "8742573_3_Ent1", "role": "Treatment", "text": "Human insulin", "start": 0, "end": 2}, {"entity_id": "8742573_3_Ent2", "role": "Treatment_Drug", "text": "Human insulin", "start": 0, "end": 2}, {"entity_id": "8742573_3_Ent0", "role": "Effect", "text": "lipoatrophy", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "8742573_3_Ent1", "text": "Human insulin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8742573_3_Ent2", "text": "Human insulin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8742573_3_Ent0", "text": "lipoatrophy", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "8749646_1", "wnd_id": "8749646_1_1", "text": "Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .", "tokens": ["Improved", "awareness", "of", "and", "further", "investigation", "into", "the", "neurotoxic", "effects", "of", "ofloxacin", "may", "enhance", "its", "safe", "use", "."], "event_mentions": [{"id": "8749646_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 10, "end": 11}, "arguments": [{"entity_id": "8749646_1_Ent0", "role": "Effect", "text": "neurotoxic effects", "start": 8, "end": 10}, {"entity_id": "8749646_1_Ent1", "role": "Treatment", "text": "ofloxacin", "start": 11, "end": 12}, {"entity_id": "8749646_1_Ent2", "role": "Treatment_Drug", "text": "ofloxacin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8749646_1_Ent0", "text": "neurotoxic effects", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8749646_1_Ent1", "text": "ofloxacin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8749646_1_Ent2", "text": "ofloxacin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "876914_1", "wnd_id": "876914_1_1", "text": "A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis .", "tokens": ["A", "patient", "is", "described", "who", "developed", "a", "poorly", "differentiated", "sarcoma", "after", "cyclophosphamide", "was", "used", "to", "treat", "his", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "876914_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "876914_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "876914_1_Ent3", "role": "Effect", "text": "poorly differentiated sarcoma", "start": 7, "end": 10}, {"entity_id": "876914_1_Ent4", "role": "Treatment", "text": "cyclophosphamide", "start": 11, "end": 12}, {"entity_id": "876914_1_Ent5", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 11, "end": 12}, {"entity_id": "876914_1_Ent2", "role": "Subject_Gender", "text": "his", "start": 16, "end": 17}, {"entity_id": "876914_1_Ent1", "role": "Subject", "text": "his rheumatoid arthritis", "start": 16, "end": 19}, {"entity_id": "876914_1_Ent6", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "876914_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "876914_1_Ent3", "text": "poorly differentiated sarcoma", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "876914_1_Ent4", "text": "cyclophosphamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "876914_1_Ent5", "text": "cyclophosphamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "876914_1_Ent2", "text": "his", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "876914_1_Ent1", "text": "his rheumatoid arthritis", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "876914_1_Ent6", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "8771575_2", "wnd_id": "8771575_2_1", "text": "Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .", "tokens": ["Acute", "pulmonary", "reactions", "to", "nitrofurantoin", "are", "an", "uncommon", "side", "effect", "of", "therapy", "and", "can", "cause", "minor", "or", "life", "-", "threatening", "pulmonary", "dysfunction", "."], "event_mentions": [{"id": "8771575_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "are", "start": 5, "end": 6}, "arguments": [{"entity_id": "8771575_2_Ent0", "role": "Effect", "text": "Acute pulmonary reactions", "start": 0, "end": 3}, {"entity_id": "8771575_2_Ent2", "role": "Treatment", "text": "nitrofurantoin", "start": 4, "end": 5}, {"entity_id": "8771575_2_Ent3", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 4, "end": 5}, {"entity_id": "8771575_2_Ent1", "role": "Effect", "text": "can cause minor or life - threatening pulmonary dysfunction", "start": 13, "end": 22}]}], "entity_mentions": [{"id": "8771575_2_Ent0", "text": "Acute pulmonary reactions", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8771575_2_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8771575_2_Ent3", "text": "nitrofurantoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8771575_2_Ent1", "text": "can cause minor or life - threatening pulmonary dysfunction", "entity_type": "Entity", "start": 13, "end": 22}], "lang": "en"}
{"doc_id": "8771575_4", "wnd_id": "8771575_4_1", "text": "Nitrofurantoin - induced pulmonary toxicity during pregnancy : a report of a case and review of the literature .", "tokens": ["Nitrofurantoin", "-", "induced", "pulmonary", "toxicity", "during", "pregnancy", ":", "a", "report", "of", "a", "case", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "8771575_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8771575_4_Ent1", "role": "Treatment", "text": "Nitrofurantoin", "start": 0, "end": 1}, {"entity_id": "8771575_4_Ent2", "role": "Treatment_Drug", "text": "Nitrofurantoin", "start": 0, "end": 1}, {"entity_id": "8771575_4_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "8771575_4_Ent1", "text": "Nitrofurantoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8771575_4_Ent2", "text": "Nitrofurantoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8771575_4_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8792511_1", "wnd_id": "8792511_1_1", "text": "Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .", "tokens": ["Less", "common", "adverse", "events", "to", "dapsone", "include", "the", "idiosyncratic", "reactions", "of", "leukopenia", "and", "agranulocytosis", ",", "cutaneous", "eruptions", ",", "peripheral", "neuropathy", ",", "psychosis", ",", "toxic", "hepatitis", ",", "cholestatic", "jaundice", ",", "nephrotic", "syndrome", ",", "renal", "papillary", "necrosis", ",", "severe", "hypoalbuminemia", "without", "proteinuria", ",", "an", "infectious", "mononucleosis", "-", "like", "syndrome", ",", "and", "minor", "neurological", "and", "gastrointestinal", "complaints", "."], "event_mentions": [{"id": "8792511_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "include", "start": 6, "end": 7}, "arguments": [{"entity_id": "8792511_1_Ent1", "role": "Treatment", "text": "dapsone", "start": 5, "end": 6}, {"entity_id": "8792511_1_Ent2", "role": "Treatment_Drug", "text": "dapsone", "start": 5, "end": 6}, {"entity_id": "8792511_1_Ent0", "role": "Effect", "text": "the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints", "start": 7, "end": 54}]}], "entity_mentions": [{"id": "8792511_1_Ent1", "text": "dapsone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8792511_1_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8792511_1_Ent0", "text": "the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints", "entity_type": "Entity", "start": 7, "end": 54}], "lang": "en"}
{"doc_id": "879939_5", "wnd_id": "879939_5_1", "text": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms , including increased renal calcium excretion .", "tokens": ["Acetazolamide", "may", "have", "accelerated", "the", "development", "of", "osteomalacia", "by", "several", "mechanisms", ",", "including", "increased", "renal", "calcium", "excretion", "."], "event_mentions": [{"id": "879939_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accelerated", "start": 3, "end": 4}, "arguments": [{"entity_id": "879939_5_Ent1", "role": "Treatment", "text": "Acetazolamide", "start": 0, "end": 1}, {"entity_id": "879939_5_Ent2", "role": "Treatment_Drug", "text": "Acetazolamide", "start": 0, "end": 1}, {"entity_id": "879939_5_Ent0", "role": "Effect", "text": "osteomalacia", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "879939_5_Ent1", "text": "Acetazolamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "879939_5_Ent2", "text": "Acetazolamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "879939_5_Ent0", "text": "osteomalacia", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "8816294_1", "wnd_id": "8816294_1_1", "text": "The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate .", "tokens": ["The", "delayed", "encephalopathy", "developed", "9", "and", "22", "months", "respectively", "after", "the", "first", "dose", "of", "intrathecal", "methotrexate", "."], "event_mentions": [{"id": "8816294_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "8816294_1_Ent0", "role": "Effect", "text": "delayed encephalopathy", "start": 1, "end": 3}, {"entity_id": "8816294_1_Ent2", "role": "Treatment_Time_elapsed", "text": "9 and 22 months", "start": 4, "end": 8}, {"entity_id": "8816294_1_Ent4", "role": "Treatment_Route", "text": "intrathecal", "start": 14, "end": 15}, {"entity_id": "8816294_1_Ent1", "role": "Treatment", "text": "intrathecal methotrexate", "start": 14, "end": 16}, {"entity_id": "8816294_1_Ent3", "role": "Treatment_Dosage", "text": "methotrexate", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "8816294_1_Ent0", "text": "delayed encephalopathy", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8816294_1_Ent2", "text": "9 and 22 months", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "8816294_1_Ent4", "text": "intrathecal", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8816294_1_Ent1", "text": "intrathecal methotrexate", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8816294_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "8816294_2", "wnd_id": "8816294_2_1", "text": "We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .", "tokens": ["We", "report", "the", "case", "histories", "of", "identical", "twin", "brothers", "who", "developed", "concordant", "acute", "lymphoblastic", "leukemia", "at", "the", "age", "of", "4", "years", "and", "who", "later", "developed", "leukoencephalopathy", "and", "hydrocephalus", "related", "to", "central", "nervous", "system", "prophylaxis", "by", ",", "in", "the", "first", "case", "intrathecally", "administered", "methotrexate", "and", ",", "in", "the", "second", "by", "intrathecally", "administered", "methotrexate", "and", "cranial", "irradiation", "."], "event_mentions": [{"id": "8816294_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 24, "end": 25}, "arguments": [{"entity_id": "8816294_2_Ent0", "role": "Subject", "text": "identical twin brothers", "start": 6, "end": 9}, {"entity_id": "8816294_2_Ent1", "role": "Subject_Gender", "text": "brothers", "start": 8, "end": 9}, {"entity_id": "8816294_2_Ent2", "role": "Effect", "text": "leukoencephalopathy and hydrocephalus", "start": 25, "end": 28}, {"entity_id": "8816294_2_Ent7", "role": "Treatment_Route", "text": "intrathecally", "start": 40, "end": 41}, {"entity_id": "8816294_2_Ent3", "role": "Treatment", "text": "intrathecally administered methotrexate", "start": 40, "end": 43}, {"entity_id": "8816294_2_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 42, "end": 43}, {"entity_id": "8816294_2_Ent8", "role": "Treatment_Route", "text": "intrathecally", "start": 49, "end": 50}, {"entity_id": "8816294_2_Ent4", "role": "Treatment", "text": "intrathecally administered methotrexate and cranial irradiation", "start": 49, "end": 55}, {"entity_id": "8816294_2_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 51, "end": 52}]}], "entity_mentions": [{"id": "8816294_2_Ent0", "text": "identical twin brothers", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8816294_2_Ent1", "text": "brothers", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8816294_2_Ent2", "text": "leukoencephalopathy and hydrocephalus", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "8816294_2_Ent7", "text": "intrathecally", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "8816294_2_Ent3", "text": "intrathecally administered methotrexate", "entity_type": "Entity", "start": 40, "end": 43}, {"id": "8816294_2_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "8816294_2_Ent8", "text": "intrathecally", "entity_type": "Entity", "start": 49, "end": 50}, {"id": "8816294_2_Ent4", "text": "intrathecally administered methotrexate and cranial irradiation", "entity_type": "Entity", "start": 49, "end": 55}, {"id": "8816294_2_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 51, "end": 52}], "lang": "en"}
{"doc_id": "8828999_2", "wnd_id": "8828999_2_1", "text": "Lithium - induced Creutzfeldt - Jakob syndrome .", "tokens": ["Lithium", "-", "induced", "Creutzfeldt", "-", "Jakob", "syndrome", "."], "event_mentions": [{"id": "8828999_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8828999_2_Ent1", "role": "Treatment", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8828999_2_Ent2", "role": "Treatment_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8828999_2_Ent0", "role": "Effect", "text": "Creutzfeldt - Jakob syndrome", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "8828999_2_Ent1", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8828999_2_Ent2", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8828999_2_Ent0", "text": "Creutzfeldt - Jakob syndrome", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "8835752_3", "wnd_id": "8835752_3_1", "text": "We describe a case of prolonged terbinafine - induced cholestatic liver disease .", "tokens": ["We", "describe", "a", "case", "of", "prolonged", "terbinafine", "-", "induced", "cholestatic", "liver", "disease", "."], "event_mentions": [{"id": "8835752_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "8835752_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "8835752_3_Ent2", "role": "Treatment", "text": "prolonged terbinafine", "start": 5, "end": 7}, {"entity_id": "8835752_3_Ent3", "role": "Treatment_Drug", "text": "terbinafine", "start": 6, "end": 7}, {"entity_id": "8835752_3_Ent1", "role": "Effect", "text": "cholestatic liver disease", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "8835752_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8835752_3_Ent2", "text": "prolonged terbinafine", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8835752_3_Ent3", "text": "terbinafine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8835752_3_Ent1", "text": "cholestatic liver disease", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "8880251_3", "wnd_id": "8880251_3_1", "text": "This case supports the assessment that MH and diabetes are associated diseases and that cresol could possibly trigger MH .", "tokens": ["This", "case", "supports", "the", "assessment", "that", "MH", "and", "diabetes", "are", "associated", "diseases", "and", "that", "cresol", "could", "possibly", "trigger", "MH", "."], "event_mentions": [{"id": "8880251_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "trigger", "start": 17, "end": 18}, "arguments": [{"entity_id": "8880251_3_Ent1", "role": "Treatment", "text": "cresol", "start": 14, "end": 15}, {"entity_id": "8880251_3_Ent2", "role": "Treatment_Drug", "text": "cresol", "start": 14, "end": 15}, {"entity_id": "8880251_3_Ent0", "role": "Effect", "text": "MH", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8880251_3_Ent1", "text": "cresol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8880251_3_Ent2", "text": "cresol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8880251_3_Ent0", "text": "MH", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "889156_7", "wnd_id": "889156_7_1", "text": "While a lower systemic steroid dosage may have been the provoking factor , we feel that an adverse reaction to oleic acid , a dispersing agent in the aerosol freon vehicle , is a strong possibility .", "tokens": ["While", "a", "lower", "systemic", "steroid", "dosage", "may", "have", "been", "the", "provoking", "factor", ",", "we", "feel", "that", "an", "adverse", "reaction", "to", "oleic", "acid", ",", "a", "dispersing", "agent", "in", "the", "aerosol", "freon", "vehicle", ",", "is", "a", "strong", "possibility", "."], "event_mentions": [{"id": "889156_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 19, "end": 20}, "arguments": [{"entity_id": "889156_7_Ent0", "role": "Effect", "text": "adverse reaction", "start": 17, "end": 19}, {"entity_id": "889156_7_Ent1", "role": "Treatment", "text": "oleic acid", "start": 20, "end": 22}, {"entity_id": "889156_7_Ent2", "role": "Treatment_Drug", "text": "oleic acid", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "889156_7_Ent0", "text": "adverse reaction", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "889156_7_Ent1", "text": "oleic acid", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "889156_7_Ent2", "text": "oleic acid", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "8891729_1", "wnd_id": "8891729_1_1", "text": "Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia .", "tokens": ["Fatal", "intravascular", "autoimmune", "hemolytic", "anemia", "after", "fludarabine", "treatment", "for", "chronic", "lymphocytic", "leukemia", "."], "event_mentions": [{"id": "8891729_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "8891729_1_Ent0", "role": "Effect", "text": "Fatal intravascular autoimmune hemolytic anemia", "start": 0, "end": 5}, {"entity_id": "8891729_1_Ent2", "role": "Treatment_Drug", "text": "fludarabine", "start": 6, "end": 7}, {"entity_id": "8891729_1_Ent1", "role": "Treatment", "text": "fludarabine treatment", "start": 6, "end": 8}, {"entity_id": "8891729_1_Ent3", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "8891729_1_Ent0", "text": "Fatal intravascular autoimmune hemolytic anemia", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8891729_1_Ent2", "text": "fludarabine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8891729_1_Ent1", "text": "fludarabine treatment", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8891729_1_Ent3", "text": "chronic lymphocytic leukemia", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "8891729_5", "wnd_id": "8891729_5_1", "text": "When the patient was treated again with fludarabine nine months later , the DAT became positive with anti - IgG and anti - C3d antiglobulins after the second course of treatment .", "tokens": ["When", "the", "patient", "was", "treated", "again", "with", "fludarabine", "nine", "months", "later", ",", "the", "DAT", "became", "positive", "with", "anti", "-", "IgG", "and", "anti", "-", "C3d", "antiglobulins", "after", "the", "second", "course", "of", "treatment", "."], "event_mentions": [{"id": "8891729_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 4, "end": 5}, "arguments": [{"entity_id": "8891729_5_Ent0", "role": "Subject", "text": "the patient", "start": 1, "end": 3}, {"entity_id": "8891729_5_Ent2", "role": "Treatment", "text": "fludarabine", "start": 7, "end": 8}, {"entity_id": "8891729_5_Ent4", "role": "Treatment_Drug", "text": "fludarabine", "start": 7, "end": 8}, {"entity_id": "8891729_5_Ent5", "role": "Treatment_Time_elapsed", "text": "nine months later", "start": 8, "end": 11}, {"entity_id": "8891729_5_Ent1", "role": "Effect", "text": "the DAT became positive with anti - IgG and anti - C3d antiglobulins", "start": 12, "end": 25}, {"entity_id": "8891729_5_Ent3", "role": "Treatment", "text": "second course of treatment", "start": 27, "end": 31}]}], "entity_mentions": [{"id": "8891729_5_Ent0", "text": "the patient", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8891729_5_Ent2", "text": "fludarabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8891729_5_Ent4", "text": "fludarabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8891729_5_Ent5", "text": "nine months later", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8891729_5_Ent1", "text": "the DAT became positive with anti - IgG and anti - C3d antiglobulins", "entity_type": "Entity", "start": 12, "end": 25}, {"id": "8891729_5_Ent3", "text": "second course of treatment", "entity_type": "Entity", "start": 27, "end": 31}], "lang": "en"}
{"doc_id": "8908396_3", "wnd_id": "8908396_3_1", "text": "OBJECTIVE : To test the hypothesis that tumor necrosis factor ( TNF) - alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin - induced lipoatrophies of a diabetic patient who presented extensive lesions .", "tokens": ["OBJECTIVE", ":", "To", "test", "the", "hypothesis", "that", "tumor", "necrosis", "factor", "(", "TNF)", "-", "alpha", "may", "mediate", "the", "loss", "and", "the", "dedifferentiation", "of", "subcutaneous", "fat", "tissue", "in", "the", "insulin", "-", "induced", "lipoatrophies", "of", "a", "diabetic", "patient", "who", "presented", "extensive", "lesions", "."], "event_mentions": [{"id": "8908396_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 29, "end": 30}, "arguments": [{"entity_id": "8908396_3_Ent1", "role": "Treatment", "text": "insulin", "start": 27, "end": 28}, {"entity_id": "8908396_3_Ent2", "role": "Treatment_Drug", "text": "insulin", "start": 27, "end": 28}, {"entity_id": "8908396_3_Ent0", "role": "Effect", "text": "lipoatrophies", "start": 30, "end": 31}, {"entity_id": "8908396_3_Ent3", "role": "Treatment_Disorder", "text": "diabetic", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "8908396_3_Ent1", "text": "insulin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "8908396_3_Ent2", "text": "insulin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "8908396_3_Ent0", "text": "lipoatrophies", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "8908396_3_Ent3", "text": "diabetic", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "8912599_7", "wnd_id": "8912599_7_1", "text": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression .", "tokens": ["Painful", "erosion", "of", "psoriatic", "plaques", "is", "a", "less", "common", "sign", "of", "methotrexate", "toxicity", "that", "may", "precede", "evidence", "of", "bone", "marrow", "suppression", "."], "event_mentions": [{"id": "8912599_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "sign", "start": 9, "end": 10}, "arguments": [{"entity_id": "8912599_7_Ent0", "role": "Effect", "text": "Painful erosion of psoriatic plaques", "start": 0, "end": 5}, {"entity_id": "8912599_7_Ent5", "role": "Treatment_Disorder", "text": "psoriatic plaques", "start": 3, "end": 5}, {"entity_id": "8912599_7_Ent3", "role": "Treatment", "text": "methotrexate", "start": 11, "end": 12}, {"entity_id": "8912599_7_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 11, "end": 12}, {"entity_id": "8912599_7_Ent1", "role": "Effect", "text": "methotrexate toxicity", "start": 11, "end": 13}, {"entity_id": "8912599_7_Ent2", "role": "Effect", "text": "bone marrow suppression", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "8912599_7_Ent0", "text": "Painful erosion of psoriatic plaques", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8912599_7_Ent5", "text": "psoriatic plaques", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8912599_7_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8912599_7_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8912599_7_Ent1", "text": "methotrexate toxicity", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "8912599_7_Ent2", "text": "bone marrow suppression", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "8912599_8", "wnd_id": "8912599_8_1", "text": "Well - known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration .", "tokens": ["Well", "-", "known", "signs", "of", "methotrexate", "toxicity", "include", "bone", "marrow", "suppression", "and", "oral", "and", "gastrointestinal", "ulceration", "."], "event_mentions": [{"id": "8912599_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "signs", "start": 3, "end": 4}, "arguments": [{"entity_id": "8912599_8_Ent1", "role": "Treatment", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "8912599_8_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "8912599_8_Ent0", "role": "Effect", "text": "bone marrow suppression and oral and gastrointestinal ulceration", "start": 8, "end": 16}]}], "entity_mentions": [{"id": "8912599_8_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8912599_8_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8912599_8_Ent0", "text": "bone marrow suppression and oral and gastrointestinal ulceration", "entity_type": "Entity", "start": 8, "end": 16}], "lang": "en"}
{"doc_id": "8921647_2", "wnd_id": "8921647_2_1", "text": "Caution with use of cimetidine in tolazoline induced upper gastrointestinal bleeding .", "tokens": ["Caution", "with", "use", "of", "cimetidine", "in", "tolazoline", "induced", "upper", "gastrointestinal", "bleeding", "."], "event_mentions": [{"id": "8921647_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "8921647_2_Ent1", "role": "Treatment", "text": "tolazoline", "start": 6, "end": 7}, {"entity_id": "8921647_2_Ent2", "role": "Treatment_Drug", "text": "tolazoline", "start": 6, "end": 7}, {"entity_id": "8921647_2_Ent0", "role": "Effect", "text": "upper gastrointestinal bleeding", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "8921647_2_Ent1", "text": "tolazoline", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8921647_2_Ent2", "text": "tolazoline", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8921647_2_Ent0", "text": "upper gastrointestinal bleeding", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "8921647_4", "wnd_id": "8921647_4_1", "text": "Hypoxemia improved during continuous tolazoline infusion , but gastrointestinal bleeding occurred .", "tokens": ["Hypoxemia", "improved", "during", "continuous", "tolazoline", "infusion", ",", "but", "gastrointestinal", "bleeding", "occurred", "."], "event_mentions": [{"id": "8921647_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 10, "end": 11}, "arguments": [{"entity_id": "8921647_4_Ent2", "role": "Treatment_Disorder", "text": "Hypoxemia", "start": 0, "end": 1}, {"entity_id": "8921647_4_Ent1", "role": "Treatment", "text": "Hypoxemia improved during continuous tolazoline infusion", "start": 0, "end": 6}, {"entity_id": "8921647_4_Ent3", "role": "Treatment_Drug", "text": "tolazoline", "start": 4, "end": 5}, {"entity_id": "8921647_4_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 5, "end": 6}, {"entity_id": "8921647_4_Ent0", "role": "Effect", "text": "gastrointestinal bleeding", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "8921647_4_Ent2", "text": "Hypoxemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8921647_4_Ent1", "text": "Hypoxemia improved during continuous tolazoline infusion", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "8921647_4_Ent3", "text": "tolazoline", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8921647_4_Ent4", "text": "infusion", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8921647_4_Ent0", "text": "gastrointestinal bleeding", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "8926752_1", "wnd_id": "8926752_1_1", "text": "Zolpidem ( Ambien ) , a relatively new nonbenzodiazepine sedative - hypnotic , was involved in the death of a 39 - year - old obese male who was being treated for depression and insomnia .", "tokens": ["Zolpidem", "(", "Ambien", ")", ",", "a", "relatively", "new", "nonbenzodiazepine", "sedative", "-", "hypnotic", ",", "was", "involved", "in", "the", "death", "of", "a", "39", "-", "year", "-", "old", "obese", "male", "who", "was", "being", "treated", "for", "depression", "and", "insomnia", "."], "event_mentions": [{"id": "8926752_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "involved", "start": 14, "end": 15}, "arguments": [{"entity_id": "8926752_1_Ent7", "role": "Treatment_Drug", "text": "Zolpidem", "start": 0, "end": 1}, {"entity_id": "8926752_1_Ent5", "role": "Treatment", "text": "Zolpidem ( Ambien )", "start": 0, "end": 4}, {"entity_id": "8926752_1_Ent4", "role": "Effect", "text": "death", "start": 17, "end": 18}, {"entity_id": "8926752_1_Ent0", "role": "Subject", "text": "a 39 - year - old obese male", "start": 19, "end": 27}, {"entity_id": "8926752_1_Ent1", "role": "Subject_Age", "text": "39 - year - old", "start": 20, "end": 25}, {"entity_id": "8926752_1_Ent2", "role": "Subject_Disorder", "text": "obese", "start": 25, "end": 26}, {"entity_id": "8926752_1_Ent3", "role": "Subject_Gender", "text": "male", "start": 26, "end": 27}, {"entity_id": "8926752_1_Ent6", "role": "Treatment_Disorder", "text": "depression and insomnia", "start": 32, "end": 35}]}], "entity_mentions": [{"id": "8926752_1_Ent7", "text": "Zolpidem", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8926752_1_Ent5", "text": "Zolpidem ( Ambien )", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8926752_1_Ent4", "text": "death", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8926752_1_Ent0", "text": "a 39 - year - old obese male", "entity_type": "Entity", "start": 19, "end": 27}, {"id": "8926752_1_Ent1", "text": "39 - year - old", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "8926752_1_Ent2", "text": "obese", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "8926752_1_Ent3", "text": "male", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "8926752_1_Ent6", "text": "depression and insomnia", "entity_type": "Entity", "start": 32, "end": 35}], "lang": "en"}
{"doc_id": "8936932_2", "wnd_id": "8936932_2_1", "text": "After induction of general anesthesia and administration of a standard dose of intravenous esmolol hydrochloride , her cardiac rhythm progressed to asystole .", "tokens": ["After", "induction", "of", "general", "anesthesia", "and", "administration", "of", "a", "standard", "dose", "of", "intravenous", "esmolol", "hydrochloride", ",", "her", "cardiac", "rhythm", "progressed", "to", "asystole", "."], "event_mentions": [{"id": "8936932_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "8936932_2_Ent3", "role": "Treatment", "text": "induction of general anesthesia and administration of a standard dose of intravenous esmolol hydrochloride", "start": 1, "end": 15}, {"entity_id": "8936932_2_Ent6", "role": "Treatment_Drug", "text": "general anesthesia", "start": 3, "end": 5}, {"entity_id": "8936932_2_Ent7", "role": "Combination_Drug", "text": "general anesthesia", "start": 3, "end": 5}, {"entity_id": "8936932_2_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 12, "end": 13}, {"entity_id": "8936932_2_Ent5", "role": "Treatment_Drug", "text": "esmolol hydrochloride", "start": 13, "end": 15}, {"entity_id": "8936932_2_Ent8", "role": "Combination_Drug", "text": "esmolol hydrochloride", "start": 13, "end": 15}, {"entity_id": "8936932_2_Ent0", "role": "Subject", "text": "her", "start": 16, "end": 17}, {"entity_id": "8936932_2_Ent1", "role": "Subject_Gender", "text": "her", "start": 16, "end": 17}, {"entity_id": "8936932_2_Ent2", "role": "Effect", "text": "asystole", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "8936932_2_Ent3", "text": "induction of general anesthesia and administration of a standard dose of intravenous esmolol hydrochloride", "entity_type": "Entity", "start": 1, "end": 15}, {"id": "8936932_2_Ent6", "text": "general anesthesia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8936932_2_Ent7", "text": "general anesthesia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8936932_2_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8936932_2_Ent5", "text": "esmolol hydrochloride", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8936932_2_Ent8", "text": "esmolol hydrochloride", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8936932_2_Ent0", "text": "her", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8936932_2_Ent1", "text": "her", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8936932_2_Ent2", "text": "asystole", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "8936932_3", "wnd_id": "8936932_3_1", "text": "Cardiac arrest after esmolol administration : a review of acute beta - blocker toxicity .", "tokens": ["Cardiac", "arrest", "after", "esmolol", "administration", ":", "a", "review", "of", "acute", "beta", "-", "blocker", "toxicity", "."], "event_mentions": [{"id": "8936932_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "8936932_3_Ent0", "role": "Effect", "text": "Cardiac arrest", "start": 0, "end": 2}, {"entity_id": "8936932_3_Ent1", "role": "Treatment", "text": "esmolol", "start": 3, "end": 4}, {"entity_id": "8936932_3_Ent2", "role": "Treatment_Drug", "text": "esmolol", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "8936932_3_Ent0", "text": "Cardiac arrest", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8936932_3_Ent1", "text": "esmolol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8936932_3_Ent2", "text": "esmolol", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "897744_2", "wnd_id": "897744_2_1", "text": "A drug addict with staphylococcal endocarditis treated with methicillin , who developed massive proteinuria and acute nephritic syndrome is described .", "tokens": ["A", "drug", "addict", "with", "staphylococcal", "endocarditis", "treated", "with", "methicillin", ",", "who", "developed", "massive", "proteinuria", "and", "acute", "nephritic", "syndrome", "is", "described", "."], "event_mentions": [{"id": "897744_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "897744_2_Ent0", "role": "Subject", "text": "A drug addict", "start": 0, "end": 3}, {"entity_id": "897744_2_Ent1", "role": "Subject_Disorder", "text": "drug addict", "start": 1, "end": 3}, {"entity_id": "897744_2_Ent4", "role": "Treatment_Disorder", "text": "staphylococcal endocarditis", "start": 4, "end": 6}, {"entity_id": "897744_2_Ent3", "role": "Treatment", "text": "methicillin", "start": 8, "end": 9}, {"entity_id": "897744_2_Ent5", "role": "Treatment_Drug", "text": "methicillin", "start": 8, "end": 9}, {"entity_id": "897744_2_Ent2", "role": "Effect", "text": "massive proteinuria and acute nephritic syndrome", "start": 12, "end": 18}]}], "entity_mentions": [{"id": "897744_2_Ent0", "text": "A drug addict", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "897744_2_Ent1", "text": "drug addict", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "897744_2_Ent4", "text": "staphylococcal endocarditis", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "897744_2_Ent3", "text": "methicillin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "897744_2_Ent5", "text": "methicillin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "897744_2_Ent2", "text": "massive proteinuria and acute nephritic syndrome", "entity_type": "Entity", "start": 12, "end": 18}], "lang": "en"}
{"doc_id": "897744_3", "wnd_id": "897744_3_1", "text": "Discontinuation of methicillin therapy and appropriate antibiotic treatment of endocarditis led to clinical improvement , emphasizing the need to promptly discontinue potential nephrotoxic agents when abnormalities in renal function appear .", "tokens": ["Discontinuation", "of", "methicillin", "therapy", "and", "appropriate", "antibiotic", "treatment", "of", "endocarditis", "led", "to", "clinical", "improvement", ",", "emphasizing", "the", "need", "to", "promptly", "discontinue", "potential", "nephrotoxic", "agents", "when", "abnormalities", "in", "renal", "function", "appear", "."], "event_mentions": [{"id": "897744_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appear", "start": 29, "end": 30}, "arguments": [{"entity_id": "897744_3_Ent1", "role": "Treatment", "text": "methicillin", "start": 2, "end": 3}, {"entity_id": "897744_3_Ent2", "role": "Treatment_Drug", "text": "methicillin", "start": 2, "end": 3}, {"entity_id": "897744_3_Ent3", "role": "Treatment_Drug", "text": "antibiotic", "start": 6, "end": 7}, {"entity_id": "897744_3_Ent5", "role": "Treatment_Disorder", "text": "endocarditis", "start": 9, "end": 10}, {"entity_id": "897744_3_Ent4", "role": "Treatment_Drug", "text": "nephrotoxic agents", "start": 22, "end": 24}, {"entity_id": "897744_3_Ent0", "role": "Effect", "text": "abnormalities in renal function", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "897744_3_Ent1", "text": "methicillin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "897744_3_Ent2", "text": "methicillin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "897744_3_Ent3", "text": "antibiotic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "897744_3_Ent5", "text": "endocarditis", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "897744_3_Ent4", "text": "nephrotoxic agents", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "897744_3_Ent0", "text": "abnormalities in renal function", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "9007910_6", "wnd_id": "9007910_6_1", "text": "The principle treatment for DPD - deficient patients with severe acute 5 - FU reactions is supportive care ; however , the administration of thymidine potentially may reverse severe 5 - FU - induced neurologic symptoms such as encephalopathy and coma .", "tokens": ["The", "principle", "treatment", "for", "DPD", "-", "deficient", "patients", "with", "severe", "acute", "5", "-", "FU", "reactions", "is", "supportive", "care", ";", "however", ",", "the", "administration", "of", "thymidine", "potentially", "may", "reverse", "severe", "5", "-", "FU", "-", "induced", "neurologic", "symptoms", "such", "as", "encephalopathy", "and", "coma", "."], "event_mentions": [{"id": "9007910_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reverse", "start": 27, "end": 28}, "arguments": [{"entity_id": "9007910_6_Ent1", "role": "Subject_Disorder", "text": "DPD - deficient", "start": 4, "end": 7}, {"entity_id": "9007910_6_Ent0", "role": "Subject", "text": "DPD - deficient patients with severe acute 5 - FU reactions", "start": 4, "end": 15}, {"entity_id": "9007910_6_Ent4", "role": "Treatment_Disorder", "text": "severe acute 5 - FU reactions", "start": 9, "end": 15}, {"entity_id": "9007910_6_Ent2", "role": "Treatment", "text": "thymidine", "start": 24, "end": 25}, {"entity_id": "9007910_6_Ent5", "role": "Treatment_Drug", "text": "thymidine", "start": 24, "end": 25}, {"entity_id": "9007910_6_Ent3", "role": "Treatment_Disorder", "text": "5 - FU - induced neurologic symptoms such as encephalopathy and coma", "start": 29, "end": 41}]}, {"id": "9007910_6_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 33, "end": 34}, "arguments": [{"entity_id": "9007910_6_Ent7", "role": "Treatment", "text": "5 - FU", "start": 29, "end": 32}, {"entity_id": "9007910_6_Ent8", "role": "Treatment_Drug", "text": "5 - FU", "start": 29, "end": 32}, {"entity_id": "9007910_6_Ent6", "role": "Effect", "text": "neurologic symptoms such as encephalopathy and coma", "start": 34, "end": 41}]}], "entity_mentions": [{"id": "9007910_6_Ent1", "text": "DPD - deficient", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "9007910_6_Ent0", "text": "DPD - deficient patients with severe acute 5 - FU reactions", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "9007910_6_Ent4", "text": "severe acute 5 - FU reactions", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "9007910_6_Ent2", "text": "thymidine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "9007910_6_Ent5", "text": "thymidine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "9007910_6_Ent7", "text": "5 - FU", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "9007910_6_Ent8", "text": "5 - FU", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "9007910_6_Ent3", "text": "5 - FU - induced neurologic symptoms such as encephalopathy and coma", "entity_type": "Entity", "start": 29, "end": 41}, {"id": "9007910_6_Ent6", "text": "neurologic symptoms such as encephalopathy and coma", "entity_type": "Entity", "start": 34, "end": 41}], "lang": "en"}
{"doc_id": "9013348_1", "wnd_id": "9013348_1_1", "text": "A 49 - year - old man with Crohn 's disease treated with prednisone and mesalamine ( 5 - ASA ) developed worsening respiratory distress and fever .", "tokens": ["A", "49", "-", "year", "-", "old", "man", "with", "Crohn", "'s", "disease", "treated", "with", "prednisone", "and", "mesalamine", "(", "5", "-", "ASA", ")", "developed", "worsening", "respiratory", "distress", "and", "fever", "."], "event_mentions": [{"id": "9013348_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 21, "end": 22}, "arguments": [{"entity_id": "9013348_1_Ent1", "role": "Subject_Age", "text": "49 - year - old", "start": 1, "end": 6}, {"entity_id": "9013348_1_Ent0", "role": "Subject", "text": "49 - year - old man with Crohn 's disease", "start": 1, "end": 11}, {"entity_id": "9013348_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "9013348_1_Ent5", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 8, "end": 11}, {"entity_id": "9013348_1_Ent7", "role": "Treatment_Drug", "text": "prednisone", "start": 13, "end": 14}, {"entity_id": "9013348_1_Ent8", "role": "Combination_Drug", "text": "prednisone", "start": 13, "end": 14}, {"entity_id": "9013348_1_Ent4", "role": "Treatment", "text": "prednisone and mesalamine ( 5 - ASA )", "start": 13, "end": 21}, {"entity_id": "9013348_1_Ent6", "role": "Treatment_Drug", "text": "mesalamine", "start": 15, "end": 16}, {"entity_id": "9013348_1_Ent9", "role": "Combination_Drug", "text": "mesalamine", "start": 15, "end": 16}, {"entity_id": "9013348_1_Ent3", "role": "Effect", "text": "worsening respiratory distress and fever .", "start": 22, "end": 28}]}], "entity_mentions": [{"id": "9013348_1_Ent1", "text": "49 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9013348_1_Ent0", "text": "49 - year - old man with Crohn 's disease", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "9013348_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9013348_1_Ent5", "text": "Crohn 's disease", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "9013348_1_Ent7", "text": "prednisone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9013348_1_Ent8", "text": "prednisone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9013348_1_Ent4", "text": "prednisone and mesalamine ( 5 - ASA )", "entity_type": "Entity", "start": 13, "end": 21}, {"id": "9013348_1_Ent6", "text": "mesalamine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9013348_1_Ent9", "text": "mesalamine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9013348_1_Ent3", "text": "worsening respiratory distress and fever .", "entity_type": "Entity", "start": 22, "end": 28}], "lang": "en"}
{"doc_id": "9022114_1", "wnd_id": "9022114_1_1", "text": "BACKGROUND : Colchicine has a known adverse effect on wound healing through its inhibitory effect on tubulin - dependent cell functions and through collagenase activation .", "tokens": ["BACKGROUND", ":", "Colchicine", "has", "a", "known", "adverse", "effect", "on", "wound", "healing", "through", "its", "inhibitory", "effect", "on", "tubulin", "-", "dependent", "cell", "functions", "and", "through", "collagenase", "activation", "."], "event_mentions": [{"id": "9022114_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effect", "start": 6, "end": 8}, "arguments": [{"entity_id": "9022114_1_Ent1", "role": "Treatment", "text": "Colchicine", "start": 2, "end": 3}, {"entity_id": "9022114_1_Ent2", "role": "Treatment_Drug", "text": "Colchicine", "start": 2, "end": 3}, {"entity_id": "9022114_1_Ent0", "role": "Effect", "text": "wound healing", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9022114_1_Ent1", "text": "Colchicine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9022114_1_Ent2", "text": "Colchicine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9022114_1_Ent0", "text": "wound healing", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9022114_4", "wnd_id": "9022114_4_1", "text": "The authors report on two patients with corneal ulcers refractory to conventional treatment while the patients were undergoing oral colchicine therapy .", "tokens": ["The", "authors", "report", "on", "two", "patients", "with", "corneal", "ulcers", "refractory", "to", "conventional", "treatment", "while", "the", "patients", "were", "undergoing", "oral", "colchicine", "therapy", "."], "event_mentions": [{"id": "9022114_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "undergoing", "start": 17, "end": 18}, "arguments": [{"entity_id": "9022114_4_Ent1", "role": "Subject_Population", "text": "two", "start": 4, "end": 5}, {"entity_id": "9022114_4_Ent0", "role": "Subject", "text": "two patients", "start": 4, "end": 6}, {"entity_id": "9022114_4_Ent2", "role": "Effect", "text": "corneal ulcers", "start": 7, "end": 9}, {"entity_id": "9022114_4_Ent5", "role": "Treatment_Route", "text": "oral", "start": 18, "end": 19}, {"entity_id": "9022114_4_Ent3", "role": "Treatment", "text": "oral colchicine therapy", "start": 18, "end": 21}, {"entity_id": "9022114_4_Ent4", "role": "Treatment_Drug", "text": "colchicine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "9022114_4_Ent1", "text": "two", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9022114_4_Ent0", "text": "two patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9022114_4_Ent2", "text": "corneal ulcers", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9022114_4_Ent5", "text": "oral", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9022114_4_Ent3", "text": "oral colchicine therapy", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "9022114_4_Ent4", "text": "colchicine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9039216_1", "wnd_id": "9039216_1_1", "text": "A 17 - year - old female patient who had been taking oral minocycline ( 50 mg twice daily ) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis .", "tokens": ["A", "17", "-", "year", "-", "old", "female", "patient", "who", "had", "been", "taking", "oral", "minocycline", "(", "50", "mg", "twice", "daily", ")", "for", "3", "weeks", "for", "acne", "developed", "an", "eruption", "that", "progressed", "to", "an", "exfoliative", "dermatitis", "."], "event_mentions": [{"id": "9039216_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "9039216_1_Ent0", "role": "Subject", "text": "A 17 - year - old female patient", "start": 0, "end": 8}, {"entity_id": "9039216_1_Ent1", "role": "Subject_Age", "text": "17 - year - old", "start": 1, "end": 6}, {"entity_id": "9039216_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 6, "end": 7}, {"entity_id": "9039216_1_Ent11", "role": "Treatment_Route", "text": "oral", "start": 12, "end": 13}, {"entity_id": "9039216_1_Ent5", "role": "Treatment", "text": "oral minocycline ( 50 mg twice daily ) for 3 weeks", "start": 12, "end": 23}, {"entity_id": "9039216_1_Ent7", "role": "Treatment_Drug", "text": "minocycline", "start": 13, "end": 14}, {"entity_id": "9039216_1_Ent8", "role": "Treatment_Dosage", "text": "50 mg", "start": 15, "end": 17}, {"entity_id": "9039216_1_Ent9", "role": "Treatment_Freq", "text": "twice daily", "start": 17, "end": 19}, {"entity_id": "9039216_1_Ent10", "role": "Treatment_Duration", "text": "3 weeks", "start": 21, "end": 23}, {"entity_id": "9039216_1_Ent6", "role": "Treatment_Disorder", "text": "acne", "start": 24, "end": 25}, {"entity_id": "9039216_1_Ent3", "role": "Effect", "text": "eruption", "start": 27, "end": 28}, {"entity_id": "9039216_1_Ent4", "role": "Effect", "text": "an exfoliative dermatitis", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "9039216_1_Ent0", "text": "A 17 - year - old female patient", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "9039216_1_Ent1", "text": "17 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9039216_1_Ent2", "text": "female", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9039216_1_Ent11", "text": "oral", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9039216_1_Ent5", "text": "oral minocycline ( 50 mg twice daily ) for 3 weeks", "entity_type": "Entity", "start": 12, "end": 23}, {"id": "9039216_1_Ent7", "text": "minocycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9039216_1_Ent8", "text": "50 mg", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "9039216_1_Ent9", "text": "twice daily", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9039216_1_Ent10", "text": "3 weeks", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "9039216_1_Ent6", "text": "acne", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "9039216_1_Ent3", "text": "eruption", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "9039216_1_Ent4", "text": "an exfoliative dermatitis", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "9039216_2", "wnd_id": "9039216_2_1", "text": "Fever , lymphadenopathy , eosinophilia , lymphocytosis , hepatitis , and dermatitis : a severe adverse reaction to minocycline .", "tokens": ["Fever", ",", "lymphadenopathy", ",", "eosinophilia", ",", "lymphocytosis", ",", "hepatitis", ",", "and", "dermatitis", ":", "a", "severe", "adverse", "reaction", "to", "minocycline", "."], "event_mentions": [{"id": "9039216_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse reaction", "start": 15, "end": 17}, "arguments": [{"entity_id": "9039216_2_Ent0", "role": "Effect", "text": "Fever , lymphadenopathy , eosinophilia , lymphocytosis , hepatitis , and dermatitis", "start": 0, "end": 12}, {"entity_id": "9039216_2_Ent1", "role": "Treatment", "text": "minocycline", "start": 18, "end": 19}, {"entity_id": "9039216_2_Ent2", "role": "Treatment_Drug", "text": "minocycline", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9039216_2_Ent0", "text": "Fever , lymphadenopathy , eosinophilia , lymphocytosis , hepatitis , and dermatitis", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "9039216_2_Ent1", "text": "minocycline", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9039216_2_Ent2", "text": "minocycline", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9039216_3", "wnd_id": "9039216_3_1", "text": "This severe illness was likely caused by minocycline , and we speculate that minocycline may have acted as a superantigen , causing lymphocyte over - activation and massive cytokine release .", "tokens": ["This", "severe", "illness", "was", "likely", "caused", "by", "minocycline", ",", "and", "we", "speculate", "that", "minocycline", "may", "have", "acted", "as", "a", "superantigen", ",", "causing", "lymphocyte", "over", "-", "activation", "and", "massive", "cytokine", "release", "."], "event_mentions": [{"id": "9039216_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 5, "end": 6}, "arguments": [{"entity_id": "9039216_3_Ent0", "role": "Effect", "text": "severe illness", "start": 1, "end": 3}, {"entity_id": "9039216_3_Ent1", "role": "Treatment", "text": "minocycline", "start": 7, "end": 8}, {"entity_id": "9039216_3_Ent2", "role": "Treatment_Drug", "text": "minocycline", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9039216_3_Ent0", "text": "severe illness", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "9039216_3_Ent1", "text": "minocycline", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9039216_3_Ent2", "text": "minocycline", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9052919_3", "wnd_id": "9052919_3_1", "text": "We postulate that cyclosporin , possibly together with ganciclovir , can produce transient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients .", "tokens": ["We", "postulate", "that", "cyclosporin", ",", "possibly", "together", "with", "ganciclovir", ",", "can", "produce", "transient", "brain", "stem", "or", "neuromuscular", "dysfunction", "with", "eye", "movement", "abnormality", "in", "occasional", "patients", "."], "event_mentions": [{"id": "9052919_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produce", "start": 11, "end": 12}, "arguments": [{"entity_id": "9052919_3_Ent2", "role": "Treatment", "text": "cyclosporin", "start": 3, "end": 4}, {"entity_id": "9052919_3_Ent5", "role": "Treatment_Drug", "text": "cyclosporin", "start": 3, "end": 4}, {"entity_id": "9052919_3_Ent6", "role": "Combination_Drug", "text": "cyclosporin", "start": 3, "end": 4}, {"entity_id": "9052919_3_Ent3", "role": "Treatment", "text": "together with ganciclovir", "start": 6, "end": 9}, {"entity_id": "9052919_3_Ent4", "role": "Treatment_Drug", "text": "ganciclovir", "start": 8, "end": 9}, {"entity_id": "9052919_3_Ent7", "role": "Combination_Drug", "text": "ganciclovir", "start": 8, "end": 9}, {"entity_id": "9052919_3_Ent1", "role": "Effect", "text": "transient brain stem or neuromuscular dysfunction with eye movement abnormality", "start": 12, "end": 22}, {"entity_id": "9052919_3_Ent0", "role": "Subject", "text": "occasional patients", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "9052919_3_Ent2", "text": "cyclosporin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9052919_3_Ent5", "text": "cyclosporin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9052919_3_Ent6", "text": "cyclosporin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9052919_3_Ent3", "text": "together with ganciclovir", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "9052919_3_Ent4", "text": "ganciclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9052919_3_Ent7", "text": "ganciclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9052919_3_Ent1", "text": "transient brain stem or neuromuscular dysfunction with eye movement abnormality", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "9052919_3_Ent0", "text": "occasional patients", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "9100429_3", "wnd_id": "9100429_3_1", "text": "Four cases of adverse experiences with clonidine are described .", "tokens": ["Four", "cases", "of", "adverse", "experiences", "with", "clonidine", "are", "described", "."], "event_mentions": [{"id": "9100429_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 5, "end": 6}, "arguments": [{"entity_id": "9100429_3_Ent1", "role": "Subject_Population", "text": "Four", "start": 0, "end": 1}, {"entity_id": "9100429_3_Ent0", "role": "Subject", "text": "Four cases", "start": 0, "end": 2}, {"entity_id": "9100429_3_Ent2", "role": "Effect", "text": "adverse experiences", "start": 3, "end": 5}, {"entity_id": "9100429_3_Ent3", "role": "Treatment", "text": "clonidine", "start": 6, "end": 7}, {"entity_id": "9100429_3_Ent4", "role": "Treatment_Drug", "text": "clonidine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "9100429_3_Ent1", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9100429_3_Ent0", "text": "Four cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9100429_3_Ent2", "text": "adverse experiences", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9100429_3_Ent3", "text": "clonidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9100429_3_Ent4", "text": "clonidine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "9111724_1", "wnd_id": "9111724_1_1", "text": "Discontinuation of the itraconazole caused resolution of the drug eruption .", "tokens": ["Discontinuation", "of", "the", "itraconazole", "caused", "resolution", "of", "the", "drug", "eruption", "."], "event_mentions": [{"id": "9111724_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 4, "end": 5}, "arguments": [{"entity_id": "9111724_1_Ent1", "role": "Treatment", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "9111724_1_Ent2", "role": "Treatment_Drug", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "9111724_1_Ent0", "role": "Effect", "text": "drug eruption", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "9111724_1_Ent1", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9111724_1_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9111724_1_Ent0", "text": "drug eruption", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "9128433_1", "wnd_id": "9128433_1_1", "text": "Its overall toxicity is considerably less compared to standard induction chemotherapy ; however , it is associated with a high incidence of a potentially fatal symptom complex referred to as \" retinoic acid syndrome . \" This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis .", "tokens": ["Its", "overall", "toxicity", "is", "considerably", "less", "compared", "to", "standard", "induction", "chemotherapy", ";", "however", ",", "it", "is", "associated", "with", "a", "high", "incidence", "of", "a", "potentially", "fatal", "symptom", "complex", "referred", "to", "as", "\"", "retinoic", "acid", "syndrome", ".", "\"", "This", "report", "describes", "a", "patient", "with", "APL", "who", "developed", "the", "syndrome", "a", "few", "weeks", "after", "initiating", "induction", "therapy", "with", "ATRA", "despite", "being", "treated", "for", "hyperleukocytosis", "."], "event_mentions": [{"id": "9128433_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 44, "end": 45}, "arguments": [{"entity_id": "9128433_1_Ent1", "role": "Effect", "text": "symptom complex referred to as \" retinoic acid syndrome . \"", "start": 25, "end": 36}, {"entity_id": "9128433_1_Ent0", "role": "Subject", "text": "a patient with APL", "start": 39, "end": 43}, {"entity_id": "9128433_1_Ent5", "role": "Treatment_Disorder", "text": "APL", "start": 42, "end": 43}, {"entity_id": "9128433_1_Ent4", "role": "Treatment_Time_elapsed", "text": "a few weeks", "start": 47, "end": 50}, {"entity_id": "9128433_1_Ent2", "role": "Treatment", "text": "a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis", "start": 47, "end": 61}, {"entity_id": "9128433_1_Ent3", "role": "Treatment_Drug", "text": "ATRA", "start": 55, "end": 56}]}], "entity_mentions": [{"id": "9128433_1_Ent1", "text": "symptom complex referred to as \" retinoic acid syndrome . \"", "entity_type": "Entity", "start": 25, "end": 36}, {"id": "9128433_1_Ent0", "text": "a patient with APL", "entity_type": "Entity", "start": 39, "end": 43}, {"id": "9128433_1_Ent5", "text": "APL", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "9128433_1_Ent4", "text": "a few weeks", "entity_type": "Entity", "start": 47, "end": 50}, {"id": "9128433_1_Ent2", "text": "a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis", "entity_type": "Entity", "start": 47, "end": 61}, {"id": "9128433_1_Ent3", "text": "ATRA", "entity_type": "Entity", "start": 55, "end": 56}], "lang": "en"}
{"doc_id": "9161656_15", "wnd_id": "9161656_15_1", "text": "CONCLUSIONS : Sustained - release verapamil is thought to be the cause of the asthma attack in this patient because she was not taking any other preparations ; the symptoms started with the administration of sustained - release verapamil and were relieved after its discontinuation .", "tokens": ["CONCLUSIONS", ":", "Sustained", "-", "release", "verapamil", "is", "thought", "to", "be", "the", "cause", "of", "the", "asthma", "attack", "in", "this", "patient", "because", "she", "was", "not", "taking", "any", "other", "preparations", ";", "the", "symptoms", "started", "with", "the", "administration", "of", "sustained", "-", "release", "verapamil", "and", "were", "relieved", "after", "its", "discontinuation", "."], "event_mentions": [{"id": "9161656_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "9161656_15_Ent1", "role": "Treatment", "text": "Sustained - release verapamil", "start": 2, "end": 6}, {"entity_id": "9161656_15_Ent2", "role": "Treatment_Drug", "text": "verapamil", "start": 5, "end": 6}, {"entity_id": "9161656_15_Ent0", "role": "Effect", "text": "asthma attack", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "9161656_15_Ent1", "text": "Sustained - release verapamil", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "9161656_15_Ent2", "text": "verapamil", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9161656_15_Ent0", "text": "asthma attack", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "9161656_16", "wnd_id": "9161656_16_1", "text": "She continued taking verapamil for 6 months , then , on her own , stopped all medications including the sustained - release verapamil , and her asthma symptoms disappeared .", "tokens": ["She", "continued", "taking", "verapamil", "for", "6", "months", ",", "then", ",", "on", "her", "own", ",", "stopped", "all", "medications", "including", "the", "sustained", "-", "release", "verapamil", ",", "and", "her", "asthma", "symptoms", "disappeared", "."], "event_mentions": [{"id": "9161656_16_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "disappeared", "start": 28, "end": 29}, "arguments": [{"entity_id": "9161656_16_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "9161656_16_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "9161656_16_Ent2", "role": "Treatment", "text": "continued taking verapamil for 6 months , then , on her own , stopped all medications including the sustained - release verapamil", "start": 1, "end": 23}, {"entity_id": "9161656_16_Ent4", "role": "Treatment_Drug", "text": "verapamil", "start": 3, "end": 4}, {"entity_id": "9161656_16_Ent5", "role": "Treatment_Duration", "text": "for 6 months", "start": 4, "end": 7}, {"entity_id": "9161656_16_Ent3", "role": "Treatment_Disorder", "text": "asthma", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "9161656_16_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9161656_16_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9161656_16_Ent2", "text": "continued taking verapamil for 6 months , then , on her own , stopped all medications including the sustained - release verapamil", "entity_type": "Entity", "start": 1, "end": 23}, {"id": "9161656_16_Ent4", "text": "verapamil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9161656_16_Ent5", "text": "for 6 months", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "9161656_16_Ent3", "text": "asthma", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "9169264_2", "wnd_id": "9169264_2_1", "text": "The ampicillin rash occurring in cases of infectious mononucleosis is well documented .", "tokens": ["The", "ampicillin", "rash", "occurring", "in", "cases", "of", "infectious", "mononucleosis", "is", "well", "documented", "."], "event_mentions": [{"id": "9169264_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 3, "end": 4}, "arguments": [{"entity_id": "9169264_2_Ent0", "role": "Effect", "text": "The ampicillin rash", "start": 0, "end": 3}, {"entity_id": "9169264_2_Ent1", "role": "Treatment", "text": "ampicillin", "start": 1, "end": 2}, {"entity_id": "9169264_2_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 1, "end": 2}, {"entity_id": "9169264_2_Ent3", "role": "Treatment_Disorder", "text": "infectious mononucleosis", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "9169264_2_Ent0", "text": "The ampicillin rash", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9169264_2_Ent1", "text": "ampicillin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9169264_2_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9169264_2_Ent3", "text": "infectious mononucleosis", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "9169264_4", "wnd_id": "9169264_4_1", "text": "The rash seen in this patient , who was treated with cephalexin , may be similar to the rash seen with ampicillin treatment of patients with infectious mononucleosis .", "tokens": ["The", "rash", "seen", "in", "this", "patient", ",", "who", "was", "treated", "with", "cephalexin", ",", "may", "be", "similar", "to", "the", "rash", "seen", "with", "ampicillin", "treatment", "of", "patients", "with", "infectious", "mononucleosis", "."], "event_mentions": [{"id": "9169264_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 2, "end": 3}, "arguments": [{"entity_id": "9169264_4_Ent1", "role": "Effect", "text": "rash", "start": 1, "end": 2}, {"entity_id": "9169264_4_Ent0", "role": "Subject", "text": "patient", "start": 5, "end": 6}, {"entity_id": "9169264_4_Ent2", "role": "Treatment", "text": "cephalexin", "start": 11, "end": 12}, {"entity_id": "9169264_4_Ent3", "role": "Treatment_Drug", "text": "cephalexin", "start": 11, "end": 12}]}, {"id": "9169264_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 19, "end": 20}, "arguments": [{"entity_id": "9169264_4_Ent7", "role": "Treatment_Drug", "text": "ampicillin", "start": 21, "end": 22}, {"entity_id": "9169264_4_Ent6", "role": "Treatment", "text": "ampicillin treatment", "start": 21, "end": 23}, {"entity_id": "9169264_4_Ent4", "role": "Subject", "text": "patients", "start": 24, "end": 25}, {"entity_id": "9169264_4_Ent5", "role": "Effect", "text": "infectious mononucleosis", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "9169264_4_Ent1", "text": "rash", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9169264_4_Ent0", "text": "patient", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9169264_4_Ent2", "text": "cephalexin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9169264_4_Ent3", "text": "cephalexin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9169264_4_Ent7", "text": "ampicillin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9169264_4_Ent6", "text": "ampicillin treatment", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "9169264_4_Ent4", "text": "patients", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "9169264_4_Ent5", "text": "infectious mononucleosis", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "9177620_3", "wnd_id": "9177620_3_1", "text": "The evidence of high plasmatic levels of CBZ and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating of the episode of acute pancreatitis .", "tokens": ["The", "evidence", "of", "high", "plasmatic", "levels", "of", "CBZ", "and", "the", "absence", "of", "other", "aetiologic", "factors", "lead", "the", "authors", "to", "conclude", "that", "the", "overdose", "of", "CBZ", "could", "have", "represented", "the", "precipitating", "of", "the", "episode", "of", "acute", "pancreatitis", "."], "event_mentions": [{"id": "9177620_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitating", "start": 29, "end": 30}, "arguments": [{"entity_id": "9177620_3_Ent2", "role": "Treatment_Drug", "text": "CBZ", "start": 7, "end": 8}, {"entity_id": "9177620_3_Ent1", "role": "Treatment", "text": "overdose of CBZ", "start": 22, "end": 25}, {"entity_id": "9177620_3_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 34, "end": 36}]}], "entity_mentions": [{"id": "9177620_3_Ent2", "text": "CBZ", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9177620_3_Ent1", "text": "overdose of CBZ", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "9177620_3_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 34, "end": 36}], "lang": "en"}
{"doc_id": "9191742_1", "wnd_id": "9191742_1_1", "text": "Recent studies have shown that under experimental conditions ferrous sulfate may reduce the gastrointestinal absorption of orally administered levothyroxine sodium in patients with primary hypothyroidism .", "tokens": ["Recent", "studies", "have", "shown", "that", "under", "experimental", "conditions", "ferrous", "sulfate", "may", "reduce", "the", "gastrointestinal", "absorption", "of", "orally", "administered", "levothyroxine", "sodium", "in", "patients", "with", "primary", "hypothyroidism", "."], "event_mentions": [{"id": "9191742_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reduce", "start": 11, "end": 12}, "arguments": [{"entity_id": "9191742_1_Ent3", "role": "Treatment", "text": "ferrous sulfate", "start": 8, "end": 10}, {"entity_id": "9191742_1_Ent5", "role": "Treatment_Drug", "text": "ferrous sulfate", "start": 8, "end": 10}, {"entity_id": "9191742_1_Ent8", "role": "Combination_Drug", "text": "ferrous sulfate", "start": 8, "end": 10}, {"entity_id": "9191742_1_Ent2", "role": "Effect", "text": "reduce the gastrointestinal absorption of orally administered levothyroxine sodium", "start": 11, "end": 20}, {"entity_id": "9191742_1_Ent7", "role": "Treatment_Route", "text": "orally", "start": 16, "end": 17}, {"entity_id": "9191742_1_Ent4", "role": "Treatment", "text": "orally administered levothyroxine sodium", "start": 16, "end": 20}, {"entity_id": "9191742_1_Ent6", "role": "Treatment_Drug", "text": "levothyroxine sodium", "start": 18, "end": 20}, {"entity_id": "9191742_1_Ent9", "role": "Combination_Drug", "text": "levothyroxine sodium", "start": 18, "end": 20}, {"entity_id": "9191742_1_Ent0", "role": "Subject", "text": "patients with primary hypothyroidism", "start": 21, "end": 25}, {"entity_id": "9191742_1_Ent1", "role": "Subject_Disorder", "text": "primary hypothyroidism", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "9191742_1_Ent3", "text": "ferrous sulfate", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9191742_1_Ent5", "text": "ferrous sulfate", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9191742_1_Ent8", "text": "ferrous sulfate", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9191742_1_Ent2", "text": "reduce the gastrointestinal absorption of orally administered levothyroxine sodium", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "9191742_1_Ent7", "text": "orally", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9191742_1_Ent4", "text": "orally administered levothyroxine sodium", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "9191742_1_Ent6", "text": "levothyroxine sodium", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "9191742_1_Ent9", "text": "levothyroxine sodium", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "9191742_1_Ent0", "text": "patients with primary hypothyroidism", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "9191742_1_Ent1", "text": "primary hypothyroidism", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "921427_2", "wnd_id": "921427_2_1", "text": "Circulating anticoagulant in the procainamide - induced lupus syndrome .", "tokens": ["Circulating", "anticoagulant", "in", "the", "procainamide", "-", "induced", "lupus", "syndrome", "."], "event_mentions": [{"id": "921427_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "921427_2_Ent1", "role": "Treatment", "text": "procainamide", "start": 4, "end": 5}, {"entity_id": "921427_2_Ent2", "role": "Treatment_Drug", "text": "procainamide", "start": 4, "end": 5}, {"entity_id": "921427_2_Ent0", "role": "Effect", "text": "lupus syndrome", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "921427_2_Ent1", "text": "procainamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "921427_2_Ent2", "text": "procainamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "921427_2_Ent0", "text": "lupus syndrome", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "9220046_4", "wnd_id": "9220046_4_1", "text": "Erythromycin is a macrolide antibiotic that may increase the risk of lovastatin - induced rhabdomyolysis .", "tokens": ["Erythromycin", "is", "a", "macrolide", "antibiotic", "that", "may", "increase", "the", "risk", "of", "lovastatin", "-", "induced", "rhabdomyolysis", "."], "event_mentions": [{"id": "9220046_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "9220046_4_Ent1", "role": "Treatment", "text": "Erythromycin", "start": 0, "end": 1}, {"entity_id": "9220046_4_Ent2", "role": "Treatment_Drug", "text": "Erythromycin", "start": 0, "end": 1}, {"entity_id": "9220046_4_Ent5", "role": "Combination_Drug", "text": "Erythromycin", "start": 0, "end": 1}, {"entity_id": "9220046_4_Ent0", "role": "Effect", "text": "increase the risk of lovastatin - induced rhabdomyolysis", "start": 7, "end": 15}, {"entity_id": "9220046_4_Ent3", "role": "Treatment_Drug", "text": "lovastatin", "start": 11, "end": 12}, {"entity_id": "9220046_4_Ent4", "role": "Combination_Drug", "text": "lovastatin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9220046_4_Ent1", "text": "Erythromycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9220046_4_Ent2", "text": "Erythromycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9220046_4_Ent5", "text": "Erythromycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9220046_4_Ent0", "text": "increase the risk of lovastatin - induced rhabdomyolysis", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "9220046_4_Ent3", "text": "lovastatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9220046_4_Ent4", "text": "lovastatin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9247841_4", "wnd_id": "9247841_4_1", "text": "We report 3 patients who developed cutaneous vasculitis which is a rare and serious side - effect during antithyroid drug therapy .", "tokens": ["We", "report", "3", "patients", "who", "developed", "cutaneous", "vasculitis", "which", "is", "a", "rare", "and", "serious", "side", "-", "effect", "during", "antithyroid", "drug", "therapy", "."], "event_mentions": [{"id": "9247841_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "9247841_4_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "9247841_4_Ent0", "role": "Subject", "text": "3 patients", "start": 2, "end": 4}, {"entity_id": "9247841_4_Ent2", "role": "Effect", "text": "cutaneous vasculitis", "start": 6, "end": 8}, {"entity_id": "9247841_4_Ent3", "role": "Treatment", "text": "during antithyroid drug therapy", "start": 17, "end": 21}, {"entity_id": "9247841_4_Ent4", "role": "Treatment_Drug", "text": "antithyroid", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9247841_4_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9247841_4_Ent0", "text": "3 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9247841_4_Ent2", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9247841_4_Ent3", "text": "during antithyroid drug therapy", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "9247841_4_Ent4", "text": "antithyroid", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9291634_4", "wnd_id": "9291634_4_1", "text": "Thirty - six patients with AL received , in a three - month period , 51 cycles of combined chemotherapy which included , in all of them , cytosine arabinoside ( ARA - C ) ; among them , along with myelosuppression , five experienced fever , infectious complications , gastrointestinal tract symptoms and severe myalgias .", "tokens": ["Thirty", "-", "six", "patients", "with", "AL", "received", ",", "in", "a", "three", "-", "month", "period", ",", "51", "cycles", "of", "combined", "chemotherapy", "which", "included", ",", "in", "all", "of", "them", ",", "cytosine", "arabinoside", "(", "ARA", "-", "C", ")", ";", "among", "them", ",", "along", "with", "myelosuppression", ",", "five", "experienced", "fever", ",", "infectious", "complications", ",", "gastrointestinal", "tract", "symptoms", "and", "severe", "myalgias", "."], "event_mentions": [{"id": "9291634_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 44, "end": 45}, "arguments": [{"entity_id": "9291634_4_Ent6", "role": "Treatment_Duration", "text": "three - month", "start": 10, "end": 13}, {"entity_id": "9291634_4_Ent3", "role": "Treatment", "text": "chemotherapy", "start": 19, "end": 20}, {"entity_id": "9291634_4_Ent5", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 28, "end": 30}, {"entity_id": "9291634_4_Ent4", "role": "Treatment", "text": "cytosine arabinoside ( ARA - C )", "start": 28, "end": 35}, {"entity_id": "9291634_4_Ent0", "role": "Subject", "text": "five", "start": 43, "end": 44}, {"entity_id": "9291634_4_Ent1", "role": "Subject_Population", "text": "five", "start": 43, "end": 44}, {"entity_id": "9291634_4_Ent2", "role": "Effect", "text": "fever , infectious complications , gastrointestinal tract symptoms and severe myalgias", "start": 45, "end": 56}]}], "entity_mentions": [{"id": "9291634_4_Ent6", "text": "three - month", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "9291634_4_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9291634_4_Ent5", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "9291634_4_Ent4", "text": "cytosine arabinoside ( ARA - C )", "entity_type": "Entity", "start": 28, "end": 35}, {"id": "9291634_4_Ent0", "text": "five", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "9291634_4_Ent1", "text": "five", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "9291634_4_Ent2", "text": "fever , infectious complications , gastrointestinal tract symptoms and severe myalgias", "entity_type": "Entity", "start": 45, "end": 56}], "lang": "en"}
{"doc_id": "9311175_2", "wnd_id": "9311175_2_1", "text": "Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin : one , involving intrahepatic artery infusion , manifested general erythema , dyspnea , and hypotension ; the other , involving intravenous infusion , manifested abdominal pain , general erythema , and fever .", "tokens": ["Two", "patients", "with", "ovarian", "cancer", "who", "had", "received", "multiple", "courses", "of", "cisplatin", "without", "complications", "experienced", "hypersensitivity", "reactions", "to", "cisplatin", ":", "one", ",", "involving", "intrahepatic", "artery", "infusion", ",", "manifested", "general", "erythema", ",", "dyspnea", ",", "and", "hypotension", ";", "the", "other", ",", "involving", "intravenous", "infusion", ",", "manifested", "abdominal", "pain", ",", "general", "erythema", ",", "and", "fever", "."], "event_mentions": [{"id": "9311175_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reactions", "start": 16, "end": 17}, "arguments": [{"entity_id": "9311175_2_Ent5", "role": "Treatment_Disorder", "text": "ovarian cancer", "start": 3, "end": 5}, {"entity_id": "9311175_2_Ent2", "role": "Treatment", "text": "cisplatin", "start": 18, "end": 19}, {"entity_id": "9311175_2_Ent4", "role": "Treatment_Drug", "text": "cisplatin", "start": 18, "end": 19}, {"entity_id": "9311175_2_Ent0", "role": "Subject", "text": "one", "start": 20, "end": 21}, {"entity_id": "9311175_2_Ent3", "role": "Treatment", "text": "involving intrahepatic artery infusion", "start": 22, "end": 26}, {"entity_id": "9311175_2_Ent6", "role": "Treatment_Route", "text": "intrahepatic artery infusion", "start": 23, "end": 26}, {"entity_id": "9311175_2_Ent1", "role": "Effect", "text": "manifested general erythema , dyspnea , and hypotension", "start": 27, "end": 35}]}, {"id": "9311175_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "reactions", "start": 16, "end": 17}, "arguments": [{"entity_id": "9311175_2_Ent9", "role": "Treatment", "text": "cisplatin", "start": 18, "end": 19}, {"entity_id": "9311175_2_Ent11", "role": "Treatment_Drug", "text": "cisplatin", "start": 18, "end": 19}, {"entity_id": "9311175_2_Ent7", "role": "Subject", "text": "the other", "start": 36, "end": 38}, {"entity_id": "9311175_2_Ent10", "role": "Treatment", "text": "involving intravenous infusion", "start": 39, "end": 42}, {"entity_id": "9311175_2_Ent12", "role": "Treatment_Route", "text": "intravenous infusion", "start": 40, "end": 42}, {"entity_id": "9311175_2_Ent8", "role": "Effect", "text": "manifested abdominal pain , general erythema , and fever", "start": 43, "end": 52}]}], "entity_mentions": [{"id": "9311175_2_Ent5", "text": "ovarian cancer", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9311175_2_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9311175_2_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9311175_2_Ent9", "text": "cisplatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9311175_2_Ent11", "text": "cisplatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9311175_2_Ent0", "text": "one", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "9311175_2_Ent3", "text": "involving intrahepatic artery infusion", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "9311175_2_Ent6", "text": "intrahepatic artery infusion", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "9311175_2_Ent1", "text": "manifested general erythema , dyspnea , and hypotension", "entity_type": "Entity", "start": 27, "end": 35}, {"id": "9311175_2_Ent7", "text": "the other", "entity_type": "Entity", "start": 36, "end": 38}, {"id": "9311175_2_Ent10", "text": "involving intravenous infusion", "entity_type": "Entity", "start": 39, "end": 42}, {"id": "9311175_2_Ent12", "text": "intravenous infusion", "entity_type": "Entity", "start": 40, "end": 42}, {"id": "9311175_2_Ent8", "text": "manifested abdominal pain , general erythema , and fever", "entity_type": "Entity", "start": 43, "end": 52}], "lang": "en"}
{"doc_id": "9337441_8", "wnd_id": "9337441_8_1", "text": "Furosemide , spironolactone , allopurinol , and hydroxyurea were considered possible causes of the reaction and were discontinued .", "tokens": ["Furosemide", ",", "spironolactone", ",", "allopurinol", ",", "and", "hydroxyurea", "were", "considered", "possible", "causes", "of", "the", "reaction", "and", "were", "discontinued", "."], "event_mentions": [{"id": "9337441_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 11, "end": 12}, "arguments": [{"entity_id": "9337441_8_Ent2", "role": "Treatment_Drug", "text": "Furosemide", "start": 0, "end": 1}, {"entity_id": "9337441_8_Ent1", "role": "Treatment", "text": "Furosemide , spironolactone , allopurinol , and hydroxyurea", "start": 0, "end": 8}, {"entity_id": "9337441_8_Ent3", "role": "Treatment_Drug", "text": "spironolactone", "start": 2, "end": 3}, {"entity_id": "9337441_8_Ent4", "role": "Treatment_Drug", "text": "allopurinol", "start": 4, "end": 5}, {"entity_id": "9337441_8_Ent5", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 7, "end": 8}, {"entity_id": "9337441_8_Ent0", "role": "Effect", "text": "reaction", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "9337441_8_Ent2", "text": "Furosemide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9337441_8_Ent1", "text": "Furosemide , spironolactone , allopurinol , and hydroxyurea", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "9337441_8_Ent3", "text": "spironolactone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9337441_8_Ent4", "text": "allopurinol", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9337441_8_Ent5", "text": "hydroxyurea", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9337441_8_Ent0", "text": "reaction", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "9347384_1", "wnd_id": "9347384_1_1", "text": "Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients .", "tokens": ["Carbamazepine", "toxicity", "induced", "by", "clarithromycin", "coadministration", "in", "psychiatric", "patients", "."], "event_mentions": [{"id": "9347384_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9347384_1_Ent5", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "9347384_1_Ent7", "role": "Combination_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "9347384_1_Ent2", "role": "Effect", "text": "Carbamazepine toxicity", "start": 0, "end": 2}, {"entity_id": "9347384_1_Ent3", "role": "Treatment", "text": "clarithromycin", "start": 4, "end": 5}, {"entity_id": "9347384_1_Ent4", "role": "Treatment_Drug", "text": "clarithromycin", "start": 4, "end": 5}, {"entity_id": "9347384_1_Ent6", "role": "Combination_Drug", "text": "clarithromycin", "start": 4, "end": 5}, {"entity_id": "9347384_1_Ent1", "role": "Subject_Disorder", "text": "psychiatric", "start": 7, "end": 8}, {"entity_id": "9347384_1_Ent0", "role": "Subject", "text": "psychiatric patients", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "9347384_1_Ent5", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9347384_1_Ent7", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9347384_1_Ent2", "text": "Carbamazepine toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9347384_1_Ent3", "text": "clarithromycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9347384_1_Ent4", "text": "clarithromycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9347384_1_Ent6", "text": "clarithromycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9347384_1_Ent1", "text": "psychiatric", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9347384_1_Ent0", "text": "psychiatric patients", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "9352164_1", "wnd_id": "9352164_1_1", "text": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure .", "tokens": ["Acute", "hemorrhagic", "gastritis", "associated", "with", "acetazolamide", "intoxication", "in", "a", "patient", "with", "chronic", "renal", "failure", "."], "event_mentions": [{"id": "9352164_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "9352164_1_Ent2", "role": "Effect", "text": "Acute hemorrhagic gastritis", "start": 0, "end": 3}, {"entity_id": "9352164_1_Ent3", "role": "Treatment", "text": "acetazolamide", "start": 5, "end": 6}, {"entity_id": "9352164_1_Ent4", "role": "Treatment_Drug", "text": "acetazolamide", "start": 5, "end": 6}, {"entity_id": "9352164_1_Ent0", "role": "Subject", "text": "a patient with chronic renal failure", "start": 8, "end": 14}, {"entity_id": "9352164_1_Ent1", "role": "Subject_Disorder", "text": "chronic renal failure", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "9352164_1_Ent2", "text": "Acute hemorrhagic gastritis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9352164_1_Ent3", "text": "acetazolamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9352164_1_Ent4", "text": "acetazolamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9352164_1_Ent0", "text": "a patient with chronic renal failure", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "9352164_1_Ent1", "text": "chronic renal failure", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "9352164_4", "wnd_id": "9352164_4_1", "text": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication .", "tokens": ["We", "experienced", "a", "case", "of", "chronic", "renal", "failure", "in", "a", "patient", "suffering", "from", "acute", "hemorrhagic", "gastritis", "associated", "with", "AZ", "intoxication", "."], "event_mentions": [{"id": "9352164_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 16, "end": 18}, "arguments": [{"entity_id": "9352164_4_Ent0", "role": "Subject", "text": "a case of chronic renal failure in a patient", "start": 2, "end": 11}, {"entity_id": "9352164_4_Ent1", "role": "Subject_Disorder", "text": "chronic renal failure", "start": 5, "end": 8}, {"entity_id": "9352164_4_Ent2", "role": "Effect", "text": "acute hemorrhagic gastritis", "start": 13, "end": 16}, {"entity_id": "9352164_4_Ent3", "role": "Treatment", "text": "AZ", "start": 18, "end": 19}, {"entity_id": "9352164_4_Ent4", "role": "Treatment_Drug", "text": "AZ", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9352164_4_Ent0", "text": "a case of chronic renal failure in a patient", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "9352164_4_Ent1", "text": "chronic renal failure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9352164_4_Ent2", "text": "acute hemorrhagic gastritis", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9352164_4_Ent3", "text": "AZ", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9352164_4_Ent4", "text": "AZ", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9360190_2", "wnd_id": "9360190_2_1", "text": "Magnesium tocolysis as the cause of urinary calculus during pregnancy .", "tokens": ["Magnesium", "tocolysis", "as", "the", "cause", "of", "urinary", "calculus", "during", "pregnancy", "."], "event_mentions": [{"id": "9360190_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "9360190_2_Ent2", "role": "Treatment_Drug", "text": "Magnesium", "start": 0, "end": 1}, {"entity_id": "9360190_2_Ent1", "role": "Treatment", "text": "Magnesium tocolysis", "start": 0, "end": 2}, {"entity_id": "9360190_2_Ent0", "role": "Effect", "text": "urinary calculus during pregnancy", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "9360190_2_Ent2", "text": "Magnesium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9360190_2_Ent1", "text": "Magnesium tocolysis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9360190_2_Ent0", "text": "urinary calculus during pregnancy", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "9362107_1", "wnd_id": "9362107_1_1", "text": "Danazol induced thrombocytopenia .", "tokens": ["Danazol", "induced", "thrombocytopenia", "."], "event_mentions": [{"id": "9362107_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "9362107_1_Ent1", "role": "Treatment", "text": "Danazol", "start": 0, "end": 1}, {"entity_id": "9362107_1_Ent2", "role": "Treatment_Drug", "text": "Danazol", "start": 0, "end": 1}, {"entity_id": "9362107_1_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "9362107_1_Ent1", "text": "Danazol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9362107_1_Ent2", "text": "Danazol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9362107_1_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "9362107_3", "wnd_id": "9362107_3_1", "text": "We diagnosed this case as danazol induced thrombocytopenia .", "tokens": ["We", "diagnosed", "this", "case", "as", "danazol", "induced", "thrombocytopenia", "."], "event_mentions": [{"id": "9362107_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "9362107_3_Ent0", "role": "Subject", "text": "this case", "start": 2, "end": 4}, {"entity_id": "9362107_3_Ent2", "role": "Treatment", "text": "danazol", "start": 5, "end": 6}, {"entity_id": "9362107_3_Ent3", "role": "Treatment_Drug", "text": "danazol", "start": 5, "end": 6}, {"entity_id": "9362107_3_Ent1", "role": "Effect", "text": "thrombocytopenia", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9362107_3_Ent0", "text": "this case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9362107_3_Ent2", "text": "danazol", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9362107_3_Ent3", "text": "danazol", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9362107_3_Ent1", "text": "thrombocytopenia", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9375469_2", "wnd_id": "9375469_2_1", "text": "Therefore , we diagnosed her eruption as contact dermatitis due to sodium bisulfite .", "tokens": ["Therefore", ",", "we", "diagnosed", "her", "eruption", "as", "contact", "dermatitis", "due", "to", "sodium", "bisulfite", "."], "event_mentions": [{"id": "9375469_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 3, "end": 4}, "arguments": [{"entity_id": "9375469_2_Ent0", "role": "Effect", "text": "her eruption as contact dermatitis", "start": 4, "end": 9}, {"entity_id": "9375469_2_Ent1", "role": "Treatment", "text": "sodium bisulfite", "start": 11, "end": 13}, {"entity_id": "9375469_2_Ent2", "role": "Treatment_Drug", "text": "sodium bisulfite", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "9375469_2_Ent0", "text": "her eruption as contact dermatitis", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "9375469_2_Ent1", "text": "sodium bisulfite", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "9375469_2_Ent2", "text": "sodium bisulfite", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "9399776_1", "wnd_id": "9399776_1_1", "text": "Acute pancreatitis after long - term 5 - aminosalicylic acid therapy .", "tokens": ["Acute", "pancreatitis", "after", "long", "-", "term", "5", "-", "aminosalicylic", "acid", "therapy", "."], "event_mentions": [{"id": "9399776_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "9399776_1_Ent0", "role": "Effect", "text": "Acute pancreatitis", "start": 0, "end": 2}, {"entity_id": "9399776_1_Ent3", "role": "Treatment_Time_elapsed", "text": "long - term", "start": 3, "end": 6}, {"entity_id": "9399776_1_Ent1", "role": "Treatment", "text": "long - term 5 - aminosalicylic acid therapy", "start": 3, "end": 11}, {"entity_id": "9399776_1_Ent2", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "9399776_1_Ent0", "text": "Acute pancreatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9399776_1_Ent3", "text": "long - term", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9399776_1_Ent1", "text": "long - term 5 - aminosalicylic acid therapy", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "9399776_1_Ent2", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "9399776_3", "wnd_id": "9399776_3_1", "text": "A rechallenge , performed in both patients , confirmed the diagnosis of mesalamine - induced pancreatitis .", "tokens": ["A", "rechallenge", ",", "performed", "in", "both", "patients", ",", "confirmed", "the", "diagnosis", "of", "mesalamine", "-", "induced", "pancreatitis", "."], "event_mentions": [{"id": "9399776_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "9399776_3_Ent0", "role": "Subject", "text": "both patients", "start": 5, "end": 7}, {"entity_id": "9399776_3_Ent2", "role": "Treatment", "text": "mesalamine", "start": 12, "end": 13}, {"entity_id": "9399776_3_Ent3", "role": "Treatment_Drug", "text": "mesalamine", "start": 12, "end": 13}, {"entity_id": "9399776_3_Ent1", "role": "Effect", "text": "pancreatitis", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "9399776_3_Ent0", "text": "both patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9399776_3_Ent2", "text": "mesalamine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9399776_3_Ent3", "text": "mesalamine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9399776_3_Ent1", "text": "pancreatitis", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "9403220_1", "wnd_id": "9403220_1_1", "text": "A 35 - year - old nephrotic man developed acute renal failure with serum creatinine to 1543 micromol / l after a month of therapy with enalapril .", "tokens": ["A", "35", "-", "year", "-", "old", "nephrotic", "man", "developed", "acute", "renal", "failure", "with", "serum", "creatinine", "to", "1543", "micromol", "/", "l", "after", "a", "month", "of", "therapy", "with", "enalapril", "."], "event_mentions": [{"id": "9403220_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "9403220_1_Ent0", "role": "Subject", "text": "A 35 - year - old nephrotic man", "start": 0, "end": 8}, {"entity_id": "9403220_1_Ent1", "role": "Subject_Age", "text": "35 - year - old", "start": 1, "end": 6}, {"entity_id": "9403220_1_Ent5", "role": "Treatment_Disorder", "text": "nephrotic", "start": 6, "end": 7}, {"entity_id": "9403220_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "9403220_1_Ent3", "role": "Effect", "text": "acute renal failure with serum creatinine to 1543 micromol / l", "start": 9, "end": 20}, {"entity_id": "9403220_1_Ent6", "role": "Treatment_Duration", "text": "a month", "start": 21, "end": 23}, {"entity_id": "9403220_1_Ent4", "role": "Treatment", "text": "a month of therapy with enalapril", "start": 21, "end": 27}, {"entity_id": "9403220_1_Ent7", "role": "Treatment_Drug", "text": "enalapril", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "9403220_1_Ent0", "text": "A 35 - year - old nephrotic man", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "9403220_1_Ent1", "text": "35 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9403220_1_Ent5", "text": "nephrotic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9403220_1_Ent2", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9403220_1_Ent3", "text": "acute renal failure with serum creatinine to 1543 micromol / l", "entity_type": "Entity", "start": 9, "end": 20}, {"id": "9403220_1_Ent6", "text": "a month", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "9403220_1_Ent4", "text": "a month of therapy with enalapril", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "9403220_1_Ent7", "text": "enalapril", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "9426968_2", "wnd_id": "9426968_2_1", "text": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "tokens": ["We", "report", "a", "case", "of", "vitiligo", "that", "occurred", "during", "the", "second", "month", "of", "interferon", "alpha", "2a", "therapy", "for", "chronic", "active", "hepatitis", "C."], "event_mentions": [{"id": "9426968_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 7, "end": 8}, "arguments": [{"entity_id": "9426968_2_Ent0", "role": "Effect", "text": "vitiligo", "start": 5, "end": 6}, {"entity_id": "9426968_2_Ent1", "role": "Treatment", "text": "during the second month of interferon alpha 2a therapy", "start": 8, "end": 17}, {"entity_id": "9426968_2_Ent3", "role": "Treatment_Duration", "text": "the second month", "start": 9, "end": 12}, {"entity_id": "9426968_2_Ent4", "role": "Treatment_Drug", "text": "interferon alpha 2a", "start": 13, "end": 16}, {"entity_id": "9426968_2_Ent2", "role": "Treatment_Disorder", "text": "chronic active hepatitis C.", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "9426968_2_Ent0", "text": "vitiligo", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9426968_2_Ent1", "text": "during the second month of interferon alpha 2a therapy", "entity_type": "Entity", "start": 8, "end": 17}, {"id": "9426968_2_Ent3", "text": "the second month", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "9426968_2_Ent4", "text": "interferon alpha 2a", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9426968_2_Ent2", "text": "chronic active hepatitis C.", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "9433539_2", "wnd_id": "9433539_2_1", "text": "Agranulocytosis associated with ticlopidine : a possible benefit with filgastim .", "tokens": ["Agranulocytosis", "associated", "with", "ticlopidine", ":", "a", "possible", "benefit", "with", "filgastim", "."], "event_mentions": [{"id": "9433539_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "9433539_2_Ent0", "role": "Effect", "text": "Agranulocytosis", "start": 0, "end": 1}, {"entity_id": "9433539_2_Ent1", "role": "Treatment", "text": "ticlopidine", "start": 3, "end": 4}, {"entity_id": "9433539_2_Ent2", "role": "Treatment_Drug", "text": "ticlopidine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "9433539_2_Ent0", "text": "Agranulocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9433539_2_Ent1", "text": "ticlopidine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9433539_2_Ent2", "text": "ticlopidine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "946400_2", "wnd_id": "946400_2_1", "text": "Methyldopa - induced liver injury .", "tokens": ["Methyldopa", "-", "induced", "liver", "injury", "."], "event_mentions": [{"id": "946400_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "946400_2_Ent1", "role": "Treatment", "text": "Methyldopa", "start": 0, "end": 1}, {"entity_id": "946400_2_Ent2", "role": "Treatment_Drug", "text": "Methyldopa", "start": 0, "end": 1}, {"entity_id": "946400_2_Ent0", "role": "Effect", "text": "liver injury", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "946400_2_Ent1", "text": "Methyldopa", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "946400_2_Ent2", "text": "Methyldopa", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "946400_2_Ent0", "text": "liver injury", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "9466030_2", "wnd_id": "9466030_2_1", "text": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic ( respiratory rate : 4 - 5 bpm ) , hypotensive ( BP 70/40 mmHg ) , and responded only partially to command .", "tokens": ["Approximately", "15", "min", "after", "the", "first", "administration", "of", "nebulised", "morphine", "the", "patient", "became", "markedly", "bradypneic", "(", "respiratory", "rate", ":", "4", "-", "5", "bpm", ")", ",", "hypotensive", "(", "BP", "70/40", "mmHg", ")", ",", "and", "responded", "only", "partially", "to", "command", "."], "event_mentions": [{"id": "9466030_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 12, "end": 13}, "arguments": [{"entity_id": "9466030_2_Ent5", "role": "Treatment_Time_elapsed", "text": "15 min", "start": 1, "end": 3}, {"entity_id": "9466030_2_Ent4", "role": "Treatment_Route", "text": "nebulised", "start": 8, "end": 9}, {"entity_id": "9466030_2_Ent2", "role": "Treatment", "text": "nebulised morphine", "start": 8, "end": 10}, {"entity_id": "9466030_2_Ent3", "role": "Treatment_Drug", "text": "morphine", "start": 9, "end": 10}, {"entity_id": "9466030_2_Ent0", "role": "Subject", "text": "patient", "start": 11, "end": 12}, {"entity_id": "9466030_2_Ent1", "role": "Effect", "text": "markedly bradypneic ( respiratory rate : 4 - 5 bpm ) , hypotensive ( BP 70/40 mmHg ) , and responded only partially to command", "start": 13, "end": 38}]}], "entity_mentions": [{"id": "9466030_2_Ent5", "text": "15 min", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "9466030_2_Ent4", "text": "nebulised", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9466030_2_Ent2", "text": "nebulised morphine", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9466030_2_Ent3", "text": "morphine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9466030_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9466030_2_Ent1", "text": "markedly bradypneic ( respiratory rate : 4 - 5 bpm ) , hypotensive ( BP 70/40 mmHg ) , and responded only partially to command", "entity_type": "Entity", "start": 13, "end": 38}], "lang": "en"}
{"doc_id": "9476721_3", "wnd_id": "9476721_3_1", "text": "We reported 3 patients who developed acute generalized dystonia and akinetic rigid syndrome following an initial therapy with d - penicillamine 125 - 500 mg daily .", "tokens": ["We", "reported", "3", "patients", "who", "developed", "acute", "generalized", "dystonia", "and", "akinetic", "rigid", "syndrome", "following", "an", "initial", "therapy", "with", "d", "-", "penicillamine", "125", "-", "500", "mg", "daily", "."], "event_mentions": [{"id": "9476721_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 13, "end": 14}, "arguments": [{"entity_id": "9476721_3_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "9476721_3_Ent0", "role": "Subject", "text": "3 patients", "start": 2, "end": 4}, {"entity_id": "9476721_3_Ent2", "role": "Effect", "text": "acute generalized dystonia and akinetic rigid syndrome", "start": 6, "end": 13}, {"entity_id": "9476721_3_Ent4", "role": "Treatment_Drug", "text": "d - penicillamine", "start": 18, "end": 21}, {"entity_id": "9476721_3_Ent3", "role": "Treatment", "text": "d - penicillamine 125 - 500 mg daily", "start": 18, "end": 26}, {"entity_id": "9476721_3_Ent5", "role": "Treatment_Dosage", "text": "125 - 500 mg daily", "start": 21, "end": 26}]}], "entity_mentions": [{"id": "9476721_3_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9476721_3_Ent0", "text": "3 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9476721_3_Ent2", "text": "acute generalized dystonia and akinetic rigid syndrome", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "9476721_3_Ent4", "text": "d - penicillamine", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "9476721_3_Ent3", "text": "d - penicillamine 125 - 500 mg daily", "entity_type": "Entity", "start": 18, "end": 26}, {"id": "9476721_3_Ent5", "text": "125 - 500 mg daily", "entity_type": "Entity", "start": 21, "end": 26}], "lang": "en"}
{"doc_id": "9512187_1", "wnd_id": "9512187_1_1", "text": "Because the combination of bleomycin and vinca alkaloids is commonly used for the treatment of AIDS - related Kaposi 's sarcoma , clinicians should be aware of the risk of provoking acral necrosis in patients who develop Raynaud 's phenomenon under chemotherapy .", "tokens": ["Because", "the", "combination", "of", "bleomycin", "and", "vinca", "alkaloids", "is", "commonly", "used", "for", "the", "treatment", "of", "AIDS", "-", "related", "Kaposi", "'s", "sarcoma", ",", "clinicians", "should", "be", "aware", "of", "the", "risk", "of", "provoking", "acral", "necrosis", "in", "patients", "who", "develop", "Raynaud", "'s", "phenomenon", "under", "chemotherapy", "."], "event_mentions": [{"id": "9512187_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoking", "start": 30, "end": 31}, "arguments": [{"entity_id": "9512187_1_Ent2", "role": "Treatment", "text": "bleomycin", "start": 4, "end": 5}, {"entity_id": "9512187_1_Ent4", "role": "Treatment_Drug", "text": "bleomycin", "start": 4, "end": 5}, {"entity_id": "9512187_1_Ent6", "role": "Combination_Drug", "text": "bleomycin", "start": 4, "end": 5}, {"entity_id": "9512187_1_Ent3", "role": "Treatment", "text": "vinca alkaloids", "start": 6, "end": 8}, {"entity_id": "9512187_1_Ent5", "role": "Treatment_Drug", "text": "vinca alkaloids", "start": 6, "end": 8}, {"entity_id": "9512187_1_Ent7", "role": "Combination_Drug", "text": "vinca alkaloids", "start": 6, "end": 8}, {"entity_id": "9512187_1_Ent0", "role": "Effect", "text": "acral necrosis", "start": 31, "end": 33}, {"entity_id": "9512187_1_Ent1", "role": "Effect", "text": "Raynaud 's phenomenon", "start": 37, "end": 40}]}], "entity_mentions": [{"id": "9512187_1_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9512187_1_Ent4", "text": "bleomycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9512187_1_Ent6", "text": "bleomycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9512187_1_Ent3", "text": "vinca alkaloids", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9512187_1_Ent5", "text": "vinca alkaloids", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9512187_1_Ent7", "text": "vinca alkaloids", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9512187_1_Ent0", "text": "acral necrosis", "entity_type": "Entity", "start": 31, "end": 33}, {"id": "9512187_1_Ent1", "text": "Raynaud 's phenomenon", "entity_type": "Entity", "start": 37, "end": 40}], "lang": "en"}
{"doc_id": "9512187_2", "wnd_id": "9512187_2_1", "text": "In this report , one patient who developed gangrene after bleomycin and vincristine / vinblastine chemotherapy for AIDS - related Kaposi 's sarcoma and another HIV - infected patient who exhibited symptoms of severe Raynaud 's phenomenon related to the same regimen are presented .", "tokens": ["In", "this", "report", ",", "one", "patient", "who", "developed", "gangrene", "after", "bleomycin", "and", "vincristine", "/", "vinblastine", "chemotherapy", "for", "AIDS", "-", "related", "Kaposi", "'s", "sarcoma", "and", "another", "HIV", "-", "infected", "patient", "who", "exhibited", "symptoms", "of", "severe", "Raynaud", "'s", "phenomenon", "related", "to", "the", "same", "regimen", "are", "presented", "."], "event_mentions": [{"id": "9512187_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "9512187_2_Ent1", "role": "Subject_Population", "text": "one", "start": 4, "end": 5}, {"entity_id": "9512187_2_Ent0", "role": "Subject", "text": "one patient", "start": 4, "end": 6}, {"entity_id": "9512187_2_Ent2", "role": "Effect", "text": "gangrene", "start": 8, "end": 9}, {"entity_id": "9512187_2_Ent4", "role": "Treatment_Drug", "text": "bleomycin", "start": 10, "end": 11}, {"entity_id": "9512187_2_Ent7", "role": "Combination_Drug", "text": "bleomycin", "start": 10, "end": 11}, {"entity_id": "9512187_2_Ent3", "role": "Treatment", "text": "bleomycin and vincristine / vinblastine", "start": 10, "end": 15}, {"entity_id": "9512187_2_Ent5", "role": "Treatment_Drug", "text": "vincristine", "start": 12, "end": 13}, {"entity_id": "9512187_2_Ent8", "role": "Combination_Drug", "text": "vincristine", "start": 12, "end": 13}, {"entity_id": "9512187_2_Ent6", "role": "Treatment_Drug", "text": "vinblastine", "start": 14, "end": 15}, {"entity_id": "9512187_2_Ent9", "role": "Combination_Drug", "text": "vinblastine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "9512187_2_Ent1", "text": "one", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9512187_2_Ent0", "text": "one patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9512187_2_Ent2", "text": "gangrene", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9512187_2_Ent4", "text": "bleomycin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9512187_2_Ent7", "text": "bleomycin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9512187_2_Ent3", "text": "bleomycin and vincristine / vinblastine", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "9512187_2_Ent5", "text": "vincristine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9512187_2_Ent8", "text": "vincristine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9512187_2_Ent6", "text": "vinblastine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9512187_2_Ent9", "text": "vinblastine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "9527943_1", "wnd_id": "9527943_1_1", "text": "Effect of beta - blockade on symptomatic dexamethasone - induced hypertrophic obstructive cardiomyopathy in premature infants : three case reports and literature review .", "tokens": ["Effect", "of", "beta", "-", "blockade", "on", "symptomatic", "dexamethasone", "-", "induced", "hypertrophic", "obstructive", "cardiomyopathy", "in", "premature", "infants", ":", "three", "case", "reports", "and", "literature", "review", "."], "event_mentions": [{"id": "9527943_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Effect", "start": 0, "end": 1}, "arguments": [{"entity_id": "9527943_1_Ent9", "role": "Treatment", "text": "beta - blockade", "start": 2, "end": 5}, {"entity_id": "9527943_1_Ent11", "role": "Treatment_Drug", "text": "beta - blockade", "start": 2, "end": 5}, {"entity_id": "9527943_1_Ent10", "role": "Treatment_Disorder", "text": "symptomatic dexamethasone - induced hypertrophic obstructive cardiomyopathy", "start": 6, "end": 13}, {"entity_id": "9527943_1_Ent7", "role": "Subject_Disorder", "text": "premature", "start": 14, "end": 15}, {"entity_id": "9527943_1_Ent6", "role": "Subject", "text": "premature infants", "start": 14, "end": 16}, {"entity_id": "9527943_1_Ent8", "role": "Subject_Age", "text": "infants", "start": 15, "end": 16}]}, {"id": "9527943_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "9527943_1_Ent4", "role": "Treatment", "text": "dexamethasone", "start": 7, "end": 8}, {"entity_id": "9527943_1_Ent5", "role": "Treatment_Drug", "text": "dexamethasone", "start": 7, "end": 8}, {"entity_id": "9527943_1_Ent3", "role": "Effect", "text": "hypertrophic obstructive cardiomyopathy", "start": 10, "end": 13}, {"entity_id": "9527943_1_Ent1", "role": "Subject_Disorder", "text": "premature", "start": 14, "end": 15}, {"entity_id": "9527943_1_Ent0", "role": "Subject", "text": "premature infants", "start": 14, "end": 16}, {"entity_id": "9527943_1_Ent2", "role": "Subject_Age", "text": "infants", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "9527943_1_Ent9", "text": "beta - blockade", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9527943_1_Ent11", "text": "beta - blockade", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9527943_1_Ent10", "text": "symptomatic dexamethasone - induced hypertrophic obstructive cardiomyopathy", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "9527943_1_Ent4", "text": "dexamethasone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9527943_1_Ent5", "text": "dexamethasone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9527943_1_Ent3", "text": "hypertrophic obstructive cardiomyopathy", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "9527943_1_Ent1", "text": "premature", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9527943_1_Ent7", "text": "premature", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9527943_1_Ent0", "text": "premature infants", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "9527943_1_Ent6", "text": "premature infants", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "9527943_1_Ent2", "text": "infants", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9527943_1_Ent8", "text": "infants", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "9527943_2", "wnd_id": "9527943_2_1", "text": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment , none of which was clinically significant .", "tokens": ["One", "patient", "had", "a", "lower", "average", "heart", "rate", "and", "two", "patients", "had", "lower", "average", "mean", "blood", "pressure", "values", "during", "propranolol", "treatment", ",", "none", "of", "which", "was", "clinically", "significant", "."], "event_mentions": [{"id": "9527943_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 18, "end": 19}, "arguments": [{"entity_id": "9527943_2_Ent1", "role": "Subject_Population", "text": "two", "start": 9, "end": 10}, {"entity_id": "9527943_2_Ent0", "role": "Subject", "text": "two patients", "start": 9, "end": 11}, {"entity_id": "9527943_2_Ent2", "role": "Effect", "text": "lower average mean blood pressure values", "start": 12, "end": 18}, {"entity_id": "9527943_2_Ent3", "role": "Treatment", "text": "propranolol", "start": 19, "end": 20}, {"entity_id": "9527943_2_Ent4", "role": "Treatment_Drug", "text": "propranolol", "start": 19, "end": 20}]}, {"id": "9527943_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 18, "end": 19}, "arguments": [{"entity_id": "9527943_2_Ent6", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "9527943_2_Ent5", "role": "Subject", "text": "One patient", "start": 0, "end": 2}, {"entity_id": "9527943_2_Ent7", "role": "Effect", "text": "lower average heart rate", "start": 4, "end": 8}, {"entity_id": "9527943_2_Ent8", "role": "Treatment", "text": "propranolol", "start": 19, "end": 20}, {"entity_id": "9527943_2_Ent9", "role": "Treatment_Drug", "text": "propranolol", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "9527943_2_Ent6", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9527943_2_Ent5", "text": "One patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9527943_2_Ent7", "text": "lower average heart rate", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "9527943_2_Ent1", "text": "two", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9527943_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9527943_2_Ent2", "text": "lower average mean blood pressure values", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "9527943_2_Ent3", "text": "propranolol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9527943_2_Ent4", "text": "propranolol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9527943_2_Ent8", "text": "propranolol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9527943_2_Ent9", "text": "propranolol", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9527943_3", "wnd_id": "9527943_3_1", "text": "STUDY DESIGN : Case reports are presented of three premature infants ( mean gestational age 27 weeks ) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia .", "tokens": ["STUDY", "DESIGN", ":", "Case", "reports", "are", "presented", "of", "three", "premature", "infants", "(", "mean", "gestational", "age", "27", "weeks", ")", "cared", "for", "in", "the", "intensive", "care", "nursery", "in", "whom", "clinically", "significant", "septal", "hypertrophy", "and", "left", "ventricular", "outflow", "tract", "obstruction", "developed", "during", "dexamethasone", "treatment", "for", "bronchopulmonary", "dysplasia", "."], "event_mentions": [{"id": "9527943_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 37, "end": 38}, "arguments": [{"entity_id": "9527943_3_Ent1", "role": "Subject_Population", "text": "three", "start": 8, "end": 9}, {"entity_id": "9527943_3_Ent0", "role": "Subject", "text": "three premature infants ( mean gestational age 27 weeks ) cared for in the intensive care nursery", "start": 8, "end": 25}, {"entity_id": "9527943_3_Ent2", "role": "Subject_Age", "text": "premature infants ( mean gestational age 27 weeks )", "start": 9, "end": 18}, {"entity_id": "9527943_3_Ent3", "role": "Effect", "text": "clinically significant septal hypertrophy and left ventricular outflow tract obstruction", "start": 27, "end": 37}, {"entity_id": "9527943_3_Ent4", "role": "Treatment", "text": "during dexamethasone treatment for bronchopulmonary dysplasia", "start": 38, "end": 44}, {"entity_id": "9527943_3_Ent5", "role": "Treatment_Drug", "text": "dexamethasone", "start": 39, "end": 40}, {"entity_id": "9527943_3_Ent6", "role": "Treatment_Disorder", "text": "bronchopulmonary dysplasia .", "start": 42, "end": 45}]}], "entity_mentions": [{"id": "9527943_3_Ent1", "text": "three", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9527943_3_Ent0", "text": "three premature infants ( mean gestational age 27 weeks ) cared for in the intensive care nursery", "entity_type": "Entity", "start": 8, "end": 25}, {"id": "9527943_3_Ent2", "text": "premature infants ( mean gestational age 27 weeks )", "entity_type": "Entity", "start": 9, "end": 18}, {"id": "9527943_3_Ent3", "text": "clinically significant septal hypertrophy and left ventricular outflow tract obstruction", "entity_type": "Entity", "start": 27, "end": 37}, {"id": "9527943_3_Ent4", "text": "during dexamethasone treatment for bronchopulmonary dysplasia", "entity_type": "Entity", "start": 38, "end": 44}, {"id": "9527943_3_Ent5", "text": "dexamethasone", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "9527943_3_Ent6", "text": "bronchopulmonary dysplasia .", "entity_type": "Entity", "start": 42, "end": 45}], "lang": "en"}
{"doc_id": "9533061_8", "wnd_id": "9533061_8_1", "text": "DISCUSSION : No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea .", "tokens": ["DISCUSSION", ":", "No", "published", "clinical", "studies", "in", "patients", "receiving", "clindamycin", "vaginal", "cream", "for", "bacterial", "vaginosis", "have", "documented", "C.", "difficile", "toxin", "in", "stool", "samples", "of", "patients", "with", "diarrhea", "."], "event_mentions": [{"id": "9533061_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 12, "end": 13}, "arguments": [{"entity_id": "9533061_8_Ent0", "role": "Subject", "text": "patients", "start": 7, "end": 8}, {"entity_id": "9533061_8_Ent1", "role": "Treatment", "text": "receiving clindamycin vaginal cream", "start": 8, "end": 12}, {"entity_id": "9533061_8_Ent2", "role": "Treatment_Drug", "text": "clindamycin", "start": 9, "end": 10}, {"entity_id": "9533061_8_Ent3", "role": "Treatment_Route", "text": "vaginal cream", "start": 10, "end": 12}, {"entity_id": "9533061_8_Ent4", "role": "Treatment_Disorder", "text": "bacterial vaginosis", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "9533061_8_Ent0", "text": "patients", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9533061_8_Ent1", "text": "receiving clindamycin vaginal cream", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "9533061_8_Ent2", "text": "clindamycin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9533061_8_Ent3", "text": "vaginal cream", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9533061_8_Ent4", "text": "bacterial vaginosis", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "9554064_2", "wnd_id": "9554064_2_1", "text": "Putaminal infarct in methanol intoxication : case report and role of brain imaging studies .", "tokens": ["Putaminal", "infarct", "in", "methanol", "intoxication", ":", "case", "report", "and", "role", "of", "brain", "imaging", "studies", "."], "event_mentions": [{"id": "9554064_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "intoxication", "start": 4, "end": 5}, "arguments": [{"entity_id": "9554064_2_Ent0", "role": "Effect", "text": "Putaminal infarct in methanol intoxication", "start": 0, "end": 5}, {"entity_id": "9554064_2_Ent1", "role": "Treatment", "text": "methanol", "start": 3, "end": 4}, {"entity_id": "9554064_2_Ent2", "role": "Treatment_Drug", "text": "methanol", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "9554064_2_Ent0", "text": "Putaminal infarct in methanol intoxication", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9554064_2_Ent1", "text": "methanol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9554064_2_Ent2", "text": "methanol", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "961329_2", "wnd_id": "961329_2_1", "text": "Suxamethonium apnoea terminated with commercial serumcholinesterase .", "tokens": ["Suxamethonium", "apnoea", "terminated", "with", "commercial", "serumcholinesterase", "."], "event_mentions": [{"id": "961329_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "terminated", "start": 2, "end": 3}, "arguments": [{"entity_id": "961329_2_Ent0", "role": "Effect", "text": "Suxamethonium apnoea", "start": 0, "end": 2}, {"entity_id": "961329_2_Ent1", "role": "Treatment", "text": "commercial serumcholinesterase", "start": 4, "end": 6}, {"entity_id": "961329_2_Ent2", "role": "Treatment_Drug", "text": "commercial serumcholinesterase", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "961329_2_Ent0", "text": "Suxamethonium apnoea", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "961329_2_Ent1", "text": "commercial serumcholinesterase", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "961329_2_Ent2", "text": "commercial serumcholinesterase", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "9634122_3", "wnd_id": "9634122_3_1", "text": "This case illustrates the potential decoupling of PSA response from disease status in flutamide withdrawal .", "tokens": ["This", "case", "illustrates", "the", "potential", "decoupling", "of", "PSA", "response", "from", "disease", "status", "in", "flutamide", "withdrawal", "."], "event_mentions": [{"id": "9634122_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "illustrates", "start": 2, "end": 3}, "arguments": [{"entity_id": "9634122_3_Ent0", "role": "Effect", "text": "potential decoupling of PSA response", "start": 4, "end": 9}, {"entity_id": "9634122_3_Ent2", "role": "Treatment_Drug", "text": "flutamide", "start": 13, "end": 14}, {"entity_id": "9634122_3_Ent1", "role": "Treatment", "text": "flutamide withdrawal", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "9634122_3_Ent0", "text": "potential decoupling of PSA response", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "9634122_3_Ent2", "text": "flutamide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9634122_3_Ent1", "text": "flutamide withdrawal", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "9634122_4", "wnd_id": "9634122_4_1", "text": "We describe a patient with androgen - independent prostate cancer in whom PSA continued to decrease for a period of 15 months after flutamide withdrawal .", "tokens": ["We", "describe", "a", "patient", "with", "androgen", "-", "independent", "prostate", "cancer", "in", "whom", "PSA", "continued", "to", "decrease", "for", "a", "period", "of", "15", "months", "after", "flutamide", "withdrawal", "."], "event_mentions": [{"id": "9634122_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 22, "end": 23}, "arguments": [{"entity_id": "9634122_4_Ent0", "role": "Subject", "text": "a patient with androgen - independent prostate cancer", "start": 2, "end": 10}, {"entity_id": "9634122_4_Ent4", "role": "Treatment_Disorder", "text": "androgen - independent prostate cancer", "start": 5, "end": 10}, {"entity_id": "9634122_4_Ent1", "role": "Effect", "text": "PSA continued to decrease for a period of 15 months", "start": 12, "end": 22}, {"entity_id": "9634122_4_Ent3", "role": "Treatment_Drug", "text": "flutamide", "start": 23, "end": 24}, {"entity_id": "9634122_4_Ent2", "role": "Treatment", "text": "flutamide withdrawal", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "9634122_4_Ent0", "text": "a patient with androgen - independent prostate cancer", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "9634122_4_Ent4", "text": "androgen - independent prostate cancer", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "9634122_4_Ent1", "text": "PSA continued to decrease for a period of 15 months", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "9634122_4_Ent3", "text": "flutamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "9634122_4_Ent2", "text": "flutamide withdrawal", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "9642842_2", "wnd_id": "9642842_2_1", "text": "We describe the case of a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance who developed a dramatic anaphylactic reaction to oral prednisone .", "tokens": ["We", "describe", "the", "case", "of", "a", "nonatopic", "17", "-", "year", "-", "old", "girl", "with", "bronchial", "asthma", "and", "aspirin", "intolerance", "who", "developed", "a", "dramatic", "anaphylactic", "reaction", "to", "oral", "prednisone", "."], "event_mentions": [{"id": "9642842_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "9642842_2_Ent0", "role": "Subject", "text": "a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance", "start": 5, "end": 19}, {"entity_id": "9642842_2_Ent1", "role": "Subject_Disorder", "text": "nonatopic", "start": 6, "end": 7}, {"entity_id": "9642842_2_Ent3", "role": "Subject_Age", "text": "17 - year - old", "start": 7, "end": 12}, {"entity_id": "9642842_2_Ent4", "role": "Subject_Gender", "text": "girl", "start": 12, "end": 13}, {"entity_id": "9642842_2_Ent9", "role": "Treatment_Disorder", "text": "bronchial asthma", "start": 14, "end": 16}, {"entity_id": "9642842_2_Ent2", "role": "Subject_Disorder", "text": "aspirin intolerance", "start": 17, "end": 19}, {"entity_id": "9642842_2_Ent5", "role": "Effect", "text": "a dramatic anaphylactic reaction", "start": 21, "end": 25}, {"entity_id": "9642842_2_Ent7", "role": "Treatment_Route", "text": "oral", "start": 26, "end": 27}, {"entity_id": "9642842_2_Ent6", "role": "Treatment", "text": "oral prednisone", "start": 26, "end": 28}, {"entity_id": "9642842_2_Ent8", "role": "Treatment_Drug", "text": "prednisone", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "9642842_2_Ent0", "text": "a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "9642842_2_Ent1", "text": "nonatopic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9642842_2_Ent3", "text": "17 - year - old", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "9642842_2_Ent4", "text": "girl", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9642842_2_Ent9", "text": "bronchial asthma", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "9642842_2_Ent2", "text": "aspirin intolerance", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9642842_2_Ent5", "text": "a dramatic anaphylactic reaction", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "9642842_2_Ent7", "text": "oral", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "9642842_2_Ent6", "text": "oral prednisone", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "9642842_2_Ent8", "text": "prednisone", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "9651465_3", "wnd_id": "9651465_3_1", "text": "The vomiting occurred on switching to different pancreatic enzymes preparations , ie , Creon 10 , Viokase , and Pancrease MT 16 .", "tokens": ["The", "vomiting", "occurred", "on", "switching", "to", "different", "pancreatic", "enzymes", "preparations", ",", "ie", ",", "Creon", "10", ",", "Viokase", ",", "and", "Pancrease", "MT", "16", "."], "event_mentions": [{"id": "9651465_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "switching", "start": 4, "end": 5}, "arguments": [{"entity_id": "9651465_3_Ent0", "role": "Effect", "text": "vomiting", "start": 1, "end": 2}, {"entity_id": "9651465_3_Ent1", "role": "Treatment", "text": "different pancreatic enzymes preparations , ie , Creon 10 , Viokase , and Pancrease MT 16", "start": 6, "end": 22}, {"entity_id": "9651465_3_Ent2", "role": "Treatment_Drug", "text": "Creon 10", "start": 13, "end": 15}, {"entity_id": "9651465_3_Ent3", "role": "Treatment_Drug", "text": "Viokase", "start": 16, "end": 17}, {"entity_id": "9651465_3_Ent4", "role": "Treatment_Drug", "text": "Pancrease MT 16", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "9651465_3_Ent0", "text": "vomiting", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9651465_3_Ent1", "text": "different pancreatic enzymes preparations , ie , Creon 10 , Viokase , and Pancrease MT 16", "entity_type": "Entity", "start": 6, "end": 22}, {"id": "9651465_3_Ent2", "text": "Creon 10", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "9651465_3_Ent3", "text": "Viokase", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9651465_3_Ent4", "text": "Pancrease MT 16", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "9653495_6", "wnd_id": "9653495_6_1", "text": "Patients with inoperable or metastatic colorectal cancer were randomized to receive monthly FU 400 mg / m2/day plus LV 20 mg / m2/day as intravenous push daily for five days , or FU alone .", "tokens": ["Patients", "with", "inoperable", "or", "metastatic", "colorectal", "cancer", "were", "randomized", "to", "receive", "monthly", "FU", "400", "mg", "/", "m2/day", "plus", "LV", "20", "mg", "/", "m2/day", "as", "intravenous", "push", "daily", "for", "five", "days", ",", "or", "FU", "alone", "."], "event_mentions": [{"id": "9653495_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receive", "start": 10, "end": 11}, "arguments": [{"entity_id": "9653495_6_Ent0", "role": "Subject", "text": "Patients with inoperable or metastatic colorectal cancer", "start": 0, "end": 7}, {"entity_id": "9653495_6_Ent3", "role": "Treatment_Disorder", "text": "inoperable", "start": 2, "end": 3}, {"entity_id": "9653495_6_Ent2", "role": "Treatment_Disorder", "text": "metastatic colorectal cancer", "start": 4, "end": 7}, {"entity_id": "9653495_6_Ent10", "role": "Treatment_Freq", "text": "monthly", "start": 11, "end": 12}, {"entity_id": "9653495_6_Ent1", "role": "Treatment", "text": "monthly FU 400 mg / m2/day plus LV 20 mg / m2/day as intravenous push daily for five days", "start": 11, "end": 30}, {"entity_id": "9653495_6_Ent6", "role": "Treatment_Drug", "text": "FU", "start": 12, "end": 13}, {"entity_id": "9653495_6_Ent12", "role": "Combination_Drug", "text": "FU", "start": 12, "end": 13}, {"entity_id": "9653495_6_Ent4", "role": "Treatment_Dosage", "text": "400 mg / m2/day", "start": 13, "end": 17}, {"entity_id": "9653495_6_Ent7", "role": "Treatment_Drug", "text": "LV", "start": 18, "end": 19}, {"entity_id": "9653495_6_Ent13", "role": "Combination_Drug", "text": "LV", "start": 18, "end": 19}, {"entity_id": "9653495_6_Ent5", "role": "Treatment_Dosage", "text": "20 mg / m2/day", "start": 19, "end": 23}, {"entity_id": "9653495_6_Ent8", "role": "Treatment_Route", "text": "intravenous push", "start": 24, "end": 26}, {"entity_id": "9653495_6_Ent9", "role": "Treatment_Freq", "text": "daily", "start": 26, "end": 27}, {"entity_id": "9653495_6_Ent11", "role": "Treatment_Duration", "text": "five days", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "9653495_6_Ent0", "text": "Patients with inoperable or metastatic colorectal cancer", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9653495_6_Ent3", "text": "inoperable", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9653495_6_Ent2", "text": "metastatic colorectal cancer", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "9653495_6_Ent10", "text": "monthly", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9653495_6_Ent1", "text": "monthly FU 400 mg / m2/day plus LV 20 mg / m2/day as intravenous push daily for five days", "entity_type": "Entity", "start": 11, "end": 30}, {"id": "9653495_6_Ent6", "text": "FU", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9653495_6_Ent12", "text": "FU", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9653495_6_Ent4", "text": "400 mg / m2/day", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "9653495_6_Ent7", "text": "LV", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9653495_6_Ent13", "text": "LV", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9653495_6_Ent5", "text": "20 mg / m2/day", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "9653495_6_Ent8", "text": "intravenous push", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "9653495_6_Ent9", "text": "daily", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "9653495_6_Ent11", "text": "five days", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "9671138_1", "wnd_id": "9671138_1_1", "text": "CD4 T - lymphocyte depletion , myelosuppression , and subsequent severe infections are the major side effects of fludarabine phosphate therapy .", "tokens": ["CD4", "T", "-", "lymphocyte", "depletion", ",", "myelosuppression", ",", "and", "subsequent", "severe", "infections", "are", "the", "major", "side", "effects", "of", "fludarabine", "phosphate", "therapy", "."], "event_mentions": [{"id": "9671138_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 17, "end": 18}, "arguments": [{"entity_id": "9671138_1_Ent0", "role": "Effect", "text": "CD4 T - lymphocyte depletion , myelosuppression , and subsequent severe infections", "start": 0, "end": 12}, {"entity_id": "9671138_1_Ent1", "role": "Treatment", "text": "fludarabine phosphate", "start": 18, "end": 20}, {"entity_id": "9671138_1_Ent2", "role": "Treatment_Drug", "text": "fludarabine phosphate", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "9671138_1_Ent0", "text": "CD4 T - lymphocyte depletion , myelosuppression , and subsequent severe infections", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "9671138_1_Ent1", "text": "fludarabine phosphate", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "9671138_1_Ent2", "text": "fludarabine phosphate", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "968449_2", "wnd_id": "968449_2_1", "text": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera ( PV ) at the time of diagnosis and several times subsequently during therapy with chlorambucil .", "tokens": ["Bone", "marrow", "chromosomes", "were", "studied", "in", "2", "patients", "with", "polycythaemia", "vera", "(", "PV", ")", "at", "the", "time", "of", "diagnosis", "and", "several", "times", "subsequently", "during", "therapy", "with", "chlorambucil", "."], "event_mentions": [{"id": "968449_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 24, "end": 25}, "arguments": [{"entity_id": "968449_2_Ent1", "role": "Subject_Population", "text": "2", "start": 6, "end": 7}, {"entity_id": "968449_2_Ent0", "role": "Subject", "text": "2 patients with polycythaemia vera ( PV )", "start": 6, "end": 14}, {"entity_id": "968449_2_Ent3", "role": "Treatment_Disorder", "text": "polycythaemia vera ( PV )", "start": 9, "end": 14}, {"entity_id": "968449_2_Ent2", "role": "Treatment", "text": "chlorambucil", "start": 26, "end": 27}, {"entity_id": "968449_2_Ent4", "role": "Treatment_Drug", "text": "chlorambucil", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "968449_2_Ent1", "text": "2", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "968449_2_Ent0", "text": "2 patients with polycythaemia vera ( PV )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "968449_2_Ent3", "text": "polycythaemia vera ( PV )", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "968449_2_Ent2", "text": "chlorambucil", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "968449_2_Ent4", "text": "chlorambucil", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "9695308_1", "wnd_id": "9695308_1_1", "text": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared .", "tokens": ["Administration", "of", "steroid", "and", "decreasing", "the", "dose", "of", "PTU", "produced", "a", "good", "clinical", "response", "and", "the", "ANCA", "disappeared", "."], "event_mentions": [{"id": "9695308_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "produced", "start": 9, "end": 10}, "arguments": [{"entity_id": "9695308_1_Ent1", "role": "Treatment", "text": "steroid", "start": 2, "end": 3}, {"entity_id": "9695308_1_Ent3", "role": "Treatment_Drug", "text": "steroid", "start": 2, "end": 3}, {"entity_id": "9695308_1_Ent2", "role": "Treatment", "text": "PTU", "start": 8, "end": 9}, {"entity_id": "9695308_1_Ent4", "role": "Treatment_Drug", "text": "PTU", "start": 8, "end": 9}, {"entity_id": "9695308_1_Ent0", "role": "Effect", "text": "a good clinical response and the ANCA disappeared", "start": 10, "end": 18}]}], "entity_mentions": [{"id": "9695308_1_Ent1", "text": "steroid", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9695308_1_Ent3", "text": "steroid", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9695308_1_Ent2", "text": "PTU", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9695308_1_Ent4", "text": "PTU", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9695308_1_Ent0", "text": "a good clinical response and the ANCA disappeared", "entity_type": "Entity", "start": 10, "end": 18}], "lang": "en"}
{"doc_id": "9695308_4", "wnd_id": "9695308_4_1", "text": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA .", "tokens": ["It", "was", "concluded", "that", "ANCA", "is", "closely", "related", "to", "the", "pathogenesis", "of", "crescentic", "glomerulonephritis", "and", "that", "treatment", "with", "PTU", "appeared", "to", "induce", "ANCA", "."], "event_mentions": [{"id": "9695308_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 21, "end": 22}, "arguments": [{"entity_id": "9695308_4_Ent1", "role": "Treatment", "text": "PTU", "start": 18, "end": 19}, {"entity_id": "9695308_4_Ent2", "role": "Treatment_Drug", "text": "PTU", "start": 18, "end": 19}, {"entity_id": "9695308_4_Ent0", "role": "Effect", "text": "ANCA", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "9695308_4_Ent1", "text": "PTU", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9695308_4_Ent2", "text": "PTU", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9695308_4_Ent0", "text": "ANCA", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "9719245_1", "wnd_id": "9719245_1_1", "text": "Excluding other causes , Pentasa - associated pancytopenia was considered .", "tokens": ["Excluding", "other", "causes", ",", "Pentasa", "-", "associated", "pancytopenia", "was", "considered", "."], "event_mentions": [{"id": "9719245_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "9719245_1_Ent1", "role": "Treatment", "text": "Pentasa", "start": 4, "end": 5}, {"entity_id": "9719245_1_Ent2", "role": "Treatment_Drug", "text": "Pentasa", "start": 4, "end": 5}, {"entity_id": "9719245_1_Ent0", "role": "Effect", "text": "pancytopenia", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9719245_1_Ent1", "text": "Pentasa", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9719245_1_Ent2", "text": "Pentasa", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9719245_1_Ent0", "text": "pancytopenia", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9719245_3", "wnd_id": "9719245_3_1", "text": "Pancytopenia associated with 5 - aminosalicylic acid use in a patient with Crohn 's disease .", "tokens": ["Pancytopenia", "associated", "with", "5", "-", "aminosalicylic", "acid", "use", "in", "a", "patient", "with", "Crohn", "'s", "disease", "."], "event_mentions": [{"id": "9719245_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "9719245_3_Ent1", "role": "Effect", "text": "Pancytopenia", "start": 0, "end": 1}, {"entity_id": "9719245_3_Ent2", "role": "Treatment", "text": "5 - aminosalicylic acid", "start": 3, "end": 7}, {"entity_id": "9719245_3_Ent4", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 3, "end": 7}, {"entity_id": "9719245_3_Ent0", "role": "Subject", "text": "a patient with Crohn 's disease", "start": 9, "end": 15}, {"entity_id": "9719245_3_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "9719245_3_Ent1", "text": "Pancytopenia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9719245_3_Ent2", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "9719245_3_Ent4", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "9719245_3_Ent0", "text": "a patient with Crohn 's disease", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "9719245_3_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "9723127_3", "wnd_id": "9723127_3_1", "text": "Decreased plasma cortisol level during alprazolam treatment of panic disorder : a case report .", "tokens": ["Decreased", "plasma", "cortisol", "level", "during", "alprazolam", "treatment", "of", "panic", "disorder", ":", "a", "case", "report", "."], "event_mentions": [{"id": "9723127_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "9723127_3_Ent0", "role": "Effect", "text": "Decreased plasma cortisol level", "start": 0, "end": 4}, {"entity_id": "9723127_3_Ent1", "role": "Treatment", "text": "alprazolam", "start": 5, "end": 6}, {"entity_id": "9723127_3_Ent2", "role": "Treatment_Drug", "text": "alprazolam", "start": 5, "end": 6}, {"entity_id": "9723127_3_Ent3", "role": "Treatment_Disorder", "text": "panic disorder", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "9723127_3_Ent0", "text": "Decreased plasma cortisol level", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9723127_3_Ent1", "text": "alprazolam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9723127_3_Ent2", "text": "alprazolam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9723127_3_Ent3", "text": "panic disorder", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "9733234_1", "wnd_id": "9733234_1_1", "text": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss .", "tokens": ["Young", "children", "undergoing", "cisplatin", "chemotherapy", "are", "known", "to", "be", "at", "risk", "for", "progressive", "sensorineural", "hearing", "loss", "."], "event_mentions": [{"id": "9733234_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 10, "end": 11}, "arguments": [{"entity_id": "9733234_1_Ent1", "role": "Subject_Age", "text": "Young", "start": 0, "end": 1}, {"entity_id": "9733234_1_Ent0", "role": "Subject", "text": "Young children", "start": 0, "end": 2}, {"entity_id": "9733234_1_Ent2", "role": "Subject_Age", "text": "children", "start": 1, "end": 2}, {"entity_id": "9733234_1_Ent4", "role": "Treatment", "text": "undergoing cisplatin chemotherapy", "start": 2, "end": 5}, {"entity_id": "9733234_1_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 3, "end": 4}, {"entity_id": "9733234_1_Ent6", "role": "Treatment_Route", "text": "chemotherapy", "start": 4, "end": 5}, {"entity_id": "9733234_1_Ent3", "role": "Effect", "text": "progressive sensorineural hearing loss", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "9733234_1_Ent1", "text": "Young", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9733234_1_Ent0", "text": "Young children", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9733234_1_Ent2", "text": "children", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9733234_1_Ent4", "text": "undergoing cisplatin chemotherapy", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9733234_1_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9733234_1_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9733234_1_Ent3", "text": "progressive sensorineural hearing loss", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "9737132_3", "wnd_id": "9737132_3_1", "text": "Pentazocine - induced fibrous myopathy and localized neuropathy .", "tokens": ["Pentazocine", "-", "induced", "fibrous", "myopathy", "and", "localized", "neuropathy", "."], "event_mentions": [{"id": "9737132_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9737132_3_Ent1", "role": "Treatment", "text": "Pentazocine", "start": 0, "end": 1}, {"entity_id": "9737132_3_Ent2", "role": "Treatment_Drug", "text": "Pentazocine", "start": 0, "end": 1}, {"entity_id": "9737132_3_Ent0", "role": "Effect", "text": "fibrous myopathy and localized neuropathy", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "9737132_3_Ent1", "text": "Pentazocine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9737132_3_Ent2", "text": "Pentazocine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9737132_3_Ent0", "text": "fibrous myopathy and localized neuropathy", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "9754850_1", "wnd_id": "9754850_1_1", "text": "In two of these cases akathisia resolved after withdrawal of olanzapine and substitution by a classical or an atypical neuroleptic agent , respectively .", "tokens": ["In", "two", "of", "these", "cases", "akathisia", "resolved", "after", "withdrawal", "of", "olanzapine", "and", "substitution", "by", "a", "classical", "or", "an", "atypical", "neuroleptic", "agent", ",", "respectively", "."], "event_mentions": [{"id": "9754850_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resolved", "start": 6, "end": 7}, "arguments": [{"entity_id": "9754850_1_Ent1", "role": "Subject_Population", "text": "two", "start": 1, "end": 2}, {"entity_id": "9754850_1_Ent0", "role": "Subject", "text": "two of these cases", "start": 1, "end": 5}, {"entity_id": "9754850_1_Ent2", "role": "Effect", "text": "akathisia", "start": 5, "end": 6}, {"entity_id": "9754850_1_Ent3", "role": "Treatment", "text": "withdrawal of olanzapine and substitution by a classical", "start": 8, "end": 16}, {"entity_id": "9754850_1_Ent5", "role": "Treatment_Drug", "text": "olanzapine", "start": 10, "end": 11}, {"entity_id": "9754850_1_Ent4", "role": "Treatment", "text": "neuroleptic agent", "start": 19, "end": 21}, {"entity_id": "9754850_1_Ent6", "role": "Treatment_Drug", "text": "neuroleptic agent", "start": 19, "end": 21}]}, {"id": "9754850_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "resolved", "start": 6, "end": 7}, "arguments": [{"entity_id": "9754850_1_Ent7", "role": "Effect", "text": "akathisia", "start": 5, "end": 6}, {"entity_id": "9754850_1_Ent8", "role": "Treatment", "text": "withdrawal of olanzapine and substitution by", "start": 8, "end": 14}, {"entity_id": "9754850_1_Ent9", "role": "Treatment", "text": "an atypical neuroleptic agent", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "9754850_1_Ent1", "text": "two", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9754850_1_Ent0", "text": "two of these cases", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "9754850_1_Ent2", "text": "akathisia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9754850_1_Ent7", "text": "akathisia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9754850_1_Ent8", "text": "withdrawal of olanzapine and substitution by", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "9754850_1_Ent3", "text": "withdrawal of olanzapine and substitution by a classical", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "9754850_1_Ent5", "text": "olanzapine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9754850_1_Ent9", "text": "an atypical neuroleptic agent", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "9754850_1_Ent4", "text": "neuroleptic agent", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "9754850_1_Ent6", "text": "neuroleptic agent", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "9760614_2", "wnd_id": "9760614_2_1", "text": "However , repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage .", "tokens": ["However", ",", "repeated", "intracameral", "tPA", "injections", "may", "cause", "unwanted", "complications", "such", "as", "vitreous", "hemorrhage", "."], "event_mentions": [{"id": "9760614_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "9760614_2_Ent1", "role": "Treatment", "text": "repeated intracameral tPA injections", "start": 2, "end": 6}, {"entity_id": "9760614_2_Ent3", "role": "Treatment_Route", "text": "intracameral", "start": 3, "end": 4}, {"entity_id": "9760614_2_Ent2", "role": "Treatment_Drug", "text": "tPA", "start": 4, "end": 5}, {"entity_id": "9760614_2_Ent4", "role": "Treatment_Route", "text": "injections", "start": 5, "end": 6}, {"entity_id": "9760614_2_Ent0", "role": "Effect", "text": "unwanted complications such as vitreous hemorrhage", "start": 8, "end": 14}]}], "entity_mentions": [{"id": "9760614_2_Ent1", "text": "repeated intracameral tPA injections", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "9760614_2_Ent3", "text": "intracameral", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9760614_2_Ent2", "text": "tPA", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9760614_2_Ent4", "text": "injections", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9760614_2_Ent0", "text": "unwanted complications such as vitreous hemorrhage", "entity_type": "Entity", "start": 8, "end": 14}], "lang": "en"}
{"doc_id": "9788533_2", "wnd_id": "9788533_2_1", "text": "A 53 - year - old Caucasian male victim of suicide was suspected of overdose with sertraline and alprazolam after death - scene investigation .", "tokens": ["A", "53", "-", "year", "-", "old", "Caucasian", "male", "victim", "of", "suicide", "was", "suspected", "of", "overdose", "with", "sertraline", "and", "alprazolam", "after", "death", "-", "scene", "investigation", "."], "event_mentions": [{"id": "9788533_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 15, "end": 16}, "arguments": [{"entity_id": "9788533_2_Ent1", "role": "Subject_Age", "text": "53 - year - old", "start": 1, "end": 6}, {"entity_id": "9788533_2_Ent0", "role": "Subject", "text": "53 - year - old Caucasian male victim of suicide", "start": 1, "end": 11}, {"entity_id": "9788533_2_Ent2", "role": "Subject_Race", "text": "Caucasian", "start": 6, "end": 7}, {"entity_id": "9788533_2_Ent3", "role": "Subject_Gender", "text": "male", "start": 7, "end": 8}, {"entity_id": "9788533_2_Ent4", "role": "Treatment", "text": "overdose", "start": 14, "end": 15}, {"entity_id": "9788533_2_Ent6", "role": "Treatment_Dosage", "text": "overdose", "start": 14, "end": 15}, {"entity_id": "9788533_2_Ent7", "role": "Treatment_Drug", "text": "sertraline", "start": 16, "end": 17}, {"entity_id": "9788533_2_Ent9", "role": "Combination_Drug", "text": "sertraline", "start": 16, "end": 17}, {"entity_id": "9788533_2_Ent5", "role": "Treatment", "text": "sertraline and alprazolam", "start": 16, "end": 19}, {"entity_id": "9788533_2_Ent8", "role": "Treatment_Drug", "text": "alprazolam", "start": 18, "end": 19}, {"entity_id": "9788533_2_Ent10", "role": "Combination_Drug", "text": "alprazolam", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9788533_2_Ent1", "text": "53 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9788533_2_Ent0", "text": "53 - year - old Caucasian male victim of suicide", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "9788533_2_Ent2", "text": "Caucasian", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9788533_2_Ent3", "text": "male", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9788533_2_Ent4", "text": "overdose", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9788533_2_Ent6", "text": "overdose", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9788533_2_Ent7", "text": "sertraline", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9788533_2_Ent9", "text": "sertraline", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9788533_2_Ent5", "text": "sertraline and alprazolam", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "9788533_2_Ent8", "text": "alprazolam", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9788533_2_Ent10", "text": "alprazolam", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9788533_8", "wnd_id": "9788533_8_1", "text": "The cause of death was multiple drug intoxication following acute use of sertraline , the manner of death was suicide , and the mechanism of death is an unexplained drug interaction and/or toxicity .", "tokens": ["The", "cause", "of", "death", "was", "multiple", "drug", "intoxication", "following", "acute", "use", "of", "sertraline", ",", "the", "manner", "of", "death", "was", "suicide", ",", "and", "the", "mechanism", "of", "death", "is", "an", "unexplained", "drug", "interaction", "and/or", "toxicity", "."], "event_mentions": [{"id": "9788533_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "9788533_8_Ent0", "role": "Effect", "text": "multiple drug intoxication", "start": 5, "end": 8}, {"entity_id": "9788533_8_Ent1", "role": "Treatment", "text": "sertraline", "start": 12, "end": 13}, {"entity_id": "9788533_8_Ent2", "role": "Treatment_Drug", "text": "sertraline", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "9788533_8_Ent0", "text": "multiple drug intoxication", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9788533_8_Ent1", "text": "sertraline", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9788533_8_Ent2", "text": "sertraline", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "9819544_3", "wnd_id": "9819544_3_1", "text": "This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID - related permanent sensorineural hearing loss .", "tokens": ["This", "article", "reports", "the", "case", "of", "an", "otherwise", "healthy", "patient", "who", "experienced", "permanent", "sensorineural", "hearing", "loss", "after", "a", "brief", "course", "of", "naproxen", "and", "reviews", "the", "literature", "on", "NSAID", "-", "related", "permanent", "sensorineural", "hearing", "loss", "."], "event_mentions": [{"id": "9819544_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "9819544_3_Ent0", "role": "Subject", "text": "an otherwise healthy patient", "start": 6, "end": 10}, {"entity_id": "9819544_3_Ent1", "role": "Effect", "text": "permanent sensorineural hearing loss", "start": 12, "end": 16}, {"entity_id": "9819544_3_Ent2", "role": "Treatment", "text": "a brief course of naproxen", "start": 17, "end": 22}, {"entity_id": "9819544_3_Ent4", "role": "Treatment_Duration", "text": "brief course", "start": 18, "end": 20}, {"entity_id": "9819544_3_Ent3", "role": "Treatment_Drug", "text": "naproxen", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "9819544_3_Ent0", "text": "an otherwise healthy patient", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "9819544_3_Ent1", "text": "permanent sensorineural hearing loss", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "9819544_3_Ent2", "text": "a brief course of naproxen", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "9819544_3_Ent4", "text": "brief course", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "9819544_3_Ent3", "text": "naproxen", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "9824032_3", "wnd_id": "9824032_3_1", "text": "Two 65 - year - old white men with coronary heart disease , given niacin therapy for dyslipidemia for 5 months , developed intense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment .", "tokens": ["Two", "65", "-", "year", "-", "old", "white", "men", "with", "coronary", "heart", "disease", ",", "given", "niacin", "therapy", "for", "dyslipidemia", "for", "5", "months", ",", "developed", "intense", "dental", "and", "gingival", "pain", "that", "was", "associated", "with", "increases", "in", "dose", "and", "that", "was", "relieved", "with", "discontinuance", "of", "niacin", "treatment", "."], "event_mentions": [{"id": "9824032_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "9824032_3_Ent2", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "9824032_3_Ent0", "role": "Subject", "text": "Two 65 - year - old white men with coronary heart disease", "start": 0, "end": 12}, {"entity_id": "9824032_3_Ent3", "role": "Subject_Age", "text": "65 - year - old", "start": 1, "end": 6}, {"entity_id": "9824032_3_Ent4", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "9824032_3_Ent5", "role": "Subject_Gender", "text": "men", "start": 7, "end": 8}, {"entity_id": "9824032_3_Ent1", "role": "Subject_Disorder", "text": "coronary heart disease", "start": 9, "end": 12}, {"entity_id": "9824032_3_Ent10", "role": "Treatment_Drug", "text": "niacin", "start": 14, "end": 15}, {"entity_id": "9824032_3_Ent7", "role": "Treatment", "text": "niacin therapy for dyslipidemia for 5 months", "start": 14, "end": 21}, {"entity_id": "9824032_3_Ent9", "role": "Treatment_Disorder", "text": "dyslipidemia", "start": 17, "end": 18}, {"entity_id": "9824032_3_Ent12", "role": "Treatment_Duration", "text": "5 months", "start": 19, "end": 21}, {"entity_id": "9824032_3_Ent6", "role": "Effect", "text": "intense dental and gingival pain", "start": 23, "end": 28}, {"entity_id": "9824032_3_Ent8", "role": "Treatment", "text": "increases in dose", "start": 32, "end": 35}, {"entity_id": "9824032_3_Ent11", "role": "Treatment_Dosage", "text": "increases in dose", "start": 32, "end": 35}]}], "entity_mentions": [{"id": "9824032_3_Ent2", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9824032_3_Ent0", "text": "Two 65 - year - old white men with coronary heart disease", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "9824032_3_Ent3", "text": "65 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9824032_3_Ent4", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9824032_3_Ent5", "text": "men", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9824032_3_Ent1", "text": "coronary heart disease", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "9824032_3_Ent10", "text": "niacin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9824032_3_Ent7", "text": "niacin therapy for dyslipidemia for 5 months", "entity_type": "Entity", "start": 14, "end": 21}, {"id": "9824032_3_Ent9", "text": "dyslipidemia", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9824032_3_Ent12", "text": "5 months", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "9824032_3_Ent6", "text": "intense dental and gingival pain", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "9824032_3_Ent8", "text": "increases in dose", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "9824032_3_Ent11", "text": "increases in dose", "entity_type": "Entity", "start": 32, "end": 35}], "lang": "en"}
{"doc_id": "9831311_3", "wnd_id": "9831311_3_1", "text": "It was concluded that potassium loss occurred by a non - renal ( intestinal ) route in phosphate - induced hypokalemia .", "tokens": ["It", "was", "concluded", "that", "potassium", "loss", "occurred", "by", "a", "non", "-", "renal", "(", "intestinal", ")", "route", "in", "phosphate", "-", "induced", "hypokalemia", "."], "event_mentions": [{"id": "9831311_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "9831311_3_Ent0", "role": "Effect", "text": "potassium loss", "start": 4, "end": 6}, {"entity_id": "9831311_3_Ent2", "role": "Treatment", "text": "phosphate", "start": 17, "end": 18}, {"entity_id": "9831311_3_Ent3", "role": "Treatment_Drug", "text": "phosphate", "start": 17, "end": 18}, {"entity_id": "9831311_3_Ent1", "role": "Effect", "text": "hypokalemia", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "9831311_3_Ent0", "text": "potassium loss", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9831311_3_Ent2", "text": "phosphate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9831311_3_Ent3", "text": "phosphate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9831311_3_Ent1", "text": "hypokalemia", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "9831311_5", "wnd_id": "9831311_5_1", "text": "The mechanism of the decrease in plasma potassium induced by phosphate treatment was investigated in a 24 - year - old hypertensive patient with hypophosphatemic osteomalacia , who was the youngest of four patients , belonging to a 23 number kindred of five generations .", "tokens": ["The", "mechanism", "of", "the", "decrease", "in", "plasma", "potassium", "induced", "by", "phosphate", "treatment", "was", "investigated", "in", "a", "24", "-", "year", "-", "old", "hypertensive", "patient", "with", "hypophosphatemic", "osteomalacia", ",", "who", "was", "the", "youngest", "of", "four", "patients", ",", "belonging", "to", "a", "23", "number", "kindred", "of", "five", "generations", "."], "event_mentions": [{"id": "9831311_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "9831311_5_Ent3", "role": "Effect", "text": "decrease in plasma potassium", "start": 4, "end": 8}, {"entity_id": "9831311_5_Ent5", "role": "Treatment_Drug", "text": "phosphate", "start": 10, "end": 11}, {"entity_id": "9831311_5_Ent4", "role": "Treatment", "text": "phosphate treatment", "start": 10, "end": 12}, {"entity_id": "9831311_5_Ent0", "role": "Subject", "text": "a 24 - year - old hypertensive patient with hypophosphatemic osteomalacia , who was the youngest of four patients , belonging to a 23 number kindred of five generations", "start": 15, "end": 44}, {"entity_id": "9831311_5_Ent1", "role": "Subject_Age", "text": "24 - year - old", "start": 16, "end": 21}, {"entity_id": "9831311_5_Ent2", "role": "Subject_Disorder", "text": "hypertensive", "start": 21, "end": 22}, {"entity_id": "9831311_5_Ent6", "role": "Treatment_Disorder", "text": "hypophosphatemic osteomalacia", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "9831311_5_Ent3", "text": "decrease in plasma potassium", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "9831311_5_Ent5", "text": "phosphate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9831311_5_Ent4", "text": "phosphate treatment", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9831311_5_Ent0", "text": "a 24 - year - old hypertensive patient with hypophosphatemic osteomalacia , who was the youngest of four patients , belonging to a 23 number kindred of five generations", "entity_type": "Entity", "start": 15, "end": 44}, {"id": "9831311_5_Ent1", "text": "24 - year - old", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "9831311_5_Ent2", "text": "hypertensive", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9831311_5_Ent6", "text": "hypophosphatemic osteomalacia", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "9847899_1", "wnd_id": "9847899_1_1", "text": "As this relapse coincided with development of a strong delayed - type hypersensitivity response to tuberculin and improved after treatment with the anti - inflammatory agent oxpentifylline , it was probably caused by restoration of pathogen - specific cellular immunity .", "tokens": ["As", "this", "relapse", "coincided", "with", "development", "of", "a", "strong", "delayed", "-", "type", "hypersensitivity", "response", "to", "tuberculin", "and", "improved", "after", "treatment", "with", "the", "anti", "-", "inflammatory", "agent", "oxpentifylline", ",", "it", "was", "probably", "caused", "by", "restoration", "of", "pathogen", "-", "specific", "cellular", "immunity", "."], "event_mentions": [{"id": "9847899_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 5, "end": 6}, "arguments": [{"entity_id": "9847899_1_Ent0", "role": "Effect", "text": "a strong delayed - type hypersensitivity response", "start": 7, "end": 14}, {"entity_id": "9847899_1_Ent1", "role": "Treatment", "text": "tuberculin", "start": 15, "end": 16}, {"entity_id": "9847899_1_Ent2", "role": "Treatment_Drug", "text": "tuberculin", "start": 15, "end": 16}]}, {"id": "9847899_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 17, "end": 18}, "arguments": [{"entity_id": "9847899_1_Ent4", "role": "Treatment_Disorder", "text": "this relapse", "start": 1, "end": 3}, {"entity_id": "9847899_1_Ent3", "role": "Treatment", "text": "anti - inflammatory agent oxpentifylline", "start": 22, "end": 27}, {"entity_id": "9847899_1_Ent5", "role": "Treatment_Drug", "text": "oxpentifylline", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "9847899_1_Ent4", "text": "this relapse", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "9847899_1_Ent0", "text": "a strong delayed - type hypersensitivity response", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "9847899_1_Ent1", "text": "tuberculin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9847899_1_Ent2", "text": "tuberculin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9847899_1_Ent3", "text": "anti - inflammatory agent oxpentifylline", "entity_type": "Entity", "start": 22, "end": 27}, {"id": "9847899_1_Ent5", "text": "oxpentifylline", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "9855339_2", "wnd_id": "9855339_2_1", "text": "Coadministration of antidepressant agents such as nefazodone , or any other drug that inhibits the CYP3A4 isoenzyme subfamily , should be anticipated to interfere with tacrolimus metabolism .", "tokens": ["Coadministration", "of", "antidepressant", "agents", "such", "as", "nefazodone", ",", "or", "any", "other", "drug", "that", "inhibits", "the", "CYP3A4", "isoenzyme", "subfamily", ",", "should", "be", "anticipated", "to", "interfere", "with", "tacrolimus", "metabolism", "."], "event_mentions": [{"id": "9855339_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interfere", "start": 23, "end": 24}, "arguments": [{"entity_id": "9855339_2_Ent2", "role": "Treatment", "text": "Coadministration of antidepressant agents such as nefazodone , or any other drug that inhibits the CYP3A4 isoenzyme subfamily", "start": 0, "end": 18}, {"entity_id": "9855339_2_Ent4", "role": "Treatment_Drug", "text": "nefazodone", "start": 6, "end": 7}, {"entity_id": "9855339_2_Ent5", "role": "Combination_Drug", "text": "nefazodone", "start": 6, "end": 7}, {"entity_id": "9855339_2_Ent1", "role": "Treatment", "text": "tacrolimus", "start": 25, "end": 26}, {"entity_id": "9855339_2_Ent3", "role": "Treatment_Drug", "text": "tacrolimus", "start": 25, "end": 26}, {"entity_id": "9855339_2_Ent6", "role": "Combination_Drug", "text": "tacrolimus", "start": 25, "end": 26}, {"entity_id": "9855339_2_Ent0", "role": "Effect", "text": "tacrolimus metabolism", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "9855339_2_Ent2", "text": "Coadministration of antidepressant agents such as nefazodone , or any other drug that inhibits the CYP3A4 isoenzyme subfamily", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "9855339_2_Ent4", "text": "nefazodone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9855339_2_Ent5", "text": "nefazodone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9855339_2_Ent1", "text": "tacrolimus", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "9855339_2_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "9855339_2_Ent6", "text": "tacrolimus", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "9855339_2_Ent0", "text": "tacrolimus metabolism", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "9865241_3", "wnd_id": "9865241_3_1", "text": "The patient was initially treated with hydration and furosemide but developed congestive heart failure .", "tokens": ["The", "patient", "was", "initially", "treated", "with", "hydration", "and", "furosemide", "but", "developed", "congestive", "heart", "failure", "."], "event_mentions": [{"id": "9865241_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "9865241_3_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "9865241_3_Ent2", "role": "Treatment", "text": "furosemide", "start": 8, "end": 9}, {"entity_id": "9865241_3_Ent3", "role": "Treatment_Drug", "text": "furosemide", "start": 8, "end": 9}, {"entity_id": "9865241_3_Ent1", "role": "Effect", "text": "congestive heart failure", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "9865241_3_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9865241_3_Ent2", "text": "furosemide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9865241_3_Ent3", "text": "furosemide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9865241_3_Ent1", "text": "congestive heart failure", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "9865241_4", "wnd_id": "9865241_4_1", "text": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication .", "tokens": ["The", "use", "of", "pamidronate", "for", "hypercalcemia", "secondary", "to", "acute", "vitamin", "D", "intoxication", "."], "event_mentions": [{"id": "9865241_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 4, "end": 5}, "arguments": [{"entity_id": "9865241_4_Ent0", "role": "Treatment", "text": "pamidronate", "start": 3, "end": 4}, {"entity_id": "9865241_4_Ent2", "role": "Treatment_Drug", "text": "pamidronate", "start": 3, "end": 4}, {"entity_id": "9865241_4_Ent1", "role": "Treatment_Disorder", "text": "hypercalcemia secondary to acute vitamin D intoxication", "start": 5, "end": 12}]}, {"id": "9865241_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 6, "end": 7}, "arguments": [{"entity_id": "9865241_4_Ent3", "role": "Effect", "text": "hypercalcemia", "start": 5, "end": 6}, {"entity_id": "9865241_4_Ent4", "role": "Treatment", "text": "vitamin D", "start": 9, "end": 11}, {"entity_id": "9865241_4_Ent5", "role": "Treatment_Drug", "text": "vitamin D", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9865241_4_Ent0", "text": "pamidronate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9865241_4_Ent2", "text": "pamidronate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9865241_4_Ent3", "text": "hypercalcemia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9865241_4_Ent1", "text": "hypercalcemia secondary to acute vitamin D intoxication", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "9865241_4_Ent4", "text": "vitamin D", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9865241_4_Ent5", "text": "vitamin D", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9865241_5", "wnd_id": "9865241_5_1", "text": "We report the use of pamidronate for acute , severe hypercalcemia secondary to iatrogenic vitamin D poisoning .", "tokens": ["We", "report", "the", "use", "of", "pamidronate", "for", "acute", ",", "severe", "hypercalcemia", "secondary", "to", "iatrogenic", "vitamin", "D", "poisoning", "."], "event_mentions": [{"id": "9865241_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 6, "end": 7}, "arguments": [{"entity_id": "9865241_5_Ent0", "role": "Treatment", "text": "pamidronate", "start": 5, "end": 6}, {"entity_id": "9865241_5_Ent2", "role": "Treatment_Drug", "text": "pamidronate", "start": 5, "end": 6}, {"entity_id": "9865241_5_Ent1", "role": "Treatment_Disorder", "text": "acute , severe hypercalcemia secondary to iatrogenic vitamin D poisoning", "start": 7, "end": 17}]}, {"id": "9865241_5_Evt1", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 11, "end": 12}, "arguments": [{"entity_id": "9865241_5_Ent3", "role": "Effect", "text": "hypercalcemia", "start": 10, "end": 11}, {"entity_id": "9865241_5_Ent4", "role": "Treatment", "text": "vitamin D", "start": 14, "end": 16}, {"entity_id": "9865241_5_Ent5", "role": "Treatment_Drug", "text": "vitamin D", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "9865241_5_Ent0", "text": "pamidronate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9865241_5_Ent2", "text": "pamidronate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9865241_5_Ent1", "text": "acute , severe hypercalcemia secondary to iatrogenic vitamin D poisoning", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "9865241_5_Ent3", "text": "hypercalcemia", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9865241_5_Ent4", "text": "vitamin D", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "9865241_5_Ent5", "text": "vitamin D", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "9876809_1", "wnd_id": "9876809_1_1", "text": "Ticlopidine - induced phenytoin toxicity .", "tokens": ["Ticlopidine", "-", "induced", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "9876809_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9876809_1_Ent1", "role": "Treatment", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "9876809_1_Ent2", "role": "Treatment_Drug", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "9876809_1_Ent5", "role": "Combination_Drug", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "9876809_1_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 3, "end": 4}, {"entity_id": "9876809_1_Ent4", "role": "Combination_Drug", "text": "phenytoin", "start": 3, "end": 4}, {"entity_id": "9876809_1_Ent0", "role": "Effect", "text": "toxicity", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "9876809_1_Ent1", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9876809_1_Ent2", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9876809_1_Ent5", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9876809_1_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9876809_1_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9876809_1_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "9876809_2", "wnd_id": "9876809_2_1", "text": "To report a probable case of ticlopidine - induced phenytoin toxicity .", "tokens": ["To", "report", "a", "probable", "case", "of", "ticlopidine", "-", "induced", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "9876809_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "9876809_2_Ent0", "role": "Subject", "text": "a probable case", "start": 2, "end": 5}, {"entity_id": "9876809_2_Ent3", "role": "Treatment", "text": "ticlopidine", "start": 6, "end": 7}, {"entity_id": "9876809_2_Ent4", "role": "Treatment_Drug", "text": "ticlopidine", "start": 6, "end": 7}, {"entity_id": "9876809_2_Ent6", "role": "Combination_Drug", "text": "ticlopidine", "start": 6, "end": 7}, {"entity_id": "9876809_2_Ent2", "role": "Treatment", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "9876809_2_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "9876809_2_Ent7", "role": "Combination_Drug", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "9876809_2_Ent1", "role": "Effect", "text": "phenytoin toxicity", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9876809_2_Ent0", "text": "a probable case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9876809_2_Ent3", "text": "ticlopidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9876809_2_Ent4", "text": "ticlopidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9876809_2_Ent6", "text": "ticlopidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9876809_2_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9876809_2_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9876809_2_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9876809_2_Ent1", "text": "phenytoin toxicity", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9876809_3", "wnd_id": "9876809_3_1", "text": "A 72 - year - old white man suddenly developed combative behavior , refused to leave his room , stopped eating , and began falling to the floor 6 weeks after being given ticlopidine .", "tokens": ["A", "72", "-", "year", "-", "old", "white", "man", "suddenly", "developed", "combative", "behavior", ",", "refused", "to", "leave", "his", "room", ",", "stopped", "eating", ",", "and", "began", "falling", "to", "the", "floor", "6", "weeks", "after", "being", "given", "ticlopidine", "."], "event_mentions": [{"id": "9876809_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "9876809_3_Ent0", "role": "Subject", "text": "A 72 - year - old white man", "start": 0, "end": 8}, {"entity_id": "9876809_3_Ent1", "role": "Subject_Age", "text": "72 - year - old", "start": 1, "end": 6}, {"entity_id": "9876809_3_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "9876809_3_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "9876809_3_Ent4", "role": "Effect", "text": "combative behavior , refused to leave his room , stopped eating , and began falling to the floor", "start": 10, "end": 28}, {"entity_id": "9876809_3_Ent6", "role": "Treatment_Time_elapsed", "text": "6 weeks", "start": 28, "end": 30}, {"entity_id": "9876809_3_Ent5", "role": "Treatment", "text": "6 weeks after being given ticlopidine", "start": 28, "end": 34}, {"entity_id": "9876809_3_Ent7", "role": "Treatment_Drug", "text": "ticlopidine", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "9876809_3_Ent0", "text": "A 72 - year - old white man", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "9876809_3_Ent1", "text": "72 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9876809_3_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9876809_3_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9876809_3_Ent4", "text": "combative behavior , refused to leave his room , stopped eating , and began falling to the floor", "entity_type": "Entity", "start": 10, "end": 28}, {"id": "9876809_3_Ent6", "text": "6 weeks", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "9876809_3_Ent5", "text": "6 weeks after being given ticlopidine", "entity_type": "Entity", "start": 28, "end": 34}, {"id": "9876809_3_Ent7", "text": "ticlopidine", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "9876812_3", "wnd_id": "9876812_3_1", "text": "OBJECTIVE : To describe onset of syndrome of inappropriate antidiuretic hormone ( SIADH ) associated with vinorelbine therapy for advanced breast cancer .", "tokens": ["OBJECTIVE", ":", "To", "describe", "onset", "of", "syndrome", "of", "inappropriate", "antidiuretic", "hormone", "(", "SIADH", ")", "associated", "with", "vinorelbine", "therapy", "for", "advanced", "breast", "cancer", "."], "event_mentions": [{"id": "9876812_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 14, "end": 16}, "arguments": [{"entity_id": "9876812_3_Ent0", "role": "Effect", "text": "syndrome of inappropriate antidiuretic hormone ( SIADH )", "start": 6, "end": 14}, {"entity_id": "9876812_3_Ent1", "role": "Treatment", "text": "vinorelbine", "start": 16, "end": 17}, {"entity_id": "9876812_3_Ent2", "role": "Treatment_Drug", "text": "vinorelbine", "start": 16, "end": 17}, {"entity_id": "9876812_3_Ent3", "role": "Treatment_Disorder", "text": "advanced breast cancer", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "9876812_3_Ent0", "text": "syndrome of inappropriate antidiuretic hormone ( SIADH )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "9876812_3_Ent1", "text": "vinorelbine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9876812_3_Ent2", "text": "vinorelbine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9876812_3_Ent3", "text": "advanced breast cancer", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "9876812_4", "wnd_id": "9876812_4_1", "text": "Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy .", "tokens": ["Syndrome", "of", "inappropriate", "antidiuretic", "hormone", "associated", "with", "vinorelbine", "therapy", "."], "event_mentions": [{"id": "9876812_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "9876812_4_Ent0", "role": "Effect", "text": "Syndrome of inappropriate antidiuretic hormone", "start": 0, "end": 5}, {"entity_id": "9876812_4_Ent1", "role": "Treatment", "text": "vinorelbine", "start": 7, "end": 8}, {"entity_id": "9876812_4_Ent2", "role": "Treatment_Drug", "text": "vinorelbine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9876812_4_Ent0", "text": "Syndrome of inappropriate antidiuretic hormone", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9876812_4_Ent1", "text": "vinorelbine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9876812_4_Ent2", "text": "vinorelbine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9892272_4", "wnd_id": "9892272_4_1", "text": "The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of alteplase should strongly suggest the possibility of diffuse subfascial hematoma .", "tokens": ["The", "development", "of", "cutaneous", "ecchymosis", "associated", "with", "a", "sudden", "fall", "in", "hemoglobin", "after", "the", "administration", "of", "alteplase", "should", "strongly", "suggest", "the", "possibility", "of", "diffuse", "subfascial", "hematoma", "."], "event_mentions": [{"id": "9892272_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 1, "end": 2}, "arguments": [{"entity_id": "9892272_4_Ent0", "role": "Effect", "text": "cutaneous ecchymosis", "start": 3, "end": 5}, {"entity_id": "9892272_4_Ent1", "role": "Effect", "text": "a sudden fall in hemoglobin", "start": 7, "end": 12}, {"entity_id": "9892272_4_Ent3", "role": "Treatment", "text": "alteplase", "start": 16, "end": 17}, {"entity_id": "9892272_4_Ent4", "role": "Treatment_Drug", "text": "alteplase", "start": 16, "end": 17}, {"entity_id": "9892272_4_Ent2", "role": "Effect", "text": "diffuse subfascial hematoma", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "9892272_4_Ent0", "text": "cutaneous ecchymosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9892272_4_Ent1", "text": "a sudden fall in hemoglobin", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "9892272_4_Ent3", "text": "alteplase", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9892272_4_Ent4", "text": "alteplase", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9892272_4_Ent2", "text": "diffuse subfascial hematoma", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "9920368_1", "wnd_id": "9920368_1_1", "text": "Amiodarone - induced thyrotoxicosis associated with thyrotropin receptor antibody .", "tokens": ["Amiodarone", "-", "induced", "thyrotoxicosis", "associated", "with", "thyrotropin", "receptor", "antibody", "."], "event_mentions": [{"id": "9920368_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9920368_1_Ent1", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "9920368_1_Ent2", "role": "Treatment_Drug", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "9920368_1_Ent0", "role": "Effect", "text": "thyrotoxicosis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "9920368_1_Ent1", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9920368_1_Ent2", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9920368_1_Ent0", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "9925865_1", "wnd_id": "9925865_1_1", "text": "CONCLUSION : Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population .", "tokens": ["CONCLUSION", ":", "Lipoid", "pneumonia", "as", "a", "result", "of", "mineral", "oil", "aspiration", "still", "occurs", "in", "the", "pediatric", "population", "."], "event_mentions": [{"id": "9925865_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 6, "end": 7}, "arguments": [{"entity_id": "9925865_1_Ent2", "role": "Effect", "text": "Lipoid pneumonia", "start": 2, "end": 4}, {"entity_id": "9925865_1_Ent4", "role": "Treatment_Drug", "text": "mineral oil", "start": 8, "end": 10}, {"entity_id": "9925865_1_Ent3", "role": "Treatment", "text": "mineral oil aspiration", "start": 8, "end": 11}, {"entity_id": "9925865_1_Ent0", "role": "Subject", "text": "pediatric", "start": 15, "end": 16}, {"entity_id": "9925865_1_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "9925865_1_Ent2", "text": "Lipoid pneumonia", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9925865_1_Ent4", "text": "mineral oil", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9925865_1_Ent3", "text": "mineral oil aspiration", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "9925865_1_Ent0", "text": "pediatric", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9925865_1_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "9988365_1", "wnd_id": "9988365_1_1", "text": "Eosinophilia caused by clozapine was observed in challenge , preceded by a faster neutrophil production and consecutive decrease ( z = 2.27 , p = 0.01 ) .", "tokens": ["Eosinophilia", "caused", "by", "clozapine", "was", "observed", "in", "challenge", ",", "preceded", "by", "a", "faster", "neutrophil", "production", "and", "consecutive", "decrease", "(", "z", "=", "2.27", ",", "p", "=", "0.01", ")", "."], "event_mentions": [{"id": "9988365_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 1, "end": 2}, "arguments": [{"entity_id": "9988365_1_Ent0", "role": "Effect", "text": "Eosinophilia", "start": 0, "end": 1}, {"entity_id": "9988365_1_Ent2", "role": "Treatment", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "9988365_1_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "9988365_1_Ent1", "role": "Effect", "text": "preceded by a faster neutrophil production and consecutive decrease ( z = 2.27 , p = 0.01 )", "start": 9, "end": 27}]}], "entity_mentions": [{"id": "9988365_1_Ent0", "text": "Eosinophilia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9988365_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9988365_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9988365_1_Ent1", "text": "preceded by a faster neutrophil production and consecutive decrease ( z = 2.27 , p = 0.01 )", "entity_type": "Entity", "start": 9, "end": 27}], "lang": "en"}
